PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Murphy, CT; Rock, RS; Spudich, JA				Murphy, CT; Rock, RS; Spudich, JA			A myosin II mutation uncouples ATPase activity from motility and shortens step size	NATURE CELL BIOLOGY			English	Article							MOTOR DOMAIN; DICTYOSTELIUM MYOSIN; CRYSTAL-STRUCTURE; MOLECULAR MOTORS; SINGLE-MOLECULE; LIGHT-CHAIN; SALT-BRIDGE; ACTIN; DISCOIDEUM; MUSCLE	It is thought that Switch II of myosin, kinesin and G proteins has an important function in relating nucleotide state to protein conformation, Here we examine a myosin mutant containing an S456L substitution in the Switch II region. In this protein, mechanical activity is uncoupled from the chemical energy of ATP hydrolysis so that its gliding velocity on actin filaments is only one-tenth of that of the wild type. The mutant spends longer in the strongly bound state and exhibits a shorter step size, which together account for the reduction in in vitro velocity. This is the first single point mutation in myosin that has been found to affect step size.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Stanford University	Spudich, JA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.			Murphy, Coleen/0000-0002-8257-984X				Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Marriott G, 1996, BIOCHEMISTRY-US, V35, P3170, DOI 10.1021/bi952207o; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mehta AD, 1998, METHOD ENZYMOL, V298, P436, DOI 10.1016/S0076-6879(98)98039-9; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; SELLERS JR, 1995, MOTOR PROTEINS, V2; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; SPRINGER ML, 1994, DEVELOPMENT, V120, P2651; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104	30	66	68	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					311	315		10.1038/35060110	http://dx.doi.org/10.1038/35060110			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231583				2022-12-25	WOS:000167365800020
J	Patolsky, F; Lichtenstein, A; Willner, I				Patolsky, F; Lichtenstein, A; Willner, I			Detection of single-base DNA mutations by enzyme-amplified electronic transduction	NATURE BIOTECHNOLOGY			English	Article							CRYSTAL-MICROBALANCE ANALYSES; IMPEDANCE SPECTROSCOPY; INSOLUBLE PRODUCT; OLIGONUCLEOTIDE; BIOSENSOR; SURFACES; GOLD; HYBRIDIZATION; PRECIPITATION; PROBES	Here we describe a method for the sensitive detection of a single-base mutation in DNA. We assembled a primer thiolated oligonucleotide, complementary to the target DNA as far as one base before the mutation site, on an electrode or a gold-quartz piezoelectric crystal. After hybridizing the target DNA, normal or mutant, with the sensing oligonucleotide, the resulting assembly is reacted with the biotinylated nucleotide, complementary to the mutation site, in the presence of polymerase. The labeled nucleotide is coupled only to the double-stranded assembly that includes the mutant site. Subsequent binding of avidin-alkaline phosphatase to the assembly, and the biocatalyzed precipitation of an insoluble product on the transducer, provides a means to confirm and amplify detection of the mutant. Faradaic impedance spectroscopy and microgravimetric quartz-crystal microbalance analyses were employed for electronic detection of single-base mutants. The lower limit of sensitivity for the detection of the mutant DNA is 1 x 10(-14) mol/ml. We applied the method for the analysis of polymorphic blood samples that include the Tay-Sachs genetic disorder. The sensitivity of the method enables the quantitative analysis of the mutant with no PCR pre-amplification.	Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Willner, I (corresponding author), Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.		patolsky, Fernando/AAD-1188-2021	patolsky, Fernando/0000-0002-1382-5357				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bardea A, 1999, CHEM COMMUN, P21, DOI 10.1039/a808319c; Bardea A, 1998, CHEM COMMUN, P839, DOI 10.1039/a800215k; Boon EM, 2000, NAT BIOTECHNOL, V18, P1096, DOI 10.1038/80301; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Caruana DJ, 1999, J AM CHEM SOC, V121, P769, DOI 10.1021/ja983328p; Frutos AG, 1998, J AM CHEM SOC, V120, P10277, DOI 10.1021/ja982030w; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASHIMOTO K, 1994, ANAL CHEM, V66, P3830, DOI 10.1021/ac00093a045; Jordan CE, 1997, ANAL CHEM, V69, P4939, DOI 10.1021/ac9709763; KorriYoussoufi H, 1997, J AM CHEM SOC, V119, P7388, DOI 10.1021/ja964261d; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Liu QH, 1998, J COMPUT BIOL, V5, P269, DOI 10.1089/cmb.1998.5.269; Mikkelsen Susan R., 1996, Electroanalysis, V8, P15, DOI 10.1002/elan.1140080104; MILLAN KM, 1994, ANAL CHEM, V66, P2943, DOI 10.1021/ac00090a023; MYEROWITZ R, 1988, J BIOL CHEM, V263, P18587; Patolsky F, 1999, LANGMUIR, V15, P3703, DOI 10.1021/la981682v; Patolsky F, 1999, ANAL CHEM, V71, P3171, DOI 10.1021/ac9901541; RODRIGUEZ M, 1990, ANAL CHEM, V62, P2658, DOI 10.1021/ac00223a002; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q; Wang J, 1996, J AM CHEM SOC, V118, P7667, DOI 10.1021/ja9608050; Watanabe H, 1999, CANCER, V86, P1441, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1441::AID-CNCR9>3.0.CO;2-I; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194	25	335	363	1	130	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					253	257		10.1038/85704	http://dx.doi.org/10.1038/85704			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231559				2022-12-25	WOS:000167283100026
J	Turcanu, V; Williams, NA				Turcanu, V; Williams, NA			Cell identification and isolation on the basis of cytokine secretion: A novel tool for investigating immune responses	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; T-CELLS; FLOW-CYTOMETRY; CD4(+); MICRODROPLETS; COLITIS; SURFACE		Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	University of Bristol	Williams, NA (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.							Beech JT, 1997, J IMMUNOL METHODS, V205, P163, DOI 10.1016/S0022-1759(97)00072-0; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Davies M, 1997, INT J CANCER, V73, P68, DOI 10.1002/(SICI)1097-0215(19970926)73:1<68::AID-IJC12>3.3.CO;2-D; Gift EA, 2000, CYTOMETRY, V39, P243; GRAY F, 1995, J IMMUNOL METHODS, V182, P155, DOI 10.1016/0022-1759(94)00319-R; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; JOHNSTON JB, 1995, AM J CLIN PATHOL, V103, P574; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Mossmann TR, 1987, IMMUNOL TODAY, V8, P223; Parikh I, 1974, Methods Enzymol, V34, P77; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Scheffold A, 2000, NAT MED, V6, P107, DOI 10.1038/71441; Weaver JC, 1997, NAT MED, V3, P583, DOI 10.1038/nm0597-583	18	23	39	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					373	376		10.1038/85533	http://dx.doi.org/10.1038/85533			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231640				2022-12-25	WOS:000167380400047
J	Elenitoba-Johnson, KSJ; Bohling, SD; Wittwer, CT; King, TC				Elenitoba-Johnson, KSJ; Bohling, SD; Wittwer, CT; King, TC			Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis	NATURE MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; NEAREST-NEIGHBOR THERMODYNAMICS; RESONANCE ENERGY-TRANSFER; MOLECULAR BEACONS; HYBRIDIZATION PROBES; AMPLIFICATION; PARAMETERS; MUTATION; GENE		Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA; ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Brown Univ, Lifespan Med Ctr, Providence, RI 02912 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Brown University; Brown University; Lifespan Health Rhode Island	Elenitoba-Johnson, KSJ (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA.			Elenitoba-Johnson, Kojo/0000-0002-1082-1545	NATIONAL CANCER INSTITUTE [R21CA083984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R42GM058983, R41GM058983] Funding Source: NIH RePORTER; NCI NIH HHS [CA83984] Funding Source: Medline; NIGMS NIH HHS [GM58983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGWELL CB, 1993, ANN NY ACAD SCI, V677, P167, DOI 10.1111/j.1749-6632.1993.tb38775.x; Bernard PS, 1999, ANAL BIOCHEM, V273, P221, DOI 10.1006/abio.1999.4217; Bernard PS, 1998, ANAL BIOCHEM, V255, P101, DOI 10.1006/abio.1997.2427; Bernard PS, 1998, AM J PATHOL, V153, P1055, DOI 10.1016/S0002-9440(10)65650-7; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HELLER MJ, 1985, RAPID DETECTION IDEN, P245; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; Kostrikis LG, 1998, SCIENCE, V279, P1228, DOI 10.1126/science.279.5354.1228; Kyger EM, 1998, ANAL BIOCHEM, V260, P142, DOI 10.1006/abio.1998.2687; Lay MJ, 1997, CLIN CHEM, V43, P2262; Lee LG, 1999, BIOTECHNIQUES, V27, P342, DOI 10.2144/99272rr01; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236; WETMUR JG, 1995, MOL BIOL BIOTECHNOLO, P605; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01	22	61	71	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					249	253		10.1038/84708	http://dx.doi.org/10.1038/84708			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175859				2022-12-25	WOS:000166756300045
J	Bays, NW; Gardner, RG; Seelig, LP; Joazeiro, CA; Hampton, RY				Bays, NW; Gardner, RG; Seelig, LP; Joazeiro, CA; Hampton, RY			Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation	NATURE CELL BIOLOGY			English	Article							HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; CONJUGATING ENZYMES; PROTEIN-DEGRADATION; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; DEPENDENT PROTEOLYSIS; PROTEASOME; YEAST; IDENTIFICATION; SUBSTRATE	In eukaryotes, endoplasmic reticulum-associated degradation (ERAD) functions in cellular quality control and regulation of normal ER-resident proteins. ERAD proceeds by the ubiquitin-proteasome pathway, in which the covalent attachment of ubiquitin to proteins targets them for proteasomal degradation. Ubiquitin-protein ligases (E3s) play a crucial role in this process by recognizing target proteins and initiating their ubiquitination. Here we show that Hrd1p, which is identical to Der3p, is an E3 for ERAD. Hrd1p is required for the degradation and ubiquitination of several ERAD substrates and physically associates with relevant ubiquitin-conjugating enzymes (E2s). A soluble Hrd1 fusion protein shows E3 activity in vitro - catalysing the ubiquitination of itself and test proteins. In this capacity, Hrd1p has an apparent preference for misfolded proteins. We also show that Hrd1p functions as an E3 in vivo, using only Ubc7p or Ubc1p to specifically program the ubiquitination of ERAD substrates.	Univ Calif San Diego, Dept Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Salk Institute	Hampton, RY (corresponding author), Univ Calif San Diego, Dept Biol, Sect Cell & Dev Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Gardner, Richard/0000-0003-2162-6275				Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Blackburn P, 1982, ENZYMES, VXV, P317; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Cronin SR, 1999, METHOD ENZYMOL, V302, P58, DOI 10.1016/S0076-6879(99)02010-8; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KIM JS, 1993, PROTEIN SCI, V2, P348; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; RICHARDS FM, 1958, P NATL ACAD SCI USA, V44, P162, DOI 10.1073/pnas.44.2.162; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	38	356	368	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					24	29		10.1038/35050524	http://dx.doi.org/10.1038/35050524			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146622				2022-12-25	WOS:000166146400016
J	Chawla, A; Barak, Y; Nagy, L; Liao, D; Tontonoz, P; Evans, RM				Chawla, A; Barak, Y; Nagy, L; Liao, D; Tontonoz, P; Evans, RM			PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDIZED LDL; DIFFERENTIATION; LIGAND; LIPOPROTEIN; REGULATOR; DISEASE; CULTURE	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is highly expressed in lipid-accumulating macrophages of the coronary artery. In light of this, the wide-spread clinical use of thiazolidinediones (TZDs) in the treatment of type II diabetes raises concerns about the role of PPAR-gamma in macrophage function and disease progression. To define the role of PPAR-gamma in macrophage biology, we used homologous recombination to create embryonic stem cells that were homozygous for a null mutation in the PPAR-gamma gene. We demonstrate here that PPAR-gamma is neither essential for nor substantially affects the development of the macrophage lineage both in vitro and in vivo. In contrast, we show it is an important regulator of the scavenger receptor CD36, which has been genetically linked to lipid accumulation in macrophages. Both 15-deoxy-Delta (12,14)prostaglandin J(2) and thiazolidinediones have anti-inflammatory effects that are independent of PPAR-gamma. We show that PPAR-gamma is required for positive effects of its ligands in modulating macrophage lipid metabolism, but that inhibitory effects on cytokine production and inflammation may be receptor independent.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Debrecen	Chawla, A (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	evans@salk.edu	Nagy, Laszlo/A-3814-2008	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965	NHLBI NIH HHS [T32 HL07770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rocchi S, 1999, ANN MED, V31, P342, DOI 10.3109/07853899908995901; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tontonoz P, 1999, CURR OPIN LIPIDOL, V10, P485, DOI 10.1097/00041433-199912000-00002; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TONTONOZ P, 1995, CELL, V80, P957; WILES MV, 1991, DEVELOPMENT, V111, P259	25	937	970	0	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					48	52		10.1038/83336	http://dx.doi.org/10.1038/83336			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135615				2022-12-25	WOS:000166243100034
J	Chitaley, K; Wingard, CJ; Webb, RC; Branam, H; Stopper, VS; Lewis, RW; Mills, TM				Chitaley, K; Wingard, CJ; Webb, RC; Branam, H; Stopper, VS; Lewis, RW; Mills, TM			Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE; ANDROGENIC MAINTENANCE; G-PROTEINS; MYOSIN; ENDOTHELIN-1; PHOSPHATASE; PHYSIOLOGY	Relaxation of the smooth muscle cells in the cavernosal arterioles and sinuses results in increased blood flow into the penis, raising corpus cavernosum pressure to culminate in penile erection(1). Nitric oxide, released from non-adrenergic/non-cholinergic nerves, is considered the principle stimulator of cavernosal smooth muscle relaxation(2-4), however, the inhibition of vasoconstrictors (that is, norepinephrine and endothelin-1, refs. 5-9) cannot be ignored as a potential regulator of penile erection. The calcium-sensitizing rho -A/Rho-kinase pathway may play a synergistic role in cavernosal vasoconstriction to maintain penile flaccidity. Rho-kinase is known to inhibit myosin light chain phosphatase(10-12), and to directly phosphorylate myosin light-chain (in solution), altogether resulting in a net increase in activated myosin and the promotion of cellular contraction(10,11,13-16) Although Rho-kinase protein and mRNA have been detected in cavernosal tissue(17), the role of Rho-kinase in the regulation of cavernosal tone is unknown. Using pharmacologic antagonism (Y-27632, ref. 13, 18), we examined the role of Rho-kinase in cavernosal tone, based on the hypothesis that antagonism of Rho-kinase results in increased corpus cavernosum pressure, initiating the erectile response independently of nitric oxide. Our finding, that Rho-kinase antagonism stimulates rat penile erection independently of nitric oxide, introduces a potential alternate avenue for the treatment of erectile dysfunction.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA	University of Michigan System; University of Michigan; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Chitaley, K (corresponding author), Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA.	kanchanc@umich.du	Wingard, Christopher/R-5042-2019	Wingard, Christopher/0000-0002-8251-5678	NHLBI NIH HHS [HL18575] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM0832211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anderssen B, 1997, J SOIL CONTAM, V6, P15, DOI 10.1080/15320389709383543; Ari G, 1996, EUR J PHARMACOL, V307, P69, DOI 10.1016/0014-2999(96)00172-0; BURNETT AL, 1999, HDB SEXUAL DYSFUNCTI, P12; Cellek S, 1997, P NATL ACAD SCI USA, V94, P8226, DOI 10.1073/pnas.94.15.8226; Cellek S, 2000, DRUG TODAY, V36, P135, DOI 10.1358/dot.2000.36.2-3.568787; Chang H, 2000, BIOPHYS J, V78, p137A; Dai Y, 2000, AM J PHYSIOL-REG I, V279, pR25, DOI 10.1152/ajpregu.2000.279.1.R25; Escrig A, 1999, J PHYSIOL-LONDON, V516, P261, DOI 10.1111/j.1469-7793.1999.261aa.x; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Giraldi A, 1998, J UROLOGY, V160, P1856, DOI 10.1016/S0022-5347(01)62432-7; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jarow JP, 1999, J UROLOGY, V162, P722, DOI 10.1097/00005392-199909010-00024; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mills TM, 1998, BIOL REPROD, V59, P1413, DOI 10.1095/biolreprod59.6.1413; Moody JA, 1997, J UROLOGY, V158, P942, DOI 10.1016/S0022-5347(01)64368-4; Reilly CM, 1997, J ANDROL, V18, P110; Reilly CM, 1997, J ANDROL, V18, P588; Rosselli M, 1998, HUM REPROD UPDATE, V4, P3, DOI 10.1093/humupd/4.1.3; Somlyo AP, 1998, ACTA PHYSIOL SCAND, V164, P437; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Virag R, 1999, UROLOGY, V54, P1073, DOI 10.1016/S0090-4295(99)00310-6; WEBER DS, IN PRESS PHARMACOLOG	26	258	306	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					119	122		10.1038/83258	http://dx.doi.org/10.1038/83258			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135626				2022-12-25	WOS:000166243100045
J	Zhang, K; Kniazeva, M; Han, M; Li, W; Yu, ZY; Yang, ZL; Li, Y; Metzker, ML; Allikmets, R; Zack, DJ; Kakuk, LE; Lagali, PS; Wong, PW; MacDonald, IM; Sieving, PA; Figueroa, DJ; Austin, CP; Gould, RJ; Ayyagari, R; Petrukhin, K				Zhang, K; Kniazeva, M; Han, M; Li, W; Yu, ZY; Yang, ZL; Li, Y; Metzker, ML; Allikmets, R; Zack, DJ; Kakuk, LE; Lagali, PS; Wong, PW; MacDonald, IM; Sieving, PA; Figueroa, DJ; Austin, CP; Gould, RJ; Ayyagari, R; Petrukhin, K			A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy	NATURE GENETICS			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; DISEASE GENE; ABCR; IDENTIFICATION; MEMBRANE; ACID; BIOSYNTHESIS; ELONGATION; MUTATIONS	Stargardt-like macular dystrophy (STGD3, MIM 600110) and autosomal dominant macular dystrophy (adMD) are inherited forms of macular degeneration characterized by decreased visual acuity, macular atrophy and extensive fundus flecks(1-3). Genetic mapping data suggest that mutations in a single gene may be responsible for both conditions, already known to bear clinical resemblance(1-3). Here we limit the minimum genetic region for STGD3 and adMD to a 0.6-cM interval by recombination breakpoint mapping and identify a single 5-bp deletion within the protein-coding region of a new retinal photoreceptor-specific gene, ELOVL4, in all affected members of STGD3 and adMD families. Bioinformatic analysis of ELOVL4 revealed that it has homology to a group of yeast proteins that function in the biosynthesis of Very long chain fatty acids. Our results are therefore the first to implicate the biosynthesis of fatty acids in the pathogenesis of inherited macular degeneration.	Merck Res Labs, Dept Pharmacol, W Point, PA USA; Merck Res Labs, Dept Human Genet, W Point, PA USA; Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD USA; Univ Colorado, Howard Hughes Med Inst, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Columbia Univ, Dept Ophthalmol, New York, NY USA; Columbia Univ, Dept Pathol, New York, NY USA; Univ Michigan, WK Kellogg Eye Ctr, Ann Arbor, MI 48109 USA; Univ Alberta, Dept Sci Biol, Edmonton, AB, Canada; Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada	Merck & Company; Merck & Company; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Columbia University; Columbia University; University of Michigan System; University of Michigan; University of Alberta; University of Alberta; University of Alberta	Petrukhin, K (corresponding author), Merck Res Labs, Dept Pharmacol, W Point, PA USA.		Allikmets, Rando/ABD-4533-2021; Kniazeva, Marina/D-4085-2012; Zhang, Kang/Y-2740-2019	Zhang, Kang/0000-0002-4549-1697; Petrukhin, Konstantin/0000-0002-5545-6924; MacDonald, Ian/0000-0001-7472-8385; Zack, Don/0000-0002-7966-1973	NEI NIH HHS [EY00401] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Edwards AO, 1999, AM J OPHTHALMOL, V127, P426, DOI 10.1016/S0002-9394(98)00331-6; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Griesinger IB, 2000, INVEST OPHTH VIS SCI, V41, P248; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lagali PS, 2000, CAN J OPHTHALMOL, V35, P315, DOI 10.1016/S0008-4182(00)80059-9; Luthria DL, 1996, J BIOL CHEM, V271, P16020, DOI 10.1074/jbc.271.27.16020; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sprecher H, 1995, J LIPID RES, V36, P2471; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; ZHANG K, 1994, ARCH OPHTHALMOL-CHIC, V112, P759, DOI 10.1001/archopht.1994.01090180057035	30	331	348	2	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					89	93		10.1038/83817	http://dx.doi.org/10.1038/83817			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138005				2022-12-25	WOS:000166187900022
J	Kmita, M; Kondo, T; Duboule, D				Kmita, M; Kondo, T; Duboule, D			Targeted inversion of a polar silencer within the HoxD complex re-allocates domains of enhancer sharing	NATURE GENETICS			English	Article							GENE-EXPRESSION; REGULATORY CONTROLS; COLINEARITY; MOUSE; LIMBS; MICE	Mammalian Hox genes are clustered at four genomic loci. During development, neighbouring genes are coordinately regulated by global enhancer sequences, which control multiple genes at once, as exemplified by the expression of series of contiguous Hoxd genes in either limbs or gut. The link between vertebrate Hox gene transcription and their clustered distribution is poorly understood. Experimental and comparative approaches have revealed that various mechanisms, such as gene clustering or global enhancer sequences, might have constrained this genomic organization and stabilized it throughout evolution(1-3) To understand what restricts the effect of a particular enhancer to a precise set of genes, we generated a loxP/Cre-mediated targeted inversion within the HoxD cluster. Mice carrying the inversion showed a reciprocal re-assignment of the limb versus gut regulatory specificities, suggesting the presence of a silencer element with a unidirectional property. This polar silencer appears to limit the number of genes that respond to one type of regulation and thus indicates how separate regulatory domains may be implemented within intricate gene clusters.	Univ Geneva, Dept Zool & Anim Biol, Geneva, Switzerland	University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Geneva, Switzerland.		kmita, marie/AAU-9620-2020	Kmita, Marie/0000-0003-4021-0478; duboule, denis/0000-0001-9961-2960; jin teng, long/0000-0002-1948-9331				Davis AP, 1996, DEVELOPMENT, V122, P1175; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; Dupe V, 1997, DEVELOPMENT, V124, P399; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; Goff DJ, 1997, DEVELOPMENT, V124, P627; Herault Y, 1999, DEV BIOL, V208, P157, DOI 10.1006/dbio.1998.9179; Kmita M, 2000, GENE DEV, V14, P198; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Peichel CL, 1997, DEVELOPMENT, V124, P3481; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Zakany J, 1999, NATURE, V401, P761, DOI 10.1038/44511; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	19	59	62	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					451	454		10.1038/82593	http://dx.doi.org/10.1038/82593			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101844				2022-12-25	WOS:000165671700019
J	Limmer, A; Ohl, J; Kurts, C; Ljunggren, HG; Reiss, Y; Groettrup, M; Momburg, F; Arnold, B; Knolle, PA				Limmer, A; Ohl, J; Kurts, C; Ljunggren, HG; Reiss, Y; Groettrup, M; Momburg, F; Arnold, B; Knolle, PA			Efficient presentation of exogenous antigen by liver endothelial cells to CD8(+) T cells results in antigen-specific T-cell tolerance	NATURE MEDICINE			English	Article							CLASS-I PRESENTATION; RECEPTOR-TRANSGENIC MICE; DENDRITIC CELLS; PERIPHERAL TOLERANCE; CYTOKINE PRODUCTION; INDUCTION; LYMPHOCYTES; PATHWAY; LOCALIZATION; MACROPHAGES	Myeloid antigen-presenting cells (APC) are known to cross-present exogenous antigen on major histocompatibility class I molecules to CD8(+) T cells and thereby induce protective immunity against infecting microorganisms. Here we report that liver sinusoidal endothelial cells (LSEC) are organ-resident, non-myeloid APC capable of cross-presenting soluble exogenous antigen to CD8(+) T cells. Though LSEC employ similar molecular mechanisms for cross-presentation as dendritic cells, the outcome of cross-presentation by LSEC is CD8(+) T cell tolerance rather than immunity. As uptake of circulating antigens into LSEC occurs efficiently in vivo, it is likely that cross-presentation by LSEC contributes to CD8(+) T cell tolerance observed in situations where soluble antigen is present in the circulation.	ZMBH, D-69120 Heidelberg, Germany; Med Hsch Hannover, Dept Nephrol, Hannover, Germany; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel; Cantonal Hosp St Gall, Res Dept, St Gallen, Switzerland; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Hannover Medical School; Karolinska Institutet; Tel Aviv University; Kantonsspital St. Gallen; Helmholtz Association; German Cancer Research Center (DKFZ)	Knolle, PA (corresponding author), ZMBH, D-69120 Heidelberg, Germany.			Knolle, Percy A./0000-0003-2983-0414				ASHWELL G, 1981, JAMA-J AM MED ASSOC, V246, P2358, DOI 10.1001/jama.246.20.2358; Belz GT, 1998, P NATL ACAD SCI USA, V95, P13812, DOI 10.1073/pnas.95.23.13812; Bercovici N, 1999, EUR J IMMUNOL, V29, P345, DOI 10.1002/(SICI)1521-4141(199901)29:01<345::AID-IMMU345>3.0.CO;2-K; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CALLERY MP, 1989, TRANSPLANTATION, V47, P1092; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Falb D, 1996, EUR J IMMUNOL, V26, P130, DOI 10.1002/eji.1830260120; Gorczynski L, 1999, J IMMUNOL, V162, P774; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HAMMERLING GJ, 1993, IMMUNOL REV, V133, P93, DOI 10.1111/j.1600-065X.1993.tb01511.x; HARDING CV, 1994, J IMMUNOL, V153, P4925; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; HUANG L, 1994, IMMUNITY, V1, P741, DOI 10.1016/S1074-7613(94)80016-2; KAMADA N, 1984, TRANSPLANTATION, V38, P217, DOI 10.1097/00007890-198409000-00004; Ke Y, 1996, J EXP MED, V184, P1179, DOI 10.1084/jem.184.3.1179; KINDBERG GM, 1990, BIOCHEM J, V270, P197, DOI 10.1042/bj2700197; Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; Kurts C, 1999, P NATL ACAD SCI USA, V96, P12703, DOI 10.1073/pnas.96.22.12703; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Liblau RS, 1996, P NATL ACAD SCI USA, V93, P3031, DOI 10.1073/pnas.93.7.3031; Ljunggren HG, 1996, IMMUNOL REV, V151, P123, DOI 10.1111/j.1600-065X.1996.tb00706.x; MACPHEE PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG692, DOI 10.1152/ajpgi.1995.269.5.G692; Mitchell DA, 1998, EUR J IMMUNOL, V28, P1923, DOI 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9; Morelli AE, 2000, TRANSPLANTATION, V69, P2647, DOI 10.1097/00007890-200006270-00027; O'Connell PJ, 2000, J IMMUNOL, V165, P795, DOI 10.4049/jimmunol.165.2.795; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; RUBINSTEIN D, 1986, J IMMUNOL, V137, P1803; Schwarz K, 2000, J IMMUNOL METHODS, V237, P199, DOI 10.1016/S0022-1759(99)00236-7; SCOAZEC JY, 1994, J HEPATOL, V20, P296, DOI 10.1016/S0168-8278(05)80072-8; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; Sprent J, 1999, J IMMUNOL, V163, P4629; Starzl TE, 1998, NEW ENGL J MED, V339, P1905, DOI 10.1056/NEJM199812243392607; Sun JR, 1999, J IMMUNOL, V162, P5868; Thomson AW, 1999, IMMUNOL TODAY, V20, P27, DOI 10.1016/S0167-5699(98)01378-4; Vabulas RM, 2000, J IMMUNOL, V164, P2372, DOI 10.4049/jimmunol.164.5.2372; Wong J, 1997, J CLIN INVEST, V99, P2782, DOI 10.1172/JCI119468; WOO J, 1994, TRANSPLANTATION, V58, P484, DOI 10.1097/00007890-199408270-00015; WU JY, 1994, CELL IMMUNOL, V154, P393, DOI 10.1006/cimm.1994.1086; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	45	548	571	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1348	1354		10.1038/82161	http://dx.doi.org/10.1038/82161			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100119	Green Submitted			2022-12-25	WOS:000165704100038
J	Zhang, YM; Muyrers, JPP; Testa, G; Stewart, AF				Zhang, YM; Muyrers, JPP; Testa, G; Stewart, AF			DNA cloning by homologous recombination in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article							ARTIFICIAL CHROMOSOMES; BACTERIOPHAGE-LAMBDA; REPLACEMENT		European Mol Biol Lab, Gene Express Program, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Stewart, AF (corresponding author), European Mol Biol Lab, Gene Express Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.	stewart@embl-heidelberg.de	Testa, Giuseppe/J-4572-2012; Stewart, A. Francis/E-7789-2010	Testa, Giuseppe/0000-0002-9104-0918				Angrand P O, 1999, Nucleic Acids Res, V27, pe16, DOI 10.1093/nar/27.17.e16; Baskaran K, 1997, ONCOGENE, V15, P1967, DOI 10.1038/sj.onc.1201365; Bhargava L, 1999, GENOMICS, V62, P285, DOI 10.1006/geno.1999.6000; Bradshaw MS, 1995, NUCLEIC ACIDS RES, V23, P4850, DOI 10.1093/nar/23.23.4850; CLARK AJ, 1974, GENETICS, V78, P259; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Hill F, 2000, GENOMICS, V64, P111, DOI 10.1006/geno.1999.6106; Larionov V, 1999, GENET ENG P, V21, P37; METCALF WW, 1994, GENE, V138, P1, DOI 10.1016/0378-1119(94)90776-5; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Muyrers J P, 2000, Genet Eng (N Y), V22, P77; Muyrers JPP, 2000, EMBO REP, V1, P239, DOI 10.1093/embo-reports/kvd049; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Muyrers JPP, 2000, GENE DEV, V14, P1971; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; Nefedov M, 2000, Nucleic Acids Res, V28, pE79, DOI 10.1093/nar/28.17.e79; Shashikant CS, 1998, GENE, V223, P9, DOI 10.1016/S0378-1119(98)00369-2; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	20	309	382	3	90	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1314	1317		10.1038/82449	http://dx.doi.org/10.1038/82449			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101815				2022-12-25	WOS:000165659000033
J	Richter, LJ; Thanavala, Y; Arntzen, CJ; Mason, HS				Richter, LJ; Thanavala, Y; Arntzen, CJ; Mason, HS			Production of hepatitis B surface antigen in transgenic plants for oral immunization	NATURE BIOTECHNOLOGY			English	Article						hepatitis B surface antigen; transgenic plants; edible vaccine; potato; oral vaccine; protein engineering	ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; GENE; EXPRESSION; VACCINE; PATHWAY; REGION; CELLS; LEAF; ER	Here we present data showing oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) in preclinical animal trials. Mice fed transgenic HBsAS potato tubers showed a primary immune response (increases in HBsAg-specific serum antibody) that could be greatly boosted by intraperitoneal delivery of a single subimmunogenic dose of commercial HBsAS vaccine, indicating that plants expressing HBsAg in edible tissues may be a new means for oral hepatitis B immunization. However, attainment of such a goal will require higher HBsAS expression than was observed for the potatoes used in this study. We conducted a systematic analysis of factors influencing the accumulation of HBsAg in transgenic potato, including 5' and 3' flanking elements and protein targeting within plant cells. The most striking improvements resulted from (1) alternative polyadenylation signals, and (2) fusion proteins containing targeting signals designed to enhance integration or retention of HBsAS in the endoplasmic reticulum (ER) of plant cells.	Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Cornell University; Boyce Thompson Institute for Plant Research; Roswell Park Cancer Institute	Mason, HS (corresponding author), Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.		Richter, Lee/N-7730-2016	Richter, Lee/0000-0002-9433-3724; Mason, Hugh/0000-0002-0192-6716	NIAID NIH HHS [AI42836] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042836] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIZPURUA HJ, 1988, J EXP MED, V167, P440; AN GH, 1989, PLANT CELL, V1, P115, DOI 10.1105/tpc.1.1.115; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BEDNAREK SY, 1992, PLANT MOL BIOL, V20, P133, DOI 10.1007/BF00029156; Bruss V, 1996, INTERVIROLOGY, V39, P23, DOI 10.1159/000150471; Chan MT, 1998, P NATL ACAD SCI USA, V95, P6543, DOI 10.1073/pnas.95.11.6543; DEWALD D, 1992, THESIS TEXAS A M U; Dogan B, 2000, BIOTECHNOL PROGR, V16, P435, DOI 10.1021/bp0000454; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; Florence A.T, 1993, DRUGS PHARM SCI, P65; Gomord V, 1997, PLANT J, V11, P313, DOI 10.1046/j.1365-313X.1997.11020313.x; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; JEFFERSON RA, 1987, EMBO J, V6, P3901; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Muraskin William, 1995, WAR HEPATITIS B HIST; MURRAY K, 1984, EMBO J, V3, P645, DOI 10.1002/j.1460-2075.1984.tb01861.x; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; Neuhaus JM, 1998, PLANT MOL BIOL, V38, P127, DOI 10.1023/A:1006032627036; Prevelige PE, 1998, TRENDS BIOTECHNOL, V16, P61, DOI 10.1016/S0167-7799(97)01154-2; SUH SG, 1991, PLANTA, V184, P423, DOI 10.1007/BF00197888; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; WAMPLER DE, 1985, P NATL ACAD SCI USA, V82, P6830, DOI 10.1073/pnas.82.20.6830; WANDELT CI, 1992, PLANT J, V2, P181; WENZLER HC, 1989, PLANT MOL BIOL, V12, P41, DOI 10.1007/BF00017446; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; 1991, MORBIDITY MORTALITY, V40, P1	30	308	378	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1167	1171		10.1038/81153	http://dx.doi.org/10.1038/81153			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062435				2022-12-25	WOS:000165176600021
J	Ehrhard, KN; Jacoby, JJ; Fu, XY; Jahn, R; Dohlman, HG				Ehrhard, KN; Jacoby, JJ; Fu, XY; Jahn, R; Dohlman, HG			Use of G-protein fusions to monitor integral membrane protein-protein interactions in yeast	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR RECEPTOR-3; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ACTIVATING MUTATIONS; SPLIT-UBIQUITIN; GENETIC SYSTEM; FIBROBLAST; IDENTIFICATION; STRAINS	The control of protein-protein interactions is a fundamental aspect of cell regulation. Here we describe a new approach to detect the interaction of two proteins in vivo. By this method, one binding partner is an integral membrane protein whereas the other is soluble but fused to a G-protein gamma-subunit. If the binding partners interact, G-protein signaling is disrupted. We demonstrate interaction between known binding partners, syntaxin 1a with neuronal Sec1 (nSec1), and the fibroblast-derived growth factor receptor 3 (FGFR3) with SNT-1. In addition, we describe a genetic screen to identify nSec1 mutants that are expressed normally, but are no longer able to bind to syntaxin la. This provides a convenient method to study interactions of integral membrane proteins, a class of molecules that has been difficult to study by existing biochemical or genetic methods.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06536 USA	Yale University; Yale University	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Jahn, Reinhard/0000-0003-1542-3498; Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM55316, R01 GM055316, GM59167, T32-GM07324, R01 GM059167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, T32GM007324, R29GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bai C, 1996, METHOD ENZYMOL, V273, P331; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hallett M, 1999, NEW ENGL J MED, V341, P118, DOI 10.1056/NEJM199907083410209; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rossi FMV, 2000, TRENDS CELL BIOL, V10, P119, DOI 10.1016/S0962-8924(99)01707-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; STAPLES RR, 1993, GENETICS, V135, P981; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Walkenhorst J, 1996, ONCOGENE, V12, P1513; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	32	57	61	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1075	1079		10.1038/80274	http://dx.doi.org/10.1038/80274			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017046	Green Published			2022-12-25	WOS:000089744700030
J	Lamartine, J; Essenfelder, GM; Kibar, Z; Lanneluc, I; Callouet, E; Laoudj, D; Lemaitre, G; Hand, C; Hayflick, SJ; Zonana, J; Antonarakis, S; Radhakrishna, U; Kelsell, DP; Christianson, AL; Pitaval, A; Der Kaloustian, V; Fraser, C; Blanchet-Bardon, C; Rouleau, GA; Waksman, G				Lamartine, J; Essenfelder, GM; Kibar, Z; Lanneluc, I; Callouet, E; Laoudj, D; Lemaitre, G; Hand, C; Hayflick, SJ; Zonana, J; Antonarakis, S; Radhakrishna, U; Kelsell, DP; Christianson, AL; Pitaval, A; Der Kaloustian, V; Fraser, C; Blanchet-Bardon, C; Rouleau, GA; Waksman, G			Mutations in GJB6 cause hidrotic ectodermal dysplasia	NATURE GENETICS			English	Article							SENSORINEURAL DEAFNESS; DOMINANT DEAFNESS; GENE		Univ Evry, CEA, Lab Genom & Radiobiol Keratinocyte, Serv Genom Fonct,Dept Radiobiol & Radiopathol, Evry, France; McGill Univ, Ctr Res Neurosci, Montreal, PQ H3A 2T5, Canada; Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; Genethon, Evry, France; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Geneva, Switzerland; St Bartholomews & Royal London Hosp, Ctr Cutaneous Res, London, England; Univ Pretoria, Fac Med, Dept Human Genet & Dev Biol, ZA-0002 Pretoria, South Africa; Montreal Childrens Hosp, Div Med Genet, F Clarke Fraser Clin Genet Unit, Montreal, PQ H3H 1P3, Canada; Hop St Louis, Inst Rech Peau, Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; McGill University; McGill University; Oregon Health & Science University; University of Geneva; University of Geneva; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of Pretoria; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Waksman, G (corresponding author), Univ Evry, CEA, Lab Genom & Radiobiol Keratinocyte, Serv Genom Fonct,Dept Radiobiol & Radiopathol, EA 2541, Evry, France.		Antonarakis, Stylianos E/N-8866-2014; Lemaître, Gilles/AAL-5889-2021; Kelsell, David P/F-8767-2011; Hand, Collette/GRY-7269-2022; Lanneluc, Isabelle/N-6646-2014	Antonarakis, Stylianos E/0000-0001-8907-5823; Lemaitre, Gilles/0000-0002-0898-1582; Kelsell, David/0000-0002-9910-7144; PITAVAL, Amandine/0000-0002-0279-2553; Hand, Collette/0000-0003-2348-5058; Lamartine, Jerome/0000-0003-2322-1618; Lanneluc, Isabelle/0000-0002-7268-3950				ANDO Y, 1988, DERMATOLOGICA, V176, P205, DOI 10.1159/000248705; Clouston HR, 1929, CAN MED ASSOC J, V21, P18; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Grifa A, 1999, NAT GENET, V23, P16, DOI 10.1038/12612; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kibar Z, 2000, EUR J HUM GENET, V8, P372, DOI 10.1038/sj.ejhg.5200471; Kibar Z, 1996, HUM MOL GENET, V5, P543, DOI 10.1093/hmg/5.4.543; Lamartine J, 2000, BRIT J DERMATOL, V142, P248, DOI 10.1046/j.1365-2133.2000.03292.x; Lamartine J, 2000, GENOMICS, V67, P232, DOI 10.1006/geno.2000.6202; Maestrini E, 1999, HUM MOL GENET, V8, P1237, DOI 10.1093/hmg/8.7.1237; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; WOROBECVICTOR SM, 1988, PEDIAT DERMATOLOGY, P328; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	15	177	192	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					142	144		10.1038/79851	http://dx.doi.org/10.1038/79851			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017065				2022-12-25	WOS:000089638800007
J	Ioshikhes, IP; Zhang, MQ				Ioshikhes, IP; Zhang, MQ			Large-scale human promoter mapping using CpG islands	NATURE GENETICS			English	Article							DNA METHYLATION; HUMAN GENOME; BIOLOGY; REGIONS; CANCER; GENES	Vertebrate genomic DNA is generally CpG depleted(1,2), possibly because methylation of cytosines at 80% of CpG dinucleotides results in their frequent mutation to thymine. and thus CpG to TpG dinucleotides(3). There are, however, genomic regions of high G+C content (CpG islands), where the occurrence of CpGs is significantly higher, close to the expected frequency, whereas the methylation concentration is significantly lower than the overall genome(4). CpG islands(5) are longer than 200 bp and have over 50% of G+C content and CpG frequency, at least 0.6 of that statistically expected. Approximately 50% of mammalian gene promoters are associated with one or more CpG islands(6). Although biologists often intuitively use CpG islands for 5' gene identification(7,8). this has not been rigorously quantified(9). We have determined the features that discriminate the promoter-associated and non-associated CpG islands. This led to an effective algorithm for large-scale promoter mapping (with 2kb resolution) with a concentration of false-positive predictions of promoters much lower than previously obtained. Using this algorithm, we correctly discriminated approximately 85% of the CpG islands within an interval (-500 to +1500) around a transcriptional start site (TSS) from those that lie further away from TSSs. We also correctly mapped approximately 93% of the promoters containing CpG islands.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Zhang, MQ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01696] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MCLACHLAN GJ, 1994, DISCRIMINANT ANAL ST; Pedersen AG, 1999, COMPUT CHEM, V23, P191, DOI 10.1016/S0097-8485(99)00015-7; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; VENABLES WN, 1994, MOD APPL STAT S PLUS; Zhang M Q, 1998, Pac Symp Biocomput, P240; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565	22	206	213	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					61	63		10.1038/79189	http://dx.doi.org/10.1038/79189			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973249				2022-12-25	WOS:000089078000018
J	Minamide, LS; Striegl, AM; Boyle, JA; Meberg, PJ; Bamburg, JR				Minamide, LS; Striegl, AM; Boyle, JA; Meberg, PJ; Bamburg, JR			Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function	NATURE CELL BIOLOGY			English	Article							DEPOLYMERIZING FACTOR; OXIDATIVE STRESS; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; COFILIN PHOSPHORYLATION; BINDING-PROTEINS; HIRANO BODIES; AGED RATS; BRAIN; DYNAMICS	Inclusions containing actin-depolymerizing factor (ADF) and cofilin, abundant proteins in adult human brain, are prominent in hippocampal and cortical neurites of the post-mortem brains of Alzheimer's patients, especially in neurites contacting amyloid deposits. The origin and role of these inclusions in neurodegeneration are, however unknown. Here we show that mediators of neurodegeneration induce the vapid formation of transient or persistent rod-like inclusions containing ADF/cofilin and actin in axons and dendrites of cultured hippocampal neurons. Rods form spontaneously within neurons overexpressing active ADF/cofilin, suggesting that the activation (by dephosphorylation) of ADF/cofilin that occurs in response to neurodegenerative stimuli is sufficient to induce rod formation. Persistent rods that span the diameter of the neurite disrupt microtubules and cause degeneration of the distal neurite without killing the neuron. These findings suggest a common pathway that can lead to loss of synapses.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Mol Cellular & Integrat Neurosci Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Bamburg, JR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	jbamburg@lamar.colostate.edu			NIGMS NIH HHS [GM54004, R01 GM035126, GM35126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035126, R01GM054004] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BEHJ C, 1994, CEL, V77, P817; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BERSHADSKY AD, 1980, EXP CELL RES, V127, P421, DOI 10.1016/0014-4827(80)90446-2; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; FELDMAN ML, 1972, J NEUROCYTOL, V1, P109, DOI 10.1007/BF01099179; FUKUN Y, 1979, EXP CELL RES, V120, P452; Grondahl TO, 1998, BRAIN RES, V796, P125, DOI 10.1016/S0006-8993(98)00279-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall GF, 2000, J CELL SCI, V113, P1373; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HIRANO A, 1994, NEUROPATH APPL NEURO, V20, P3, DOI 10.1111/j.1365-2990.1994.tb00951.x; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; MACIVER SK, 1995, NEUROREPORT, V6, P1985, DOI 10.1097/00001756-199510010-00008; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MATTSON MP, 1988, INT J DEV NEUROSCI, V6, P439, DOI 10.1016/0736-5748(88)90050-0; McGough A, 1999, J MOL BIOL, V291, P513, DOI 10.1006/jmbi.1999.2968; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Meberg PJ, 2000, J NEUROSCI, V20, P2459; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; Rao A, 1998, J NEUROSCI, V18, P1217; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; Richardson J S, 1997, Ann N Y Acad Sci, V826, P437, DOI 10.1111/j.1749-6632.1997.tb48499.x; RUDELLI RD, 1984, ACTA NEUROPATHOL, V64, P273, DOI 10.1007/BF00690393; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; Velasco ME, 1998, BRAIN RES, V813, P329, DOI 10.1016/S0006-8993(98)01034-8; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	50	280	292	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					628	636		10.1038/35023579	http://dx.doi.org/10.1038/35023579			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980704				2022-12-25	WOS:000089250600015
J	Nair, SK; Heiser, A; Boczkowski, D; Majumdar, A; Naoe, M; Lebkowski, JS; Vieweg, J; Gilboa, E				Nair, SK; Heiser, A; Boczkowski, D; Majumdar, A; Naoe, M; Lebkowski, JS; Vieweg, J; Gilboa, E			Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.	NATURE MEDICINE			English	Article							CATALYTIC SUBUNIT GENE; IN-VITRO; LYMPHOCYTE RESPONSES; MOUSE TELOMERASE; ANTIGEN; EPITOPES; CANCER; LENGTH; IMMUNODOMINANCE; IMMUNOTHERAPY	The polypeptide component of telomerase (TERT) is an attractive candidate for a broadly expressed tumor rejection antigen because telomerase is silent in normal tissues but is reactivated in more than 85% of cancers. Here we show that immunization against TERT induces immunity against tumors of unrelated origin. Immunization of mice with TERT RNA-transfected dendritic cells (DC) stimulated cytotoxic T lymphocytes (CTL), which lysed melanoma and thymoma tumor cells and inhibited the growth of three unrelated tumors in mice of distinct genetic backgrounds. TERT RNA-transfected human DC stimulated TERT-specific CTL in vitro that lysed human tumor cells, including Epstein Barr virus (EBV)-transformed B cells as well as autologous tumor targets from patients with renal and prostate cancer. Tumor RNA-transfected DC were used as surrogate targets in the CTL assays, obviating the difficulties in obtaining tumor cells from cancer patients. In one instance, where a tumor cell line was successfully established in culture from a patient with renal cancer, the patient's tumor cells were efficiently lysed by the CTL. Immunization with tumor RNA was generally more effective than immunization with TERT RNA, suggesting that an optimal immunization protocol may have to include TERT as well as additional tumor antigens.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Div Urol, Durham, NC 27710 USA; Geron Corp, Menlo Park, CA 94025 USA	Duke University; Duke University; Geron Corporation	Gilboa, E (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.		Heiser, Axel/W-4473-2019; Nair, Smita/GYR-2993-2022; Nair Jain, Smita/M-2765-2018	Heiser, Axel/0000-0003-0389-6132; Nair, Smita/0000-0001-5615-7056; Nair Jain, Smita/0000-0002-1542-9913				Ashley DM, 1997, J EXP MED, V186, P1177, DOI 10.1084/jem.186.7.1177; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boczkowski D, 2000, CANCER RES, V60, P1028; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Chen YJ, 1998, J IMMUNOL, V160, P2425; Coveney E, 1996, SURGERY, V120, P265, DOI 10.1016/S0039-6060(96)80297-2; DeKernion J B, 1974, Urology, V4, P63, DOI 10.1016/0090-4295(74)90110-1; Fu TM, 1997, J VIROL, V71, P2715, DOI 10.1128/JVI.71.4.2715-2721.1997; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hodes RJ, 1999, J EXP MED, V190, P153, DOI 10.1084/jem.190.2.153; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYLIN LM, 1995, J VIROL, V69, P6665, DOI 10.1128/JVI.69.11.6665-6677.1995; Nair SK, 1999, INT J CANCER, V82, P121, DOI 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Oukka M, 1996, J IMMUNOL, V157, P3039; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ramakrishnan S, 1998, CANCER RES, V58, P622; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; VanWaes C, 1996, TISSUE ANTIGENS, V47, P399; VOLGMANN T, 1989, J IMMUNOL METHODS, V119, P45, DOI 10.1016/0022-1759(89)90379-7; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weidt G, 1998, J IMMUNOL, V160, P2923; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	42	304	368	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1011	1017		10.1038/79519	http://dx.doi.org/10.1038/79519			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973321				2022-12-25	WOS:000089190500033
J	Wakamatsu, N; Yamada, Y; Yamada, K; Ono, T; Nomura, N; Taniguchi, H; Kitoh, H; Mutoh, N; Yamanaka, T; Mushiake, K; Kato, K; Sonta, S; Nagaya, M				Wakamatsu, N; Yamada, Y; Yamada, K; Ono, T; Nomura, N; Taniguchi, H; Kitoh, H; Mutoh, N; Yamanaka, T; Mushiake, K; Kato, K; Sonta, S; Nagaya, M			Mutations in SIP1, encoding Smad interacting protein-1, cause a form of Hirschsprung disease	NATURE GENETICS			English	Article							GOLDBERG-SHPRINTZEN-SYNDROME; MENTAL-RETARDATION; UNUSUAL FACE; FAMILY	Hirschsprung disease (HSCR) is sometimes associated with a set of characteristics including mental retardation, microcephaly, and distinct facial features(1-3), but the gene mutated in this condition has not yet been identified. Here we report that mutations in SIP1, encoding Smad interacting protein-1, cause disease in a series of cases. SIP1 is located in the deleted segment at 2q22 from a patient with a de novo t(2;13)(q22;q22) translocation, SIP1 seems to have crucial roles in normal embryonic neural and neural crest development.	Aichi Human Serv Ctr, Cent Hosp, Dept Genet, Inst Dev Res, Aichi, Japan; Aichi Human Serv Ctr, Cent Hosp, Dept Biochem, Inst Dev Res, Aichi, Japan; Aichi Human Serv Ctr, Cent Hosp, Dept Pediat, Aichi, Japan; Aichi Human Serv Ctr, Cent Hosp, Dept Pediat Surg, Aichi, Japan; Toki Gen Hosp, Dept Pediat, Gifu, Japan		Wakamatsu, N (corresponding author), Aichi Human Serv Ctr, Cent Hosp, Dept Genet, Inst Dev Res, Aichi, Japan.		Kitoh, Hiroshi/AAC-2093-2021; KITOH, Hiroshi/I-7256-2014; Ono, Takao/C-6065-2017	Ono, Takao/0000-0002-0498-8293; Nobuaki, Wakamatsu/0000-0003-1956-8977; Yamada, Kenichiro/0000-0003-0486-284X; Wakamatsu, Nobuaki/0000-0001-5693-2227				Brooks AS, 1999, J MED GENET, V36, P485; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Fryer AE, 1998, CLIN DYSMORPHOL, V7, P97, DOI 10.1097/00019605-199804000-00003; GOLDBERG RB, 1981, J CRAN GENET DEV BIO, V1, P185; HALAL F, 1990, AM J MED GENET, V37, P106, DOI 10.1002/ajmg.1320370125; Hofstra RMW, 1999, AM J HUM GENET, V64, P304, DOI 10.1086/302184; HURST JA, 1988, J MED GENET, V25, P494, DOI 10.1136/jmg.25.7.494; KUMASAKA K, 1988, AM J MED GENET, V31, P465, DOI 10.1002/ajmg.1320310227; Lurie I. W., 1994, Genetic Counseling, V5, P11; Mowat DR, 1998, J MED GENET, V35, P617, DOI 10.1136/jmg.35.8.617; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; TANAKA H, 1993, PEDIATR NEUROL, V9, P479, DOI 10.1016/0887-8994(93)90029-C; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YOMO A, 1991, AM J MED GENET, V41, P188, DOI 10.1002/ajmg.1320410211	15	235	243	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					369	370		10.1038/86860	http://dx.doi.org/10.1038/86860			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279515				2022-12-25	WOS:000167811200008
J	Bejaoui, K; Wu, CY; Sheffler, MD; Haan, G; Ashby, P; Wu, LC; de Jong, P; Brown, RH				Bejaoui, K; Wu, CY; Sheffler, MD; Haan, G; Ashby, P; Wu, LC; de Jong, P; Brown, RH			SPTLC1 is mutated in hereditary sensory neuropathy, type 1	NATURE GENETICS			English	Letter							SPHINGOLIPID SYNTHESIS; AUTONOMIC NEUROPATHY; GENE; FAMILY; LINKAGE; ENZYME; MOTOR	Hereditary sensory neuropathy type 1 (HSN1, MIM 162400; ref. 1) genetically maps to chromosome 9q22 (refs. 2-4). We report here that the gene encoding a sub-unit of serine palmitoyltransferase is located within the HSN1 locus, expressed in dorsal root ganglia (DRG) and mutated in HSN1.	Massachusetts Gen Hosp E, CB Day Lab Neuromuscular Res, Charlestown, MA USA; Toronto Western Hosp, Neuromuscular Clin, Toronto, ON M5T 2S8, Canada; Pfizer Lab Mol Genet, Alameda, CA USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Pfizer	Brown, RH (corresponding author), Massachusetts Gen Hosp E, CB Day Lab Neuromuscular Res, Charlestown, MA USA.							Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Auer-Grumbach M, 2000, NEUROLOGY, V54, P45, DOI 10.1212/WNL.54.1.45; Bejaoui K, 1999, NEUROLOGY, V52, P510, DOI 10.1212/WNL.52.3.510; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; Dubourg O, 2000, MUSCLE NERVE, V23, P1508, DOI 10.1002/1097-4598(200010)23:10<1508::AID-MUS6>3.0.CO;2-D; Dyck P. J., 1993, PERIPHERAL NEUROPATH, V3rd, P1065; Ferdinandusse S, 2000, NAT GENET, V24, P188, DOI 10.1038/72861; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; JESTICO JV, 1985, J NEUROL NEUROSUR PS, V48, P1259, DOI 10.1136/jnnp.48.12.1259; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KWON JM, 1995, AM J HUM GENET, V57, P853; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; Nicholson GA, 1996, NAT GENET, V13, P101, DOI 10.1038/ng0596-101; SARAIVA MJM, 1983, T ASSOC AM PHYSICIAN, V96, P261; Shivji ZM, 1999, MUSCLE NERVE, V22, P1283, DOI 10.1002/(SICI)1097-4598(199909)22:9<1283::AID-MUS19>3.0.CO;2-#; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x	18	211	220	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					261	262		10.1038/85817	http://dx.doi.org/10.1038/85817			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242106				2022-12-25	WOS:000167304200016
J	Chen, K; Aradi, I; Thon, N; Eghbal-Ahmadi, M; Baram, TZ; Soltesz, I				Chen, K; Aradi, I; Thon, N; Eghbal-Ahmadi, M; Baram, TZ; Soltesz, I			Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; HYPERPOLARIZATION-ACTIVATED CURRENT; CA1 PYRAMIDAL NEURONS; CURRENT I-H; PACEMAKER CHANNELS; GUINEA-PIG; HIPPOCAMPAL-NEURONS; GABA(A) RECEPTORS; DEVELOPING BRAIN; INCREASED NUMBER	Febrile seizures are the most common type of developmental seizures, affecting up to 5% of children. Experimental complex febrile seizures involving the immature rat hippocampus led to a persistent lowering of seizure threshold despite an upregulation of inhibition. Here we provide a mechanistic resolution to this paradox by showing that, in the hippocampus of rats that had febrile seizures, the long-lasting enhancement of the widely expressed intrinsic: membrane conductance I-h converts the potentiated synaptic inhibition to hyperexcitability in a frequency-dependent manner. The altered gain of this molecular inhibition-excitation converter reveals a new mechanism for controlling the balance of excitation-inhibition in the limbic system. In addition, here we show for the first time that h-channels are modified in a human neurological disease paradigm.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.		Thon, Niklas/AAI-9069-2021; Baram, Tallie Z/J-6447-2014	Thon, Niklas/0000-0003-0011-5281; 	NINDS NIH HHS [R01 NS035439, NS35439, R37 NS035439, NS38580, R01 NS038580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035439, R01NS038580, R37NS035439] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aradi I, 1999, J COMPUT NEUROSCI, V6, P215, DOI 10.1023/A:1008801821784; Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; BOSMITH RE, 1993, BRIT J PHARMACOL, V110, P343, DOI 10.1111/j.1476-5381.1993.tb13815.x; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Hines M, 1995, HDB BRAIN THEORY NEU, P226; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Holmes GL, 1998, NEURON, V21, P1231, DOI 10.1016/S0896-6273(00)80642-X; Krause M, 2000, NEUROPHARMACOLOGY, V39, P1274, DOI 10.1016/S0028-3908(99)00227-0; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Luthi A, 1999, NAT NEUROSCI, V2, P634, DOI 10.1038/10189; MACCAFERRI G, 1993, J NEUROPHYSIOL, V69, P2129, DOI 10.1152/jn.1993.69.6.2129; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Magee JC, 1998, J NEUROSCI, V18, P7613; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; NUMANN RE, 1987, J PHYSIOL-LONDON, V393, P331, DOI 10.1113/jphysiol.1987.sp016826; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Shinnar S, 1998, ANN NEUROL, V43, P411, DOI 10.1002/ana.410430402; Siegelbaum SA, 2000, NAT NEUROSCI, V3, P101, DOI 10.1038/72038; SMITH RL, 1995, J NEUROSCI, V15, P4057; SOLTESZ I, 1991, J PHYSIOL-LONDON, V441, P175, DOI 10.1113/jphysiol.1991.sp018745; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; SPRUSTON N, 1992, J NEUROPHYSIOL, V67, P508, DOI 10.1152/jn.1992.67.3.508; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; Villeneuve N, 2000, ANN NEUROL, V47, P729, DOI 10.1002/1531-8249(200006)47:6<729::AID-ANA5>3.3.CO;2-3; Walker MC, 1999, NAT MED, V5, P871, DOI 10.1038/11308	45	366	374	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					331	337		10.1038/85480	http://dx.doi.org/10.1038/85480			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231632	Green Accepted, Green Published			2022-12-25	WOS:000167380400039
J	Wang, N; Chintala, SK; Fini, ME; Schuman, JS				Wang, N; Chintala, SK; Fini, ME; Schuman, JS			Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype	NATURE MEDICINE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; TRABECULAR MESHWORK; ADHESION MOLECULES; MATRIX-METALLOPROTEINASE; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; INTERLEUKIN-1; BIOLOGY	The glaucomas are a group of optic neuropathies comprising the leading cause of irreversible blindness worldwide. Elevated intraocular pressure due to a reduction in normal aqueous outflow is a major causal risk factor. We found that endothelial leukocyte adhesion molecule-1 (ELAM-1), the earliest marker for the atherosclerotic plaque in the vasculature, was consistently present on trabecular meshwork (TM) cells in the outflow pathways of eyes with glaucomas of diverse etiology. We determined expression of ELAM-1 to be controlled by activation of an interleukin-1 (IL-1) autocrine feedback loop through transcription factor NF-kappaB, and activity of this signaling pathway was shown to protect TM cells against oxidative stress. These findings characterize a protective stress response specific to the eye's aqueous outflow pathways and provide the first known diagnostic indicator of glaucomatous TM cells. They further indicate that common mechanisms contribute to the pathophysiology of the glaucomas and vascular diseases.	Tufts Univ, Sch Med, New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Schuman, JS (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA.	jss@mediaone.net	Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019	Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766	NEI NIH HHS [EY09828, R01 EY009828-08, R01 EY009828] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009828] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexander JP, 1998, CURR EYE RES, V17, P276, DOI 10.1076/ceyr.17.3.276.5219; Bacon AS, 1998, INVEST OPHTH VIS SCI, V39, P322; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUERLE PA, 1988, SCIENCE, V242, P540; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cook JR, 1999, INVEST OPHTH VIS SCI, V40, P3122; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DUNN CJ, 1991, CYTOKINES INFLAMMATI, P1; EPSTEIN DL, 1996, CHANDLER GRANTS GLAU, P18; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; Flammer J, 1999, J GLAUCOMA, V8, P212; FOETS B, 1992, GRAEF ARCH CLIN EXP, V230, P269, DOI 10.1007/BF00176303; Gimbrone MA, 1997, J CLIN INVEST, V99, P1809, DOI 10.1172/JCI119346; GRANT WM, 1963, ARCH OPHTHALMOL-CHIC, V69, P783; GREEN K, 1995, OPHTHALMIC RES, V27, P143, DOI 10.1159/000267860; Itoh H, 1999, DIABETES RES CLIN PR, V45, P83, DOI 10.1016/S0168-8227(99)00035-2; KAWA JE, 1993, EXP EYE RES, V14, P560; Kee C, 1997, J GLAUCOMA, V6, P246; Krohn J, 1999, ACTA OPHTHALMOL SCAN, V77, P9, DOI 10.1034/j.1600-0420.1999.770102.x; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; LUTJENDRECOLL E, 1986, EXP EYE RES, V42, P443, DOI 10.1016/0014-4835(86)90004-7; LYNCH MG, 1987, OPHTHALMOLOGY, V94, P851; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Pappa A, 1997, CLIN EXP IMMUNOL, V108, P309, DOI 10.1046/j.1365-2249.1997.3621258.x; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; Petruzzelli L, 1999, AM J MED, V106, P467, DOI 10.1016/S0002-9343(99)00058-3; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Price DT, 1999, AM J MED, V107, P85, DOI 10.1016/S0002-9343(99)00153-9; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUMAN JS, 1994, INT CONGR SER, V1068, P47; SCHUMAN JS, 1995, EXP EYE RES, V61, P609, DOI 10.1016/S0014-4835(05)80054-5; TRIPATHI RC, 1971, EXP EYE RES, V11, P116, DOI 10.1016/S0014-4835(71)80073-8; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WHITCUP SM, 1992, INVEST OPHTH VIS SCI, V33, P2626; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838	42	198	207	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					304	309		10.1038/85446	http://dx.doi.org/10.1038/85446			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231628	Green Accepted			2022-12-25	WOS:000167380400035
J	Casares, S; Stan, AC; Bona, CA; Brumeanu, TD				Casares, S; Stan, AC; Bona, CA; Brumeanu, TD			Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MI-IC II-peptide chimera	NATURE BIOTECHNOLOGY			English	Article						CD4 T cells; MHC class II-peptide chimera; doxorubicin; T-cell downregulation	MHC CLASS-II; ADRIAMYCIN; TOLERANCE; DRUG; RECOGNITION; INDUCTION; COMPLEXES; KINETICS	As the number of drugs with potential therapeutic use for T-cell-mediated diseases increases, there is a need to find methods of delivering such drugs to T cells. The major histocompatibility complex (MHC)-peptide complexes are the only antigen-specific ligands for the T-cell receptor (TCR) expressed on T cells, and they may be an appropriate drug delivery system. We engineered a soluble bivalent MHC class Ii-peptide chimera on the immunoglobulin scaffold (I-E(d)alpha beta /Fc gamma 2a/HA110-120, DEF) that binds stably and specifically to CD4 T cells recognizing the HA110-120 peptide. Doxorubicin, a powerful antimitogenic anthracycline, was enzymatically assembled on the galactose residues of a DEF chimera. The DEF-gal-Dox construct preserved both the binding capacity to hemagglutinin (HA)-specific T cells, and the drug toxicity. Brief exposure of HA-specific T cells to DEF-gal-Dox construct in vitro was followed by drug internalization in the lysosomes, translocation to the nucleus, and apoptosis. Administration of DEF-gal-Dox to mice expressing the TCR-HA transgene reduced the frequency of TCR-HA T cells in the spleen and thymus by 27% and 42%, and inhibited HA proliferative capacity by 40% and 60%, respectively. It has not been demonstrated previously that pharmacologically active drugs able to modulate T-cell functions can be delivered to T cells in an antigen-specific manner by soluble, bivalent MHC II-peptide chimeras.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Hannover Med Sch, Inst Neuropathol, D-30625 Hannover, Germany	Icahn School of Medicine at Mount Sinai; Hannover Medical School	Brumeanu, TD (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	brumet01@doc.mssm.edu	Stan, Alexandru/W-9301-2019; Brumeanu, Teodor/AAB-1965-2020		NIDDK NIH HHS [1R41-DK54461-01A1, 1R55-DK55744] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK055744] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEGRE ML, 1995, DIGEST DIS SCI, V40, P58, DOI 10.1007/BF02063942; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; Bour-Dill C, 2000, CYTOMETRY, V39, P16, DOI 10.1002/(SICI)1097-0320(20000101)39:1<16::AID-CYTO4>3.0.CO;2-I; BRUMEANU TD, 1995, J IMMUNOL METHODS, V183, P185, DOI 10.1016/0022-1759(95)00092-O; Casares S, 1997, PROTEIN ENG, V10, P1295, DOI 10.1093/protein/10.11.1295; Casares S, 1999, J EXP MED, V190, P543, DOI 10.1084/jem.190.4.543; CLARK BR, 1994, J BIOL CHEM, V269, P94; GOLDMAN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P254, DOI 10.1016/0005-2736(78)90251-1; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hong JC, 2000, SEMIN NEPHROL, V20, P108; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; Nagler-Anderson C, 2000, CRIT REV IMMUNOL, V20, P103; Nihira SI, 1996, EUR J IMMUNOL, V26, P1736, DOI 10.1002/eji.1830260811; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; Sissi C, 1999, P NATL ACAD SCI USA, V96, P10643, DOI 10.1073/pnas.96.19.10643; Spack EG, 1995, J AUTOIMMUN, V8, P787, DOI 10.1016/S0896-8411(95)80018-2; Stan AC, 1999, ANTICANCER RES, V19, P941; Stan AC, 1999, CANCER RES, V59, P115; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TRITTON TR, 1991, PHARMACOL THERAPEUT, V49, P293, DOI 10.1016/0163-7258(91)90060-Y; Wang E, 2000, J CELL PHYSIOL, V184, P263, DOI 10.1002/1097-4652(200008)184:2<263::AID-JCP15>3.0.CO;2-F; Wang H, 1997, BIOCHEM BIOPH RES CO, V237, P217, DOI 10.1006/bbrc.1997.7115; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	29	18	40	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					142	147		10.1038/84404	http://dx.doi.org/10.1038/84404			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175728				2022-12-25	WOS:000166754700020
J	Jones, SM; Kazlauskas, A				Jones, SM; Kazlauskas, A			Growth-factor-dependent mitogenesis requires two distinct phases of signalling	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE MACHINERY; RESTRICTION POINT; RAS ACTIVITY; C-MYC; COOPERATING ONCOGENES; INHIBITOR P27(KIP1); EMBRYO FIBROBLASTS; 3T3 CELLS; PROLIFERATION; PROGRESSION	Prolonged and continuous exposure to growth factors is required to commit cells to the cell cycle. Here we show that the prolonged requirement for growth factor can be replaced with two short pulses of mitogen. The first pulse of growth factor moves the cell through the initial segment of the GO to S interval. This initial pulse also makes cells responsive to a second pulse of growth factor, which engages components of the cell-cycle machinery necessary for progression into S phase. We also show that activation of MAP kinase kinase (MEK) and induction of the transcription factor c-Myc are sufficient to drive the first, but not the second, phase of signalling. Furthermore, synthetic phosphatidylinositol-3-OH kinase (Pi(3)K) lipid products are sufficient to drive the second phase of signalling, but not the first. These findings suggest that there is a common signalling cascade by which mitogens drive arrested cells into the cell cycle, and that this cascade involves the temporally coordinated input of MEK, c-Myc and PI(3)K.	Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Schepens Eye Research Institute; Harvard University; Harvard Medical School	Kazlauskas, A (corresponding author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alberts B., 1994, MOL BIOL CELL; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 1997, NATURE, V387, P932, DOI 10.1038/43230; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Peeper DS, 1997, NATURE, V386, P521, DOI 10.1038/386521a0; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Winston JT, 1996, ONCOGENE, V12, P127	40	216	218	1	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					165	172		10.1038/35055073	http://dx.doi.org/10.1038/35055073			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175749				2022-12-25	WOS:000166793000018
J	Benaroudj, N; Goldberg, AL				Benaroudj, N; Goldberg, AL			PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone	NATURE CELL BIOLOGY			English	Article							THERMOPLASMA-ACIDOPHILUM; REGULATORY PARTICLE; ESCHERICHIA-COLI; TAGGING SYSTEM; DEGRADATION; CLPA; PROTEOLYSIS; 20S	The proteasome-activating nucleotidase (PAN) from Methanococcus jannaschii is a complex of relative molecular mass 650,000 that is homologous to the ATPases in the eukaryotic 26S proteasome. When mixed with 20S archaeal proteasomes and ATP, PAN stimulates protein degradation. Here we show that PAN reduces aggregation of denatured proteins and enhances their refolding, these processes do not require ATP hydrolysis, although ATP binding enhances the ability of PAN to prevent aggregation. PAN also catalyses the unfolding of the green fluorescent protein with an 11-residue ssrA extension at its carboxy terminus (GFP11). This unfolding requires ATP hydrolysis, and is linked to GFP11 degradation when 20S proteasomes are also present. This unfolding activity seems to be essential for ATP-dependent proteolysis, although PAN may function by itself as a molecular chaperone.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Benaroudj, N (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	Alfred_Goldberg@hms.harvard.edu		Benaroudj, Nadia/0000-0002-6475-0041	NIGMS NIH HHS [GM51923, GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051923] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Furutani M, 1998, J BIOL CHEM, V273, P28399, DOI 10.1074/jbc.273.43.28399; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Herman T, 1998, GLYCOBIOLOGY, V8, P1107; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; NG D, UNPUB ATP HYDROLYSIS; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SMITH LD, 1989, BIOCHEM J, V261, P973, DOI 10.1042/bj2610973; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; TANDON S, 1986, J BIOL CHEM, V261, P5615; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Williams KP, 2000, NUCLEIC ACIDS RES, V28, P168, DOI 10.1093/nar/28.1.168; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; ZWICKL P, IN PRESS PROTEASOMES	35	107	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					833	839		10.1038/35041081	http://dx.doi.org/10.1038/35041081			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056539				2022-12-25	WOS:000165207500018
J	Fell, DA; Wagner, A				Fell, DA; Wagner, A			The small world of metabolism	NATURE BIOTECHNOLOGY			English	Editorial Material							ESCHERICHIA-COLI; NETWORKS; PATHWAYS; BIOMASS		Oxford Brookes Univ, Sch Biol & Mol Sci, Oxford OX3 0BP, England; Univ New Mexico, Dept Biochem, Albuquerque, NM 87131 USA	Oxford Brookes University; University of New Mexico	Fell, DA (corresponding author), Oxford Brookes Univ, Sch Biol & Mol Sci, Oxford OX3 0BP, England.	daf@bms.brookes.ac.uk	Fell, David A/B-2109-2009	Fell, David A/0000-0001-6669-2247				Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P310, DOI 10.1093/nar/27.1.310; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; CASCANTE M, 1995, BIOCHEM J, V308, P895, DOI 10.1042/bj3080895; EASTERBY JS, 1986, BIOCHEM J, V233, P871, DOI 10.1042/bj2330871; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Fell D, 2000, ANIMATING CELLULAR M, P79; HOLMS WH, 1986, CURR TOP CELL REGUL, V28, P69; Ingraham J. L., 1983, GROWTH BACTERIAL CEL; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Karp PD, 1999, NUCLEIC ACIDS RES, V27, P55, DOI 10.1093/nar/27.1.55; MIGRAM S, 1967, PSYCHOL TODAY, V2, P60; Morowitz H.J., 1992, BEGINNINGS CELLULAR; NEIDHARDT FC, 1996, ESCHERICHLA COLI SAL; Pramanik J, 1997, BIOTECHNOL BIOENG, V56, P398, DOI 10.1002/(SICI)1097-0290(19971120)56:4<398::AID-BIT6>3.0.CO;2-J; Schilling CH, 1999, BIOTECHNOL PROGR, V15, P296, DOI 10.1021/bp990048k; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Selkov E, 1996, NUCLEIC ACIDS RES, V24, P26, DOI 10.1093/nar/24.1.26; VARMA A, 1993, J THEOR BIOL, V165, P477, DOI 10.1006/jtbi.1993.1202; WAGNER A, 2000, 0007041 SANT FE I; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; 2000, ERDOS NUMBER PROJECT; 2000, ORACLE BACON VIRGINI	22	283	299	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1121	1122		10.1038/81025	http://dx.doi.org/10.1038/81025			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062388				2022-12-25	WOS:000165176600002
J	Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA				Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA			Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation	NATURE MEDICINE			English	Article							EPIDERMAL PERMEABILITY BARRIER; ALLERGIC CONTACT-DERMATITIS; ATOPIC-DERMATITIS; DRUG-DELIVERY; ALOPECIA-AREATA; DOUBLE-BLIND; PSORIASIS; EFFICACY; SKIN; PROTEINS	Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7-CsA. In contrast to unmodified cyclosporin A,which fails to penetrate skin, topically applied R7-CsA was efficiently transported into cells in mouse and human skin. R7-CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.	CellGate, Sunnyvale, CA 94086 USA; Vet Adm Palo Alto, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Khavari, PA (corresponding author), CellGate, Sunnyvale, CA 94086 USA.	Khavari@cmgm.stanford.edu	Chen, Yao/AAJ-2409-2020					Bach M, 1998, EUR J PHARM BIOPHARM, V46, P1, DOI 10.1016/S0939-6411(97)00149-5; BAUMANN L, 1999, TOPICAL GLUCOCORTICO, P2713; BerthJones J, 1996, BRIT J DERMATOL, V135, P775; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; DEPROST Y, 1986, LANCET, V2, P803; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Doering T, 1999, J BIOL CHEM, V274, P11038, DOI 10.1074/jbc.274.16.11038; DUNCAN JI, 1993, ACTA DERM-VENEREOL, V73, P84; Furlanut M, 1996, PHARMACOL RES, V33, P349, DOI 10.1006/phrs.1996.0048; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gilbertson EO, 1998, J AM ACAD DERMATOL, V38, P318, DOI 10.1016/S0190-9622(98)70573-0; GILHAR A, 1989, ACTA DERM-VENEREOL, V69, P252; Hadgraft J, 1998, J Investig Dermatol Symp Proc, V3, P131; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Ho VC, 1999, BRIT J DERMATOL, V141, P283; Kim DT, 1997, J IMMUNOL, V159, P1666; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Koo J, 1998, BRIT J DERMATOL, V139, P88; MIYACHI Y, 1982, ARCH DERMATOL, V118, P451, DOI 10.1001/archderm.118.7.451; MROWIETZ U, 1992, ACTA DERM-VENEREOL, V72, P321; Naeyaert JM, 1999, DERMATOLOGY, V198, P145, DOI 10.1159/000018091; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oikarinen A, 1998, BRIT J DERMATOL, V139, P1106; Powles AV, 1998, BRIT J DERMATOL, V138, P443; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; RANADE VV, 1991, J CLIN PHARMACOL, V31, P401, DOI 10.1002/j.1552-4604.1991.tb01895.x; Roberts MS, 1997, CLIN EXP PHARMACOL P, V24, P874, DOI 10.1111/j.1440-1681.1997.tb02708.x; SCHMOOK FP, 1993, SKIN PHARMACOL, V6, P116; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SIEG P, 1995, BRIT J DERMATOL, V132, P790; Simpson J, 1998, THER DRUG MONIT, V20, P294, DOI 10.1097/00007691-199806000-00009; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SURBER C, 1992, CONTACT DERMATITIS, V26, P116, DOI 10.1111/j.1600-0536.1992.tb00895.x; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	38	533	623	5	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1253	1257		10.1038/81359	http://dx.doi.org/10.1038/81359			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062537				2022-12-25	WOS:000165114800033
J	Vermeulen, W; Bergmann, E; Auriol, J; Rademakers, S; Frit, P; Appeldoorn, E; Hoeijmakers, JHJ; Egly, JM				Vermeulen, W; Bergmann, E; Auriol, J; Rademakers, S; Frit, P; Appeldoorn, E; Hoeijmakers, JHJ; Egly, JM			Sublimiting concentration of TFIIH transcription/DNA repair factor causes TTD-A trichothiodystrophy disorder	NATURE GENETICS			English	Article							NUCLEOTIDE-EXCISION-REPAIR; RNA-POLYMERASE-II; DNA-REPAIR; XERODERMA-PIGMENTOSUM; GENE; MUTATIONS; HELICASE; SUBUNIT; XPD; COMPLEX	The repair-deficient form of trichothiodystrophy (TTD) most often results from mutations in the genes XPB or XPD. encoding helicases of the transcription/repair factor TFIIH. The genetic defect in a third group, TTD-A, is unknown, but is also caused by dysfunctioning TFIIH. None of the TFIIH subunits carry a mutation and TFIIH from fro-A cells is active in both transcription and repair. Instead, immunoblot and immunofluorescence analyses reveal a strong reduction in the TFIIH concentration. Thus, the phenotype of TTD-A appears to result from sublimiting amounts of TFIIH, probably due to a mutation in a gene determining the complex stability. The reduction of TFIIH mainly affects its repair function and hardly influences transcription.	Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, Rotterdam, Netherlands; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France	Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, Rotterdam, Netherlands.		Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021	Vermeulen, Wim/0000-0003-3616-734X; 				Araujo SJ, 2000, GENE DEV, V14, P349; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BOOTSMA D, 1998, NUCLEOTIDE EXCISION, P245; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; de Boer J, 1999, CANCER RES, V59, P3489; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Hwang BJ, 1996, MUTAT RES-DNA REPAIR, V362, P105, DOI 10.1016/0921-8777(95)00040-2; Lehmann AR, 1998, BIOESSAYS, V20, P146, DOI 10.1002/(SICI)1521-1878(199802)20:2<146::AID-BIES7>3.3.CO;2-5; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; ROY R, 1994, J BIOL CHEM, V269, P9826; Sambrook J., 2002, MOL CLONING LAB MANU; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; Satoh MS, 1997, BBA-GENE STRUCT EXPR, V1354, P241, DOI 10.1016/S0167-4781(97)00102-4; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; STEFANINI M, 1993, AM J HUM GENET, V53, P817; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; van Oosterwijk MF, 1998, J BIOL CHEM, V273, P13599, DOI 10.1074/jbc.273.22.13599; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Weeda G, 1997, AM J HUM GENET, V60, P320; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258	41	101	101	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					307	313		10.1038/81603	http://dx.doi.org/10.1038/81603			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062469				2022-12-25	WOS:000165176500018
J	Li, B; Nolte, LA; Ju, JS; Han, DH; Coleman, T; Holloszy, JO; Semenkovich, CF				Li, B; Nolte, LA; Ju, JS; Han, DH; Coleman, T; Holloszy, JO; Semenkovich, CF			Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice	NATURE MEDICINE			English	Article							HIGH-FAT DIET; LIPOPROTEIN-LIPASE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; PROTEIN-KINASE; MITOCHONDRIAL; HOMEOSTASIS; RESTRICTION; GLYCOGEN; EXERCISE	To determine whether uncoupling respiration from oxidative phosphorylation in skeletal muscle is a suitable treatment for obesity and type 2 diabetes, we generated transgenic mice expressing the mitochondrial uncoupling protein (Ucp) in skeletal muscle. Skeletal muscle oxygen consumption was 98% higher in Ucp-L mice (with low expression) and 246% higher in Ucp-H mice (with high expression) than in wild-type mice. Ucp mice fed a chow diet had the same food intake as wild-type mice, but weighed less and had lower levels of glucose and triglycerides and better glucose tolerance than did control mice. Ucp-L mice were resistant to obesity induced by two different high-fat diets. Ucp-L mice fed a high-fat diet had less adiposity, lower levels of glucose, insulin and cholesterol, and an increased metabolic rate at rest and with exercise. They were also more responsive to insulin, and had enhanced glucose transport in skeletal muscle in the setting of increased muscle triglyceride content. These data suggest that manipulating respiratory uncoupling in muscle is a viable treatment for obesity and its metabolic sequelae.	Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Div Geriatr & Gerontol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.			Semenkovich, Clay/0000-0003-1163-1871; Ju, Jeong-sun/0000-0001-7276-9941	NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG00425] Funding Source: Medline; NIDDK NIH HHS [DK53198] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R56AG000425, R37AG000425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; DOBUSH GR, CAN J ZOOL, V63; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Han DH, 1997, DIABETES, V46, P1761, DOI 10.2337/diabetes.46.11.1761; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hoppeler H, 2000, ACTA PHYSIOL SCAND, V168, P445, DOI 10.1046/j.1365-201x.2000.00696.x; Huang X, 1999, DIABETES, V48, P1508, DOI 10.2337/diabetes.48.8.1508; Klaus S, 1998, AM J PHYSIOL-REG I, V274, pR287, DOI 10.1152/ajpregu.1998.274.2.R287; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Portillo MP, 1999, REPROD NUTR DEV, V39, P189, DOI 10.1051/rnd:19990204; Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCOTT MD, 1992, J CHROMATOGR-BIOMED, V576, P149, DOI 10.1016/0378-4347(92)80186-T; Seip RL, 1998, EXERCISE SPORT SCI R, V26, P191; TATARANNI PA, 1995, INT J OBESITY, V19, pS102; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; UYEDA K, 1965, J BIOL CHEM, V240, P4682; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199	44	254	275	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1115	1120		10.1038/80450	http://dx.doi.org/10.1038/80450			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017142				2022-12-25	WOS:000089674700035
J	Molldrem, JJ; Lee, PP; Wang, CQ; Felio, K; Kantarjian, HM; Champlin, RE; Davis, MM				Molldrem, JJ; Lee, PP; Wang, CQ; Felio, K; Kantarjian, HM; Champlin, RE; Davis, MM			Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGEN; BONE-MARROW TRANSPLANTATION; TUMOR-ASSOCIATED ANTIGENS; VERSUS-HOST DISEASE; INTERFERON-ALPHA; CELL THERAPY; REMISSION; PEPTIDE; IDENTIFICATION	Although the immune system has long been implicated in the control of cancer, evidence for specific and efficacious immune responses in human cancer has been lacking. In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-alpha 2b (IFN alpha 2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. We previously demonstrated that PR1, a peptide derived from proteinase 3, is a potential target for CML-specific T cells. Here we studied 38 CML patients treated with allogeneic BMT, IFN-alpha 2b or chemotherapy to look for PR1-specific T cells using PR1/HLA-A*0201 tetrameric complexes. There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-alpha and allogeneic BMT. This provides for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Transplantat Immunol, Houston, TX 77030 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Texas System; UTMD Anderson Cancer Center; Stanford University; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Stanford University; Stanford University	Molldrem, JJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Transplantat Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Peter P./0000-0002-2660-4377; Davis, Mark/0000-0001-6868-657X	NATIONAL CANCER INSTITUTE [R01CA081247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022511, R01AI022511] Funding Source: NIH RePORTER; NCI NIH HHS [CA81247] Funding Source: Medline; NIAID NIH HHS [AI22511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Childs R, 1999, BRIT J HAEMATOL, V107, P396, DOI 10.1046/j.1365-2141.1999.01706.x; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dermime S, 1997, BONE MARROW TRANSPL, V19, P989, DOI 10.1038/sj.bmt.1700778; DOWDING C, 1991, BRIT J HAEMATOL, V77, P165, DOI 10.1111/j.1365-2141.1991.tb07972.x; FABER LM, 1995, J CLIN INVEST, V96, P877, DOI 10.1172/JCI118134; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Gordon MY, 1998, J CLIN INVEST, V102, P710, DOI 10.1172/JCI3094; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GREINER JW, 1984, CANCER RES, V44, P3208; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Konstantinidou P, 2000, BONE MARROW TRANSPL, V25, P143, DOI 10.1038/sj.bmt.1702133; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; MARIJT WA, 1995, BLOOD, V82, P3778; McGlave P, 1998, HEMATOL ONCOL CLIN N, V12, P93, DOI 10.1016/S0889-8588(05)70498-6; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Molldrem JJ, 1999, CANCER RES, V59, P2675; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Natali P G, 1988, Int J Biol Markers, V3, P211; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; VANRHEE F, 1994, BLOOD, V83, P3377	29	541	570	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1018	1023		10.1038/79526	http://dx.doi.org/10.1038/79526			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973322				2022-12-25	WOS:000089190500034
J	Kuramochi, M; Fukuhara, H; Nobukuni, T; Kanbe, T; Maruyama, T; Ghosh, HP; Pletcher, M; Isomura, M; Onizuka, M; Kitamura, T; Sekiya, T; Reeves, RH; Murakami, Y				Kuramochi, M; Fukuhara, H; Nobukuni, T; Kanbe, T; Maruyama, T; Ghosh, HP; Pletcher, M; Isomura, M; Onizuka, M; Kitamura, T; Sekiya, T; Reeves, RH; Murakami, Y			TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer	NATURE GENETICS			English	Article							NUDE-MICE; LINES; METHYLATION; HMLH1; HETEROZYGOSITY; ADENOCARCINOMA; TUMORIGENICITY; LOCALIZATION; CISPLATIN; FRAGMENTS	The existence of tumor-suppressor genes was originally demonstrated by functional complementation through whole-cell and microcell fusion(1,2). Transfer of chromosome 11 into a human non-small-cell lung cancer (NSCLC) cell line, A549, suppresses tumorigenicity(3). Loss of heterozygosity (LOH) on the long arm of chromosome 11 has been reported in NSCLC and other cancers(4-6). Several independent studies indicate that multiple tumor-suppressor genes are found in this region, including the gene PPP2R1B at 11q23-24 (ref. 7). Linkage studies of NSCLC are precluded because no hereditary forms are known(8,9). We previously identified a region of 700 kb on 11q23.2 that completely suppresses tumorigenicity of A549 human NSCLC cells(10). Most of this tumor-suppressor activity localizes to a 100-kb segment by functional complementation. Here we report that this region contains a single confirmed gene, TSLC1, whose expression is reduced or absent in A549 and several other NSCLC, hepatocellular carcinoma (HCC) and pancreatic cancer (PaC) cell lines. TSLC1 expression or suppression is correlated with promoter methylation state in these cell lines. Restoration of TSLC1 expression to normal or higher levels suppresses tumor formation by A549 cells in nude mice. Only 2 inactivating mutations of TSLC1 were discovered in 161 tumors and tumor cell lines, both among the 20 primary tumors with LOH for 11q23.2. Promoter methylation was observed in 15 of the other 18 primary NSCLC, HCC and Pac tumors with LOH for 11q23.2. Thus, attenuation of TSLC1 expression occurred in 85% of primary tumors with LOH. Hypermethylation of the TSLC1 promoter would seem to represent the 'second hit' in NSCLC with LOH.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Tokyo 104, Japan; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan; Univ Tsukuba, Inst Clin Med, Dept Surg, Ibaraki, Osaka, Japan; Univ Tokyo, Fac Med, Dept Urol, Tokyo 113, Japan	National Cancer Center - Japan; Johns Hopkins University; University of Tokyo; University of Tsukuba; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Tokyo 104, Japan.		Kitamura, Toshio/AAA-2071-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024605] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-24605] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoe K, 1999, ANTICANCER RES, V19, P291; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Ghosh K, 1999, BIOCHEM CELL BIOL, V77, P165; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HIRAI KI, 1991, CLIN EXP METASTAS, V9, P517, DOI 10.1007/BF01768580; IHDE DC, 1991, CURR PROB CANCER, V15, P61; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kanamori M, 2000, ONCOGENE, V19, P1564, DOI 10.1038/sj.onc.1203454; Kane MF, 1997, CANCER RES, V57, P808; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami Y, 1998, MUTAT RES-FUND MOL M, V400, P421, DOI 10.1016/S0027-5107(98)00031-1; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Ohsaki Y, 1996, ONCOLOGY, V53, P327; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RASIO D, 1995, CANCER RES, V55, P3988; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTON JB, 1986, CANCER RES, V46, P4701; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Schutte M, 1997, CANCER RES, V57, P3126; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang SSQ, 1999, GENE CHROMOSOME CANC, V25, P154, DOI 10.1002/(SICI)1098-2264(199906)25:2<154::AID-GCC11>3.3.CO;2-N; WEISBERG LA, 1987, COMPUT RADIOL, V11, P175, DOI 10.1016/0730-4862(87)90047-3; Yamori T, 1997, JPN J CANCER RES, V88, P1205, DOI 10.1111/j.1349-7006.1997.tb00350.x	29	367	402	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					427	430		10.1038/86934	http://dx.doi.org/10.1038/86934			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279526	Green Submitted			2022-12-25	WOS:000167811200019
J	Siddiqui, MR; Meisner, S; Tosh, K; Balakrishnan, K; Ghei, S; Fisher, SE; Golding, M; Narayan, NPS; Sitaraman, T; Sengupta, U; Pitchappan, R; Hill, AVS				Siddiqui, MR; Meisner, S; Tosh, K; Balakrishnan, K; Ghei, S; Fisher, SE; Golding, M; Narayan, NPS; Sitaraman, T; Sengupta, U; Pitchappan, R; Hill, AVS			A major susceptibility locus for leprosy in India maps to chromosome 10p13	NATURE GENETICS			English	Article							GENETICALLY COMPLEX TRAITS; AFFECTED RELATIVE PAIRS; GENOME-WIDE SEARCH; SCHISTOSOMA-MANSONI; LINKAGE STRATEGIES; INFECTION; EPIDEMIOLOGY; INTENSITY; 5Q31-Q33; DISEASE	Leprosy, a chronic infectious disease caused by Mycobacterium leprae, is prevalent in India, where about half of the world's estimated 800,000 cases occur(1). A role for the genetics of the host in variable susceptibility to leprosy has been indicated by familial clustering, twin studies, complex segregation analyses and human leukocyte antigen (HLA) association studies. We report here a genetic linkage scan of the genomes of 224 families from South India, containing 245 independent affected sibpairs with leprosy, mainly of the paucibacillary type. In a two-stage genome screen using 396 microsatellite markers, we found significant linkage (maximum lod score (MLS)=4.09, P<2x10(-5)) on chromosome 10p13 for a series of neighboring microsatellite markers, providing evidence for a major locus for this prevalent infectious disease. Thus, despite the polygenic nature of infectious disease susceptibility, some major, non-HLA-linked loci exist that may be mapped through obtainable numbers of affected sibling pairs.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Madurai Kamaraj Univ, Madurai 625021, Tamil Nadu, India; JALMA Inst, Agra, Uttar Pradesh, India; Leprosy Project, Sakthi Nagar, India; Hindu Mission Hosp, Kumbakonam, India	University of Oxford; Wellcome Centre for Human Genetics; Madurai Kamaraj University; Indian Council of Medical Research (ICMR); ICMR - National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.		Peng, Bo/A-6920-2009; Fisher, Simon E./E-9130-2012; HILL, Adrian V>S>/C-1306-2008	Peng, Bo/0000-0001-8225-2284; Fisher, Simon E./0000-0002-3132-1996; Karuppiah, Balakrishnan/0000-0002-7494-5010; Siddiqui, Ruby/0000-0002-9638-594X				Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830; ABEL L, 1988, AM J HUM GENET, V42, P256; ALI PM, 1966, INT J LEPROSY, V34, P405; Aredath S P, 1984, Lepr Rev, V55, P47; Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897; Chakravartti MR, 1973, TOPICS HUMAN GENETIC, P1; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FEITOSA MF, 1995, AM J HUM GENET, V56, P1179; HAILE RWC, 1985, HUM HERED, V35, P43, DOI 10.1159/000153514; HOLMANS P, 1993, AM J HUM GENET, V52, P362; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1987, AM J HUM GENET, V40, P1; Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199; SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930; TODD JR, 1990, REV INFECT DIS, V12, P63; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P308	24	143	151	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					439	441		10.1038/86958	http://dx.doi.org/10.1038/86958			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279529				2022-12-25	WOS:000167811200022
J	Wolfers, J; Lozier, A; Raposo, G; Regnault, A; Thery, C; Masurier, C; Flament, C; Pouzieux, S; Faure, F; Tursz, T; Angevin, E; Amigorena, S; Zitvogel, L				Wolfers, J; Lozier, A; Raposo, G; Regnault, A; Thery, C; Masurier, C; Flament, C; Pouzieux, S; Faure, F; Tursz, T; Angevin, E; Amigorena, S; Zitvogel, L			Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming	NATURE MEDICINE			English	Article							DENDRITIC CELLS ACQUIRE; CYTOLYTIC T-LYMPHOCYTES; CLASS-II MOLECULES; APOPTOTIC CELLS; IN-VITRO; B7 COSTIMULATION; MURINE TUMORS; MATURATION; COMPLEX; IMMUNOTHERAPY	The initiation of T-cell-mediated antitumor immune responses requires the uptake and processing of tumor antigens by dendritic cells and their presentation on MHC-I molecules. Here we show in a human in vitro model system that exosomes, a population of small membrane vesicles secreted by living tumor cells, contain and transfer tumor antigens to dendritic cells. After mouse tumor exosome uptake, dendritic cells induce potent CD8(+) T-cell-dependent antitumor effects on syngeneic and allogeneic established mouse tumors. Therefore, exosomes represent a novel source of tumor-rejection antigens for T-cell cross priming, relevant for immunointerventions.	Inst Curie, INSERM, U520, Paris, France; Inst Curie, CNRS, UMR 144, Paris, France; Inst Gustave Roussy, APCells SA, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biol Clin, Immunol Unit, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Amigorena, S (corresponding author), Inst Curie, INSERM, U520, Paris, France.		thery, clotilde/F-6373-2013; faure, florence/P-9064-2016; REGNAULT, Armelle/G-4142-2011	thery, clotilde/0000-0001-8294-6884; faure, florence/0000-0002-8359-4283; REGNAULT, Armelle/0000-0001-7286-9491; Amigorena, Sebastian/0000-0001-8583-8416; ANGEVIN, Eric/0000-0001-6249-7209; ZITVOGEL, laurence/0000-0003-1596-0998				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Angevin E, 1999, LAB INVEST, V79, P879; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Brandle D, 1998, EUR J IMMUNOL, V28, P4010, DOI 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5; Caignard A, 1996, INT J CANCER, V66, P564, DOI 10.1002/(SICI)1097-0215(19960516)66:4<564::AID-IJC23>3.0.CO;2-6; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COGGIN JHJ, 1989, MOL BIOTHER, V4, P223; Dufour E, 1997, J IMMUNOL, V158, P3787; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Imro MA, 1999, CANCER RES, V59, P2287; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; KLEIN G, 1960, CANCER RES, V20, P1561; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; OLD LJ, 1981, CANCER RES, V41, P361; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Russo V, 2000, P NATL ACAD SCI USA, V97, P2185, DOI 10.1073/pnas.040540197; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stauss HJ, 1999, IMMUNOL TODAY, V20, P180, DOI 10.1016/S0167-5699(99)01443-7; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87; Zorn E, 1999, EUR J IMMUNOL, V29, P592, DOI 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2	41	1123	1217	5	150	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					297	303		10.1038/85438	http://dx.doi.org/10.1038/85438			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231627				2022-12-25	WOS:000167380400034
J	Bakhiet, M; Tjernlund, A; Mousa, A; Gad, A; Stromblad, S; Kuziel, WA; Seiger, A; Andersson, J				Bakhiet, M; Tjernlund, A; Mousa, A; Gad, A; Stromblad, S; Kuziel, WA; Seiger, A; Andersson, J			RANTES promotes growth and survival of human first-trimester forebrain astrocytes	NATURE CELL BIOLOGY			English	Article							MULTIPLE-SCLEROSIS; CHEMOKINE RECEPTORS; IFN-GAMMA; EXPRESSION; INDUCTION; CELLS; DIFFERENTIATION; MIP-1-ALPHA; INTERFERON; ACTIVATION	We have examined the role of alpha and beta chemokines in the promotion of the ontogenetic development of the brain. RANTES was expressed preferentially in human fetal astrocytes in an age-dependent manner. Astrocytes from 5-week-old brains showed high proliferation and reduced survival, whereas 10-week-old astrocytes exhibited opposite effects. These effects were suppressed by anti-RANTES or anti-RANTES receptor antibodies and were enhanced by recombinant RANTES. RANTES induced tyrosine phosphorylation of several cellular proteins and nuclear translocation of STAT-1 in astrocytes. Interferons (IFN-gamma) was required for RANTES effects because RANTES induced IFN-gamma, and only 10-week-old astrocytes expressed the IFN-gamma receptor. Blocking of IFN-gamma with antibody reversed the effects of RANTES, indicating that cytokine/chemokine networks are critically involved in brain development.	Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, SE-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci, Div Geriatr Med, SE-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol & Pathol, Div Pathol, SE-14186 Stockholm, Sweden; Sodertorns Hogskola, Stockholm, Sweden; Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodertorn University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Bakhiet, M (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, SE-14186 Stockholm, Sweden.	moiz.bakhiet@medhs.ki.se	Gad, Annica/X-8294-2018; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Tjernlund, Annelie/0000-0002-1061-5223; Stromblad, Staffan/0000-0002-1236-6339				Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Bakhiet M, 1999, CLIN DIAGN LAB IMMUN, V6, P415, DOI 10.1128/CDLI.6.3.415-419.1999; Bonecchi R, 1999, J IMMUNOL, V162, P474; Brew R, 1997, BIOCHEM SOC T, V25, pS264, DOI 10.1042/bst025264s; Chihara J, 1997, J ALLERGY CLIN IMMUN, V100, pS52, DOI 10.1016/S0091-6749(97)70005-8; Colletti LM, 1998, SHOCK, V10, P248, DOI 10.1097/00024382-199810000-00004; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; JONAKAIT GM, 1994, NEURON, V12, P1149; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; McManus CM, 1998, J IMMUNOL, V160, P1449; MEHLER MF, 1994, DEV NEUROSCI-BASEL, V16, P180, DOI 10.1159/000112105; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; MIYAGISHI R, 1995, J NEUROL SCI, V129, P223, DOI 10.1016/0022-510X(95)00004-L; Mousa A, 1998, INT J MOL MED, V1, P171; Mousa A, 1999, CYTOKINE, V11, P55, DOI 10.1006/cyto.1998.0381; Mousa A, 1998, NEUROREPORT, V9, P4097, DOI 10.1097/00001756-199812210-00017; Mrowietz U, 1999, BRIT J CANCER, V79, P1025, DOI 10.1038/sj.bjc.6690164; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Patterson BK, 1999, CLIN IMMUNOL, V91, P254, DOI 10.1006/clim.1999.4713; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Xiao BG, 1998, J NEUROCYTOL, V27, P575, DOI 10.1023/A:1006918110952	34	68	73	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					150	157		10.1038/35055057	http://dx.doi.org/10.1038/35055057			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175747				2022-12-25	WOS:000166793000016
J	Morello, R; Zhou, G; Dreyer, SD; Harvey, SJ; Ninomiya, Y; Thorner, PS; Miner, JH; Cole, W; Winterpacht, A; Zabel, B; Oberg, KC; Lee, B				Morello, R; Zhou, G; Dreyer, SD; Harvey, SJ; Ninomiya, Y; Thorner, PS; Miner, JH; Cole, W; Winterpacht, A; Zabel, B; Oberg, KC; Lee, B			Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome	NATURE GENETICS			English	Article							ALPORT-SYNDROME; IV COLLAGEN; MONOCLONAL-ANTIBODIES; GENE; ALPHA-3(IV); MUTATIONS; IDENTIFICATION; ORGANIZATION; DROSOPHILA; ENHANCER	Basement membrane (BM) morphogenesis is critical for normal kidney function(1). Heterotrimeric type IV collagen, composed of different combinations of six ct-chains lid), is a major matrix component of all BMs (ref. 2). Unlike in other BMs, glomerular BM (CBM) contains primarily the alpha3(IV) and alpha4(IV) chains, together with the alpha5(IV) chain(3,4). A poorly understood, coordinated temporal and spatial switch in gene expression from ubiquitously expressed alpha1(IV) and alpha2(IV) collagen to the alpha3(IV), alpha4(IV) and alpha5(IV) chains occurs during nqrmat embryogenesis of CBM (ref. 4). Structural abnormalities of type IV collagen have been associated with diverse biological processes including defects in molecular filtration in Alport syndrome(5,6), cell differentiation in hereditary leiomyomatosis(7), and autoimmunity in Goodpasture syndrome(7); however, the transcriptional and developmental regulation of type IV collagen expression is unknown. Nail patella syndrome (NPS) is caused by mutations in LMX1B, encoding a LIM homeodomain transcription factor. Some patients have nephrosis-associated renal disease characterized by typical ultrastructural abnormalities of GEM (refs. 8,9). In Lmx1b(-/-) mice, expression of both alpha (3)IV and alpha (4)IV collagen is strongly diminished in GEM, whereas that of alpha1, alpha2 and alpha5(IV) collagen is unchanged. Moreover, LMX1B binds specifically to a putative enhancer sequence in intron 1 of both mouse and human COL4A4 and upregulates reporter constructs containing this enhancer-like sequence. These data indicate that LMX1B directly regulates the coordinated expression of alpha3(IV) and alpha (IV) collagen required for normal CBM morphogenesis and that its dysregulation in CBM contributes to the renal pathology and nephrosis in NPS.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Mainz, Dept Pediat, D-6500 Mainz, Germany; Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Washington Univ, Sch Med, Dept Med, Div Renal, St Louis, MO USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO USA; Hosp Sick Children, Div Orthoped, Toronto, ON M5G 1X8, Canada; Univ Hamburg, Inst Human Genet, D-2000 Hamburg, Germany; Loma Linda Univ, Dept Pathol & Human Anat, Loma Linda, CA 92350 USA	Baylor College of Medicine; Johannes Gutenberg University of Mainz; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Okayama University; Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Hamburg; Loma Linda University	Lee, B (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Harvey, Scott/C-8938-2011	Harvey, Scott/0000-0001-6007-785X; Oberg, Kerby/0000-0002-1241-4273	NIAMS NIH HHS [AR44738] Funding Source: Medline; NIDDK NIH HHS [DK53196, DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044738, R01AR044738, R55AR044738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053196, P01DK053763] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht U., 1998, HUMAN GENOME METHODS, P93; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Dreyer SD, 2000, HUM MOL GENET, V9, P1067, DOI 10.1093/hmg/9.7.1067; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Haerry TE, 1997, DEV BIOL, V186, P1, DOI 10.1006/dbio.1997.8582; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Kalluri R, 2000, J BIOL CHEM, V275, P12719, DOI 10.1074/jbc.275.17.12719; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0; Lu W, 1999, GENOMICS, V61, P113, DOI 10.1006/geno.1999.5943; McIntosh I, 1998, AM J HUM GENET, V63, P1651, DOI 10.1086/302165; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Momota R, 1998, FEBS LETT, V424, P11, DOI 10.1016/S0014-5793(98)00128-8; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Sado Y, 1998, J BIOCHEM-TOKYO, V123, P767; SUTCLIFFE NP, 1989, NEPHROL DIAL TRANSPL, V4, P262, DOI 10.1093/oxfordjournals.ndt.a091869; TAGUCHI T, 1988, ULTRASTRUCT PATHOL, V12, P175, DOI 10.3109/01913128809058216; VALNIO S, 1997, CELL, V90, P975	30	144	147	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					205	208		10.1038/84853	http://dx.doi.org/10.1038/84853			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175791				2022-12-25	WOS:000166839200024
J	Jenne, A; Hartig, JS; Piganeau, N; Tauer, A; Samarsky, DA; Green, MR; Davies, J; Famulok, M				Jenne, A; Hartig, JS; Piganeau, N; Tauer, A; Samarsky, DA; Green, MR; Davies, J; Famulok, M			Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology	NATURE BIOTECHNOLOGY			English	Article						antibiotic libraries; combinatorial libraries; hammerhead ribozyme; high-throughput screening; RNA-drug interaction	ENERGY-TRANSFER FRET; 16S RIBOSOMAL-RNA; AMINOGLYCOSIDE ANTIBIOTICS; DRUG TARGET; TAT-PROTEIN; REV-PROTEIN; METAL-IONS; BINDING; HIV-1; NEOMYCIN	The ability to rapidly identify small molecules that interact with RNA would have significant clinical and research applications. Low-molecular-weight molecules that bind to RNA have the potential to be used as drugs. Therefore, technologies facilitating the rapid and reliable identification of such activities become increasingly important. We have applied a fluorescence-based assay to screen for modulators of hammerhead ribozyme (HHR) catalysis from a small library of antibiotic compounds. Several unknown potent inhibitors of the hammerhead cleavage reaction were identified and further characterized. Tuberactinomycin A, for which positive cooperativity of inhibition in vitro was found, also reduced ribozyme cleavage in vivo. The assay is applicable to the screening of mixtures of compounds, as inhibitory activities were detected within a collection of 2,000 extracts from different actinomycete strains. This approach allows the rapid, reliable, and convenient identification and characterization of ribozyme modulators leading to insights difficult to obtain by classical methodology.	Kekule Inst Organ Chem & Biochem, D-35121 Bonn, Germany; Univ Munich, Inst Biochem, D-81377 Munich, Germany; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Gene Funct, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Express, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of Bonn; University of Munich; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of British Columbia	Famulok, M (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-35121 Bonn, Germany.							Afshar M, 1999, CURR OPIN BIOTECH, V10, P59, DOI 10.1016/S0958-1669(99)80011-1; Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460; CLOUETDORVAL B, 1995, BIOCHEMISTRY-US, V34, P11186, DOI 10.1021/bi00035a025; Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Earnshaw DJ, 1998, NUCLEIC ACIDS RES, V26, P5551, DOI 10.1093/nar/26.24.5551; Ecker DJ, 1999, DRUG DISCOV TODAY, V4, P420, DOI 10.1016/S1359-6446(99)01389-6; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; Hermann T, 1998, CURR OPIN BIOTECH, V9, P66, DOI 10.1016/S0958-1669(98)80086-4; Hermann T, 1998, J MOL BIOL, V276, P903, DOI 10.1006/jmbi.1997.1590; Hoch I, 1998, J MOL BIOL, V282, P557, DOI 10.1006/jmbi.1998.2035; Jenne A, 1999, ANGEW CHEM INT EDIT, V38, P1300, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1300::AID-ANIE1300>3.0.CO;2-Q; Mestre B, 1999, BBA-GENE STRUCT EXPR, V1445, P86, DOI 10.1016/S0167-4781(99)00019-6; Michael K, 1998, CHEM-EUR J, V4, P2091, DOI 10.1002/(SICI)1521-3765(19981102)4:11<2091::AID-CHEM2091>3.0.CO;2-3; Mikkelsen NE, 1999, P NATL ACAD SCI USA, V96, P6155, DOI 10.1073/pnas.96.11.6155; Murray JB, 1996, BIOCHEM J, V317, P855, DOI 10.1042/bj3170855; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; Pearson ND, 1997, CHEM BIOL, V4, P409, DOI 10.1016/S1074-5521(97)90192-7; PILCH DS, 1995, BIOCHEMISTRY-US, V34, P9962, DOI 10.1021/bi00031a019; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; Rossi JJ, 1999, SCIENCE, V285, P1685, DOI 10.1126/science.285.5434.1685; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Singh KK, 1999, RNA, V5, P1348, DOI 10.1017/S1355838299991185; STAGE TK, 1995, RNA, V1, P95; Stage-Zimmermann TK, 1998, RNA, V4, P875, DOI 10.1017/S1355838298980876; Tor Y, 1999, ANGEW CHEM INT EDIT, V38, P1579, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1579::AID-ANIE1579>3.0.CO;2-H; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; Walter F, 1999, CURR OPIN CHEM BIOL, V3, P694, DOI 10.1016/S1367-5931(99)00028-9; Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a; Wang Y, 1997, BIOCHEMISTRY-US, V36, P768, DOI 10.1021/bi962095g; Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B; Zhu KC, 1999, BIOCHEM BIOPH RES CO, V266, P361, DOI 10.1006/bbrc.1999.1815	39	52	66	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					56	61		10.1038/83513	http://dx.doi.org/10.1038/83513			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135553	Green Submitted			2022-12-25	WOS:000166261400020
J	Zhou, W; Galizia, G; Goodman, SN; Romans, KE; Kinzler, KW; Vogelstein, B; Choti, MA; Montgomery, EA				Zhou, W; Galizia, G; Goodman, SN; Romans, KE; Kinzler, KW; Vogelstein, B; Choti, MA; Montgomery, EA			Counting alleles reveals a connection between chromosome 18q loss and vascular invasion	NATURE BIOTECHNOLOGY			English	Article							COLORECTAL-CARCINOMA; CANCER; PROGNOSIS; GENE	The analysis of loss of heterozygosity (LOH) is perhaps the most widely used technique in cancer genetics. In primary tumors, however, the analysis of LOH is fraught with technical problems that have limited its reproducibility and interpretation. In particular, tumors are mixtures of neoplastic and nonneoplastic cells, and the DNA from the nonneoplastic cells can mask LOH. We here describe a new experimental approach, involving two components, to overcome these problems. First, a form of digital PCR1 was employed to directly count, one by one, the number of each of the two alleles in tumor samples. Second, Bayesian-type likelihood methods were used to measure the strength of the evidence for the allele distribution being different from normal. This approach imparts a rigorous statistical basis to LOH analyses, and should be able to provide more reliable information than heretofore possible in LOH studies of diverse tumor types.	Johns Hopkins Oncol Ctr, Genet Mol Lab, Baltimore, MD 21231 USA; Univ Naples 2, Dept Surg Sci, Sch Med, Naples, Italy; Johns Hopkins Oncol Ctr, Div Biostat, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Universita della Campania Vanvitelli; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Vogelstein, B (corresponding author), Johns Hopkins Oncol Ctr, Genet Mol Lab, Baltimore, MD 21231 USA.		Galizia, Gennaro/A-3924-2010	GALIZIA, Gennaro/0000-0002-6897-0391; Goodman, Steven/0000-0002-3872-5723	NATIONAL CANCER INSTITUTE [P50CA062924, R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460, CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boland CR, 1998, CANCER RES, V58, P5248; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KIYOAKI O, 1996, CANCER, V78, P2313; KRASNA MJ, 1988, CANCER-AM CANCER SOC, V61, P1018, DOI 10.1002/1097-0142(19880301)61:5<1018::AID-CNCR2820610527>3.0.CO;2-H; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; MARTENS E, 1898, MITT ZOOL SAMML MUS, V1, P1; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULERIS M, 1985, Annales de Genetique, V28, P206; Ogunbiyi OA, 1998, J CLIN ONCOL, V16, P427, DOI 10.1200/JCO.1998.16.2.427; Ouchi K, 1996, CANCER, V78, P2313, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2313::AID-CNCR7>3.0.CO;2-N; Royall R., 1997, STAT EVIDENCE LIKELI; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SUNDERLAND DA, 1949, CANCER, V2, P429, DOI 10.1002/1097-0142(194905)2:3<429::AID-CNCR2820020307>3.0.CO;2-G; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236; WAID A, 1947, SEQUENTIAL ANAL	20	67	155	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					78	81		10.1038/83572	http://dx.doi.org/10.1038/83572			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135558				2022-12-25	WOS:000166261400025
J	Buhman, KK; Accad, M; Novak, S; Choi, RS; Wong, JS; Hamilton, RL; Turley, S; Farese, RV				Buhman, KK; Accad, M; Novak, S; Choi, RS; Wong, JS; Hamilton, RL; Turley, S; Farese, RV			Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice	NATURE MEDICINE			English	Article							COA-CHOLESTEROL ACYLTRANSFERASE; HUMAN ACYL-COENZYME; APOLIPOPROTEIN-B; ESTERIFICATION ENZYMES; BILIARY CHOLESTEROL; MOLECULAR-CLONING; TRANSGENIC MICE; INBRED STRAINS; HUMAN LIVER; EXPRESSION	The importance of cholesterol ester synthesis by acyl CoA:cholesterol acyltransferase (ACAT) enzymes in intestinal and hepatic cholesterol metabolism has been unclear. We now demonstrate that ACAT2 is the major ACAT in mouse small intestine and liver, and suggest that ACAT2 deficiency has profound effects on cholesterol metabolism in mice fed a cholesterol-rich diet, including complete resistance to diet-induced hypercholesterolemia and cholesterol gallstone formation. The underlying mechanism involves the lack of cholesterol ester synthesis in the intestine and a resultant reduced capacity to absorb cholesterol. Our results indicate that ACAT2 has an important role in the response to dietary cholesterol, and suggest that ACAT2 inhibition may be a useful strategy for treating hypercholesterolemia or cholesterol gallstones.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Texas, SW Med Sch, Dept Med, Dallas, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	bfarese@gladstone.ucsf.edu	Buhman, Kimberly/AAV-3111-2021	Buhman, Kimberly/0000-0002-3784-1028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL009610, R01HL057170, R01HL060844, R01HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57170, HL09610, R01 HL057170, HL60844] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang CCY, 1999, CIRCULATION, V100, P612; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DIXON JL, 1993, J LIPID RES, V34, P167; ERICKSON SK, 1980, J LIPID RES, V21, P930; Farese RV, 1996, J LIPID RES, V37, P347; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; HAMILTON RL, 1980, J LIPID RES, V21, P981; HORIE Y, 1992, J BIOL CHEM, V267, P1962; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; KHANUJA B, 1995, P NATL ACAD SCI USA, V92, P7729, DOI 10.1073/pnas.92.17.7729; KLEIN RL, 1983, J LIPID RES, V24, P343; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; Lammert F, 1999, FALK SYMP, V108, P224; Lee O, 1998, J LIPID RES, V39, P1722; Machleder D, 1997, J CLIN INVEST, V99, P1406, DOI 10.1172/JCI119300; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MORTENSEN R, 1999, CURRENT PROTOCOLS MO, V2; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; Schwarz M, 1998, J LIPID RES, V39, P1833; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SMITH JL, 1995, J LIPID RES, V36, P641; SMITH JL, 1990, J LIPID RES, V31, P1993; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; WILSON MD, 1994, J LIPID RES, V35, P943; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	38	257	267	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1341	1347		10.1038/82153	http://dx.doi.org/10.1038/82153			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100118				2022-12-25	WOS:000165704100037
J	Shen, CN; Slack, JMW; Tosh, D				Shen, CN; Slack, JMW; Tosh, D			Molecular basis of transdifferentiation of pancreas to liver	NATURE CELL BIOLOGY			English	Article							DEDIFFERENTIATED HEPATOMA-CELLS; EPITHELIAL PROGENITOR CELLS; ENHANCER BINDING-PROTEIN; ACINAR AR42J CELLS; TRANSCRIPTION FACTORS; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; GROWTH-FACTOR; HNF-4 GENE	The appearance of hepatic foci in the pancreas has been described in animal experiments and in human pathology. Here we show that pancreatic cells can be converted into hepatocytes by treatment with a synthetic glucocorticoid, dexamethasone. This occurs both in a pancreatic cell line, AR42J-B13, and in organ cultures of pancreatic buds from mouse embryos. We have established several features of the mechanism behind this transdifferentiation. We show that a proportion of the hepatocytes arises directly from differentiated exocrine-like cells, with no intervening cell division. This conversion is associated with induction of the transcription factor C/EBP beta and the activation of differentiated hepatic products. Transfection of C/EBP beta into the cells can provoke transdifferentiation; conversely, a dominant-negative form of C/EBP beta can inhibit the process. These results indicate that C/EBP beta is a key component that distinguishes the liver and pancreatic programmes of differentiation.	Univ Bath, Dept Biol & Biochem, Dev Biol Programme, Bath BA2 7AY, Avon, England	University of Bath	Tosh, D (corresponding author), Univ Bath, Dept Biol & Biochem, Dev Biol Programme, Bath BA2 7AY, Avon, England.		SHEN, CHIA-NING/C-6878-2011	SHEN, CHIA-NING/0000-0002-0747-217X				Beck CW, 1999, MECH DEVELOP, V88, P221, DOI 10.1016/S0925-4773(99)00217-8; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOU JY, 1988, MOL CELL BIOL, V8, P203, DOI 10.1128/MCB.8.1.203; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; DABEVA MD, 1995, AM J PATHOL, V147, P1633; Dabeva MD, 1997, P NATL ACAD SCI USA, V94, P7356, DOI 10.1073/pnas.94.14.7356; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Eguchi G, 1993, CURR OPIN CELL BIOL, V5, P1023, DOI 10.1016/0955-0674(93)90087-7; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Krakowski ML, 1999, AM J PATHOL, V154, P683, DOI 10.1016/S0002-9440(10)65315-1; Li JX, 2000, GENE DEV, V14, P464; Liu S, 1998, DIABETES, V47, pA295; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; LONGNECKER DS, 1979, CANCER LETT, V7, P197, DOI 10.1016/S0304-3835(79)80080-4; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nomura S, 1998, GUT, V42, P663, DOI 10.1136/gut.42.5.663; Okada T.S, 1991, TRANSDIFFERENTIATION; Percival AC, 1999, EXP CELL RES, V247, P123, DOI 10.1006/excr.1998.4322; RAO MS, 1995, SEMIN CELL BIOL, V6, P151; Rao MS, 1996, GENE EXPRESSION, V6, P15; RAO MS, 1986, CELL DIFFER DEV, V18, P109, DOI 10.1016/0045-6039(86)90005-9; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SLACK JMW, 1986, LANCET, V2, P268; SLACK JMW, 1985, J THEOR BIOL, V114, P463, DOI 10.1016/S0022-5193(85)80179-X; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SLACK JMW, 1992, OXFORD TXB PATHOLOGY, P565; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Tanaka M, 1997, RRD MET MAT SCI, V1, P1; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WOLF HK, 1990, AM J SURG PATHOL, V14, P590, DOI 10.1097/00000478-199006000-00011; WolfeCoote S, 1996, CELL BIOL INT, V20, P95, DOI 10.1006/cbir.1996.0013; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3	48	331	371	4	51	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					879	887		10.1038/35046522	http://dx.doi.org/10.1038/35046522			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146651				2022-12-25	WOS:000165814500009
J	Osusky, M; Zhou, GQ; Osuska, L; Hancock, RE; Kay, WW; Misra, S				Osusky, M; Zhou, GQ; Osuska, L; Hancock, RE; Kay, WW; Misra, S			Transgenic plants expressing cationic peptide chimeras exhibit broad-spectrum resistance to phytopathogens	NATURE BIOTECHNOLOGY			English	Article						cationic peptides; transgenic potato; phytopathogens; disease resistance	CONFERS ENHANCED RESISTANCE; PROGRAMMED CELL-DEATH; SOFT-ROT RESISTANCE; CECROPIN-B; AGROBACTERIUM-TUMEFACIENS; BACTERIAL PATHOGENS; DISEASE RESISTANCE; TOBACCO; GENES; TRANSFORMATION	Here we describe a strategy for engineering transgenic plants with broad-spectrum resistance to bacterial and fungal phytopathogens. We expressed a synthetic gene encoding a N terminus-modified, cecropin-melitiin cationic peptide chimera (MsrA1), with broad-spectrum antimicrobial activity. The synthetic gene was introduced into two potato (Solanum tuberosum L,) cultivars, Desiree and Russet Burbank, stable incorporation was confirmed by PCR and DNA sequencing, and expression confirmed by reverse transcription (RT)-PCR and recovery of the biologically active peptide. The morphology and yield of transgenic Desiree plants and tubers was unaffected. Highly stringent challenges with bacterial or fungal phytopathogens demonstrated powerful resistance. Tubers retained their resistance to infectious challenge for more than a year, and did not appear to be harmful when fed to mice. Expression of msrA1 in the cultivar Russet Burbank caused a striking lesion-mimic phenotype during leaf and tuber development, indicating its utility may be cultivar specific. Given the ubiquity of antimicrobial cationic peptides as well as their inherent capacity for recombinant and combinatorial variants, this approach may potentially be used to engineer a range of disease-resistant plants.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1W5, Canada	University of Victoria; University of British Columbia	Kay, WW (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.		Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				Abad MS, 1997, MOL PLANT MICROBE IN, V10, P635, DOI 10.1094/MPMI.1997.10.5.635; Allefs SJHM, 1996, MOL BREEDING, V2, P97, DOI 10.1007/BF00441425; ALLEFS SJHM, 1995, AM POTATO J, V72, P437, DOI 10.1007/BF02851677; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BOHMAN HG, 1987, ANNU REV MICROBIOL, V41, P103; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; CARMONA MJ, 1993, PLANT J, V3, P457, DOI 10.1046/j.1365-313X.1993.t01-24-00999.x; Cavallarin L, 1998, MOL PLANT MICROBE IN, V11, P218, DOI 10.1094/MPMI.1998.11.3.218; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; DALTA RSS, 1993, PLANT SCI, V94, P139; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DEBLOCK M, 1988, THEOR APPL GENET, V76, P767, DOI 10.1007/BF00303524; Dempsey DA, 1998, TRENDS MICROBIOL, V6, P54, DOI 10.1016/S0966-842X(97)01186-4; During K, 1996, MOL BREEDING, V2, P297, DOI 10.1007/BF00437908; Epple P, 1997, PLANT CELL, V9, P509, DOI 10.1105/tpc.9.4.509; FLORACK D, 1995, TRANSGENIC RES, V4, P132, DOI 10.1007/BF01969415; FLORACK DEA, 1994, PLANT MOL BIOL, V24, P83, DOI 10.1007/BF00040576; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HANCOCK REW, 1992, Patent No. 07913492; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; JAYNES JM, 1987, BIOESSAYS, V6, P263, DOI 10.1002/bies.950060605; JAYNES JM, 1993, PLANT SCI, V89, P43, DOI 10.1016/0168-9452(93)90169-Z; MITRA A, 1994, PLANT PHYSIOL, V106, P977, DOI 10.1104/pp.106.3.977; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; Mourgues F, 1998, TRENDS BIOTECHNOL, V16, P203, DOI 10.1016/S0167-7799(98)01189-5; NICHOLAS P, 1995, ANNU REV MICROBIOL, V49, P277; NORDEEN RO, 1992, PLANT SCI, V82, P101, DOI 10.1016/0168-9452(92)90012-B; PIERS KL, 1994, MOL MICROBIOL, V12, P951, DOI 10.1111/j.1365-2958.1994.tb01083.x; POWELL WA, 1995, MOL PLANT MICROBE IN, V8, P792, DOI 10.1094/MPMI-8-0792; Ross H., 1986, Fortschritte der Pflanzenzuchtung; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697; VANHOFSTEN P, 1985, P NATL ACAD SCI USA, V82, P2240; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WAGNER DB, 1987, P NATL ACAD SCI USA, V84, P2097, DOI 10.1073/pnas.84.7.2097; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	43	169	198	4	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1162	1166		10.1038/81145	http://dx.doi.org/10.1038/81145			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062434				2022-12-25	WOS:000165176600020
J	Constancia, M; Dean, W; Lopes, S; Moore, T; Kelsey, G; Reik, W				Constancia, M; Dean, W; Lopes, S; Moore, T; Kelsey, G; Reik, W			Deletion of a silencer element in lgf2 results in loss of imprinting independent of H19	NATURE GENETICS			English	Letter							BECKWITH-WIEDEMANN-SYNDROME; GROWTH-FACTOR-II; DEVELOPMENTAL CONTROL; WILMS-TUMOR; MOUSE IGF2; METHYLATION; GENE; EXPRESSION; CHROMATIN; PATTERN	Igf2 and H19 are closely linked, reciprocally imprinted genes on mouse distal chromosome 7. The paternally expressed Igf2 encodes a potent fetal growth factor and the maternally expressed H19 encodes a non-coding RNA (refs 1,2). Shared endoderm-specific enhancers 3' to H19 are necessary for transcription of the maternal copy of H19 and the paternal copy of Igf2 (ref. 3), a chromatin boundary upstream of H19 preventing access of the enhancers to the maternal Igf2 promoters(4-8). Mesoderm-specific control elements have not been identified, and the role of differentially methylated regions (DMRs) in Igf2 has not been addressed. Two DMRs in Igf2 are methylated on the active paternal allele, suggesting that they contain silencers(9-12). Here we have deleted the DMR1 region in Igf2. Maternal transmission of the deletion results in biallelic expression of Igf2 in most mesodermally derived tissues without altering H19 imprinting or expression. Paternal or maternal transmission leads to continued postnatal transcription of Igf2, in contrast to the wild-type allele, which is silenced soon after birth. These results reveal a mesodermal silencer, which may be regulated by methylation and which has a major role in H19-independent expression and imprinting control of Igf2. Our results establish a new mechanistic principle for imprinted genes whereby epigenetically regulated silencers interact with enhancers to control expression, and suggest a new mechanism for loss of imprinting (LOI) of Igf2, which may be important in a number of diseases.	Babraham Inst, Dev Genet Programme, Lab Dev Genet & Imprinting, Cambridge, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Reik, W (corresponding author), Babraham Inst, Dev Genet Programme, Lab Dev Genet & Imprinting, Cambridge, England.	wolf.reik@bbsrc.ac.uk	Constancia, Miguel/F-6654-2013; Reik, Wolf/I-6794-2012	Moore, Tom/0000-0001-9712-9625; Constancia, Miguel/0000-0002-8976-1679; Dean, Wendy/0000-0001-9441-5044; Reik, Wolf/0000-0003-0216-9881; Kelsey, Gavin/0000-0002-9762-5634				Ainscough JFX, 2000, DEVELOPMENT, V127, P3923; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Brown LS, 1996, WOMEN THER, V19, P5, DOI 10.1300/J015v19n01_02; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; Dean W, 1998, DEVELOPMENT, V125, P2273; Drewell RA, 2000, DEVELOPMENT, V127, P3419; FEIL R, 1995, DEV GENET, V17, P240, DOI 10.1002/dvg.1020170309; FEIL R, 1994, DEVELOPMENT, V120, P2933; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; RAINIER S, 1995, CANCER RES, V55, P1836; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ward Andrew, 1997, Genes and Function, V1, P25	31	165	173	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2000	26	2					203	206		10.1038/79930	http://dx.doi.org/10.1038/79930			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017078				2022-12-25	WOS:000089638800019
J	Lutter, M; Fang, M; Luo, X; Nishijima, M; Xie, XS; Wang, XD				Lutter, M; Fang, M; Luo, X; Nishijima, M; Xie, XS; Wang, XD			Cardiolipin provides specificity for targeting of tBid to mitochondria	NATURE CELL BIOLOGY			English	Article							CELL; APOPTOSIS; PROTEIN; RELEASE; DEATH	Recent evidence supports the theory that mitochondrial homeostasis is the key regulatory step in apoptosis through the actions of members of the Bcl-2 family(1-3). Pro-apoptotic members of the family, such as Bar, Bad and Bid, can induce the loss of outer-membrane integrity with subsequent redistribution of pro-apoptotic proteins such as cytochrome c that are normally located in the intermembrane spaces of mitochondvia(2). The anti-apoptotic members of the family, such as Bcl-2 and Bcl-X-L, protect the integrity of the mitochondrion and prevent the release of death-inducing factors(1-3). Bid normally exists in an inactive state in the cytosol, but after cleavage by caspase 8, the carboxy-terminal portion (tBid) moves from cytosol to mitochondria, where it induces release of cytochrome C-4,C-5. Here we address the question of what mediates specific targeting of tBid to the mitochondria. We provide evidence that cardiolipin, which is present in mitochondrial membranes, mediates the targeting of tBid to mitochondria through a previously unkown three-helix domain in tBid. These findings implicate cardiolipin in the pathway for cytochrome c release.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institute of Infectious Diseases (NIID)	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.			Wang, Xiaodong/0000-0001-9885-356X	NIDDK NIH HHS [DKRO1-33627] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08014, GMRO1-55942] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lieser MJ, 1998, GASTROENTEROLOGY, V115, P693, DOI 10.1016/S0016-5085(98)70149-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4	14	395	408	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					754	756		10.1038/35036395	http://dx.doi.org/10.1038/35036395			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025668				2022-12-25	WOS:000089697000023
J	Kirschner, LS; Carney, JA; Pack, SD; Taymans, SE; Giatzakis, C; Cho, YS; Cho-Chung, YS; Stratakis, CA				Kirschner, LS; Carney, JA; Pack, SD; Taymans, SE; Giatzakis, C; Cho, YS; Cho-Chung, YS; Stratakis, CA			Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex	NATURE GENETICS			English	Article							SPOTTY SKIN PIGMENTATION; ENDOCRINE OVERACTIVITY; ACTIVATING MUTATIONS; CARDIAC MYXOMAS; RI-ALPHA; SCHWANNOMAS; DIAGNOSIS; DISEASE; TUMORS; MICE	Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas(1-5). CNC is inherited as an autosomal dominant trait and the genes responsible have been mapped to 2p16 and 17q22-24 (refs 6,7). Because of its similarities to the McCune-Albright syndrome(5,8) and other features, such as paradoxical responses to endocrine signals(9), genes implicated in cyclic nucleotide-dependent signalling have been considered candidates for causing CNC (ref. 10). In CNC families mapping to 17q. we detected loss of heterozygosity (LOH) in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory subunit 1-alpha (Rl alpha), including a polymorphic site within its 5' region. We subsequently identified three unrelated kindreds with an identical mutation in the coding region of PRKAR1A. Analysis of additional cases revealed the same mutation in a sporadic case of CNC, and different mutations in three other families, including one with isolated inherited cardiac myxomas. Analysis of PKA activity in CNC tumours demonstrated a decreased basal activity, but an increase in cAMP-stimulated activity compared with non-CNC tumours, We conclude that germline mutations in PRKAR1A, an apparent tumour-suppressor gene, are responsible for the CNC phenotype in a subset of patients with this disease.	NICHHD, Unit Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA; Mayo Clin, Emeritus Staff, Dept Lab Med & Pathol, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Stratakis, CA (corresponding author), NICHHD, Unit Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA.	stratakc@ccl.nichd.nih.gov	Pack, Svetlana D./C-2020-2014; Stratakis, Constantine/AAP-4745-2020	Pack, Svetlana D./0000-0003-3256-6626; /0000-0002-6224-6685	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000642, ZIAHD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEEBE SJ, 1984, J BIOL CHEM, V259, P3539; CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DANOFF A, 1987, ARCH INTERN MED, V147, P443, DOI 10.1001/archinte.147.3.443; DeMarco L, 1996, HUM GENET, V98, P185, DOI 10.1007/s004390050187; Jones AC, 1999, CLIN CHEM, V45, P1133; KUO JF, 1970, BIOCHIM BIOPHYS ACTA, V212, P79, DOI 10.1016/0005-2744(70)90180-4; LIEBLER GA, 1976, J THORAC CARDIOV SUR, V71, P605; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Schoenberg-Fejzo M, 1999, AM J HUM GENET, V65, pA444; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; Stratakis CA, 1998, AM J MED GENET, V80, P183, DOI 10.1002/(SICI)1096-8628(19981102)80:2<183::AID-AJMG19>3.0.CO;2-I; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 1998, J CLIN ENDOCR METAB, V83, P2972, DOI 10.1210/jc.83.8.2972; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; Stratakis CA, 1999, AM J HUM GENET, V65, pA447; Stratakis CA, 2000, FRONT BIOSCI-LANDMRK, V5, pD353, DOI 10.2741/Stratakis; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	28	768	794	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					89	92		10.1038/79238	http://dx.doi.org/10.1038/79238			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973256				2022-12-25	WOS:000089078000025
J	Verpy, E; Leibovici, M; Zwaenepoel, I; Liu, XZ; Gal, A; Salem, N; Mansour, A; Blanchard, S; Kobayashi, I; Keats, BJB; Slim, R; Petit, C				Verpy, E; Leibovici, M; Zwaenepoel, I; Liu, XZ; Gal, A; Salem, N; Mansour, A; Blanchard, S; Kobayashi, I; Keats, BJB; Slim, R; Petit, C			A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C	NATURE GENETICS			English	Article							MYOSIN-VIIA; DEAFNESS; REGION; GENE; IDENTIFICATION; TRANSCRIPTION; LOCALIZATION; MODULES; SYSTEM; SITES	Usher syndrome type 1 (USH1) is an autosomal recessive sensory defect involving congenital profound sensorineural deafness, vestibular dysfunction and blindness (due to progressive retinitis pigmentosa)(1). Six different USH1 loci have been reported. So far, only MYO7A (USH1B), encoding myosin VIIA (ref. 2), has been identified as a gene whose mutation causes the disease. Here, we report a gene underlying USH1C (MIM 276904), a USH1 subtype described in a population of Acadian descendants from Louisiana(3) and in a Lebanese family(4). We identified this gene (USH1C), encoding a PDZ-domain-containing protein, harmonin, in a subtracted mouse cDNA library derived from inner ear sensory areas. In patients we found a splice-site mutation, a frameshift mutation and the expansion of an intronic variable number of tandem repeat (VNTR). We showed that, in the mouse inner ear, only the sensory hair cells express harmonin. The inner ear Ush1c transcripts predicted several harmonin isoforms, some containing an additional coiled-coil domain and a proline- and serine-rich region. As several of these transcripts were absent from the eye, we propose that USH1C also underlies the DFNB18 form of isolated deafness.	Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, Paris 15, France; Virginia Commonwealth Univ, Coll Med, Dept Human Genet, Richmond, VA USA; Virginia Commonwealth Univ, Coll Med, Dept Otolaryngol, Richmond, VA USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Humangenet, D-2000 Hamburg, Germany; Univ St Joseph, Fac Med, Unite Genet Med, Beirut, Lebanon; Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon; Hokkaido Univ, Sch Med, Dept Pediat, Sapporo, Hokkaido 060, Japan; Louisiana State Univ, Hlth Sci Ctr, Dept Biometry & Genet, New Orleans, LA USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Virginia Commonwealth University; Virginia Commonwealth University; University of Hamburg; Saint Joseph University Beirut; American University of Beirut; American University of Beirut; Hokkaido University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Petit, C (corresponding author), Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, Paris 15, France.	cpetit@pasteur.fr	Kobayashi, Ichiro/G-8638-2012; Slim, Rima/J-4104-2019; Leibovici, Michel/ABB-6745-2020	Slim, Rima/0000-0002-4060-2159; Petit, Christine/0000-0002-9069-002X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002530, R03DC004530] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC02530, R03 DC04530] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bitner-Glindzicz M, 2000, NAT GENET, V26, P56, DOI 10.1038/79178; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; DeAngelis MM, 1998, BBA-MOL BASIS DIS, V1407, P84, DOI 10.1016/S0925-4439(98)00025-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Higgins MJ, 1998, GENOME RES, V8, P57, DOI 10.1101/gr.8.1.57; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; Kimberling W J, 1995, J Am Acad Audiol, V6, P63; Kobayashi I, 1999, GASTROENTEROLOGY, V117, P823, DOI 10.1016/S0016-5085(99)70340-9; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; Saouda M, 1998, HUM GENET, V103, P193, DOI 10.1007/s004390050806; Scanlan MJ, 1999, BBA-GENE STRUCT EXPR, V1445, P39, DOI 10.1016/S0167-4781(99)00033-0; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; Steel KP, 1995, ANNU REV GENET, V29, P675; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	31	349	361	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					51	55		10.1038/79171	http://dx.doi.org/10.1038/79171			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973247				2022-12-25	WOS:000089078000016
J	Staller, P; Peukert, K; Kiermaier, A; Seoane, J; Lukas, J; Karsunky, H; Moroy, T; Bartek, J; Massague, J; Hanel, F; Eilers, M				Staller, P; Peukert, K; Kiermaier, A; Seoane, J; Lukas, J; Karsunky, H; Moroy, T; Bartek, J; Massague, J; Hanel, F; Eilers, M			Repression of p15(INK4b) expression by Myc through association with Miz-1	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE PROGRESSION; C-MYC; INHIBITOR P15(INK4B); GENE-TRANSFER; TARGET GENE; DNA-BINDING; TGF-BETA; IN-VIVO; PROTEIN	Deregulated expression of c-myc can induce cell proliferation in established cell lines and in primary mouse embryonic fibroblasts (MEFs), through a combination of both transcriptional activation and repression by Myc. Here we show that a Myc-associated transcription factor, Miz-1, arrests cells in G1 phase and inhibits cyclin D-associated kinase activity. Miz-1 upregulates expression of the cyclin-dependent kinases (CDK) inhibitor p15(INK4b) by binding to the initiator element of the p15(INK4b) promoter. Myc and Max form a complex with Miz-1 at the p15 initiator and inhibit transcriptional activation by Miz-1. Expression of Myc in primary cells inhibits the accumulation of p15(INK4b) that is associated with cellular senescence; conversely deletion of c-myc in an established cell line activates p15(INK4b) expression. Alleles of c-myc that are unable to bind to Miz-1 fail to inhibit accumulation of p15(INK4b) messenger RNA in primary cells and are, as a consequence, deficient in immortalization.	Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Essen Gesamthsch, Inst Cell Biol, D-45122 Essen, Germany; Hans Knoll Inst Naturstoff Forsch, D-07745 Jena, Germany	Memorial Sloan Kettering Cancer Center; University of Duisburg Essen; Hans Knoll Institute (HKI)	Eilers, M (corresponding author), Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Seoane, Joan/AAG-9173-2019; Moroy, Tarik/D-9923-2011; Bartek, Jiri/G-5870-2014	Seoane, Joan/0000-0002-6541-5974; Massague, Joan/0000-0001-9324-8408; Lukas, Jiri/0000-0001-9087-506X; Eilers, Martin/0000-0002-0376-6533				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Grignani F, 1998, CANCER RES, V58, P14; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARVEY M, 1993, ONCOGENE, V8, P2457; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Herman JG, 1997, CANCER RES, V57, P837; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUKAS J, 1994, ONCOGENE, V9, P707; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; QUELLE DE, 1995, ONCOGENE, V11, P635; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SEOANE J, NATURE CELL BIOL, V4, P400; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	47	433	450	1	23	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					392	399		10.1038/35070076	http://dx.doi.org/10.1038/35070076			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283613				2022-12-25	WOS:000168043900018
J	Amann, KJ; Pollard, TD				Amann, KJ; Pollard, TD			The Arp2/3 complex nucleates actin filament branches from the sides of pre-existing filaments	NATURE CELL BIOLOGY			English	Article							CAPPING PROTEIN; NETWORKS; BINDING; POLYMERIZATION; ACANTHAMOEBA; PROFILIN; MOTILITY; DYNAMICS; GELSOLIN; AGAROSE	Regulated assembly of actin-filament networks provides the mechanical force that pushes forward the leading edge of motile eukaryotic cells(1) and intracellular pathogenic bacteria(2) and viruses(3). When activated by binding to actin filaments and to the WA domain of Wiskott-Aldrich syndrome protein (WASP)/Scar proteins, the Arp2/3 complex nucleates new filaments that grow from their barbed ends(4-8). The Arp2/3 complex binds to the sides(9) and pointed ends(10,11) of actin filaments, localizes to distinctive 70 degrees actin-filament branches present in lamellae(12), and forms similar branches in vitro(6,8,10). These observations have given rise to the dendritic nucleation model for actin-network assembly(10,13) in which the Arp2/3 complex initiates branches on the sides of older filaments. Recently, however, an alternative mechanism for branch formation has been proposed(8). In the 'barbed-end nucleation' model, the Arp2/3 complex binds to the free barbed end of a filament and two filaments subsequently grow from the branch. Here we report the use of kinetic and microscopic experiments to distinguish between these models. Our results indicate that the activated Arp2/3 complex preferentially nucleates filament branches directly on the sides of pre-existing filaments.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; Xu JY, 1999, CELL MOTIL CYTOSKEL, V42, P73, DOI 10.1002/(SICI)1097-0169(1999)42:1<73::AID-CM7>3.0.CO;2-Z; YU FX, 1991, J BIOL CHEM, V266, P19269	23	169	176	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					306	310		10.1038/35060104	http://dx.doi.org/10.1038/35060104			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231582				2022-12-25	WOS:000167365800019
J	Han, BH; DeMattos, RB; Dugan, LL; Kim-Han, JS; Brendza, RP; Fryer, JD; Kierson, M; Cirrito, J; Quick, K; Harmony, JAK; Aronow, BJ; Holtzman, DM				Han, BH; DeMattos, RB; Dugan, LL; Kim-Han, JS; Brendza, RP; Fryer, JD; Kierson, M; Cirrito, J; Quick, K; Harmony, JAK; Aronow, BJ; Holtzman, DM			Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SULFATED GLYCOPROTEIN-2; CELL-DEATH; IN-VITRO; APOLIPOPROTEIN-J/CLUSTERIN; RAT MODEL; NEURONS; APOPTOSIS; PROTECTS; RECEPTOR	Clusterin, also known as apolipoprotein J, is a ubiquitously expressed molecule thought to influence a variety of processes including cell death. In the brain, it accumulates in dying neurons following seizures and hypoxic-ischemic (H-I) Injury. Despite this, in vivo evidence that clusterin directly influences cell death is lacking. Following neonatal H-I brain injury in mice (a model of cerebral palsy), there was evidence of apoptotic changes (neuronal caspase-3 activation), as well as accumulation of clusterin in dying neurons. Clusterin-deficient mice had 50% less brain injury following neonatal H-I. Surprisingly, the absence of clusterin had no effect on caspase-3 activation, and clusterin accumulation and caspase-3 activation did not colocalize to the same cells. Studies with cultured cortical neurons demonstrated that exogenous purified astrocyte-secreted clusterin exacerbated oxygen/glucose-deprivation-induced necrotic death. These results indicate that clusterin may be a new therapeutic target to modulate non-caspase-dependent neuronal death following acute brain injury.	Washington Univ, Sch Med, Ctr Study Nervous System Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Childrens Hosp Res Fdn, Div Mol & Dev Biol, Cincinnati, OH 45229 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous System Injury, St Louis, MO 63110 USA.		Aronow, Bruce J/F-8438-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS035902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355, P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG05681, AG11355] Funding Source: Medline; NINDS NIH HHS [NS35902] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Boggs LN, 1996, J NEUROCHEM, V67, P1324; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; DUGAN LL, 1995, J NEUROSCI, V15, P6377; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Han BH, 2000, NEUROBIOL DIS, V7, P38; Humphreys D, 1997, BIOCHEMISTRY-US, V36, P15233, DOI 10.1021/bi9703507; KISSINGER C, 1982, BIOL REPROD, V27, P233, DOI 10.1095/biolreprod27.1.233; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lendon CL, 2000, EUR J NEUROSCI, V12, P2235, DOI 10.1046/j.1460-9568.2000.00113.x; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Nakajima W, 2000, J NEUROSCI, V20, P7994; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; PASINETTI GM, 1991, NEUROSCI LETT, V130, P1, DOI 10.1016/0304-3940(91)90213-D; PASINETTI GM, 1994, J COMP NEUROL, V339, P387, DOI 10.1002/cne.903390307; Plummer KL, 1999, J COMP NEUROL, V404, P408; Pulera MR, 1998, STROKE, V29, P2622, DOI 10.1161/01.STR.29.12.2622; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Schwochau GB, 1998, KIDNEY INT, V53, P1647, DOI 10.1046/j.1523-1755.1998.00902.x; SENSIBAR JA, 1995, CANCER RES, V55, P2431; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sintich SM, 1999, PROSTATE, V39, P87; VANUCCI RC, 1990, PEDIATR RES, V27, P317; Volpe J., 1995, NEUROLOGY NEWBORN; Walton M, 1996, MOL BRAIN RES, V39, P137, DOI 10.1016/0169-328X(96)00019-8; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	38	173	183	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					338	343		10.1038/85487	http://dx.doi.org/10.1038/85487			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231633				2022-12-25	WOS:000167380400040
J	Kobinger, GP; Weiner, DJ; Yu, QC; Wilson, JM				Kobinger, GP; Weiner, DJ; Yu, QC; Wilson, JM			Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo	NATURE BIOTECHNOLOGY			English	Article							MEDIATED GENE-TRANSFER; HUMAN BRONCHIAL EPITHELIA; CYSTIC-FIBROSIS; EBOLA-VIRUS; ENVELOPE GLYCOPROTEINS; ADENOASSOCIATED VIRUS; FUSION PROTEINS; CELL-LINES; RETROVIRUS; XENOGRAFTS	Traditional gene therapy vectors have demonstrated limited utility for treatment of chronic lung diseases such as cystic fibrosis (CF). Herein we describe a vector based on a Filovirus envelope protein-pseudotyped HIV vector, which we chose after systematically evaluating multiple strategies. The vector efficiently transduces intact airway epithelium from the apical surface, as demonstrated in both in vitro and in vivo model systems. This shows the potential of pseudotyping in expanding the utility of lentiviral vectors. Pseudotyped lentiviral vectors may hold promise for the treatment of CF.	Univ Penn Hlth Syst, Inst Human Gene Therapy, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Wilson, JM (corresponding author), Univ Penn Hlth Syst, Inst Human Gene Therapy, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Weiner, Daniel/0000-0001-8245-1961	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47757-08] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bais R, 1999, J VIROL, V73, P6085, DOI 10.1128/JVI.73.7.6085-6088.1999; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; Blomer U, 1997, J VIROL, V71, P6641; Buchschacher GL, 2000, BLOOD, V95, P2499; Chan SY, 2000, J VIROL, V74, P4933, DOI 10.1128/JVI.74.10.4933-4937.2000; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; Duan DS, 2000, J CLIN INVEST, V105, P1573, DOI 10.1172/JCI8317; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; Goldman MJ, 1997, HUM GENE THER, V8, P2261, DOI 10.1089/hum.1997.8.18-2261; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; Johnson LG, 2000, GENE THER, V7, P568, DOI 10.1038/sj.gt.3301138; Kobinger GP, 1998, J VIROL, V72, P5441, DOI 10.1128/JVI.72.7.5441-5448.1998; Lodge R, 1998, GENE THER, V5, P655, DOI 10.1038/sj.gt.3300646; LOPEZVIDRIERO MT, 1978, AM REV RESPIR DIS, V117, P465; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; Peng KW, 1999, CURR OPIN BIOTECH, V10, P454, DOI 10.1016/S0958-1669(99)00009-9; Schnierle BS, 1996, GENE THER, V3, P1069; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Wang GS, 1999, J CLIN INVEST, V104, pR55, DOI 10.1172/JCI8390; Wang GS, 1998, J VIROL, V72, P9818, DOI 10.1128/JVI.72.12.9818-9826.1998; Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000	32	244	257	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					225	230		10.1038/85664	http://dx.doi.org/10.1038/85664			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231554				2022-12-25	WOS:000167283100021
J	Wilde, A; Lizarraga, SB; Zhang, LJ; Wiese, C; Gliksman, NR; Walczak, CE; Zheng, YX				Wilde, A; Lizarraga, SB; Zhang, LJ; Wiese, C; Gliksman, NR; Walczak, CE; Zheng, YX			Ran stimulates spindle assembly by altering microtubule dynamics and the balance of motor activities	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; KINESIN-RELATED PROTEIN; GTP-BOUND RAN; MITOTIC SPINDLE; CELL-CYCLE; SELF-ORGANIZATION; NUCLEAR-ENVELOPE; CHROMOSOMES; CENTROSOMES; ASTERS	The guanosine tri-phosphatase Ran stimulates assembly of microtubule spindles. However, it is not known what aspects of the microtubule cytoskeleton are subject to regulation by Ran in mitosis, Here we show that Ran-GTP stimulates microtubule assembly by increasing the rescue frequency of microtubules three- to eightfold. In addition to changing microtubule dynamics, Ran-GTP also alters the balance of motor activities, partly as a result of an increase in the amount of motile Eg5, a plus end-directed microtubule motor that is essential for spindle formation. Thus, Ran regulates multiple processes that are involved in spindle assembly.	Carnegie Inst Sci, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA; Johns Hopkins Univ, Grad Program Biol, Baltimore, MD 21210 USA; Universal Imaging Corp, W Chester, PA 19380 USA; Indiana Univ, Med Sci Program, Bloomington, IN 47405 USA	Carnegie Institution for Science; Howard Hughes Medical Institute; Johns Hopkins University; Indiana University System; Indiana University Bloomington	Zheng, YX (corresponding author), Carnegie Inst Sci, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	zheng@ciwemb.edu		Wilde, Andrew/0000-0002-9812-3847	NIGMS NIH HHS [R01 GM059618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; Fanara P, 1999, EMBO J, V18, P565, DOI 10.1093/emboj/18.3.565; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; Heald R, 1999, CURR OPIN STRUC BIOL, V9, P268, DOI 10.1016/S0959-440X(99)80037-2; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HYMAN AA, 1991, J CELL SCI, P125; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tournebize R, 1997, Prog Cell Cycle Res, V3, P271; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; Zhang CM, 1999, J CELL SCI, V112, P2453; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	39	179	183	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					221	227		10.1038/35060000	http://dx.doi.org/10.1038/35060000			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231570				2022-12-25	WOS:000167365800007
J	Greener, T; Grant, B; Zhang, YH; Wu, XF; Greene, LE; Hirsh, D; Eisenberg, E				Greener, T; Grant, B; Zhang, YH; Wu, XF; Greene, LE; Hirsh, D; Eisenberg, E			Caenorhabditis elegans auxilin: a J-domain protein essential for clathrin-mediated endocytosis in vivo	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRANDED-RNA; UNCOATING ATPASE; GENETIC INTERFERENCE; COATED VESICLES; DISSOCIATION; EXPRESSION; BASKETS	The budding of clathrin-coated vesicles is essential for protein transport. After budding, clathrin must be uncoated before the Vesicles can fuse with other membranous structures. In vitro, the molecular chaperone Hsc70 uncoats clathrin-coated vesicles in an ATP-dependent process that requires a specific J-domain protein such as auxilin. However, there is little evidence that either Hsc70 or auxilin is essential in vivo. Here we show that C. elegans has a single auxilin homologue that is identical to mammalian auxilin in its in vitro activity. When RNA-mediated interference (RNAi) is used to inhibit auxilin expression in C. elegans, oocytes show markedly reduced receptor-mediated endocytosis of yolk protein tagged with green fluorescent protein (GFP). In addition, most of these worms arrest during larval development, exhibit defective distribution of GFP-clathrin in many cell types, and show a marked change in clathrin dynamics, as determined by fluorescence recovery after photobleaching (FRAP). We conclude that auxilin is required for in vivo clathrin-mediated endocytosis and development in C. elegans.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Columbia University	Eisenberg, E (corresponding author), NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.			Grant, Barth/0000-0002-5943-8336; Zhang, Yinhua/0000-0003-0592-9153	NIGMS NIH HHS [F32 GM019167-02, F32 GM019167-01, F32 GM019167] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAROUCH W, 1994, J BIOL CHEM, V269, P28563; BRENNER S, 1974, GENETICS, V77, P71; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelly WG, 1997, GENETICS, V146, P227; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; Yochem J, 1999, DEVELOPMENT, V126, P597	26	78	82	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					215	219		10.1038/35055137	http://dx.doi.org/10.1038/35055137			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175756				2022-12-25	WOS:000166793000025
J	Keller, P; Toomre, D; Diaz, E; White, J; Simons, K				Keller, P; Toomre, D; Diaz, E; White, J; Simons, K			Multicolour imaging of post-Golgi sorting and trafficking in live cells	NATURE CELL BIOLOGY			English	Article							POLARIZED EPITHELIAL-CELLS; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; BIOSYNTHETIC TRANSPORT; LIVING CELLS; PROTEIN; COMPLEX; NETWORK; SURFACE; LOCALIZATION	The biogenesis and maintenance of asymmetry is crucial to many cellular functions including absorption and secretion, signalling, development and morphogenesis, Here we have directly visualized the segregation and trafficking of apical (glycosyl phosphatidyl inositol-anchored) and basolateral (vesicular stomatitis virus glycoprotein) cargo in living cells using multicolour imaging of green fluorescent protein variants. Apical and basolateral cargo segregate progressively into large domains in Golgi/trans-Golgi network structures, exclude resident proteins, and exit in separate transport containers. These remain distinct and do not merge with endocytic structures suggesting that lateral segregation in the trans-Golgi network is the primary sorting event. Fusion with the plasma membrane was detected by total internal reflection microscopy and reveals differences between apical and basolateral carriers as well as new 'hot spots' for exocytosis.	European Mol Biol Lab, Cell Biol Biophys Programme, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Simons, K (corresponding author), European Mol Biol Lab, Cell Biol Biophys Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	simons@mpi-cbg.de	Diaz, Maria Elena/H-5996-2011	Diaz, Maria Elena/0000-0002-6818-6943; Simons, Kai/0000-0002-9231-9996				AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DIGGLE PJ, 1983, STAT SNALYSIS SPATIA; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Fullekrug J, 1999, J CELL SCI, V112, P2813; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Girotti M, 1996, J CELL SCI, V109, P2915; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARRISON PT, 1994, NUCLEIC ACIDS RES, V22, P3813, DOI 10.1093/nar/22.18.3813; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEDMAN K, 1987, J HISTOCHEM CYTOCHEM, V35, P233, DOI 10.1177/35.2.3025294; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Keller P, 1997, J CELL SCI, V110, P3001; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MELLMAN I, 1993, J CELL SCI, P1; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rottger S, 1998, J CELL SCI, V111, P45; SCHEIFFELE P, 1999, EPITHELIAL MORPHOGEN, P41; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Toomre D, 1999, J CELL SCI, V112, P21; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17789; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	47	360	366	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					140	149		10.1038/35055042	http://dx.doi.org/10.1038/35055042			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175746				2022-12-25	WOS:000166793000015
J	Krishnamurthy, K; Giroux, MJ				Krishnamurthy, K; Giroux, MJ			Expression of wheat puroindoline genes in transgenic rice enhances grain softness	NATURE BIOTECHNOLOGY			English	Article						puroindoline; wheat; rice; transformation; texture modification	NUTRIENT DIGESTIBILITY; KERNEL HARDNESS; PARTICLE-SIZE; PROTEIN; STARCH; ENDOSPERM; FRIABILIN; PLANTS; INHERITANCE; PERFORMANCE	The puroindoline genes (pinA and pinB) are believed to play critical roles in wheat (Triticum aestivum L.) grain texture. Mutations in either gene are associated with hard wheat. No direct evidence exists for the ability of puroindolines to modify cereal grain texture. Interestingly, puroindolines appear to be absent in cereal species outside of the tribe Triticeae, in which the dominant form of grain texture is hard. To assess the ability of the puroindolines to modify cereal grain texture, the puroindolines were introduced into rice (Oryzae sativa L.) under the control of the maize ubiquitin promoter. Textural analysis of transgenic rice seeds indicated that expression of PINA and/or PINB reduced rice grain hardness. After milling, flour prepared from these softer seeds had reduced starch damage and an increased percentage of fine flour particles. Our data support the hypothesis that puroindolines play important roles in controlling wheat grain texture and may be useful in modifying grain texture of other cereals.	Montana State Univ, Dept Plant Sci, Agr Biosci Facil, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Giroux, MJ (corresponding author), Montana State Univ, Dept Plant Sci, Agr Biosci Facil, POB 173150, Bozeman, MT 59717 USA.		Giroux, Michael J/F-4413-2010					[Anonymous], APPR METH AM ASS CER; BAKER RJ, 1977, CROP SCI, V17, P960, DOI 10.2135/cropsci1977.0011183X001700060036x; BARLOW KK, 1973, CEREAL CHEM, V50, P443; Chen LL, 1998, NAT BIOTECHNOL, V16, P1060, DOI 10.1038/3511; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Dubreil L, 1998, PLANT SCI, V138, P121, DOI 10.1016/S0168-9452(98)00121-6; EDWARDS ML, 1985, J VIROL METHODS, V11, P309, DOI 10.1016/0166-0934(85)90024-2; GAUTIER MF, 1994, PLANT MOL BIOL, V25, P43, DOI 10.1007/BF00024197; Giroux MJ, 2000, CROP SCI, V40, P370, DOI 10.2135/cropsci2000.402370x; Giroux MJ, 1997, THEOR APPL GENET, V95, P857, DOI 10.1007/s001220050636; Giroux MJ, 1998, P NATL ACAD SCI USA, V95, P6262, DOI 10.1073/pnas.95.11.6262; GREENBLATT GA, 1995, CEREAL CHEM, V72, P172; GREENWELL P, 1986, CEREAL CHEM, V63, P379; HONG BH, 1989, CEREAL CHEM, V66, P369; JOHNSON C W, 1986, Crop Science, V26, P198, DOI 10.2135/cropsci1986.0011183X002600010052x; JOLLY CJ, 1993, THEOR APPL GENET, V86, P589, DOI 10.1007/BF00838714; Knowlton KF, 1996, J DAIRY SCI, V79, P557, DOI 10.3168/jds.S0022-0302(96)76400-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law C. N., 1978, Seed protein improvement by nuclear technique. Proceedings of the two Research Co-ordination Meetings, Baden, 28 March - 1 April 1977 and Vienna, 26-30 September 1977. Aneuploids in wheat protein improvement., P483; Mattern P. J., 1973, Proceedings of the Fourth International Wheat Genetics Symposium. Cytogenetics., P703; Morris CF, 1996, CEREAL GRAIN QUALITY, P3, DOI DOI 10.1007/978-94-009-1513-8_1; MORRIS CF, 1994, J CEREAL SCI, V21, P167; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; Sivamani E, 1996, PLANT CELL REP, V15, P322, DOI 10.1007/BF00232364; SYMES KJ, 1969, AUST J AGR RES, V20, P971, DOI 10.1071/AR9690971; SYMES KJ, 1965, AUST J AGR RES, V16, P113, DOI 10.1071/AR9650113; WONDRA KJ, 1995, J ANIM SCI, V73, P757	28	89	104	1	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					162	166		10.1038/84435	http://dx.doi.org/10.1038/84435			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175732				2022-12-25	WOS:000166754700024
J	Xu, X; Leo, C; Jang, YJ; Chan, E; Padilla, D; Huang, BCB; Lin, T; Gururaja, T; Hitoshi, Y; Lorens, JB; Anderson, DC; Sikic, B; Luo, Y; Payan, DG; Nolan, GP				Xu, X; Leo, C; Jang, YJ; Chan, E; Padilla, D; Huang, BCB; Lin, T; Gururaja, T; Hitoshi, Y; Lorens, JB; Anderson, DC; Sikic, B; Luo, Y; Payan, DG; Nolan, GP			Dominant effector genetics in mammalian cells	NATURE GENETICS			English	Article							HEAT-SHOCK-FACTOR; VIRUS-X PROTEIN; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PROTEASOME INHIBITORS; SUPPRESSOR ELEMENTS; PHAGE DISPLAY; SUBUNIT-ZETA; EXPRESSION; ACTIVATION	We have expressed libraries of peptides in mammalian cells to select for trans-dominant effects on intracellular signaling systems. As an example-and to reveal pharmacologically relevant points in pathways that lead to Taxol resistance-we selected for peptide motifs that confer resistance to Taxol-induced cell death. Of several peptides selected, one, termed RGP8.5, was linked to upregulation of expression of the gene ABCB1 (also known as MDR1, for multiple drug resistance) in HeLa cells. Our data indicate that trans-dominant effector peptides can point to potential mechanisms by which signaling systems operate. Such tools may be useful in functional genomic analysis of signaling pathways in mammalian disease processes.	Rigel Inc, San Francisco, CA USA; Stanford Univ, Dept Microbiol & Immunol, Dept Mol Pharmacol, Palo Alto, CA 94304 USA; Stanford Univ, Dept Med Oncol, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Xu, X (corresponding author), Rigel Inc, San Francisco, CA USA.		Nolan, Garry/AAE-7903-2019; Lorens, James/B-9737-2017	Lorens, James/0000-0002-6782-3349; Nolan, Garry/0000-0002-8862-9043				Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BELLOREUSS E, 1994, AM J PHYSIOL-CELL PH, V267, pC1351, DOI 10.1152/ajpcell.1994.267.5.C1351; Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; BODENMULLER H, 1986, EMBO J, V5, P1825, DOI 10.1002/j.1460-2075.1986.tb04433.x; Cabilly S, 1999, MOL BIOTECHNOL, V12, P143, DOI 10.1385/MB:12:2:143; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; CASTRO B, 1975, TETRAHEDRON LETT, V14, P1219; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Doong SL, 1998, J HEPATOL, V29, P872, DOI 10.1016/S0168-8278(98)80113-X; Dumontet C, 1996, CANCER RES, V56, P1091; Gallagher WM, 1997, ONCOGENE, V14, P185; Gao YH, 2000, J CLIN INVEST, V106, P439, DOI 10.1172/JCI9826; Groettrup M, 1999, DRUG DISCOV TODAY, V4, P63, DOI 10.1016/S1359-6446(98)01292-6; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Gururaja TL, 1996, PEPTIDE RES, V9, P283; Gururaja TL, 2000, CHEM BIOL, V7, P515, DOI 10.1016/S1074-5521(00)00137-X; HART SM, 1993, LEUKEMIA LYMPHOMA, V11, P239, DOI 10.3109/10428199309087001; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Huang Y, 1997, LEUKEMIA, V11, P253, DOI 10.1038/sj.leu.2400557; Jorgensen L, 1999, MOL BIOL REP, V26, P119, DOI 10.1023/A:1006965602142; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kaye Stanley B., 1998, Current Opinion in Oncology, V10, pS15; Kim SH, 1997, CANCER LETT, V115, P9, DOI 10.1016/S0304-3835(97)04725-3; Klimka A, 1999, BRIT J CANCER, V80, P1214, DOI 10.1038/sj.bjc.6690488; Kundu B, 1999, Prog Drug Res, V53, P89; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEE JS, 1994, MOL PHARMACOL, V46, P627; Leith C, 1998, Curr Opin Hematol, V5, P287; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Mechetner E, 1998, CLIN CANCER RES, V4, P389; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petit F, 1997, BIOCHEM J, V326, P93, DOI 10.1042/bj3260093; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Tsurumi C, 1996, Nihon Rinsho, V54, P861; Volm M, 1998, ANTICANCER RES, V18, P2905; Wong DWS, 1998, ANN NY ACAD SCI, V864, P555, DOI 10.1111/j.1749-6632.1998.tb10379.x; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YAMAGUCHI M, 1995, CANCER, V76, P2351, DOI 10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1	47	82	91	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					23	29		10.1038/83717	http://dx.doi.org/10.1038/83717			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137994				2022-12-25	WOS:000166187900011
J	Riazuddin, S; Castelein, CM; Ahmed, ZM; Lalwani, AK; Mastroianni, MA; Naz, S; Smith, TN; Liburd, NA; Friedman, TB; Griffith, AJ; Riazuddin, S; Wilcox, ER				Riazuddin, S; Castelein, CM; Ahmed, ZM; Lalwani, AK; Mastroianni, MA; Naz, S; Smith, TN; Liburd, NA; Friedman, TB; Griffith, AJ; Riazuddin, S; Wilcox, ER			Dominant modifier DFNM1 suppresses recessive deafness DFNB26	NATURE GENETICS			English	Article							SUSCEPTIBILITY LOCUS; HEARING IMPAIRMENT; GENE; MUTATION; EXISTENCE; PROTEIN; FORM	More than 50% of severe childhood deafness is genetically determined, approximately 70% of which occurs without other abnormalities and is thus termed nonsyndromic(1,2). So far, 30 nonsyndromic recessive deafness loci have been mapped and the defective genes at 6 loci, DFNB1, DFNB2, DFNB3, DFNB4, DFNB9 and DFNB21, have been identified, encoding connexin-26 (ref. 3), myosin VIIA (ref. 4), myosin XV (ref. 5), pendrin(6) otoferlin(7) and alpha -tectorin(8), respectively. Here we map a new recessive nonsyndromic deafness locus, DFNB26, to a 1.5-cM interval of chromosome 4q31 in a consanguineous Pakistani family. A maximum rod score of 8.10 at theta =0 was obtained with D4S1610 when only the 8 affected individuals in this family were included in the calculation. There are seven unaffected family members who are also homozygous for the DFNB26-linked haplotype and thus are non-penetrant. A dominant modifier, DFNM1. that suppresses deafness in the 7 nonpenetrant individuals was mapped to a 5.6-cM region on chromosome 1q24 with a rod score of 4.31 at theta =0 for D1S2815.	NIDCD, Genet Mol Lab, NIH, Rockville, MD 20852 USA; Univ Punjab, Ctr Excellence Mol Biol, Lahore, Pakistan; Univ Calif San Francisco, Dept Otolaryngol, Lab Mol Otol, San Francisco, CA 94143 USA; NIDCD, Neurootol Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Punjab; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Wilcox, ER (corresponding author), NIDCD, Genet Mol Lab, NIH, Rockville, MD 20852 USA.	wilcoxe@nidcd.nih.gov	Naz, Sadaf/C-3911-2019	Naz, Sadaf/0000-0002-1912-0235	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000035, Z01DC000039, Z01DC000048] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01DC00035] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Bejjani BA, 2000, HUM MOL GENET, V9, P367, DOI 10.1093/hmg/9.3.367; BORK JM, IN PRESS AM J HUM GE; Bridges CB, 1919, J EXP ZOOL, V28, P337, DOI 10.1002/jez.1400280302; Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; Fagerheim T, 1996, HUM MOL GENET, V5, P1187, DOI 10.1093/hmg/5.8.1187; Friedman T, 2000, CURR OPIN NEUROBIOL, V10, P487, DOI 10.1016/S0959-4388(00)00120-3; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ikeda A, 1999, HUM MOL GENET, V8, P1761, DOI 10.1093/hmg/8.9.1761; KEISELL DP, 1997, NATURE, V387, P80; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Sertie AL, 1999, AM J HUM GENET, V65, P433, DOI 10.1086/302491; SLYNN G, 1990, NUCLEIC ACIDS RES, V18, P681, DOI 10.1093/nar/18.3.681; TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421; Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; Zielenski J, 1999, NAT GENET, V22, P128, DOI 10.1038/9635	31	95	99	1	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2000	26	4					431	434		10.1038/82558	http://dx.doi.org/10.1038/82558			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101839				2022-12-25	WOS:000165671700014
J	Sato, N; Urano, F; Leem, JY; Kim, SH; Li, MQ; Donoviel, D; Bernstein, A; Lee, AS; Ron, D; Veselits, ML; Sisodia, SS; Thinakaran, G				Sato, N; Urano, F; Leem, JY; Kim, SH; Li, MQ; Donoviel, D; Bernstein, A; Lee, AS; Ron, D; Veselits, ML; Sisodia, SS; Thinakaran, G			Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression	NATURE CELL BIOLOGY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; ENDOPLASMIC-RETICULUM; IN-VIVO; MISSENSE MUTATIONS; SIGNALING PATHWAY; TRANSGENIC MICE; GENE; BRAINS; KINASE	Presenilin 1 (Ps1), a polytopic membrane protein, has a critical role in the trafficking and proteolysis of a selected set of transmembrane proteins. The vast majority of individuals affected with early onset familial Alzheimer's disease (FAD) carry missense mutations in PSI. Two studies have suggested that loss of Ps1 function, or expression of FAD-linked Ps1 variants, compromises the mammalian unfolded-protein response (UPR), and we sought to evaluate the potential role of Ps1 in the mammalian UPR. Here we show that neither the endoplasmic reticulum (ER) stress-induced accumulation of BiP and CHOP messenger RNA, nor the activation of ER stress kinases IRE1 alpha and PERK, is compromised in cells lacking both PS1 and PS2 or in cells expressing FAD-linked PS1 variants. We also show that the levels of BiP are not significantly different in the brains of individuals with sporadic Alzheimer's disease or PS1-mediated FAD to levels in control brains. Our findings provide evidence that neither loss of PS1 and PS2 function, nor expression of PS1 variants, has a discernable impact on ER stress-mediated induction of the several established 'readouts' of the UPR pathway.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ Toronto, Dept Mol & Med Genet, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada	University of Chicago; New York University; University of Southern California; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Thinakaran, G (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Knapp R212,924 E 57th St, Chicago, IL 60637 USA.		Urano, Fumihiko/AAF-4492-2020	Ron, David/0000-0002-3014-5636; Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NIA NIH HHS [1PO1 AG14248] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CRUTCHER LA, 1995, IEEE PARALL DISTRIB, V3, P4, DOI 10.1109/88.393226; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hendriks L, 1997, NEUROREPORT, V8, P1717, DOI 10.1097/00001756-199705060-00030; Hogan B, 1994, MANIPULATING MOUSE E; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WWF, 1993, J BIOL CHEM, V268, P12003; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matthias C, 1998, PHARMACOGENETICS, V8, P1, DOI 10.1097/00008571-199802000-00001; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; PRICE BD, 1992, CANCER RES, V52, P3814; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; WANG JA, 1996, J CHINA COAL SCI, V1, P16; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	41	112	116	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					863	870		10.1038/35046500	http://dx.doi.org/10.1038/35046500			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146649				2022-12-25	WOS:000165814500007
J	Jochum, W; David, JP; Elliott, C; Wutz, A; Plenk, H; Matsuo, K; Wagner, EF				Jochum, W; David, JP; Elliott, C; Wutz, A; Plenk, H; Matsuo, K; Wagner, EF			Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-l	NATURE MEDICINE			English	Article							C-FOS; AP-1 COMPLEX; GENE; TRANSFORMATION; MUTATION; PROTEINS; JUN; DIFFERENTIATION; EXPRESSION; CELLS	Bone formation by osteoblasts is essential for skeletal growth and remodeling. Fra-1 is a c-fos-related protein belonging to the AP-1 family of transcription factors. Here we show that transgenic mice overexpressing Fra-1 in various organs develop a progressive increase in bone mass leading to osteosclerosis of the entire skeleton, which is due to a cell-autonomous increase in the number of mature osteoblasts. Moreover, osteoblast differentiation, but not proliferation, was enhanced and osteoclastogenesis was also elevated in vitro. These data indicate that, unlike c-Fos, which causes osteosarcomas, Fra-1 specifically enhances bone formation, which may be exploited to stimulate bone formation in pathological conditions.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Vienna, Inst Histol & Embryol Bone & Biomat Res, A-1090 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Vienna	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Elliott, Candace/F-1860-2011; Matsuo, Koichi/K-5695-2012	Elliott, Candace/0000-0002-9174-0244; Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHAMBERS TJ, 2000, IN PRESS J PATHOL; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960-9822(98)70434-8; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kajimoto Y, 1998, ENDOCR J, V45, P1, DOI 10.1507/endocrj.45.1; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Plenk HJ., 1986, TECHNIQUES BIOCOMPAT, P35; Recker RR., 1983, BONE HISTOMORPHOMETR; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	30	245	254	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					980	984		10.1038/79676	http://dx.doi.org/10.1038/79676			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973316				2022-12-25	WOS:000089190500028
J	Good, L; Awasthi, SK; Dryselius, R; Larsson, O; Nielsen, PE				Good, L; Awasthi, SK; Dryselius, R; Larsson, O; Nielsen, PE			Bactericidal antisense effects of peptide-PNA conjugates	NATURE BIOTECHNOLOGY			English	Article							NUCLEIC-ACIDS; MESSENGER-RNA; ANTIBIOTIC-RESISTANCE; SELECTIVE-INHIBITION; ESCHERICHIA-COLI; GENE-EXPRESSION; DNA; OLIGONUCLEOTIDES; TRANSLATION; REPLICATION	Antisense peptide nucleic acids (PNAs) can specifically inhibit Escherichia coli gene expression and growth and hold promise as anti-infective agents and as tools for microbial functional genomics. Here we demonstrate that chemical modification improves the potency of standard PNAs. We show that 9- to 12-mer PNAs, especially when attached to the cell wall/membrane-active peptide KFFKFFKFFK, provide improvements in antisense potency in E. coli amounting to two orders of magnitude while retaining target specificity. Peptide-PNA conjugates targeted to ribosomal RNA (rRNA) and to messenger RNA (mRNA) encoding the essential fatty acid biosynthesis protein Acp prevented cell growth. The anti-acpP PNA at 2 muM concentration cured HeLa cell cultures noninvasively infected with E. coli K12 without any apparent toxicity to the human cells. These results indicate that peptides can be used to carry antisense PNA agents into bacteria. Such peptide-PNA conjugates open exciting possibilities for anti-infective drug development and provide new tools for microbial genetics.	Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden; Univ Copenhagen, Panum Inst, Dept Biochem B, IMBG,Ctr Biomol Recognit, DK-2200 Copenhagen N, Denmark; Pantheco AS, DK-2970 Horsholm, Denmark	Karolinska Institutet; University of Copenhagen	Good, L (corresponding author), Karolinska Inst, Ctr Genom Res, Berzelius Vag 37, S-17177 Stockholm, Sweden.			Larsson, Ola/0000-0003-1412-1308				Aldrian-Herrada G, 1998, NUCLEIC ACIDS RES, V26, P4910, DOI 10.1093/nar/26.21.4910; Christensen L, 1995, J Pept Sci, V1, P175; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Giesen U, 1998, NUCLEIC ACIDS RES, V26, P5004, DOI 10.1093/nar/26.21.5004; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; Good L, 2000, MICROBIOL-SGM, V146, P2665, DOI 10.1099/00221287-146-10-2665; Good L, 1998, P NATL ACAD SCI USA, V95, P2073, DOI 10.1073/pnas.95.5.2073; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Harth G, 2000, P NATL ACAD SCI USA, V97, P418, DOI 10.1073/pnas.97.1.418; Jensen KK, 1997, BIOCHEMISTRY-US, V36, P5072, DOI 10.1021/bi9627525; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; Miller J.H., 1972, EXPT MOL GENETICS; Murray RW, 1998, ANTIMICROB AGENTS CH, V42, P947, DOI 10.1128/AAC.42.4.947; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1997, CHEM SOC REV, V96, P73; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SEKIGUCHI M, 1967, P NATL ACAD SCI USA, V58, P2315, DOI 10.1073/pnas.58.6.2315; Tan YT, 2000, MOL MED TODAY, V6, P309, DOI 10.1016/S1357-4310(00)01739-1; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; Vaara M, 1996, ANTIMICROB AGENTS CH, V40, P1801, DOI 10.1128/AAC.40.8.1801; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; White DG, 1997, ANTIMICROB AGENTS CH, V41, P2699, DOI 10.1128/AAC.41.12.2699; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0	31	286	328	4	56	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					360	364		10.1038/86753	http://dx.doi.org/10.1038/86753			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283595	Green Submitted			2022-12-25	WOS:000167940700026
J	Marth, G; Yeh, R; Minton, M; Donaldson, R; Li, Q; Duan, SG; Davenport, R; Miller, RD; Kwok, PY				Marth, G; Yeh, R; Minton, M; Donaldson, R; Li, Q; Duan, SG; Davenport, R; Miller, RD; Kwok, PY			Single-nucleotide polymorphisms in the public domain: how useful are they?	NATURE GENETICS			English	Article								There is a concerted effort by a number of public and private groups to identify a large set of human single-nucleotide polymorphisms(1,2) (SNPs). As of March 2001, 2.84 million SNPs have been deposited in the public database, dbSNP, at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/SNP/). The 2.84 million SNPs can he grouped into 1.65 million non-redundant SNPs. As part of the International SNP Map Working Group, we recently published a high-density SNP map of the human genome consisting of 1.42 million SNPs (ref. 3). In addition, numerous SNPs are maintained in proprietary databases. Our survey of more than 1,200 SNPs indicates that more than 80% of TSC and Washington University candidate SNPs are polymorphic and that approximately 50% of the candidate SNPs from these two sources are common SNPs (with minor allele frequency of greater than or equal to 20%) in any given population.	Washington Univ, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Div Dermatol, St Louis, MO 63130 USA; Natl Ctr Biotechnol Informat, Bethesda, MD USA	Washington University (WUSTL); Washington University (WUSTL)	Kwok, PY (corresponding author), Washington Univ, Div Dermatol, St Louis, MO 63130 USA.		Kwok, Pui-Yan/F-7725-2014	Kwok, Pui-Yan/0000-0002-5087-3059	NHGRI NIH HHS [HG01720] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001720] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000158] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Marshall E, 1999, SCIENCE, V284, P406, DOI 10.1126/science.284.5413.406; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Rozen S, 2000, Methods Mol Biol, V132, P365; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Taillon-Miller P, 1999, GENOME RES, V9, P499; Taillon-Miller P, 2000, NAT GENET, V25, P324, DOI 10.1038/77100; Taillon-Miller P, 1998, GENOME RES, V8, P748, DOI 10.1101/gr.8.7.748	10	120	130	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					371	372		10.1038/86864	http://dx.doi.org/10.1038/86864			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279516				2022-12-25	WOS:000167811200009
J	Saito, N; Okada, T; Horiuchi, H; Murakami, N; Takahashi, J; Nawata, M; Ota, H; Nozaki, K; Takaoka, K				Saito, N; Okada, T; Horiuchi, H; Murakami, N; Takahashi, J; Nawata, M; Ota, H; Nozaki, K; Takaoka, K			A biodegradable polymer as a cytokine delivery system for inducing bone formation	NATURE BIOTECHNOLOGY			English	Article							DRUG-DELIVERY; MORPHOGENETIC PROTEIN-2; BLOCK-COPOLYMERS; REGENERATION; CARRIERS	Bone morphogenetic proteins (BMPs) that have the potential to elicit new bone in vivo have been used in a tissue-engineering approach for the repair of bone injuries and bone defects. Although it is now possible to generate large amounts of recombinant human (rh) BMPs for medical use, the major challenge remains in the development of optimal local delivery systems for these proteins. Here we describe the development of a synthetic biodegradable polymer, poly-D,L-lactic acid-p-dioxanone-polyethylene glycol block copolymer (PLA-DX-PEG). This polymer exhibits promising degradation characteristics for BMP delivery systems and good biocompatibility under test conditions. PLA-DX-PEG/rhBMP-2 composite implants induced ectopic new bone formation effectively when tested in vivo, and can repair large bone defects orthotopically. This polymeric delivery system represents an advance in the technology for the enhancement of bone repair.	Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano 3908621, Japan; Taki Chem Co Ltd, Res Inst, Kakogawa, Hyogo 6750125, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Appl Pharmacol Labs, Tsukuba, Ibaraki 3058585, Japan	Shinshu University; Astellas Pharmaceuticals	Saito, N (corresponding author), Shinshu Univ, Sch Med, Dept Orthopaed Surg, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.							Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; Boyne P J, 1997, Int J Periodontics Restorative Dent, V17, P11; Butler D, 1998, NATURE, V391, P320; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; DELUSTRO F, 1990, CLIN ORTHOP RELAT R, P263; EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623-199506000-00016; Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753; Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301-620X.81B4.9311; Hollinger JO, 1996, BIOMATERIALS, V17, P187, DOI 10.1016/0142-9612(96)85763-2; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; KENLEY R, 1994, J BIOMED MATER RES, V28, P1139, DOI 10.1002/jbm.820281004; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; Langer R, 1998, NATURE, V392, P5; MIYAMOTO S, 1993, CLIN ORTHOP RELAT R, P333; MIYAMOTO S, 1992, CLIN ORTHOP RELAT R, P274; RAY JA, 1981, SURG GYNECOL OBSTET, V153, P497; REDDI AH, 1994, J CELL BIOCHEM, V56, P192, DOI 10.1002/jcb.240560213; Reddi AH, 1997, NAT MED, V3, P837, DOI 10.1038/nm0897-837; Rodeo SA, 1999, AM J SPORT MED, V27, P476, DOI 10.1177/03635465990270041201; Saito N, 1999, J BIOMED MATER RES, V47, P104, DOI 10.1002/(SICI)1097-4636(199910)47:1<104::AID-JBM15>3.3.CO;2-Z; Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217; TAKAOKA K, 1991, J ORTHOPAED RES, V9, P902, DOI 10.1002/jor.1100090617; TOMFORD WW, 1995, J BONE JOINT SURG AM, V77A, P1742, DOI 10.2106/00004623-199511000-00017; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zegzula HD, 1997, J BONE JOINT SURG AM, V79A, P1778, DOI 10.2106/00004623-199712000-00003; ZHU KJ, 1990, J APPL POLYM SCI, V39, P1, DOI 10.1002/app.1990.070390101	29	210	223	1	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					332	335		10.1038/86715	http://dx.doi.org/10.1038/86715			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283590				2022-12-25	WOS:000167940700021
J	Pena, L; Martin-Trillo, M; Juarez, J; Pina, JA; Navarro, L; Martinez-Zapater, JM				Pena, L; Martin-Trillo, M; Juarez, J; Pina, JA; Navarro, L; Martinez-Zapater, JM			Constitutive expression of Arabidopsis LEAFY or APETALA1 genes in citrus reduces their generation time	NATURE BIOTECHNOLOGY			English	Article							TRANSFORMATION	Citrus trees have a long juvenile phase that delays their reproductive development by between 6 and 20 years, depending on the species. With the aim of accelerating their flowering time, we transformed juvenile citrus seedlings to constitutively express the Arabidopsis LEAFY(LFY) or APETALA1 (AP1) genes, which promote flower initiation in Arabidopsis. Both types of transgenic citrus produced fertile flowers and fruits as early as the first year, notably through a mechanism involving an appreciable shortening of their juvenile phase. Furthermore, expression of AP1 was as efficient as LFY in the initiation of flowers, and did not produce any severe developmental abnormality. Both types of transgenic trees flowered in consecutive years, and their flowering response was under environmental control. In addition, zygotic and nucellar derived transgenic seedlings had a very short juvenile phase and flowered in their first spring, demonstrating the stability and inheritance of this trait. These results open new possibilities for domestication, genetic improvement, and experimental research in citrus and other woody species.	Inst Nacl Invest & Tecnol Agr & Alimentaria, Dept Mejora Genet & Biotecnol, Madrid 28040, Spain; Inst Valenciano Invest Agr, Dept Protecc Vegetal & Biotecnol, Valencia 46113, Spain; CSIC, Ctr Nacl Biotecnol, Dept Genet Mol Plantas, E-28049 Madrid, Spain	Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); Instituto Valenciano de Investigaciones Agrarias (IVIA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Martinez-Zapater, JM (corresponding author), Inst Nacl Invest & Tecnol Agr & Alimentaria, Dept Mejora Genet & Biotecnol, Ctra Coruna Km7, Madrid 28040, Spain.	zapater@cnb.uam.es	Martinez Zapater, Jose/I-4892-2012; Navarro, Luis/D-1001-2012; del Mar Martín-Trillo, María/I-2071-2015; Peña, Leandro/F-9089-2014	Martinez Zapater, Jose/0000-0001-7217-4454; Navarro, Luis/0000-0001-5163-5960; del Mar Martín-Trillo, María/0000-0002-6185-2798; Peña, Leandro/0000-0002-9853-366X				BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Busch MA, 1999, SCIENCE, V285, P585, DOI 10.1126/science.285.5427.585; Cervera M, 1998, PLANT CELL REP, V18, P271, DOI 10.1007/s002990050570; ECKES P, 1985, MOL GEN GENET, V199, P216, DOI 10.1007/BF00330262; He ZH, 2000, TRANSGENIC RES, V9, P223, DOI 10.1023/A:1008992719010; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nilsson O, 1997, CURR OPIN BIOTECH, V8, P195, DOI 10.1016/S0958-1669(97)80102-4; Ow DW, 1996, CURR OPIN BIOTECH, V7, P181, DOI 10.1016/S0958-1669(96)80010-3; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PENA L, 1999, TRANSGENIC TREES, V44, P39; POETHIG RS, 1990, SCIENCE, V250, P923, DOI 10.1126/science.250.4983.923; Rottmann WH, 2000, PLANT J, V22, P235, DOI 10.1046/j.1365-313x.2000.00734.x; SIMPSON GG, 1999, ANNU REV CELL DEV BI, V99, P19; Speigel-Roy P., 1996, BIOL CITRUS; Telfer A, 1998, DEVELOPMENT, V125, P1889; VACCANEYT G, 1990, MOL GEN GENET, V220, P245; Wagner D, 1999, SCIENCE, V285, P582, DOI 10.1126/science.285.5427.582; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	24	267	356	2	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					263	267		10.1038/85719	http://dx.doi.org/10.1038/85719			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231561				2022-12-25	WOS:000167283100028
J	Selvarajan, S; Lund, LR; Takeuchi, T; Craik, CS; Werb, Z				Selvarajan, S; Lund, LR; Takeuchi, T; Craik, CS; Werb, Z			A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation	NATURE CELL BIOLOGY			English	Article							MOLECULAR-WEIGHT KININOGEN; NECROSIS-FACTOR-ALPHA; ADIPOSE CONVERSION; MAMMARY-GLAND; FACTOR-XIIA; ACTIVATOR INHIBITOR-1; ESSENTIAL REGULATOR; POTENT INHIBITOR; GENE-EXPRESSION; PRO-UROKINASE	Here we show that plasma kallikrein (PKal) mediates a plasminogen (Plg) cascade in adipocyte differentiation. Ecotin, an inhibitor of serine proteases, inhibits cell-shape change, adipocyte-specific gene expression, and lipid accumulation during adipogenesis in culture. Deficiency of pig, but not of urokinase or tissue-type plasminogen activator, suppresses adipogenesis during differentiation of 3T3-L1 cells and mammary-gland involution. PKal, which is inhibited by ecotin, is required for adipose conversion, pig activation and 3T3-L1 differentiation. Human plasma lacking PKal does not support differentiation of 3T3-L1 cells. PKal is therefore a physiological regulator that acts in the pig cascade during adipogenesis. We propose that the pig cascade fosters adipocyte differentiation by degradation of the fibronectin-rich preadipocyte stromal matrix.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Copenhagen Hosp, Finsen Lab, DK-2100 Copenhagen, Denmark	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Copenhagen	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, Box 0452,513 Parnasssus Ave, San Francisco, CA 94143 USA.				NCI NIH HHS [P01 CA072006-07, P01 CA072006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; ALEXANDER CM, IN PRESS J CELL BIOL; ALI IU, 1977, BIOCHIM BIOPHYS ACTA, V471, P16, DOI 10.1016/0005-2736(77)90388-1; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Booth BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE465, DOI 10.1152/ajpendo.1996.271.3.E465; BORTELL R, 1994, J CELL BIOCHEM, V54, P256, DOI 10.1002/jcb.240540214; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; COLMAN RW, 1969, BIOCHEM BIOPH RES CO, V35, P273, DOI 10.1016/0006-291X(69)90278-2; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; HAUERT J, 1989, BLOOD, V73, P994; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; Lascelles A. K., 1978, Anderson, R. R. : Lactation. A comprehensive treatise. Vol. IV., P115; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; LIOTTA LA, 1981, CANCER RES, V41, P4629; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; LOZA JP, 1994, THROMB HAEMOSTASIS, V71, P347; Lund LR, 1996, DEVELOPMENT, V122, P181; Lund LR, 2000, DEVELOPMENT, V127, P4481; MILES LA, 1983, THROMB RES, V29, P407, DOI 10.1016/0049-3848(83)90244-X; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Rajkumar K, 1999, J ENDOCRINOL, V162, P457, DOI 10.1677/joe.0.1620457; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Raspi G, 1996, J CHROMATOGR B, V684, P265, DOI 10.1016/0378-4347(96)00144-2; RIJKEN DC, 1995, BAILLIERE CLIN HAEM, V8, P291, DOI 10.1016/S0950-3536(05)80269-0; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SAITO H, 1981, NEW ENGL J MED, V305, P910, DOI 10.1056/NEJM198110153051602; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; Schousboe I, 1999, THROMB HAEMOSTASIS, V82, P1041; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; ULMER JS, 1995, FEBS LETT, V365, P159, DOI 10.1016/0014-5793(95)00466-M; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; Zheng B, 1998, ENDOCRINOLOGY, V139, P1708, DOI 10.1210/endo.139.4.5945	52	120	130	1	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					267	275		10.1038/35060059	http://dx.doi.org/10.1038/35060059			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231576	Green Accepted			2022-12-25	WOS:000167365800013
J	Song, HJ; Poo, MM				Song, HJ; Poo, MM			The cell biology of neuronal navigation	NATURE CELL BIOLOGY			English	Review							GROWTH CONE GUIDANCE; CENTRAL-NERVOUS-SYSTEM; AXON GUIDANCE; NEUTROPHIL CHEMOTAXIS; SIGNAL-TRANSDUCTION; CEREBRAL-CORTEX; MAMMALIAN BRAIN; LEADING-EDGE; MIGRATION; CHEMOATTRACTANT	Morphogenesis of the nervous system requires the directed migration of postmitotic neurons to designated locations in the nervous system and the guidance of axon growth cones to their synaptic targets. Evidence suggests that both forms of navigation depend on common guidance molecules, surface receptors and signal transduction pathways that link receptor activation to cytoskeletal reorganization. Future challenges remain not only in identifying all the components of the signalling pathways, but also in understanding how these pathways achieve signal amplification and adaptation-two essential cellular processes for neuronal navigation.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Salk Institute; University of California System; University of California Berkeley	Song, HJ (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.							Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BENTLEY D, 1983, NATURE, V304, P62, DOI 10.1038/304062a0; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Branda CS, 1999, CURR OPIN GENET DEV, V9, P479, DOI 10.1016/S0959-437X(99)80073-2; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; CAJAL SRY, 1995, HISTOLOGY NERVOUS SY, V1, P532; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Condic ML, 1997, NATURE, V389, P852, DOI 10.1038/39878; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Doetsch F, 1997, J NEUROSCI, V17, P5046; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; EBENDAL T, 1977, EXP CELL RES, V105, P379, DOI 10.1016/0014-4827(77)90135-5; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; Gilmore EC, 2000, CURR BIOL, V10, pR162, DOI 10.1016/S0960-9822(00)00332-8; Goldberg DJ, 1996, PERSPECT DEV NEUROBI, V4, P183; Goodhill GJ, 1999, J NEUROBIOL, V41, P230, DOI 10.1002/(SICI)1097-4695(19991105)41:2<230::AID-NEU6>3.0.CO;2-9; Halloran MC, 2000, DEVELOPMENT, V127, P1953; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; Harrison RG, 1914, J EXP ZOOL, V17, P521, DOI 10.1002/jez.1400170403; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holtfreter J, 1944, J EXP ZOOL, V95, P307, DOI 10.1002/jez.1400950303; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; JODAN JD, 2000, CELL, V103, P193; Jurata LW, 2000, CURR OPIN NEUROBIOL, V10, P72, DOI 10.1016/S0959-4388(99)00053-7; Kandel E., 2000, PRINCIPLES NEURAL SC; Keynes R, 1997, NEURON, V18, P889, DOI 10.1016/S0896-6273(00)80329-3; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEDOUARIN NM, 1994, PROG BRAIN RES, V100, P3; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LOSCHINGER J, 2000, PHIL T R SOC LOND B, V355, P1; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; MCKENNA MP, 1988, DEV BIOL, V130, P232, DOI 10.1016/0012-1606(88)90429-0; Meinhardt H, 1999, J CELL SCI, V112, P2867; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Nieto M, 1997, J EXP MED, V186, P153, DOI 10.1084/jem.186.1.153; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RAKIC P, 1995, J NEUROBIOL, V26, P299, DOI 10.1002/neu.480260303; Rakic P, 1998, J AM ACAD CHILD PSY, V37, P116, DOI 10.1097/00004583-199801000-00026; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosentreter SM, 1998, J NEUROBIOL, V37, P541, DOI 10.1002/(SICI)1097-4695(199812)37:4<541::AID-NEU4>3.3.CO;2-C; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SANE DH, 2000, DEV NERVOUS SYSTEM; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; Sym M, 1999, CELL, V98, P25, DOI 10.1016/S0092-8674(00)80603-0; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trowe T, 1996, DEVELOPMENT, V123, P439; Walsh CA, 2000, CURR OPIN GENET DEV, V10, P270, DOI 10.1016/S0959-437X(00)00076-9; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Wang XH, 1998, J NEUROSCI, V18, P4985; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Weiss P, 1934, J EXP ZOOL, V68, P393, DOI 10.1002/jez.1400680304; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2; Zheng C, 1996, SCIENCE, V272, P417, DOI 10.1126/science.272.5260.417; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zhu Y, 1999, NEURON, V23, P473, DOI 10.1016/S0896-6273(00)80801-6; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606; [No title captured]	100	296	305	7	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					E81	E88		10.1038/35060164	http://dx.doi.org/10.1038/35060164			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231595				2022-12-25	WOS:000167365800006
J	Vercoutere, W; Winters-Hilt, S; Olsen, H; Deamer, D; Haussler, D; Akeson, M				Vercoutere, W; Winters-Hilt, S; Olsen, H; Deamer, D; Haussler, D; Akeson, M			Rapid discrimination among individual DNA hairpin molecules at single-nucleotide resolution using an ion channel	NATURE BIOTECHNOLOGY			English	Article							POLYNUCLEOTIDE MOLECULES	RNA and DNA strands produce ionic current signatures when driven through an alpha -hemolysin channel by an applied voltage. Here we combine this nanopore detector with a support vector machine (SVM) to analyze DNA hairpin molecules on the millisecond time scare. Measurable properties include duplex stem length, base pair mismatches, and loop length. This nanopore instrument can discriminate between individual DNA hairpins that differ by one base pair or by one nucleotide.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Akeson, M (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.							Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5; Bayley H, 2000, ADV MATER, V12, P139, DOI 10.1002/(SICI)1521-4095(200001)12:2<139::AID-ADMA139>3.3.CO;2-H; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Cormen T. H., 1989, INTRO ALGORITHMS; JAAKKOLA T, 1999, ADV NEURAL INFORMATI; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079; MICHAEL D, 1999, CHEM SITE 3 01; Nievergelt Y., 1999, WAVELETS MADE EASY; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; Rief M, 1999, NAT STRUCT BIOL, V6, P346; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Vapnik V., 1999, NATURE STAT LEARNING; Voss D, 1999, NEW SCI, V164, P40	17	352	420	2	123	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					248	252		10.1038/85696	http://dx.doi.org/10.1038/85696			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231558				2022-12-25	WOS:000167283100025
J	Washburn, MP; Wolters, D; Yates, JR				Washburn, MP; Wolters, D; Yates, JR			Large-scale analysis of the yeast proteome by multidimensional protein identification technology	NATURE BIOTECHNOLOGY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; IMMOBILIZED PH GRADIENTS; LOW-FEMTOMOLE LEVEL; MEMBRANE H+-ATPASE; MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; MESSENGER-RNA; GENE-PRODUCTS	We describe a largely unbiased method for rapid and large-scale proteome analysis by multidimensional liquid chromatography, tandem mass spectrometry, and database searching by the SEQUEST algorithm, named multidimensional protein identification technology (MudPIT). MudPIT was applied to the proteome of the Saccharomyces cerevisiae strain BJ5460 grown to mid-log phase and yielded the largest proteome analysis to date. A total of 1,484 proteins were detected and identified. Categorization of these hits demonstrated the ability of this technology to detect and identify proteins rarely seen in proteome analysis, including low-abundance proteins like transcription factors and protein kinases. Furthermore, we identified 131 proteins with three or more predicted transmembrane domains, which allowed us to map the soluble domains of many of the integral membrane proteins. MudPIT is useful for proteome analysis and may be specifically applied to integral membrane proteins to obtain detailed biochemical information on this unwieldy class of proteins.	Syngenta Agr Discovery Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol SR11, La Jolla, CA 92037 USA	Syngenta; Scripps Research Institute	Yates, JR (corresponding author), Syngenta Agr Discovery Inst, 3115 Merryfield Row,Suite 100, San Diego, CA 92121 USA.	jyates@scripps.edu		Washburn, Michael/0000-0001-7568-2585	NCI NIH HHS [R33 CA212973, R33CA81665-01] Funding Source: Medline; NCRR NIH HHS [RR11823-03] Funding Source: Medline; NHGRI NIH HHS [T32HG000035-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA081665, R33CA212973] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AITKEN A, 1989, PROTEIN SEQUENCING P, P43; Ambesi A, 2000, J EXP BIOL, V203, P155; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fountoulakis M, 1999, J CHROMATOGR A, V833, P157, DOI 10.1016/S0021-9673(98)00929-7; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P2181, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2181::AID-ELPS2181>3.0.CO;2-Q; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GIDDINGS JC, 1987, J HIGH RES CHROMATOG, V10, P319, DOI 10.1002/jhrc.1240100517; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash SM, 2000, ELECTROPHORESIS, V21, P1202, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1202::AID-ELPS1202>3.3.CO;2-9; Hatzimanikatis V, 1999, BIOTECHNOL PROGR, V15, P312, DOI 10.1021/bp990004b; Hatzimanikatis V, 1999, METAB ENG, V1, P275, DOI 10.1006/mben.1999.0115; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kawamoto S, 1996, GENE, V174, P151, DOI 10.1016/0378-1119(96)00512-4; Kuhlbrandt W, 1998, CURR OPIN STRUC BIOL, V8, P510, DOI 10.1016/S0959-440X(98)80130-9; Langen H, 2000, ELECTROPHORESIS, V21, P411, DOI 10.1002/(SICI)1522-2683(20000101)21:2<411::AID-ELPS411>3.3.CO;2-W; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Molloy MP, 2000, ANAL BIOCHEM, V280, P1, DOI 10.1006/abio.2000.4514; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Nilsson CL, 2000, MASS SPECTROM REV, V19, P390, DOI 10.1002/1098-2787(2000)19:6<390::AID-MAS2>3.3.CO;2-T; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Oh-Ishi M, 2000, ELECTROPHORESIS, V21, P1653, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1653::AID-ELPS1653>3.0.CO;2-9; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Pasa-Tolic L, 1999, J AM CHEM SOC, V121, P7949, DOI 10.1021/ja991063o; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Washburn MP, 2000, CURR OPIN MICROBIOL, V3, P292, DOI 10.1016/S1369-5274(00)00092-8; WASHBURN MP, 2000, PROTEOMICS CURRENT S, P28; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	52	3718	3939	5	583	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					242	247		10.1038/85686	http://dx.doi.org/10.1038/85686			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231557				2022-12-25	WOS:000167283100024
J	de la Serna, IL; Carlson, KA; Imbalzano, AN				de la Serna, IL; Carlson, KA; Imbalzano, AN			Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation	NATURE GENETICS			English	Article							SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; CELL-CYCLE; CHROMATIN; TRANSCRIPTION; BINDING; BRG1; FIBROBLASTS; ACETYLATION	Mammalian SWI/SNF complexes are ATP-dependent chromatin remodeling enzymes that have been implicated in the regulation of gene expression, cell-cycle control and oncogenesis(1-4) MyoD is a muscle-specific regulator able to induce myogenesis in numerous cell types(5). To ascertain the requirement for chromatin remodeling enzymes in cellular differentiation processes, we examined MyoD-mediated induction of muscle differentiation in fibroblasts expressing dominant-negative versions of the human brahma-related gene-1 (BRG1) or human brahma (BRM), the ATPase subunits of two distinct SWI/SNF enzymes. We find that induction of the myogenic phenotype is completely abrogated in the presence of the mutant enzymes. We further demonstrate that failure to induce muscle-specific gene expression correlates with inhibition of chromatin remodeling in the promoter region of an endogenous muscle-specific gene. Our results demonstrate that SWI/SNF enzymes promote MyoD-mediated muscle differentiation and indicate that these enzymes function by altering chromatin structure in promoter regions of endogenous, differentiation-specific loci.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.				NIGMS NIH HHS [R01 GM056244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Javed A, 1999, MOL CELL BIOL, V19, P7491; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	30	254	257	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					187	190		10.1038/84826	http://dx.doi.org/10.1038/84826			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175787				2022-12-25	WOS:000166839200020
J	Xu, YZ; Karalkar, NB; Kool, ET				Xu, YZ; Karalkar, NB; Kool, ET			Nonenzymatic autoligation in direct three-color detection of RNA and DNA point mutations	NATURE BIOTECHNOLOGY			English	Article						diagnostics; genomics; ligation detection reaction; T4 DNA ligase	RESONANCE ENERGY-TRANSFER; CHEMICAL AMPLIFICATION; SINGLE NUCLEOTIDE; NUCLEIC-ACIDS; LIGASE; LIGATION; TEMPLATE; OLIGONUCLEOTIDE; FLUORESCENCE; GENE	Enzymatic ligation methods are useful in diagnostic detection of DNA sequences. Here we describe the investigation of nonenzymatic phosphorothioate-iodide DNA autoligation chemistry as a method for detection and identification of both RNA and DNA sequences. Combining ligation specificity with the hybridization specificity of the ligated product is shown to yield discrimination of a point mutation as high as >10(4)-fold. Unlike enzymatic ligations, this reaction is found to be equally efficient on RNA or DNA templates. The reaction is also shown to exhibit a significant level of self-amplification, with the template acting in catalytic fashion to ligate multiple pairs of probes. A strategy for fluorescence labeling of three autoligating energy transfer (ALET) probes and directly competing them for autoligation on a target sequence is described. The method is tested in several formats, including solution phase, gel, and blot assays. the ALET probe design offers direct RNA detection, combining high sequence specificity with an easily detectable color change by fluorescence resonance energy transfer (FRET).	Univ Rochester, Dept Chem, Rochester, NY 14627 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of Rochester; Stanford University	Kool, ET (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.			Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [GM60612] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albagli D, 1999, J AM CHEM SOC, V121, P6954, DOI 10.1021/ja990434y; ALVES AM, 1988, NUCLEIC ACIDS RES, V16, P8723, DOI 10.1093/nar/16.17.8723; ASHLEY GW, 1991, BIOCHEMISTRY-US, V30, P2927, DOI 10.1021/bi00225a028; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BARRINGER KJ, 1990, GENE, V89, P117, DOI 10.1016/0378-1119(90)90213-B; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CHLADEK S, 1972, J AM CHEM SOC, V94, P2079, DOI 10.1021/ja00761a047; COOK AF, 1970, J AM CHEM SOC, V92, P190, DOI 10.1021/ja00704a032; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; GRYAZNOV SM, 1994, NUCLEIC ACIDS RES, V22, P2366, DOI 10.1093/nar/22.12.2366; GRYAZNOV SM, 1993, J AM CHEM SOC, V115, P3808, DOI 10.1021/ja00062a070; Gunderson KL, 1998, GENOME RES, V8, P1142, DOI 10.1101/gr.8.11.1142; Guo Z, 1997, NAT BIOTECHNOL, V15, P331, DOI 10.1038/nbt0497-331; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HERRLEIN MK, 1995, J AM CHEM SOC, V117, P10151, DOI 10.1021/ja00145a042; Hung SC, 1997, ANAL BIOCHEM, V252, P78, DOI 10.1006/abio.1997.2287; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Landegren Ulf, 1996, Methods (Orlando), V9, P84, DOI 10.1006/meth.1996.0011; Liu JQ, 1998, NUCLEIC ACIDS RES, V26, P3300, DOI 10.1093/nar/26.13.3300; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; Luo PZ, 1998, J AM CHEM SOC, V120, P3019, DOI 10.1021/ja972869w; Luther A, 1998, NATURE, V396, P245, DOI 10.1038/24343; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NICKERSON DA, 1990, P NATL ACAD SCI USA, V87, P8923, DOI 10.1073/pnas.87.22.8923; Nilsson M, 2000, NAT BIOTECHNOL, V18, P791, DOI 10.1038/77367; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Pritchard CE, 1997, NUCLEIC ACIDS RES, V25, P3403, DOI 10.1093/nar/25.17.3403; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAMIOTAKI M, 1994, GENOMICS, V20, P238, DOI 10.1006/geno.1994.1159; SOKOLOV BP, 1990, NUCLEIC ACIDS RES, V18, P3671, DOI 10.1093/nar/18.12.3671; SOKOLOVA NI, 1988, FEBS LETT, V232, P153, DOI 10.1016/0014-5793(88)80406-X; Soto D, 1992, PCR Methods Appl, V2, P96; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Whitcombe D, 1998, CURR OPIN BIOTECH, V9, P602, DOI 10.1016/S0958-1669(98)80137-7; Whitcombe D, 1999, NAT BIOTECHNOL, V17, P804, DOI 10.1038/11751; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0; WU DY, 1989, GENOMICS, V4, P560, DOI 10.1016/0888-7543(89)90280-2; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; XU Y, 1999, THESIS U ROCHESTER R; Xu YZ, 1999, NUCLEIC ACIDS RES, V27, P875, DOI 10.1093/nar/27.3.875; Xu YZ, 1997, TETRAHEDRON LETT, V38, P5595, DOI 10.1016/S0040-4039(97)01266-5; Xu YZ, 1998, NUCLEIC ACIDS RES, V26, P3159, DOI 10.1093/nar/26.13.3159; Yang MS, 1997, METHOD ENZYMOL, V278, P417; Zhan ZYJ, 1997, J AM CHEM SOC, V119, P12420, DOI 10.1021/ja972870v	47	143	190	0	56	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					148	152		10.1038/84414	http://dx.doi.org/10.1038/84414			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175729				2022-12-25	WOS:000166754700021
J	Bellaiche, Y; Gho, M; Kaltschmidt, JA; Brand, AH; Schweisguth, F				Bellaiche, Y; Gho, M; Kaltschmidt, JA; Brand, AH; Schweisguth, F			Frizzled regulates localization of cell-fate determinants and mitotic spindle rotation during asymmetric cell division	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA NEUROBLASTS; FUSION PROTEIN; NUMB PROTEIN; DYNAMICS; EMBRYOS; ORIENTATION; ENDODERM; COMPLEX	Cell-fate diversity is generated in part by the unequal segregation of cell-fate determinants during asymmetric cell divisions. In the Drosophila pupa, the pI sense organ precursor cell is polarized along the anterior-posterior axis of the fly and divides asymmetrically to generate a posterior pIIa cell and an anterior pIIb cell. The anterior pIIb cell specifically inherits the determinant Numb and the adaptor protein Partner of Numb (Pon). By labelling both the Pon crescent and the microtubules in living pupae, we show that determinants localize at the anterior cortex before mitotic-spindle formation; and that the spindle forms with random orientation and rotates to line up with the Pon crescent. By imaging living frizzled (fz) mutant pupae we show that Fz regulates the orientation of the polarity axis of pI, the initiation of spindle rotation and the unequal partitioning of determinants. We conclude that Fz participates in establishing the polarity of pI.	Ecole Normale Super, UMR 8544, F-75230 Paris 05, France; Univ Cambridge, Wellcome, CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Cambridge; University of Cambridge	Schweisguth, F (corresponding author), Ecole Normale Super, UMR 8544, 46 Rue Ulm, F-75230 Paris 05, France.		Brand, Andrea H/F-8220-2014	Brand, Andrea H/0000-0002-2089-6954; bellaiche, yohanns/0000-0003-1686-2943				ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buescher M, 1998, GENE DEV, V12, P1858, DOI 10.1101/gad.12.12.1858; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gho M, 1996, DEVELOPMENT, V122, P1673; Gho M, 1999, DEVELOPMENT, V126, P3573; HASELOFF J, 1999, PROTOCOLS CONFOCAL M; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Keating HH, 1998, J CELL SCI, V111, P3027; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; USUI K, 1993, ROUX ARCH DEV BIOL, V203, P151, DOI 10.1007/BF00365054; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128	31	192	195	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					50	57		10.1038/35050558	http://dx.doi.org/10.1038/35050558			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146626				2022-12-25	WOS:000166146400020
J	Jenison, R; Yang, S; Haeberli, A; Polisky, B				Jenison, R; Yang, S; Haeberli, A; Polisky, B			Interference-based detection of nucleic acid targets on optically coated silicon	NATURE BIOTECHNOLOGY			English	Article						biosensor; DNA chip; nucleic acid detection; antibiotic resistance; molecular diagnostics	STAPHYLOCOCCUS-AUREUS; VISUAL DETECTION; DNA; RESISTANCE; BIOSENSOR	Sequence-specific detection of polynucleotides typically requires modified reporter probes that are labeled with radioactive, fluorescent, or luminescent moieties. Although these detection methods are capable of high sensitivity, they require instrumentation for signal detection. In certain settings, such as clinical point of care, instrumentation might be impractical or unavailable. Here we describe a detection approach in which formation of a nucleic acid hybrid is enzymatically transduced into a molecular thin film that can be visually detected in white light. The system exploits a flat, optically coated silicon-based surface to which capture oligonucleotides are covalently attached. The optimized system is capable of detection of nucleic acid targets present at sub-attomole levels. To supplement visual detection, signals can be quantitated by a charge-coupled device. The design and composition of the optical surface, optimization of immobilization chemistry for attachment of capture probes, and characterization of the efficiency of the hybridization process are presented. We describe the application of this system to detection of a clinically relevant target, the mecA gene present in methicillin-resistant Staphylococcus aureus.	BioStar Inc, Boulder, CO 80301 USA		Polisky, B (corresponding author), BioStar Inc, 6655 Lookout Rd, Boulder, CO 80301 USA.							BOBROW MN, 1991, J IMMUNOL METHODS, V137, P103, DOI 10.1016/0022-1759(91)90399-Z; BORN M, 1980, PRINTIPLES OPTICS; BROWN DFJ, 1980, FEBS LETT, V122, P275, DOI 10.1016/0014-5793(80)80455-8; Covalciuc KA, 1999, J CLIN MICROBIOL, V37, P3971, DOI 10.1128/JCM.37.12.3971-3974.1999; *EDW BROTH INC, 1953, SCI COL; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Gerber MA, 1997, JAMA-J AM MED ASSOC, V277, P899, DOI 10.1001/jama.277.11.899; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; Kricka LJ, 1999, CLIN CHEM, V45, P453; Lin VSY, 1997, SCIENCE, V278, P840, DOI 10.1126/science.278.5339.840; Ostroff RM, 1999, CLIN CHEM, V45, P1659; POSPIECH A, 1995, TRENDS GENET, V11, P217, DOI 10.1016/S0168-9525(00)89052-6; Rule GS, 1996, CLIN CHEM, V42, P1206; RUNNING JA, 1990, BIOTECHNIQUES, V8, P276; SANDSTROM T, 1985, APPL OPTICS, V24, P472, DOI 10.1364/AO.24.000472; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; Whitcombe D, 1998, CURR OPIN BIOTECH, V9, P602, DOI 10.1016/S0958-1669(98)80137-7	17	99	160	0	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					62	65		10.1038/83530	http://dx.doi.org/10.1038/83530			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135554				2022-12-25	WOS:000166261400021
J	Stenoien, DL; Patel, K; Mancini, MG; Dutertre, M; Smith, CL; O'Malley, BW; Mancini, MA				Stenoien, DL; Patel, K; Mancini, MG; Dutertre, M; Smith, CL; O'Malley, BW; Mancini, MA			FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent	NATURE CELL BIOLOGY			English	Article							HORMONE-RECEPTOR; GLUCOCORTICOID-RECEPTORS; MOLECULAR DETERMINANTS; PROTEIN-SYNTHESIS; NUCLEAR-MATRIX; COACTIVATOR; BINDING; CELLS; ANTIESTROGEN; TURNOVER	Here we report the use of fluorescence recovery after photobleaching (FRAP) to examine the intranuclear dynamics of fluorescent oestrogen receptor-alpha (ER). After bleaching, unliganded ER exhibits high mobility (recovery t(1/2) < 1 s). Agonist (oestradiol; E2) or partial antagonist (4-hydroxytamoxifen) slows ER recovery (t(1/2) <similar to>5-6 s), whereas the pure antagonist (ICI 182,780) and, surprisingly, proteasome inhibitors each immobilize ER to the nuclear matrix. Dual FRAP experiments show that fluorescent ER and SRC-1 exhibit similar dynamics only in the presence of E2. In contrast to reports that several nuclear proteins show uniform dynamics, ER exhibits differential mobility depending upon several factors that ave linked to its transcription function.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Stenoien, DL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	fmancini@bcm.tmc.edu	Dutertre, Martin/N-7060-2017; DUTERTRE, Martin/Q-1815-2019	Dutertre, Martin/0000-0003-0278-4120; DUTERTRE, Martin/0000-0003-0278-4120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053002, F32DK009787, R01DK055622] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53002, 1F3DK09787, R01 DK55622] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DAUVOIS S, 1993, J CELL SCI, V106, P1377; De Conto F, 2000, J CELL SCI, V113, P2399; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Ellenberg J, 1999, METHODS, V19, P362, DOI 10.1006/meth.1999.0872; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORWITZ KB, 1978, J BIOL CHEM, V253, P6319; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; HU LM, 1994, J BIOL CHEM, V269, P6571; JENSEN EV, 1969, STEROIDS, V13, P417, DOI 10.1016/0039-128X(69)90053-1; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; ONATE SA, 1995, SCIENCE, V270, P1354; Pederson T, 2000, NAT CELL BIOL, V2, pE73, DOI 10.1038/35010501; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHOLL S, 1984, ENDOCRINOLOGY, V115, P1295, DOI 10.1210/endo-115-4-1295; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shopland LS, 2000, J CELL BIOL, V150, pF1, DOI 10.1083/jcb.150.1.F1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Tokumoto M, 2000, FEBS LETT, V472, P62, DOI 10.1016/S0014-5793(00)01441-1; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451	47	340	347	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					15	23		10.1038/35050515	http://dx.doi.org/10.1038/35050515			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146621				2022-12-25	WOS:000166146400015
J	Stewart, CN; Wheaton, SK				Stewart, CN; Wheaton, SK			GM crop data - agronomy and ecology in tandem	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of North Carolina; University of North Carolina Greensboro; University of Rhode Island	Stewart, CN (corresponding author), Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA.		Stewart, Neal/B-4709-2009	Stewart, Neal/0000-0003-3026-9193				*NAT RES COUNC, 2000, EC MON TRANSG CROPS; Stewart CN, 2000, BIOTECHNIQUES, V29, P832, DOI 10.2144/00294bi01	2	9	9	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					3	3		10.1038/83479	http://dx.doi.org/10.1038/83479			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135511	Bronze			2022-12-25	WOS:000166261400002
J	Hanes, J; Schaffitzel, C; Knappik, A; Pluckthun, A				Hanes, J; Schaffitzel, C; Knappik, A; Pluckthun, A			Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display	NATURE BIOTECHNOLOGY			English	Article						ribosome display; in vitro selection; single-chain antibody fragments; Human Combinatorial Antibody Library; affinity maturation	IN-VITRO SELECTION; PHAGE DISPLAY; MOLECULAR EVOLUTION; RNA-POLYMERASE; PROTEIN; MUTAGENESIS; EXPRESSION; PEPTIDE; RECOMBINATION; TRANSCRIPTION	Here we applied ribosome display to in vitro selection and evolution of single-chain antibody fragments (scFvs) from a large synthetic library (Human Combinatorial Antibody Library; HuCAL) against bovine insulin. In three independent ribosome display experiments different clusters of closely related scFvs were selected, all of which bound the antigen with high affinity and specificity. All selected scFvs had affinity-matured up to 40-fold compared to their HuCAL progenitors, by accumulating point mutations during the ribosome display cycles. The dissociation constants of the isolated scfvs were as low as 82 pM, which validates the design of the naive library and the power of this evolutionary method. We have thus mimicked the process of antibody generation and affinity maturation with a synthetic library in a cell-free system in just a few days, obtaining molecules with higher affinities than most natural antibodies.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; MorphoSys AG, D-82152 Munich, Germany	University of Zurich; MorphoSys	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Knappik, Achim/D-3677-2011; Plückthun, Andreas/C-2746-2009; Hanes, Jozef/ABE-6106-2020	Plückthun, Andreas/0000-0003-4191-5306; Berger-Schaffitzel, Christiane Helene/0000-0002-1516-9760; Knappik, Achim/0000-0002-2693-6750				Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Ge L, 1995, ANTIBODY ENG, P229; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hanes J, 1999, CURR TOP MICROBIOL, V243, P107; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; He MY, 1999, J IMMUNOL METHODS, V231, P105, DOI 10.1016/S0022-1759(99)00144-1; JOHNSON G, 1996, HDB EXPT IMMUNOLOGY, V1; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Krebber C, 1995, FEBS LETT, V377, P227, DOI 10.1016/0014-5793(95)01348-2; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; Nemoto N, 1997, FEBS LETT, V414, P405, DOI 10.1016/S0014-5793(97)01026-0; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH WP, 1978, P NATL ACAD SCI USA, V75, P5922, DOI 10.1073/pnas.75.12.5922; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	37	279	418	1	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1287	1292		10.1038/82407	http://dx.doi.org/10.1038/82407			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101809				2022-12-25	WOS:000165659000027
J	Dragatsis, I; Levine, MS; Zeitlin, S				Dragatsis, I; Levine, MS; Zeitlin, S			Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice	NATURE GENETICS			English	Article							HUNTINGTONS-DISEASE GENE; CAG REPEAT; NEURONAL DEGENERATION; WIDESPREAD EXPRESSION; TARGETED DISRUPTION; EMBRYONIC LETHALITY; BASAL GANGLIA; WILD-TYPE; PROTEIN; CELL	Inactivation of the mouse homologue of the Huntington disease gene (Hdh) results in early embryonic lethality. To investigate the normal function of Hdh in the adult and to evaluate current models for Huntington disease (HD), we have used the Cre/IoxP site-specific recombination strategy to inactivate Hdh expression in the forebrain and testis, resulting in a progressive degenerative neuronal phenotype and sterility. On the basis of these results, we propose that huntingtin is required for neuronal function and survival in the brain and that a loss-of-function mechanism may contribute to HD pathogenesis.	Columbia Univ, Dept Pathol, New York, NY USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Mental Retardat Res Ctr, Los Angeles, CA 90024 USA; Columbia Univ, Dept Genet & Dev, New York, NY USA	Columbia University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Columbia University	Zeitlin, S (corresponding author), Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA.		Zeitlin, Scott/P-5787-2019					BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Bordelon YM, 1999, NEUROSCIENCE, V93, P843, DOI 10.1016/S0306-4522(99)00239-0; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; Dragatsis I, 2000, GENESIS, V26, P133, DOI 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V; Dragatsis I, 1998, DEVELOPMENT, V125, P1529; Dragatsis I, 2000, NEUROSCI LETT, V282, P37, DOI 10.1016/S0304-3940(00)00872-7; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Ferrante RJ, 1997, J NEUROSCI, V17, P3052; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LALONDE R, 1987, EXP BRAIN RES, V65, P479; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matsuoka Y, 1997, EXP NEUROL, V146, P57, DOI 10.1006/exnr.1997.6488; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Metzler M, 1999, J NEUROCHEM, V72, P1009, DOI 10.1046/j.1471-4159.1999.0721009.x; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; O'Kusky JR, 1999, BRAIN RES, V818, P468, DOI 10.1016/S0006-8993(98)01312-2; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; Reddy PH, 1999, TRENDS NEUROSCI, V22, P248, DOI 10.1016/S0166-2236(99)01415-0; Rich T, 1999, HUM MOL GENET, V8, P2451, DOI 10.1093/hmg/8.13.2451; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; SANTAROSA R, 1994, LAB INVEST, V70, P503; Sapp E, 1999, J NEUROPATH EXP NEUR, V58, P165, DOI 10.1097/00005072-199902000-00006; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; van den Akker E, 1999, MECH DEVELOP, V89, P103, DOI 10.1016/S0925-4773(99)00212-9; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	46	404	422	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					300	306		10.1038/81593	http://dx.doi.org/10.1038/81593			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062468				2022-12-25	WOS:000165176500017
J	Melchionna, R; Chen, XB; Blasina, A; McGowan, CH				Melchionna, R; Chen, XB; Blasina, A; McGowan, CH			Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1	NATURE CELL BIOLOGY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; IONIZING-RADIATION; KINASE; ATM; P53; PROTEIN; DOWNSTREAM; CHK2	In response to DMA damage, eukaryotic cells use a system of checkpoint controls to delay cell-cycle progression. Checkpoint delays provide time for repair of damaged DNA before its replication in S phase and before segregation of chromatids in M phase(1). The Cds1 (Chk2) tumour-suppressor protein(2) has been implicated in certain checkpoint responses in mammalian cells. It directly phosphorylates and inactivates the mitosis-inducing phosphatase Cdc25 in vitro and is required to maintain the G2 arrest that is observed in response to gamma-irradiation(3-5). Cds1 also directly phosphorylates p53 in vitro at a site that is implicated in its stabilization, and is required for stabilization of p53 and induction of p53-dependent transcripts in vivo upon gamma-ionizing radiation(5-7). Thus, Cds1 functions in both the G1 and G2 checkpoint responses. Like Cds1, the checkpoint protein kinase ATM (ataxiate-tangiectasia-mutated) is required for correct operation of both the G1 and G2 damage checkpoints. ATM is necessary for phosphorylation and activation of Gds1 in vivo(4) and can phosphorylate Cds1 in vitro(8), although evidence that the sites that are phosphorylated by ATM are required for activation is lacking, Here we show that threonine 68 of Cds1 is the preferred site of phosphorylation by ATM in vitro, and is the principal irradiation-induced site of phosphorylation in vivo. The importance of this phosphorylation site is demonstrated by the failure of a mutant, non-phosphorylatable form of Cds1 to be fully activated, and by its reduced ability to induce G1 arrest in response to ionising radiation.	Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	McGowan, CH (corresponding author), Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.		Melchionna, Roberta/AAZ-4111-2021; melchionna, Roberta/G-2479-2011	Melchionna, Roberta/0000-0002-8410-9681; 				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	23	256	263	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					762	765		10.1038/35036406	http://dx.doi.org/10.1038/35036406			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025670				2022-12-25	WOS:000089697000025
J	Weil, CF; Kunze, R				Weil, CF; Kunze, R			Transposition of maize Ac/Ds transposable elements in the yeast Saccharomyces cerevisiae	NATURE GENETICS			English	Article							ACTIVATOR AC TRANSPOSASE; DNA TRANSPOSITION; IN-VIVO; EXCISION; EXPRESSION; GENE; ARABIDOPSIS; TOBACCO; RECOMBINATION; DISSOCIATION	Excision by transposons is associated with chromosome breaks; generally, host-cell proteins repair this damage, often introducing mutations. Many transposons also use host proteins in the transposition mechanism or in regulation(1-4). Transposition in systems lacking host factors that influence the behaviour of these transpositions is useful in determining what those factors are and how they work. In addition, features of transposition and regulation intrinsic to the element itself can be determined. Maize Activator/Dissociation (Ac/Ds) elements transpose in a wide variety of heterologous plants, but their characteristics in these other systems differ from those in maize, including their response to increasing genetic dosage(5,6) and the types of repair products recovered following excision(7). Two Arabidopsis thaliana mutants (iae1 and iae2) show increased Ac transposition frequencies(8). These mutants, and the differences mentioned above, suggest the involvement of host proteins in Ac/Ds activity and potential differences between these proteins among plant species. Here we report that Ac/Ds elements, members of the hAT (hobo, Ac, Tam3) superfamily, transpose in the yeast Saccharomyces cerevisiae, an organism lacking class II ('cut and paste') transposons. This demonstrates that plant-specific proteins are not essential for Ac/Ds transposition. The yeast system is valuable for dissecting the Ac/Ds transposition mechanism and identifying host factors that can influence transposition and the repair of DNA damage induced by Ac/Ds. Mutations caused by Ds excision in yeast suggest formation of a DNA-hairpin intermediate, and reinsertions occur throughout the genome with a frequency similar to that in plants. The high proportion of Ac/Ds reinsertions also makes this system an in vivo mutagenesis and reverse genetics tool in yeast and, presumably, other eukaryotic systems.	Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA; Univ Munich, Inst Genet & Mikrobiol, D-8000 Munich, Germany	Idaho; University of Idaho; University of Munich	Kunze, R (corresponding author), Univ Cologne, Bot Inst 2, Cologne, Germany.			Kunze, Reinhard/0000-0002-3304-5550				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; COEN ES, 1989, MOBILE DNA; Colot V, 1998, MOL CELL BIOL, V18, P4337, DOI 10.1128/MCB.18.7.4337; DABOUSSI MJ, 1994, GENETICA, V93, P1; ESSER SL, 2000, PLANT CELL, V12, P211; FELDMAR S, 1991, EMBO J, V10, P4003, DOI 10.1002/j.1460-2075.1991.tb04975.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINLEIN M, 1994, PLANT J, V5, P705, DOI 10.1111/j.1365-313X.1994.00705.x; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOUBAHERIN N, 1990, MOL GEN GENET, V224, P17, DOI 10.1007/BF00259446; Jarvis P, 1997, PLANT J, V11, P907; KELLER J, 1993, PLANT MOL BIOL, V21, P157, DOI 10.1007/BF00039626; Kempken F, 1996, MOL CELL BIOL, V16, P6563; Kunze R, 1997, ADV BOT RES, V27, P331; KUNZE R, 1995, PLANT J, V8, P45, DOI 10.1046/j.1365-313X.1995.08010045.x; KUNZE R, 1993, P NATL ACAD SCI USA, V90, P7094, DOI 10.1073/pnas.90.15.7094; LAUFS J, 1990, P NATL ACAD SCI USA, V87, P7752, DOI 10.1073/pnas.87.19.7752; MAKRIS JC, 1990, J BACTERIOL, V172, P1368, DOI 10.1128/jb.172.3.1368-1373.1990; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Rinehart TA, 1997, PLANT J, V12, P1419, DOI 10.1046/j.1365-313x.1997.12061419.x; SCOFIELD SR, 1993, CELL, V75, P507, DOI 10.1016/0092-8674(93)90385-4; SIGNON L, 1995, GENE DEV, V9, P1123, DOI 10.1101/gad.9.9.1123; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SWINBURNE J, 1992, PLANT CELL, V4, P583, DOI 10.1105/tpc.4.5.583; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	28	71	79	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					187	190		10.1038/82827	http://dx.doi.org/10.1038/82827			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017074				2022-12-25	WOS:000089638800015
J	Bargal, R; Avidan, N; Ben-Asher, E; Olender, Z; Zeigler, M; Frumkin, A; Raas-Rothschild, A; Glusman, G; Lancet, D; Bach, G				Bargal, R; Avidan, N; Ben-Asher, E; Olender, Z; Zeigler, M; Frumkin, A; Raas-Rothschild, A; Glusman, G; Lancet, D; Bach, G			Identification of the gene causing mucolipidosis type IV	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; NATURAL-HISTORY; PROTEIN; PREDICTION; DATABASE; DNA	Mucolipidosis type IV (MLIV) is an autosomal recessive, neurodegenerative, lysosomal storage disorder(1) characterized by psychomotor retardation and ophthalmological abnormalities including corneal opacities, retinal degeneration and strabismus. Most patients reach a maximal developmental level of 12-15 months(2). The disease was classified as a mucolipidosis following observations by electron microscopy indicating the lysosomal storage of lipids together with water-soluble, granulated substances(1,3-6). Over 80% of the MLIV patients diagnosed are Ashkenazi Jews, including severely affected and mildly affected patients(3,4). The gene causing MLIV was previously mapped to human chromosome 19p13.2-13.3 in a region of approximately 1 cM (ref. 7). Haplotype analysis in the MLIV gene region of over 70 MLIV Ashkenazi chromosomes indicated the existence of two founder chromosomes among 95% of the Ashkenazi MLIV families: a major haplotype in 72% and a minor haplotype in 23% of the MLIV chromosomes (ref. 7, and G.B., unpublished data). The remaining 5% are distinct haplotypes found only in single patients. The basic metabolic defect causing the lysosomal storage in MLIV has not yet been identified. Thus. positional cloning was an alternative to identify the MLIV gene. We report here the identification of a new gene in this human chromosomal region in which MLIV-specific mutations were identified.	Hadassah Hebrew Univ Hosp, Dept Human Genet, Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Genet, Crown Human Genome Ctr, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Weizmann Institute of Science	Bach, G (corresponding author), Hadassah Hebrew Univ Hosp, Dept Human Genet, Jerusalem, Israel.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMIR N, 1987, PEDIATRICS, V79, P953; BACH G, 1992, GENETIC DIVERSITY AMONG JEWS, P301; BERMAN ER, 1974, J PEDIATR-US, V84, P519, DOI 10.1016/S0022-3476(74)80671-2; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHITAYAT D, 1991, AM J MED GENET, V41, P313, DOI 10.1002/ajmg.1320410310; Glusman G, 2000, BIOINFORMATICS, V16, P482, DOI 10.1093/bioinformatics/16.5.482; GOEBEL HH, 1982, CLIN NEUROPATHOL, V1, P73; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MERIN S, 1975, INVEST OPHTH VISUAL, V14, P437; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REIS S, 1993, AM J MED GENET, V47, P392; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sessa A, 1997, J NEPHROL, V10, P295; Slaugenhaupt SA, 1999, AM J HUM GENET, V65, P773, DOI 10.1086/302549; SOLOVYEV V, 1997, ISMB, V5, P294	21	274	282	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					118	121		10.1038/79095	http://dx.doi.org/10.1038/79095			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973263				2022-12-25	WOS:000089078000032
J	Huynh, DP; Figueroa, K; Hoang, N; Pulst, SM				Huynh, DP; Figueroa, K; Hoang, N; Pulst, SM			Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; MACHADO-JOSEPH DISEASE; TRANSGENIC MICE; EXPANDED POLYGLUTAMINE; HUNTINGTONS-DISEASE; CAG REPEAT; PURKINJE-CELL; SPINOCEREBELLAR ATAXIA-2; TRINUCLEOTIDE REPEAT; ALZHEIMERS-DISEASE	Instability of CAG DNA trinucleotide repeats is the mutational mechanism for several neurodegenerative diseases resulting in the expansion of a polyglutamine (polyQ) tract. Proteins with long polyQ tracts have an increased tendency to aggregate, often as truncated fragments forming ubiquitinated intranuclear inclusion bodies. We examined whether similar features define spinocerebellar ataxia type 2 (SCA2) pathogenesis using cultured cells, human brains and transgenic mouse lines. In SCA2 brains, we found cytoplasmic, but not nuclear, microaggregates. Mice expressing ataxin-2 with Q58 showed progressive functional deficits accompanied by loss of the Purkinje cell dendritic arbor and finally loss of Purkinje cells. Despite similar functional deficits and anatomical changes observed in ataxin-1[Q80] transgenic lines, ataxin-2[Q58] remained cytoplasmic without detectable ubiquitination.	Univ Calif Los Angeles, Sch Med, CSMC Burns & Allen Res Inst, Rose Moss Lab Parkinsons & Neurodegenerat Dis, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Neurol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pulst, SM (corresponding author), Univ Calif Los Angeles, Sch Med, CSMC Burns & Allen Res Inst, Rose Moss Lab Parkinsons & Neurodegenerat Dis, Los Angeles, CA 90024 USA.	Pulst@CSHS.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033123] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS33123] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Clark HB, 1997, J NEUROSCI, V17, P7385; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Huynh DP, 1999, ANN NEUROL, V45, P232, DOI 10.1002/1531-8249(199902)45:2<232::AID-ANA14>3.0.CO;2-7; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishikawa K, 1999, HUM MOL GENET, V8, P1185, DOI 10.1093/hmg/8.7.1185; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kim M, 1999, J NEUROSCI, V19, P964; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOEPPEN AH, 1991, J NEUROPATH EXP NEUR, V50, P505, DOI 10.1097/00005072-199107000-00010; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Kuemmerle S, 1999, ANN NEUROL, V46, P842; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Nechiporuk T, 1998, HUM MOL GENET, V7, P1301, DOI 10.1093/hmg/7.8.1301; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Trottier Y, 1998, NEUROBIOL DIS, V5, P335, DOI 10.1006/nbdi.1998.0208; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; Vig PJS, 1998, NEUROLOGY, V50, P106, DOI 10.1212/WNL.50.1.106; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	48	228	237	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					44	50		10.1038/79162	http://dx.doi.org/10.1038/79162			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973246				2022-12-25	WOS:000089078000015
J	Coleman, ML; Sahai, EA; Yeo, M; Bosch, M; Dewar, A; Olson, MF				Coleman, ML; Sahai, EA; Yeo, M; Bosch, M; Dewar, A; Olson, MF			Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I	NATURE CELL BIOLOGY			English	Article							RHO-ASSOCIATED KINASE; BINDING PROTEIN-RHO; LIGHT-CHAIN PHOSPHORYLATION; ACTIN CYTOSKELETON; MYOSIN PHOSPHATASE; FOCAL ADHESIONS; PUTATIVE TARGET; REORGANIZATION; CELLS; PAK2	The execution phase of apoptosis is characterized by marked changes in cell morphology that include contraction and membrane blebbing. The actin-myosin system has been proposed to be the source of contractile force that drives bleb formation, although the biochemical pathway that promotes actin-myosin contractility during apoptosis has not been identified. Here we show that the Rho effector protein ROCK I, which contributes to phosphorylation of myosin light-chains, myosin ATPase activity and coupling of actin-myosin filaments to the plasma membrane, is cleaved during apoptosis to generate a truncated active form. The activity of ROCK proteins is both necessary and sufficient for formation of membrane blebs and for re-localization of fragmented DNA into blebs and apoptotic bodies.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cellular & Mol Biol, London SW3 6JB, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6NP, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Royal Brompton Hospital	Coleman, ML (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cellular & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael/ABA-4240-2021; Coleman, Mathew L/C-1676-2014; Olson, Michael F/A-3240-2011; Bosch, Marta/AAU-9099-2020	Olson, Michael/0000-0003-3428-3507; Coleman, Mathew L/0000-0001-6020-9023; Bosch, Marta/0000-0003-3934-6781; Sahai, Erik/0000-0002-3932-5086				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; COTTER TG, 1992, CANCER RES, V52, P997; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kaneko T, 2000, BIOCHEM BIOPH RES CO, V273, P110, DOI 10.1006/bbrc.2000.2901; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Torgerson RR, 1998, J CELL SCI, V111, P2911; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Zeng Q, 2000, J CELL SCI, V113, P471	32	927	957	2	71	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					339	345		10.1038/35070009	http://dx.doi.org/10.1038/35070009			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283606				2022-12-25	WOS:000168043900011
J	Costa, RM; Yang, T; Huynh, DP; Pulst, SM; Viskochil, DH; Silva, AJ; Brannan, CI				Costa, RM; Yang, T; Huynh, DP; Pulst, SM; Viskochil, DH; Silva, AJ; Brannan, CI			Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1	NATURE GENETICS			English	Article							NEUROFIBROMATOSIS TYPE-1 NF1; LONG-TERM-MEMORY; RAS SIGNALING PATHWAY; MORRIS WATER MAZE; TARGETED MUTATION; MUTANT MICE; MOUSE MODEL; GENE; EXPRESSION; GAP	Neurofibromatosis type 1 (NF1) is a commonly inherited autosomal dominant disorder. Previous studies indicated that mice homozygous for a null mutation in Nf1 exhibit mid-gestation lethality, whereas heterozygous mice have an increased predisposition to tumors and learning impairments. Here we show that mice lacking the alternatively spliced exon 23a, which modifies the GTPase-activating protein (CAP) domain of Nf1, are viable and physically normal, and do not have an increased tumor predisposition, but show specific learning impairments. Our findings have implications for the development of a treatment for the learning disabilities associated with NF1 and indicate that the CAP domain of NF1 modulates learning and memory.	Univ Calif Los Angeles, Dept Neurobiol, BRI, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Psychiat, BRI, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Psychol, BRI, Los Angeles, CA USA; Univ Florida, Coll Med, Inst Brain, Gainesville, FL USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA USA; Univ Utah, Div Med Genet, Salt Lake City, UT USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Utah System of Higher Education; University of Utah	Brannan, CI (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, BRI, Los Angeles, CA 90024 USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Costa, Rui M./0000-0003-0495-8374; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038480] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38480] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson JC., 1992, J BUS-BUS MARK, V1, P3, DOI [DOI 10.1300/J033V01N01_02, 10.1300/J033v01n01_02]; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Bunsey M, 1995, HIPPOCAMPUS, V5, P546, DOI 10.1002/hipo.450050606; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; Cho YH, 1999, BEHAV BRAIN RES, V98, P77; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Gutmann DH, 1999, ANN NEUROL, V46, P777, DOI 10.1002/1531-8249(199911)46:5<777::AID-ANA15>3.0.CO;2-H; GUTMANN DH, 1994, METABOLIC MOL BASIS, P1; Hogan B, 1994, MANIPULATING MOUSE E; Huson SHR, 1994, NEUROFIBROMATOSES PA; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kogan JH, 1997, CURR BIOL, V7, P1, DOI 10.1016/S0960-9822(06)00022-4; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; NORDLUND ML, 1995, J NEUROPATH EXP NEUR, V54, P588, DOI 10.1097/00005072-199507000-00013; Ozonoff S, 1999, AM J MED GENET, V89, P45, DOI 10.1002/(SICI)1096-8628(19990326)89:1<45::AID-AJMG9>3.0.CO;2-J; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; UPADHYAYA M, 1998, NEUROFIBROMATOSIS TY, V1; Upadhyaya M., 1998, NEUROFIBROMATOSIS TY, P39; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253	38	136	144	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					399	405		10.1038/86898	http://dx.doi.org/10.1038/86898			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279521				2022-12-25	WOS:000167811200014
J	Hughes, TR; Mao, M; Jones, AR; Burchard, J; Marton, MJ; Shannon, KW; Lefkowitz, SM; Ziman, M; Schelter, JM; Meyer, MR; Kobayashi, S; Davis, C; Dai, HY; He, YDD; Stephaniants, SB; Cavet, G; Walker, WL; West, A; Coffey, E; Shoemaker, DD; Stoughton, R; Blanchard, AP; Friend, SH; Linsley, PS				Hughes, TR; Mao, M; Jones, AR; Burchard, J; Marton, MJ; Shannon, KW; Lefkowitz, SM; Ziman, M; Schelter, JM; Meyer, MR; Kobayashi, S; Davis, C; Dai, HY; He, YDD; Stephaniants, SB; Cavet, G; Walker, WL; West, A; Coffey, E; Shoemaker, DD; Stoughton, R; Blanchard, AP; Friend, SH; Linsley, PS			Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer	NATURE BIOTECHNOLOGY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; HYBRIDIZATION; PATTERNS; ARRAYS; CELLS; DIFFERENTIATION; DISCOVERY; SEQUENCE; NUMBER	We describe a flexible system for gene expression profiling using arrays of tens of thousands of oligonucleotides synthesized in situ by an ink-jet printing method employing standard phosphoramidite chemistry. We have characterized the dependence of hybridization specificity and sensitivity on parameters including oligonucleotide length, hybridization stringency, sequence identity, sample abundance, and sample preparation method. We find that 60-mer oligonucleotides reliably detect transcript ratios at one copy per cell in complex biological samples, and that ink-jet arrays are compatible with several different sample amplification and labeling techniques. Furthermore, results using only a single carefully selected oligonucleotide per gene correlate closely with those obtained using complementary DNA (cDNA) arrays. Most of the genes for which measurements differ are members of gene families that can only be distinguished by oligonucleotides. Because different oligonucleotide sequences can be specified for each array, we anticipate that ink-jet oligonucleotide array technology will be useful in a wide variety of DNA microarray applications.	Rosetta Inpharm Inc, Kirkland, WA 98034 USA; Agilent Technol Inc, Palo Alto, CA 94304 USA	Agilent Technologies	Linsley, PS (corresponding author), Rosetta Inpharm Inc, 12040 115th Ave NE, Kirkland, WA 98034 USA.			Blanchard, Alan/0000-0002-4446-1648				Blanchard AP, 1996, BIOSENS BIOELECTRON, V11, P687, DOI 10.1016/0956-5663(96)83302-1; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; HUNG SH, 1994, NUCLEIC ACIDS RES, V22, P4326, DOI 10.1093/nar/22.20.4326; Khan J, 1998, CANCER RES, V58, P5009; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHANNON K, 2000, Patent No. 6132997; Shchepinov MS, 1997, NUCLEIC ACIDS RES, V25, P1155, DOI 10.1093/nar/25.6.1155; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Zhao S, 1998, BIOTECHNIQUES, V24, P842, DOI 10.2144/98245rr01	26	949	1074	0	96	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					342	347		10.1038/86730	http://dx.doi.org/10.1038/86730			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283592				2022-12-25	WOS:000167940700023
J	Shih, DQ; Bussen, M; Sehayek, E; Ananthanarayanan, M; Shneider, BL; Suchy, FJ; Shefer, S; Bollileni, JS; Gonzalez, FJ; Breslow, JL; Stoffel, M				Shih, DQ; Bussen, M; Sehayek, E; Ananthanarayanan, M; Shneider, BL; Suchy, FJ; Shefer, S; Bollileni, JS; Gonzalez, FJ; Breslow, JL; Stoffel, M			Hepatocyte nuclear factor-1 alpha is an essential regulator of bile acid and plasma cholesterol metabolism	NATURE GENETICS			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR LXR-ALPHA; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GENE; EXPRESSION; ATHEROSCLEROSIS; LIVER; PROTEIN; PATHWAY	Maturity-onset diabetes of the young type 3 (MODY3) is caused by haploinsufficiency of hepatocyte nuclear factor-let (encoded by TCF1). Tcf1(-/-) mice have type 2 diabetes, dwarfism, renal Fanconi syndrome, hepatic dysfunction and hypercholestrolemia. Here we explore the molecular basis for the hypercholesterolemia using oligonucleotide microchip expression analysis. We demonstrate that Tcf1(-/-) mice have a defect in bile acid transport, increased bile acid and liver cholesterol synthesis, and impaired HDL metabolism. Tcf1(-/-) liver has decreased expression of the basolateral membrane bile acid transporters Slc10a1, Slc21a3 and Slc21a5, leading to impaired portal bile acid uptake and elevated plasma bile acid concentrations. In intestine and kidneys, Tcf1(-/-) mice lack expression of the ileal bile acid transporter (Slc10a2), resulting in increased fecal and urinary bile acid excretion. The Tcf1 protein (also known as HNF-1 alpha) also regulates transcription of the gene ((Nr1h4) encoding the farnesoid X receptor-1 (Fxr-1), thereby leading to reduced expression of small heterodimer partner-1 (Shp-1) and repression of Cyp7a1, the rate-limiting enzyme in the classic bile acid biosynthesis pathway. In addition, hepatocyte bile acid storage protein is absent from Tcf1(-/-) mice. Increased plasma cholesterol of Tcf1(-/-) mice resides predominantly in large, buoyant, high-density lipoprotein (HDL) particles. This is most likely due to reduced activity of the HDL-catabolic enzyme hepatic lipase (Lipc) and increased expression of HDL-cholesterol esterifying enzyme lecithin:cholesterol acyl transferase (Lcat). Our studies demonstrate that Tcf1, in addition to being an important regulator of insulin secretion, is an essential transcriptional regulator of bile acid and HDL-cholesterol metabolism.	Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Univ Med & Dent New Jersey, Dept Med, Piscataway, NJ 08854 USA; NCI, Bethesda, MD 20892 USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stoffel, M (corresponding author), Rockefeller Univ, Lab Metab Dis, 1230 York Ave, New York, NY 10021 USA.		Breslow, Jan L/B-7544-2008	Stoffel, Markus/0000-0003-1304-5817	NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [R01DK55033-01, DK02076, DK26756] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002076, R01DK055033, R37DK026756, R01DK026756] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1994, J CLIN INVEST, V93, P1776, DOI 10.1172/JCI117163; ANANTHANARAYANAN M, 1991, AM J PHYSIOL, V261, pG810, DOI 10.1152/ajpgi.1991.261.5.G810; Austin MA, 1996, CURR OPIN LIPIDOL, V7, P167, DOI 10.1097/00041433-199606000-00010; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chiang John Y. L., 1998, Frontiers in Bioscience, V3, pD176; Christie DM, 1996, AM J PHYSIOL-GASTR L, V271, pG377, DOI 10.1152/ajpgi.1996.271.2.G377; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; FELKER TE, 1978, P NATL ACAD SCI USA, V75, P3459, DOI 10.1073/pnas.75.7.3459; Foger B, 1999, J BIOL CHEM, V274, P36912, DOI 10.1074/jbc.274.52.36912; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; LAGGNER P, 1977, EUR J BIOCHEM, V77, P165, DOI 10.1111/j.1432-1033.1977.tb11654.x; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Levine DM, 1997, CLIN CHEM, V43, P669; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MAHLEY RW, 1975, BIOCHEMISTRY-US, V14, P2817, DOI 10.1021/bi00684a005; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANZATO E, 1976, J CLIN INVEST, V57, P1248, DOI 10.1172/JCI108393; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; NORUM KR, 1971, J CLIN INVEST, V50, P1131, DOI 10.1172/JCI106585; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; POWELL DR, 1993, DNA CELL BIOL, V12, P283, DOI 10.1089/dna.1993.12.283; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SETCHELL KDR, 1983, J LIPID RES, V24, P1085; SETCHELL KDR, 1995, BIOCHEMISTRY-US, V34, P4169, DOI 10.1021/bi00013a004; Shneider BL, 1997, J BIOL CHEM, V272, P31006, DOI 10.1074/jbc.272.49.31006; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stieger B, 1998, CURR OPIN CELL BIOL, V10, P462, DOI 10.1016/S0955-0674(98)80059-8; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; STOLZ A, 1993, J BIOL CHEM, V268, P10448; TRANCHE T, 1994, LIVER GENE EXPRESSIO, P155; vanAntwerpen R, 1997, J LIPID RES, V38, P659; WONG MH, 1994, J BIOL CHEM, V269, P1340; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	43	339	353	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					375	382		10.1038/86871	http://dx.doi.org/10.1038/86871			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279518				2022-12-25	WOS:000167811200011
J	Zhou, HL; Watts, JD; Aebersold, R				Zhou, HL; Watts, JD; Aebersold, R			A systematic approach to the analysis of protein phosphorylation	NATURE BIOTECHNOLOGY			English	Article							TRAP MASS-SPECTROMETRY; TYROSINE PHOSPHORYLATION; PEPTIDES; IDENTIFICATION; PHASE; YEAST; SITES	Reversible protein phosphorylation has been known for some time to control a wide range of biological functions and activities(1-3). Thus determination of the site(s) of protein phosphorylation has been an essential step in the analysis of the control of many biological systems. However, direct determination of individual phosphorylation sites occurring on phosphoproteins in vivo has been difficult to date, typically requiring the purification to homogeneity of the phosphoprotein of interest before analysis(4-6) Thus, there has been a substantial need for a more rapid and general method for the analysis of protein phosphorylation in complex protein mixtures. Here we describe such an approach to protein phosphorylation analysis. It consists of three steps: (1) selective phosphopeptide isolation from a peptide mixture via a sequence of chemical reactions, (2) phosphopeptide analysis by automated liquid chromatography-tandem mass spectrometry (LC-MS/MS), and (3) identification of the phosphoprotein and the phosphorylated residue(s) by correlation of tandem mass spectrometric data with sequence databases. By utilizing Various phosphoprotein standards and a whole yeast cell lysate, we demonstrate that the method is equally applicable to serine-, threonine- and tyrosine-phosphorylated proteins, and is capable of selectively isolating and identifying phosphopeptides present in a highly complex peptide mixture.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Aebersold, R (corresponding author), Inst Syst Biol, 4225 Roosevelt Way NE,Suite 200, Seattle, WA 98105 USA.				NATIONAL CANCER INSTITUTE [R33CA084698] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCI NIH HHS [1R33 CA84698] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; PHS HHS [R01 A141109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AEBERSOLD R, 1991, ANAL BIOCHEM, V199, P51, DOI 10.1016/0003-2697(91)90268-X; BODANSZKY AMB, 1984, PRACTICE PEPTIDE SYN, V21; CARRAWAY KL, 1968, BIOCHIM BIOPHYS ACTA, V160, P272, DOI 10.1016/0005-2795(68)90102-5; CHU BCF, 1983, NUCLEIC ACIDS RES, V11, P6513, DOI 10.1093/nar/11.18.6513; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HOARE DG, 1967, J BIOL CHEM, V242, P2447; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; Jonscher KR, 1997, J BIOL CHEM, V272, P1735, DOI 10.1074/jbc.272.3.1735; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Moore D.D., 1987, CURRENT PROTOCOLS MO; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Qin J, 1997, ANAL CHEM, V69, P4002, DOI 10.1021/ac970489n; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WATTS JD, 1994, J BIOL CHEM, V269, P29520	19	629	678	2	101	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					375	378		10.1038/86777	http://dx.doi.org/10.1038/86777			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283598				2022-12-25	WOS:000167940700029
J	El-Maarri, O; Buiting, K; Peery, EG; Kroisel, PM; Balaban, B; Wagner, K; Urman, B; Heyd, J; Lich, C; Brannan, CI; Walter, J; Horsthemke, B				El-Maarri, O; Buiting, K; Peery, EG; Kroisel, PM; Balaban, B; Wagner, K; Urman, B; Heyd, J; Lich, C; Brannan, CI; Walter, J; Horsthemke, B			Maternal methylation imprints on human chromosome 15 are established during or after fertilization	NATURE GENETICS			English	Letter							PRADER-WILLI; SNRPN GENE; ANGELMAN; DEMETHYLATION; DELETIONS; DEFINE; GENOME	Prader-Willi syndrome (PWS) is a neurogenetic disorder that results from the lack of transcripts expressed from the paternal copy of the imprinted chromosomal region 15q11-q13 (refs, 1,2). In some patients, this is associated with a deletion of the SNURF-SNRPN exon 1 region inherited from the paternal grandmother and the presence of a maternal imprint on the paternal chromosome. Assuming that imprints are reset in the germ line, we and others have suggested that this region constitutes part of the 15q imprinting center (IC) and is important for the maternal to paternal imprint switch in the male germ line(3,4). Here we report that sperm DNA from two males with an IC deletion had a normal paternal methylation pattern along 15q11-q13, Similar findings were made in a mouse model. Our results indicate that the incorrect maternal methylation imprint in IC deletion patients is established de novo after fertilization, Moreover, we found that CpG-rich regions in SNURF-SNRPN and NDN, which in somatic tissues are methylated on the maternal allele, are hypomethylated in unfertilized human oocytes, Our results indicate that the normal maternal methylation imprints in 15q11-q13 also are established during or after fertilization.	Max Planck Inst Mol Genet, Berlin, Germany; Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-4300 Essen, Germany; Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Mol Genet & Microbiol, Gainesville, FL USA; Univ Florida, Coll Med, Inst Brain, Gainesville, FL USA; Graz Univ, Inst Med Biol & Human Genet, Graz, Austria; Amer Hastanasi, Assisted Reprod Technol Unit, TR-80200 Istanbul, Turkey	Max Planck Society; University of Duisburg Essen; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Graz; Amerikan Hospital	Walter, J (corresponding author), Univ Saarland, Postfach 151150, Saarbrucken, Germany.	j.walter@mx.uni-saarland.de		El-Maarri, Osman/0000-0002-6859-5819				BLELINSKA B, 2000, NAT GENET, V25, P74; Buiting K, 2000, CLIN GENET, V58, P284, DOI 10.1034/j.1399-0004.2000.580406.x; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; Lyko F, 1998, P NATL ACAD SCI USA, V95, P1698, DOI 10.1073/pnas.95.4.1698; Mann MRW, 2000, NAT GENET, V25, P4, DOI 10.1038/75575; Mann MRW, 1999, HUM MOL GENET, V8, P1867, DOI 10.1093/hmg/8.10.1867; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Prissette M, 2001, HUM MOL GENET, V10, P31, DOI 10.1093/hmg/10.1.31; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Shemer R, 2000, NAT GENET, V26, P440, DOI 10.1038/82571; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; Tilghman SM, 1998, NAT GENET, V18, P206, DOI 10.1038/ng0398-206; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387	20	164	166	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					341	344		10.1038/85927	http://dx.doi.org/10.1038/85927			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242121				2022-12-25	WOS:000167304200031
J	O'Connell, J; Houston, A; Bennett, MW; O'Sullivan, G; Shanahan, F				O'Connell, J; Houston, A; Bennett, MW; O'Sullivan, G; Shanahan, F			Immune privilege or inflammation? Insights into the Fas ligand enigma	NATURE MEDICINE			English	Editorial Material							SMOOTH-MUSCLE CELLS; COLON-CANCER; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; LIVER METASTASES; BREAST-CANCER; TUMOR-CELLS; IN-VIVO; EXPRESSION; COUNTERATTACK		Natl Univ Ireland, Univ Hosp, Dept Med, Cork, Ireland; Natl Univ Ireland, Mercy Hosp, Dept Surg, Cork, Ireland	University College Cork; University College Cork	O'Connell, J (corresponding author), Natl Univ Ireland, Univ Hosp, Dept Med, Cork, Ireland.		Houston, Aileen/ABF-2473-2020; Shanahan, Fergus/ABF-2390-2020	Houston, Aileen/0000-0003-1362-5256; Shanahan, Fergus/0000-0003-0467-0936				Arbuckle E, 2000, ONCOL REP, V7, P45; Bennett MW, 1998, J IMMUNOL, V160, P5669; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Eberl LP, 1999, INT J CANCER, V81, P772, DOI 10.1002/(SICI)1097-0215(19990531)81:5<772::AID-IJC18>3.0.CO;2-S; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Ito Y, 2000, BRIT J CANCER, V82, P1211; Jarry A, 1999, GUT, V45, P246, DOI 10.1136/gut.45.2.246; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kelly L, 1999, INT J EXP PATHOL, V80, P217, DOI 10.1046/j.1365-2613.1999.00117.x; Khar A, 1998, CELL IMMUNOL, V189, P85, DOI 10.1006/cimm.1998.1367; Kim YS, 2000, ARCH PATHOL LAB MED, V124, P687; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Li XK, 1998, TRANSPLANTATION, V66, P1416, DOI 10.1097/00007890-199812150-00003; Mann B, 1999, BRIT J CANCER, V79, P1262, DOI 10.1038/sj.bjc.6690202; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Mor G, 2000, J STEROID BIOCHEM, V73, P185, DOI 10.1016/S0960-0760(00)00081-9; Mottolese M, 2000, INT J CANCER, V89, P127, DOI 10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4; Munakata S, 2000, BRIT J CANCER, V82, P1446, DOI 10.1054/bjoc.1999.1073; Nagarkatti N, 2000, CANCER IMMUNOL IMMUN, V49, P46, DOI 10.1007/s002620050025; O'Connell J, 1998, J PATHOL, V186, P240; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Okada K, 2000, CLIN CANCER RES, V6, P3560; PAPOFF G, 1998, SCIENCE, V279, pA2015; Reimer T, 2000, CANCER RES, V60, P822; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; Sampalo A, 2000, BLOOD, V96, P3168; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Shibakita M, 1999, CLIN CANCER RES, V5, P2464; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Sikora J, 1998, NAT IMMUN, V16, P244, DOI 10.1159/000069450; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Swenson KM, 1998, TRANSPLANTATION, V65, P155; Volm M, 2000, BRIT J CANCER, V82, P1747; Waku T, 2000, J IMMUNOL, V165, P5884, DOI 10.4049/jimmunol.165.10.5884; Yakes FM, 2000, CANCER RES, V60, P5740; Yoong KF, 1999, AM J PATHOL, V154, P693, DOI 10.1016/S0002-9440(10)65316-3; Zaks TZ, 1999, J IMMUNOL, V162, P3273	40	132	135	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					271	274		10.1038/85395	http://dx.doi.org/10.1038/85395			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231613				2022-12-25	WOS:000167380400018
J	Pleschka, S; Wolff, T; Ehrhardt, C; Hobom, G; Planz, O; Rapp, UR; Ludwig, S				Pleschka, S; Wolff, T; Ehrhardt, C; Hobom, G; Planz, O; Rapp, UR; Ludwig, S			Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; IMMUNODEFICIENCY-VIRUS; REGULATED KINASE; NUCLEAR EXPORT; NS2 PROTEIN; PATHWAY; CELLS; MAP; RIBONUCLEOPROTEINS; PHOSPHORYLATION	Influenza A viruses are important worldwide pathogens in humans and different animal species. The functions of most of the ten different viral proteins of this negative-strand RNA virus have been well elucidated(1). However, little is known about the virus-induced intracellular signalling events that support viral replication. The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival(2-5). investigation of the function of this pathway has been facilitated by the identification of specific inhibitors such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK)(6-8). Here we show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade. Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus production. Thus, signalling through the mitogenic cascade seems to be essential for virus production and RNP export from the nucleus during the viral life cycle.	Univ Giessen, Inst Virol, Fac Med Vet, D-35392 Giessen, Germany; Robert Koch Inst, D-13353 Berlin, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany; Bundesforschungsanstalt Viruserkrankungen Tiere, D-72076 Tubingen, Germany	Justus Liebig University Giessen; Robert Koch Institute; University of Wurzburg; Justus Liebig University Giessen	Pleschka, S (corresponding author), Univ Giessen, Inst Virol, Fac Med Vet, D-35392 Giessen, Germany.		Pleschka, Stephan/HGU-9354-2022	Ludwig, Stephan/0000-0003-4490-3052; Pleschka, Stephan/0000-0002-7372-7089				Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bruder JT, 1997, J VIROL, V71, P398, DOI 10.1128/JVI.71.1.398-404.1997; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GREGORIADES A, 1990, VIRUS RES, V16, P27, DOI 10.1016/0168-1702(90)90041-9; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; KISTNER O, 1989, J GEN VIROL, V70, P2421, DOI 10.1099/0022-1317-70-9-2421; Lamb R. A., 1996, FIELDS VIROLOGY, P1353; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; Popik W, 1998, VIROLOGY, V252, P210, DOI 10.1006/viro.1998.9466; RICHARDSON JC, 1991, ARCH VIROL, V116, P69, DOI 10.1007/BF01319232; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodems SM, 1998, J VIROL, V72, P9173, DOI 10.1128/JVI.72.11.9173-9180.1998; SCHOLTISSEK C, 1988, ARCH VIROL, V100, P27, DOI 10.1007/BF01310905; SCHOLTISSEK C, 1991, ARCH VIROL, V119, P111, DOI 10.1007/BF01314327; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Whittaker G, 1996, J VIROL, V70, P2743, DOI 10.1128/JVI.70.5.2743-2756.1996	23	407	444	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					301	305		10.1038/35060098	http://dx.doi.org/10.1038/35060098			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231581				2022-12-25	WOS:000167365800018
J	Zhou, BHP; Liao, Y; Xia, WY; Spohn, B; Lee, NH; Hung, MC				Zhou, BHP; Liao, Y; Xia, WY; Spohn, B; Lee, NH; Hung, MC			Cytoplasmic localization of p21(Cip1/WAF1) by Akt-induced phosphorylation in HER-2/neu-overexpressing cells	NATURE CELL BIOLOGY			English	Article							CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; PROTEIN-KINASE; INDUCED APOPTOSIS; HUMAN-BREAST; ACTIVATION; TRANSLOCATION; SURVIVAL; ELECTROPHORESIS; INHIBITION	Amplification or overexpression of HER-2/neu in cancer cells confers resistance to apoptosis and promotes cell growth. The cellular localization of p21(Cip1/WAF1) has been proposed to be critical either in promoting cell survival or in inhibiting cell growth. Here we show that HER-2/neu-mediated cell growth requires the activation of Akt, which associates with p21(Cip1/WAF1) and phosphorylates it at threonine 145, resulting in cytoplasmic localization of p21(Cip1/WAF1). Furthermore, blocking the Akt pathway with a dominant-negative Akt mutant restores the nuclear localization and cell-growth-inhibiting activity of p21(Cip1/WAF1). Our results indicate that HER-2/neu induces cytoplasmic localization of p21(Cip1/WAF1) through activation of Akt to promote cell growth, which may have implications for the oncogenic activity of HER-2/neu and Akt.			Zhou, BHP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gatti A, 1999, ANAL BIOCHEM, V266, P198, DOI 10.1006/abio.1998.2955; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1993, CELL, V75, P805; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ozes ON, 1999, NATURE, V401, P82; PESO LD, 1997, SCIENCE, V278, P687; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; YU D, 2000, DNA ALTERATIONS CANC, pCH21; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	31	868	906	0	35	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					245	252		10.1038/35060032	http://dx.doi.org/10.1038/35060032			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231573				2022-12-25	WOS:000167365800010
J	Crisponi, L; Deiana, M; Loi, A; Chiappe, F; Uda, M; Amati, P; Bisceglia, L; Zelante, L; Nagaraja, R; Porcu, S; Ristaldi, MS; Marzella, R; Rocchi, M; Nicolino, M; Lienhardt-Roussie, A; Nivelon, A; Verloes, A; Schlessinger, D; Gasparini, P; Bonneau, D; Cao, A; Pilia, G				Crisponi, L; Deiana, M; Loi, A; Chiappe, F; Uda, M; Amati, P; Bisceglia, L; Zelante, L; Nagaraja, R; Porcu, S; Ristaldi, MS; Marzella, R; Rocchi, M; Nicolino, M; Lienhardt-Roussie, A; Nivelon, A; Verloes, A; Schlessinger, D; Gasparini, P; Bonneau, D; Cao, A; Pilia, G			The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome	NATURE GENETICS			English	Article							PREMATURE OVARIAN FAILURE; IN-SITU HYBRIDIZATION; EYELID DEVELOPMENT; HELIX GENE; HUMAN HOMOLOG; BLEPHAROPHIMOSIS; PTOSIS; MOUSE; POSITION; MAP	In type I blepharophimosis/ptosis/epicanthus inversus syndrome (BPES), eyelid abnormalities are associated with ovarian failure. Type II BPES shows only the eyelid defects, but both types map to chromosome 3q23. We have positionally cloned a novel. putative winged helix/forkhead transcription factor gene, FOXL2, that is mutated to produce truncated proteins in type I families and larger proteins in type II. Consistent with an involvement in those tissues, FOXL2 is selectively expressed in the mesenchyme of developing mouse eyelids and in adult ovarian follicles; in adult humans, it appears predominantly in the ovary. FOXL2 represents a candidate gene for the polled/intersex syndrome XX sex-reversal goat.	Univ Cagliari, CNR, Ist Ric Talassemie & Anemie Mediterranee, Cagliari, Italy; Univ Cagliari, Osped Reg Microcitemie, Dipartimento Sci Biomed & Biotecnol, Cagliari, Italy; Ctr Hosp Univ Poitiers, Serv Genet Med, Poitiers, France; Osped CSS, IRCCS, Serv Genet Med, I-71013 San Giovanni Rotondo, Italy; NIA, Genet Lab, Baltimore, MD 21224 USA; Univ Bari, DAPEG, Sezione Genet, Bari, Italy; Hop Debrousse, Serv Endocrinol Pediat, Lyon, France; Ctr Hosp Univ Limoges, Serv Pediat, Limoges, France; Ctr Hosp Univ Dijion, Serv Genet, Dijon, France; Univ Liege, Wallonia Ctr Human Genet, Liege, Belgium	Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; University of Cagliari; CHU Poitiers; Universite de Poitiers; IRCCS Casa Sollievo Della Sofferenza; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universita degli Studi di Bari Aldo Moro; CHU Lyon; CHU Limoges; University of Liege	Pilia, G (corresponding author), Univ Cagliari, CNR, Ist Ric Talassemie & Anemie Mediterranee, Cagliari, Italy.	pilia@unica.it	Rocchi, Mariano/B-8451-2011; Ristaldi, Maria S/N-8549-2013; Porcu, Susanna/AAC-3031-2019; Uda, Manuela/AAC-2645-2019; Bonneau, Dominique/K-6110-2015; PORCU, SUSANNA/AAY-3325-2020; Bisceglia, Luigi/B-8720-2017; Crisponi, Laura/AAC-2642-2019; Gasparini, Paolo/B-6173-2014; Ristaldi, Maria Serafina/AAW-6270-2020; VERLOES, Alain/E-7287-2014	Uda, Manuela/0000-0002-4890-6456; PORCU, SUSANNA/0000-0001-8053-7075; Bisceglia, Luigi/0000-0001-5367-8518; Crisponi, Laura/0000-0001-9128-8537; Ristaldi, Maria Serafina/0000-0003-4122-9293; Gasparini, Paolo/0000-0002-0859-0856; VERLOES, Alain/0000-0003-4819-0264	NATIONAL INSTITUTE ON AGING [Z01AG000647, ZIAAG000647] Funding Source: NIH RePORTER; Telethon [E.0357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; Amati P, 1996, AM J HUM GENET, V58, P1089; AMATI P, 1995, HUM GENET, V96, P213, DOI 10.1007/BF00207381; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bisceglia L, 1998, MOL CELL PROBE, V12, P255, DOI 10.1006/mcpr.1998.0171; BOCCIA M, 1994, S DAK REV, V32, P51; Brown CW, 2000, NAT GENET, V25, P453, DOI 10.1038/78140; Chan JKC., 1996, ADV ANAT PATHOL, V3, P156; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; De Baere E, 1999, GENOMICS, V57, P70, DOI 10.1006/geno.1999.5747; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; FINDLATER GS, 1993, J ANAT, V183, P121; FRASER IS, 1988, FERTIL STERIL, V50, P747; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Juriloff DM, 2000, MAMM GENOME, V11, P440, DOI 10.1007/s003350010084; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaestner KH, 2000, GENE DEV, V14, P142; Kaipia A, 1997, ANNU REV PHYSIOL, V59, P349, DOI 10.1146/annurev.physiol.59.1.349; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Labosky PA, 1997, DEVELOPMENT, V124, P1263; LAWSON CT, 1995, HUM MOL GENET, V4, P963, DOI 10.1093/hmg/4.5.963; Layman LC, 1998, FERTIL STERIL, V69, P300, DOI 10.1016/S0015-0282(97)00480-9; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NICOLINO M, 1995, J PEDIATR ENDOCR MET, V8, P127; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Pilia G, 1999, HUM MUTAT, V14, P394, DOI 10.1002/(SICI)1098-1004(199911)14:5<394::AID-HUMU5>3.0.CO;2-1; Praphanphoj V, 2000, GENOMICS, V65, P67, DOI 10.1006/geno.2000.6157; Prueitt RL, 2000, CYTOGENET CELL GENET, V89, P44, DOI 10.1159/000015560; SAMBROOK J, 1989, MOL CLONING MOL LAB; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simpson JL, 1999, AM J MED GENET, V89, P186, DOI 10.1002/(SICI)1096-8628(19991229)89:4<186::AID-AJMG3>3.0.CO;2-5; SMALL KW, 1995, HUM MOL GENET, V4, P443, DOI 10.1093/hmg/4.3.443; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Vaiman D, 1999, GENOMICS, V56, P31, DOI 10.1006/geno.1998.5691; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Vegetti W, 2000, MOL CELL ENDOCRINOL, V161, P53, DOI 10.1016/S0303-7207(99)00224-5; WALL DA, 1994, WEED TECHNOL, V8, P785, DOI 10.1017/S0890037X00028694; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZLOTOGORA J, 1983, AM J HUM GENET, V35, P1020	51	729	776	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2001	27	2					159	166		10.1038/84781	http://dx.doi.org/10.1038/84781			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175783				2022-12-25	WOS:000166839200016
J	Crosbie, RH				Crosbie, RH			NO vascular control in Duchenne muscular dystrophy	NATURE MEDICINE			English	Editorial Material							SKELETAL-MUSCLE; SMOOTH-MUSCLE; NITRIC-OXIDE; GLYCOPROTEIN; COMPLEX; VASOCONSTRICTION	A new investigation into Duchenne muscular dystrophy (DMD) pathogenesis suggests that at least part of the muscle degeneration observed in DMD patients may result from the reduced production of muscle membrane-associated neuronal nitric oxide synthase. This reduction may lead to impaired regulation of the vasoconstrictor response and eventual muscle damage.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Crosbie, RH (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048179] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR048179] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRENNAN JE, 1995, CELL, V85, P743; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1998, HUM MOL GENET, V7, P823, DOI 10.1093/hmg/7.5.823; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; MENKE A, 1995, J CELL SCI, V108, P727; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Thomas GD, 1997, J CLIN INVEST, V99, P2602, DOI 10.1172/JCI119448; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	18	28	28	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					27	29		10.1038/83309	http://dx.doi.org/10.1038/83309			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135610				2022-12-25	WOS:000166243100025
J	Raw, M				Raw, M			Fighting tobacco dependence in Europe	NATURE MEDICINE			English	Editorial Material								The World Health Organization estimates that tobacco will become the largest single health problem by 2020, causing an estimated 8.4 million deaths annually. But the smoking burden will not be distributed evenly across the globe; deaths in developed nations are set to rise 50% to 2.4 million while those in Asia will soar fourfold to an estimated 4.2 million in 2020. In the face of such discrepancy, Martin Raw, Honorary Lecturer in evidence-based treatment at Guys, Kings and St Thomas' School of Medicine, London, explains why attention can not be focused solely on Asia and why efforts are still needed to stop smoking in Europe.	Univ London, Guys Kings & St Thomas Sch Med, London WC1E 7HU, England	University of London; King's College London	Raw, M (corresponding author), Univ London, Guys Kings & St Thomas Sch Med, London WC1E 7HU, England.							CALLUM C, 2000, UK SMOKING EPIDEMIC; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Peto R., 2001, CRITICAL ISSUES GLOB, P154, DOI DOI 10.4314/NMP.V55I6.45441; *ROYAL COLL PHYS, 2000, NIC ADD BRIT REP TOB; *WHO EUR PARTN PRO, 2000, 1 EUR REC TREATM TOB; World Bank, 1999, CURB EP GOV EC TOB C	6	2	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					13	14		10.1038/83281	http://dx.doi.org/10.1038/83281			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135600				2022-12-25	WOS:000166243100017
J	Gao, AG; Hakimi, SM; Mittanck, CA; Wu, Y; Woerner, BM; Stark, DM; Shah, DM; Liang, JH; Rommens, CMT				Gao, AG; Hakimi, SM; Mittanck, CA; Wu, Y; Woerner, BM; Stark, DM; Shah, DM; Liang, JH; Rommens, CMT			Fungal pathogen protection in potato by expression of a plant defensin peptide	NATURE BIOTECHNOLOGY			English	Article						potato; defensins; transgenic; disease control; Verticillium	TRANSGENIC PLANTS; RESISTANCE; DISEASE	Defensins are small cysteine-rich peptides with antimicrobial activity. We demonstrate that the alfalfa antifungal peptide (alfAFP) defensin isolated from seeds of Medicago sativa displays strong activity against the agronomically important fungal pathogen Verticillium dahliae, Expression of the alfAFP peptide in transgenic potato plants provides robust resistance in the greenhouse, Importantly, this resistance is maintained under field conditions. There have been no previous demonstrations of a single transgene imparting a disease resistance phenotype that is at least equivalent to those achieved through current practices using fumigants.	Monsanto Co, St Louis, MO 63198 USA	Monsanto	Liang, JH (corresponding author), Monsanto Co, 700 Chesterfield Pkwy, St Louis, MO 63198 USA.		Shah, Dilip/M-2850-2013	SHAH, DILIP/0000-0001-9503-4729				ANDERSON NA, 1988, AM POTATO J, V65, P469; BARRY G, 1992, J CELL BIOCH SF, V16, P202; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CORNELISSEN BJC, 1997, Patent No. 5670706; Epple P, 1997, PLANT CELL, V9, P509, DOI 10.1105/tpc.9.4.509; Estruch JJ, 1997, NAT BIOTECHNOL, V15, P137, DOI 10.1038/nbt0297-137; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; HAIN R, 1993, NATURE, V361, P153, DOI 10.1038/361153a0; Hudyncia J, 2000, PLANT DIS, V84, P316, DOI 10.1094/PDIS.2000.84.3.316; JACH G, 1995, PLANT J, V8, P97, DOI 10.1046/j.1365-313X.1995.08010097.x; JAMES WC, 1990, CRC HDB PEST MANAGEM, P15; Kaniewski WK, 1999, MOL BIOTECHNOL, V12, P101, DOI 10.1385/MB:12:1:101; LIANG J, 2000, Patent No. 06121436; Long DH, 2000, PLANT DIS, V84, P403, DOI 10.1094/PDIS.2000.84.4.403; Lorito M, 1998, P NATL ACAD SCI USA, V95, P7860, DOI 10.1073/pnas.95.14.7860; MCRAE KB, 1987, PHYTOPATHOLOGY, V77, P1181, DOI 10.1094/Phyto-77-1181; Sambrook J., 2002, MOL CLONING LAB MANU; Shah DM, 1997, CURR OPIN BIOTECH, V8, P208, DOI 10.1016/S0958-1669(97)80104-8; Thevissen K, 1999, APPL ENVIRON MICROB, V65, P5451	19	328	393	3	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1307	1310		10.1038/82436	http://dx.doi.org/10.1038/82436			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101813				2022-12-25	WOS:000165659000031
J	Stiewe, T; Putzer, BM				Stiewe, T; Putzer, BM			Role of the p53-homologue p73 in EZF1-induced apoptosis	NATURE GENETICS			English	Article							P53; BINDING; PROTEIN; NEUROBLASTOMA; ACTIVATION; EXPRESSION; TARGET; GROWTH; E2F; RB	Most human cancers harbour aberrations of cell-cycle control(1), which result in deregulated activity of the E2F transcription factors with concomitant enhanced cell-cycle progression(2). Oncogenic signalling by E2F1 has recently been linked to stabilization and activation of the tumour suppressor p53 (refs 1,3,4). The p73 protein shares substantial sequence homology and functional similarity with p53 (refs 5-7). Hence, several previously considered p53-independent cellular activities may be attributable to p73. Here we provide evidence that E2F1 directly activates transcription of TP73, leading to activation of p53-responsive target genes and apoptosis. Disruption of p73 function by a tumour-derived p53 mutant reduced E2F1-mediated apoptosis. Thus, p73 activation by deregulated E2F1 activity might constitute a p53-independent, anti-tumorigenic safeguard mechanism.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Essen, Germany	University of Duisburg Essen	Putzer, BM (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Essen, Germany.	brigitte.puetzer@uni-essen.de		Stiewe, Thorsten/0000-0003-0134-7826				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zhu JH, 1998, CANCER RES, V58, P5061; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	28	302	306	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2000	26	4					464	469		10.1038/82617	http://dx.doi.org/10.1038/82617			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101847				2022-12-25	WOS:000165671700022
J	[Anonymous]				[Anonymous]			Recent patents in phage display	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1321	1321						1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101819				2022-12-25	WOS:000165659000038
J	Zheng, TS; Hunot, S; Kuida, K; Momoi, T; Srinivasan, A; Nicholson, DW; Lazebnik, Y; Flavell, RA				Zheng, TS; Hunot, S; Kuida, K; Momoi, T; Srinivasan, A; Nicholson, DW; Lazebnik, Y; Flavell, RA			Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation	NATURE MEDICINE			English	Article							ANTI-FAS ANTIBODY; CYTOCHROME-C; IN-VIVO; APOPTOSIS; MICE; PATHWAYS; RELEASE; BCL-2; MITOCHONDRIA; CLEAVAGE	Dysregulation of apoptosis contributes to the pathogenesis of many human diseases. As effecters of the apoptotic machinery, caspases are considered potential therapeutic targets. Using an established in vivo model of Fas-mediated apoptosis, we demonstrate here that elimination of certain caspases was compensated in vivo by the activation of other caspases. Hepatocyte apoptosis and mouse death induced by the Fas agonistic antibody Jo2 required proapoptotic Bcl-2 family member Bid and used a Bid-mediated mitochondrial pathway of caspase activation; deficiency in caspases essential for this pathway, caspase-9 or caspase-3, unexpectedly resulted in rapid activation of alternate caspases after injection of Jo2, and therefore failed to protect mice against Jo2 toxicity. Moreover, both ultraviolet and gamma irradiation, two established inducers of the mitochondrial caspase-activation pathway, also elicited compensatory activation of caspases in cultured caspase-3(-/-) hepatocytes, indicating that the compensatory caspase activation was mediated through the mitochondria. Our findings provide direct experimental evidence for compensatory pathways of caspase activation. This issue should therefore be considered in developing caspase inhibitors for therapeutic applications.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA; NCNP, Natl Inst Neurosci, Div Dev & Differentiat, Tokyo 187, Japan; IDUN Pharmaceut, La Jolla, CA 92037 USA; Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Yale University; Howard Hughes Medical Institute; Yale University; Vertex Pharmaceuticals; National Center for Neurology & Psychiatry - Japan; Merck & Company; Cold Spring Harbor Laboratory	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA.	richard.flavell@yale.edu	Hunot, Stephane/ABE-4204-2021	Hunot, Stephane/0000-0002-8266-5211	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106-25] Funding Source: Medline; NIDDK NIH HHS [1 P30 DK34989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V247, P780, DOI 10.1006/bbrc.1998.8815; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Woo M, 1999, J IMMUNOL, V163, P4909; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	31	262	263	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1241	1247		10.1038/81343	http://dx.doi.org/10.1038/81343			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062535				2022-12-25	WOS:000165114800031
J	Yin, CC; Lai, FA				Yin, CC; Lai, FA			Intrinsic lattice formation by the ryanodine receptor calcium-release channel	NATURE CELL BIOLOGY			English	Article							SKELETAL-MUSCLE; ELEMENTARY EVENTS; RECONSTITUTION; SENSITIVITY	Recent theoretical analysis of a model lattice of interacting transmembrane receptor proteins has indicated that such clustering in the membrane could provide a novel mechanism for regulating receptor signalling in cells(1,2). It has been calculated that cooperative interactions between receptors organized into a cluster, or array, in the membrane would dramatically increase their sensitivity to activation by ligand(1,2). Sensitivity to ligand would increase with the extent of spread of activity within the receptor lattice. Hence, formation of extensive receptor lattices in the membrane would allow a large population of receptors to be simultaneously switched on, or off, by a very small change in ligand concentration. We show here that lattice formation is an intrinsic property of an integral membrane protein, the ryanodine-sensitive calcium-release channel (RyR) of endoplasmic reticulum, The purified protein spontaneously assembled into two-dimensional lattices in solution, enabling the construction of a 25 Angstrom projection map that identifies the mode of interaction between RyR oligomers. Our observations on the RyR provide a new perspective on various properties of cell signalling via this and other receptors.	Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, S Glam, Wales; Natl Inst Med Res, MRC, London NW7 1AA, England	Cardiff University; MRC National Institute for Medical Research	Lai, FA (corresponding author), Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	lait@cf.ac.uk		Lai, Tony/0000-0003-2852-8547; Yin, Chang-Cheng/0000-0001-7748-3205				Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG HP, 1995, SCIENCE, V267, P2009, DOI 10.1126/science.7701326; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; Franzini-Armstrong C, 1999, FASEB J, V13, pS266, DOI 10.1096/fasebj.13.9002.S266; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0	15	97	101	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					669	671		10.1038/35023625	http://dx.doi.org/10.1038/35023625			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980710				2022-12-25	WOS:000089250600021
J	Chheda, MG; Ashery, U; Thakur, P; Rettig, J; Sheng, ZH				Chheda, MG; Ashery, U; Thakur, P; Rettig, J; Sheng, ZH			Phosphorylation of Snapin by PKA modulates its interaction with the SNARE complex	NATURE CELL BIOLOGY			English	Article							LONG-TERM POTENTIATION; PROTEIN-PROTEIN INTERACTIONS; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; TRANSMITTER RELEASE; MEMBRANE-FUSION; HIPPOCAMPAL-NEURONS; SECRETORY MACHINERY; CHROMAFFIN CELLS; CALCIUM CHANNELS	cAMP-dependent protein kinase A (PKA) can modulate synaptic transmission by acting directly on unknown targets in the neurotransmitter secretory machinery. Here we identify Snapin, a protein of relative molecular mass 15,000 that is implicated in neurotransmission by binding to SNAP-25, as a possible target. Deletion mutation and site-directed mutagenetic experiments pinpoint the phosphorylation site to serine 50. PKA-phosphorylation of Snapin significantly increases its binding to synaptosomal-associated protein-25 (SNAP-25). Mutation of Snapin serine 50 to aspartic acid (S50D) mimics this effect of PKA phosphorylation and enhances the association of synaptotagmin with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. Furthermore, treatment of rat hippocampal slices with nonhydrolysable cAMP analogue induces in vivo phosphorylation of Snapin and enhances the interaction of both Snapin and synaptotagmin with the SNARE complex. In adrenal chromaffin cells, overexpression of the Snapin S50D mutant leads to an increase in the number of release-competent vesicles. Our results indicate that Snapin may be a PKA target for modulating transmitter release through the cAMP-dependent signal-transduction pathway.	Natl Inst Neurol Disorders & Stroke, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Max Planck Society	Sheng, ZH (corresponding author), Natl Inst Neurol Disorders & Stroke, Synapt Funct Unit, NIH, 36 Convent Dr, Bethesda, MD 20892 USA.		Rettig, Jens/K-5103-2013	Rettig, Jens/0000-0001-6160-3954; Ashery, Uri/0000-0001-6338-7888	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002946, ZIANS002946] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Bouron A, 1997, P NATL ACAD SCI USA, V94, P12224, DOI 10.1073/pnas.94.22.12224; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; Chavis P, 1998, NEURON, V20, P773, DOI 10.1016/S0896-6273(00)81015-6; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Diamond JS, 1998, NEURON, V21, P425, DOI 10.1016/S0896-6273(00)80551-6; DIXON D, 1989, J NEUROSCI, V9, P4245; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hilfiker S, 1999, NAT NEUROSCI, V2, P104, DOI 10.1038/5659; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN M, 1994, NEURON, V13, P159, DOI 10.1016/0896-6273(94)90466-9; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Trudeau LE, 1996, NEURON, V17, P789, DOI 10.1016/S0896-6273(00)80210-X; Trudeau LE, 1998, P NATL ACAD SCI USA, V95, P7163, DOI 10.1073/pnas.95.12.7163; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISSKOPF MG, 1994, SCIENCE, V265, P1876; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	49	131	143	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					331	338		10.1038/35070000	http://dx.doi.org/10.1038/35070000			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283605	Green Published			2022-12-25	WOS:000168043900010
J	Seetharaman, S; Zivarts, M; Sudarsan, N; Breaker, RR				Seetharaman, S; Zivarts, M; Sudarsan, N; Breaker, RR			Immobilized RNA switches for the analysis of complex chemical and biological mixtures	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO SELECTION; HAMMERHEAD RIBOZYMES; ALLOSTERIC SELECTION; ACTIVATED RIBOZYME; MOLECULAR SWITCHES; GENE-EXPRESSION; DESIGN; DIVERSITY; KINETICS; DELETION	A prototype biosensor array has been assembled from engineered RNA molecular switches that undergo ribozyme-mediated self-cleavage when triggered by specific effectors. Each type of switch is prepared with a 5 ' -thiotriphosphate moiety that permits immobilization on gold to form individually addressable pixels. The ribozymes comprising each pixel become active only when presented with their corresponding effector, such that each type of switch serves as a specific analyte sensor. An addressed array created with seven different RNA switches was used to report the status of targets in complex mixtures containing metal ion, enzyme cofactor, metabolite, and drug analytes. The RNA switch array also was used to determine the phenotypes of Escherichia coli strains for adenylate cyclase function by detecting naturally produced 3 ' ,5 ' -cyclic adenosine monophosphate (cAMP) in bacterial culture media.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.		Breaker, Ronald/E-9679-2010	Breaker, Ronald/0000-0002-2165-536X				Araki M, 1998, NUCLEIC ACIDS RES, V26, P3379, DOI 10.1093/nar/26.14.3379; Atkins J.F, 1999, RNA WORLD; Breaker RR, 1997, CHEM REV, V97, P371, DOI 10.1021/cr960008k; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Guisan JM, 1981, APPL BIOCHEM BIOTECH, V6, P25, DOI 10.1007/BF02779684; Guisan JM, 1981, APPL BIOCHEM BIOTECH, V6, P37, DOI 10.1007/BF02779685; Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; JOSE AM, IN PRESS NUCL ACIDS; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Komatsu Y, 2000, J MOL BIOL, V299, P1231, DOI 10.1006/jmbi.2000.3825; Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4; Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p; Li YF, 1999, CURR OPIN STRUC BIOL, V9, P315, DOI 10.1016/S0959-440X(99)80042-6; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MacBeath G, 2000, SCIENCE, V289, P1760; Marshall KA, 1999, NAT STRUCT BIOL, V6, P992; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; PORTA H, 1995, BIO-TECHNOL, V13, P161, DOI 10.1038/nbt0295-161; POTTER K, 1974, BIOCHEM BIOPH RES CO, V57, P379, DOI 10.1016/0006-291X(74)90941-3; Robertson MP, 2000, NUCLEIC ACIDS RES, V28, P1751, DOI 10.1093/nar/28.8.1751; Robertson MP, 1999, NAT BIOTECHNOL, V17, P62, DOI 10.1038/5236; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SAMBROOK J, 1989, MOL CLONIKNG LAB MAN; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHAH S, 1991, J BACTERIOL, V173, P3238, DOI 10.1128/JB.173.10.3238-3242.1991; Soukup GA, 2000, J MOL BIOL, V298, P623, DOI 10.1006/jmbi.2000.3704; Soukup GA, 1999, TRENDS BIOTECHNOL, V17, P469, DOI 10.1016/S0167-7799(99)01383-9; Soukup GA, 1999, STRUCTURE, V7, P783, DOI 10.1016/S0969-2126(99)80102-6; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Soukup GA, 2000, CURR OPIN STRUC BIOL, V10, P318, DOI 10.1016/S0959-440X(00)00090-7; SOUKUP GA, IN PRESS RNA; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Tang J, 1998, NUCLEIC ACIDS RES, V26, P4214, DOI 10.1093/nar/26.18.4214; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Tang J, 2000, P NATL ACAD SCI USA, V97, P5784, DOI 10.1073/pnas.97.11.5784; WANG DY, IN PRESS J MOL BIOL; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	42	177	195	1	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					336	341		10.1038/86723	http://dx.doi.org/10.1038/86723			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283591				2022-12-25	WOS:000167940700022
J	Stock, RP; Olvera, A; Sanchez, R; Saralegui, A; Scarfi, S; Sanchez-Lopez, R; Ramos, MA; Boffa, LC; Benatti, U; Alagon, A				Stock, RP; Olvera, A; Sanchez, R; Saralegui, A; Scarfi, S; Sanchez-Lopez, R; Ramos, MA; Boffa, LC; Benatti, U; Alagon, A			Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers	NATURE BIOTECHNOLOGY			English	Article							LOCALIZATION SIGNAL; RECEPTOR; CELL; DNA; VIRULENCE; ERD2; RNA	Peptide nucleic acids (PNAs) may be a potent tool for gene function studies in medically important parasitic organisms, especially those that have not before been accessible to molecular genetic knockout approaches. One such organism is Entamoeba histolytica, the causative agent of amebiasis, which infects about 500 million people and is the cause of clinical disease in over 40 million each year, mainly in the tropical and subtropical world. We used PNA antisense oligomers to inhibit expression of an episomally expressed gene (neomycin phosphorotransferase, NPT) and a chromosomal gene (EhErd2, a homolog of Erd2, a marker of the Golgi system in eukaryotic cells) in axenically cultured trophozoites of E. histolytica. Measurement of NPT enzyme activity and EhErd2 protein levels, as well as measurement of cellular proliferation, revealed specific decreases in expression of the target genes, and concomitant inhibition of cell growth, in trophozoites treated with micromolar concentrations of unmodified antisense PNA oligomers.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62210, Morelos, Mexico; Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; IST, Natl Canc Inst, I-16132 Genoa, Italy	Universidad Nacional Autonoma de Mexico; University of Genoa	Alagon, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Av Univ 2001, Cuernavaca 62210, Morelos, Mexico.	alagon@ibt.unam.mx	Scarfi, Sonia/AAJ-2387-2020; Ramos-Ibarra, Marco A./D-5438-2012	Scarfi, Sonia/0000-0002-7079-6919; Ramos-Ibarra, Marco A./0000-0002-8950-2079; SANCHEZ-LOPEZ, ROSANA/0000-0002-1628-7240				Ankri S, 1999, MOL MICROBIOL, V33, P327, DOI 10.1046/j.1365-2958.1999.01476.x; BAKKERGRUNWALD T, 1993, PARASITOL TODAY, V9, P27, DOI 10.1016/0169-4758(93)90161-8; Bhattacharya A, 2000, INT J PARASITOL, V30, P401, DOI 10.1016/S0020-7519(99)00189-7; BLOOM B, 1989, ANN NY ACAD SCI, V569, P36; Bracha R, 1999, MOL MICROBIOL, V34, P463, DOI 10.1046/j.1365-2958.1999.01607.x; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; Dhar SK, 1998, J EUKARYOT MICROBIOL, V45, P656, DOI 10.1111/j.1550-7408.1998.tb04563.x; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P413; Giovine M, 1998, FEBS LETT, V426, P33, DOI 10.1016/S0014-5793(98)00302-0; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; Good L, 1998, P NATL ACAD SCI USA, V95, P2073, DOI 10.1073/pnas.95.5.2073; HYRUP B, 1996, BIOORGAN MED CHEM, V1, P5; LOPEZREVILLA R, 1978, EXP PARASITOL, V44, P243, DOI 10.1016/0014-4894(78)90105-4; MARTINEZPALOMO A, 1982, BIOL ENTAMOEBA HISTO; MCLAUGHLIN J, 1985, J PROTOZOOL, V32, P221; Petri WA, 1999, TRENDS MICROBIOL, V7, P471, DOI 10.1016/S0966-842X(99)01626-1; PLATT SG, 1987, ANAL BIOCHEM, V162, P529, DOI 10.1016/0003-2697(87)90429-5; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Sanchez-Lopez R, 1998, MOL BIOCHEM PARASIT, V92, P355, DOI 10.1016/S0166-6851(98)00017-6; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Soomets Ursel, 1999, Frontiers in Bioscience, V4, pd782, DOI 10.2741/Soomets; Tyler BM, 1999, P NATL ACAD SCI USA, V96, P7053, DOI 10.1073/pnas.96.12.7053; Willhoeft U, 1999, MOL BIOCHEM PARASIT, V99, P41, DOI 10.1016/S0166-6851(98)00178-9	24	39	40	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					231	234		10.1038/85671	http://dx.doi.org/10.1038/85671			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231555				2022-12-25	WOS:000167283100022
J	Yang, JW; Nagavarapu, U; Relloma, K; Sjaastad, MD; Moss, WC; Passaniti, A; Herron, GS				Yang, JW; Nagavarapu, U; Relloma, K; Sjaastad, MD; Moss, WC; Passaniti, A; Herron, GS			Telomerized human microvasculature is functional in vivo	NATURE BIOTECHNOLOGY			English	Article							ENDOTHELIAL PROGENITOR CELLS; ANGIOGENESIS; TISSUE; FIBROBLASTS; MECHANISMS; EXPRESSION; EXTENSION; LINE	Previously we showed the superior in vitro survival of human telomerase reverse transcriptase (hTERT)transduced human endothelial cells (EC). Here we show that retroviral-mediated transduction of hTERT in human dermal microvascular EC (HDMEC) results in cell lines that form microvascular structures when subcutaneously implanted in severe combined immunodeficiency (SCID) mice. Anti-human type IV collagen basement membrane immunoreactivity and visualization of enhanced green fluorescent protein (eGFP)labeled microvessels confirmed the human origin of these capillaries. No human vasculature was observed after implantation of HT1080 fibrosarcoma cells, 293 human embryonic kidney cells, or human skin fibroblasts. Intravascular red fluorescent microspheres injected into host circulation were found within green "telomerized" microvessels, indicating functional murine-human vessel anastamoses. Whereas primary HDMEC-derived vessel density decreased with time, telomerized HDMEC maintained durable vessels six weeks after xenografting. Modulation of implant vessel density by exposure to different angiogenic and angiostatic factors demonstrated the utility of this system for the study of human microvascular remodeling in vivo.	Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA; Mol Med Res Inst, Mountain View, CA 94043 USA; Universal Imaging Corp, W Chester, PA 19380 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol, Baltimore, MD 21201 USA	Stanford University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University System of Maryland; University of Maryland Baltimore	Herron, GS (corresponding author), Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA.	gsherron@mmrx.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022511, R37AI022511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22511] Funding Source: Medline; NIAMS NIH HHS [P0-1 AR44012] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; CAPOGROSSI M, 1999, VASCULAR DIS MOL BIO, P367; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; COCKERILL GW, 1994, LAB INVEST, V71, P497; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Helmlinger G, 2000, NATURE, V405, P139, DOI 10.1038/35012132; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; NORMAND J, 1995, IN VITRO CELL DEV-AN, V31, P447; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PASSANITI A, 1992, LAB INVEST, V67, P519; PILI R, 1994, JNCI-J NATL CANCER I, V86, P1303, DOI 10.1093/jnci/86.17.1303; Reed MJ, 2000, J CELL BIOCHEM, V77, P116, DOI 10.1002/(SICI)1097-4644(20000401)77:1<116::AID-JCB12>3.3.CO;2-Z; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Romero LI, 1997, J CELL PHYSIOL, V173, P84, DOI 10.1002/(SICI)1097-4652(199710)173:1<84::AID-JCP10>3.0.CO;2-N; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Shay JW, 2000, NAT BIOTECHNOL, V18, P22, DOI 10.1038/71872; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Swift ME, 1999, LAB INVEST, V79, P1479; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Whikehart DR, 2000, INVEST OPHTH VIS SCI, V41, P1070; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	41	120	138	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					219	224		10.1038/85655	http://dx.doi.org/10.1038/85655			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231553				2022-12-25	WOS:000167283100020
J	Joosten, PHLJ; Toepoel, M; Mariman, ECM; Van Zoelen, EJJ				Joosten, PHLJ; Toepoel, M; Mariman, ECM; Van Zoelen, EJJ			Promoter haplotype combinations of the platelet-derived growth factor alpha-receptor gene predispose to human neural tube defects	NATURE GENETICS			English	Article							SPINA-BIFIDA OCCULTA; BINDING PROTEIN; TRANSCRIPTION; PREVALENCE; EXPRESSION; PAX1	Neural tube defects (NTDs), including anencephaly and spina bifida, are multifactorial diseases that occur with an incidence of 1 in 300 births in the United Kingdom(1). Mouse models have indicated that deregulated expression of the gene encoding the platelet-derived growth factor alpha -receptor (Pdgfra) causes congenital NTDs (refs. 2-4), whereas mutant forms of Pax-1 that have been associated with NTDs cause deregulated activation of the human PDGFRA promoter(2,5). There is an increasing awareness that genetic polymorphisms may have an important role in the susceptibility for NTDs (ref. 6). Here we identify five different haplotypes in the human PDGFRA promoter, of which the two most abundant ones, designated H1 and H2 alpha, differ in at least six polymorphic sites. In a transient transfection assay in human bone cells, the five haplotypes differ strongly in their ability to enhance reporter gene activity. In a group of patients with sporadic spina bifida, haplotypes with low transcriptional activity, including H1, were under-represented, whereas those with high transcriptional activity, including H2 alpha, were over-represented. When testing for haplotype combinations, HI homozygotes were fully absent from the group of sporadic patients, whereas H1/H2 alpha heterozygotes were over-represented in the groups of both sporadic and familial spina bifida patients, but strongly underrepresented in unrelated controls. Our data indicate that specific combinations of naturally occurring PDGFRA promoter haplotypes strongly affect NTD genesis.	Univ Nijmegen, Dept Cell Biol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Joosten, PHLJ (corresponding author), Univ Nijmegen, Dept Cell Biol, Nijmegen, Netherlands.		van Zoelen, Everardus J./D-9192-2012					AFINK GB, 1995, ONCOGENE, V10, P1667; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Barber RC, 1998, AM J MED GENET, V76, P310, DOI 10.1002/(SICI)1096-8628(19980401)76:4<310::AID-AJMG6>3.0.CO;2-T; Barber RC, 1999, MOL GENET METAB, V66, P1, DOI 10.1006/mgme.1998.2787; BOONE D, 1985, CLIN RADIOL, V36, P159, DOI 10.1016/S0009-9260(85)80100-8; CAMPBELL LR, 1986, TERATOLOGY, V34, P171, DOI 10.1002/tera.1420340206; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; DOLK H, 1991, TERATOLOGY, V44, P547, DOI 10.1002/tera.1420440508; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; FIDAS A, 1987, CLIN RADIOL, V38, P537, DOI 10.1016/S0009-9260(87)80150-2; Fleming A, 2000, HUM MOL GENET, V9, P575, DOI 10.1093/hmg/9.4.575; Fukuoka T, 1999, J BIOL CHEM, V274, P25576, DOI 10.1074/jbc.274.36.25576; HELWIG U, 1995, NAT GENET, V11, P60, DOI 10.1038/ng0995-60; Herrmann SM, 2000, J MOL MED-JMM, V78, P287, DOI 10.1007/s001090000111; Hol FA, 1996, J MED GENET, V33, P655, DOI 10.1136/jmg.33.8.655; Joosten PHLJ, 1998, P NATL ACAD SCI USA, V95, P14459, DOI 10.1073/pnas.95.24.14459; Kondo T, 2000, EMBO J, V19, P1998, DOI 10.1093/emboj/19.9.1998; Payne J, 1997, DEV DYNAM, V209, P105; Peters H, 1999, DEVELOPMENT, V126, P5399; Pirrotta V, 1999, BBA-REV CANCER, V1424, pM1; ROUSSET F, 1995, GENETICS, V140, P1413; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu-Nishikawa K, 1999, DEV GROWTH DIFFER, V41, P731; Soriano P, 1997, DEVELOPMENT, V124, P2691; WALLIN J, 1994, DEVELOPMENT, V120, P1109; Wang CY, 1996, MOL CELL BIOL, V16, P712; Zhang XQ, 1998, MECH DEVELOP, V70, P167, DOI 10.1016/S0925-4773(97)00190-1	28	77	79	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					215	217		10.1038/84867	http://dx.doi.org/10.1038/84867			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175793				2022-12-25	WOS:000166839200026
J	Ochoa, MT; Stenger, S; Sieling, PA; Thoma-Uszynski, S; Sabet, S; Cho, SG; Krensky, AM; Rollinghoff, M; Sarno, EN; Burdick, AE; Rea, TH; Modlin, RL				Ochoa, MT; Stenger, S; Sieling, PA; Thoma-Uszynski, S; Sabet, S; Cho, SG; Krensky, AM; Rollinghoff, M; Sarno, EN; Burdick, AE; Rea, TH; Modlin, RL			T-cell release of granulysin contributes to host defense in leprosy	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS; CYTOTOXICITY; INFECTION; PATHWAYS; PERFORIN; IDENTIFICATION; INTERLEUKIN-2; MECHANISMS; ACTIVATION	A novel mechanism by which T cells contribute to host defense against microbial pathogens is release of the antimicrobial protein granulysin. We investigated the role of granulysin in human infectious disease using leprosy as a model. Granulysin-expressing T cells were detected in cutaneous leprosy lesions at a six-fold greater frequency in patients with the localized tuberculoid as compared with the disseminated lepromatous form of the disease. In contrast, perforin, a cytolytic molecule that colocalizes with granulysin in cytotoxic granules, was expressed at similar levels across the spectrum of disease. Within leprosy lesions, granulysin colocalized in CD4(+) T cells and was expressed in CD4(+) T-cell lines derived from skin lesions. These CD4(+) T-cell lines lysed targets by the granule exocytosis pathway and reduced the viability of mycobacteria in infected targets. Given the broad antimicrobial spectrum of granulysin, these data provide evidence that T-cell release of granulysin contributes to host defense in human infectious disease.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Erlangen Nurnberg, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany; Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33152 USA; Univ So Calif, Sch Med, Los Angeles, CA USA; Univ So Calif, Dermatol Sect, Los Angeles, CA USA; Int Ctr Med Res & Training CIDEIM, Cali, Colombia	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Erlangen Nuremberg; Stanford University; Fundacao Oswaldo Cruz; University of Miami; University of Southern California; University of Southern California	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90024 USA.		Modlin, Robert L/M-7941-2014; Sabet, Shereen/K-8575-2019; Krensky, Alan/F-7956-2011	Modlin, Robert L/0000-0003-4720-031X; Nunes Sarno, Euzenir/0000-0003-0129-2159; Ochoa, Maria T/0000-0001-6550-5008	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22553, AI 07118] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ab B K, 1990, Eur J Immunol, V20, P369, DOI 10.1002/eji.1830200221; ANDERSSON M, 1995, EMBO J, V14, P1615; ANG Z, 2000, J IMMUNOL, V165, P1486; Bloom BR, 1999, NAT MED, V5, P872, DOI 10.1038/11309; Bloom BR, 1999, NATURE, V402, pC63, DOI [10.1038/35011557, 10.1038/44959]; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gamen S, 1998, J IMMUNOL, V161, P1758; Hansen GHA., 1874, NORSK MAG LAEGEVIDEN, V4, P1; Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kim J, 1997, J IMMUNOL, V159, P335; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; Lewinsohn DM, 1998, J IMMUNOL, V160, P2374; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MANNING WC, 1992, J IMMUNOL, V148, P4036; MODLIN RL, 1984, J IMMUNOL, V132, P3085; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MUTIS T, 1993, EUR J IMMUNOL, V23, P2189, DOI 10.1002/eji.1830230921; NEIGHBOUR PA, 1982, EUR J IMMUNOL, V12, P588, DOI 10.1002/eji.1830120711; Pena SV, 1997, J IMMUNOL, V158, P2680; QUAN PC, 1982, J IMMUNOL, V128, P1786; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Sieling PA, 2000, J IMMUNOL, V164, P4790, DOI 10.4049/jimmunol.164.9.4790; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; Stenger S, 1998, J IMMUNOL, V161, P3582; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; WEMAMBU SNC, 1969, LANCET, V2, P933	35	136	142	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					174	179		10.1038/84620	http://dx.doi.org/10.1038/84620			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175847				2022-12-25	WOS:000166756300033
J	Brunkow, ME; Jeffery, EW; Hjerrild, KA; Paeper, B; Clark, LB; Yasayko, SA; Wilkinson, JE; Galas, D; Ziegler, SF; Ramsdell, F				Brunkow, ME; Jeffery, EW; Hjerrild, KA; Paeper, B; Clark, LB; Yasayko, SA; Wilkinson, JE; Galas, D; Ziegler, SF; Ramsdell, F			Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse	NATURE GENETICS			English	Article							STATIONARY NIGHT BLINDNESS; SF MOUSE; X-CHROMOSOME; DNA-BINDING; T-CELLS; GENE; MUTATION; DISEASE; EXPRESSION; MUTANT	Scurfy (sf) is an X-linked recessive mouse mutant resulting in lethality in hemizygous males 16-25 days after birth, and is characterized by overproliferation of CD4+CD8- T lymphocytes, extensive multiorgan infiltration and elevation of numerous cytokines(1-4). Similar to animals that lack expression of either Ctla-4 (refs, 5,6) or Tgf-beta (refs, 7,8), the pathology observed in sf mice seems to result from an inability to properly regulate CD4+CD8- T-cell activity(3,9). Here we identify the gene defective in sf mice by combining high-resolution genetic and physical mapping with large-scale sequence analysis. The protein encoded by this gene (designated Foxp3) is a new member of the forkhead/winged-helix family of transcriptional regulators and is highly conserved in humans. In sf mice, a frameshift mutation results in a product lacking the forkhead domain. Genetic complementation demonstrates that the protein product of Foxp3, scurfin, is essential for normal immune homeostasis.	Celltech Chirosci Inc, Bothell, WA USA; Oak Ridge Natl Lab, Oak Ridge, TN USA; Keck Grad Inst Appl Life Sci, Claremont, CA USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; Claremont Colleges; Keck Graduate Institute; Keck Graduate Institute of Applied Life Sciences; Virginia Mason Medical Center	Brunkow, ME (corresponding author), Celltech Chirosci Inc, Bothell, WA USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BLAIR PJ, 1994, J IMMUNOL, V153, P3764; BLAIR PJ, 1994, MAMM GENOME, V5, P652, DOI 10.1007/BF00411464; Boyd Y, 1997, MAMM GENOME, V7, pS313, DOI 10.1007/s003359900332; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clark LB, 1999, J IMMUNOL, V162, P2546; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; GODFREY VL, 1994, AM J PATHOL, V145, P281; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hong NA, 1997, MOL CELL BIOL, V17, P2151, DOI 10.1128/MCB.17.4.2151; Kaestner KH, 2000, GENE DEV, V14, P142; Kanangat S, 1996, EUR J IMMUNOL, V26, P161, DOI 10.1002/eji.1830260125; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Means GD, 2000, GENOMICS, V65, P213, DOI 10.1006/geno.2000.6173; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	31	1853	1993	0	71	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					68	73		10.1038/83784	http://dx.doi.org/10.1038/83784			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138001				2022-12-25	WOS:000166187900018
J	Lee, MH; Lu, K; Hazard, S; Yu, HW; Shulenin, S; Hidaka, H; Kojima, H; Allikmets, R; Sakuma, N; Pegoraro, R; Srivastava, AK; Salen, G; Dean, M; Patel, SB				Lee, MH; Lu, K; Hazard, S; Yu, HW; Shulenin, S; Hidaka, H; Kojima, H; Allikmets, R; Sakuma, N; Pegoraro, R; Srivastava, AK; Salen, G; Dean, M; Patel, SB			Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption	NATURE GENETICS			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; SITOSTEROLEMIA; XANTHOMATOSIS; MUTATIONS	The molecular mechanisms regulating the amount of dietary cholesterol retained in the body, as well as the body's ability to exclude selectively other dietary sterols, are poorly understood. An average western diet will contain about 250-500 mg of dietary cholesterol and about 200-400 mg of non-cholesterol sterols. About 50-60% of the dietary cholesterol is absorbed and retained by the normal human body, but less than 1% of the non-cholesterol sterols are retained. Thus, there exists a subtle mechanism that allows the body to distinguish between cholesterol and non-cholesterol sterols. In sitosterolemia, a rare autosomal recessive disorder, affected individuals hyperabsorb not only cholesterol but also all other sterols, including plant and shellfish sterols from the intestine(1,2). The major plant sterol species is sitosterol; hence the name of the disorder. Consequently, patients with this disease have very high levels of plant sterols in the plasma and develop tendon and tuberous xanthomas, accelerated atherosclerosis, and premature coronary artery disease(3). We previously mapped the STSL locus to human chromosome 2p21 (ref. 4) and further localized it to a region of less than 2 cM bounded by markers D2S2294 and D2S2291 (M.-H.L. et al., manuscript submitted). We now report that a new member of the ABC transporter family, ABCG5, is mutant in nine unrelated sitosterolemia patients.	Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD USA; Sanyo Elect Grp Hlth Insurance Assoc, Osaka, Japan; Shiga Univ Med Sci, Dept Med 3, Shiga 52021, Japan; Columbia Univ, Coll Phys & Surg, Dept Ophthalmol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA; Nagoya City Univ, Dept Med 3, Nagoya, Aichi 467861, Japan; Univ Natal, Nelson R Mandela Sch Med, Dept Chem Pathol, ZA-4013 Durban, South Africa; JC Self Res Inst Human Genet, Greenwood Genet Ctr, Greenwood, SC USA; Univ Med & Dent New Jersey, Div Gastroenterol, Newark, NJ 07103 USA	Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Panasonic; Shiga University of Medical Science; Columbia University; Columbia University; Nagoya City University; University of Kwazulu Natal; Greenwood Genetic Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SB (corresponding author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.		Eckhardt, Erik/G-1567-2010; Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019; Allikmets, Rando/ABD-4533-2021	Dean, Michael C/0000-0003-2234-0631; Patel, Shailendra/0000-0003-0046-5513	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060613] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000633] Funding Source: Medline; NHLBI NIH HHS [R01 HL060613] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Erlinger S, 1996, J GASTROEN HEPATOL, V11, P575, DOI 10.1111/j.1440-1746.1996.tb01705.x; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel SB, 1998, J LIPID RES, V39, P1055; Patel SB, 1998, J CLIN INVEST, V102, P1041, DOI 10.1172/JCI3963; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SHULENIN S, IN PRESS CYTO CELL G; Sossey-Alaoui K, 1999, GENOMICS, V60, P330, DOI 10.1006/geno.1999.5924; Swofford David L., 1990, P411; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Witsch-Baumgartner M, 2000, AM J HUM GENET, V66, P402, DOI 10.1086/302760; Wu JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE1087, DOI 10.1152/ajpendo.1999.277.6.E1087; Yu HW, 2000, AM J MED GENET, V90, P347, DOI 10.1002/(SICI)1096-8628(20000214)90:4<347::AID-AJMG16>3.0.CO;2-7	22	517	546	1	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					79	83		10.1038/83799	http://dx.doi.org/10.1038/83799			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138003	Green Accepted			2022-12-25	WOS:000166187900020
J	Arsenijevic, D; Onuma, H; Pecqueur, C; Raimbault, S; Manning, BS; Miroux, B; Couplan, E; Alves-Guerra, MC; Goubern, M; Surwit, R; Bouillaud, F; Richard, D; Collins, S; Ricquier, D				Arsenijevic, D; Onuma, H; Pecqueur, C; Raimbault, S; Manning, BS; Miroux, B; Couplan, E; Alves-Guerra, MC; Goubern, M; Surwit, R; Bouillaud, F; Richard, D; Collins, S; Ricquier, D			Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production	NATURE GENETICS			English	Article							OBESITY; MOUSE	The gene Ucp2 is a member of a family of genes found in animals and plants, encoding a protein homologous to the brown fat uncoupling protein Ucp1 (refs 1-3). As Ucp2 is widely expressed in mammalian tissues(4,5), uncouples respiration(6) and resides within a region of genetic linkage to obesity(4), a role in energy dissipation has been proposed. We demonstrate here, however, that mice lacking Ucp2 following targeted gene disruption are not obese and have a normal response to cold exposure or high-fat diet. Expression of Ucp2 is robust in spleen, lung and isolated macrophages(4,5,7), suggesting a role for Ucp2 In immunity or inflammatory responsiveness(4). We investigated the response to infection with Toxoplasma gondii in Ucp2(-/-) mice, and found that they are completely resistant to infection, in contrast with the lethality observed in wild-type littermates. Parasitic cysts and inflammation sites in brain were significantly reduced in Ucp2(-/-) mice (63% decrease, P<0.04). Macrophages from Ucp2(-/-) mice generated more reactive oxygen species than wild-type mice (80% increase, P<0.001) in response to T. gondii, and had a fivefold greater toxoplasmacidal activity in vitro compared with wild-type mice (P<0.001), which was absent in the presence of a quencher of reactive oxygen species (ROS). Our results indicate a role for Ucp2 in the limitation of ROS and macrophage-mediated immunity.	Ctr Rech Endocrinol Mol & Dev, CNRS, UPR 9078, Meudon, France; INRA, Ecole Prat Hautes Etud, Jouy En Josas, France; Duke Univ, Med Ctr, Durham, NC USA; Univ Laval, Ctr Rech Metab Energet, Quebec City, PQ, Canada; Hop Laval, Ctr Rech, Quebec City, PQ, Canada	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Duke University; Laval University; Laval University	Ricquier, D (corresponding author), Ctr Rech Endocrinol Mol & Dev, CNRS, UPR 9078, Meudon, France.		Alves-Guerra, Marie-Clotilde/P-4356-2017; Bouillaud, Frédéric R/L-3238-2017; Pecqueur, Claire/L-3073-2015; Arsenijevic, Denis/O-8315-2016; Miroux, Bruno/E-9267-2017	Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Bouillaud, Frédéric R/0000-0002-7518-9237; Pecqueur, Claire/0000-0002-7612-1672; Arsenijevic, Denis/0000-0001-5741-9652; Miroux, Bruno/0000-0002-3066-4700	NIDDK NIH HHS [R01 DK54024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKINSHINA G T, 1975, Byulleten' Eksperimental'noi Biologii i Meditsiny, V80, P60; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Cohen RD, 1999, INFLAMM BOWEL DIS, V5, P1; Diehl AM, 1999, J BIOENERG BIOMEMBR, V31, P493, DOI 10.1023/A:1005452624640; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Makioka A, 1995, J PARASITOL, V81, P1021, DOI 10.2307/3284064; MARINI M, 1993, MUTAT RES, V301, P243, DOI 10.1016/0165-7992(93)90064-3; MURRAY HW, 1979, J EXP MED, V150, P950, DOI 10.1084/jem.150.4.950; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Pecqueur C, 1999, BIOCHEM BIOPH RES CO, V255, P40, DOI 10.1006/bbrc.1998.0146; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Richard D, 1998, J COMP NEUROL, V397, P549; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zamora R, 1997, BIOCHEMISTRY-US, V36, P15765, DOI 10.1021/bi971641i	28	891	923	2	68	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					435	439		10.1038/82565	http://dx.doi.org/10.1038/82565			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101840				2022-12-25	WOS:000165671700015
J	Chan, GKT; Jablonski, SA; Starr, DA; Goldberg, ML; Yen, TJ				Chan, GKT; Jablonski, SA; Starr, DA; Goldberg, ML; Yen, TJ			Human Zw10 and ROD ave mitotic checkpoint proteins that bind to kinetochores	NATURE CELL BIOLOGY			English	Article							ACCURATE CHROMOSOME SEGREGATION; CENP-E; UNATTACHED KINETOCHORES; ANAPHASE ONSET; ROUGH DEAL; SPINDLE; DROSOPHILA; GENE; MITOSIS; CELLS	Here we show that human Zeste White 10 (Zw10) and Rough deal (Rod) are new components of the mitotic checkpoint, as cells lacking these proteins at kinetochores fail to arrest in mitosis when exposed to microtubule inhibitors. Checkpoint failure and premature mitotic exit may explain why cells defective for hZw10 and hRod divide with lagging chromosomes. As Zw10 and Rod are not conserved in yeast, our data, combined with an accompanying study of Drosophila Zw10 and Rod, indicate that metazoans may require an elaborate spindle checkpoint to monitor complex kinetochore functions.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Fox Chase Cancer Center; Cornell University	Yen, TJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Chan, Gordon/AAN-7784-2020	Chan, Gordon/0000-0003-0497-9407; Starr, Daniel/0000-0001-7339-6606; Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Basu J, 1998, CHROMOSOMA, V107, P376, DOI 10.1007/s004120050321; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; Scaerou F, 1999, J CELL SCI, V112, P3757; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	30	160	165	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					944	947		10.1038/35046598	http://dx.doi.org/10.1038/35046598			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146660				2022-12-25	WOS:000165814500018
J	Chung, SB; Gumienny, TL; Hengartner, MO; Driscoll, M				Chung, SB; Gumienny, TL; Hengartner, MO; Driscoll, M			A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in C-elegans	NATURE CELL BIOLOGY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NEURONAL DEGENERATION; PROTEIN CED-9; DEATH; BCL-2; ENCODES; DOMAIN; RECOGNITION; ACTIVATION; NEURODEGENERATION	Similar to mammalian excitotoxic cell death, necrotic-like cell death (NCD) in Caenorhabditis elegans can be initiated by hyperactive ion channels. Here we investigate the requirements for genes that execute and regulate programmed cell death (PCD) in necrotic-like neuronal death caused by a toxic MEG-4 channel. Neither the kinetics of necrosis onset nor the total number of necrotic corpses generated is altered by any C. elegans mutation known to block PCD, which provides genetic evidence that, the activating mechanisms for NCD and apoptotic cell death are distinct. In contrast, all previously reported ced genes required for phagocytotic removal of apoptotic corpses, as well as ced-12, a new engulfment gene we have identified, are required for efficient elimination of corpses generated by distinct necrosis-inducing stimuli. Our results show that a common set of genes acts to eliminate cell corpses irrespective of the mode of cell death, and provide the first identification of the C. elegans genes that are required for orderly removal of necrotic cells. As phagocytotic mechanisms seem to be conserved from nematodes to humans, our findings indicate that injured necrotic cells in higher organisms might also be eliminated before lysis through a controlled process of corpse removal, a hypothesis that has significant therapeutic implications.	Rutgers State Univ, Nelson Biol Labs, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	Rutgers State University New Brunswick; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Driscoll, M (corresponding author), Rutgers State Univ, Nelson Biol Labs, Dept Mol Biol & Biochem, 604 Allison Rd, Piscataway, NJ 08854 USA.	driscoll@mbcl.rutgers.edu	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008; Gumienny, Tina/AAJ-5273-2020	Chung, Sambath/0000-0002-3369-3830; Hengartner, Michael/0000-0002-7584-596X; Gumienny, Tina/0000-0002-3932-7815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008360, R01GM052540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034435] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08360, GM-52540] Funding Source: Medline; NINDS NIH HHS [R01NS34435] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; Barger AJ, 1998, J NEUROSCI, V18, P2871; BRENNER S, 1974, GENETICS, V77, P71; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DRISCOLL M, 1995, METHOD CELL BIOL, V46, P323; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Hall DH, 1997, J NEUROSCI, V17, P1033; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Moynault A, 1998, BIOCHEM SOC T, V26, P629, DOI 10.1042/bst0260629; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shah A, 1999, AGING MENT HEALTH, V3, P153, DOI 10.1080/13607869956316; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2045; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; Vaux DL, 1996, MICROSC RES TECHNIQ, V34, P259, DOI 10.1002/(SICI)1097-0029(19960615)34:3<259::AID-JEMT8>3.0.CO;2-K; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	123	147	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					931	937		10.1038/35046585	http://dx.doi.org/10.1038/35046585			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146658				2022-12-25	WOS:000165814500016
J	Larisch, S; Yi, YS; Lotan, R; Kerner, H; Eimerl, S; Parks, WT; Gottfried, Y; Reffey, SB; de Caestecker, MP; Danielpour, D; Book-Melamed, N; Timberg, R; Duckett, CS; Lechleider, RJ; Steller, H; Orly, J; Kim, SJ; Roberts, AB				Larisch, S; Yi, YS; Lotan, R; Kerner, H; Eimerl, S; Parks, WT; Gottfried, Y; Reffey, SB; de Caestecker, MP; Danielpour, D; Book-Melamed, N; Timberg, R; Duckett, CS; Lechleider, RJ; Steller, H; Orly, J; Kim, SJ; Roberts, AB			A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; CYTOCHROME-C; EPITHELIAL-CELLS; MAMMALIAN SEPTIN; TGF-BETA; CYTOSKELETAL; DROSOPHILA; INDUCTION; GENE	Here we describe a protein product of the human septin H5/PNUTL2/CDCrel2b gene, which we call ARTS (for apoptosis-related protein in the TGF-beta signalling pathway). ARTS is expressed in many cells and acts to enhance cell death induced by TGF-beta or, to a lesser extent, by other apoptotic agents. Unlike related septin gene products, ARTS is localized to mitochondria and translocates to the nucleus when apoptosis occurs. Mutation of the P-loop of ARTS abrogates its competence to activate caspase 3 and to induce apoptosis. Taken together, these observations expand the functional attributes of septins previously described as having roles in cytokinesis and cellular morphogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA; Rambam Med Ctr, Dept Pathol, Haifa, Israel; Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.		Yi, Young-Su/U-7789-2019	Duckett, Colin/0000-0001-9413-2263				Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; FLANDERS KC, 2000, TRANSFORMING GROWTH; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Haufel T, 1999, ANTICANCER RES, V19, P105; Hsing AY, 1996, CANCER RES, V56, P5146; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Massague J, 2000, GENE DEV, V14, P627; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; McKie JM, 1997, HUM GENET, V101, P6, DOI 10.1007/s004390050576; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; RUBIN Y, 1995, CELL CALCIUM, V18, P135, DOI 10.1016/0143-4160(95)90004-7; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zieger B, 1997, J CLIN INVEST, V99, P520, DOI 10.1172/JCI119188; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	188	207	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					915	921		10.1038/35046566	http://dx.doi.org/10.1038/35046566			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146656				2022-12-25	WOS:000165814500014
J	Dove, A				Dove, A			Milking the genome for profit	NATURE BIOTECHNOLOGY			English	Article																		HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; Onishi A, 2000, SCIENCE, V289, P1188, DOI 10.1126/science.289.5482.1188; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Wells K, 1999, NAT BIOTECHNOL, V17, P25, DOI 10.1038/5196	4	25	27	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1045	1048		10.1038/80231	http://dx.doi.org/10.1038/80231			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017040				2022-12-25	WOS:000089744700024
J	Horikawa, Y; Oda, N; Cox, NJ; Li, XQ; Orho-Melander, M; Hara, M; Hinokio, Y; Lindner, TH; Mashima, H; Schwarz, PEH; del Bosque-Plata, L; Horikawa, Y; Oda, Y; Yoshiuchi, I; Colilla, S; Polonsky, KS; Wei, S; Concannon, P; Iwasaki, N; Schulze, T; Baier, LJ; Bogardus, C; Groop, L; Boerwinkle, E; Hanis, CL; Bell, GI				Horikawa, Y; Oda, N; Cox, NJ; Li, XQ; Orho-Melander, M; Hara, M; Hinokio, Y; Lindner, TH; Mashima, H; Schwarz, PEH; del Bosque-Plata, L; Horikawa, Y; Oda, Y; Yoshiuchi, I; Colilla, S; Polonsky, KS; Wei, S; Concannon, P; Iwasaki, N; Schulze, T; Baier, LJ; Bogardus, C; Groop, L; Boerwinkle, E; Hanis, CL; Bell, GI			Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus	NATURE GENETICS			English	Article							MAJOR SUSCEPTIBILITY LOCUS; GENOME-WIDE SEARCH; DROSOPHILA-MELANOGASTER; MEXICAN-AMERICANS; LINKAGE; MUTATIONS; ONSET; CHROMOSOME-2; PROTEASE; NIDDM1	Type 2 or non-insulin-dependent diabetes mellitus (NIDDM) is the most common form of diabetes worldwide, affecting approximately 4% of the world's adult population. It is multifactorial in origin with both genetic and environmental factors contributing to its development. A genome-wide screen for type 2 diabetes genes carried out in Mexican Americans localized a susceptibility gene, designated NIDDM1, to chromosome 2. Here we describe the positional cloning of a gene located in the NIDDM1 region that shows association with type 2 diabetes in Mexican Americans and a Northern European population from the Botnia region of Finland. This putative diabetes-susceptibility gene encodes a ubiquitously expressed member of the calpain-like cysteine protease family, calpain-10 (CAPN10). This finding suggests a novel pathway that may contribute to the development of type 2 diabetes.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Lund, Malmo Univ Hosp, Dept Endocrinol, Malmo, Sweden; Univ Washington, Mol Genet Program, Virginia Mason Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Tokyo Womens Med Univ, Ctr Diabet, Tokyo, Japan; Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Internal Med 3, D-8027 Dresden, Germany; NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Lund University; Skane University Hospital; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Tokyo Women's Medical University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; University of Texas Health Science Center Houston	Bell, GI (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Mashima, Hirosato/ABE-6412-2020	del Bosque-Plata, Laura/0000-0003-3224-378X; YOSHIUCHI, ISSEI/0000-0002-6025-7962; Concannon, Patrick/0000-0002-5801-1859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020595, Z01DK069071, P60DK020595, R01DK047486, P30DK042086] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42086, DK-20595, DK-47486] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Barner H B, 1996, Semin Thorac Cardiovasc Surg, V8, P3; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Boehnke M, 1997, AM J HUM GENET, V61, P423, DOI 10.1086/514862; Braun C, 1999, BIOCHEM BIOPH RES CO, V260, P671, DOI 10.1006/bbrc.1999.0948; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Ciccarese M, 1997, DIABETOLOGIA, V40, P1366, DOI 10.1007/s001250050835; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Cox NJ, 1999, NAT GENET, V21, P213, DOI 10.1038/6002; Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; Elbein SC, 1999, DIABETES, V48, P1175, DOI 10.2337/diabetes.48.5.1175; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gavin JR, 1997, DIABETES CARE, V20, P1183; Ghosh S, 1998, J CLIN INVEST, V102, P704, DOI 10.1172/JCI2512; Groop L, 1996, DIABETES, V45, P1585, DOI 10.2337/diabetes.45.11.1585; Hani EH, 1997, DIABETES, V46, P1225, DOI 10.2337/diab.46.7.1225; HANIS CL, 1991, DIABETES CARE, V14, P618, DOI 10.2337/diacare.14.7.618; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Khoury M, 1993, FUNDAMENTALS GENETIC; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LEWONTIN RC, 1964, GENETICS, V49, P49; Maassen JA, 1996, DIABETOLOGIA, V39, P375; MACLEAN C J, 1985, Genetic Epidemiology, V2, P263, DOI 10.1002/gepi.1370020304; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Stam LF, 1996, GENETICS, V144, P1559; Steiner D. F., 1995, METABOLIC MOL BASES, P897; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Taylor S. I., 1995, METABOLIC MOL BASES, P843; Thomas AW, 1997, HUM GENET, V101, P212, DOI 10.1007/s004390050617; Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; YAMASAKI H, 1984, MECHANISMS TUMOR PRO, V4, P1	50	1120	1205	0	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					163	175		10.1038/79876	http://dx.doi.org/10.1038/79876			13	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017071				2022-12-25	WOS:000089638800012
J	Liu, WG; Dong, XY; Mai, M; Seelan, RS; Taniguchi, K; Krishnadath, KK; Halling, KC; Cunningham, JM; Qian, CP; Christensen, E; Roche, PC; Smith, DI; Thibodeau, SN				Liu, WG; Dong, XY; Mai, M; Seelan, RS; Taniguchi, K; Krishnadath, KK; Halling, KC; Cunningham, JM; Qian, CP; Christensen, E; Roche, PC; Smith, DI; Thibodeau, SN			Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling	NATURE GENETICS			English	Article							BAX GENE; CONDUCTIN; HOMOLOG; TUMOR		Mayo Clin & Mayo Med Sch, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	Liu, WG (corresponding author), Mayo Clin & Mayo Med Sch, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA.			Seelan, Ratnam/0000-0002-8925-1070	NATIONAL CANCER INSTITUTE [U01CA060117, R01CA048031, R01CA060117] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48031, CA 60117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Mai M, 1999, GENOMICS, V55, P341, DOI 10.1006/geno.1998.5650; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MIYASHITA T, 1995, CELL, V80, P293; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448	14	414	434	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					146	147		10.1038/79859	http://dx.doi.org/10.1038/79859			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017067				2022-12-25	WOS:000089638800009
J	Bruey, JM; Ducasse, C; Bonniaud, P; Ravagnan, L; Susin, SA; Diaz-Latoud, C; Gurbuxani, S; Arrigo, AP; Kroemer, G; Solary, E; Garrido, C				Bruey, JM; Ducasse, C; Bonniaud, P; Ravagnan, L; Susin, SA; Diaz-Latoud, C; Gurbuxani, S; Arrigo, AP; Kroemer, G; Solary, E; Garrido, C			Hsp27 negatively regulates cell death by interacting with cytochrome c	NATURE CELL BIOLOGY			English	Article							HEAT-SHOCK-PROTEIN; GRANZYME-B; CASPASE-9 ACTIVATION; PROTECTIVE ACTIVITY; BREAST-CANCER; APOPTOSIS; STRESS; RESISTANCE; KINASE; PROTEASES	Mammalian cells respond to stress by accumulating or activating a set of highly conserved proteins known as heat-shock proteins (HSPs), Several of these proteins interfere negatively with apoptosis, We show that the small HSP known as Hsp27 inhibits cytochrome-c-mediated activation of caspases in the cytosol, Hsp27 does not interfere with granzyme-B-induced activation of caspases, nor with apoptosis-inducing factor-mediated, caspase-independent, nuclear changes. Hsp27 binds to cytochrome c released from the mitochondria to the cytosol and prevents cytochrome-c-mediated interaction of Apaf-1 with procaspase-9, Thus, Hsp27 interferes specifically with the mitochondrial pathway of caspase-dependent cell death.	INSERM, U517, Fac Med & Pharm, F-21033 Dijon, France; CNRS, UMR 5534, Stress Lab, F-69622 Villeurbanne, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Bruey, JM (corresponding author), INSERM, U517, Fac Med & Pharm, 7 Blvd Jeanne Darc, F-21033 Dijon, France.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Susin, Santos A/Q-6754-2017; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018	KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENNIG B, 1983, METHOD ENZYMOL, V97, P261; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUOT J, 1991, CANCER RES, V51, P5245; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; MARTIN F, 1985, INT J CANCER, V36, P373; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OESTERREICH S, 1993, CANCER RES, V53, P4443; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; TETU B, 1992, CANCER RES, V52, P2325; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VandeCraen M, 1997, EUR J IMMUNOL, V27, P1296, DOI 10.1002/eji.1830270535; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Zavialov A, 1998, INT J BIOL MACROMOL, V22, P163, DOI 10.1016/S0141-8130(98)00014-2; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	49	797	836	0	36	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					645	652		10.1038/35023595	http://dx.doi.org/10.1038/35023595			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980706				2022-12-25	WOS:000089250600017
J	McKenna, N; O'Malley, BW				McKenna, N; O'Malley, BW			An issue of tissues: divining the split personalities of selective estrogen receptor modulators	NATURE MEDICINE			English	News Item							COACTIVATOR GENE; BREAST-CANCER; AMPLIFICATION; SRC-1; AIB1; RNA; RECRUITMENT; EXPRESSION		Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	McKenna, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			McKenna, Neil/0000-0001-6689-0104				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; *ATL HILT TOW, 2000, ER HOP DEP DEF BREAS; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; GRAHAM JD, 1998, KEYST S NUCL REC GEN; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leygue E, 1999, CANCER RES, V59, P4190; Leygue E, 1999, CANCER RES, V59, P1175; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	17	55	57	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					960	962		10.1038/79637	http://dx.doi.org/10.1038/79637			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973303				2022-12-25	WOS:000089190500017
J	Ortolan, TG; Tongaonkar, P; Lambertson, D; Chen, L; Schauber, C; Madura, K				Ortolan, TG; Tongaonkar, P; Lambertson, D; Chen, L; Schauber, C; Madura, K			The DNA repair protein Rad23 is a negative regulator of multi-ubiquitin chain assembly	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCISION-REPAIR; N-END RULE; TRANSCRIPTION FACTOR TFIIH; GROUP-C PROTEIN; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; DAMAGED DNA; GENE RAD23; IN-VITRO; YEAST	Rad23 is a nucleotide-excision repair protein with a previously unknown biochemical function. We determined that yeast and human Rad23 inhibited multi-ubiquitin (Ub) chain formation and the degradation of proteolytic substrates. Significantly, Rad23 could be cc-precipitated with a substrate that contained a short multi-Ub chain. The UV sensitivity of rad23 Delta was reduced in mutants lacking the E2 enzyme Ubc4, or the multi-Db chain-promoting factor Ufd2, These studies suggest that the stability of proteolytic substrates is governed by the competing action of multi-Db chain-promoting and chain-inhibiting factors. The stabilization of DNA repair and stress factors could represent an important biological function of Rad23.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Madura, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM-RO1-52058] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052058] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN Z, 1991, J BIOL CHEM, V265, P15698; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HIVAMA H, 1999, J BIOL CHEM, V274, P28019; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lambertson D, 1999, GENETICS, V153, P69; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; NUANG H, 1997, MOL CELL BIOL, V17, P6693; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PICOLOGLOU S, 1990, MOL GEN GENET, V218, P465; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TONGAONKAR P, 1998, ANAL BIOCHEM, V260, P307; VanderSpek PJ, 1996, GENOMICS, V31, P20, DOI 10.1006/geno.1996.0004; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; XIC Y, 1999, EMBO J, V18, P6832; YOU J, 1999, BIOTECHNIQUES, V27, P2	45	163	163	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					601	608		10.1038/35023547	http://dx.doi.org/10.1038/35023547			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980700				2022-12-25	WOS:000089250600011
J	Kalantry, S; Manning, S; Haub, O; Tomihara-Newberger, C; Lee, HG; Fangman, J; Disteche, CM; Manova, K; Lacy, E				Kalantry, S; Manning, S; Haub, O; Tomihara-Newberger, C; Lee, HG; Fangman, J; Disteche, CM; Manova, K; Lacy, E			The amnionless gene, essential for mouse gastrulation, encodes a visceral-endoderm-specific protein with an extracellular cysteine-rich domain	NATURE GENETICS			English	Article							SNARE COMPLEX; EMBRYO; EMBRYOGENESIS; DROSOPHILA; DISRUPTION; LETHALITY; RECEPTOR; CHORDIN; MICE	Fate-mapping experiments in the mouse have revealed that the primitive streak can be divided into three functional regions': the proximal region gives rise to germ cells and the extra-embryonic mesoderm of the yolk sac; the distal region generates cardiac mesoderm and node-derived axial mesendoderm; and the middle streak region produces the paraxial, intermediate and lateral plate mesoderm of the trunk. To gain insight into the mechanisms that mediate the assembly of the primitive streak into these functional regions, we have cloned and functionally identified the gene disrupted in the amnionless (amn) mouse, which has a recessive, embryonic lethal mutation that interferes specifically with the formation and/or specification of the middle primitive streak region during gastrulation(2). Here we report that the gene Amn encodes a novel type I transmembrane protein that is expressed exclusively in the extra-embryonic visceral endoderm layer during gastrulation. The extracellular region of the Amn protein contains a cysteine-rich domain with similarity to bone morphogenetic protein (BMP)-binding cysteine-rich domains in chordin, its Drosophila melanogaster homolog (Short: gastrulation) and procollagen IIA (ref. 3). Our findings indicate that Amn may direct the production of trunk mesoderm derived from the middle streak by acting in the underlying visceral endoderm to modulate a BMP signaling pathway.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Mol Biol Grad Program, New York, NY USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Memorial Sloan Kettering Cancer Center; Cornell University; University of Washington; University of Washington Seattle	Lacy, E (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.			Lacy, Elizabeth/0000-0001-5457-0728	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058726] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08748] Funding Source: Medline; NIGMS NIH HHS [GM58726] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Conley CA, 2000, DEVELOPMENT, V127, P3947; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; EDELHOFF S, 1994, ONCOGENE, V9, P665; Godwin AR, 1998, P NATL ACAD SCI USA, V95, P13042, DOI 10.1073/pnas.95.22.13042; Gu ZY, 1999, DEVELOPMENT, V126, P2551; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kolle G, 2000, MECH DEVELOP, V90, P181, DOI 10.1016/S0925-4773(99)00248-8; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; Larrain J, 2000, DEVELOPMENT, V127, P821; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; MANOVA K, 1992, J NEUROSCI, V12, P4663; Matsui M, 2000, P NATL ACAD SCI USA, V97, P5291, DOI 10.1073/pnas.090020497; Mishina Y, 1999, DEV BIOL, V213, P314, DOI 10.1006/dbio.1999.9378; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; Tomihara-Newberger C, 1998, DEV BIOL, V204, P34, DOI 10.1006/dbio.1998.9034; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang X, 1996, DEV BIOL, V177, P274, DOI 10.1006/dbio.1996.0162; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yu K, 2000, DEVELOPMENT, V127, P2143; Zhang HB, 1996, DEVELOPMENT, V122, P2977	23	106	109	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					412	416		10.1038/86912	http://dx.doi.org/10.1038/86912			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279523				2022-12-25	WOS:000167811200016
J	Guy, J; Hendrich, B; Holmes, M; Martin, JE; Bird, A				Guy, J; Hendrich, B; Holmes, M; Martin, JE; Bird, A			A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome	NATURE GENETICS			English	Letter							HISTONE DEACETYLASE COMPLEX; BINDING-PROTEIN MECP2; TRANSCRIPTIONAL REPRESSOR; CHROMOSOMAL PROTEIN; METHYLATED DNA; GENE; IDENTIFICATION; LOCALIZATION; SEQUENCE; GIRLS	Rett syndrome (RTT) is an inherited neurodevelopmental disorder of females that occurs once in 10,000-15,000 births(1,2) Affected females develop normally for 6-18 months, but then lose voluntary movements, including speech and hand skills. Most RTT patients are heterozygous for mutations in the X-linked gene MECP2 (refs, 3-12), encoding a protein that binds to methylated sites in genomic DNA and facilitates gene silencing(13-17). Previous work with Mecp2-null embryonic stem cells indicated that MeCP2 is essential for mouse embryogenesis(18) Here we generate mice lacking Mecp2 using Cre-loxP technology. Both Mecp2-null mice and mice in which Mecp2 was deleted in brain showed severe neurological symptoms at approximately six weeks of age. Compensation for absence of MeCP2 in other tissues by MeCP1 (refs, 19,20) was not apparent in genetic or biochemical tests. After several months, heterozygous female mice also showed behavioral symptoms. The overlapping delay before symptom onset in humans and mice, despite their profoundly different rates of development, raises the possibility that stability of brain function, not brain development per se, is compromised by the absence of MeCP2.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Ctr Cell Biol, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland; Queen Mary Univ London, Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Inst Pathol, London E1 4NS, England	University of Edinburgh; University of Edinburgh; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Ctr Cell Biol, Kings Bldg, Edinburgh, Midlothian, Scotland.	a.bird@ed.ac.uk	Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372; Guy, Jacky/0000-0002-8440-5667				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Buyse IM, 2000, AM J HUM GENET, V67, P1428, DOI 10.1086/316913; Cheadle JP, 2000, HUM MOL GENET, V9, P1119, DOI 10.1093/hmg/9.7.1119; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; FREE A, IN PRESS J BIOL CHEM; Fujita N, 1999, MOL CELL BIOL, V19, P6415; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hampson K, 2000, J MED GENET, V37, P610, DOI 10.1136/jmg.37.8.610; HENDRICH B, IN PRESS GENES DEV; Huppke P, 2000, HUM MOL GENET, V9, P1369, DOI 10.1093/hmg/9.9.1369; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Obata K, 2000, J MED GENET, V37, P608, DOI 10.1136/jmg.37.8.608; Rett A, 1966, Wien Med Wochenschr, V116, P723; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Xiang FQ, 2000, J MED GENET, V37, P250, DOI 10.1136/jmg.37.4.250; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172	31	1134	1173	4	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					322	326		10.1038/85899	http://dx.doi.org/10.1038/85899			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242117	Green Published			2022-12-25	WOS:000167304200027
J	Pelham, RJ; Chang, F				Pelham, RJ; Chang, F			Role of actin polymerization and actin cables in actin-patch movement in Schizosaccharomyces pombe	NATURE CELL BIOLOGY			English	Article							CELL-DIVISION CYCLE; FISSION YEAST; ARP2/3 COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MICROTUBULE CYTOSKELETONS; LISTERIA-MONOCYTOGENES; LIVING CELLS; IN-VIVO; CYTOKINESIS	Factors that are involved in actin polymerization, such as the Arp2/3 complex, have been found to be packaged into discrete, motile, actin-rich foci. Here we investigate the mechanism of actin-patch motility in S. pombe using a fusion of green fluorescent protein (GFP) to a coronin homologue, Crn1p. Actin patches are associated with cables and move with rates of 0.32 mum s(-1) primarily in an undirected manner at cell tips and also in a directed manner along actin cables, often away from cell tips. Patches move more slowly or stop when actin polymerization is attenuated by Latrunculin A or in arp3 and cdc3 (profilin) mutants. In a cdc8 (tropomyosin) mutant, actin cables are absent, and patches move with similar speed but in a non-directed manner. Patches are sites of Arp3-dependent F-actin polymerization in vitro. Rapid F-actin turnover rates in vivo indicate that patches and cables are maintained continuously by actin polymerization. Our studies give rise to a model in which actin patches are centres for actin polymerization that drive their own movement on actin cables using Arp2/3-based actin polymerization.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Chang, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	fc99@columbia.edu						Arai R, 1998, EUR J CELL BIOL, V76, P288, DOI 10.1016/S0171-9335(98)80007-1; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BACKX PH, 1994, J PHYSIOL-LONDON, V476, P487, DOI 10.1113/jphysiol.1994.sp020149; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; Balasubramanian MK, 1998, GENETICS, V149, P1265; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Botstein David, 1997, P1; Chang F, 1996, J CELL SCI, V109, P131; Chang F, 1999, CURR BIOL, V9, P849, DOI 10.1016/S0960-9822(99)80372-8; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; Ding DQ, 1998, J CELL SCI, V111, P701; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Heil-Chapdelaine RA, 1998, CURR BIOL, V8, P1281, DOI 10.1016/S0960-9822(07)00539-8; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MARKS J, 1986, J CELL SCI, P229; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; May KM, 1998, CELL MOTIL CYTOSKEL, V41, P117, DOI 10.1002/(SICI)1097-0169(1998)41:2<117::AID-CM3>3.0.CO;2-B; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Morrell JL, 1999, MOL BIOL CELL, V10, P4201, DOI 10.1091/mbc.10.12.4201; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; QUINLAN RA, 1980, J CELL SCI, V46, P341; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	48	136	138	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					235	244		10.1038/35060020	http://dx.doi.org/10.1038/35060020			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231572				2022-12-25	WOS:000167365800009
J	Bosch, X				Bosch, X			BSE panic spreads to Spain	NATURE MEDICINE			English	News Item																		2000, NATURE MED, V6, P1301	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					138	138		10.1038/84553	http://dx.doi.org/10.1038/84553			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175828				2022-12-25	WOS:000166756300012
J	De Rosa, SC; Herzenberg, LA; Herzenberg, LA; Roederer, M				De Rosa, SC; Herzenberg, LA; Herzenberg, LA; Roederer, M			11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity	NATURE MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; HIV-INFECTION; L-SELECTIN; SUBSETS; CD4(+); AGE		NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; Stanford University	Roederer, M (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr, Bethesda, MD 20892 USA.		Roederer, Mario/G-1887-2011		NATIONAL CANCER INSTITUTE [R35CA042509, R21CA081543] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81543-02, CA-42509-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; Gray CM, 1998, AIDS RES HUM RETROV, V14, P561, DOI 10.1089/aid.1998.14.561; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Mitra DK, 1999, INT IMMUNOL, V11, P1801, DOI 10.1093/intimm/11.11.1801; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MORIMOTO C, 1993, CLIN EXP RHEUMATOL, V11, P241; OKUMURA M, 1993, EUR J IMMUNOL, V23, P1057, DOI 10.1002/eji.1830230512; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; Roederer M, 1997, J CLIN INVEST, V99, P1555, DOI 10.1172/JCI119318; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; ROEDERER M, 1995, CYTOMETRY, V21, P187, DOI 10.1002/cyto.990210211	18	338	358	1	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					245	248		10.1038/84701	http://dx.doi.org/10.1038/84701			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175858				2022-12-25	WOS:000166756300044
J	Dove, A				Dove, A			Betting on biogenerics	NATURE BIOTECHNOLOGY			English	Article								With patents on several blockbuster therapeutic proteins soon to expire and several companies pondering whether to manufacture their own versions of these medicines, can a commercially viable business be based on biogenerics?.											0	15	17	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					117	120		10.1038/84365	http://dx.doi.org/10.1038/84365			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175723				2022-12-25	WOS:000166754700015
J	King, C; Hoenger, RM; Cleary, MM; Murali-Krishna, K; Ahmed, R; King, E; Sarvetnick, N				King, C; Hoenger, RM; Cleary, MM; Murali-Krishna, K; Ahmed, R; King, E; Sarvetnick, N			Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+T-cell responses	NATURE MEDICINE			English	Article							T-CELLS; LYMPHOCYTIC CHORIOMENINGITIS; STIMULATORY FACTOR; IN-VITRO; ACTIVATION; CD8+; COSTIMULATION; IL-2; MICE; APOPTOSIS	The mechanism underlying suppression of immune responses by interleukin-4 (IL-4) has remained unexplained. Here we show that the antigen-presenting dendritic cell Is central to counter-regulation of autoimmune disease by IL-4. IL-4 acts at the locus of the dendritic cell to decrease the cytolytic T-cell response, preventing autoimmunity. Stimulation of cytotoxic precursors by antigen pulsed dendritic cells induces their differentiation but the process is blocked by IL-4. IL-40-influenced DC produce distinct effects on CD8(+) T cells depending on their state of activation. The molecular basis for this regulation is the alteration of the expression ratio of the costimulatory ligands B7.1/B7.2 on dendritic cells. Our findings demonstrate that B7.2 induces expansion of CD8(+) T cells and B7.1 governs their acquisition of cytolytic activity. IL-4 influences the dendritic cell to elicit qualitative differences in T-cell responses, providing the basis for counter-regulation mediated by IL-4.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Emory Univ, Emory Vaccine Ctr, Atlanta, GA USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA USA	Scripps Research Institute; Emory University; Emory University	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	noras@scripps.edu	King, Cecile/Q-9794-2019	King, Cecile/0000-0003-2193-2563				ACRES RB, 1988, ANN NY ACAD SCI, V532, P1, DOI 10.1111/j.1749-6632.1988.tb36319.x; AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; AlexanderMiller MA, 1996, J EXP MED, V184, P485, DOI 10.1084/jem.184.2.485; Aung S, 1999, J VIROL, V73, P8944, DOI 10.1128/JVI.73.11.8944-8949.1999; Bembridge GP, 1998, J VIROL, V72, P4080, DOI 10.1128/JVI.72.5.4080-4087.1998; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Chai JG, 1999, J IMMUNOL, V163, P1298; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; CRONIN DC, 1994, IMMUNOL RES, V13, P215, DOI 10.1007/BF02935614; DUTKO FJ, 1983, J GEN VIROL, V64, P1689, DOI 10.1099/0022-1317-64-8-1689; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; HARDING FA, 1993, J EXP MED, V177, P1791, DOI 10.1084/jem.177.6.1791; HENGST JCD, 1985, CELL IMMUNOL, V90, P281, DOI 10.1016/0008-8749(85)90193-5; Homann D, 1999, IMMUNITY, V11, P463, DOI 10.1016/S1074-7613(00)80121-1; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEONARD WJ, 1994, ADV EXP MED BIOL, V365, P225; Ludewig B, 1999, J IMMUNOL, V163, P1839; McAdam AJ, 2000, J VIROL, V74, P203, DOI 10.1128/JVI.74.1.203-208.2000; MCLELLAN AD, 1995, EUR J IMMUNOL, V25, P2064, DOI 10.1002/eji.1830250739; MERROW MW, 1991, INT IMMUNOL, V3, P551, DOI 10.1093/intimm/3.6.551; Mueller R, 1996, J EXP MED, V184, P1093, DOI 10.1084/jem.184.3.1093; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PALIARD X, 1988, J IMMUNOL, V141, P849; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schofield M, 1998, CLASSICAL REV, V48, P483, DOI 10.1017/S0009840X98420031; Selin LK, 1999, IMMUNITY, V11, P733, DOI 10.1016/S1074-7613(00)80147-8; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STARLING GC, 1995, EUR J IMMUNOL, V25, P2528, DOI 10.1002/eji.1830250918; Stremmel C, 1999, J EXP MED, V189, P919, DOI 10.1084/jem.189.6.919; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; VanParijs L, 1997, J IMMUNOL, V158, P3738; Villacres MC, 1999, J IMMUNOL, V162, P2663; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; WAGNER H, 1988, ANN NY ACAD SCI, V532, P128, DOI 10.1111/j.1749-6632.1988.tb36332.x; Whitmire JK, 1997, J VIROL, V71, P1736; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WIDMER MB, 1987, NATURE, V326, P795, DOI 10.1038/326795a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	47	77	79	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					206	214		10.1038/84659	http://dx.doi.org/10.1038/84659			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175852				2022-12-25	WOS:000166756300038
J	Li, XC; Demirci, G; Ferrari-Lacraz, S; Groves, C; Coyle, A; Malek, TR; Strom, TB				Li, XC; Demirci, G; Ferrari-Lacraz, S; Groves, C; Coyle, A; Malek, TR; Strom, TB			IL-15 and IL-2: a matter of life and death for T cells in vivo	NATURE MEDICINE			English	Article							GAMMA-CHAIN; ALPHA-CHAIN; RECEPTOR; CYTOKINE; INDUCTION; APOPTOSIS; IDENTIFICATION; LYMPHOCYTES; HOMEOSTASIS; ENDOCYTOSIS	Interleukin (IL)-2 and IL-15 are redundant in stimulating T-cell proliferation in vitro. Their precise role in vivo in governing T-cell expansion and T-cell homeostasis is less clear. Each may have distinct functions and regulate distinct aspects of T-cell activation(1-6). The functional receptors for IL-2 and IL-15 consist of a private ex-chain, which defines the binding specificity for IL-2 or IL-15, and shared IL-2 receptor beta- and gamma -chains. The gamma -chain is also a critical signaling component of IL-4, IL-7 and IL-9 receptors(7). Thus, the gamma -chain is called the common gamma or gamma -c. As these receptor subunits can be expressed individually or in various combinations resulting in the formation of receptors with different affinities, distinct signaling capabilities or both(7,8), We hypothesized that differential expression of IL-2 and IL-15 receptor subunits on cycling T cells in vivo may direct activated T cells to respond to IL-2 or IL-15, thereby regulating the homeostasis of T-cell response in vivo. By observing in vivo T-cell divisions and expression of IL-2 and IL-15 receptor subunits, we demonstrate that IL-15 is a critical growth factor in initiating T cell divisions in vivo, whereas IL-2 limits continued T-cell expansion via downregulation of the gamma -c expression. Decreased gamma -c expression on cycling T cells reduced sustained Bcl-2 expression and rendered cells susceptible to apoptotic cell death. Our study provides data that IL-2 and IL-15 regulate distinct aspects of primary T-cell expansion in vivo.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Boston, MA 02215 USA; Millennium Pharmaceut Inc, Cambridge, MA USA; Univ Miami, Dept Microbiol & Immunol, Miami, FL 33152 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Miami	Li, XC (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Boston, MA 02215 USA.	xli@caregroup.harvard.edu	Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762				BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Chae DW, 1996, J IMMUNOL, V157, P2813; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kim YS, 1998, J IMMUNOL, V160, P5742; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li XC, 1999, J IMMUNOL, V163, P2500; Li XC, 2000, J IMMUNOL, V164, P1193, DOI 10.4049/jimmunol.164.3.1193; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Morelon E, 1998, J BIOL CHEM, V273, P22044, DOI 10.1074/jbc.273.34.22044; Nakajima H, 1997, J EXP MED, V185, P189, DOI 10.1084/jem.185.2.189; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873	20	242	259	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					114	118		10.1038/83253	http://dx.doi.org/10.1038/83253			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135625				2022-12-25	WOS:000166243100044
J	Gold, ER				Gold, ER			Moving the gene patent debate forward - A framework for achieving compromise between industry and civil society.	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada; Univ Alberta, Hlth Law Inst, Edmonton, AB T6G 2M7, Canada	Western University (University of Western Ontario); University of Alberta	Gold, ER (corresponding author), Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada.			Gold, E. Richard/0000-0002-3789-9238				BROWN P, 1999, GUARDIAN        0825; *CAN BIOT SECR, 2000, PUBL OP RES BIOT ISS; CAULFIELD TA, 2000, FORUM APPL RES PUB P, P75; Gaskell G, 2000, NAT BIOTECHNOL, V18, P935, DOI 10.1038/79403; Gold ER, 2000, NAT BIOTECHNOL, V18, P1217, DOI 10.1038/81233; Priest SH, 2000, NAT BIOTECHNOL, V18, P939, DOI 10.1038/79412; Taylor C., 1991, MALAISE MODERNITY; WHITNEY CR, 1999, NY TIMES        0627, pD3	8	7	7	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1319	1320		10.1038/82460	http://dx.doi.org/10.1038/82460			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101818				2022-12-25	WOS:000165659000037
J	Tsukamoto, T; Hashiguchi, N; Janicki, SM; Tumbar, T; Belmont, AS; Spector, DL				Tsukamoto, T; Hashiguchi, N; Janicki, SM; Tumbar, T; Belmont, AS; Spector, DL			Visualization of gene activity in living cells	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID COHESION; GREEN FLUORESCENT PROTEIN; NUCLEAR DOMAIN-10 ND10; INSITU HYBRIDIZATION; CHROMOSOME DOMAINS; DNA-SEQUENCES; BUDDING YEAST; CYCLE; ORGANIZATION; CENTROMERES	Chromatin structure is thought to play a critical role in gene expression. Using the lac operator/repressor system and two colour variants of green fluorescent protein (GFP), we developed a system to visualize a gene and its protein product directly in living cells, allowing us to examine the spatial organization and timing of gene expression in vivo. Dynamic morphological changes in chromatin structure, from a condensed to an open structure, were observed upon gene activation, and targeting of the gene product, cyan fluorescent protein (CFP) reporter to peroxisomes was visualized directly in living cells. We found that the integrated gene locus was surrounded by a promyelocytic leukaemia (PML) nuclear body. The association was transcription independent but was dependent upon the direct in vivo binding of specific proteins (EYFP/lac repressor, tetracycline receptor/VP16 transactivator) to the locus. The ability to visualize gene expression directly in living cells provides a powerful system with which to study the dynamics of nuclear events such as transcription, RNA processing and DNA repair.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Himeji Inst Technol, Dept Life Sci, Kamigori, Hyogo 6781297, Japan; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Cold Spring Harbor Laboratory; University of Hyogo; University of Illinois System; University of Illinois Urbana-Champaign	Spector, DL (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [T32CA009311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042516, R01GM042694] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09311] Funding Source: Medline; NIGMS NIH HHS [R01 GM042694, R01 GM042516] Funding Source: Medline; PHS HHS [498100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abney JR, 1997, J CELL BIOL, V137, P1459, DOI 10.1083/jcb.137.7.1459; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BARTHOLDI MF, 1991, J CELL SCI, V99, P255; Belmont AS, 1998, TRENDS CELL BIOL, V8, P121, DOI 10.1016/S0962-8924(97)01211-7; BORDEN J, 1988, SCIENCE, V242, P1687, DOI 10.1126/science.3201257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dietzel S., 1995, Bioimaging, V3, P121, DOI 10.1002/1361-6374(199509)3:3<121::AID-BIO3>3.3.CO;2-5; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Miller J. H., 1980, OPERON; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Pederson T, 1978, Int Rev Cytol, V55, P1; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Sambrook J., 1989, MOL CLONING; Spector D. L., 1998, CELLS LAB MANUAL; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	43	243	249	1	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					871	878		10.1038/35046510	http://dx.doi.org/10.1038/35046510			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146650				2022-12-25	WOS:000165814500008
J	Pouvelle, B; Buffet, PA; Lepolard, C; Scherf, A; Gysin, J				Pouvelle, B; Buffet, PA; Lepolard, C; Scherf, A; Gysin, J			Cytoadhesion of Plasmodium falciparum ring-stage-infected erythrocytes	NATURE MEDICINE			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; CHONDROITIN-SULFATE-A; IN-VITRO MODEL; HUMAN BRAIN; PREGNANT-WOMEN; HUMAN PLACENTA; MALARIA; THROMBOMODULIN; RECEPTOR; SEQUESTRATION	A common pathological characteristic of Plasmodium folciparum infection is the cytoadhesion of mature-stage-infected erythrocytes (IE) to host endothelium and syncytiotrophoblasts. Massive accumulation of IE in the brain microvasculature or placenta is strongly correlated with severe forms of malaria(1). Extensive binding of IE to placental chondroitin sulfate A (CSA) is associated with physiopathology during pregnancy(2,3). The adhesive phenotype of IE correlates with the appearance of Plasmodium:falciparum erythrocyte membrane protein 1 (PfEMP1) at the erythrocyte surface (approximately 16 h after merozoite invasion), so that only early blood-stage (ring-stage) IE appear in the peripheral blood. Here, we describe results that challenge the existing view of blood-stage IE biology by demonstrating the specific adhesion of IE, during the early ring-stage, to endothelial cell lines from the brain and lung and to placental syncytiotrophoblasts. Later, during blood-stage development of these IE; trophozoites switch to an exclusively CSA cytoadhesion phenotype. Therefore, adhesion to an individual endothelial cell or syncytiotrophoblast may occur throughout the blood-stage cycle, indicating the presence in malaria patients of noncirculating (cryptic) parasite subpopulations. We detected two previously unknown parasite proteins on the surface of ring-stage IE. These proteins disappear shortly after the start of PfEMP1-mediated adhesion.	Univ Aix Marseille 2, Fac Med, Lab Parasitol Expt, F-13385 Marseille 5, France; Inst Pasteur, Unite Biol Interact Hote Parasite, CNRS, URA 1960, F-75724 Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gysin, J (corresponding author), Univ Aix Marseille 2, Fac Med, Lab Parasitol Expt, F-13385 Marseille 5, France.		Scherf, Artur/A-9674-2014; Buffet, Pierre A/O-6189-2017; catherine, lepolard/P-5653-2016; Pouvelle, Bruno/AAA-3968-2022	Buffet, Pierre A/0000-0003-4010-929X; Scherf, Artur/0000-0003-2411-3328				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; BOFFA MC, 1991, NOUV REV FR HEMATOL, V33, P423; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; Fernandez V, 1999, J EXP MED, V190, P1393, DOI 10.1084/jem.190.10.1393; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q; Gysin J, 1999, INFECT IMMUN, V67, P6596; GYSIN J, 1983, AM J TROP MED HYG, V32, P461, DOI 10.4269/ajtmh.1983.32.461; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; Lou J, 1997, J NEUROIMMUNOL, V77, P107, DOI 10.1016/S0165-5728(97)00067-2; MATTEELLI A, 1994, ANN TROP MED PARASIT, V88, P475, DOI 10.1080/00034983.1994.11812894; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; WATKINSON M, 1983, BMJ-BRIT MED J, V287, P251, DOI 10.1136/bmj.287.6387.251; WONG VLY, 1991, BRAIN RES, V556, P1, DOI 10.1016/0006-8993(91)90540-C	22	92	96	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1264	1268		10.1038/81374	http://dx.doi.org/10.1038/81374			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062539				2022-12-25	WOS:000165114800035
J	Hel, Z; Venzon, D; Poudyal, M; Tsai, WP; Giuliani, L; Woodward, R; Chougnet, C; Shearer, G; Altman, JD; Watkins, D; Bischofberger, N; Abimiku, A; Markham, P; Tartaglia, J; Franchini, G				Hel, Z; Venzon, D; Poudyal, M; Tsai, WP; Giuliani, L; Woodward, R; Chougnet, C; Shearer, G; Altman, JD; Watkins, D; Bischofberger, N; Abimiku, A; Markham, P; Tartaglia, J; Franchini, G			Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; VACCINIA VIRUS; IMMUNE-RESPONSES; CELL RESPONSES; HIV-1 TAT; INDIVIDUALS; APOPTOSIS; MAMU-A-ASTERISK-01; DISCONTINUATION	Prolonged antiretroviral therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4(+) and CD8(+) T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.	NCI, Basic Res Lab, Bethesda, MD 20892 USA; NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA; Adv BioSci Labs Inc, Kensington, MD 20895 USA; NCI, Expt Immunol Branch, Bethesda, MD 20892 USA; Emory Univ, Vaccine Ctr Yerkes, Atlanta, GA 30329 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Gilead Sci Inc, Foster City, CA 94404 USA; Inst Human Virol, Baltimore, MD 21201 USA; Virogenet Corp, Troy, NY 12180 USA; Ave Pasteur Ltd, N York, ON M2R 3T4, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University; University of Wisconsin System; University of Wisconsin Madison; Gilead Sciences; University System of Maryland; University of Maryland Baltimore	Franchini, G (corresponding author), NCI, Basic Res Lab, 41-D804, Bethesda, MD 20892 USA.	veffa@helix.nih.gov	Venzon, David J/B-3078-2008	Hel, Zdenek/0000-0002-4923-4794	DIVISION OF BASIC SCIENCES - NCI [Z01BC010422] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC005688, ZIABC005688] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen TM, 1998, J IMMUNOL, V160, P6062; ALLEN TM, IN PRESS NATURE; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Benson J, 1998, J VIROL, V72, P4170, DOI 10.1128/JVI.72.5.4170-4182.1998; Binley JM, 2000, J INFECT DIS, V181, P1249, DOI 10.1086/315379; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FRANCHINI G, 1995, AIDS RES HUM RETROV, V11, P909, DOI 10.1089/aid.1995.11.909; FRANCHINI G, 1987, NATURE, V328, P539, DOI 10.1038/328539a0; Gray CM, 1999, J IMMUNOL, V162, P1780; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Haslett PAJ, 2000, J INFECT DIS, V181, P1264, DOI 10.1086/315381; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; KLEIN J, 1990, IMMUNOGENETICS, V31, P217, DOI 10.1007/BF00204890; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Letvin NL, 1998, ADV EXP MED BIOL, V452, P177; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Millington G., 1991, IEEE Microwave and Guided Wave Letters, V1, P320, DOI 10.1109/75.93898; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; Romano JW, 1997, IMMUNOL INVEST, V26, P15, DOI 10.3109/08820139709048912; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YASUTOMI Y, 1995, J VIROL, V69, P2279, DOI 10.1128/JVI.69.4.2279-2284.1995	42	166	171	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1140	1146		10.1038/80481	http://dx.doi.org/10.1038/80481			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017146				2022-12-25	WOS:000089674700039
J	Olsen, MJ; Stephens, D; Griffiths, D; Daugherty, P; Georgiou, G; Iverson, BL				Olsen, MJ; Stephens, D; Griffiths, D; Daugherty, P; Georgiou, G; Iverson, BL			Function-based isolation of novel enzymes from a large library	NATURE BIOTECHNOLOGY			English	Article						flow cytometry; directed enzyme evolution; fluorescence	DIRECTED EVOLUTION; ESCHERICHIA-COLI; ANTIBODY LIBRARIES; GENETIC SELECTION; OUTER-MEMBRANE; PHAGE DISPLAY; DNA; SURFACE; OMPT; DETERMINANTS	Here we describe a high-throughput, quantitative method for the isolation of enzymes with novel substrate specificities from large libraries of protein variants. Protein variants are displayed on the surface of microorganisms and incubated with a synthetic substrate consisting of (1) a fluorescent dye (2) a positively charged moiety (3) the target scissile bond, and (4) a fluorescence resonance energy transfer (FRET) quenching partner. Enzymatic cleavage of the scissile bond results in release of the FRET quenching partner while the fluorescent product is retained on the cell surface, allowing isolation of catalytically active clones by fluorescence-activated cell sorting (FACS). Using a synthetic substrate with these characteristics, we enriched Escherichia coli expressing the serine protease OmpT from cells expressing an inactive OmpT variant by over 5,000-fold in a single round. Screening a library of 6 x 10(5) random OmpT variants by FAGS using a FRET peptide substrate with a nonpreferred Arg-Val cleavage sequence resulted in the isolation of variant proteases with catalytic activities enhanced by as much as 60-fold. This approach represents a potentially widely applicable method for high-throughput screening of large libraries on the basis of catalytic turnover.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Iverson, BL (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.		lu, zhenghui/N-2903-2014; Griffiths, Devin/R-6759-2019	Olsen, Mark/0000-0003-2871-1923				Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; Atwell S, 1999, P NATL ACAD SCI USA, V96, P9497, DOI 10.1073/pnas.96.17.9497; CADWELL RC, 1992, PCR METH APPL, V2, P128; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; Christians FC, 1996, P NATL ACAD SCI USA, V93, P6124, DOI 10.1073/pnas.93.12.6124; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Daugherty PS, 1999, PROTEIN ENG, V12, P613, DOI 10.1093/protein/12.7.613; Daugherty PS, 2000, P NATL ACAD SCI USA, V97, P2029, DOI 10.1073/pnas.030527597; Demartis S, 1999, J MOL BIOL, V286, P617, DOI 10.1006/jmbi.1998.2476; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; GRODBERG J, 1988, NUCLEIC ACIDS RES, V16, P1209, DOI 10.1093/nar/16.3.1209; HULETT HR, 1969, SCIENCE, V166, P747, DOI 10.1126/science.166.3906.747; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; KAMENTSKY LA, 1965, SCIENCE, V150, P630, DOI 10.1126/science.150.3696.630; Kast P, 1997, CURR OPIN STRUC BIOL, V7, P470, DOI 10.1016/S0959-440X(97)80109-1; LEYTUS SP, 1981, P NATL ACAD SCI-BIOL, V78, P1485, DOI 10.1073/pnas.78.3.1485; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; MANGEL WF, 1994, METHOD ENZYMOL, V244, P384; Matsumura I, 1999, NAT BIOTECHNOL, V17, P696, DOI 10.1038/10910; Pedersen H, 1998, P NATL ACAD SCI USA, V95, P10523, DOI 10.1073/pnas.95.18.10523; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; RASHTCHIAN A, 1992, ANAL BIOCHEM, V206, P91, DOI 10.1016/S0003-2697(05)80015-6; Razatos A, 1998, P NATL ACAD SCI USA, V95, P11059, DOI 10.1073/pnas.95.19.11059; Shapiro H. M., 1995, PRACTICAL FLOW CYTOM; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; WHITE CB, 1995, J BIOL CHEM, V270, P12990, DOI 10.1074/jbc.270.22.12990; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511	31	123	172	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1071	1074		10.1038/80267	http://dx.doi.org/10.1038/80267			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017045				2022-12-25	WOS:000089744700029
J	Kaufmann, SHE				Kaufmann, SHE			Is the development of a new tuberculosis vaccine possible?	NATURE MEDICINE			English	News Item							MYCOBACTERIUM-TUBERCULOSIS; PROTECTIVE EFFICACY; DNA VACCINE; GENOMICS; BCG; IMMUNOGENICITY; STRAINS; MALARIA; MODEL		Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany	Max Planck Society	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1999, WORLD HLTH REPORT 19; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Hess J, 2000, ADV IMMUNOL, V75, P1, DOI 10.1016/S0065-2776(00)75001-2; Hess J, 1998, P NATL ACAD SCI USA, V95, P5299, DOI 10.1073/pnas.95.9.5299; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Hoffman SL, 1998, NAT MED, V4, P1351, DOI 10.1038/3934; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Jungblut PR, 1999, MOL MICROBIOL, V33, P1103, DOI 10.1046/j.1365-2958.1999.01549.x; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Walsh GP, 1996, NAT MED, V2, P430, DOI 10.1038/nm0496-430; *WHO, 2000, GLOB TUB CONTR	18	190	206	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					955	960		10.1038/79631	http://dx.doi.org/10.1038/79631			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973302	Bronze			2022-12-25	WOS:000089190500016
J	Rodriguez, I; Greer, CA; Mok, MY; Mombaerts, P				Rodriguez, I; Greer, CA; Mok, MY; Mombaerts, P			A putative pheromone receptor gene expressed in human olfactory mucosa	NATURE GENETICS			English	Article							VOMERONASAL ORGAN; MULTIGENE FAMILY; MAMMALS		Rockefeller Univ, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA	Rockefeller University; Yale University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	peter@mail.rockefeller.edu		rodriguez, ivan/0000-0002-6468-0565				Dorries KM, 1997, BRAIN BEHAV EVOLUT, V49, P53, DOI 10.1159/000112981; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HUDSON R, 1986, PHYSIOL BEHAV, V37, P123, DOI 10.1016/0031-9384(86)90394-X; Humphrey T, 1940, J COMP NEUROL, V73, P431, DOI 10.1002/cne.900730305; Johnston RE, 1998, ANN NY ACAD SCI, V855, P333, DOI 10.1111/j.1749-6632.1998.tb10592.x; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1999, CURR OPIN GENET DEV, V9, P315, DOI 10.1016/S0959-437X(99)80047-1; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Saito H, 1998, MOL BRAIN RES, V60, P215, DOI 10.1016/S0169-328X(98)00183-1; STENSAAS LJ, 1991, J STEROID BIOCHEM, V39, P553, DOI 10.1016/0960-0760(91)90252-Z; Stern K, 1998, NATURE, V392, P177, DOI 10.1038/32408	14	166	177	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					18	19		10.1038/79124	http://dx.doi.org/10.1038/79124			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973240				2022-12-25	WOS:000089078000010
J	Maser, RS; Zinkel, R; Petrini, JHJ				Maser, RS; Zinkel, R; Petrini, JHJ			An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele	NATURE GENETICS			English	Article							RIBOSOME-ENTRY-SITE; ATAXIA-TELANGIECTASIA; MAMMALIAN-CELLS; DNA; GENE; REPAIR	Nijmegen breakage syndrome (NBS) is a rare chromosomal-instability syndrome associated with cancer predisposition, radiosensitivity and radioresistant DNA synthesis-S phase checkpoint deficiency, which results in the failure to suppress DNA replication origins following DNA damage. Approximately 90% of NBS patients are homozygous for the 657del5 allele(1,2), a truncating mutation of NBS1 that causes premature termination at codon 219. Because null mutations in MRE11 and RAD50, which encode binding partners of NBS1, are lethal in vertebrates(3-5), and mouse Nbs1-null mutants are inviable(6), we tested the hypothesis that the NBS1 657del5 mutation was a hypomorphic defect. We showed that NBS cells contain the predicted 26-kD amino-terminal protein fragment, NBS1(p26) and a 70-kD NBS1 protein (NBS1(p70)) lacking the native N terminus. The NBSp26 protein is not physically associated with the MRE11 complex, whereas the p70 species is physically associated with it. NBS1(p70) is produced by internal translation initiation within the NBS1 mRNA using an open reading frame generated by the 657del5 frameshift. We propose that the common NBS1 allele encodes a partially functional protein that diminishes the severity of the NBS phenotype.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59413] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; Tupler R, 1997, J MED GENET, V34, P196, DOI 10.1136/jmg.34.3.196; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	16	179	182	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					417	421		10.1038/86920	http://dx.doi.org/10.1038/86920			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279524				2022-12-25	WOS:000167811200017
J	Chen, J; Godt, D; Gunsalus, K; Kiss, I; Goldberg, M; Laski, FA				Chen, J; Godt, D; Gunsalus, K; Kiss, I; Goldberg, M; Laski, FA			Cofilin/ADF is required for cell motility during Drosophila ovary development and oogenesis	NATURE CELL BIOLOGY			English	Article							ACTIN-BASED MOTILITY; PROTEINS; MORPHOGENESIS; MUTATIONS; PHOSPHORYLATION; IDENTIFICATION; ORGANIZATION; MELANOGASTER; DYNAMICS; HOMOLOG	The driving force behind cell motility is the actin cytoskeleton. Filopodia and lamellipodia are formed by the polymerization and extension of actin filaments towards the cell membrane(1,2). This polymerization at the barbed end of the filament is balanced by depolymerization at the pointed end, recycling the actin in a 'tread-milling' process(2,3). One protein involved in this process is cofilin/actin-depolymerizing factor (ADF), which can depolymerize actin filaments, allowing treadmilling to occur at an accelerated rate(3,4). Cofilin/ADF is an actin-binding protein that is required for actin-filament disassembly, cytokinesis and the organization of muscle actin filaments(4-7). There is also evidence that cofilin/ADF enhances cell motility(3,8,9), although a direct requirement in vivo has not yet been shown. Here we show that Drosophila cofilin/ADF(6,10), which is encoded by the twin-star (tsr) gene, promotes cell movements during ovary development and oogenesis. During larval development, cofilin/ADF is required for the cell rearrangement needed for formation of terminal filaments, stacks of somatic cells that are important for the initiation of ovarioles. It is also required for the migration of border cells during oogenesis, These results show that cofilin/ADF is an important regulator of actin-based cell motility during Drosophila development.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Hungarian Acad Sci, Inst Genet, H-6701 Szeged, Hungary	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Toronto; Cornell University; Hungarian Academy of Sciences; Hungarian Biological Research Center	Laski, FA (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.			Chen, Jiong/0000-0001-5252-3936	NIGMS NIH HHS [GM40451, GM07185, GM07617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GODT D, 1995, DEVELOPMENT, V121, P173; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hopmann R, 1996, J CELL BIOL, V133, P1293, DOI 10.1083/jcb.133.6.1293; King R. C., 1970, OVARIAN DEV DROSOPHI; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; LIN H, 1993, DEV BIOL, V159, P140, DOI 10.1006/dbio.1993.1228; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Montell DJ, 1999, CELL BIOCHEM BIOPHYS, V31, P219, DOI 10.1007/BF02738240; Morgan P, 1995, J URBAN TECHNOL, V3, P97, DOI 10.1080/10630739508724519; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Reed BH, 1997, DEVELOPMENT, V124, P3543; SAHUTBARNOLA I, 1995, DEV BIOL, V170, P127, DOI 10.1006/dbio.1995.1201; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SPREADLING A, 1993, DEV DROSOPHILA MELAN, P1; TOROK T, 1993, GENETICS, V135, P71; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	30	107	111	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					204	209		10.1038/35055120	http://dx.doi.org/10.1038/35055120			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175754				2022-12-25	WOS:000166793000023
J	Batourina, E; Gim, S; Bello, N; Shy, M; Clagett-Dame, M; Srinivas, S; Costantini, F; Mendelsohn, C				Batourina, E; Gim, S; Bello, N; Shy, M; Clagett-Dame, M; Srinivas, S; Costantini, F; Mendelsohn, C			Vitamin A controls epithelial/mesenchymal interactions through Ret expression	NATURE GENETICS			English	Article							RETINOIC ACID; URETERAL BUD; KIDNEY; RAT; DEFECTS; MICE; RESPONSIVENESS; ORGANOGENESIS; METANEPHROS; DEFICIENCY	Mutations or rearrangements in the gene encoding the receptor tyrosine kinase RET result in Hirschsprung disease, cancer and renal malformations, The standard model of renal development involves reciprocal signaling between the ureteric bud epithelium, inducing metanephric mesenchyme to differentiate into nephrons, and metanephric mesenchyme, inducing the ureteric bud to grow and branch(1,2). RET and GDNF (a RET ligand) are essential mediators of these epithelial-mesenchymal interactions'. Vitamin A deficiency has been associated with widespread embryonic abnormalities, including renal malformations(4), The vitamin A signal is transduced by nuclear retinoic acid receptors (RARs), We previously showed that two RAR genes, Rara and Rarb2, were colocalized in stromal mesenchyme, a third renal cell type, where their deletion led to altered stromal cell patterning, impaired ureteric bud growth and downregulation of Ret in the ureteric bud(5,6). Here we demonstrate that forced expression of Ret in mice deficient for both Rara and Rarb2 (Rara(-/-)Rarb2(-/-)) genetically rescues renal development, restoring ureteric bud growth and stromal cell patterning. Our studies indicate the presence of a new reciprocal signaling loop between the ureteric bud epithelium and the stromal mesenchyme, dependent on Ret and vitamin A, In the first part of the loop, vitamin-A-dependent signals secreted by stromal cells control Ret expression in the ureteric bud. In the second part of the loop, ureteric bud signals dependent on Rot control stromal cell patterning.	Columbia Univ, Dept Urol, New York, NY 10027 USA; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Wisconsin, Dpet Biochem & Pharmaceut Sci, Madison, WI USA	Columbia University; Columbia University; University of Wisconsin System; University of Wisconsin Madison	Mendelsohn, C (corresponding author), Columbia Univ, Dept Urol, New York, NY 10027 USA.	clm20@columbia.edu	Bello, Natalie/J-1001-2019; Mendelsohn, Cathy/H-4280-2016	Bello, Natalie/0000-0003-3257-3623; Mendelsohn, Cathy/0000-0002-4026-4073; Srinivas, Shankar/0000-0001-5726-7791; Shy, Michael/0000-0001-8460-6971	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061459, R56DK082963] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061459-07, R56 DK082963, R01 DK061459-06, R56 DK082963-01, R01 DK061459, R01 DK061459-09, R01 DK061459-07S1, R01 DK061459-08, R01 DK061459-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brenner BM, 1997, KIDNEY INT, pS124; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Moreau E, 1998, AM J PHYSIOL-RENAL, V275, pF938, DOI 10.1152/ajprenal.1998.275.6.F938; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Patrone G, 1997, FEBS LETT, V419, P76, DOI 10.1016/S0014-5793(97)01435-X; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; ROBERTSON K, 1995, MECH DEVELOP, V53, P329, DOI 10.1016/0925-4773(95)00449-1; Sariola H, 1999, INT J DEV BIOL, V43, P413; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Srinivas S, 1999, DEV GENET, V24, P241; Srinivas S, 1999, DEVELOPMENT, V126, P1375; Thang SH, 2000, J NEUROSCI, V20, P2917; Vilar J, 1996, KIDNEY INT, V49, P1478, DOI 10.1038/ki.1996.208; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; White JC, 1998, P NATL ACAD SCI USA, V95, P13459, DOI 10.1073/pnas.95.23.13459; White JC, 2000, DEV BIOL, V220, P263, DOI 10.1006/dbio.2000.9635; WILSON JG, 1948, AM J ANAT, V83, P357, DOI 10.1002/aja.1000830303	26	186	191	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					74	78		10.1038/83792	http://dx.doi.org/10.1038/83792			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138002				2022-12-25	WOS:000166187900019
J	Peter, M; Castro, A; Lorca, T; Le Peuch, C; Magnaghi-Jaulin, L; Doree, M; Labbe, JC				Peter, M; Castro, A; Lorca, T; Le Peuch, C; Magnaghi-Jaulin, L; Doree, M; Labbe, JC			The APC is dispensable for first meiotic anaphase in Xenopus oocytes	NATURE CELL BIOLOGY			English	Article							CHROMATID COHESION; PROMOTING COMPLEX; PROTEIN-KINASE; EGG EXTRACTS; CYCLIN-B; DESTRUCTION; PROTEOLYSIS; METAPHASE; MEIOSIS; YEAST	Here we show that segregation of homologous chromosomes and that of sister chromatids are differentially regulated in Xenopus and possibly in other higher eukaryotes. Upon hormonal stimulation, Xenopus oocytes microinjected with antibodies against the anaphase-promoting complex (APC) activator Fizzy or the APC core subunit Cdc27, or with the checkpoint protein Mad2, a destruction-box peptide or methylated ubiquitin, readily progress through the first meiotic cell cycle and arrest at second meiotic metaphase. However, they fail to segregate sister chromatids and remain arrested at second meiotic metaphase when electrically stimulated or when treated with ionophore A34187, two treatments that mimic fertilization and readily induce chromatid segregation in control oocytes. Thus, APC is required for second meiotic anaphase but not for first meiotic anaphase.	CRBM, UPR 1086 CNRS, F-34293 Montpellier 5, France	Universite de Montpellier	Labbe, JC (corresponding author), CRBM, UPR 1086 CNRS, 1919 Route Mende, F-34293 Montpellier 5, France.		CASTRO, ANNA/F-4350-2010; labbe, jean-claude/B-2277-2009; Peter, Marion/Y-5024-2019	CASTRO, ANNA/0000-0002-3655-1352; Peter, Marion/0000-0002-5720-4798; Lorca, Thierry/0000-0003-2007-8924				Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fisher D, 1998, BIOL CELL, V90, P497; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; GALAS S, 1993, MOL BIOL CELL, V4, P1295, DOI 10.1091/mbc.4.12.1295; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; OHSUMI K, 1994, J CELL SCI, V107, P3305; Rieder CL, 1999, J CELL SCI, V112, P2607; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; SIMCHEN G, 1974, GENETICS, V76, P745; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	30	119	124	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					83	87		10.1038/35050607	http://dx.doi.org/10.1038/35050607			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146630				2022-12-25	WOS:000166146400024
J	Wildin, RS; Ramsdell, F; Peake, J; Faravelli, F; Casanova, JL; Buist, N; Levy-Lahad, E; Mazzella, M; Goulet, O; Perroni, L; Bricarelli, FD; Byrne, G; McEuen, M; Proll, S; Appleby, M; Brunkow, ME				Wildin, RS; Ramsdell, F; Peake, J; Faravelli, F; Casanova, JL; Buist, N; Levy-Lahad, E; Mazzella, M; Goulet, O; Perroni, L; Bricarelli, FD; Byrne, G; McEuen, M; Proll, S; Appleby, M; Brunkow, ME			X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy	NATURE GENETICS			English	Article							MUTANT; DIARRHEA; HEAD	To determine whether human X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome (IPEX; MIM 304930) is the genetic equivalent of the scurfy (sf) mouse, we sequenced the human ortholog (FOXP3) of the gene mutated in scurfy mice (Foxp3), in IPEX patients. We found four non-polymorphic mutations. Each mutation affects the forkhead/winged-helix domain of the scurfin protein, indicating that the mutations may disrupt critical DNA interactions.	Oregon Hlth Sci Univ, Dept Mol & Med Genet L103A, Portland, OR 97201 USA; Celltech Chirosci Inc, Bothell, WA USA; Royal Childrens Hosp, Dept Paediat, Brisbane, Qld, Australia; Royal Childrens Hosp, Dept Child Hlth, Brisbane, Qld 4029, Australia; Galliera Hosp, Lab Human Genet, Genoa, Italy; Univ Paris, Hosp Necker Enfants Malad, Serv Immunol & Hematol Pediat, Lab Human Genet Infect Dis, F-75252 Paris, France; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Shaare Zedek Med Ctr, Med Genet Unit, Jerusalem, Israel; G Gaslini Inst, Dept Neonatol, Neonatol Intens Care Unit, Genoa, Italy; Princess Margaret Hosp, Dept Endocrinol, Perth, WA, Australia	Oregon Health & Science University; Royal Children's Hospital Brisbane; Royal Children's Hospital Brisbane; Ente Ospedaliero Ospedali Galliera; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Oregon Health & Science University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini	Wildin, RS (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet L103A, Portland, OR 97201 USA.		Casanova, Jean-Laurent/I-3418-2017; Peake, Jane/B-4488-2011; Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921; Casanova, Jean-Laurent/0000-0002-7782-4169; Peake, Jane/0000-0001-9003-5861	Telethon [C.42] Funding Source: Medline	Telethon(Fondazione Telethon)		Bennett CL, 2000, AM J HUM GENET, V66, P461, DOI 10.1086/302761; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clark LB, 1999, J IMMUNOL, V162, P2546; Ferguson PJ, 2000, AM J MED GENET, V90, P390, DOI 10.1002/(SICI)1096-8628(20000228)90:5<390::AID-AJMG9>3.0.CO;2-M; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LEVYLAHAD E, IN PRESS J PEDIAT; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Means GD, 2000, GENOMICS, V65, P213, DOI 10.1006/geno.2000.6173; Peake JE, 1996, ARCH DIS CHILD-FETAL, V74, pF195, DOI 10.1136/fn.74.3.F195; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8	13	1340	1385	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					18	20		10.1038/83707	http://dx.doi.org/10.1038/83707			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137992				2022-12-25	WOS:000166187900009
J	Basto, R; Gomes, R; Karess, RE				Basto, R; Gomes, R; Karess, RE			Rough deal and Zw10 are required for the metaphase checkpoint in Drosophila	NATURE CELL BIOLOGY			English	Article							ACCURATE CHROMOSOME SEGREGATION; KINETOCHORE LOCALIZATION; PROMOTING COMPLEX; ANAPHASE ONSET; SPINDLE; PROTEIN; MITOSIS; BUB1; DESTRUCTION; MUTATIONS	The metaphase-anaphase transition during mitosis is carefully regulated in order to assure high-fidelity transmission of genetic information to the daughter cells. A surveillance mechanism known as the metaphase checkpoint (or spindle-assembly checkpoint) monitors the attachment of kinetochores to the spindle microtubules, and inhibits anaphase onset until all chromosomes have achieved a proper bipolar orientation on the spindle. Defects in this checkpoint lead to premature anaphase onset, and consequently to greatly increased rates of aneuploidy. Here we show that the Drosophila kinetochore components Rough deal (Rod) and Zeste-White 10 (Zw10) are required for the proper functioning of the metaphase checkpoint in flies. Drosophila cells lacking either ROD or ZwlO exhibit a phenotype that is similar to that of bub1 mutants - they do not arrest in metaphase in response to spindle damage, but instead separate sister chromatids, degrade cyclin B and exit mitosis. These ave the first checkpoint components to be identified that do not have obvious homologues in budding yeast.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Lisbon, Fac Ciencias, Dept Biol Vegetal, Ctr Genet & Biol Mol, P-1600 Lisbon, Portugal	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universidade de Lisboa	Karess, RE (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91198 Gif Sur Yvette, France.		Gomes, Rui/AAE-9130-2022; Gomes, Rui APL/M-1803-2015	Gomes, Rui/0000-0002-7242-6540; Gomes, Rui APL/0000-0002-7242-6540; Karess, Roger/0000-0002-7299-0600				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Avides MD, 1999, SCIENCE, V283, P1733, DOI 10.1126/science.283.5408.1733; Basu J, 1998, CHROMOSOMA, V107, P376, DOI 10.1007/s004120050321; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; GONZALEZ C, 1990, J CELL SCI, V96, P605; Gorbsky GJ, 1999, FASEB J, V13, pS231, DOI 10.1096/fasebj.13.9002.S231; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; Scaerou F, 1999, J CELL SCI, V112, P3757; SCAEROU F, UNPUB ZW10 ROUGH DEA; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	30	92	94	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					939	943		10.1038/35046592	http://dx.doi.org/10.1038/35046592			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146659				2022-12-25	WOS:000165814500017
J	Peto, J; Mack, TM				Peto, J; Mack, TM			High constant incidence in twins and other relatives of women with breast cancer	NATURE GENETICS			English	Article							RISK-FACTORS; FAMILIAL RISK; ONSET; GENES; BRCA1	The incidence of breast cancer rises steeply between ages 25 and 50, and more slowly thereafter. In contrast, the incidence in the unaffected (contralateral) breast of women who have had breast cancer remains constant at about 0.7% per year for at least the next 20 years after diagnosis, irrespective of age at first diagnosis. The incidence in relatives of the patients seems to show a similar pattern. The incidence in a prospective study of monozygotic twins of patients was approximately constant at 1.3% per year (77 cases), again about 0.7% per breast. At ages older than a patient's age at diagnosis, her mother and sisters have an incidence of 0.3-0.4% per year. Above the index patient's age at diagnosis, the rate in relatives shows no temporal trend and is independent of the patient's age at diagnosis. A statistically simple explanation is that incidence in susceptible women increases to a high constant level by a predetermined age that varies between families, but this seems inconsistent with conventional models of carcinogenesis and susceptibility. The very high incidence in monozygotic twins of patients indicates that a high proportion, and perhaps the majority, of breast cancers arise in a susceptible minority of women.	Inst Canc Res, Epidemiol Sect, Surrey, England; London Sch Hyg & Trop Med, London WC1, England; USC Norris comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA USA	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; University of Southern California	Peto, J (corresponding author), Inst Canc Res, Epidemiol Sect, Surrey, England.				NATIONAL CANCER INSTITUTE [R01CA032262, R35CA042581] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA42581, R01CA32262] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlbom A, 1997, J NATL CANCER I, V89, P287, DOI 10.1093/jnci/89.4.287; BERNSTEIN JL, 1992, AM J EPIDEMIOL, V136, P937, DOI 10.1093/oxfordjournals.aje.a116566; BERNSTEIN JL, 1992, AM J EPIDEMIOL, V136, P925, DOI 10.1093/oxfordjournals.aje.a116565; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; Cerhan JR, 2000, J NATL CANCER I, V92, P261, DOI 10.1093/jnci/92.3.261; CHILVERS C, 1989, LANCET, V1, P973; Clarke M, 1998, LANCET, V351, P1451; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; CLAUS EB, 1988, THESIS YALE U; Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HISLOP TG, 1984, BRIT J CANCER, V49, P79, DOI 10.1038/bjc.1984.12; Houlston Richard S., 1996, P208; Olsen JH, 1999, BRIT J CANCER, V79, P673, DOI 10.1038/sj.bjc.6690106; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; ROBBINS GF, 1964, CANCER, V12, P1502; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Slack F, 1997, ANNU REV GENET, V31, P611, DOI 10.1146/annurev.genet.31.1.611; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; Waterhouse J., 1976, IARC SCI PUBLICATION, V15	25	222	231	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					411	414		10.1038/82533	http://dx.doi.org/10.1038/82533			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101836				2022-12-25	WOS:000165671700011
J	Gold, ER				Gold, ER			Finding common cause in the patent debate	NATURE BIOTECHNOLOGY			English	Article									Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada	Western University (University of Western Ontario)	Gold, ER (corresponding author), Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada.			Gold, E. Richard/0000-0002-3789-9238				[Anonymous], 1980, PUBL; Campbell CS, 1998, KENNEDY INST ETHIC J, V8, P275, DOI 10.1353/ken.1998.0019; CAULFIELD TA, 2000, FORUM APPL RES PUB P, V75; Dunner Donald R., 1995, FED CIR BJ, V5, P151; Gold E R, 2000, McGill Law J, V45, P413; HANSON MJ, 1997, HASTINGS CTR REPORT, V27, pS1; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; HO M, 1996, GREENPEACE INT GENET; Hunt R., 1999, FBI LAW ENFORCEMENT, V68, P15; Mann C., 1999, TECHNOLOGY REV   JUL, P37; MANSFIELD E, 1981, ECON J, V91, P907, DOI 10.2307/2232499; MERGES RP, 1993, HIGH TECH L J, V7, P1; MERGES RP, 1992, MARKET STRUCTURE TEC; PRESS E, 2000, J ATLANTIC MONTHLY, P39; SCHANKERMAN M, 1986, ECON J, V96, P1052, DOI 10.2307/2233173; SEURET F, 2000, MONDE DIPL, P24; *UN ESC, 2000, ECN1720007ADD2 UN; WRONG M, 2000, FINANCIAL TIMES	18	13	13	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1217	1218		10.1038/81233	http://dx.doi.org/10.1038/81233			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	371JV	11062446				2022-12-25	WOS:000165176600033
J	Simizu, S; Osada, H				Simizu, S; Osada, H			Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines	NATURE CELL BIOLOGY			English	Article							POLO-LIKE KINASES; COMPLEX; CYCLE; HSP90; LOCALIZATION; ASSOCIATION	It has been established that mutations in Drosophila Polo cause abnormalities in mitosis(1). In human cells, maximal Plk activity is reached in the M phase of the cell cycle, and the function of Plk is therefore considered to be required for mitotic cellular events such as spindle formation, chromosome segregation and cytokinesis. Microinjection of antiPlk antibody into living cells has been found to induce a mitotic abnormality that contributes to the generation of aneuploidy(2), and this is an important finding in relation to tumour development. Indeed, previous studies have shown that the level of expression of a mitotic checkpoint gene, hsMAD2, is reduced(3) and that another checkpoint gene, BUB1, is mutated in certain human cancer cells(4).	RIKEN, Antiobiot Lab, Wako, Saitama 3510198, Japan	RIKEN	Simizu, S (corresponding author), RIKEN, Antiobiot Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.		Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014	Simizu, Siro/0000-0003-2949-2427				Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SUNKEL CE, 1988, J CELL SCI, V89, P25; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	15	117	122	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					852	854		10.1038/35041102	http://dx.doi.org/10.1038/35041102			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056542				2022-12-25	WOS:000165207500021
J	Sun, YH; Bakshi, S; Chalmers, R; Tang, CM				Sun, YH; Bakshi, S; Chalmers, R; Tang, CM			Functional genomics of Neisseria meningitidis pathogenesis	NATURE MEDICINE			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ANTIBODIES; STRAINS	The pathogenic bacterium Neisseria meningitidis is an important cause of septicemia and meningitis, especially in childhood(1). The establishment and maintenance of bacteremic infection is a prerequisite for all the pathological sequelae of meningococcal infection. To further understand the genetic basis of this essential step in pathogenesis, we analyzed a library of 2,850 insertional mutants of N. meningitidis for their capacity to cause systemic infection in an infant rat model. The library was constructed by in vitro modification of Neisseria genomic DNA with the purified components of Tn10 transposition(2). We identified 73 genes in the N. meningitidis genome that are essential for bacteremic disease. Eight insertions were in genes encoding known pathogenicity factors. Involvement of the remaining 65 genes in meningocoocal pathogenesis has not been demonstrated previously, and the identification of these genes provides insights into the pathogenic mechanisms that underlie meningococcal infection. Our results provide a genome-wide analysis of the attributes of N, meningitidis required for disseminated infection, and may lead to new interventions to prevent and treat meningococcal infection.	Univ Oxford, John Radcliffe Hosp, Univ Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Tang, CM (corresponding author), Univ Oxford, John Radcliffe Hosp, Univ Dept Paediat, Oxford OX3 9DU, England.			chalmers, ronald/0000-0002-1395-7173				AlaAldeen DAA, 1996, VACCINE, V14, P49, DOI 10.1016/0264-410X(95)00136-O; CATLIN BW, 1960, J BACTERIOL, V79, P579, DOI 10.1128/JB.79.4.579-590.1960; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; Feavers IM, 2000, NATURE, V404, P451, DOI 10.1038/35006546; Granoff DM, 1998, J IMMUNOL, V160, P5028; Hajnsdorf E, 2000, P NATL ACAD SCI USA, V97, P1501, DOI 10.1073/pnas.040549897; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hinton JCD, 1997, MOL MICROBIOL, V26, P417, DOI 10.1046/j.1365-2958.1997.6371988.x; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; LAVITOLA A, 1992, RES MICROBIOL, V143, P295, DOI 10.1016/0923-2508(92)90021-F; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PAWLOWSKI K, 1991, MOL GEN GENET, V231, P124, DOI 10.1007/BF00293830; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Ramsay M, 1997, COMMUN DIS REP CDR R, V7, pR49; Tacket CO, 1997, INFECT IMMUN, V65, P452, DOI 10.1128/IAI.65.2.452-456.1997; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; VIRJI M, 1991, MOL MICROBIOL, V5, P1831, DOI 10.1111/j.1365-2958.1991.tb00807.x	20	170	179	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1269	1273		10.1038/81380	http://dx.doi.org/10.1038/81380			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062540	Bronze			2022-12-25	WOS:000165114800036
J	Beninati, C; Oggioni, MR; Boccanera, M; Spinosa, MR; Maggi, T; Conti, S; Magliani, W; De Bernardis, F; Teti, G; Cassone, A; Pozzi, G; Polonelli, L				Beninati, C; Oggioni, MR; Boccanera, M; Spinosa, MR; Maggi, T; Conti, S; Magliani, W; De Bernardis, F; Teti, G; Cassone, A; Pozzi, G; Polonelli, L			Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria	NATURE BIOTECHNOLOGY			English	Article						engineered commensal bacteria; mucosal colonization; microbicidal scFv deliver; vaginal candidiasis; therapeutic treatment	GRAM-POSITIVE BACTERIA; KILLER TOXIN; STREPTOCOCCUS-GORDONII; VAGINAL IMMUNIZATION; ANTIBODIES; SURFACE; INFECTION; COLONIZATION; RESISTANCE; DISCOVERY	Two recombinant strains of Streptococcus gordonii, secreting or displaying a microbicidal single-chain antibody (H6), and stably colonizing rat vagina, were used to treat an experimental vaginitis caused by Candida albicans. A post-challenge intravaginal delivery of the HG-secreting strain was as efficacious as fluconazole in rapidly abating the fungal burden. Three weeks after challenge, 75% and 37.5% of the rats treated with the He-secreting or displaying bacteria, respectively, were cured of the infection, which persisted in 100% of the animals treated with a S. gordonii strain expressing an irrelevant single-chain antibody. Thus, a human commensal bacterium can be suitably engineered to locally release a therapeutic antibody fragment.	Univ Parma, Dipartimento Patol & Med Lab, Sez Microbiol, I-43100 Parma, Italy; Univ Siena, Dipartimento Biol Mol Microbiol, I-53100 Siena, Italy; Univ Messina, Ist Microbiol, Messina, Italy; Ist Super Sanita, Batteriol & Micol Med Lab, I-00161 Rome, Italy	University of Parma; University of Siena; University of Messina; Istituto Superiore di Sanita (ISS)	Polonelli, L (corresponding author), Univ Parma, Dipartimento Patol & Med Lab, Sez Microbiol, I-43100 Parma, Italy.	lucpol@unipr.it	Pozzi, Gianni/Q-2713-2018; Cassone, Antonio/J-4666-2019; Oggioni, Marco Rinaldo/K-3839-2016; DE BERNARDIS, FLAVIA/C-9589-2016; Conti, Stefania/N-3558-2015	Pozzi, Gianni/0000-0002-9557-4714; Oggioni, Marco Rinaldo/0000-0003-4117-793X; DE BERNARDIS, FLAVIA/0000-0001-9440-8629; Conti, Stefania/0000-0001-9973-8352; BENINATI, Concetta/0000-0001-8305-1337				Alexander BD, 1997, DRUGS, V54, P657, DOI 10.2165/00003495-199754050-00002; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Boyd MR, 1996, J ETHNOPHARMACOL, V51, P17, DOI 10.1016/0378-8741(95)01346-6; Cassone A, 1997, IMMUNOL TODAY, V18, P164, DOI 10.1016/S0167-5699(97)84662-2; CASSONE A, 1995, INFECT IMMUN, V63, P2619, DOI 10.1128/IAI.63.7.2619-2624.1995; Cauda R, 1999, J ACQ IMMUN DEF SYND, V21, P20, DOI 10.1097/00126334-199905010-00003; Conti S, 1998, J INFECT DIS, V177, P807, DOI 10.1086/517815; De Bernardis F., 1999, HDB ANIMAL MODELS IN, P735; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; Di Fabio S, 1998, VACCINE, V16, P485, DOI 10.1016/S0264-410X(97)80002-3; Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Kelly CG, 1999, NAT BIOTECHNOL, V17, P42, DOI 10.1038/5213; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Magliani W, 1997, CLIN MICROBIOL REV, V10, P369, DOI 10.1128/CMR.10.3.369; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; Magliani W, 1998, NAT MED, V4, P705, DOI 10.1038/nm0698-705; Medaglini D, 1997, VACCINE, V15, P1330, DOI 10.1016/S0264-410X(97)00026-1; Medaglini D, 1998, AM J REPROD IMMUNOL, V39, P199; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Oggioni MR, 1999, METHODS, V19, P163, DOI 10.1006/meth.1999.0842; OGGIONI MR, 1995, VACCINE, V13, P775; Oggioni MR, 1996, GENE, V169, P85, DOI 10.1016/0378-1119(95)00775-X; Osaki T, 1998, J MED MICROBIOL, V47, P505, DOI 10.1099/00222615-47-6-505; Polonelli L, 1999, CURR OPIN INFECT DIS, V12, P61, DOI 10.1097/00001432-199902000-00011; Polonelli L, 1996, J IMMUNOL, V156, P1880; Polonelli L, 1997, CLIN DIAGN LAB IMMUN, V4, P142, DOI 10.1128/CDLI.4.2.142-146.1997; POLONELLI L, 1987, J CLIN MICROBIOL, V25, P460, DOI 10.1128/JCM.25.2.460-462.1987; POZZI G, 1992, INFECT IMMUN, V60, P1902, DOI 10.1128/IAI.60.5.1902-1907.1992; Qu XD, 1997, INFECT IMMUN, V65, P636, DOI 10.1128/IAI.65.2.636-639.1997; REX JH, 1988, ADV INTERNAL MED, V43, P321; Ricci S, 2000, INFECT IMMUN, V68, P760, DOI 10.1128/IAI.68.2.760-766.2000; Rosenthal SL, 1998, SEX TRANSM DIS, V25, P368, DOI 10.1097/00007435-199808000-00009; Seguy N, 1998, FEMS IMMUNOL MED MIC, V22, P145, DOI 10.1016/S0928-8244(98)00072-8; Sobel J D, 1988, Ann N Y Acad Sci, V544, P547, DOI 10.1111/j.1749-6632.1988.tb40450.x; SOBEL JD, 1984, ANTIMICROB AGENTS CH, V26, P266, DOI 10.1128/AAC.26.2.266	37	104	113	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1060	1064		10.1038/80250	http://dx.doi.org/10.1038/80250			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017043				2022-12-25	WOS:000089744700027
J	Betthauser, J; Forsberg, E; Augenstein, M; Childs, L; Eilertsen, K; Enos, J; Forsythe, T; Golueke, P; Jurgella, G; Koppang, R; Lesmeister, T; Mallon, K; Mell, G; Misica, P; Pace, M; Pfister-Genskow, M; Strelchenko, N; Voelker, G; Watt, S; Thompson, S; Bishop, M				Betthauser, J; Forsberg, E; Augenstein, M; Childs, L; Eilertsen, K; Enos, J; Forsythe, T; Golueke, P; Jurgella, G; Koppang, R; Lesmeister, T; Mallon, K; Mell, G; Misica, P; Pace, M; Pfister-Genskow, M; Strelchenko, N; Voelker, G; Watt, S; Thompson, S; Bishop, M			Production of cloned pigs from in vitro systems	NATURE BIOTECHNOLOGY			English	Article						nuclear transfer; oocyte maturation; oocyte activation; embryo culture; porcine; in vitro fertilization	INNER CELL MASS; NUCLEAR TRANSFER; IN-VITRO; EMBRYONIC-DEVELOPMENT; PORCINE OOCYTES; MALE PRONUCLEUS; FERTILIZATION; MATURATION; INVITRO; GENERATION	Here we describe a procedure for cloning pigs by the use of in vitro culture systems. Four healthy male piglets from two litters were born following nuclear transfer of cultured somatic cells and subsequent embryo transfer. The initiation of five additional pregnancies demonstrates the reproducibility of this procedure. Its important features include extended in vitro culture of fetal cells preceding nuclear transfer, as well as in vitro maturation and activation of oocytes and in vitro embryo culture. The cell culture and nuclear transfer techniques described here should allow the use of genetic modification procedures to produce tissues and organs from cloned pigs with reduced immunogenicity for use in xenotransplantation.	Infigen Inc, De Forest, WI 53532 USA; Imutran Ltd, Cambridge, England		Bishop, M (corresponding author), Infigen Inc, 1825 Infin Dr, De Forest, WI 53532 USA.	mbishop@infigen.com	Eilertsen, Kenneth/N-1960-2017					Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Bhatti FNK, 1999, TRANSPLANT P, V31, P958, DOI 10.1016/S0041-1345(98)01855-7; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; Cozzi E, 2000, CLIN NEPHROL, V53, pB13; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; FUNAHASHI H, 1993, J REPROD FERTIL, V98, P179; Funahashi H, 1997, BIOL REPROD, V57, P49, DOI 10.1095/biolreprod57.1.49; GORDON I, 1997, CONTROLLED REPROD PI; Grupen C. G., 2000, Theriogenology, V53, P422; Grupen CG, 1997, REPROD FERT DEVELOP, V9, P571, DOI 10.1071/R96115; Hazeleger W, 1999, THERIOGENOLOGY, V51, P81, DOI 10.1016/S0093-691X(98)00233-7; HUNTER RHF, 1974, ANAT REC, V178, P169, DOI 10.1002/ar.1091780203; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Long CR, 1999, THERIOGENOLOGY, V51, P1375, DOI 10.1016/S0093-691X(99)00081-3; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; Mueller S, 1999, MOL REPROD DEV, V54, P244, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;244::AID-MRD5&gt;3.0.CO;2-5; NAITO K, 1988, GAMETE RES, V21, P289, DOI 10.1002/mrd.1120210310; Niemann H, 2000, ANIM REPROD SCI, V60, P277, DOI 10.1016/S0378-4320(00)00091-9; Onishi A, 2000, SCIENCE, V289, P1188, DOI 10.1126/science.289.5482.1188; PAPAIOANNOU VE, 1988, DEVELOPMENT, V102, P793; PETTERS RM, 1993, J REPROD FERTIL, P61; Piedrahita JA, 2000, THERIOGENOLOGY, V53, P105, DOI 10.1016/S0093-691X(99)00244-7; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; POLGE C, 1966, J REPROD FERTIL, V12, P395, DOI 10.1530/jrf.0.0120395; Prather RS, 1999, THERIOGENOLOGY, V51, P487, DOI 10.1016/S0093-691X(98)00242-8; PRATHER RS, 1989, BIOL REPROD, V41, P414, DOI 10.1095/biolreprod41.3.414; Rath D, 1997, THERIOGENOLOGY, V47, P795, DOI 10.1016/S0093-691X(97)00035-6; REICHELT B, 1994, J REPROD FERTIL, V100, P163, DOI 10.1530/jrf.0.1000163; ROSENKRANS C F JR, 1991, Theriogenology, V35, P266, DOI 10.1016/0093-691X(91)90242-6; SAITO S, 1991, BIOL REPROD, V44, P927, DOI 10.1095/biolreprod44.5.927; STRELCHENKO NS, 2000, Patent No. 6011197; SUSKOPARRISH JL, 1994, DEV BIOL, V166, P729, DOI 10.1006/dbio.1994.1351; TAO T, 1995, J REPROD FERTIL, V104, P251, DOI 10.1530/jrf.0.1040251; Tao T, 2000, ZYGOTE, V8, P69, DOI 10.1017/S0967199400000848; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YOSHIDA M, 1993, BIOL REPROD, V49, P89, DOI 10.1095/biolreprod49.1.89	42	371	454	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1055	1059		10.1038/80242	http://dx.doi.org/10.1038/80242			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017042				2022-12-25	WOS:000089744700026
J	Xu, WT; Edmondson, DG; Evrard, YA; Wakamiya, M; Behringer, RR; Roth, SY				Xu, WT; Edmondson, DG; Evrard, YA; Wakamiya, M; Behringer, RR; Roth, SY			Loss of Gcn5/2 leads to increased apoptosis and mesodermal defects during mouse development	NATURE GENETICS			English	Letter							ADENOVIRAL ONCOPROTEIN E1A; DNA-DAMAGE; PCAF; P300; GENE; ACETYLTRANSFERASES; EXPRESSION; FAMILY; EMBRYO; TWIST	Histone acetyltransferases regulate transcription, but little is known about the role of these enzymes in developmental processes. Gcn5 (encoded by Gcn5/2) and Pcaf. mouse histone acetyltransferases. share similar sequences and enzymatic activities(1). Both interact with p300 and CBP (encoded by Ep300 and Crebbp, respectively), two other histone acetyltransferases that integrate multiple signalling pathways(1). Pcaf is thought to participate in many of the cellular processes regulated by p300/CBP (refs 2-8). but the functions of Gcn5 are unknown in mammalian cells. Here we show that the gene Pcaf is dispensable in mice. In contrast. Gcn5/2-null embryos die during embryogenesis. These embryos develop normally to 7.5 days post coitum (d.p.c.). but their growth is severely retarded by 8.5 d.p.c. and they fail to form dorsal mesoderm lineages, including chordamesoderm and paraxial mesoderm. Differentiation of extra-embryonic and cardiac mesoderm seems to be unaffected. Loss of the dorsal mesoderm lineages is due to a high incidence of apoptosis in the Gcn5/2 mutants that begins before the onset of morphological abnormality. Embryos null for both Gcn5/2 and Pcaf show even more severe defects, indicating that these histone acetyltransferases have overlapping functions during embryogenesis. Our studies are the first to demonstrate that specific acetyltransferases are required for cell survival and mesoderm formation during mammalian development.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Roth, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715				ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; Hogan B, 1994, MANIPULATING MOUSE E; Liu L, 1999, MOL CELL BIOL, V19, P1202; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SASAKI H, 1993, DEVELOPMENT, V118, P47; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	20	194	204	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					229	232		10.1038/79973	http://dx.doi.org/10.1038/79973			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017084				2022-12-25	WOS:000089638800025
J	Howe, AK; Juliano, RL				Howe, AK; Juliano, RL			Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR ACTIVATION; SMOOTH-MUSCLE CELLS; MAP-KINASE; PAXILLIN DEPHOSPHORYLATION; TYROSINE PHOSPHORYLATION; RAT-1 FIBROBLASTS; SMALL GTPASE; PAK FAMILY; CAMP	Activation of the canonical mitogen-activated protein kinase (MAPK) cascade by soluble mitogens is blocked in nonadherent cells. It is also blocked in cells in which the cAMP-dependent protein kinase (PKA) is activated. Here we show that inhibition of PKA allows anchorage-independent stimulation of the MAPK cascade by growth factors. This effect is transient, and its duration correlates with sustained tyrosine phosphorylation of paxillin and focal-adhesion kinase (FAK) in non-adherent cells. The effect is sensitive to cytochalasin D, implicating the actin cytoskeleton as an important factor in mediating this anchorage-independent signalling. Interestingly, constitutively active p21-activated kinase (PAK) also allows anchorage-independent MAPK signalling. Furthermore, PKA negatively regulates PAK in vivo, and whereas the induction of anchorage-independent signaling resulting from PKA suppression is blocked by dominant negative PAK, it is markedly prolonged by constitutively active PAK, These observations indicate that PKA and PAK are important regulators of anchorage-dependent signal transduction.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Howe, AK (corresponding author), Univ N Carolina, Dept Pharmacol, Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	alanhowe@med.unc.edu						Aplin AE, 1998, PHARMACOL REV, V50, P197; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; Cybulsky AV, 1997, BIOCHEM BIOPH RES CO, V231, P160, DOI 10.1006/bbrc.1997.6064; DAY RN, 1989, J BIOL CHEM, V264, P431; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Fong JHJ, 1996, BIOCHEM BIOPH RES CO, V221, P19, DOI 10.1006/bbrc.1996.0537; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; Holt MR, 1998, INT J BIOCHEM CELL B, V30, P307, DOI 10.1016/S1357-2725(97)00101-5; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Howe DG, 1998, J NEUROSCI METH, V83, P133, DOI 10.1016/S0165-0270(98)00068-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lin TH, 1997, J BIOL CHEM, V272, P8849; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; OHTA Y, 1987, FEBS LETT, V222, P305, DOI 10.1016/0014-5793(87)80391-5; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Takahashi T, 1996, FEBS LETT, V397, P89, DOI 10.1016/S0014-5793(96)01145-3; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Troyer DA, 1996, J AM SOC NEPHROL, V7, P415; TURNER JS, 1951, ANNU REV PLANT PHYS, V2, P145, DOI 10.1146/annurev.pp.02.060151.001045; Vilgrain I, 1998, BIOCHEM J, V332, P533, DOI 10.1042/bj3320533; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	52	176	179	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					593	600		10.1038/35023536	http://dx.doi.org/10.1038/35023536			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980699				2022-12-25	WOS:000089250600010
J	Gangwani, L; Mikrut, M; Theroux, S; Sharma, M; Davis, RJ				Gangwani, L; Mikrut, M; Theroux, S; Sharma, M; Davis, RJ			Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein	NATURE CELL BIOLOGY			English	Article							SURVIVAL MOTOR-NEURON; DISEASE GENE-PRODUCT; COILED BODIES; SUBCELLULAR-LOCALIZATION; SINGLE NUCLEOTIDE; SNRNP BIOGENESIS; BINDING-PROTEIN; MOUSE MODEL; ORTHOLOGUE; COMPLEX	The survival motor neurons (smn) gene in mice is essential for embryonic viability. In humans, mutation of the telomeric copy of the SMN1 gene causes spinal muscular atrophy, an autosomal recessive disease. Here we report that the SMN protein interacts with the zinc-finger protein ZPR1 and that these proteins colocalize in small subnuclear structures, including gems and Cajal bodies. SMN and ZPR1 redistribute from the cytoplasm to the nucleus in response to serum. This process is disrupted in cells from patients with Werdnig-Hoffman syndrome (spinal muscular atrophy type I) that have SMN1 mutations. Similarly, decreased ZPR1 expression prevents SMN localization to nuclear bodies. Our data show that ZPR1 is required for the localization of SMN in nuclear bodies.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Assumption Coll, Dept Biol, Worcester, MA 01615 USA; Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Assumption College; Howard Hughes Medical Institute	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	roger.davis@umassmed.edu	Gangwani, Laxman/R-3688-2019					Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Coovert DD, 2000, J MED GENET, V37, P536, DOI 10.1136/jmg.37.7.536; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Frugier T, 2000, HUM MOL GENET, V9, P849, DOI 10.1093/hmg/9.5.849; Galcheva-Gargova Z, 1998, MOL BIOL CELL, V9, P2963, DOI 10.1091/mbc.9.10.2963; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gangwani L, 1998, J CELL BIOL, V143, P1471, DOI 10.1083/jcb.143.6.1471; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; MUNSAT TL, 1992, NEUROMUSCULAR DISORD, V2, P423, DOI 10.1016/S0960-8966(06)80015-5; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Pagliardini S, 2000, HUM MOL GENET, V9, P47, DOI 10.1093/hmg/9.1.47; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	44	102	105	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					376	383		10.1038/35070059	http://dx.doi.org/10.1038/35070059			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283611				2022-12-25	WOS:000168043900016
J	Oda, Y; Nagasu, T; Chait, BT				Oda, Y; Nagasu, T; Chait, BT			Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome	NATURE BIOTECHNOLOGY			English	Article							PHOSPHOSERINE-CONTAINING PEPTIDES; MASS-SPECTROMETRY; BETA-ELIMINATION; IDENTIFICATION; RESIDUES; ELECTROPHORESIS; INFORMATION; SEQUENCE	The current progression from genomics to proteomics is fueled by the realization that many properties of proteins (e.g., interactions, post-translational modifications) cannot be predicted from DNA sequence(1). Although it has become feasible to rapidly identify proteins from crude cell extracts using mass spectrometry after two-dimensional electrophoretic separation, it can be difficult to elucidate low-abundance proteins of interest in the presence of a large excess of relatively abundant proteins(2,3). Therefore, for effective proteome analysis it becomes critical to enrich the sample to be analyzed in subfractions of interest. For example, the analysis of protein kinase substrates can be greatly enhanced by enriching the sample of phosphorylated proteins. Although enrichment of phosphotyrosine-containing proteins has been achieved through the use of high-affinity anti-phosphotyrosine antibodies(4), the enrichment of phosphoserine/threonine-containing proteins has not been routinely possible. Here, we describe a method for enriching phosphoserine/threonine-containing proteins from crude cell extracts, and for subsequently identifying the phosphoproteins and sites of phosphorylation. The method, which involves chemical replacement of the phosphate moieties by affinity tags, should be of widespread utility for defining signaling pathways and control mechanisms that involve phosphorylation or dephosphorylation of serine/threonine residues.	Rockefeller Univ, New York, NY 10021 USA; Eisai & Co Ltd, Tsukuba, Ibaraki 3002635, Japan	Rockefeller University; Eisai Co Ltd	Chait, BT (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	chait@rockvax.rockefeller.edu			NCRR NIH HHS [RR00862] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANNAN WD, 1982, ANAL BIOCHEM, V121, P62, DOI 10.1016/0003-2697(82)90557-7; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; FADDEN P, 1995, ANAL BIOCHEM, V225, P81, DOI 10.1006/abio.1995.1111; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; HOLMES CFB, 1987, FEBS LETT, V215, P21, DOI 10.1016/0014-5793(87)80106-0; Jaffe H, 1998, BIOCHEMISTRY-US, V37, P16211, DOI 10.1021/bi981264p; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; MEGA T, 1990, J BIOCHEM-TOKYO, V107, P68, DOI 10.1093/oxfordjournals.jbchem.a123013; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PATCHORNIK A, 1964, J AM CHEM SOC, V86, P1206, DOI 10.1021/ja01060a049; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Taborsky G, 1974, Adv Protein Chem, V28, P1, DOI 10.1016/S0065-3233(08)60230-2; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	19	706	754	3	148	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					379	382		10.1038/86783	http://dx.doi.org/10.1038/86783			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283599				2022-12-25	WOS:000167940700030
J	Ganoth, D; Bornstein, G; Ko, TK; Larsen, B; Tyers, M; Pagano, M; Hershko, A				Ganoth, D; Bornstein, G; Ko, TK; Larsen, B; Tyers, M; Pagano, M; Hershko, A			The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27	NATURE CELL BIOLOGY			English	Article							DEPENDENT KINASE INHIBITOR; XENOPUS SUC1/CKS PROTEIN; SACCHAROMYCES-CEREVISIAE; NEDD8 MODIFICATION; S-PHASE; COMPLEX; PHOSPHORYLATION; UBIQUITINATION; DEGRADATION; P27(KIP1)	The cyclin-dependent kinase (CDK) inhibitor p27 is degraded in late G1 phase by the ubiquitin pathway(1), allowing CDK activity to drive cells into S phase(2). Ubiquitinylation of p27 requires its phosphorylation at Thr 187 (refs 3, 4) and subsequent recognition by S-phase kinase associated protein 2 (Skp2; refs 5-8), a member of the F-box family of proteins that associates with Skp1, Cul-1 and ROC1/Rbx1 to form an scF ubiquitin ligase complex(9). However, in vitro ligation of p27 to ubiquitin could not be reconstituted by known purified components of the SCFSkp2 complex. Here we show that the missing factor is CDK subunit 1 (Cks1), which belongs to the highly conserved Suc1/Cks family of proteins that bind to some CDKs and phosphorylated proteins and are essential for cell-cycle progression. Human Cks1, but not other members of the family, reconstitutes ubiquitin ligation of p27 in a completely purified system, binds to Skp2 and greatly increases binding of T187-phosphorylated p27 to Skp2. Our results represent the first evidence that an SCF complex requires an accessory protein for activity as well as for binding to its phosphorylated substrate.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Mt Sinai Hosp, Program Mol Biol & Canc, Samuel Lunenfeld Res Inst, Toronto, ON M56 1X5, Canada	New York University; New York University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ganoth, D (corresponding author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.	paganm02@med.nyu.edu; hershko@techunix.technion.ac.il	Tyers, Michael/ABE-3194-2021	pagano, michele/0000-0003-3210-2442				Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	28	411	440	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					321	324		10.1038/35060126	http://dx.doi.org/10.1038/35060126			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231585				2022-12-25	WOS:000167365800022
J	Bennett, CL; Christie, J; Ramsdell, F; Brunkow, ME; Ferguson, PJ; Whitesell, L; Kelly, TE; Saulsbury, FT; Chance, PF; Ochs, HD				Bennett, CL; Christie, J; Ramsdell, F; Brunkow, ME; Ferguson, PJ; Whitesell, L; Kelly, TE; Saulsbury, FT; Chance, PF; Ochs, HD			The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3	NATURE GENETICS			English	Article							GENE; FKHL7	IPEX is a fatal disorder characterized by immune dysregulation, polyendocrinopathy, enteropathy and X-linked inheritance (MIM 304930). We present genetic evidence that different mutations of the human gene FOXP3, the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome. Recent linkage analysis studies mapped the gene mutated in IPEX to an interval of 17-20-cM at Xp11.23-Xq13.3 (refs. 1,2).	Univ Washington, Dept Pediat, Div Immunol Infect Dis & Rheumatol, Seattle, WA 98195 USA; Celltech Chirosci Inc, Bothell, WA USA; Univ Washington, Div Genet & Dev, Seattle, WA 98195 USA; Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Arizona, Steele Mem Childrens Res Ctr, Dept Pediat, Tucson, AZ USA; Univ Virginia, Dept Pediat, Charlottesville, VA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; University of Arizona; University of Virginia	Ochs, HD (corresponding author), Univ Washington, Dept Pediat, Div Immunol Infect Dis & Rheumatol, Seattle, WA 98195 USA.		Chance, Phillip/AAX-5826-2020	Bennett, CRAIG/0000-0002-5847-1687	NICHD NIH HHS [HD17427] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017427, R01HD017427] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bennett CL, 2000, AM J HUM GENET, V66, P461, DOI 10.1086/302761; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; Ferguson PJ, 2000, AM J MED GENET, V90, P390, DOI 10.1002/(SICI)1096-8628(20000228)90:5<390::AID-AJMG9>3.0.CO;2-M; Kaestner KH, 2000, GENE DEV, V14, P142; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Mirzayans F, 2000, EUR J HUM GENET, V8, P71, DOI 10.1038/sj.ejhg.5200354; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8	10	2389	2500	4	85	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					20	21		10.1038/83713	http://dx.doi.org/10.1038/83713			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137993				2022-12-25	WOS:000166187900010
J	Brenner, M; Johnson, AB; Boespflug-Tanguy, O; Rodriguez, D; Goldman, JE; Messing, A				Brenner, M; Johnson, AB; Boespflug-Tanguy, O; Rodriguez, D; Goldman, JE; Messing, A			Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease	NATURE GENETICS			English	Article							ALPHA-B-CRYSTALLIN; INTERMEDIATE FILAMENTS; PALATAL MYOCLONUS; TRANSGENIC MICE; WHITE-MATTER; GENE; MYOPATHY; DEVELOP; ATAXIA; BRAIN	Alexander disease is a rare disorder of the central nervous system of unknown etiology(1,2). Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation, leading to death usually within the first decade; patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins(3,4). We previously found that overexpression of human GFAP in astrocytes of transgenic mice is fatal and accompanied by the presence of inclusion bodies indistinguishable from human Rosenthal fibers(5). These results suggested that a primary alteration in GFAP may be responsible for Alexander disease. Sequence analysis of DNA samples from patients representing different Alexander disease phenotypes revealed that most cases are associated with non-conservative mutations in the coding region of GFAP. Alexander disease therefore represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the vertebrate CNS.	Univ Wisconsin, Dept Pathobiol Sci, Waisman Ctr, Madison, WI USA; Univ Wisconsin, Sch Vet Med, Waisman Ctr, Madison, WI USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA; Fac Med, INSERM U384, Clermont Ferrand, France; Hop St Vincent de Paul, Serv neuropediat, AP HP, F-75674 Paris, France; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Columbia University; Columbia University	Messing, A (corresponding author), Univ Wisconsin, Dept Pathobiol Sci, Waisman Ctr, Madison, WI USA.	messing@waisman.wisc.edu	Rodriguez, Diana/GVR-7668-2022		NATIONAL EYE INSTITUTE [R01EY009331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022475] Funding Source: NIH RePORTER; Telethon [C.20] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		BESNARD F, 1991, J BIOL CHEM, V266, P18877; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BRENNER M, 1990, MOL BRAIN RES, V7, P277, DOI 10.1016/0169-328X(90)90078-R; Coffeen CM, 2000, HUM MOL GENET, V9, P787, DOI 10.1093/hmg/9.5.787; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DUCKETT S, 1995, PEDIAT NEUROPATHOLOG, P620; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; HERNDON RM, 1970, J NEUROPATH EXP NEUR, V29, P524, DOI 10.1097/00005072-197010000-00002; HOWARD RS, 1993, J NEUROL NEUROSUR PS, V56, P977, DOI 10.1136/jnnp.56.9.977; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Isaacs A, 1998, GENOMICS, V51, P152, DOI 10.1006/geno.1998.5360; IWAKI A, 1992, NEUROSCI LETT, V140, P89, DOI 10.1016/0304-3940(92)90689-5; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JOHNSON AB, 1989, AM J ANAT, V185, P335, DOI 10.1002/aja.1001850228; JOHNSON AB, 1996, HDB CLIN NEUROLOGY, V22, P701; KLEIN EA, 1994, CLIN NEUROPATHOL, V13, P31; Leegwater PAJ, 1999, AM J HUM GENET, V65, P728, DOI 10.1086/302548; Liedtke W, 1998, AM J PATHOL, V152, P251; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Messing A, 1998, AM J PATHOL, V152, P391; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Reichard EAP, 1996, PEDIATR PATHOL LAB M, V16, P327, DOI 10.1080/107710496175804; Rosenthal W., 1898, BEITR PATHOL ANAT AL, V23, P111; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Schwankhaus JD, 1995, NEUROLOGY, V45, P2266, DOI 10.1212/WNL.45.12.2266; Sjoberg G, 1999, HUM MOL GENET, V8, P2191, DOI 10.1093/hmg/8.12.2191	30	496	509	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					117	120		10.1038/83679	http://dx.doi.org/10.1038/83679			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138011				2022-12-25	WOS:000166187900028
J	Joki, T; Machluf, M; Atala, A; Zhu, JH; Seyfried, NT; Dunn, IF; Abe, T; Carroll, RS; Black, PM				Joki, T; Machluf, M; Atala, A; Zhu, JH; Seyfried, NT; Dunn, IF; Abe, T; Carroll, RS; Black, PM			Continuous release of endostatin from microencapsulated engineered cells for tumor therapy	NATURE BIOTECHNOLOGY			English	Article						endostatin; encapsulation; angiogenesis; glioma	MALIGNANT GLIOMA; ANGIOGENESIS; GROWTH; INHIBITION; ANGIOSTATIN; RECURRENCE; PATTERNS; DORMANCY; TRANSDUCTION; METASTASES	Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2% inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3% reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 x 10(5) encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Dept Neurosurg,Brain Tumor Lab, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Jikei Univ, Sch Med, Dept Neurosurg, Tokyo, Japan; Harvard Univ, Childrens Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Jikei University; Harvard University; Boston Children's Hospital; Harvard Medical School	Carroll, RS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Dept Neurosurg,Brain Tumor Lab, Boston, MA 02115 USA.	rcarroll@rics.bwh.harvard.edu		Atala, Anthony/0000-0001-8186-2160				BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BREM S, 1976, CANCER RES, V36, P2807; CARROLL RS, 1999, CANCER, V7, P1335; CHARTIER C, 1991, J VIROL, V113, P178; Deroanne CF, 1997, CANCER RES, V57, P5590; FENSTERMACHER JD, 1981, PHARMACOL THERAPEUT, V14, P217, DOI 10.1016/0163-7258(81)90062-0; FOLKMAN J, 1995, MOL MED, V1, P120, DOI 10.1007/BF03401559; GASPAR LE, 1992, INT J RADIAT ONCOL, V24, P55, DOI 10.1016/0360-3016(92)91021-E; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ismail N, 1999, TISS ENG SER, P343; JAIN RK, 1991, INT J RADIAT BIOL, V60, P85, DOI 10.1080/09553009114551621; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kirsch M, 1998, CANCER RES, V58, P4654; Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107; LEE JK, 1990, J NEUROSURG, V73, P429, DOI 10.3171/jns.1990.73.3.0429; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; LIANG BC, 1991, J NEUROSURG, V75, P559, DOI 10.3171/jns.1991.75.4.0559; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Machluf M, 2000, WORLD J UROL, V18, P80, DOI 10.1007/s003450050014; Machluf M, 1997, J CONTROL RELEASE, V43, P35, DOI 10.1016/S0168-3659(96)01466-6; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Prakash S, 1996, NAT MED, V2, P883, DOI 10.1038/nm0896-883; SAVELKOUL HFJ, 1994, J IMMUNOL METHODS, V170, P185, DOI 10.1016/0022-1759(94)90394-8; SNEED PK, 1994, INT J RADIAT ONCOL, V29, P719, DOI 10.1016/0360-3016(94)90559-2; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; TAKAMIYA Y, 1994, NEUROSURGERY, V34, P869, DOI 10.1227/00006123-199405000-00013; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; TAMARGO RJ, 1990, J NEURO-ONCOL, V9, P131, DOI 10.1007/BF02427833; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	38	295	319	0	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					35	39		10.1038/83481	http://dx.doi.org/10.1038/83481			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135549				2022-12-25	WOS:000166261400016
J	Ng, L; Hurley, LB; Dierks, B; Srinivas, M; Salto, C; Vennstrom, B; Reh, TA; Forrest, D				Ng, L; Hurley, LB; Dierks, B; Srinivas, M; Salto, C; Vennstrom, B; Reh, TA; Forrest, D			A thyroid hormone receptor that is required for the development of green cone photoreceptors	NATURE GENETICS			English	Article							MICE LACKING; BETA; EXPRESSION; ALPHA; RESISTANCE; MOUSE; ISOFORM; GENE; PIGMENTS; CELLS	Color vision is facilitated by distinct populations of cone photoreceptors in the retina. In rodents, cones expressing different opsin photopigments are sensitive to middle (M, 'green') and short (S, 'blue') wavelengths, and are differentially distributed across the retina(1,2). The mechanisms that control which opsin is expressed in a particular cone are poorly understood(2,3), but previous in vitro studies implicated thyroid hormone in cone differentiation(4,5). Thyroid hormone receptor beta2 (TR beta2) is a ligand-activated transcription factor that is expressed in the outer nuclear layer of the embryonic retina(6,7). Here we delete Thrb (encoding Tr beta2) in mice, causing the selective loss of M-cones and a concomitant increase in S-opsin immunoreactive cones. Moreover, the gradient of cone distribution is disturbed, with S-cones becoming widespread across the retina. The results indicate that cone photoreceptors throughout the retina have the potential to follow a default S-cone pathway and reveal an essential role for Tr beta2 in the commitment to an M-cone identity. Our findings raise the possibility that Thrb mutations may be associated with human cone disorders(8).	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Washington, Hlth Sci Ctr, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Hlth Sci Ctr, Dept Biol Struct, Seattle, WA 98195 USA; Karolinska Inst, Dev Biol Lab, CMB, Stockholm, Sweden	Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Karolinska Institutet	Forrest, D (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498, New York, NY 10029 USA.	tomreh@u.washington.edu; douglas.forrest@mssm.edu		Forrest, Douglas/0000-0002-3463-4162				Abel ED, 1999, J CLIN INVEST, V104, P291, DOI 10.1172/JCI6397; Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551; Bayer AU, 1999, DOC OPHTHALMOL, V98, P233, DOI 10.1023/A:1002416918247; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BROWMAN HI, 1994, VISION RES, V34, P1397, DOI 10.1016/0042-6989(94)90139-2; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHIU MI, 1994, VISUAL NEUROSCI, V11, P773, DOI 10.1017/S0952523800003072; Chomez P, 2000, DEVELOPMENT, V127, P1489; Dacey DM, 2000, ANNU REV NEUROSCI, V23, P743, DOI 10.1146/annurev.neuro.23.1.743; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; KELLEY MW, 1995, INVEST OPHTH VIS SCI, V36, P1280; KELLEY MW, 1995, DEVELOPMENT, V121, P3777; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lyubarsky AL, 1999, J NEUROSCI, V19, P442, DOI 10.1523/JNEUROSCI.19-01-00442.1999; NEWELL FW, 1977, KLIN MONATSBL AUGENH, V171, P731; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; ROHLICH P, 1994, NEURON, V13, P1159, DOI 10.1016/0896-6273(94)90053-1; Rusch A, 1998, P NATL ACAD SCI USA, V95, P15758, DOI 10.1073/pnas.95.26.15758; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SJOBERG M, 1992, DEVELOPMENT, V114, P39; SJOBERG M, 1994, EXPRESSION FUNCTION; SZEL A, 1993, J COMP NEUROL, V331, P564, DOI 10.1002/cne.903310411; Szel A, 2000, J OPT SOC AM A, V17, P568, DOI 10.1364/JOSAA.17.000568; SZEL A, 1994, NATURE, V370, P336, DOI 10.1038/370336a0; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049	31	400	404	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					94	98		10.1038/83829	http://dx.doi.org/10.1038/83829			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138006				2022-12-25	WOS:000166187900023
J	Busjahn, A; Knoblauch, H; Faulhaber, HD; Aydin, A; Uhlmann, R; Tuomilehto, J; Kaprio, J; Jedrusik, P; Januszewicz, A; Strelau, J; Schuster, H; Luft, FC; Muller-Myhsok, B				Busjahn, A; Knoblauch, H; Faulhaber, HD; Aydin, A; Uhlmann, R; Tuomilehto, J; Kaprio, J; Jedrusik, P; Januszewicz, A; Strelau, J; Schuster, H; Luft, FC; Muller-Myhsok, B			A region on chromosome 3 is linked to dizygotic twinning	NATURE GENETICS			English	Article							VANISHING TWIN; GAMMA GENE; LOCUS		Humboldt Univ, Charite, Fac Med, Franz Volhard Clin, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Natl Publ Hlth Inst, Helsinki, Finland; Infogen, Helsinki, Finland; Univ Helsinki, Finnish Twin Cohort Study, Helsinki, Finland; Warsaw Med Univ, Warsaw, Poland; Warsaw Univ, Warsaw, Poland; Natl Inst Cardiol, Warsaw, Poland; Bernhard Nocht Inst Trop Med, Hamburg, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Finland National Institute for Health & Welfare; University of Helsinki; Medical University of Warsaw; University of Warsaw; Institute of Cardiology - Poland; Bernhard Nocht Institut fur Tropenmedizin	Luft, FC (corresponding author), Humboldt Univ, Charite, Fac Med, Franz Volhard Clin, Berlin, Germany.		Kaprio, Jaakko/A-1820-2008; Busjahn, Andreas/P-5023-2019; Müller-Myhsok, Bertram/A-3289-2013; Busjahn, Andreas/F-9936-2011	Kaprio, Jaakko/0000-0002-3716-2455; Busjahn, Andreas/0000-0001-9650-6919; Luft, Friedrich/0000-0002-8635-1199; Jedrusik, Piotr/0000-0003-0037-6035				CLARK P, 1982, HUM GENET, V61, P171, DOI 10.1007/BF00274213; ERIKSSON AW, 1973, HUM HERED, V23, P511, DOI 10.1159/000152619; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; KELLY MP, 1991, FERTIL STERIL, V56, P221; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Knoblauch H, 1999, ARTERIOSCL THROM VAS, V19, P2940, DOI 10.1161/01.ATV.19.12.2940; Landy HJ, 1998, HUM REPROD UPDATE, V4, P177, DOI 10.1093/humupd/4.2.177; Lewis CM, 1996, AM J MED GENET, V61, P237, DOI 10.1002/(SICI)1096-8628(19960122)61:3<237::AID-AJMG7>3.0.CO;2-R; Lummaa V, 1998, NATURE, V394, P533, DOI 10.1038/28977; Matte U., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P431; Milad MP, 1998, HUM REPROD, V13, P2296, DOI 10.1093/humrep/13.8.2296; Nielsen DM, 1998, AM J HUM GENET, V63, P1531, DOI 10.1086/302114; Weinberg W., 1909, ARCH RASSEN GES BIOL, V6,, P28; WYSHAK G, 1965, AM J PUBLIC HEALTH N, V55, P1586, DOI 10.2105/AJPH.55.10.1586	14	21	21	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					398	399		10.1038/82515	http://dx.doi.org/10.1038/82515			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101833				2022-12-25	WOS:000165671700009
J	Kung, AL; Wang, S; Klco, JM; Kaelin, WG; Livingston, DM				Kung, AL; Wang, S; Klco, JM; Kaelin, WG; Livingston, DM			Suppression of tumor growth through disruption of hypoxia-inducible transcription	NATURE MEDICINE			English	Article							BINDING-PROTEIN; FACTOR 1-ALPHA; SOLID TUMORS; TRANSACTIVATION; ANGIOGENESIS; HIF-1-ALPHA; ACTIVATION; P300/CBP; CELLS; STABILIZATION	Chronic hypoxia, a hallmark of many tumors, is associated with angiogenesis and tumor progression. Strategies to treat tumors have been developed in which tumor cells are targeted with drugs or gene-therapy vectors specifically activated under hypoxic conditions. Here we report a different approach, in which the normal transcriptional response to hypoxia is selectively disrupted. Our data indicate that specific blockade of the interaction of hypoxia-inducible factor with the CH1 domain of its p300 and CREB binding protein transcriptional coactivators leads to attenuation of hypoxia-inducible gene expression and diminution of tumor growth. Thus, disrupting the normal co-activational response to hypoxia may be a new and useful therapeutic strategy.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Livingston, DM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Klco, Jeffery/M-9717-2018; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Klco, Jeffery/0000-0003-2961-6960; Kung, Andrew L/0000-0002-9091-488X				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Binley K, 1999, GENE THER, V6, P1721, DOI 10.1038/sj.gt.3301001; Brizel DM, 1996, CANCER RES, V56, P941; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hockel M, 1996, CANCER RES, V56, P4509; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NORDSMARK M, 1994, ACTA ONCOL, V33, P383, DOI 10.3109/02841869409098433; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Olumi AF, 1999, CANCER RES, V59, P5002; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZEMAN EM, 1986, INT J RADIAT ONCOL, V12, P1239, DOI 10.1016/0360-3016(86)90267-1; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	44	450	484	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1335	1340		10.1038/82146	http://dx.doi.org/10.1038/82146			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100117				2022-12-25	WOS:000165704100036
J	Yan, SF; Fujita, T; Lu, JS; Okada, K; Zou, YS; Mackman, N; Pinsky, DJ; Stern, DM				Yan, SF; Fujita, T; Lu, JS; Okada, K; Zou, YS; Mackman, N; Pinsky, DJ; Stern, DM			Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; VASCULAR-PERMEABILITY FACTOR; MIDDLE CEREBRAL-ARTERY; NGFI-A EGR-1; NF-KAPPA-B; IN-VIVO; RENAL ISCHEMIA; MESSENGER-RNA; TISSUE FACTOR	Activation of the zinc-finger transcription factor early growth response (Egr)-1, initially linked to developmental processes, is shown here to function as a master switch activated by ischemia to trigger expression of pivotal regulators of inflammation, coagulation and vascular hyperpermeability. Chemokine, adhesion receptor, procoagulant and permeability-related genes are coordinately upregulated by rapid ischemia-mediated activation of Egr-1. Deletion of the gene encoding Egr-1 strikingly diminished expression of these mediators of vascular injury in a murine model of lung ischemia/reperfusion, and enhanced animal survival and organ function. Rapid activation of Egr-1 in response to oxygen deprivation primes the vasculature for dysfunction manifest during reperfusion. These studies define a central and unifying role for Egr-1 activation in the pathogenesis of ischemic tissue damage.	Columbia Univ, Dept Surg, New York, NY 10032 USA; Columbia Univ, Dept Physiol, New York, NY 10032 USA; Columbia Univ, Dept Cellular Biophys & Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Columbia University; Columbia University; Columbia University; Columbia University; Scripps Research Institute	Yan, SF (corresponding author), Columbia Univ, Dept Surg, 630 W 168th St, New York, NY 10032 USA.		Tomoyuki, Fujita/AAC-7464-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397, R37HL063967, R01HL063967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59488, HL55397, HL63967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bless NM, 1999, AM J PHYSIOL-LUNG C, V276, pL57, DOI 10.1152/ajplung.1999.276.1.L57; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COLLEN D, 1992, ANN NY ACAD SCI, V667, P259, DOI 10.1111/j.1749-6632.1992.tb51623.x; Colletti LM, 2000, HEPATOLOGY, V31, P435, DOI 10.1002/hep.510310225; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; IKOMMINOTH P, 1996, NONRADIOACTIVE IN SI, P126; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kunkel SL, 1999, J CLIN INVEST, V104, P1333, DOI 10.1172/JCI8511; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lefer AM, 1999, ANN THORAC SURG, V68, P1920, DOI 10.1016/S0003-4975(99)01017-6; Lemay S, 2000, TRANSPLANTATION, V69, P959; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu PT, 2000, SHOCK, V13, P217, DOI 10.1097/00024382-200003000-00008; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Mitsui Y, 1999, BRAIN RES, V844, P192, DOI 10.1016/S0006-8993(99)01830-2; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang CY, 1998, CIRC RES, V82, P762, DOI 10.1161/01.RES.82.7.762; Wang XK, 1998, J NEUROCHEM, V71, P1194; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yoshidome H, 1999, AM J PHYSIOL-LUNG C, V277, pL919, DOI 10.1152/ajplung.1999.277.5.L919; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	50	381	413	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1355	1361		10.1038/82168	http://dx.doi.org/10.1038/82168			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100120				2022-12-25	WOS:000165704100039
J	Amagai, M; Matsuyoshi, N; Wang, ZH; Andl, C; Stanley, JR				Amagai, M; Matsuyoshi, N; Wang, ZH; Andl, C; Stanley, JR			Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1	NATURE MEDICINE			English	Article							VULGARIS; CADHERIN; ANTIGEN	Exfoliative toxin A, produced by Staphylococcus aureus, causes blisters in bullous impetigo and its more generalized form, staphylococcal scalded-skin syndrome(1-3). The toxin shows exquisite specificity in causing loss of cell adhesion only in the superficial epidermis. Although exfoliative toxin A has the structure of a serine protease, a target protein has not been identified(4,5). Desmoglein (Dsg) 1, a desmosomal cadherin that mediates cell-cell adhesion, may be the target of exfoliative toxin A, because it is the target of autoantibodies in pemphigus foliaceus, in which blisters form with identical tissue specificity and histology. We show here that exfoliative toxin A cleaved mouse and human Dsg1, but not closely related cadherins such as Dsg3. We demonstrate this specific cleavage in cell culture, in neonatal mouse skin and with recombinant Dsg1, and conclude that Dsg1 is the specific receptor for exfoliative toxin A cleavage. This unique proteolytic attack on the desmosome causes a blister just below the stratum corneum, which forms the epidermal barrier, presumably allowing the bacteria in bullous impetigo to proliferate and spread beneath this barrier.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan	University of Pennsylvania; Keio University	Stanley, JR (corresponding author), Univ Penn, Sch Med, Dept Dermatol, 211 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	jrstan@mail.med.upenn.edu	Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052				Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; DANCER SJ, 1990, FEBS LETT, V268, P129, DOI 10.1016/0014-5793(90)80990-Z; ELIAS PM, 1977, ARCH DERMATOL, V113, P207, DOI 10.1001/archderm.113.2.207; Farrell AM, 1999, LANCET, V354, P880, DOI 10.1016/S0140-6736(99)90120-4; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ishii K, 1997, J IMMUNOL, V159, P2010; Ishikawa H, 2000, EXP DERMATOL, V9, P229, DOI 10.1034/j.1600-0625.2000.009004229.x; ISHIKAWA H, 1994, MAMM GENOME, V5, P803, DOI 10.1007/BF00292018; Koch PJ, 1998, J CELL SCI, V111, P2529; LYELL A, 1983, J AM ACAD DERMATOL, V9, P285, DOI 10.1016/S0190-9622(83)80161-3; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MELISH ME, 1971, J PEDIATR-US, V78, P958, DOI 10.1016/S0022-3476(71)80425-0; MELISH ME, 1970, NEW ENGL J MED, V282, P1114, DOI 10.1056/NEJM197005142822002; NILLES LA, 1991, J CELL SCI, V99, P809; Rago JV, 2000, J IMMUNOL, V164, P2207, DOI 10.4049/jimmunol.164.4.2207; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Wu H, 2000, NEW ENGL J MED, V343, P31, DOI 10.1056/NEJM200007063430105	18	305	316	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1275	1277		10.1038/81385	http://dx.doi.org/10.1038/81385			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062541				2022-12-25	WOS:000165114800037
J	Duelli, DM; Lazebnik, YA				Duelli, DM; Lazebnik, YA			Primary cells suppress oncogene-dependent apoptosis	NATURE CELL BIOLOGY			English	Article							CYTOCHROME-C; ISOLATED-MITOCHONDRIA; BAX TRANSLOCATION; BCL-2; RELEASE; INDUCTION; PROTEINS; CYTOSOL; P53; E1A	Oncogenes that promote cell-cycle progression also sensitize cells to agents that induce apoptosis. Sensitization is thought to be caused by the induction of proapoptotic factors. Alternatively, sensitization may require the inactivation inhibitors that ordinarily provide protection against cell death. Here we show that the adenoviral oncogene EIA sensitizes cells to an anti-cancer drug by at least two pathways. One establishes a link between the drug and pro-apoptotic factors, but is not sufficient for sensitization without the second pathway, which suppresses inhibitors of apoptosis.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Duelli, DM (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BOLS NC, 1981, STAIN TECHNOL, V56, P103, DOI 10.3109/10520298109067291; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DYSON N, 1992, CANCER SURV, V12, P161; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guan RJ, 1996, ONCOGENE, V12, P2605; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nomura M, 1999, CANCER RES, V59, P5542; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	54	57	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					859	862		10.1038/35041112	http://dx.doi.org/10.1038/35041112			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056544				2022-12-25	WOS:000165207500023
J	Tong, ZB; Gold, L; Pfeifer, KE; Dorward, H; Lee, E; Bondy, CA; Dean, J; Nelson, LM				Tong, ZB; Gold, L; Pfeifer, KE; Dorward, H; Lee, E; Bondy, CA; Dean, J; Nelson, LM			Mater, a maternal effect gene required for early embryonic development in mice	NATURE GENETICS			English	Article							MOUSE EMBRYO; TRANSCRIPTION; ACTIVATION; PROTEINS; EXPRESSION; TRANSITION; DIVERSITY; FAMILY; STAGE		NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD USA; NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD USA; NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD USA; Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University	Dean, J (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD USA.	jurrien@helix.nih.gov; nelsonl@cc1.nichd.nih.gov		Pfeifer, Karl/0000-0002-0254-682X				Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CONOVER JC, 1991, DEV BIOL, V144, P392, DOI 10.1016/0012-1606(91)90431-2; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; Gardner RL, 1996, HUM REPROD UPDATE, V2, P3, DOI 10.1093/humupd/2.1.3; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; LATHAM KE, 1993, MOL REPROD DEV, V35, P140, DOI 10.1002/mrd.1080350207; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nothias JY, 1996, EMBO J, V15, P5715, DOI 10.1002/j.1460-2075.1996.tb00955.x; SCHULTZ RM, 1993, BIOESSAYS, V15, P531, DOI 10.1002/bies.950150806; Tong ZB, 1999, ENDOCRINOLOGY, V140, P3720, DOI 10.1210/en.140.8.3720; Tong ZB, 2000, MAMM GENOME, V11, P281, DOI 10.1007/s003350010053	15	408	443	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2000	26	3					267	268		10.1038/81547	http://dx.doi.org/10.1038/81547			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062459				2022-12-25	WOS:000165176500008
J	Geyer, RK; Yu, ZK; Maki, CG				Geyer, RK; Yu, ZK; Maki, CG			The MDM2 RING-finger domain is required to promote p53 nuclear export	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR P53; UBIQUITIN LIGASE; WILD-TYPE; DEGRADATION; PROTEIN; LOCALIZATION; INHIBITION; STABILIZES; COMPLEXES; P19(ARF)	MDM2 can bind to p53 and promote its ubiquitination and subsequent degradation by the proteasome. Current models propose that nuclear export of p53 is required for MDM2-mediated degradation, although the function of MDM2 in p53 nuclear export has not been clarified. Here we show that MDM2 can promote the nuclear export of p53 in transiently transfected cells. This activity requires the nuclear-export signal (NES) of p53, but not the NES of MDM2. A mutation within the MDM2 RING-finger domain that inhibits p53 ubiquitination also inhibits the ability of MDM2 to promote p53 nuclear export. Finally, inhibition of nuclear export stabilizes wild-type p53 and leads to accumulation of ubiquitinated p53 in the nucleus. Our results indicate that MDM2-mediated ubiquitination, or other activities associated with the RING-finger domain, can stimulate the export of p53 to the cytoplasm through the activity of the p53 NES.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	cmaki@hsph.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA80918] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1996, CANCER RES, V56, P2649; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Olivier M, 1998, MOL CARCINOGEN, V23, P1; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	26	299	302	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					569	573		10.1038/35023507	http://dx.doi.org/10.1038/35023507			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980696				2022-12-25	WOS:000089250600007
J	Matkowskyj, KA; Danilkovich, A; Marrero, J; Savkovic, SD; Hecht, G; Benya, RV				Matkowskyj, KA; Danilkovich, A; Marrero, J; Savkovic, SD; Hecht, G; Benya, RV			Galanin-l receptor up-regulation mediates the excess colonic fluid production caused by infection with enteric pathogens	NATURE MEDICINE			English	Article							NF-KAPPA-B; ESCHERICHIA-COLI; SALMONELLA; EXPRESSION; GLUCOCORTICOIDS; DEXAMETHASONE; MECHANISM; MODEL	Galanin is widely distributed in enteric nerve terminals lining the gastrointestinal tract(1,2). We previously showed that pathogenic Escherichia coli, but not normal commensal organisms, increase galanin-1 receptor expression by epithelial cells lining the colon(3) (i.e., colonocytes), When present, galanin-l receptor activation by ligand causes colonocyte Cl secretion(4). We herein demonstrate that disparate pathogens including Salmonella typhimurium and Shigella flexerii also increase colonocyte galanin-1 receptor expression, whose activation is responsible for a principal component of the increased colonic fluid secretion observed. Although eliminating the GAL1R gene by homologous recombination does not alter basal colonic fluid secretion, removal of one or both alleles completely attenuates the increase in fluid secretion due to infection with enteric pathogens. Galanin-1 receptor up-regulation therefore represents a novel mechanism accounting for the increased colonic fluid secretion observed in infectious diarrhea due to several different pathogens.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; W Side Vet Adm Med Ctr, W Side Div, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Benya, RV (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.		Danilkovich, Alexey/E-4014-2010	Danilkovich, Alexey/0000-0002-4650-9860	NIDDK NIH HHS [DK-50694, DK-54777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054777, R01DK050694] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BNYA RV, 1999, AM J PHYSIOL, V276, pG64; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Davis LG, 1994, BASIC METHODS MOL BI; DYER RB, 1993, INFECT IMMUN, V61, P4427, DOI 10.1128/IAI.61.10.4427-4433.1993; Everest P, 1999, INFECT IMMUN, V67, P2815, DOI 10.1128/IAI.67.6.2815-2821.1999; GALLIN JI, 1982, BLOOD, V59, P1317; Hecht G, 1999, J CLIN INVEST, V104, P253, DOI 10.1172/JCI6373; HOYLE CHV, 1989, J ANAT, V166, P23; Jasani B, 1993, IMMUNOCYTOCHEMISTRY; Lorimer DD, 1996, BIOCHEM BIOPH RES CO, V222, P379, DOI 10.1006/bbrc.1996.0752; Marrero JA, 2000, AM J PHYSIOL-GASTR L, V278, pG797, DOI 10.1152/ajpgi.2000.278.5.G797; Matkowskyj KA, 2000, J HISTOCHEM CYTOCHEM, V48, P303, DOI 10.1177/002215540004800216; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Peterson JW, 1998, LAB INVEST, V78, P523; Rosen T, 1998, J CLIN ENDOCR METAB, V83, P3647, DOI 10.1210/jc.83.10.3647; Sacks M, 1998, BIOCHEM BIOPH RES CO, V253, P181, DOI 10.1006/bbrc.1998.9763; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Waynforth HB, 1992, EXPT SURG TECHNIQUE, P1; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Zunjic M, 1997, GASTROENTEROLOGY, V112, pA1128	21	59	59	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1048	1051		10.1038/79563	http://dx.doi.org/10.1038/79563			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973327	Bronze			2022-12-25	WOS:000089190500039
J	Monier, K; Armas, JCG; Etteldorf, S; Ghazal, P; Sullivan, KF				Monier, K; Armas, JCG; Etteldorf, S; Ghazal, P; Sullivan, KF			Annexation of the interchromosomal space during viral infection	NATURE CELL BIOLOGY			English	Article							SIMPLEX VIRUS TYPE-1; INTRANUCLEAR LOCATION; DNA-REPLICATION; HISTONE H3; CELLS; LOCALIZATION; PROTEINS; NUCLEUS; COMPARTMENTALIZATION; HYBRIDIZATION	The nucleus is known to be compartmentalized into units of function(1), but the processes leading to the spatial organization of chromosomes and nuclear compartments are not yet well defined. Here we report direct quantitative analysis of the global structural perturbations of interphase chromosome and interchromosome domain distribution caused by infection with herpes simplex virus-1 (HSV-1). Our results show that the peripheral displacement of host chromosomes that correlates with expansion of the viral replication compartment (VRC)(2-5) is coupled to a twofold increase in nuclear volume. Live cell dynamic measurements suggest that viral compartment formation is driven by the functional activity of viral components and underscore the significance of spatial regulation of nuclear activities.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, Div Virol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Sullivan, KF (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ghazal@scripps.edu; ksullivan@scripps.edu	Monier, Karine/AAP-4806-2021	Sullivan, Kevin/0000-0002-5374-8245	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030627, R01AI030627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039068, R29GM039068] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30627] Funding Source: Medline; NIGMS NIH HHS [GM39068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; DEBRUYNKOPS A, 1994, J VIROL, V68, P3512, DOI 10.1128/JVI.68.6.3512-3526.1994; DUPUYCOIN AM, 1978, J ULTRA MOL STRUCT R, V65, P60, DOI 10.1016/S0022-5320(78)90022-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; GILULA NB, 1978, J CELL BIOL, V78, P58, DOI 10.1083/jcb.78.1.58; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; MAO JCH, 1975, BIOCHEMISTRY-US, V14, P5475, DOI 10.1021/bi00696a015; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; PARAZZA F, 1993, COMPUT MED IMAG GRAP, V17, P189, DOI 10.1016/0895-6111(93)90043-M; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Puvion-Dutilleul F, 1988, Electron Microsc Rev, V1, P279, DOI 10.1016/0892-0354(88)90005-6; PUVIONDUTILLEUL F, 1994, CHROMOSOMA, V103, P104, DOI 10.1007/s004120050013; PUVIONDUTILLEUL F, 1989, EUR J CELL BIOL, V49, P99; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; RANDALL RE, 1986, J GEN VIROL, V67, P2163, DOI 10.1099/0022-1317-67-10-2163; RIXON FJ, 1983, J GEN VIROL, V64, P2087, DOI 10.1099/0022-1317-64-9-2087; Roizman B., 1974, COMPREHENSIVE VIROLO, P229, DOI DOI 10.1007/978-1-4684-2703-5_4; SCHWARTZ J, 1969, VIROLOGY, V38, P42, DOI 10.1016/0042-6822(69)90126-3; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; SIRTORI C, 1967, CANCER RES, V27, P367; Sullivan KF, 1999, METHOD CELL BIOL, V58, P183; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Tjerneld F, 2000, INT REV CYTOL, V192, P137; Uprichard SL, 1997, VIROLOGY, V229, P113, DOI 10.1006/viro.1996.8430	30	125	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					661	665		10.1038/35023615	http://dx.doi.org/10.1038/35023615			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980708				2022-12-25	WOS:000089250600019
J	Habelhah, H; Shah, K; Huang, L; Ostareck-Lederer, A; Burlingame, AL; Shokat, KM; Hentze, MW; Ronai, Z				Habelhah, H; Shah, K; Huang, L; Ostareck-Lederer, A; Burlingame, AL; Shokat, KM; Hentze, MW; Ronai, Z			ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation	NATURE CELL BIOLOGY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-K; UNNATURAL NUCLEOTIDE SPECIFICITY; BINDING-PROTEINS; SH3 DOMAINS; SRC; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; KINASE; EXPORT	Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) is one of a family of 20 proteins that are involved in transcription and post-transcriptional messenger RNA metabolism. The mechanisms that underlie regulation of hnRNP-K activities remain largely unknown. Here we show that cytoplasmic accumulation of hnRNP-K is phosphorylation-dependent. Mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) efficiently phosphorylates hnRNP-K both in vitro and in vivo at serines 284 and 353. Serum stimulation or constitutive activation of ERK kinase (MEK1),results in phosphorylation and cytoplasmic accumulation of hnRNP-K. Mutation at ERK phosphoacceptor sites in hnRNP-K abolishes the ability to accumulate in the cytoplasm and renders the protein incapable of regulating translation of mRNAs that have a differentiation-control element (DICE) in the 3' untranslated region (UTR). Similarly, treatment with a pharmacological inhibitor of the ERK pathway abolishes cytoplasmic accumulation of hnRNP-K and attenuates inhibition of mRNA translation. Our results establish the role of MAPK/ERK in phosphorylation-dependent cellular localization of hnRNP-K, which is required for its ability to silence mRNA translation.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; European Mol Biol Lab, Gene Express Program, D-69117 Heidelberg, Germany	Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco; University of California System; University of California San Francisco; European Molecular Biology Laboratory (EMBL)	Habelhah, H (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Hentze, Matthias W/V-3980-2017; Huang, Lan/C-3618-2011	Hentze, Matthias W/0000-0002-4023-7876; RONAI, ZEEV/0000-0002-3859-0400; Habelhah, Hasem/0000-0003-4097-1007				Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; BSTELO X, 1995, MOL CELL BIOL, V15, P1324; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Gillespie PG, 1999, J BIOL CHEM, V274, P31373, DOI 10.1074/jbc.274.44.31373; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Hovemann BT, 2000, GENE, V245, P127, DOI 10.1016/S0378-1119(00)00027-5; JAYAWICKREME S, 1999, AM J PHYSIOL, V276, P596; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee MH, 1996, J BIOL CHEM, V271, P3420; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; SEUNINGEN L, 1995, J BIOL CHEM, V270, P26976; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thiele BJ, 1999, NUCLEIC ACIDS RES, V27, P1828, DOI 10.1093/nar/27.8.1828; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	30	240	245	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					325	330		10.1038/35060131	http://dx.doi.org/10.1038/35060131			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231586				2022-12-25	WOS:000167365800023
J	Harpur, AG; Wouters, FS; Bastiaens, PIH				Harpur, AG; Wouters, FS; Bastiaens, PIH			Imaging FRET between spectrally similar GFP molecules in single cells	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEINS; ENERGY-TRANSFER; APOPTOSIS; DEATH; MICROSCOPY; CLEAVAGE		Imperial Canc Res Fund, Cell Biophys Lab, London, England	Cancer Research UK	Bastiaens, PIH (corresponding author), European Mol Biol Lab, Cell Biol & Cell Biophys Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.	philippe.bastiaens@embl-heidelberg.de						CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CLEGG RM, 1992, P SOC PHOTO-OPT INS, V1640, P448, DOI 10.1117/12.58237; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; LAKOWICZ JR, 1991, REV SCI INSTRUM, V62, P1727, DOI 10.1063/1.1142413; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mahajan NP, 1999, CHEM BIOL, V6, P401, DOI 10.1016/S1074-5521(99)80051-9; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Squire A, 1999, J MICROSC-OXFORD, V193, P36, DOI 10.1046/j.1365-2818.1999.00427.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Xu X, 1998, NUCLEIC ACIDS RES, V26, P2034, DOI 10.1093/nar/26.8.2034	20	162	168	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					167	169		10.1038/84443	http://dx.doi.org/10.1038/84443			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175733				2022-12-25	WOS:000166754700025
J	Morahan, G; Huang, DX; Ymer, SI; Cancilla, MR; Stephen, K; Dabadghao, P; Werther, G; Tait, BD; Harrison, LC; Colman, PG				Morahan, G; Huang, DX; Ymer, SI; Cancilla, MR; Stephen, K; Dabadghao, P; Werther, G; Tait, BD; Harrison, LC; Colman, PG			Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele	NATURE GENETICS			English	Article							DISTAL CHROMOSOME 2Q; GENETIC SUSCEPTIBILITY; INSULIN; CELLS; CYTOKINE; MELLITUS; IDDM; TH2	Type 1 diabetes (T1D; or insulin-dependent diabetes mellitus, IDDM) is an autoimmune disease with both genetic and environmental components. In addition to the human leukocyte antigen (HLA) complex, the single major genetic contributor of susceptibility(1), an unknown number of other unidentified genes are required to mediate disease. Although many loci conferring susceptibility to T1D have been mapped(2), their identification has proven problematic(3) due to the complex nature of this disease. Our strategy for finding T1D susceptibility genes has been to test for human homologues of loci implicated in diabetes-prone NOD (non-obese diabetic) mice, together with application of biologically relevant stratification methods(4). We report here a new susceptibility locus, IDDM18 located near the interleukin-12 (IL-12)p40 gene, IL12B. Significant bias in transmission of IL12B alleles was observed in affected sibpairs and was confirmed in an independent cohort of simplex families. A single base change in the 3' UTR showed strong linkage disequilibrium with the T1D susceptibility locus. The IL12B 3' UTR alleles showed different levers of expression in cell lines. Variation in IL-12p40 production may influence T-cell responses crucial for either mediating or protecting against this and other autoimmune diseases.	Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; Royal Childrens Hosp, Dept Endocrinol, Melbourne, Vic, Australia; Royal Melbourne Hosp, Australian Red Cross Blood Serv, Victorian Transplantat & Immunogenet Serv, Rotary Bone Marrow Res Ctr, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; Royal Children's Hospital Melbourne; Australian Red Cross Blood Service; Royal Melbourne Hospital	Morahan, G (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic, Australia.	morahan@wehi.edu.au	Werther, George/B-3784-2012; Morahan, Grant/T-7501-2019	Colman, Peter/0000-0001-8718-6175				Adorini L, 1996, ANN NY ACAD SCI, V795, P208, DOI 10.1111/j.1749-6632.1996.tb52670.x; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; DEGLIESPOSTI MA, 1993, HUM IMMUNOL, V38, P3, DOI 10.1016/0198-8859(93)90514-2; Fu J, 1998, DIABETOLOGIA, V41, P228, DOI 10.1007/s001250050894; GERMANN T, 1993, EUR J IMMUNOL, V23, P1762, DOI 10.1002/eji.1830230805; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HUANG D, IN PRESS GENES IMMUN; JOHNSON KJ, 1992, GENOMICS, V14, P745, DOI 10.1016/S0888-7543(05)80178-8; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; Larsen ZM, 1999, AUTOIMMUNITY, V31, P35, DOI 10.3109/08916939908993857; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Lernmark A, 1998, NAT GENET, V19, P213, DOI 10.1038/881; Martin ER, 1997, AM J HUM GENET, V61, P439, DOI 10.1086/514860; Mein CA, 1998, NAT GENET, V19, P297, DOI 10.1038/991; Morahan G, 1996, SCIENCE, V272, P1811, DOI 10.1126/science.272.5269.1811; ROBINSON WP, 1993, GENET EPIDEMIOL, V10, P273, DOI 10.1002/gepi.1370100502; Sambrook J, 1989, MOL CLONING; She JX, 1998, CURR OPIN IMMUNOL, V10, P682, DOI 10.1016/S0952-7915(98)80089-7; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Szelachowska M, 1997, HORM METAB RES, V29, P168, DOI 10.1055/s-2007-979014; Trembleau S, 1997, EUR J IMMUNOL, V27, P2330, DOI 10.1002/eji.1830270930; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; WARRINGTON JA, 1994, GENOMICS, V24, P395, DOI 10.1006/geno.1994.1636; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOLF SF, 1991, J IMMUNOL, V146, P3074; YOUNES RN, 1994, SHOCK S, V1, P2; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	29	261	271	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2001	27	2					218	221		10.1038/84872	http://dx.doi.org/10.1038/84872			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175794				2022-12-25	WOS:000166839200027
J	Steinwaerder, DS; Carlson, CA; Otto, DL; Li, ZY; Ni, SH; Lieber, A				Steinwaerder, DS; Carlson, CA; Otto, DL; Li, ZY; Ni, SH; Lieber, A			Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector	NATURE MEDICINE			English	Article							IN-VIVO; THERAPY; GENERATION; CANCER; LIVER	Clinical applications of tumor gene therapy require tumor-specific delivery or expression of therapeutic genes in order to maximize the oncolytic index and minimize side effects(1,2). This study demonstrates activation of transgene expression exclusively in hepatic metastases after systemic application of a modified first-generation (E1A/E1B-deleted) adenovirus vector (AdE1(-)) in mouse tumor models. The discrimination between tumors and normal liver tissue is based on selective DNA replication of AdE1(-) vectors in tumor cells. This new AdE1(-) based vector system uses homologous recombination between inverted repeats to mediate precise rearrangements within the viral genome. As a result of these rearrangements, a promoter is brought into conjunction with a reporter gene creating a functional expression cassette. Genomic rearrangements are dependent upon viral DNA replication, which in turn occurs specifically in tumor cells. In a mouse tumor model with liver metastases derived from human tumor cells, a single systemic administration of replication activated AdE1(-) vectors achieved transgene expression in every metastasis, whereas no extra-tumoral transgene induction was observed. Here we provide a new concept for tumor-specific gene expression that is also applicable for other conditionally replicating adenovirus vectors.	Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lieber, A (corresponding author), Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.			Lieber, Andre/0000-0001-6742-6266	NCI NIH HHS [R01 CA80192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; BABISS LE, 1986, MOL CELL BIOL, V6, P3798, DOI 10.1128/MCB.6.11.3798; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dachs GU, 1997, ONCOL RES, V9, P313; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Haag A, 2000, HUM GENE THER, V11, P597, DOI 10.1089/10430340050015789; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; LIU ML, 1994, HEPATOLOGY, V19, P1521; Nelson JE, 1997, J VIROL, V71, P8902, DOI 10.1128/JVI.71.11.8902-8907.1997; Peeters MJTFDV, 1996, BIOTECHNIQUES, V20, P278; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; SATOH J, 1995, J NEUROPATH EXP NEUR, V54, P504, DOI 10.1097/00005072-199507000-00004; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Steinwaerder DS, 1999, J VIROL, V73, P9303, DOI 10.1128/JVI.73.11.9303-9313.1999; Steinwaerder DS, 2000, HUM GENE THER, V11, P1933, DOI 10.1089/10430340050129549; Steinwaerder DS, 2000, GENE THER, V7, P556, DOI 10.1038/sj.gt.3301139; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sullivan DE, 1997, HUM GENE THER, V8, P1195, DOI 10.1089/hum.1997.8.10-1195; SUSSENBACH JS, 1973, VIROLOGY, V54, P299, DOI 10.1016/0042-6822(73)90142-6; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Zhang WW, 1999, CANCER GENE THER, V6, P113, DOI 10.1038/sj.cgt.7700024	25	47	52	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					240	243		10.1038/84696	http://dx.doi.org/10.1038/84696			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175857				2022-12-25	WOS:000166756300043
J	Straub, B; Meyer, E; Fromherz, P				Straub, B; Meyer, E; Fromherz, P			Recombinant maxi-K channels on transistor, a prototype of iono-electronic interfacing	NATURE BIOTECHNOLOGY			English	Article						ion channels; transistors; cell-chip sensors; bioelectronics	NEURON-SILICON JUNCTION; CELL; MEMBRANE; VOLTAGE; CONDUCTANCES; EXPRESSION; ACTIVATION; ADHESION; CURRENTS; HSLO	We report on the direct electrical interfacing of a recombinant ion channel to a field-effect transistor on a silicon chip. The ion current through activated maxi-K-Ca channels in human embryonic kidney (HEK293) cells gives rise to an extracellular voltage between cell and chip that controls the electronic source-drain current. A comparison with patch-clamp recording shows that the channels at the cell/chip interface are fully functional and that they are significantly accumulated there. The direct coupling of potassium channels to a semiconductor on the level of an individual cell is the prototype for an iono-electronic interface of ligand-gated or G protein-coupled ion channels and the development of screening biosensors with many transfected cells on a chip with a targe array of transistors.	Max Planck Inst Biochem, Dept Membrane & Neurophys, D-82152 Martinsried, Germany	Max Planck Society	Fromherz, P (corresponding author), Max Planck Inst Biochem, Dept Membrane & Neurophys, D-82152 Martinsried, Germany.							Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; Braun D, 1998, PHYS REV LETT, V81, P5241, DOI 10.1103/PhysRevLett.81.5241; Dichiara TJ, 1995, J PHYSIOL-LONDON, V489, P403, DOI 10.1113/jphysiol.1995.sp021061; DiChiara TJ, 1997, J NEUROSCI, V17, P4942; FROMHERZ P, 1991, SCIENCE, V252, P1290, DOI 10.1126/science.1925540; Fromherz P, 1999, EUR BIOPHYS J BIOPHY, V28, P254, DOI 10.1007/s002490050206; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; HIROKAWA N, 1982, J NEUROCYTOL, V11, P487, DOI 10.1007/BF01257990; Kiessling V, 2000, LANGMUIR, V16, P3517, DOI 10.1021/la991157b; Lambacher A, 1996, APPL PHYS A-MATER, V63, P207, DOI 10.1007/BF01567871; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Rentschler M, 1998, LANGMUIR, V14, P547, DOI 10.1021/la970976y; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schatzthauer R, 1998, EUR J NEUROSCI, V10, P1956, DOI 10.1046/j.1460-9568.1998.00205.x; SCHELLER FW, 1996, FRONTIERS BIOSENSORI; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vassanelli S, 1999, J NEUROSCI, V19, P6767, DOI 10.1523/JNEUROSCI.19-16-06767.1999; Weis R, 1997, PHYS REV E, V55, P877, DOI 10.1103/PhysRevE.55.877; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	21	77	85	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					121	124		10.1038/84369	http://dx.doi.org/10.1038/84369			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175724				2022-12-25	WOS:000166754700016
J	Surolia, N; Surolia, A				Surolia, N; Surolia, A			Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum	NATURE MEDICINE			English	Article							CARRIER PROTEIN REDUCTASE; FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; BRASSICA-NAPUS; TARGET; FABI; NADH; PURIFICATION; MYCOPLASMAS; EXPRESSION	The antimicrobial biocide triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol] potently inhibits the growth of Plasmodium falciparum in vitro and, in a mouse model, Plasmodium berghei in vivo. Inhibition of [C-14]acetate and [C-14]malonyl-CoA incorporation into fatty acids in vivo and in vitro, respectively, by triclosan implicate FabI as its target. Here we demonstrate that the enoyl-ACP reductase purified from P. falciparum is triclosan sensitive. Also, we present the evidence for the existence of FabI gene in P, falciparum. We establish the existence of the de novo fatty acid biosynthetic pathway in this parasite, and identify a key enzyme of this pathway for the development of new antimalarials.	Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Surolia, N (corresponding author), Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					AGARWAL AK, 1987, BIOCHEM BIOPH RES CO, V148, P357; Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; DUSSURGET O, 1994, APPL ENVIRON MICROB, V60, P953, DOI 10.1128/AEM.60.3.953-959.1994; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; HEUSSER D, 1968, J CHROMATOGR, V33, P62, DOI 10.1016/S0021-9673(00)98620-5; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; Matesanz F, 1999, J MOL BIOL, V291, P59, DOI 10.1006/jmbi.1999.2964; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MITRUKA M, 1977, CLIN BIOCH HEMATOLOG; PETERS W, 1980, MALARIA; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5; Sambrook J., 2002, MOL CLONING LAB MANU; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WEEKS G, 1968, J BIOL CHEM, V243, P1180	40	367	378	0	51	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					167	173		10.1038/84612	http://dx.doi.org/10.1038/84612			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175846				2022-12-25	WOS:000166756300032
J	Peterson, SE; Stellwagen, AE; Diede, SJ; Singer, MS; Haimberger, ZW; Johnson, CO; Tzoneva, M; Gottschling, DE				Peterson, SE; Stellwagen, AE; Diede, SJ; Singer, MS; Haimberger, ZW; Johnson, CO; Tzoneva, M; Gottschling, DE			The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; YEAST KU; MAINTENANCE; GENE; EST1; DISRUPTION; STRAINS; VECTORS	The telomerase enzyme lengthens telomeres, an activity essential for chromosome stability in most eukaryotes. The enzyme is composed of a specialized reverse transcriptase and a template RNA (ref. 1). In Saccharomyces cerevisiae, overexpression of TLC1, the telomerase RNA gene, disrupts telomeric structure(2). The result is both shortened telomere length and loss of a special chromatin structure that normally silences telomere-proximal genes. Because telomerase function is not required for telomeric silencing, we postulated that the dominant-negative effect caused by overexpression of TLC1 RNA originates in a normal interaction between the RNA and an unknown telomeric factor important for silencing; the overexpressed RNA presumably continues to bind the factor and compromises its function(3). Here we show that a 48-nt stem-loop structure within the 1.3-kb TLC1 RNA is necessary and sufficient for disrupting telomeric silencing and shortening telomeres. Moreover, this short RNA sequence appears to function through an interaction with the conserved DNA end-binding protein Ku (ref. 4). We propose that, in addition to its roles in telomeric silencing, homologous recombination and non-homologous end-joining (NHEJ), S. cerevisiae Ku also helps to recruit or activate telomerase at the telomere through an interaction with this stem-loop of TLC1 RNA.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Chicago, Chicago, IL 60637 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Chicago; University of Washington; University of Washington Seattle	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.	dgottsch@fhcrc.org	Diede, Scott/G-2288-2012	Diede, Scott/0000-0001-5422-549X				Brachmann CB, 1998, YEAST, V14, P115; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HABER JE, 1984, GENETICS, V106, P207; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Potter PM, 1996, BIOTECHNIQUES, V21, P198; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Singer MS, 1998, GENETICS, V150, P613; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SINGER MS, 1997, THESIS U CHICAGO; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177	30	181	184	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					64	67		10.1038/83778	http://dx.doi.org/10.1038/83778			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138000				2022-12-25	WOS:000166187900017
J	Wylie, SR; Chantler, PD				Wylie, SR; Chantler, PD			Separate but linked functions of conventional myosins modulate adhesion and neurite outgrowth	NATURE CELL BIOLOGY			English	Article							NEURONAL GROWTH CONES; FOCAL ADHESIONS; CELL; RHO; PHOSPHORYLATION; ISOFORMS; MOTILITY; DRIVES; CONTRACTILITY; LOCALIZATION	The potential functional diversity of closely related myosin isoforms found in eukaryotic cells is not yet understood in detail. We have previously provided evidence from functional knockouts of Neuro-2A neuroblastoma cells that myosin IIB is essential for neurite outgrowth(1). Here we investigate the role of non-muscle myosin IIA in the same cell line. We show that suppression of myosin IIA transcript and protein expression, brought about through exposure to isoform-specific antisense oligonucleotides, caused a rearrangement of the actin cytoskeleton and loss of cell adhesion. This also led to disruption of focal contacts, as evidenced by coincident reduction in paxillin and vinculin immunofluorescence, but did not diminish transcript expression, All effects were fully reversible. Before myosin IIA antisense-induced detachment, neurite outgrowth remained unaffected. By contrast, antisense oligonucleotides directed against myosin IIB transcripts had no effect on adhesion but severely attenuated neurite outgrowth. We infer that the two main isoforms of neuronal conventional myosin, myosins IIA and IIB, have separate but linked functions during neuronal adhesion and neurite outgrowth.	Univ London Royal Vet Coll, Unit Mol & Cellular Biol, London NW1 0TU, England	University of London; University of London Royal Veterinary College	Chantler, PD (corresponding author), Univ London Royal Vet Coll, Unit Mol & Cellular Biol, 32 Belgrave Sq, London NW1 0TU, England.							Alatortsev VE, 1997, FEBS LETT, V413, P197, DOI 10.1016/S0014-5793(97)00901-0; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; deCurtis I, 1997, EXP CELL RES, V230, P233, DOI 10.1006/excr.1996.3423; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; Gomez TM, 1996, J NEUROBIOL, V29, P18, DOI 10.1002/(SICI)1097-4695(199601)29:1<18::AID-NEU2>3.0.CO;2-A; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kolega J, 1998, J CELL SCI, V111, P2085; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; LETOURNEAU PC, 1991, NERVE GROWTH CONE; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; Lewis AK, 1996, CELL MOTIL CYTOSKEL, V33, P130, DOI 10.1002/(SICI)1097-0169(1996)33:2<130::AID-CM5>3.3.CO;2-H; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; MAUPIN P, 1994, J CELL SCI, V107, P3077; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; NAGY JI, 1995, J NEUROSCI, V15, P241; Palecek SP, 1997, NATURE, V388, P210, DOI 10.1038/40687; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; SIMS JR, 1992, J CELL SCI, V103, P1215; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967	31	79	81	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					88	92		10.1038/35050613	http://dx.doi.org/10.1038/35050613			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146631				2022-12-25	WOS:000166146400025
J	Younkin, SG				Younkin, SG			Amyloid beta vaccination: reduced plaques and improved cognition	NATURE MEDICINE			English	Editorial Material							TRANSGENIC MICE	Studies in three different transgenic mouse models suggest that the amyloid beta -protein contributes to memory loss in Alzheimer disease. Immunization with an amyloid beta -peptide fragment reduces learning and memory impairments in mice, and this approach may eventually be used to prevent and/or treat this disease in people.	Mayo Clin Jacksonville, Ctr Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Younkin, SG (corresponding author), Mayo Clin Jacksonville, Ctr Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.							Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; CHEN GZ, IN PRESS NATURE; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JANUS C, IN PRESS NATURE; MORGAN D, IN PRESS NATURE; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; SCHENK, 1999, NATURE, V40, P173	9	40	63	1	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					18	19		10.1038/83292	http://dx.doi.org/10.1038/83292			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135604				2022-12-25	WOS:000166243100019
J	Sharp, DJ; Rogers, GC; Scholey, JM				Sharp, DJ; Rogers, GC; Scholey, JM			Cytoplasmic dynein is required for poleward chromosome movement during mitosis in Drosophila embryos	NATURE CELL BIOLOGY			English	Article							CENP-E; CHEMOSENSORY NEURONS; RETROGRADE TRANSPORT; KINETOCHORE MOTOR; DYNACTIN REVEALS; KINESIN; ANAPHASE; SEGREGATION; PROTEIN; ZW10	The movement of chromosomes during mitosis occurs on a bipolar, microtubule-based protein machine, the mitotic spindle. It has long been proposed that poleward chromosome movements that occur during prometaphase and anaphase A are driven by the microtubule motor cytoplasmic dynein, which binds to kinetochores and transports them toward the minus ends of spindle microtubules. Here we evaluate this hypothesis using time-lapse confocal microscopy to visualize, in real time, kinetochore and chromatid movements in living Drosophila embryos in the presence and absence of specific inhibitors of cytoplasmic dynein. Our results show that dynein inhibitors disrupt the alignment of kinetochores on the metaphase spindle equator and also interfere with kinetochore- and chromatid-to-pole movements during anaphase A. Thus, dynein is essential for poleward chromosome motility throughout mitosis in Drosophila embryos.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Scholey, JM (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	jmscholey@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019262] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19262, GM55507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowman AB, 1999, J CELL BIOL, V146, P165; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; FOE VE, 1983, J CELL SCI, V61, P31; Francis-Lang H, 1999, METH MOL B, V122, P223; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Karki S, 1998, J CELL BIOL, V143, P561; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; NICKLAS RB, 1984, CELL MOTIL CYTOSKEL, V4, P1, DOI 10.1002/cm.970040102; Orozco JT, 1999, NATURE, V398, P674, DOI 10.1038/19448; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; Signor D, 1999, MOL BIOL CELL, V10, P345, DOI 10.1091/mbc.10.2.345; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERNOS I, 1998, DYNAMICS CELL DIVISI, P97; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Yucel JK, 2000, J CELL BIOL, V150, P1, DOI 10.1083/jcb.150.1.1; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	43	180	183	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					922	930		10.1038/35046574	http://dx.doi.org/10.1038/35046574			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146657				2022-12-25	WOS:000165814500015
J	Cheng, T; Rodrigues, N; Dombkowski, D; Stier, S; Scadden, DT				Cheng, T; Rodrigues, N; Dombkowski, D; Stier, S; Scadden, DT			Stem cell repopulation efficiency but not pool size is governed by p27(kip1)	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; HEMATOPOIETIC PROGENITORS; COMPETITIVE REPOPULATION; MICE LACKING; CYCLE; EXPRESSION; DIFFERENTIATION; MOUSE; INHIBITOR; ASSAY	Sustained blood cell production requires preservation of a quiescent, multipotential stem cell pool that intermittently gives rise to progenitors with robust proliferative potential. The ability of cells to shift from a highly constrained to a vigorously active proliferative state is critical for maintaining stem cells while providing the responsiveness necessary for host defense. The cy clin-dependent kinase inhibitor (CDKI), p21(cip1/waf1) (p21) dominates stem cell kinetics. Here we report that another CDKI, p27(kip1) (p27), does not affect stem cell number, cell cycling, or self-renewal, but markedly alters progenitor proliferation and pool size. Therefore, distinct CDKIs govern the highly divergent stem and progenitor cell populations. When competitively transplanted, p27-deficient stem cells generate progenitors that eventually dominate blood cell production. Modulating p27 expression in a small number of stem cells may translate into effects on the majority of mature cells, thereby providing a strategy for potentiating the impact of transduced cells in stem cell gene therapy.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr, 149 13th St,Room 5212, Boston, MA 02129 USA.	cheng-tao@mgh.harvard.edu; scadden.david@mgh.harvard.edu		Rodrigues, Neil/0000-0002-1925-7733; Cheng, Tao/0000-0002-5925-2769	NHLBI NIH HHS [HL 44851, HL 55718] Funding Source: Medline; NIAID NIH HHS [AI07387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851, R01HL055718] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; CarverMoore K, 1996, BLOOD, V88, P803; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gardner RV, 1997, EXP HEMATOL, V25, P495; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; GRZEGORZEWSKI K, 1994, J EXP MED, V180, P1047, DOI 10.1084/jem.180.3.1047; HARRISON DE, 1980, BLOOD, V55, P77; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LERNER C, 1990, EXP HEMATOL, V18, P114; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MAUCH P, 1989, BONE MARROW TRANSPL, V4, P601; MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360-3016(94)00430-S; MULLER AM, 1993, DEVELOPMENT, V118, P1343; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLOEMACHER RE, 1989, BLOOD, V74, P2755; PLOEMACHER RE, 1991, BLOOD, V78, P2527; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Roy V, 1999, EXP HEMATOL, V27, P302, DOI 10.1016/S0301-472X(98)00031-9; Shen HM, 1999, J VIROL, V73, P728, DOI 10.1128/JVI.73.1.728-737.1999; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPANGRUDE GJ, 1989, SCIENCE, V244, P1030; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Tong X, 1998, EXP HEMATOL, V26, P684; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; Yaroslavskiy B, 1999, BLOOD, V93, P2907	45	270	285	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1235	1240		10.1038/81335	http://dx.doi.org/10.1038/81335			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062534				2022-12-25	WOS:000165114800030
J	Curnis, F; Sacchi, A; Borgna, L; Magni, F; Gasparri, A; Corti, A				Curnis, F; Sacchi, A; Borgna, L; Magni, F; Gasparri, A; Corti, A			Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)	NATURE BIOTECHNOLOGY			English	Article						tumor necrosis factor; tumor targeting; immunotherapy; aminopeptidase N/CD 13; angiogenesis; vascular targeting	ISOLATED LIMB PERFUSION; SOFT-TISSUE SARCOMAS; FACTOR-ALPHA; INTERFERON-GAMMA; THERAPEUTIC INDEX; FACTOR CACHECTIN; MELPHALAN; CELLS; MELANOMA; COMBINATION	The clinical use of tumor necrosis factor alpha (TNF) as an anticancer drug is limited to local treatments because of its dose-limiting systemic toxicity. We show here that murine TNF fused with CNGRC peptide (NGR-TNF), an aminopeptidase N (CD13) ligand that targets activated blood vessels in tumors, is 12-15 times more efficient than murine TNF in decreasing the tumor burden in lymphoma and melanoma animal models, whereas its toxicity is similar. Similarly, human NGR-TNF induced stronger antitumor effects than human TNF, even with 30 times lower doses. Coadministration of murine NGR-TNF with a CNGRC peptide or an anti-CD13 antibody markedly decreased its antitumor effects. Tumor regression, induced by doses of murine NGR-TNF lower than the LD50, was accompanied by protective immunity. In contrast, no cure was induced by TNF at any dose. These results suggest that targeted delivery of TNF to CD13 may enhance its immunotherapeutic properties. Moreover, these findings reveal the potential of tumor homing peptides to generate a new class of recombinant cytokines that compared to immunocytokines have a simpler structure, could be easier to produce and are potentially less immunogenic.	San Raffaele H Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Corti, A (corresponding author), San Raffaele H Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Gasparri, Anna Maria/AAN-5071-2020; Curnis, Flavio/AAK-3542-2020; Corti, Angelo/F-7046-2012; Magni, Fulvio/A-7340-2014	Gasparri, Anna Maria/0000-0002-1757-8699; Curnis, Flavio/0000-0002-7231-9569; Corti, Angelo/0000-0002-0893-6191; Magni, Fulvio/0000-0002-8663-0374; Subba, Rajkrishna/0000-0003-0051-0062; SACCHI, ANGELINA/0000-0002-6594-0277				Alexander HR, 1998, J CLIN ONCOL, V16, P1479, DOI 10.1200/JCO.1998.16.4.1479; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; ASHER AL, 1991, J IMMUNOL, V146, P3227; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CELIK C, 1983, CANCER RES, V43, P3507; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; Corti A, 1998, CANCER RES, V58, P3866; Corti A, 1998, J DRUG TARGET, V5, P403, DOI 10.3109/10611869808997869; CORTI A, 1994, J IMMUNOL METHODS, V177, P191, DOI 10.1016/0022-1759(94)90156-2; Eggermont AMM, 1996, ANN SURG, V224, P756, DOI 10.1097/00000658-199612000-00011; Eggermont AMM, 1996, J CLIN ONCOL, V14, P2653, DOI 10.1200/JCO.1996.14.10.2653; Fiers W, 1995, BIOL THERAPY CANC, P295; Fraker DL, 1996, J CLIN ONCOL, V14, P479, DOI 10.1200/JCO.1996.14.2.479; FRAKER DL, 1995, BIOL THERAPY CANC, P329; Gasparri A, 1999, CANCER RES, V59, P2917; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; HANSEN AS, 1993, EUR J IMMUNOL, V23, P2358, DOI 10.1002/eji.1830230946; HILL S, 1993, BRIT J SURG, V80, P995, DOI 10.1002/bjs.1800800820; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koops HS, 1998, RADIOTHER ONCOL, V48, P1; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LLENARD D, 1992, WORLD J SURG, V16, P234; Moro M, 1997, CANCER RES, V57, P1922; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PFIZENMAIER K, 1987, J IMMUNOL, V138, P975; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SMITH RA, 1987, J BIOL CHEM, V262, P6951; TALMADGE JE, 1987, CANCER RES, V47, P2563; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407	35	351	388	1	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1185	1190		10.1038/81183	http://dx.doi.org/10.1038/81183			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062439				2022-12-25	WOS:000165176600025
J	Urness, LD; Sorensen, LK; Li, DY				Urness, LD; Sorensen, LK; Li, DY			Arteriovenous malformations in mice lacking activin receptor-like kinase-1	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; CARDIOVASCULAR DEVELOPMENT; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; VASCULOGENESIS; MORPHOGENESIS; ANGIOGENESIS; EPHRIN-B2; EMBRYO	The mature circulatory system is comprised of two parallel, yet distinct, vascular networks that carry blood to and from the heart. Studies have suggested that endothelial tubes are specified as arteries and veins at the earliest stages of angiogenesis, before the onset of circulation(1-4). To understand the molecular basis for arterial-venous identity, we have focused our studies on a human vascular dysplasia, hereditary haemorrhagic telangiectasia (HHT), wherein arterial and venous beds fail to remain distinct. Genetic studies have demonstrated that HHT can be caused by loss-of-function mutations in the gene encoding activin receptor-like kinase-1 (ACVRL1; ref. 5). ACVRL1 encodes a type I receptor for the TGF-P superfamily of growth factors(6-8). At the earliest stage of vascular development, mice lacking Acvrl1 develop large shunts between arteries and veins, downregulate arterial Efnb2 and fail to confine intravascular haematopoiesis to arteries. These mice die by mid-gestation with severe arteriovenous malformations resulting from fusion of major arteries and veins. The early loss of anatomical, molecular and functional distinctions between arteries and Veins indicates that Acvrl1 is required for developing distinct arterial and venous vascular beds.	Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Li, DY (corresponding author), Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.	dean.li@hci.utah.edu						Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FLAMME I, 1992, DEVELOPMENT, V116, P435; GADSON PF, 1993, IN VITRO CELL DEV-AN, V29A, P773; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; HOGAN B, 1986, MANIPULATING MOUSE E; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; JOHNSON I, 1989, J SOCIAL WORK PRACTI, V1, P13; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Manaia A, 2000, DEVELOPMENT, V127, P643; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pepper MS, 1996, CURR TOP MICROBIOL, V213, P31; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wilkinson DG, 1992, SITU HYBRIDIZATION P	26	327	341	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2000	26	3					328	331		10.1038/81634	http://dx.doi.org/10.1038/81634			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062473				2022-12-25	WOS:000165176500022
J	Griffin, CS; Simpson, PJ; Wilson, CR; Thacker, J				Griffin, CS; Simpson, PJ; Wilson, CR; Thacker, J			Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation	NATURE CELL BIOLOGY			English	Article							DNA-REPAIR; HOMOLOGOUS RECOMBINATION; CHINESE-HAMSTER; CENTROSOME; INSTABILITY; DAMAGE; CELLS; CENTROMERE; SEQUENCE; PROTEIN	Growth and development are dependent on the faithful duplication of cells. Duplication requires accurate genome replication, the repair of any DNA damage, and the precise segregation of chromosomes at mitosis; molecular checkpoints ensure the proper progression and fidelity of each stage. Loss of any of these highly conserved functions may result in genetic instability and proneness to cancer. Here we show that highly significant increases in chromosome missegregation occur in cell lines lacking the RAD51-like genes XRCC2 and XRCC3. This increased missegregation is associated with fragmentation of the centrosome, a component of the mitotic spindle, and not with loss of the spindle checkpoint. Our results show that unresolved DNA damage triggers this instability, and that XRCC2 and XRCC3 are potential tumour-suppressor genes in mammals.	MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England	MRC Harwell	Thacker, J (corresponding author), MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England.	j.thacker@har.mrc.ac.uk						Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Campbell MJ, 1999, J MOL BIOL, V286, P417, DOI 10.1006/jmbi.1998.2456; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Faravelli M, 1998, CYTOGENET CELL GENET, V83, P281, DOI 10.1159/000015171; FATYOL K, 1994, NUCLEIC ACIDS RES, V22, P3728, DOI 10.1093/nar/22.18.3728; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pihan GA, 1998, CANCER RES, V58, P3974; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; TUFT A, 1999, CURR BIOL, V9, P1107; Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	30	199	216	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					757	761		10.1038/35036399	http://dx.doi.org/10.1038/35036399			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025669				2022-12-25	WOS:000089697000024
J	Nasevicius, A; Ekker, SC				Nasevicius, A; Ekker, SC			Effective targeted gene 'knockdown' in zebrafish	NATURE GENETICS			English	Letter							ONE-EYED PINHEAD; SONIC-HEDGEHOG; NO TAIL; PROTEIN; ORGANIZER; IDENTIFICATION; INDUCTION; HOMOLOG; ENCODES; EMBRYO	The sequencing of the zebrafish genome should be completed by the end of 2002. Direct assignment of function on the basis of this information would be facilitated by the development of a rapid, targeted 'knockdown' technology in this model vertebrate. We show here that antisense, morpholino-modified oligonucleotides(1) (morpholinos) are effective and specific translational inhibitors in zebrafish. We generated phenocopies of mutations of the genes no tail (ref. 2), chordin (ref. 3), one-eyed-pinhead (ref. 4), nacre (ref. 5) and sparse (ref. 6), removing gene function from maternal through post-segmentation and organogenesis developmental stages. We blocked expression from a ubiquitous green fluorescent protein (GFP) transgene, showing that, unlike tissue-restricted limitations found with RNA-based interference in the nematode(7), all zebrafish cells readily respond to this technique. We also developed also morpholino-based zebrafish models of human disease. Morpholinos targeted to the uroporphyrinogen decarboxylase gene(8) result in embryos with hepatoerythropoietic porphyria. We also used morpholinos for the determination of new gene functions. We showed that embryos with reduced sonic hedgehog (ref. 9) signalling and reduced tiggy-winkle hedgehog(ref. 10) function exhibit partial cyclopia and other specific midline abnormalities, providing a zebrafish genetic model for the common human disorder holoprosencephaly. Conserved vertebrate processes and diseases are now amenable to a systematic, in vivo, reverse-genetic paradigm using zebrafish embryos.	Univ Minnesota, Arnold & Mabel Beckman Ctr Transposon Ress, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ekker, SC (corresponding author), Univ Minnesota, Arnold & Mabel Beckman Ctr Transposon Ress, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.			Ekker, Stephen/0000-0003-0726-4212				Arora V, 2000, J PHARMACOL EXP THER, V292, P921; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Concordet JP, 1996, DEVELOPMENT, V122, P2835; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Fekany K, 1999, DEVELOPMENT, V126, P1427; Fisher S, 1997, DEVELOPMENT, V124, P1301; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Haffter P, 1996, DEVELOPMENT, V123, P1; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Kappas A, 1995, METABOLIC MOL BASES, P2103; Koos DS, 1999, DEV BIOL, V215, P190, DOI 10.1006/dbio.1999.9479; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lister JA, 1999, DEVELOPMENT, V126, P3757; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; Parichy DM, 1999, DEVELOPMENT, V126, P3425; Qin GZ, 2000, ANTISENSE NUCLEIC A, V10, P11, DOI 10.1089/oli.1.2000.10.11; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schauerte HE, 1998, DEVELOPMENT, V125, P2983; Schier AF, 1997, DEVELOPMENT, V124, P327; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Wallis DE, 1999, MOL GENET METAB, V68, P126, DOI 10.1006/mgme.1999.2895; Wang H, 1998, NAT GENET, V20, P239, DOI 10.1038/3041; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	30	2014	2159	3	241	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					216	220		10.1038/79951	http://dx.doi.org/10.1038/79951			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017081				2022-12-25	WOS:000089638800022
J	Kuehl, P; Zhang, J; Lin, Y; Lamba, J; Assem, M; Schuetz, J; Watkins, PB; Daly, A; Wrighton, SA; Hall, SD; Maurel, P; Relling, M; Brimer, C; Yasuda, K; Venkataramanan, R; Strom, S; Thummel, K; Boguski, MS; Schuetz, E				Kuehl, P; Zhang, J; Lin, Y; Lamba, J; Assem, M; Schuetz, J; Watkins, PB; Daly, A; Wrighton, SA; Hall, SD; Maurel, P; Relling, M; Brimer, C; Yasuda, K; Venkataramanan, R; Strom, S; Thummel, K; Boguski, MS; Schuetz, E			Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; HUMAN CYTOCHROME-P450 ENZYMES; HUMAN-LIVER; CLINICAL PRESENTATION; DRUG-METABOLISM; ALLELIC VARIANT; 3A; SUBSTITUTIONS; ASSOCIATION; CANDIDATE	Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Europeans thereafter collectively referred to as 'Caucasians'). Only people with at least one CYP3A5*1 allele express large amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5 was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Maryland, Dept Mol & Cell Biol, Baltimore, MD 21201 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Johns Hopkins Univ, KcKusick Nathans Inst Geriatr Med, Baltimore, MD USA; Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; Univ N Carolina, Chapel Hill, NC USA; Newcastle Univ, Dept Pharmacol Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Eli Lilly & Co, Dept Drug Metab, Indianapolis, IN 46285 USA; Indiana Univ, Dept Clin Pharmacol, Indianapolis, IN 46204 USA; INSERM, Montpellier, France; Univ Pittsburgh, Dept Pharm, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Johns Hopkins University; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; Newcastle University - UK; Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schuetz, E (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	erin.schuetz@stjude.org	Schuetz, John D/N-2692-2018; Daly, Ann/H-3144-2011; Relling, Mary/N-5032-2018; Schuetz, Erin/N-8087-2018; Strom, Stephen C/A-6501-2008; Cline, Cynthia D/F-7065-2012	Daly, Ann/0000-0002-7321-0629; 	NATIONAL CANCER INSTITUTE [R29CA051001, P30CA021765, R01CA051001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060346, U01GM061393, U01GM061374, P01GM032165] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA51001] Funding Source: Medline; NIEHS NIH HHS [ES08658] Funding Source: Medline; NIGMS NIH HHS [GM60346, U01GM61374, GM32165, U01GM61393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1989, J BIOL CHEM, V264, P10388; Ball SE, 1999, CLIN PHARMACOL THER, V66, P288, DOI 10.1016/S0009-9236(99)70037-8; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CHOLERTON S, 1992, TRENDS PHARMACOL SCI, V13, P434, DOI 10.1016/0165-6147(92)90140-2; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P374, DOI 10.1006/abbi.1995.1177; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643; GROGAN WM, 1990, AM J PHYSIOL, V258, pC480, DOI 10.1152/ajpcell.1990.258.3.C480; Haehner BD, 1996, MOL PHARMACOL, V50, P52; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; Huang ZQ, 1998, CARCINOGENESIS, V19, P867, DOI 10.1093/carcin/19.5.867; Jounaidi Y, 1996, BIOCHEM BIOPH RES CO, V221, P466, DOI 10.1006/bbrc.1996.0618; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; MAQUAT LE, 1995, RNA, V1, P453; Nebert DW, 2000, PHARMACOGENETICS, V10, P279, DOI 10.1097/00008571-200006000-00001; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Paine MF, 1997, J PHARMACOL EXP THER, V283, P1552; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Paulussen A, 2000, PHARMACOGENETICS, V10, P415, DOI 10.1097/00008571-200007000-00005; Rebbeck TR, 1998, J NATL CANCER I, V90, P1225, DOI 10.1093/jnci/90.16.1225; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; Sata F, 2000, CLIN PHARMACOL THER, V67, P48, DOI 10.1067/mcp.2000.104391; SCHUETZ EG, 1992, ARCH BIOCHEM BIOPHYS, V294, P206, DOI 10.1016/0003-9861(92)90159-T; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ JD, 1994, PHARMACOGENETICS, V4, P11, DOI 10.1097/00008571-199402000-00002; SCHUETZ JD, 1989, ARCH BIOCHEM BIOPHYS, V274, P355, DOI 10.1016/0003-9861(89)90449-9; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WATKINS PB, 1995, HEPATOLOGY, V22, P994, DOI 10.1002/hep.1840220342; Westlind A, 1999, BIOCHEM BIOPH RES CO, V259, P201, DOI 10.1006/bbrc.1999.0752; WRIGHTON SA, 1989, MOL PHARMACOL, V36, P97; WRIGHTON SA, 1990, MOL PHARMACOL, V38, P207	44	1688	1835	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2001	27	4					383	391		10.1038/86882	http://dx.doi.org/10.1038/86882			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279519	Green Submitted			2022-12-25	WOS:000167811200012
J	Mahadevaiah, SK; Turner, JMA; Baudat, F; Rogakou, EP; de Boer, P; Blanco-Rodriguez, J; Jasin, M; Keeney, S; Bonner, WM; Burgoyne, PS				Mahadevaiah, SK; Turner, JMA; Baudat, F; Rogakou, EP; de Boer, P; Blanco-Rodriguez, J; Jasin, M; Keeney, S; Bonner, WM; Burgoyne, PS			Recombinational DNA double-strand breaks in mice precede synapsis	NATURE GENETICS			English	Letter							CHROMOSOME SYNAPSIS; SEX-CHROMOSOMES; MEIOTIC RECOMBINATION; MOUSE; PROTEIN; GENE; RAD51; MEIOSIS; DMC1; SPERMATOCYTES	In Saccharomyces cerevisiae, meiotic recombination is initiated by Spo11-dependent double-strand breaks (DSBs), a process that precedes homologous synapsis. Here we use an antibody specific for a phosphorylated histone (gamma -H2AX, which marks the sites of DSBs) to investigate the timing, distribution and Spo11-dependence of meiotic DSBs in the mouse. We show that, as in yeast, recombination in the mouse is initiated by Spo11-dependent DSBs that form during leptotene. Loss of gamma -H2AX staining (which in irradiated somatic cells is temporally linked with DSB repair) is temporally and spatially correlated with synapsis, even when this synapsis is 'non-homologous'.	Natl Inst Med Res, Div Dev Genet, London NW7 1AA, England; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Wageningen Inst Anim Sci, Genet Lab, Wageningen, Netherlands; Univ Valladolid, Sch Med, Dept Cell Biol, Valladolid, Spain	MRC National Institute for Medical Research; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wageningen University & Research; Universidad de Valladolid	Burgoyne, PS (corresponding author), Natl Inst Med Res, Div Dev Genet, Mill Hill, London NW7 1AA, England.	pburgoy@nimr.mrc.ac.uk	Keeney, Scott/GVR-8515-2022	Baudat, Frederic/0000-0003-2415-8366; Keeney, Scott/0000-0002-1283-6417				Alsheimer M, 1996, EXP CELL RES, V228, P181, DOI 10.1006/excr.1996.0315; ASHLEY T, 2000, RESULTS PROBLEMS CEL, P131; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; CALENDA A, 1994, EMBO J, V13, P100, DOI 10.1002/j.1460-2075.1994.tb06239.x; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; DOBSON MJ, 1994, J CELL SCI, V107, P2749; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Eijpe M, 2000, CHROMOSOMA, V109, P123, DOI 10.1007/s004120050420; Escalier D, 2000, CHROMOSOMA, V109, P259, DOI 10.1007/s004120000075; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kneitz B, 2000, GENE DEV, V14, P1085; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; MAHADEVAIAH S, 1988, CHROMOSOMA, V97, P145, DOI 10.1007/BF00327371; MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; MOSES MJ, 1981, CHROMOSOMA, V81, P519, DOI 10.1007/BF00285847; Page J, 1998, CHROMOSOME RES, V6, P639, DOI 10.1023/A:1009209628300; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Peters AHFM, 1997, CHROMOSOME RES, V5, P313, DOI 10.1023/B:CHRO.0000038762.60086.ef; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Plug AW, 1998, J CELL SCI, V111, P413; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	36	679	699	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					271	276		10.1038/85830	http://dx.doi.org/10.1038/85830			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242108				2022-12-25	WOS:000167304200018
J	Skobe, M; Hawighorst, T; Jackson, DG; Prevo, R; Janes, L; Velasco, P; Riccardi, L; Alitalo, K; Claffey, K; Detmar, M				Skobe, M; Hawighorst, T; Jackson, DG; Prevo, R; Janes, L; Velasco, P; Riccardi, L; Alitalo, K; Claffey, K; Detmar, M			Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis	NATURE MEDICINE			English	Article							LYMPH-NODE METASTASIS; GROWTH-FACTOR VEGF; EXPRESSION; ANGIOGENESIS; CARCINOMA; ENDOTHELIUM; RECEPTOR-3; TRANSPORT; CELLS; GENE	Metastasis of breast cancer occurs primarily through the lymphatic system, and the extent of lymph node involvement is a key prognostic factor for the disease. Whereas the significance of angiogenesis for tumor progression has been well documented, the ability of tumor cells to induce the growth of lymphatic vessels (lymphangiogenesis) and the presence of intratumoral lymphatic vessels have been controversial. Using a novel marker for lymphatic endothelium, LYVE-1, we demonstrate here the occurrence of intratumoral lymphangiogenesis within human breast cancers after orthotopic transplantation onto nude mice. Vascular endothelial growth factor (VEGF)-C overexpression in breast cancer cells potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes and to lungs. The degree of tumor lymphangiogenesis was highly correlated with the extent of lymph node and lung metastases. These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis.	Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Univ Helsinki, Haartman Inst, Helsinki, Finland; Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	Harvard University; Massachusetts General Hospital; Harvard University; University of Oxford; University of Helsinki; University of Connecticut	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; , david/0000-0002-4133-9364	NCI NIH HHS [CA69184, CA86410] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BAXTER LT, 1990, MICROVASC RES, V40, P246, DOI 10.1016/0026-2862(90)90023-K; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Detmar M, 2000, AM J PATHOL, V156, P159, DOI 10.1016/S0002-9440(10)64715-3; Eggert A, 2000, CLIN CANCER RES, V6, P1900; EVANS HM, 1908, J HOPKINS MED J, V19, P232; Fellmer PT, 1999, SURGERY, V126, P1056, DOI 10.1067/msy.2099.101432; Fisher B, 1968, LYMPH LYMPHATIC SYST, P324; Folkman J, 1996, NEW ENGL J MED, V334, P921; GILCHRIST RK, 1950, AMA ARCH SURG, V61, P913, DOI 10.1001/archsurg.1950.01250020921013; Hoffman RM, 1998, CANCER METAST REV, V17, P271, DOI 10.1023/A:1006188412324; JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364; JAIN RK, 1987, CANCER RES, V47, P3039; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P1751; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kurebayashi J, 1999, JPN J CANCER RES, V90, P977, DOI 10.1111/j.1349-7006.1999.tb00844.x; LEAK L V, 1970, Microvascular Research, V2, P361, DOI 10.1016/0026-2862(70)90031-2; Lee FC, 1933, ARCH SURG-CHICAGO, V26, P602, DOI 10.1001/archsurg.1933.01170040065004; Leu AJ, 2000, CANCER RES, V60, P4324; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niki T, 2000, CLIN CANCER RES, V6, P2431; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Ohta Y, 2000, J THORAC CARDIOV SUR, V119, P804, DOI 10.1016/S0022-5223(00)70017-1; PRICE JE, 1990, CANCER RES, V50, P717; Pullinger BD, 1935, BRIT J EXP PATHOL, V16, P49; Reichert FL, 1926, ARCH SURG-CHICAGO, V13, P871, DOI 10.1001/archsurg.1926.01130120095004; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Shushanov S, 2000, INT J CANCER, V86, P47, DOI 10.1002/(SICI)1097-0215(20000401)86:1<47::AID-IJC7>3.0.CO;2-R; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; St Croix B, 2000, SCIENCE, V289, P1197; TANIGAWA N, 1981, LYMPHOLOGY, V14, P149; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Witte M H, 1997, EXS, V79, P65; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; ZEIDMAN I, 1955, CANCER, V8, P123, DOI 10.1002/1097-0142(1955)8:1<123::AID-CNCR2820080116>3.0.CO;2-A	44	1378	1536	2	93	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					192	198		10.1038/84643	http://dx.doi.org/10.1038/84643			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175850				2022-12-25	WOS:000166756300036
J	Aronson, JK				Aronson, JK			Forbidden fruit	NATURE MEDICINE			English	Editorial Material							GRAPEFRUIT JUICE; ASCORBIC-ACID; FURANOCOUMARIN DERIVATIVES; QUALITY EVALUATION; CITRUS-FRUITS; ANTIOXIDANT; TECHNOLOGY; INHIBITION; CHEMISTRY; SAFETY	Although citrus fruits prevent and cure scurvy, they may not always be as good for you as you thought.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Woodstock Rd, Oxford OX2 6HE, England.							Auer BL, 1998, CLIN CHEM LAB MED, V36, P143, DOI 10.1515/CCLM.1998.027; BAILEY DG, 1989, CLIN INVEST MED, V12, P357; Bailey DG, 1998, BRIT J CLIN PHARMACO, V46, P101, DOI 10.1046/j.1365-2125.1998.00764.x; BARNESS LA, 1975, ANN NY ACAD SCI, V258, P523, DOI 10.1111/j.1749-6632.1975.tb29311.x; Basu TK, 1982, VITAMIN C HLTH DIS, P61; Blanchard J, 1997, AM J CLIN NUTR, V66, P1165, DOI 10.1093/ajcn/66.5.1165; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; DOUGLAS RM, 2000, COCHRANE LIB; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dresser GK, 2000, CLIN PHARMACOL THER, V68, P28, DOI 10.1067/mcp.2000.107524; Eagling VA, 1999, BRIT J CLIN PHARMACO, V48, P543, DOI 10.1046/j.1365-2125.1999.00052.x; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GERSHOFF SN, 1993, NUTR REV, V51, P313, DOI 10.1111/j.1753-4887.1993.tb03757.x; Guo LQ, 2000, DRUG METAB DISPOS, V28, P766; KAUR B, 2000, COCHRANE LIB; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; *MED CONTR AG COMM, 1999, CURR PROBL PHARMACOV, V25, P2; Meyers DG, 1996, ARCH INTERN MED, V156, P925, DOI 10.1001/archinte.156.9.925; Ohnishi A, 2000, BRIT J PHARMACOL, V130, P1369, DOI 10.1038/sj.bjp.0703433; RANGANNA S, 1983, CRC CR REV FOOD SCI, V18, P313, DOI 10.1080/10408398309527366; RANGANNA S, 1983, CRC CR REV FOOD SCI, V19, P1; Shaw PE, 2000, J AGR FOOD CHEM, V48, P2425, DOI 10.1021/jf0001076; STEWART ML, 1985, J AM DIET ASSOC, V85, P1585; TROHLER U, 2000, IMPROVE EVIDENCE MED, P68; 1998, DRUGS THER PERSPECT, V12, P12; 1997, CURR PROBL PHARMACOV, V23, P9	26	8	9	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					29	30		10.1038/83312	http://dx.doi.org/10.1038/83312			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135611				2022-12-25	WOS:000166243100026
J	Haase, SB; Winey, M; Reed, SI				Haase, SB; Winey, M; Reed, SI			Multi-step control of spindle pole body duplication by cyclin-dependent kinase	NATURE CELL BIOLOGY			English	Article							YEAST-CELL CYCLE; S-PHASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CENTROSOME DUPLICATION; PROTEIN-KINASE; PHOSPHORYLATION; G(1); DEGRADATION; TRANSITION	Organelles called centrosomes in metazoans or spindle pole bodies (SPBs) in yeast direct the assembly of a bipolar spindle that is essential for faithful segregation of chromosomes during mitosis. Abnormal accumulation of multiple Centrosomes leads to genome instability, and has been observed in both tumour cells and cells with targeted mutations in tumour-suppressor genes. The defects that lead to centrosome amplification are not understood. We have recapitulated the multiple-centrosome phenotype in budding yeast by disrupting the activity of specific cyclin-dependent kinase (CDK) complexes. Our observations are reminiscent of mechanisms that govern DNA replication, and show that specific cyclin/CDK activities function both to promote SPB duplication and to prevent SPB reduplication.	Scripps Res Inst, Dept Mol Biol, Moffett Field, CA 94035 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, Moffett Field, CA 94035 USA.	sreed@scripps.edu		Haase, Steve/0000-0001-8127-8992	NIGMS NIH HHS [GM38328, GM51312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, R01GM038328, R01GM051312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Adams IR, 1999, J CELL BIOL, V145, P809, DOI 10.1083/jcb.145.4.809; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BYERS B, 1991, METHOD ENZYMOL, V194, P602; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Haase SB, 1999, NATURE, V401, P394, DOI 10.1038/43930; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	27	72	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					38	42		10.1038/35050543	http://dx.doi.org/10.1038/35050543			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146624				2022-12-25	WOS:000166146400018
J	Liu, HX; Cartegni, L; Zhang, MQ; Krainer, AR				Liu, HX; Cartegni, L; Zhang, MQ; Krainer, AR			A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes	NATURE GENETICS			English	Article							PRE-MESSENGER-RNA; SPLICE-SITE SELECTION; SINGLE-NUCLEOTIDE POLYMORPHISMS; SR PROTEINS; ENHANCER; SEQUENCES; IDENTIFICATION; ELEMENTS; SURVEILLANCE; CONSEQUENCES	Point mutations can generate defective and sometimes harmful proteins. The nonsense-mediated mRNA decay (NMD) pathway minimizes the potential damage caused by nonsense mutations(1-4). In-frame nonsense codons located at a minimum distance upstream of the last exon-exon junction are recognized as premature termination codons (PTCs), targeting the mRNA for degradation. Some nonsense mutations cause skipping of one or more exons, presumably during pre-mRNA splicing in the nucleus; this phenomenon is termed nonsense-mediated altered splicing (NAS), and its underlying mechanism is unclear(1,2,5,6). By analyzing NAS in BRCA1, we show here that inappropriate exon skipping can be reproduced in vitro, and results from disruption of a splicing enhancer in the coding sequence. Enhancers can be disrupted by single nonsense, missense and translationally silent point mutations, without recognition of an open reading frame as such. These results argue against a nuclear reading-frame scanning mechanism for NAS. Coding-region single-nucleotide polymorphisms(7) (cSNPs) within exonic splicing enhancers or silencers may affect the patterns or efficiency of mRNA splicing, which may in turn cause phenotypic variability and variable penetrance of mutations elsewhere in a gene.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Krainer, AR (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Krainer, Adrian/0000-0001-9024-9501	NCI NIH HHS [CA13106] Funding Source: Medline; NHGRI NIH HHS [HG01696] Funding Source: Medline; NIGMS NIH HHS [GM42699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ars E, 2000, HUM MOL GENET, V9, P237, DOI 10.1093/hmg/9.2.237; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dietz HC, 1997, AM J HUM GENET, V60, P729; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; Mazoyer S, 1998, AM J HUM GENET, V62, P713, DOI 10.1086/301768; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Shen LX, 1999, P NATL ACAD SCI USA, V96, P7871, DOI 10.1073/pnas.96.14.7871; Shiga N, 1997, J CLIN INVEST, V100, P2204, DOI 10.1172/JCI119757; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Vuillaumier-Barrot S, 1999, Hum Mutat, V14, P543, DOI 10.1002/(SICI)1098-1004(199912)14:6<543::AID-HUMU17>3.0.CO;2-S; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407	30	367	394	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					55	58		10.1038/83762	http://dx.doi.org/10.1038/83762			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137998				2022-12-25	WOS:000166187900015
J	Bellanger, JM; Astier, C; Sardet, C; Ohta, Y; Stossel, TP; Debant, A				Bellanger, JM; Astier, C; Sardet, C; Ohta, Y; Stossel, TP; Debant, A			The Rac1-and RhoG-specific GEF domain of Trio targets filamin to remodel cytoskeletal actin	NATURE CELL BIOLOGY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN-INTERACTION DOMAIN; EXCHANGE FACTOR DOMAINS; BINDING PROTEIN; CELL-ADHESION; ARP2/3 COMPLEX; RAC; GTPASES; KINASE; PHOSPHATASE	Rho GTPases control actin reorganization and many other cellular functions. Guanine nucleotide-exchange factors (GEFs) activate Rho GTPases by promoting their exchange of GDP for GTP. Trio is a unique Rho GEF, because it has separate GEF domains, GEFD1 and GEFD2, that control the GTPases RhoG/Rac1 and RhoA, respectively, Dbl-homology (DH) domains that are common to GEFs catalyse nucleotide exchange, and pleckstrin-homology (PH) domains localize Rho GEFs near their downstream targets, Here we show that Trio GEFD1 interacts through its PH domain with the actin-filament-crosslinking protein filamin, and localizes with endogenous filamin in HeLa cells. Trio GEFD1 induces actin-based ruffling in filamin-expressing, but not filamin-deficient, cells and in cells transfected with a filamin construct that lacks the Trio-binding domain. In addition, Trio GEFD1 exchange activity is not affected by filamin binding. Our results indicate that filamin, as a molecular target of Trio, may be a scaffold for the spatial organization of Rho-GTPase-mediated signalling pathways.	CNRS, CRBM, UPR 1086, F-34293 Montpellier 5, France; USTL, UMR 5539, LMC, F-34090 Montpellier, France; IGMM, UMR 5535, F-34293 Montpellier, France; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Debant, A (corresponding author), CNRS, CRBM, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Bellanger, Jean-Michel/D-1579-2017; Bellanger, Jean-Michel/S-2103-2019	Bellanger, Jean-Michel/0000-0001-9289-2349	NHLBI NIH HHS [HL19429] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Astier C, 1998, FEBS LETT, V429, P95, DOI 10.1016/S0014-5793(98)00572-9; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Blangy A, 2000, J CELL SCI, V113, P729; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; LEBART MC, 1993, J BIOL CHEM, V268, P5642; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; VAN AL, 1997, GENE DEV, V11, P2295; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zhang WJ, 1998, J NEUROSCI, V18, P914	45	171	179	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					888	892		10.1038/35046533	http://dx.doi.org/10.1038/35046533			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146652				2022-12-25	WOS:000165814500010
J	Dunham, MA; Neumann, AA; Fasching, CL; Reddel, RR				Dunham, MA; Neumann, AA; Fasching, CL; Reddel, RR			Telomere maintenance by recombination in human cells	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; ALTERNATIVE MECHANISM; HUMAN CANCER; ELONGATION; SENESCENCE; YEAST; CHROMOSOMES; SEQUENCES; PATHWAY; DEFECT	Telomeres of eukaryotic chromosomes contain many tandem repeats of a G-rich sequence (for example, TTAGGC in vertebrates(1)). In most normal human cells, telomeres shorten with each cell division, and it is proposed that this limits the number of times these cells can replicate(2). Telomeres may be maintained in germline cells, and in many immortalized cells and cancers, by the telomerase holoenzyme(3) (first discovered in the ciliate Tetrahymena(4)), which uses an RNA subunit as template for synthesis of telomeric DNA by the reverse transcriptase catalytic subunit(5). Some immortalized human cell lines and some tumours maintain their telomeres in the absence of any detectable telomerase activity by a mechanism referred to as alternative lengthening of telomeres(6,7) (ALT). Here we show that DNA sequences are copied from telomere to telomere in an immortalized human ALT cell line, indicating that ALT occurs by means of homologous recombination and copy switching.	Childrens Med Res Inst, Canc Res Unit, Sydney, NSW, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, Sydney, NSW, Australia.		Neumann, Axel/D-3319-2012; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COLGIN LM, IN PRESS NEOPLASIA; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Lendvay TS, 1996, GENETICS, V144, P1399; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Roth CW, 1997, MOL CELL BIOL, V17, P5176, DOI 10.1128/MCB.17.9.5176; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sprung CN, 1999, EXP CELL RES, V247, P29, DOI 10.1006/excr.1998.4293; Stout K, 1999, CHROMOSOME RES, V7, P323, DOI 10.1023/A:1009287111661; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Teng SC, 1999, MOL CELL BIOL, V19, P8083; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; Yeager TR, 1999, CANCER RES, V59, P4175	29	682	718	0	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					447	450		10.1038/82586	http://dx.doi.org/10.1038/82586			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101843				2022-12-25	WOS:000165671700018
J	Selinger, DW; Cheung, KJ; Mei, R; Johansson, EM; Richmond, CS; Blattner, FR; Lockhart, DJ; Church, GM				Selinger, DW; Cheung, KJ; Mei, R; Johansson, EM; Richmond, CS; Blattner, FR; Lockhart, DJ; Church, GM			RNA expression analysis using a 30 base pair resolution Escherichia coli genome array	NATURE BIOTECHNOLOGY			English	Article						Escherichia coli; stationary phase; gene expression; functional genomics; DNA chips; oligonucleotide arrays; microarrays	DENSITY OLIGONUCLEOTIDE ARRAYS; DNA-PROTEIN INTERACTIONS; GENE-EXPRESSION; MESSENGER-RNA; HYBRIDIZATION; SEQUENCE; PATTERNS; K-12; TRANSCRIPT; STEP	We have developed a high-resolution "genome array" for the study of gene expression and regulation in Escherichia coli. This array contains on average one 25-mer oligonucleotide probe per 30 base pairs over the entire genome, with one every 6 bases for the intergenic regions and every 60 bases for the 4,290 open reading frames (ORFs). Twofold concentration differences can be detected at levels as low as 0.2 messenger RNA (mRNA) copies per cell, and differences can be seen over a dynamic range of three orders of magnitude. In rich medium we detected transcripts for 97% and 87% of the ORFs in stationary and log phases, respectively. We found that 1,529 transcripts were differentially expressed under these conditions. As expected, genes involved in translation were expressed at higher levels in log phase, whereas many genes known to be involved in the starvation response were expressed at higher levels in stationary phase. Many previously unrecognized growth phase-regulated genes were identified, such as a putative receptor (b0836) and a 30S ribosomal protein subunit (S22), both of which are highly upregulated in stationary phase. Transcription of between 3,000 and 4,000 predicted ORFs was observed from the antisense strand, indicating that most of the genome is transcribed at a detectable level. Examples are also presented for high-resolution array analysis of transcript start and stop sites and RNA secondary structure.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Coll, Cambridge, MA 02138 USA; Affymetrix Inc, Santa Clara, CA USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	Harvard University; Harvard Medical School; Harvard University; Affymetrix; Novartis; University of Wisconsin System; University of Wisconsin Madison	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			church, george/0000-0001-6232-9969				Aach J, 2000, GENOME RES, V10, P431, DOI 10.1101/gr.10.4.431; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bulyk ML, 1999, NAT BIOTECHNOL, V17, P573, DOI 10.1038/9878; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CHEN LH, 1991, J BACTERIOL, V173, P4578, DOI 10.1128/jb.173.15.4578-4586.1991; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gingeras TR, 1998, GENOME RES, V8, P435, DOI 10.1101/gr.8.5.435; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; Liu MY, 1997, J BIOL CHEM, V272, P17502, DOI 10.1074/jbc.272.28.17502; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mir KU, 1999, NAT BIOTECHNOL, V17, P788, DOI 10.1038/11732; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Pennisi E, 2000, SCIENCE, V287, P2183, DOI 10.1126/science.287.5461.2183; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; PORTIER C, 1984, NUCLEIC ACIDS RES, V12, P6091, DOI 10.1093/nar/12.15.6091; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Southern EM, 1997, CIBA F SYMP, V209, P38; TALJANIDISZ J, 1987, J MOL BIOL, V193, P507, DOI 10.1016/0022-2836(87)90263-4; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tao H, 1999, J BACTERIOL, V181, P6425, DOI 10.1128/JB.181.20.6425-6440.1999; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Winzeler EA, 1999, PARASITOLOGY, V118, pS73, DOI 10.1017/S0031182099004047; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; YUZAWA H, 1993, NUCLEIC ACIDS RES, V21, P5449, DOI 10.1093/nar/21.23.5449; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	40	287	320	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1262	1268		10.1038/82367	http://dx.doi.org/10.1038/82367			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101804				2022-12-25	WOS:000165659000022
J	Bergers, G; Brekken, R; McMahon, G; Vu, TH; Itoh, T; Tamaki, K; Tanzawa, K; Thorpe, P; Itohara, S; Werb, Z; Hanahan, D				Bergers, G; Brekken, R; McMahon, G; Vu, TH; Itoh, T; Tamaki, K; Tanzawa, K; Thorpe, P; Itohara, S; Werb, Z; Hanahan, D			Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis	NATURE CELL BIOLOGY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; INHIBITORS; TUMORIGENESIS; SECRETION; CELLS; MICE; GELATINASE; PROGRESSION; TRANSITION	During carcinogenesis of pancreatic islets in transgenic mice, an angiogenic switch activates the quiescent vasculature. Paradoxically, vascular endothelial growth factor (VEGF) and its receptors are expressed constitutively. Nevertheless, a synthetic inhibitor (SU5416) of VEGF signalling impairs angiogenic switching and tumour growth. Two metalloproteinases, MMP-2/gelatinase-A and MMP-9/gelatinase-B, are upregulated in angiogenic lesions. MMP-9 can render normal islets angiogenic, releasing VEGF. MMP inhibitors reduce angiogenic switching, and tumour number and growth, as does genetic ablation of MMP-9. Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, UCSF Ctr Comprehens Canc, San Francisco, CA 94143 USA; Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98104 USA; SUGEN Inc, S San Francisco, CA 94080 USA; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068397, Japan; Sankyo Co Ltd, Shinagawa Ku, Tokyo 1408710, Japan; Univ Texas, SW Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pfizer; Kyoto University; Daiichi Sankyo Company Limited; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; RIKEN	Hanahan, D (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Itohara, Shigeyoshi/I-8769-2012; Bergers, Gabriele/AAJ-5535-2020	Itohara, Shigeyoshi/0000-0002-2410-9989; Bergers, Gabriele/0000-0003-3545-5171	NCI NIH HHS [P01 CA072006-01A10003, R01 CA057621-07, R01 CA057621, P01 CA072006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Brekken RA, 1998, CANCER RES, V58, P1952; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; COUSSENS LM, IN PRESS CELL; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; PARANGI S, 1995, CANCER RES, V55, P6071; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Roberts WG, 1997, CANCER RES, V57, P765; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TAMAKI K, 1995, CHEM PHARM BULL, V43, P1883; Vajkoczy Peter, 1999, Neoplasia (New York), V1, P31, DOI 10.1038/sj.neo.7900006; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 2000, GENE DEV, V14, P163; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x	43	2108	2217	1	156	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					737	744		10.1038/35036374	http://dx.doi.org/10.1038/35036374			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025665	Green Accepted			2022-12-25	WOS:000089697000020
J	Delettre, C; Lenaers, G; Griffoin, JM; Gigarel, N; Lorenzo, C; Belenguer, P; Pelloquin, L; Grosgeorge, J; Turc-Carel, C; Perret, E; Astarie-Dequeker, C; Lasquellec, L; Arnaud, B; Ducommun, B; Kaplan, J; Hamel, CP				Delettre, C; Lenaers, G; Griffoin, JM; Gigarel, N; Lorenzo, C; Belenguer, P; Pelloquin, L; Grosgeorge, J; Turc-Carel, C; Perret, E; Astarie-Dequeker, C; Lasquellec, L; Arnaud, B; Ducommun, B; Kaplan, J; Hamel, CP			Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy	NATURE GENETICS			English	Letter							CHROMOSOME 3Q REGION; KJER TYPE; LINKAGE ANALYSIS; CLINICAL-FEATURES; DNA MAINTENANCE; LOCUS; HETEROGENEITY; IDENTIFICATION; NEUROPATHY; REFINEMENT	Optic: atrophy type 1 (OPA1. MIM 165500) is a dominantly inherited optic neuropathy occurring in 1 in 50.000 individuals(1-3) that features progressive loss in visual acuity leading, in many cases, to legal blindness(4-8). Phenotypic variations(5) and loss of retinal ganglion cells(9,10), as found in Leber hereditary optic neuropathy (LHON), have suggested possible mitochondrial impairment(11,12). The OPA1 gene has been localized to 3q28-q29 (refs 13-19). We describe here a nuclear gene, OPA1, that maps within the candidate region and encodes a dynamin-related protein localized to mitochondria. We found four different OPA1 mutations, including frameshift and missense mutations, to segregate with the disease, demonstrating a role for mitochondria in retinal ganglion cell pathophysiology.	INSERM, U254, Lab Neurobiol Audit, Montpellier, France; Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088, F-31062 Toulouse, France; Hop Necker Enfants Malad, INSERM, U393, Paris, France; Fac Med, CNRS, UNSA, UMR 6549, Nice, France; Sanofi Synthelabo, Labege, France; Inst Pharmacol & Biol Struct, CNRS, UPR 9062, Toulouse, France; Hop Gui Chauliac, Serv Ophthalmol, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CHU de Montpellier	Hamel, CP (corresponding author), INSERM, U254, Lab Neurobiol Audit, Montpellier, France.		Delettre, Cécile/AAC-3096-2020; Lenaers, guy/X-4727-2019; DUCOMMUN, Bernard/B-3208-2008; LENAERS, Guy/K-2421-2015	Delettre, Cécile/0000-0003-3269-2155; LENAERS, Guy/0000-0003-2736-3349; Astarie-Dequeker, Catherine/0000-0003-1801-8105; DUCOMMUN, Bernard/0000-0002-7126-8368; Belenguer, Pascale/0000-0003-0229-5554; Arnaune-Pelloquin, Laetitia/0000-0001-5284-4916				BONNEAU D, 1995, J MED GENET, V32, P951, DOI 10.1136/jmg.32.12.951; Brown J, 1997, ARCH OPHTHALMOL-CHIC, V115, P95, DOI 10.1001/archopht.1997.01100150097016; EIBERG H, 1994, HUM MOL GENET, V3, P977, DOI 10.1093/hmg/3.6.977; ELIOTT D, 1993, AM J OPHTHALMOL, V115, P360, DOI 10.1016/S0002-9394(14)73589-5; Howell N, 1997, J BIOENERG BIOMEMBR, V29, P165, DOI 10.1023/A:1022690030664; HOYT CS, 1980, OPHTHALMOLOGY, V87, P245; JAEGER W, 1988, PAEDIAT GENET, V9, P7; JOHNSTON PB, 1979, AM J OPHTHALMOL, V88, P668; Johnston RL, 1999, OPHTHALMOLOGY, V106, P123, DOI 10.1016/S0161-6420(99)90013-1; Johnston RL, 1997, ARCH OPHTHALMOL-CHIC, V115, P100, DOI 10.1001/archopht.1997.01100150102017; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805; KERRISON JB, 1995, OPHTHALMOLOGY, V102, P1509; KIVLIN JD, 1983, AM J HUM GENET, V35, P1190; Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; KJER P, 1959, ACTA OPHTHALMOL S54, V37, P1; LECABEC V, 1994, BIOCHEM J, V303, P481, DOI 10.1042/bj3030481; LUNKES A, 1995, AM J HUM GENET, V57, P968; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Pelloquin L, 1999, J CELL SCI, V112, P4151; Pelloquin L, 1998, BIOCHEM BIOPH RES CO, V251, P720, DOI 10.1006/bbrc.1998.9539; Seller MJ, 1997, J MED GENET, V34, P967, DOI 10.1136/jmg.34.12.967; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; SMITH DP, 1972, AMER J OPT ARCH AM A, V49, P183; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Votruba M, 1998, HUM GENET, V102, P79, DOI 10.1007/s004390050657; Votruba M, 1998, J MED GENET, V35, P793, DOI 10.1136/jmg.35.10.793; Votruba M, 1997, J MED GENET, V34, P117, DOI 10.1136/jmg.34.2.117	30	1062	1099	2	62	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					207	210		10.1038/79936	http://dx.doi.org/10.1038/79936			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017079				2022-12-25	WOS:000089638800020
J	Hazenberg, MD; Otto, SA; Stuart, JWTC; Verschuren, MCM; Borleffs, JCC; Boucher, CAB; Coutinho, RA; Lange, JMA; De Wit, TFR; Tsegaye, A; Van Dongen, JJM; Hamann, D; De Boer, RJ; Miedema, F				Hazenberg, MD; Otto, SA; Stuart, JWTC; Verschuren, MCM; Borleffs, JCC; Boucher, CAB; Coutinho, RA; Lange, JMA; De Wit, TFR; Tsegaye, A; Van Dongen, JJM; Hamann, D; De Boer, RJ; Miedema, F			Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection	NATURE MEDICINE			English	Article							DELETING ELEMENTS; TYPE-1 INFECTION; GENE DELETION; DELTA-GENE; MEMORY; LYMPHOCYTES; TURNOVER; CD4(+); REARRANGEMENTS; PHENOTYPE	Recent thymic emigrants can be identified by T cell receptor excision circles (TRECs) formed during T-cell receptor rearrangement. Decreasing numbers of TRECs have been observed with aging and in human immunodeficiency virus (HIV)-1 infected individuals, suggesting for thymic impairment. Here, we show that in healthy individuals, declining thymic output will affect the TREC content only when accompanied by naive T-cell division. The rapid decline in TRECs observed during HIV-1 infection and the increase following HAART are better explained not by thymic impairment, but by changes in peripheral T-cell division rates. Our data indicate that TREC content in healthy individuals is only indirectly related to thymic output, and in HIV-1 infection is mainly affected by immune activation.	Univ Amsterdam, Acad Med Ctr, CLB, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1066 CX Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Internal Med, NL-3584 CX Utrecht, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Virol, Eijkman Winkler Inst, NL-3584 CX Utrecht, Netherlands; Municipal Hlth Serv, Dept Publ Hlth & Environm, NL-1000 CE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; ENARP, Addis Ababa, Ethiopia; EHNRI, Addis Ababa, Ethiopia; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Erasmus University Rotterdam; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Ethiopian Health & Nutrition Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Miedema, F (corresponding author), Univ Amsterdam, Acad Med Ctr, CLB, Dept Clin Viroimmunol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	F_Miedema@CLB.nl	de Boer, Rob/B-6050-2011; de Wit, Tobias TF Rinke/A-1224-2013; van Dongen, Jacques J.M./F-8537-2015; Tsegaye, Aster/AAH-7028-2020	de Boer, Rob/0000-0002-2130-691X; van Dongen, Jacques J.M./0000-0001-7686-0021; Tsegaye, Aster/0000-0002-9026-4629; van Dongen, Jacques J.M./0000-0002-3650-7087				BAARS PA, 1995, J IMMUNOL, V154, P17; BREIT TM, 1994, IMMUNOGENETICS, V40, P70, DOI 10.1007/BF00163967; Breit TM, 1997, J IMMUNOL, V159, P4341; Clark DR, 1999, ADV IMMUNOL, V73, P301, DOI 10.1016/S0065-2776(08)60789-0; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gaulton GN, 1997, AIDS, V11, P403, DOI 10.1097/00002030-199704000-00002; George AJT, 1996, IMMUNOL TODAY, V17, P267, DOI 10.1016/0167-5699(96)80543-3; GERDES J, 1984, J IMMUNOL, V133, P1710; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hatzakis A, 2000, LANCET, V355, P599, DOI 10.1016/S0140-6736(99)10311-8; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; HAZENBERG MD, 1999, AIDS REV, V1, P67; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HINTZEN RQ, 1993, J IMMUNOL, V151, P2426; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Livak F, 1996, MOL CELL BIOL, V16, P609; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Messele T, 1999, CLIN EXP IMMUNOL, V115, P443; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; NAKAJIMA PB, 1995, IMMUNITY, V3, P609, DOI 10.1016/1074-7613(95)90132-9; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Pongers-Willemse MJ, 1998, LEUKEMIA, V12, P2006, DOI 10.1038/sj.leu.2401246; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; ROOS MTL, 1994, AIDS, V8, P1533, DOI 10.1097/00002030-199411000-00003; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; UNUTMAZ D, 1995, INT IMMUNOL, V7, P1417, DOI 10.1093/intimm/7.9.1417; VANNOORLOOS AAB, 1980, CANCER RES, V40, P2890; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; Walker RE, 1998, NAT MED, V4, P852, DOI 10.1038/nm0798-852; Wolthers KC, 1999, AIDS RES HUM RETROV, V15, P1053, DOI 10.1089/088922299310340; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	40	334	343	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1036	1042		10.1038/79549	http://dx.doi.org/10.1038/79549			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973325	Green Published			2022-12-25	WOS:000089190500037
J	Kinoshita, A; Saito, T; Tomita, H; Makita, Y; Yoshida, K; Ghadami, M; Yamada, K; Kondo, S; Ikegawa, S; Nishimura, G; Fukushima, Y; Nakagomi, T; Saito, H; Sugimoto, T; Kamegaya, M; Hisa, K; Murray, JC; Taniguchi, N; Niikawa, N; Yoshiura, K				Kinoshita, A; Saito, T; Tomita, H; Makita, Y; Yoshida, K; Ghadami, M; Yamada, K; Kondo, S; Ikegawa, S; Nishimura, G; Fukushima, Y; Nakagomi, T; Saito, H; Sugimoto, T; Kamegaya, M; Hisa, K; Murray, JC; Taniguchi, N; Niikawa, N; Yoshiura, K			Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA		Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan; Osaka Univ, Fac Med, Dept Biochem, Osaka, Japan; Asahikawa Med Coll, Dept Pediat, Asahikawa, Hokkaido 078, Japan; Asahikawa Med Coll, Dept Publ Hlth, Asahikawa, Hokkaido 078, Japan; Shinshu Univ, Sch Med, Dept Internal Med 3, Nagano, Japan; Shinshu Univ, Sch Med, Dept Med Genet, Nagano, Japan; Shinshu Univ, Sch Med, Div Clin & Mol Genet, Nagano, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo, Japan; Dokkyo Univ, Sch Med, Dept Radiol, Mibu, Tochigi, Japan; Asahigawa Ryoikuen Childrens Hosp Physically Disa, Okayama, Japan; Akita Univ, Sch Med, Dept Orthoped Surg, Akita 010, Japan; Kansal Univ Otokoyama Hosp, Dept Pediat, Kyoto, Japan; Chiba Childrens Hosp, Div Orthoped Surg, Chiba, Japan; Natl Chushin Matsumoto Hosp, Dept Orthoped Surg, Nagano, Japan; Univ Iowa, Dept Pediat & Biol Sci, Iowa City, IA USA	Nagasaki University; Osaka University; Asahikawa Medical College; Asahikawa Medical College; Shinshu University; Shinshu University; Shinshu University; University of Tokyo; Dokkyo Medical University; Akita University; Kansai University; Chiba Children's Hospital; University of Iowa	Kinoshita, A (corresponding author), Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan.		Ikegawa, Shiro/N-6895-2015; Saito, Takashi/G-2563-2015; Taniguchi, Naoyuki/I-4182-2014	Ikegawa, Shiro/0000-0003-0316-2147; Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; Tomita, Hiroaki/0000-0003-2628-880X				Ballock R. T., 1993, GROWTH FACTORS PRACT, P85; BURT DW, 1992, DNA CELL BIOL, V11, P497, DOI 10.1089/dna.1992.11.497; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; Ghadami M, 2000, AM J HUM GENET, V66, P143, DOI 10.1086/302728; Janssens K, 2000, J MED GENET, V37, P245, DOI 10.1136/jmg.37.4.245; Makita Y, 2000, AM J MED GENET, V91, P153, DOI 10.1002/(SICI)1096-8628(20000313)91:2<153::AID-AJMG15>3.0.CO;2-U; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Syrris P, 1998, CLIN SCI, V95, P659, DOI 10.1042/cs0950659; Vaughn SP, 2000, GENOMICS, V66, P119, DOI 10.1006/geno.2000.6192	12	177	188	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					19	20		10.1038/79128	http://dx.doi.org/10.1038/79128			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973241				2022-12-25	WOS:000089078000011
J	Boyartchuk, VL; Broman, KW; Mosher, RE; D'Orazio, SEF; Starnbach, MN; Dietrich, W				Boyartchuk, VL; Broman, KW; Mosher, RE; D'Orazio, SEF; Starnbach, MN; Dietrich, W			Multigenic control of Listeria monocytogenes susceptibility in mice	NATURE GENETICS			English	Letter							INFECTIOUS-DISEASES; BACTERIAL-INFECTION; RESISTANCE	We have used a novel quantitative trait locus model to study the genetics of survival of F2 progeny of susceptible BALB/cByJ and resistant C57BL/6ByJ mice that have been infected with Listeria monocytogenes. This allowed us to map modifiers of L. monocytogenes susceptibility to chromosomes 5 and 13.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA; Faulkner Hosp, Dept Pathol, Jamaica Plain, MA USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Johns Hopkins University	Dietrich, W (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.		D'Orazio, Sarah E.F./AAI-3916-2020; D'Orazio, Sarah E.F./AAI-4968-2020	D'Orazio, Sarah E.F./0000-0003-0716-3518; Broman, Karl/0000-0002-4914-6671				Abel L, 1998, EMERG INFECT DIS, V4, P593, DOI 10.3201/eid0404.980409; CHEERS C, 1978, INFECT IMMUN, V19, P755, DOI 10.1128/IAI.19.3.755-762.1978; Dietrich WF, 2001, GENOME RES, V11, P325, DOI 10.1101/gr.173101; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; GERVAIS F, 1984, J IMMUNOL, V132, P2078; KRUGLYAK L, 1995, GENETICS, V139, P1421; LANDER ES, 1989, GENETICS, V121, P185; Lorber B, 1997, CLIN INFECT DIS, V24, P1, DOI 10.1093/clinids/24.1.1; Lynch M., 1998, GENETICS ANAL QUANTI; MANDEL TE, 1980, INFECT IMMUN, V30, P851; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; Qureshi ST, 1999, EMERG INFECT DIS, V5, P36, DOI 10.3201/eid0501.990105; SKAMENE E, 1985, CURR TOP MICROBIOL, V122, P128	13	64	65	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					259	260		10.1038/85812	http://dx.doi.org/10.1038/85812			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242105				2022-12-25	WOS:000167304200015
J	Gotta, M; Ahringer, J				Gotta, M; Ahringer, J			Distinct roles for G alpha and G beta gamma in regulating spindle position and orientation in Caenorhabditis elegans embryos	NATURE CELL BIOLOGY			English	Article							C-ELEGANS; G-PROTEINS; DIVISIONS; GRANULES; MOVEMENT; POLARITY; KINASE; PAR-1; LINE	Correct placement and orientation of the mitotic spindle is essential for segregation of localized components and positioning of daughter cells. Although these processes are important in many cells, few factors that regulate spindle placement are known. Previous work has shown that GPB-1, the G beta subunit of a heterotrimeric G protein, is required for orientation of early cell division axes in C. elegans embryos. Here we show that GOA-1 (a G alpha (0)) and the related GPA-16 are the functionally redundant Get subunits and that GPC-2 is the relevant G gamma subunit that is required for spindle orientation in the early embryo. We show that G alpha and G beta gamma are involved in controlling distinct microtubule-dependent processes. G beta gamma is important in regulating migration of the centrosome around the nucleus and hence in orientating the mitotic spindle. G alpha is required for asymmetric spindle positioning in the one-celled embryo.	Wellcome CRC Inst, Cambridge CB2 1QR, England		Ahringer, J (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Gotta, Monica/0000-0002-4336-7860; Ahringer, Julie/0000-0002-7074-4051	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Boyd L, 1996, DEVELOPMENT, V122, P3075; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL DP, 1990, DEVELOPMENT, V108, P159; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Park JH, 1997, GENE, V194, P183, DOI 10.1016/S0378-1119(97)00122-4; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	17	216	218	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					297	300		10.1038/35060092	http://dx.doi.org/10.1038/35060092			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231580				2022-12-25	WOS:000167365800017
J	Kirveskari, J; Vesaluoma, MH; Moilanen, JAO; Tervo, TMT; Petroll, MW; Linnolahti, E; Renkonen, R				Kirveskari, J; Vesaluoma, MH; Moilanen, JAO; Tervo, TMT; Petroll, MW; Linnolahti, E; Renkonen, R			A novel non-invasive, in vivo technique for the quantification of leukocyte rolling and extravasation at sites of inflammation in human patients	NATURE MEDICINE			English	Article							P-SELECTIN; IN-VIVO; CONFOCAL MICROSCOPY; ADHESION; LIGANDS; MICROVESSELS; TRAFFICKING; ENDOTHELIUM; REPERFUSION; REJECTION		Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland; Hlth Care Reg Helsinki & Uusimaa, HUCH, Diagnost Lab, Helsinki, Finland; Univ Helsinki, Dept Ophthalmol, Helsinki, Finland; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX USA	University of Helsinki; University of Helsinki; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Renkonen, R (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland.			Petroll, W. Matthew/0000-0003-0795-4539				Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; CAVANAGH HD, 1993, OPHTHALMOLOGY, V100, P1444; Chee SP, 1999, J CATARACT REFR SURG, V25, P1280, DOI 10.1016/S0886-3350(99)00161-3; Jung U, 1999, J IMMUNOL, V162, P6755; JUNG U, 1998, AM J PHYSIOL, V274, P1785; Li HF, 1997, CURR EYE RES, V16, P214, DOI 10.1076/ceyr.16.3.214.15412; Liu XW, 1999, J SURG RES, V87, P77, DOI 10.1006/jsre.1999.5725; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; Petroll WM, 1996, SCANNING, V18, P45, DOI 10.1002/sca.1996.4950180107; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sanz MJ, 1999, AM J PHYSIOL-HEART C, V277, pH1823, DOI 10.1152/ajpheart.1999.277.5.H1823; Toppila S, 1999, AM J PATHOL, V155, P1303, DOI 10.1016/S0002-9440(10)65232-7; Tsujikawa A, 1999, INVEST OPHTH VIS SCI, V40, P1183; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Veihelmann A, 1999, MICROCIRCULATION, V6, P281, DOI 10.1080/713773963; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303	21	28	28	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					376	379		10.1038/85538	http://dx.doi.org/10.1038/85538			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231641				2022-12-25	WOS:000167380400048
J	Sakai, T; Johnson, KJ; Murozono, M; Sakai, K; Magnuson, MA; Wieloch, T; Cronberg, T; Isshiki, A; Erickson, HP; Fassler, R				Sakai, T; Johnson, KJ; Murozono, M; Sakai, K; Magnuson, MA; Wieloch, T; Cronberg, T; Isshiki, A; Erickson, HP; Fassler, R			Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.	NATURE MEDICINE			English	Article							PLATELET-AGGREGATION; MICE LACKING; FIBRINOGEN; GENE; ADHESION; CELLS; BCL-2; LOCALIZATION; EXPRESSION; MIGRATION	Fibronectin performs essential roles in embryonic development and is prominently expressed during tissue repair. Two forms of fibronectin have been Identified: plasma fibronectin (pFn), which Is expressed by hepatocytes and secreted In soluble form into plasma; and cellular fibronectin (cFn), an insoluble form expressed locally by fibroblasts and other cell types and deposited and assembled into the extracellular matrix. To investigate the role of pFn in vivo, we generated pfn-deficient adult mice using Cre-loxP conditional gene-knockout technology. Here we show that pfn-deficient mice show increased neuronal apoptosis and larger Infarction areas following transient focal cerebral ischemia. However, pFn is dispensable for skin-wound healing and hemostasis.	Lund Univ, Dept Expt Pathol, Lund, Sweden; Lund Univ, Wallenberg Neurosci Ctr, Lund, Sweden; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Tokyo Med Univ, Dept Anesthesiol, Tokyo, Japan; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN USA	Lund University; Lund University; Brown University; Duke University; Tokyo Medical University; Vanderbilt University	Fassler, R (corresponding author), Lund Univ, Dept Expt Pathol, Lund, Sweden.	reinhard.fassler@pat.lu.se	Magnuson, Mark/AAY-7172-2021	Magnuson, Mark/0000-0002-8824-6499; Johnson, Kamin/0000-0003-4550-5566; Wieloch, Tadeusz/0000-0002-7669-2520	NCI NIH HHS [CA47056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BROWN LF, 1993, AM J PATHOL, V142, P793; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; Corbett SA, 1996, BLOOD, V88, P158; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DENO DC, 1983, AM J PHYSIOL, V245, pR564, DOI 10.1152/ajpregu.1983.245.4.R564; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; GARCIA JH, 1994, AM J PATHOL, V144, P188; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Globus RK, 1998, J CELL SCI, V111, P1385; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HARRISON P, 1989, J CLIN INVEST, V84, P1320, DOI 10.1172/JCI114300; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mosher DF, 1989, FIBRONECTIN; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; NIWA K, 1993, BLOOD, V82, P3658; OWENS MR, 1982, BLOOD, V59, P1305; PESCIOTTAPETERS DM, 1990, J CELL BIOL, V111, P249; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Schick PK, 1996, BLOOD, V87, P1817; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; TALTS JF, 1995, J CELL SCI, V108, P2153; WENCELDRAKE JD, 1985, BLOOD, V65, P929; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; Yamada KM, 2000, J CLIN INVEST, V105, P1507, DOI 10.1172/JCI10119; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	45	264	273	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					324	330		10.1038/85471	http://dx.doi.org/10.1038/85471			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231631				2022-12-25	WOS:000167380400038
J	D'Cruz, CM; Gunther, EJ; Boxer, RB; Hartman, JL; Sintasath, L; Moody, SE; Cox, JD; Ha, SI; Belka, GK; Golant, A; Cardiff, RD; Chodosh, LA				D'Cruz, CM; Gunther, EJ; Boxer, RB; Hartman, JL; Sintasath, L; Moody, SE; Cox, JD; Ha, SI; Belka, GK; Golant, A; Cardiff, RD; Chodosh, LA			c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations	NATURE MEDICINE			English	Article							TRANSGENIC MICE; ORNITHINE DECARBOXYLASE; BREAST CARCINOMAS; HA-RAS; EXPRESSION; ONCOGENE; GENE; CELLS; DIFFERENTIATION; ACTIVATION	Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood(1,2). We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ros family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.	Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of California System; University of California Davis	Chodosh, LA (corresponding author), Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA.							ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BOS JL, 1990, CANCER RES, V50, P1352; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUERIN M, 1988, ONCOGENE RES, V3, P21; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NISHIKURA K, 1988, ONCOGENE, V2, P493; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENA A, 1993, J BIOL CHEM, V268, P27277; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; VARLEY JM, 1987, ONCOGENE, V1, P423; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	24	326	334	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					235	239		10.1038/84691	http://dx.doi.org/10.1038/84691			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175856				2022-12-25	WOS:000166756300042
J	Di Palma, F; Holme, RH; Bryda, EC; Belyantseva, IA; Pellegrino, R; Kachar, B; Steel, KP; Noben-Trauth, K				Di Palma, F; Holme, RH; Bryda, EC; Belyantseva, IA; Pellegrino, R; Kachar, B; Steel, KP; Noben-Trauth, K			Mutations in Cdh23, encoding a new type of cadherin, cause stereocilia disorganization in waltzer, the mouse model for Usher syndrome type 1D	NATURE GENETICS			English	Article							MYOSIN VIIA; GENE; MICE; IDENTIFICATION; DEAFNESS; CHROMOSOME-10; LOCALIZATION; ALLELE; ROLES; CA2+	Mouse chromosome 10 harbors several loci associated with hearing loss, including waltzer (v), modifier-of deaf waddler (mdfw) and Age-related hearing loss(1) (Ahl). The human region that is orthologous to the mouse 'waltzer' region is located at 10q21-q22 and contains the human deafness loci DFNB12 and USH1D (refs. 2,3). Numerous mutations at the waltzer locus have been documented causing erratic circling and hearing loss(4-7). Here we report the identification of a new gene mutated in v. The 10.5-kb Cdh23 cDNA encodes a very large, single-pass transmembrane protein, that we have called otocadherin. It has an extracellular domain that contains 27 repeats; these show significant homology to the cadherin ectodomain. In v(6J), a GT transversion creates a premature stop codon. In v(Alb), a Cr exchange generates an ectopic donor splice site, effecting deletion of 119 nucleotides of exonic sequence. In v(2J), a GA transition abolishes the donor splice site, leading to aberrant splice forms. All three alleles are predicted to cause loss of function. We demonstrate Cdh23 expression in the neurosensory epithelium and show that during early hair-cell differentiation, stereocilia organization is disrupted in v(2J) homozygotes. Our data indicate that otocadherin is a critical component of hair bundle formation. Mutations in human CDH23 cause Usher syndrome type 1D and thus, establish waltzer as the mouse model for USH1D.	Natl Inst Deafness & Other Commun Disorders, Sect Murine Genet, Genet Mol Lab, NIH, Rockville, MD USA; Natl Inst Deafness & Other Commun Disorders, Lab Cellular Biol, NIH, Rockville, MD USA; MRC, Inst Hearing Res, Nottingham, England; Marshall Univ, Sch Med, Dept Immunol & Mol Genet, Huntington, WV USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Marshall University	Noben-Trauth, K (corresponding author), Natl Inst Deafness & Other Commun Disorders, Sect Murine Genet, Genet Mol Lab, NIH, Rockville, MD USA.	nobentk@nidcd.nih.gov		Di-Palma, Federica/0000-0002-4394-0102	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC003771, Z01DC000002, Z01DC000036, ZIADC000002] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC03771] Funding Source: Medline; PHS HHS [DZ 00036-04] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; BOLZ H, 2000, NAT GENET, V27, P105; Bryda EC, 1997, MAMM GENOME, V8, P1, DOI 10.1007/s003359900336; Chaib H, 1996, HUM MOL GENET, V5, P1061, DOI 10.1093/hmg/5.7.1061; DEOL MS, 1956, J EMBRYOL EXP MORPH, V4, P190; DEOL MS, 1956, PROC R SOC SER B-BIO, V145, P206, DOI 10.1098/rspb.1956.0028; FLAHERTY L, 1992, P NATL ACAD SCI USA, V89, P2859, DOI 10.1073/pnas.89.7.2859; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HUNTERDUVAR IM, 1978, ACTA OTO-LARYNGOL, P3; Johnson KR, 1997, HEARING RES, V114, P83, DOI 10.1016/S0378-5955(97)00155-X; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Liu XR, 1999, J NEUROSCI, V19, P6267; *MGD, 2000, MOUS GEN INF PROJ; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Rost B, 1996, METHOD ENZYMOL, V266, P525; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Self T, 1998, DEVELOPMENT, V125, P557; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; Suzuki ST, 1996, J CELL SCI, V109, P2609; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; Yagi T, 2000, GENE DEV, V14, P1169; Yamoah EN, 1998, J NEUROSCI, V18, P610; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yonezawa S, 1999, HEARING RES, V134, P116, DOI 10.1016/S0378-5955(99)00080-5	29	331	339	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					103	107		10.1038/83660	http://dx.doi.org/10.1038/83660			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138008				2022-12-25	WOS:000166187900025
J	Stevenson, VA; Kramer, J; Kuhn, J; Theurkauf, WE				Stevenson, VA; Kramer, J; Kuhn, J; Theurkauf, WE			Centrosomes and the Scrambled protein coordinate microtubule-independent actin reorganization	NATURE CELL BIOLOGY			English	Article							DROSOPHILA EMBRYOS; SYNCYTIAL BLASTODERM; INSERTIONAL MUTAGENESIS; EARLY EMBRYOGENESIS; F-ACTIN; CYTOSKELETON; MIGRATION; CLEAVAGE; NUCLEAR; ORGANIZATION	In Drosophila syncytial blastoderm embryos, centrosomes specify the position of actin-based interphase caps and mitotic furrows. Mutations in the scrambled locus prevent assembly of mitotic furrows, but do not block actin cap formation. The scrambled gene encodes a protein that localizes to the mitotic furrows and centrosomes, Seed localization, actin reorganization from caps into mitotic furrows, and centrosome-coordinated assembly of actin caps are not blocked by microtubule disruption. Our results indicate that centrosomes may coordinate assembly of cortical actin caps through a microtubule-independent mechanism, and that Scrambled mediates a second microtubule-independent process that drives mitotic furrow assembly.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA; SUNY Stony Brook, Dept Cell Biol & Biochem, Stony Brook, NY 11794 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Theurkauf, WE (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	william.theurkauf@umassmed.edu		Theurkauf, William/0000-0001-7342-1912				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Balasubramanian MK, 2000, J CELL SCI, V113, P1503; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CALLAINI G, 1992, BIOL CELL, V74, P249, DOI 10.1016/0248-4900(92)90035-Y; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; Foe V. E., 1993, MITOSIS MORPHOGENESI; Foe VE, 2000, DEVELOPMENT, V127, P1767; FOE VE, 1983, J CELL SCI, V61, P31; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hales KG, 1999, CURR OPIN CELL BIOL, V11, P717, DOI 10.1016/S0955-0674(99)00042-3; Harlow E., 1999, USING ANTIBODIES LAB; HARTWELL LH, 1991, GENETICS, V129, P975; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; LONCAR D, 1995, P NATL ACAD SCI USA, V92, P2199, DOI 10.1073/pnas.92.6.2199; Megraw TL, 1999, DEVELOPMENT, V126, P2829; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; RAPPAPORT R, 1961, J EXP ZOOL, V148, P81, DOI 10.1002/jez.1401480107; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Rothwell WF, 1999, J CELL SCI, V112, P2885; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Small JV, 1999, FEBS LETT, V452, P96, DOI 10.1016/S0014-5793(99)00530-X; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; Theurkauf WE, 1999, METHOD CELL BIOL, V61, P317; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; Vaizel-Ohayon D, 1999, CURR BIOL, V9, P889, DOI 10.1016/S0960-9822(99)80393-5; VONDASSOW G, 1994, J CELL BIOL, V127, P1637, DOI 10.1083/jcb.127.6.1637; VONDASSOW G, 1995, J CELL BIOL, V130, P1231; WARN RM, 1984, J CELL BIOL, V98, P156, DOI 10.1083/jcb.98.1.156; WARN RM, 1986, J CELL SCI, P311; WARN RM, 1985, J CELL BIOL, V100, P1010, DOI 10.1083/jcb.100.4.1010; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; Zhang CX, 1996, J CELL BIOL, V134, P923, DOI 10.1083/jcb.134.4.923	40	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					68	75		10.1038/35050579	http://dx.doi.org/10.1038/35050579			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146628				2022-12-25	WOS:000166146400022
J	Le Stunff, C; Fallin, D; Schork, NJ; Bougneres, P				Le Stunff, C; Fallin, D; Schork, NJ; Bougneres, P			The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity	NATURE GENETICS			English	Article							DIABETES SUSCEPTIBILITY; LOCUS; MINISATELLITE; SECRETION; MELLITUS; WEIGHT; REGION; IDDM2	In millions of people, obesity leads to type 2 diabetes (T2D; also known as non-insulin-dependent diabetes mellitus(1)). During the early stages of juvenile obesity, the increase of insulin secretion in proportion to accumulated fat balances insulin resistance and protects patients from hyperglycaemia(2). After several decades, however, beta -cell function deteriorates and T2D develops in approximately 20% of obese patients(3,4). In modern societies, obesity has thus become the leading risk factor for T2D (ref. 5). The factors that predispose obese patients to alteration of insulin secretion upon gaining weight remain unknown. To determine which genetic factors predispose obese patients to beta -cell dysfunction, and possibly T2D, we studied single-nucleotide polymorphisms (SNPs) in the region of the insulin gene (INS) among 615 obese children. We found that, in the early phase of obesity, alleles of the INS variable number of tandem repeat (VNTR) locus are associated with different effects of body fatness on insulin secretion. Young obese patients homozygous for class I VNTR alleles secrete more insulin than those with other genotypes.	Hop St Vincent de Paul, Dept Pediat Endocrinol, F-75674 Paris, France; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Genset Corp, La Jolla, CA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Case Western Reserve University; Harvard University; Harvard T.H. Chan School of Public Health	Bougneres, P (corresponding author), Hop St Vincent de Paul, Dept Pediat Endocrinol, F-75674 Paris, France.		LE STUNFF, CATHERINE/Y-3270-2018	LE STUNFF, CATHERINE/0000-0001-8419-0451; Schork, Nicholas/0000-0003-0920-5013				Ahmed S, 1999, DIABETIC MED, V16, P910, DOI 10.1046/j.1464-5491.1999.00169.x; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Brancati FL, 1999, ARCH INTERN MED, V159, P957, DOI 10.1001/archinte.159.9.957; CARMELLI D, 1994, AM J HUM GENET, V55, P566; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Eaves IA, 1999, NAT GENET, V22, P324, DOI 10.1038/11890; Fallin D, 2000, AM J HUM GENET, V67, P947, DOI 10.1086/303069; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Huxtable SJ, 2000, DIABETES, V49, P126, DOI 10.2337/diabetes.49.1.126; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KARAM JH, 1963, DIABETES, V12, P197, DOI 10.2337/diab.12.3.197; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; LESTUNFF C, 1994, DIABETES, V43, P696, DOI 10.2337/diabetes.43.5.696; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Ong KKL, 1999, NAT GENET, V21, P262, DOI 10.1038/6775; OWERBACH D, 1982, LANCET, V1, P880; PEDERSEN P, 1989, DIABETES METAB REV, V5, P505; PERMUTT MA, 1985, DIABETES, V34, P311, DOI 10.2337/diabetes.34.4.311; Snieder H, 1999, GENET EPIDEMIOL, V16, P426, DOI 10.1002/(SICI)1098-2272(1999)16:4<426::AID-GEPI8>3.3.CO;2-2; WEAVER H, 1992, PHYS WORLD, V5, P22, DOI 10.1088/2058-7058/5/11/23	23	128	133	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					444	446		10.1038/82579	http://dx.doi.org/10.1038/82579			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101842				2022-12-25	WOS:000165671700017
J	Chausovsky, A; Bershadsky, AD; Borisy, GG				Chausovsky, A; Bershadsky, AD; Borisy, GG			Cadherin-mediated regulation of microtubule dynamics	NATURE CELL BIOLOGY			English	Article							INTERCELLULAR ADHERENS JUNCTIONS; BETA-CATENIN; SIGNAL-TRANSDUCTION; LIVING CELLS; ADHESION; CENTROSOME; ORGANIZATION; CYTOSKELETON; INVOLVEMENT; NUCLEATION	Epithelial polarization and neuronal outgrowth require the assembly of microtubule arrays that are not associated with centrosomes. As these processes generally involve contact interactions mediated by cadherins, we investigated the potential role of cadherin signalling in the stabilization of non-centrosomal microtubules. Here we show that expression of cadherins in centrosome-free cytoplasts increases levels of microtubule polymer and changes the behaviour of microtubules from treadmilling to dynamic instability. This effect is not a result of cadherin expression per se but depends on the formation of cell-cell contacts. The effect of cell-cell contacts is mimicked by application of beads coated with stimulatory anti-cadherin antibody and is suppressed by overexpression of the cytoplasmic cadherin tail. We therefore propose that cadherins initiate a signalling pathway that alters microtubule organization by stabilizing microtubule ends.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	University of Wisconsin System; University of Wisconsin Madison; Weizmann Institute of Science	Chausovsky, A (corresponding author), Univ Wisconsin, Mol Biol Lab, 1525 Linden Dr, Madison, WI 53706 USA.	ggborisy@facstaff.wisc.edu		Borisy, Gary/0000-0002-0266-8018; Bershadsky, Alexander/0000-0002-9571-7375	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025062, R01GM025062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; BAAS PW, 1992, J CELL BIOL, V116, P1231, DOI 10.1083/jcb.116.5.1231; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BRAY D, 1981, J NEUROCYTOL, V10, P589, DOI 10.1007/BF01262592; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; Kaufmann U, 1999, J CELL SCI, V112, P55; Keating TJ, 2000, NAT CELL BIOL, V2, P352, DOI 10.1038/35014045; Keating TJ, 1999, BIOL CELL, V91, P321, DOI 10.1016/S0248-4900(99)80093-8; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Knudsen KA, 1998, J CELL BIOCHEM, P168; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Levenberg S, 1998, J CELL SCI, V111, P347; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; Margolis RL, 1998, BIOESSAYS, V20, P830, DOI 10.1002/(SICI)1521-1878(199810)20:10<830::AID-BIES8>3.0.CO;2-N; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Moritz M, 2000, NAT CELL BIOL, V2, P365, DOI 10.1038/35014058; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; MUNEMITSU S, 1994, CANCER RES, V54, P3676; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; VOLK T, 1984, EMBO J, V3, P2249, DOI 10.1002/j.1460-2075.1984.tb02123.x; WADSWORTH P, 1990, J CELL SCI, V95, P23; Wiese C, 2000, NAT CELL BIOL, V2, P358, DOI 10.1038/35014051; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YU WQ, 1993, J CELL BIOL, V122, P349, DOI 10.1083/jcb.122.2.349; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	50	119	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					797	804		10.1038/35041037	http://dx.doi.org/10.1038/35041037			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056534				2022-12-25	WOS:000165207500013
J	Esser, D; Amanuma, H; Yoshiki, A; Kusakabe, M; Rudolph, R; Bohm, G				Esser, D; Amanuma, H; Yoshiki, A; Kusakabe, M; Rudolph, R; Bohm, G			A hyperthermostable bacterial histone-like protein as an efficient mediator for transfection of eukaryotic cells	NATURE BIOTECHNOLOGY			English	Article							DNA-BINDING PROTEIN; GENE-TRANSFER; MAMMALIAN-CELLS; THERMOTOGA-MARITIMA; DELIVERY; PEPTIDE; PURIFICATION; FUSION; HU	Gene delivery has shown potential in a variety of applications, including basic research, therapies for inborn genetic defects, cancer, AIDS, tissue engineering(1,2), and vaccination(3). Most available systems have serious drawbacks, such as safety hazards(4), inefficiency under in vivo-like conditions, and expensive production. When using naked DNA(2,5), for instance, a large amount of ultrapure DNA has to be applied as a result of degradation by nucleases(6). Similarly, the use of eukaryotic histones(7,8), synthetic peptides, or peptide nucleic acids(9,10) may be limited by high production costs. We have demonstrated a biotechnologically feasible and economical approach for gene delivery using the histone-like protein from the hyperthermostable eubacterium Thermotoga maritima, TmHU11,12 as an efficient gene transfer reagent. HU can be easily isolated from recombinant Escherichia coli, is extraordinarily stable, and protects dsDNA from thermal denaturation(12). This study demonstrates its use as an inexpensive tool for gene delivery.	Univ Halle Wittenberg, Inst Biotechnol, Halle, Germany; RIKEN, Tsukuba Inst, Mol Cell Sci Lab, Tsukuba, Ibaraki, Japan; RIKEN, Tsukuba Inst, Div Expt Anim Res, Tsukuba, Ibaraki, Japan; ACGT ProGenom AG, Halle, Germany	Martin Luther University Halle Wittenberg; RIKEN; RIKEN	Esser, D (corresponding author), AdProTech Ltd, Unit 3, Prot Funct Grp, 2 Orchard Rd, Royston SG8 5HD, Herts, England.		Kusakabe, Minoru/Q-3258-2019; Yoshiki, Atsushi/O-6162-2019	Yoshiki, Atsushi/0000-0002-9450-5151				Barry ME, 1999, HUM GENE THER, V10, P2461, DOI 10.1089/10430349950016816; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; Boussif O, 1996, GENE THER, V3, P1074; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Christodoulou E, 1998, ACTA CRYSTALLOGR D, V54, P1043, DOI 10.1107/S0907444998000341; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Esser D, 1999, J MOL BIOL, V291, P1135, DOI 10.1006/jmbi.1999.3022; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Subramanian A, 1999, NAT BIOTECHNOL, V17, P873, DOI 10.1038/12860; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Zaitsev SV, 1997, GENE THER, V4, P586, DOI 10.1038/sj.gt.3300433	17	13	17	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1211	1213		10.1038/81221	http://dx.doi.org/10.1038/81221			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062444				2022-12-25	WOS:000165176600031
J	Giannakakou, P; Sackett, DL; Ward, Y; Webster, KR; Blagosklonny, MV; Fojo, T				Giannakakou, P; Sackett, DL; Ward, Y; Webster, KR; Blagosklonny, MV; Fojo, T			p53 is associated with cellular microtubules and is transported to the nucleus by dynein	NATURE CELL BIOLOGY			English	Article							WILD-TYPE P53; PROTEIN; CANCER; CELLS; GENE; ONCOPROTEIN; CENTROSOME; DOMAIN; POLYMERIZATION; DEGRADATION	Here we show that p53 protein is physically associated with tubulin in vivo and in vitro, and that it localizes to cellular microtubules. Treatment with vincristine or paclitaxel before DNA-damage or before leptomycin B treatment reduces nuclear accumulation of p53 and expression of mdm2 and p21. Overexpression of dynamitin or microinjection of anti-dynein antibody before DNA damage abrogates nuclear accumulation of p53. Our results indicate that transport of p53 along microtubules is dynein-dependent. The first 25 amino acids of p53 contain the residues that are essential for binding to microtubules. We propose that functional microtubules and the dynein motor protein participate in transport of p53 and facilitate its accumulation in the nucleus after DNA damage.	NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Integrat & Med Biophys, NIH, Bethesda, MD 20892 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol Drug Discovery, Princeton, NJ 08543 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Bristol-Myers Squibb	Giannakakou, P (corresponding author), NCI, Med Branch, Div Clin Sci, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Balczon R, 1999, CELL MOTIL CYTOSKEL, V42, P60, DOI 10.1002/(SICI)1097-0169(1999)42:1<60::AID-CM6>3.0.CO;2-7; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KASTAN MB, 1991, CANCER RES, V51, P6304; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Magnelli L, 1997, BIOCHEM MOL MED, V62, P3, DOI 10.1006/bmme.1997.2616; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sackett D L, 1991, Protein Expr Purif, V2, P390, DOI 10.1016/1046-5928(91)90099-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wolff J, 1996, PROTEIN SCI, V5, P2020, DOI 10.1002/pro.5560051008	46	301	309	0	33	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					709	717		10.1038/35036335	http://dx.doi.org/10.1038/35036335			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025661				2022-12-25	WOS:000089697000016
J	Schnitzer, MJ; Visscher, K; Block, SM				Schnitzer, MJ; Visscher, K; Block, SM			Force production by single kinesin motors	NATURE CELL BIOLOGY			English	Article							STIMULATED ATP HYDROLYSIS; DIMERIC KINESIN; OPTICAL TRAPS; MOLECULES; MECHANICS; MOVEMENT; MICROTUBULES; PROTEIN; PATHWAY; DOMAINS	Motor proteins such as kinesin, myosin and polymerase convert chemical energy into work through a cycle that involves nucleotide hydrolysis. Kinetic rates in the cycle that depend upon load identify transitions at which structural changes, such as power strokes or diffusive motions, are likely to occur. Here we show, by modelling data obtained with a molecular force clamp, that kinesin mechanochemistry can be characterized by a mechanism in which a load-dependent isomerization follows ATP binding. This model quantitatively accounts for velocity data over a wide range of loads and ATP levels, and indicates that movement may be accomplished through two sequential 4-nm substeps. Similar considerations account for kinesin processivity, which is found to obey a load-dependent Michaelis-Menten relationship.	Univ Arizona, Dept Phys, Tucson, AZ 85721 USA; Bell Labs, Lucent Technol, Biol Computat Res Dept, Murray Hill, NJ 07974 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Arizona; Alcatel-Lucent; Lucent Technologies; AT&T; University of Arizona; Stanford University; Stanford University	Visscher, K (corresponding author), Univ Arizona, Dept Phys, Tucson, AZ 85721 USA.							Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hille B., 1992, IONIC CHANNELS EXCIT; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1995, BIOPHYS J, V68, pS245; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Nishiyama M, 2000, BIOPHYS J, V78, p122A; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902	38	442	452	0	74	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					718	723		10.1038/35036345	http://dx.doi.org/10.1038/35036345			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025662				2022-12-25	WOS:000089697000017
J	Wei, YQ; Wang, QR; Zhao, X; Yang, L; Tian, L; Lu, Y; Kang, B; Lu, CJ; Huang, MJ; Lou, YY; Xiao, F; He, QM; Shu, JM; Xie, XJ; Mao, YQ; Lei, S; Luo, F; Zhou, LQ; Liu, CE; Zhou, H; Jiang, Y; Peng, F; Yuan, LP; Li, Q; Wu, Y; Liu, JY				Wei, YQ; Wang, QR; Zhao, X; Yang, L; Tian, L; Lu, Y; Kang, B; Lu, CJ; Huang, MJ; Lou, YY; Xiao, F; He, QM; Shu, JM; Xie, XJ; Mao, YQ; Lei, S; Luo, F; Zhou, LQ; Liu, CE; Zhou, H; Jiang, Y; Peng, F; Yuan, LP; Li, Q; Wu, Y; Liu, JY			Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine	NATURE MEDICINE			English	Article							GROWTH-FACTOR; T-CELLS; GENE-THERAPY; BINDING-SITE; IN-VIVO; ANGIOGENESIS; RECEPTOR; IDENTIFICATION; ANTIGENS; VEGF	The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.	W China Univ Med Sci, Sichuan Univ, HuaXi Sch Med, Univ Hosp 1,Ctr Biotherapy Canc, Chengdu 610041, Sichuan, Peoples R China; W China Univ Med Sci, Sichuan Univ, Sch Med, Univ Hosp 1,Ctr Canc, Chengdu 610041, Sichuan, Peoples R China; W China Univ Med Sci, Sichuan Univ, HuaXi Med Sch, Univ Hosp 2,Dept Gynecol & Obstet, Chengdu 610041, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Wei, YQ (corresponding author), W China Univ Med Sci, Sichuan Univ, HuaXi Sch Med, Univ Hosp 1,Ctr Biotherapy Canc, Guo Xue Xiang 37, Chengdu 610041, Sichuan, Peoples R China.			Wei, Yu-quan/0000-0002-6211-3217				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BARTH RJ, 1990, J IMMUNOL, V144, P1531; Beekhuizen H, 1997, J IMMUNOL, V158, P774; Bicknell R, 1997, TUMOUR ANGIOGENESIS, P19; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; De Silva HD, 1998, IMMUNOLOGY, V93, P405; DJAFFAR I, 1994, BIOCHEM J, V300, P69, DOI 10.1042/bj3000069; Eichmann A, 1996, GENE, V174, P3, DOI 10.1016/0378-1119(96)00159-X; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HANAHAN D, 1996, J NATL CANCER I, V88, P1091; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kumar V, 1996, J EXP MED, V184, P1609, DOI 10.1084/jem.184.5.1609; Lin ECK, 1998, CELL ADHES COMMUN, V6, P451, DOI 10.3109/15419069809010794; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SMITH JW, 1990, J BIOL CHEM, V265, P2168; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEI YQ, 1994, CANCER RES, V54, P4952; Wei YQ, 1996, CANCER RES, V56, P1104; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yeh CH, 1999, EXP CELL RES, V251, P57, DOI 10.1006/excr.1999.4560; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	46	211	255	0	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1160	1166		10.1038/80506	http://dx.doi.org/10.1038/80506			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017149				2022-12-25	WOS:000089674700042
J	Hanke, T; McMichael, AJ				Hanke, T; McMichael, AJ			Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.	NATURE MEDICINE			English	News Item							CYTOTOXIC T-LYMPHOCYTES; IMMUNODEFICIENCY-VIRUS TYPE-1; CELL RESPONSES; EFFECTIVE INDUCTION; BETA-CHEMOKINES; EPITOPES; ANKARA; CTL; WORKERS; IMMUNOGENICITY		John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England	University of Oxford	Hanke, T (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.							Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Blank RR, 1998, INT J WILDLAND FIRE, V8, P79, DOI 10.1071/WF9980079; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CALLAHAN LF, 1995, ARTHRIT CARE RES, V8, P1; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; Dorrell L, 1999, J VIROL, V73, P1708, DOI 10.1128/JVI.73.2.1708-1714.1999; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Gahery-Segard H, 2000, J VIROL, V74, P1694, DOI 10.1128/JVI.74.4.1694-1703.2000; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hanke T, 1998, VACCINE, V16, P426, DOI 10.1016/S0264-410X(97)00296-X; Hanke T, 1999, IMMUNOL LETT, V66, P177, DOI 10.1016/S0165-2478(98)00164-3; Hanke T, 1999, VACCINE, V17, P589, DOI 10.1016/S0264-410X(98)00238-2; Hanke T, 1998, J GEN VIROL, V79, P83, DOI 10.1099/0022-1317-79-1-83; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; KALAMS SA, 1999, J VIROL, V73, P6175; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; MAYR A, 1974, INFECTION, V2, P64, DOI 10.1007/BF01642023; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 1999, NAT MED, V5, P612, DOI 10.1038/9455; Moss B, 1996, Adv Exp Med Biol, V397, P7; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; Ogg GS, 1998, AIDS, V12, P1561, DOI 10.1097/00002030-199812000-00026; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Seth A, 1998, P NATL ACAD SCI USA, V95, P10112, DOI 10.1073/pnas.95.17.10112; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; Thompson JL, 1998, INT J SPORT NUTR, V8, P160, DOI 10.1123/ijsn.8.2.160; THOMSON SA, 1995, P NATL ACAD SCI USA, V92, P5845, DOI 10.1073/pnas.92.13.5845; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; Williams SG, 1998, NUCLEIC ACIDS RES, V26, P2120, DOI 10.1093/nar/26.9.2120; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997	45	162	171	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					951	955		10.1038/79626	http://dx.doi.org/10.1038/79626			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973301				2022-12-25	WOS:000089190500015
J	Lin, YP; Ma, WL; Benchimol, S				Lin, YP; Ma, WL; Benchimol, S			Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis	NATURE GENETICS			English	Article							TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; ADAPTER MOLECULE; CELL-DEATH; INTERACTS; TRANSFORMATION; IDENTIFICATION; INHIBITION; MOTIF; RIP	The p53 tumour suppressor promotes cell-cycle arrest or apoptosis in response to cellular stress, such as DNA damage and oncogenesis. This role of p53 is important for its tumour-suppression function(1) and depends, at least in part, on its ability to bind to specific DNA sequences and activate the transcription of target genes(2-4). The pathway through which p53 promotes apoptosis is not fully understood. Here we describe a new gene regulated by p53 that encodes a predicted protein of 915 amino acids in mice (910 amino acids in humans), which we have named Pidd. The mouse Pidd cDNA contains a p53 consensus DNA binding sequence upstream of the Pidd-coding region. This sequence element bound to p53 and conferred p53-dependent inducibility on a heterologous reporter gene. Moreover, Pidd RNA was induced by ionizing radiation in a p53-dependent manner and the basal level of Pidd RNA was dependent on Trp53 status. Overexpression of Pidd inhibited cell growth in a p53-like manner by inducing apoptosis. Antisense inhibition of Pidd expression attenuated p53-mediated apoptosis. Our data suggest that Pidd is an effector of p53-dependent apoptosis.	Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, 500 Sherbourne St, Toronto, ON, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Ahmad M, 1997, CANCER RES, V57, P615; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1018; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FU L, 1966, EMBO J, V15, P4392; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Mathews DH, 1999, RNA, V5, P1458, DOI 10.1017/S1355838299991148; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1	26	264	275	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					122	125		10.1038/79102	http://dx.doi.org/10.1038/79102			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973264				2022-12-25	WOS:000089078000033
J	Jerome, LA; Papaioannou, VE				Jerome, LA; Papaioannou, VE			DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1	NATURE GENETICS			English	Letter							SYNDROME CANDIDATE GENE; CARDIO-FACIAL SYNDROME; MOUSE DEVELOPMENT; SYNDROME REGION; 22Q11 DELETION; NEURAL CREST; DEFICIENT; DEFECTS; HIRA; EXPRESSION	The DiGeorge/velocardiofacial syndrome (DGS/VCFS) is a relatively common human disorder, usually associated with deletions of chromosome 22q11. The genetic basis for the wide range of developmental anomalies in the heart. glands and facial structures has been elusive. We have investigated the potential role of one candidate gene, Tbx1, which encodes a transcription factor of the T-box family, by producing a null mutation in mice. We found that mice heterozygous for the mutation had a high incidence of cardiac outflow tract anomalies, thus modeling one of the major abnormalities of the human syndrome. Moreover, Tbx1(-/-) mice displayed a wide range of developmental anomalies encompassing almost all of the common DGS/VCFS features, including hypoplasia of the thymus and parathyroid glands, cardiac outflow tract abnormalities, abnormal facial structures, abnormal vertebrae and cleft palate. On the basis of this phenotype in mice, we propose that TBX1 in humans is a key gene in the etiology of DGS/VCFS.	Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Papaioannou, VE (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.			Papaioannou, Virginia/0000-0001-7558-8601	NICHD NIH HHS [HD33082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD033082] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chieffo C, 1997, GENOMICS, V43, P267, DOI 10.1006/geno.1997.4829; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Epstein JA, 2000, DEVELOPMENT, V127, P1869; Farrell MJ, 1999, CIRC RES, V84, P127, DOI 10.1161/01.RES.84.2.127; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; GOLDBERG R, 1993, AM J MED GENET, V45, P313, DOI 10.1002/ajmg.1320450307; GOODSHIP J, 1995, J MED GENET, V32, P746, DOI 10.1136/jmg.32.9.746; Hogan B, 1994, MANIPULATING MOUSE E; Kimber WL, 1999, HUM MOL GENET, V8, P2229, DOI 10.1093/hmg/8.12.2229; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; Mallo M, 1997, DEV DYNAM, V210, P146, DOI 10.1002/(SICI)1097-0177(199710)210:2<146::AID-AJA7>3.0.CO;2-G; McDonald-McGinn DM, 1997, GENET TEST, V1, P99, DOI 10.1089/gte.1997.1.99; MCLEAN SD, 1993, AM J DIS CHILD, V147, P1212; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; Puech A, 2000, P NATL ACAD SCI USA, V97, P10090, DOI 10.1073/pnas.97.18.10090; Roberts C, 1997, HUM MOL GENET, V6, P237, DOI 10.1093/hmg/6.2.237; Saint-Jore B, 1998, HUM MOL GENET, V7, P1841, DOI 10.1093/hmg/7.12.1841; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; Wakamiya M, 1997, COLD SPRING HARB SYM, V62, P145, DOI 10.1101/SQB.1997.062.01.019; Wakamiya M, 1998, HUM MOL GENET, V7, P1835, DOI 10.1093/hmg/7.12.1835; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; Wilming LG, 1997, HUM MOL GENET, V6, P247, DOI 10.1093/hmg/6.2.247; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158	29	760	774	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					286	291		10.1038/85845	http://dx.doi.org/10.1038/85845			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242110				2022-12-25	WOS:000167304200020
J	Pabst, T; Mueller, BU; Zhang, P; Radomska, HS; Narravula, S; Schnittger, S; Behre, G; Hiddemann, W; Tenen, DG				Pabst, T; Mueller, BU; Zhang, P; Radomska, HS; Narravula, S; Schnittger, S; Behre, G; Hiddemann, W; Tenen, DG			Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP alpha), in acute myeloid leukemia	NATURE GENETICS			English	Letter							CELL-PROLIFERATION; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION; TRANSLATION; EPSILON; GENE; SUFFICIENT; ACTIVATION; PRODUCT	The transcription factor C/EBP alpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBP alpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBP alpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner. and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia. and such mutations are likely to induce the differentiation block found in AML.	Harvard Univ, Sch Med, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA; Univ Munich, Dept Med 3, Munich, Germany	Harvard University; Harvard Medical School; University of Munich	Tenen, DG (corresponding author), Harvard Univ, Sch Med, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA.	dtenen@caregroup.harvard.edu		Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [P01CA072009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NCI NIH HHS [CA72009] Funding Source: Medline; NHLBI NIH HHS [HL56745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An MR, 1996, MOL CELL BIOL, V16, P2295; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HENDRICKSTAYLOR LR, 1992, GENOMICS, V14, P12, DOI 10.1016/S0888-7543(05)80276-9; Koike M, 1997, LEUKEMIA RES, V21, P833, DOI 10.1016/S0145-2126(97)00072-6; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PAHL HL, 1991, EXP HEMATOL, V19, P1038; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SCOTT LM, 1992, BLOOD, V80, P1725; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Watkins PJ, 1996, CANCER RES, V56, P1063; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	32	703	728	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					263	270		10.1038/85820	http://dx.doi.org/10.1038/85820			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242107				2022-12-25	WOS:000167304200017
J	Strohman, RC				Strohman, RC			Genomics and human life span - what's left to extend?	NATURE BIOTECHNOLOGY			English	Editorial Material							ORGANIZATION		Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Strohman, RC (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 229 Stanley Hall 3206, Berkeley, CA 94720 USA.							Fell DA, 2000, NAT BIOTECHNOL, V18, P1121, DOI 10.1038/81025; Forrester J.W., 1969, URBAN DYNAMICS; Horiuchi S, 2000, NATURE, V405, P744, DOI 10.1038/35015642; Horrobin DF, 2000, J ROY SOC MED, V93, P341, DOI 10.1177/014107680009300702; Jackson W., 1996, NATIVE THIS PLACE; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Strohman RC, 2000, NAT BIOTECHNOL, V18, P575, DOI 10.1038/76317; TSAI SP, 1978, AM J PUBLIC HEALTH, V68, P966, DOI 10.2105/AJPH.68.10.966; Tuljapurkar S, 2000, NATURE, V405, P789, DOI 10.1038/35015561; 1999, BIOESSAYS, V21, P983	10	7	7	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					195	195		10.1038/85611	http://dx.doi.org/10.1038/85611			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231538	Bronze			2022-12-25	WOS:000167283100010
J	Tamatani, M; Matsuyama, T; Yamaguchi, A; Mitsuda, N; Tsukamoto, Y; Taniguchi, M; Che, YH; Ozawa, K; Hori, O; Nishimura, H; Yamashita, A; Okabe, M; Yanagi, H; Stern, DM; Ogawa, S; Tohyama, M				Tamatani, M; Matsuyama, T; Yamaguchi, A; Mitsuda, N; Tsukamoto, Y; Taniguchi, M; Che, YH; Ozawa, K; Hori, O; Nishimura, H; Yamashita, A; Okabe, M; Yanagi, H; Stern, DM; Ogawa, S; Tohyama, M			ORP150 protects against hypoxia/ischemia-induced neuronal death	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; NF-KAPPA-B; ENDOPLASMIC-RETICULUM; NEUROTROPHIC FACTOR; CYTOCHROME-C; RAT-BRAIN; EXPRESSION; INDUCTION	Oxygen-regulated protein 150 kD (ORP150) is a novel endoplasmic-reticulum-associated chaperone induced by hypoxia/ischemia. Although ORP150 was sparingly upregulated in neurons from human brain undergoing ischemic stress, there was robust induction in astrocytes. Cultured neurons overexpressing ORP150 were resistant to hypoxemic stress, whereas astrocytes with inhibited ORP150 expression were more vulnerable. Mice with targeted neuronal overexpression of ORP150 had smaller strokes compared with controls. Neurons with increased ORP150 demonstrated suppressed caspase-3-like activity and enhanced brain-derived neurotrophic factor (BDNF) under hypoxia signaling. These data indicate that ORP150 is an integral participant in ischemic cytoprotective pathways.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan; Hyogo Coll Med, Dept Internal Med 5, Hyogo, Japan; Natl Ctr Cardiac Dis & Circulat Res, Dept Pathol, Osaka, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa 920, Japan; HSP Res Inst, Kyoto, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka, Japan; Columbia Univ, Coll Phys & Surg, CREST, JST, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY USA	Osaka University; Hyogo College of Medicine; National Cerebral & Cardiovascular Center - Japan; Kanazawa University; Osaka University; Columbia University; Columbia University	Tamatani, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan.		Taniguchi, Masateru/G-3185-2017; Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044				Abe K, 1997, BRAIN RES, V776, P230, DOI 10.1016/S0006-8993(97)01041-X; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Despres P, 1996, J VIROL, V70, P4090; Du C, 1996, BRAIN RES, V718, P233, DOI 10.1016/0006-8993(96)00162-X; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Fujimura M, 1999, J NEUROSCI, V19, P3414; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Hori O, 1996, J NEUROCHEM, V66, P973; IHARA K, 1997, J CEREB BLOOD FLOW M, V17, P1097; KOISTINAHO J, 1997, NEUROREPORT, V8, P1; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Larsson E, 1999, J CEREBR BLOOD F MET, V19, P1220, DOI 10.1097/00004647-199911000-00006; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531	31	171	177	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					317	323		10.1038/85463	http://dx.doi.org/10.1038/85463			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231630				2022-12-25	WOS:000167380400037
J	van de Rijke, F; Zijlmans, H; Li, S; Vail, T; Raap, AK; Niedbala, RS; Tanke, HJ				van de Rijke, F; Zijlmans, H; Li, S; Vail, T; Raap, AK; Niedbala, RS; Tanke, HJ			Up-converting phosphor reporters for nucleic acid microarrays	NATURE BIOTECHNOLOGY			English	Article								An important application of robotically spotted DNA microarrays is the monitoring of RNA expression levels(1,2). A clear limitation of this technology is the relatively large amount of RNA that is required per hybridization as a result of low hybridization efficiency and limiting detection sensitivity provided by conventional fluorescent reporters(3,4). We have used a recently introduced luminescent reporter technology, called UPT (up-converting phosphor technology(5,6)). Down-converting phosphors have been applied before to detect nucleic acids on filters using time-resolved fluorometry(7,8). The unique feature of the phosphor particles (size 0.4 mum) used here is that they emit visible light when illuminated with infrared (IR) light (980 nm) as a result of a phenomenon called up-conversiong(9,10). Because neither support material of microarrays nor biomolecules possess up-conversion properties, an enhanced image contrast is expected when these nonfading phosphor particles are applied to detect nucleic acid hybrids on microarrays. Comparison of the UPT reporter to cyanin 5 (Cy5) in a low-complexity model system showed a two order of maginitude linear relationship between phosphor luminescence and target concentration and resulted in an excellent correlation between the two reporter systems for variable target concentrations (R-2 = 0.95). However, UPT proved to be superior in sensitivity, even though a wide-field microscope equipped with a xenon lamp was used. This higher sensitivity was demonstrated by complementary DNA (cDNA) microarray hybridizations using cDNAs for housekeeping genes as probes and complex cDNA as target. These results suggest that a UPT reporter technology in combination with a dedicated IR laser array-scanner holds significant promise for various microarray applications.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Cytochem & Cytometry, Leiden, Netherlands; OraSure Technol Inc, Bethlehem, PA USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Tanke, HJ (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Cytochem & Cytometry, Leiden, Netherlands.		Abrams, William R/A-5782-2008; Vail, Thomas/S-6892-2019	Raap, Anton Klaas/0000-0003-1483-7816				AUZEL FE, 1973, P IEEE, V61, P758, DOI 10.1109/PROC.1973.9155; BEVERLOO HB, 1992, ANAL BIOCHEM, V203, P326, DOI 10.1016/0003-2697(92)90320-7; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; OSTERMAYER FW, 1971, METALL T, V752, P747; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; TANKE HJ, 1986, Patent No. 8502187; Wiegant JCAG, 1999, CYTOGENET CELL GENET, V87, P47, DOI 10.1159/000015390; Zarling DA, 1997, US Patent, Patent No. [5,674,698, 5674698]; Zijlmans HJMAA, 1999, ANAL BIOCHEM, V267, P30, DOI 10.1006/abio.1998.2965	11	424	454	3	137	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					273	276		10.1038/85734	http://dx.doi.org/10.1038/85734			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231563				2022-12-25	WOS:000167283100030
J	Tumbar, T; Belmont, AS				Tumbar, T; Belmont, AS			Interphase movements of a DNA chromosome region modulated by VP16 transcriptional activator	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE; 3-DIMENSIONAL RECONSTRUCTION; CENTROMERIC HETEROCHROMATIN; NUCLEAR-ORGANIZATION; X-CHROMOSOME; IN-VIVO; CHROMATIN; DOMAINS; TERRITORIES; LOCALIZATION	We examined changes in intranuclear chromosome positioning induced by a transcriptional activator in a simple experimental system. Targeting the VP16 acidic activation domain (AAD) to an engineered chromosome site resulted in its transcriptional activation and redistribution from a predominantly peripheral to a more interior nuclear localization. Direct visualization in vivo revealed that the chromosome site normally moves into the nuclear interior transiently in early G1 and again in early S phase. In contrast, VP16 AAD targeting induced this site's permanent interior localization in early G1. A single transcriptional activator therefore can modify the cell-cycle-dependent programme of intranuclear positioning of chromosome loci.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Belmont, AS (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Room B107 C&LSL,601 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [R01 GM042516, R01 GM058460, GM58460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058460, R01GM042516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abney JR, 1997, J CELL BIOL, V137, P1459, DOI 10.1083/jcb.137.7.1459; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; BARR ML, 1951, J ANAT, V85, P171; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; BELMONT AS, 1986, EXP CELL RES, V165, P165, DOI 10.1016/0014-4827(86)90541-0; BORDEN J, 1988, SCIENCE, V242, P1687, DOI 10.1126/science.3201257; Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Eils R, 1996, J CELL BIOL, V135, P1427, DOI 10.1083/jcb.135.6.1427; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Itoh N, 1998, J CELL SCI, V111, P3275; Kurz A, 1996, J CELL BIOL, V135, P1195, DOI 10.1083/jcb.135.5.1195; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Tagawa Y, 1997, CYTOMETRY, V27, P327; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; Ward WS, 1996, CRIT REV EUKAR GENE, V6, P139, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.30; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	35	144	150	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					134	139		10.1038/35055033	http://dx.doi.org/10.1038/35055033			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175745				2022-12-25	WOS:000166793000014
J	Moore, KJ; Rosen, ED; Fitzgerald, ML; Randow, F; Andersson, LP; Altshuler, D; Milstone, DS; Mortensen, RM; Spiegelman, BM; Freeman, MW				Moore, KJ; Rosen, ED; Fitzgerald, ML; Randow, F; Andersson, LP; Altshuler, D; Milstone, DS; Mortensen, RM; Spiegelman, BM; Freeman, MW			The role of PPAR-gamma in macrophage differentiation and cholesterol uptake	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SCAVENGER RECEPTORS; AFFINITY LIGAND; GENE-EXPRESSION; RETINOIC ACID; OXIDIZED LDL; HUMAN CD36; IN-VITRO	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma), the transcription factor target of the anti-diabetic thiazolidinedione (TZD) drugs, is reported to mediate macrophage differentiation and inflammatory responses. Using PPAR-gamma -deficient stem cells, we demonstrate that PPAR-gamma is neither essential for myeloid development, nor for such mature macrophage functions as phagocytosis and inflammatory cytokine production. PPAR-gamma is required for basal expression of CD36, but not for expression of the other major scavenger receptor responsible for uptake of modified lipoproteins, SR-A. In wild-type macrophages, TZD treatment divergently regulated CD36 and class A macrophage-scavenger receptor expression and failed to induce significant cellular cholesterol accumulation, indicating that TZDs may not exacerbate macrophage foam-cell formation.	Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Univ Michigan, Dept Physiol, Div Endocrine, Ann Arbor, MI 48109 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA.		Moore, Kathryn/ABE-6416-2020; Altshuler, David M/A-4476-2009	Moore, Kathryn/0000-0003-2505-2547; Altshuler, David M/0000-0002-7250-4107	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, P50HL056985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL5409, HL56985, HL45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; ASHKENAS J, 1993, J LIPID RES, V34, P983; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Calvo D, 1998, J LIPID RES, V39, P777; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Feng JW, 2000, J LIPID RES, V41, P688; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huh HY, 1996, BLOOD, V87, P2020; Jacobs NL, 1997, J LIPID RES, V38, P1973; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; MILSTONE DS, 1999, NUCLEIC ACIDS RES, V27, P10; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1041, DOI 10.1210/jc.83.3.1041; Moore KJ, 1998, ARTERIOSCL THROM VAS, V18, P1647, DOI 10.1161/01.ATV.18.10.1647; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Noguchi N, 1996, ATHEROSCLEROSIS, V123, P227, DOI 10.1016/0021-9150(96)05811-X; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosenzweig ML, 1999, EVOL ECOL RES, V1, P1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Shinohara E, 1998, ATHEROSCLEROSIS, V136, P275, DOI 10.1016/S0021-9150(97)00220-7; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vaidya S, 1999, J IMMUNOL, V163, P6187; Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224	47	424	443	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					41	47		10.1038/83328	http://dx.doi.org/10.1038/83328			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135614				2022-12-25	WOS:000166243100033
J	Nakatani, K; Sando, S; Saito, I				Nakatani, K; Sando, S; Saito, I			Scanning of guanine-guanine mismatches in DNA by synthetic ligands using surface plasmon resonance	NATURE BIOTECHNOLOGY			English	Article						G-G mismatch; synthetic ligand; surface plasmon resonance; SNPs; mutation detection	NUCLEOTIDE POLYMORPHISM DISCOVERY; MUTATION DETECTION; GEL-ELECTROPHORESIS; NUCLEIC-ACIDS; BASE EXCISION; SINGLE; SEQUENCE; GLYCOSYLASE; ALKYLATION; BINDING	Here we have designed and synthesized ligands that specifically bind with high affinity (K-d = 53 nM) to the guanine (G)-guanine mismatch, one of four types of single-nucleotide polymorphism (SNP). Detection of the G-G mismatch was performed by a surface plasmon resonance (SPR) assay using a sensor chip carrying the G-G specific ligand on its surface. The accuracy of the G-G mismatch detection by the SPR sensor was demonstrated by a marked SPR response obtained only for the DNA containing the G-G mismatch. DNAs containing G-A and G-T mismatches, as well as a fully matched duplex, produced only a weak response. Furthermore, this assay was found applicable for the detection of SNP existing in PCR amplification products of a 652-nucleotide sequence of the HSP70-2 gene.	Kyoto Univ, Japan Sci & Technol Corp, CREST, Fac Engn,Dept Synth Chem & Biol Chem, Kyoto 6068501, Japan	Japan Science & Technology Agency (JST); Kyoto University	Nakatani, K (corresponding author), Kyoto Univ, Japan Sci & Technol Corp, CREST, Fac Engn,Dept Synth Chem & Biol Chem, Kyoto 6068501, Japan.		Sando, Shinsuke/M-8473-2015	Sando, Shinsuke/0000-0003-0275-7237; Nakatani, Kazuhiko/0000-0002-1705-5265				[Anonymous], 1999, NAT GENET S, V21, P1; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COTTON R, 1997, MUTATION DETECTION; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352, DOI 10.1038/4333; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Mashal RD, 1996, CURR OPIN GENET DEV, V6, P275, DOI 10.1016/S0959-437X(96)80002-5; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; Nakatani K, 1999, ANGEW CHEM INT EDIT, V38, P3378, DOI 10.1002/(SICI)1521-3773(19991115)38:22<3378::AID-ANIE3378>3.3.CO;2-D; Nakatani K, 1998, J AM CHEM SOC, V120, P11219, DOI 10.1021/ja980801q; Nakatani K, 2000, J AM CHEM SOC, V122, P2172, DOI 10.1021/ja992956j; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Nilsson P, 1997, J MOL RECOGNIT, V10, P7, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<7::AID-JMR341>3.0.CO;2-9; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Shumaker JM, 1996, HUM MUTAT, V7, P346, DOI 10.1002/(SICI)1098-1004(1996)7:4<346::AID-HUMU9>3.3.CO;2-9; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Taillon-Miller P, 1999, GENOME RES, V9, P499; Taylor GR, 1999, ELECTROPHORESIS, V20, P1125, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1125::AID-ELPS1125>3.0.CO;2-O; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P8904, DOI 10.1021/bi00425a006; 1990, BIACORE USERS MANUAL	31	200	211	1	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					51	55		10.1038/83505	http://dx.doi.org/10.1038/83505			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135552				2022-12-25	WOS:000166261400019
J	Soriano, FG; Virag, L; Jagtap, P; Szabo, E; Mabley, JG; Liaudet, L; Marton, A; Hoyt, DG; Murthy, KGK; Salzman, AL; Southan, GJ; Szabo, C				Soriano, FG; Virag, L; Jagtap, P; Szabo, E; Mabley, JG; Liaudet, L; Marton, A; Hoyt, DG; Murthy, KGK; Salzman, AL; Southan, GJ; Szabo, C			Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; DNA STRAND BREAKS; RIBOSE SYNTHETASE; ENDOTOXIC-SHOCK; DEFICIENT MICE; PEROXYNITRITE; CELLS; GLUCOSE; EXPRESSION	Diabetic patients frequently suffer from retinopathy, nephropathy, neuropathy and accelerated atherosclerosis. The loss of endothelial function precedes these vascular alterations. Here we report that activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of endothelial dysfunction in diabetes. Destruction of islet cells with streptozotocin in mice induced hyperglycemia, intravascular oxidant production, DNA strand breakage, PARP activation and a selective loss of endothelium-dependent vasodilation. Treatment with a novel potent PARP inhibitor, starting after the time of islet destruction, maintained normal vascular responsiveness, despite the persistence of severe hyperglycemia. Endothelial cells incubated in high glucose exhibited production of reactive nitrogen and oxygen species, consequent single-strand DNA breakage, PARP activation and associated metabolic and functional Impairment. Basal and high-glucose-induced nuclear factor-kappaB activation were suppressed in the PARP-deficient cells. Our results indicate that PARP may be a novel drug target for the therapy of diabetic endothelial dysfunction.	Inotek Corp, Beverly, MA 01915 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ USA; Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA; Univ Sao Paulo, Hosp Clin, Dept Crit Care Med, Sao Paulo, Brazil; Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, Lausanne, Switzerland	Inotek Pharmaceuticals; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; Universidade de Sao Paulo; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Szabo, C (corresponding author), Inotek Corp, Suite 419E,100 Cummings Ctr, Beverly, MA 01915 USA.	szabocsaba@aol.com	Szabo, Csaba/D-1882-2013; Soriano, Francisco/C-3382-2012; Szabo, Csaba/ABG-2644-2021; Liaudet, Lucas/E-1322-2017; Mabley, Jon G/D-2296-2010; Szabo, Eva/B-8574-2011; Virag, Laszlo/E-6124-2010	Soriano, Francisco/0000-0003-4898-0135; Liaudet, Lucas/0000-0003-2670-4930; Mabley, Jon/0000-0001-9423-6230; Virag, Laszlo/0000-0002-7099-6718	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL065145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060915] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL65145] Funding Source: Medline; NIGMS NIH HHS [R01 GM60915] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASIK M, 1992, J BIOL CHEM, V267, P1569; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cosentino F, 1997, CIRCULATION, V96, P25; Didier M, 1996, J NEUROSCI, V16, P2238; Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FURCHGOTT RF, 1990, ACTA PHYSIOL SCAND, V139, P257, DOI 10.1111/j.1748-1716.1990.tb08923.x; Gerritsen Mary E., 1995, Microcirculation (New York), V2, P151, DOI 10.3109/10739689509146763; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Karasu C, 2000, EUR J PHARMACOL, V392, P163, DOI 10.1016/S0014-2999(00)00140-0; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Keen H, 1999, DIABETES-METAB RES, V15, P186, DOI 10.1002/(SICI)1520-7560(199905/06)15:3<186::AID-DMRR30>3.0.CO;2-5; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; Kobayashi T, 1999, BRIT J PHARMACOL, V127, P835, DOI 10.1038/sj.bjp.0702554; LAMAS S, 1991, AM J PHYSIOL, V261, P634; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Nishigaki R, 1999, Nihon Ika Daigaku Zasshi, V66, P166, DOI 10.1272/jnms.66.166; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; PIEPER GM, 1995, DIABETES, V44, P1106, DOI 10.2337/diabetes.44.9.1106; PIEPER GM, 1996, LIFE SCI, V58, P147; Rodriguez-Manas L, 1998, BRIT J PHARMACOL, V123, P1495, DOI 10.1038/sj.bjp.0701749; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shen HM, 2000, FREE RADICAL BIO MED, V28, P529, DOI 10.1016/S0891-5849(99)00234-8; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Szabo C., 2000, CELL DEATH ROLE PARP; Tooke JE, 1999, DIABETIC MED, V16, P710, DOI 10.1046/j.1464-5491.1999.00099.x; Virag L, 1999, MOL PHARMACOL, V56, P824; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Zhang J, 1997, METHOD ENZYMOL, V280, P255; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	45	506	529	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					108	113		10.1038/83241	http://dx.doi.org/10.1038/83241			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135624				2022-12-25	WOS:000166243100043
J	Irvine, AS; Trinder, PKE; Laughton, DL; Ketteringham, H; McDermott, RH; Reid, SCH; Haines, AMR; Amir, A; Husain, R; Doshi, R; Young, LS; Mountain, A				Irvine, AS; Trinder, PKE; Laughton, DL; Ketteringham, H; McDermott, RH; Reid, SCH; Haines, AMR; Amir, A; Husain, R; Doshi, R; Young, LS; Mountain, A			Efficient nonviral transfection of dendritic cells and their use for in vivo immunization	NATURE BIOTECHNOLOGY			English	Article						nonviral transfection; dendritic cells; cancer immunotherapy; genetic modification	TYROSINASE-RELATED PROTEIN-2; CYTOTOXIC T-CELLS; ANTITUMOR IMMUNITY; MELANOMA PATIENTS; IN-VITRO; ANTIGEN; VACCINATION; LYMPHOCYTES; EXPRESSION; RESPONSES	Immunization with dendritic cells (DCs) transfected with genes encoding tumor-associated antigens (TAAs) is a highly promising approach to cancer immunotherapy. We have developed a system, using complexes of plasmid DNA expression constructs with the cationic peptide CL22, that transfects human monocyte-derived DCs much more efficiently than alternative nonviral agents, After CL22 transfection, DCs expressing antigens stimulated autologous T cells in vitro and elicited primary immune responses in syngeneic mice, in an antigen-specific manner. Injection of CL22-transfected DCs expressing a TAA, but not DCs pulsed with a TAA-derived peptide, protected mice from lethal challenge with tumor cells in an aggressive model of melanoma, The CL22 system is a fast and efficient alternative to viral vectors for engineering DCs for use in immunotherapy and research.	Univ Keele, Keele ST5 5SP, Staffs, England; Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	Keele University; University of Birmingham	Mountain, A (corresponding author), Univ Keele, Sci Pk, Keele ST5 5SP, Staffs, England.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				Arthur JF, 1997, CANCER GENE THER, V4, P17; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; BOUCHARD B, 1994, EUR J BIOCHEM, V219, P127, DOI 10.1111/j.1432-1033.1994.tb19922.x; CORICO R, 2000, CURRENT PROTOCOLS IM; De Veerman M, 1999, J IMMUNOL, V162, P144; DIBRINO M, 1993, J IMMUNOL, V151, P5930; Felgner PL, 1997, HUM GENE THER, V8, P511, DOI 10.1089/hum.1997.8.5-511; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Jonuleit H, 2000, GENE THER, V7, P249, DOI 10.1038/sj.gt.3301077; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kaplan JM, 1999, J IMMUNOL, V163, P699; Knight SC, 1998, EUR J IMMUNOL, V28, P1636; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Morgan SM, 1996, J VIROL, V70, P2394, DOI 10.1128/JVI.70.4.2394-2402.1996; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Okamoto T, 1998, J INVEST DERMATOL, V111, P1034, DOI 10.1046/j.1523-1747.1998.00411.x; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Philip R, 1998, CANCER GENE THER, V5, P236; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Schnell S, 2000, J IMMUNOL, V164, P1243, DOI 10.4049/jimmunol.164.3.1243; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Tuting T, 1999, J GENE MED, V1, P400, DOI 10.1002/(SICI)1521-2254(199911/12)1:6<400::AID-JGM68>3.0.CO;2-D; Tuting T, 1997, EUR J IMMUNOL, V27, P2702, DOI 10.1002/eji.1830271033; Williams SG, 1998, NUCLEIC ACIDS RES, V26, P2120, DOI 10.1093/nar/26.9.2120; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; Zhang WP, 1999, HUM GENE THER, V10, P1151, DOI 10.1089/10430349950018148	30	77	83	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1273	1278		10.1038/82383	http://dx.doi.org/10.1038/82383			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101806				2022-12-25	WOS:000165659000024
J	Lee, YA; Wahn, U; Kehrt, R; Tarani, L; Businco, L; Gustafsson, D; Andersson, F; Oranje, AP; Wolkertstorfer, A; von Berg, A; Hoffmann, U; Kuster, W; Wienker, T; Ruschendorf, F; Reis, A				Lee, YA; Wahn, U; Kehrt, R; Tarani, L; Businco, L; Gustafsson, D; Andersson, F; Oranje, AP; Wolkertstorfer, A; von Berg, A; Hoffmann, U; Kuster, W; Wienker, T; Ruschendorf, F; Reis, A			A major susceptibility locus for atopic dermatitis maps to chromosome 3q21	NATURE GENETICS			English	Article							GENOME-WIDE SEARCH; LINKAGE ANALYSIS; LOD SCORES; ASTHMA; DISEASE; ASSOCIATION; POPULATION; ECZEMA; PREVALENCE; GUIDELINES	Atopic dermatitis (eczema) is a chronic inflammatory skin disease with onset mainly in early childhood(1). It is commonly the initial clinical manifestation of allergic disease, often preceding the onset of respiratory allergies(2,3). Along with asthma and allergic rhinitis, atopic dermatitis is an important manifestation of atopy that is characterized by the formation of allergy antibodies (IgE) to environmental allergens. In the developed countries, the prevalence of atopic dermatitis is approximately 15%, with a steady increase over the past decades(4,5). Genetic and environmental factors interact to determine disease susceptibility and expression(6), and twin studies indicate that the genetic contribution is substantial(7). To identify susceptibility loci for atopic dermatitis, we ascertained 199 families with at least two affected siblings based on established diagnostic criteria(8,9). A genome-wide linkage study revealed highly significant evidence for linkage on chromosome 3q21 (Z(all)=4.31, P= 8.42x10(-6)). Moreover, this locus provided significant evidence for linkage of allergic sensitization under the assumption of paternal imprinting (hlod=3.71, alpha =44%), further supporting the presence of an atopy gene in this region. Our findings indicate that distinct genetic factors contribute to susceptibility to atopic dermatitis and that the study of this disease opens new avenues to dissect the genetics of atopy.	Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Humboldt Univ, Dept Paediat Pneumol & Immunol, Berlin, Germany; Univ La Sapienza, Dept Paediat, Rome, Italy; Orebro Med Ctr Hosp, Dept Paediat, S-70185 Orebro, Sweden; Univ Rotterdam Hosp, Dept Dermatol & Venereol, Rotterdam, Netherlands; Marienhosp, Dept Paediat, Wesel, Germany; Tech Univ Munich, Kinderklin Schwabing, D-8000 Munich, Germany; TOMESA Fachklin, Bad Salzschlirf, Germany; Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-5300 Bonn, Germany; Humboldt Univ, Dept Human Genet, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Sapienza University Rome; Erasmus University Rotterdam; Erasmus MC; St. Marien Hospital; Technical University of Munich; University of Bonn; Humboldt University of Berlin	Reis, A (corresponding author), Univ Erlangen Nurnberg, Dept Human Genet, Erlangen, Germany.		Reis, André/D-2309-2009; Wolkerstorfer, Albert/F-8866-2013	Reis, André/0000-0002-6301-6363; Wolkerstorfer, Albert/0000-0003-1421-1493				Abreu PC, 1999, AM J HUM GENET, V65, P847, DOI 10.1086/302536; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; HANIFIN JM, 1998, ATOPIC DERMATITIS; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANIER LL, 1995, J IMMUNOL, V154, P97; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; Mao XQ, 1996, LANCET, V348, P581, DOI 10.1016/S0140-6736(95)10244-2; Marsh DG, 1997, NAT GENET, V15, P389; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806	30	201	213	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					470	473		10.1038/82625	http://dx.doi.org/10.1038/82625			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101848				2022-12-25	WOS:000165671700023
J	Zuscik, MJ; Sands, S; Ross, SA; Waugh, DJJ; Gaivin, RJ; Morilak, D; Perez, DM				Zuscik, MJ; Sands, S; Ross, SA; Waugh, DJJ; Gaivin, RJ; Morilak, D; Perez, DM			Overexpression of the alpha(1B)-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy	NATURE MEDICINE			English	Article							PARKINSONS-DISEASE; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION; MODULATION; ACTIVATION; BRAIN; ACETYLCHOLINE; SEIZURES; CLONING	Progress toward elucidating the function of alpha (1B)-adrenergic receptors (alpha (1B)ARs) in the central nervous system has been constrained by a lack of agonists and antagonists with adequate alpha (1B)-specificity. We have obviated this constraint by generating transgenic mice engineered to overexpress either wild-type or constitutively active alpha (1B)ARs in tissues that normally express the receptor, including the brain. All transgenic lines showed granulovacular neurodegeneration, beginning in alpha (1B)-expressing domains of the brain and progressing with age to encompass all areas. The degeneration was apoptotic and did not occur in non-transgenic mice. Correspondingly, transgenic mice showed an age-progressive hindlimb disorder that was parkinsonian-like, as demonstrated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergic-neuronal degeneration in the substantia nigra. Transgenic mice also had a grand mal seizure disorder accompanied by a corresponding dysplasia and neurodegeneration of the cerebral cortex. Both behavioral phenotypes (locomotor impairment and seizure) could be partially rescued with the alpha (1)AR antagonist terazosin, indicating that alpha (1)AR signaling participated directly in the pathology. Our results indicate that overstimulation of alpha (1B)AR leads to apoptotic neurodegeneration with a corresponding multiple system atrophy indicative of Shy-Drager syndrome, a disease whose etiology is unknown.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA	Cleveland Clinic Foundation; University of Texas System; University of Texas Health San Antonio	Perez, DM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Morilak, David/Q-4986-2019	Morilak, David/0000-0001-6689-6258; WAUGH, DAVID/0000-0002-4022-3765; Zuscik, Michael/0000-0003-0461-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010004, R01HL061438] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61438, F32HL1000402] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; AMABEOKU G, 1994, PROG NEURO-PSYCHOPH, V18, P753, DOI 10.1016/0278-5846(94)90082-5; BALK JH, 1995, NATURE, V377, P424; BEANI L, 1986, J PHARMACOL EXP THER, V236, P230; BRIERE R, 1986, ANN NEUROL, V19, P26, DOI 10.1002/ana.410190106; BURT AM, 1993, TXB NEUROANATOMY, P367; CASH R, 1984, BRAIN RES, V322, P269, DOI 10.1016/0006-8993(84)90117-3; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Day HEW, 1999, J NEUROSCI, V19, P10098; Domyancic AV, 1997, J COMP NEUROL, V386, P358, DOI 10.1002/(SICI)1096-9861(19970929)386:3<358::AID-CNE3>3.0.CO;2-0; DUTEIL J, 1990, EUR J PHARMACOL, V180, P49, DOI 10.1016/0014-2999(90)90591-S; FAHN S, 1998, HDB MOVEMENT DISORDE, P13; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gioanni Y, 1998, SYNAPSE, V30, P362, DOI 10.1002/(SICI)1098-2396(199812)30:4<362::AID-SYN3>3.3.CO;2-N; Haavik J, 1998, MOL NEUROBIOL, V16, P285, DOI 10.1007/BF02741387; Hein L, 1999, ANN NY ACAD SCI, V881, P265, DOI 10.1111/j.1749-6632.1999.tb09368.x; Hwa J, 1997, BIOCHEMISTRY-US, V36, P633, DOI 10.1021/bi962141c; Ivanov A, 1995, J NEUROPHYSIOL, V74, P2427, DOI 10.1152/jn.1995.74.6.2427; JAZRAWI SP, 1986, J NEUROCHEM, V47, P173; Kirkwood A, 1999, J NEUROSCI, V19, P1599; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; PALACIOS JM, 1987, BRAIN RES, V419, P65, DOI 10.1016/0006-8993(87)90569-5; Perez DM, 1996, MOL PHARMACOL, V49, P112; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sirvio J, 1999, PHARMACOL THERAPEUT, V83, P49, DOI 10.1016/S0163-7258(99)00017-0; TUMER PR, 2000, MOL ENDOCRINOL, V14, P241; Vince DG, 1997, ANAL CELL PATHOL, V15, P119, DOI 10.1155/1997/607965; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288	30	101	106	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1388	1394		10.1038/82207	http://dx.doi.org/10.1038/82207			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100125				2022-12-25	WOS:000165704100044
J	Shimizu, TS; Le Novere, N; Levin, MD; Beavil, AJ; Sutton, BJ; Bray, D				Shimizu, TS; Le Novere, N; Levin, MD; Beavil, AJ; Sutton, BJ; Bray, D			Molecular model of a lattice of signalling proteins involved in bacterial chemotaxis	NATURE CELL BIOLOGY			English	Article							ESCHERICHIA-COLI; CYTOPLASMIC DOMAIN; BINDING-SITE; CHEA KINASE; RECEPTOR; TRANSDUCTION; METHYLATION; COMPLEX; PATHWAY; METHYLTRANSFERASE	Coliform bacteria detect chemical attractants by means of a membrane-associated cluster of receptors and signalling molecules. We have used recently determined molecular structures, in conjunction with plastic models generated by three-dimensional printer technology, to predict how the proteins of the complex are arranged in relation to the plasma membrane. The proposed structure is a regular two-dimensional lattice in which the cytoplasmic ends of chemotactic-receptor dimers are inserted into a hexagonal array of CheA and CheW molecules. This structure creates separate compartments for adaptation and downstream signalling, and indicates a possible basis for the spread of activity within the cluster.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Kings Coll London, Randall Ctr, London SE1 1UL, England	University of Cambridge; University of London; King's College London	Shimizu, TS (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	d.bray@zoo.cam.ac.uk	Beavil, Andrew/B-5624-2009; Le Novère, Nicolas/F-9973-2010	Beavil, Andrew/0000-0002-0768-122X; Le Novère, Nicolas/0000-0002-6309-7327				Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Bailey MJ, 1998, CURR OPIN STRUC BIOL, V8, P202, DOI 10.1016/S0959-440X(98)80039-0; Barnakov AN, 1999, P NATL ACAD SCI USA, V96, P10667, DOI 10.1073/pnas.96.19.10667; Bass RB, 1999, BIOCHEMISTRY-US, V38, P9317, DOI 10.1021/bi9908179; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; BRAY D, 1995, MOL BIOL CELL, V6, P1367, DOI 10.1091/mbc.6.10.1367; DEFRANCO AL, 1981, J BACTERIOL, V147, P390, DOI 10.1128/JB.147.2.390-400.1981; DIXON CM, 1995, WORLD J UROL, V13, P126; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; Eisenbach M, 1996, MOL MICROBIOL, V20, P903, DOI 10.1111/j.1365-2958.1996.tb02531.x; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HAZELBAUER GL, 1980, NATURE, V283, P98, DOI 10.1038/283098a0; HAZELBAUER GL, 1983, INT REV CYTOL, V81, P33, DOI 10.1016/S0074-7696(08)62334-7; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Khantzian E.J., 1992, AM J ADDICTION, V1, P67; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; MADDOCK JR, 1993, SCIENCE, V259, P1717; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morrison TB, 1997, J BACTERIOL, V179, P5543, DOI 10.1128/jb.179.17.5543-5550.1997; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scharf BE, 1998, J BACTERIOL, V180, P5123, DOI 10.1128/JB.180.19.5123-5128.1998; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189	41	165	169	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					792	796		10.1038/35041030	http://dx.doi.org/10.1038/35041030			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056533				2022-12-25	WOS:000165207500012
J	Yoshimi, K; Tomizuka, K; Shinohara, T; Kazuki, Y; Yoshida, H; Ohguma, A; Yamamoto, T; Tanaka, S; Oshimura, M; Ishida, I				Yoshimi, K; Tomizuka, K; Shinohara, T; Kazuki, Y; Yoshida, H; Ohguma, A; Yamamoto, T; Tanaka, S; Oshimura, M; Ishida, I			Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts	NATURE BIOTECHNOLOGY			English	Article						chromosome cloning; human artificial chromosomes	EMBRYONIC STEM-CELLS; HOMOLOGOUS RECOMBINATION; EFFICIENT MODIFICATION; HUMAN DNA; CONSTRUCTION; CLONING; FRAGMENTS; LOCUS	For introducing regions of human chromosomes greater than a megabase into cells or animals, we have developed a chromosome-cloning system in which defined regions of human chromosomes can be cloned into a stable human minichromosome vector in homologous recombination-proficient chicken DT40 cells. The stable minichromosome vector allowed a 10 Mb-sized region of the mitotically unstable human chromosome 22 to be stably maintained in mouse embryonic stem (ES) cells, and in mice. Furthermore, we demonstrated functional expression of human genes from the HAC in mice, This study describes a stable cloning and expression system for greater than megabase-sized regions of human chromosomes.	Kirin Brewery Co Ltd, Pharmaceut Res Lab, Takasaki, Gumma 3701295, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan	Kirin Brewery Company Limited; Tottori University	Ishida, I (corresponding author), Kirin Brewery Co Ltd, Pharmaceut Res Lab, 3 Miyahara Cho, Takasaki, Gumma 3701295, Japan.	i-ishida@kirin.co.jp						Abuin A, 1996, MOL CELL BIOL, V16, P1851; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Co DO, 2000, CHROMOSOME RES, V8, P183, DOI 10.1023/A:1009206926548; Deursoen J.V., 1995, P NATL ACAD SCI USA, V92, P7376; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; GREENBERGER JS, 1991, CRIT REV ONCOL HEMAT, V11, P65, DOI 10.1016/1040-8428(91)90018-8; Grimes B, 1998, HUM MOL GENET, V7, P1635, DOI 10.1093/hmg/7.10.1635; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HONJO T, 1995, IMMUNOGLOBULIN GENES; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Kelleher ZT, 1998, NAT BIOTECHNOL, V16, P762, DOI 10.1038/nbt0898-762; KUPPERS JB, 1997, GENE, V191, P173; Kuroiwa Y, 1998, NUCLEIC ACIDS RES, V26, P3447, DOI 10.1093/nar/26.14.3447; Loupart ML, 1998, CHROMOSOMA, V107, P255, DOI 10.1007/s004120050305; Miller SD, 1999, J MATH PHYS, V40, P751, DOI 10.1063/1.532683; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Su H, 2000, NAT GENET, V24, P92, DOI 10.1038/71756; Telenius H, 1999, CHROMOSOME RES, V7, P3, DOI 10.1023/A:1009215026001; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Tomizuka K, 2000, P NATL ACAD SCI USA, V97, P722, DOI 10.1073/pnas.97.2.722; WEICHHOLD GM, 1993, GENOMICS, V16, P512, DOI 10.1006/geno.1993.1218; WORTON RG, 1988, SCIENCE, V239, P64, DOI 10.1126/science.3336775; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	28	111	150	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1086	1090		10.1038/80287	http://dx.doi.org/10.1038/80287			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017048				2022-12-25	WOS:000089744700032
J	Becker, A; Hessenius, C; Licha, K; Ebert, B; Sukowski, U; Semmler, W; Wiedenmann, B; Grotzinger, C				Becker, A; Hessenius, C; Licha, K; Ebert, B; Sukowski, U; Semmler, W; Wiedenmann, B; Grotzinger, C			Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands	NATURE BIOTECHNOLOGY			English	Article							SOMATOSTATIN RECEPTORS; GASTROINTESTINAL ENDOSCOPY; CONTRAST AGENTS; CHROMOENDOSCOPY; SCINTIGRAPHY; EXPRESSION; EXPERIENCE; LOCALIZATION; COLON; EYE	We report here the in vivo diagnostic use of a peptide-dye conjugate consisting of a cyanine dye and the somatostatin analog octreotate as a contrast agent for optical tumor imaging. When used in whole-body in vivo imaging of mouse xenografts, indotricarbocyanine-octreotate accumulated in tumor tissue. Tumor fluorescence rapidly increased and was more than threefold higher than that of normal tissue from 3 to 24 h after application. The targeting conjugate was also specifically internalized by primary human neuroendocrine tumor cells. This imaging approach, combining the specificity of ligand/receptor interaction with near-infrared fluorescence detection, may be applied in various other fields of cancer diagnosis.	Humboldt Univ, Klinikum Charite, Med Klin Hepatol & Gastroenterol, D-13353 Berlin, Germany; Free Univ Berlin, Inst Diagnost Forsch GMBH, D-14050 Berlin, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Wiedenmann, B (corresponding author), Humboldt Univ, Klinikum Charite, Med Klin Hepatol & Gastroenterol, Campus Virchow Klinikum, D-13353 Berlin, Germany.		Grötzinger, Carsten/B-6938-2008	Grötzinger, Carsten/0000-0001-9872-3087; Wiedenmann, Bertram/0000-0002-7890-2552				Acosta MM, 1998, J CLIN GASTROENTEROL, V27, P13, DOI 10.1097/00004836-199807000-00005; Axelrad AM, 1996, GASTROENTEROLOGY, V110, P1253, DOI 10.1053/gast.1996.v110.pm8613016; BALLOU B, 1995, CANCER IMMUNOL IMMUN, V41, P257, DOI 10.1007/s002620050226; Becker A, 2000, PHOTOCHEM PHOTOBIOL, V72, P234, DOI 10.1562/0031-8655(2000)072<0234:MCAFOI>2.0.CO;2; Brand S, 1999, INT J COLORECTAL DIS, V14, P63, DOI 10.1007/s003840050186; Denzler B, 1999, CANCER, V85, P188, DOI 10.1002/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3; Ehlers RA, 2000, ANN SURG, V231, P838, DOI 10.1097/00000658-200006000-00008; Fleischer DE, 1999, GASTROINTEST ENDOSC, V49, pS45, DOI 10.1016/S0016-5107(99)70525-0; FOLLI S, 1994, CANCER RES, V54, P2643; Goldsmith SJ, 1997, SEMIN NUCL MED, V27, P85, DOI 10.1016/S0001-2998(97)80041-4; Haringsma J, 1998, ENDOSCOPY, V30, P416, DOI 10.1055/s-2007-1001292; Jensen RT, 1997, YALE J BIOL MED, V70, P481; John M, 1996, GUT, V38, P33, DOI 10.1136/gut.38.1.33; LAMBERTS SWJ, 1992, METABOLISM, V41, P111, DOI 10.1016/0026-0495(92)90043-A; LAMBERTS SWJ, 1990, J STEROID BIOCHEM, V37, P1079, DOI 10.1016/0960-0760(90)90469-2; Lewis JS, 1999, J MED CHEM, V42, P1341, DOI 10.1021/jm980602h; Licha K, 2001, BIOCONJUGATE CHEM, V12, P44, DOI 10.1021/bc000040s; Licha K, 2000, PHOTOCHEM PHOTOBIOL, V72, P392, DOI 10.1562/0031-8655(2000)072<0392:HCDACA>2.0.CO;2; Marcon NE, 1998, ENDOSCOPY, V30, P419, DOI 10.1055/s-2007-1001293; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; REUBI JC, 1987, CANCER RES, V47, P5758; Reubi JC, 1997, ENDOCR PATHOL, V8, P11, DOI 10.1007/BF02739703; Schaer JC, 1997, INT J CANCER, V70, P530, DOI 10.1002/(SICI)1097-0215(19970304)70:5<530::AID-IJC7>3.0.CO;2-Z; Stepp H, 1998, ENDOSCOPY, V30, P379, DOI 10.1055/s-2007-1001287; Wang QX, 1996, THEOR COMP FLUID DYN, V8, P73, DOI 10.1007/BF00312403; Wang TD, 1996, GASTROENTEROLOGY, V111, P1182, DOI 10.1053/gast.1996.v111.pm8898631; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; WIEDENMANN B, 1994, SEMIN ONCOL, V21, P29	28	430	478	1	100	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					327	331		10.1038/86707	http://dx.doi.org/10.1038/86707			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283589				2022-12-25	WOS:000167940700020
J	Consiglio, A; Quattrini, A; Martino, S; Bensadoun, JC; Dolcetta, D; Trojani, A; Benaglia, G; Marchesini, S; Cestari, V; Oliverio, A; Bordignon, C; Naldini, L				Consiglio, A; Quattrini, A; Martino, S; Bensadoun, JC; Dolcetta, D; Trojani, A; Benaglia, G; Marchesini, S; Cestari, V; Oliverio, A; Bordignon, C; Naldini, L			In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice	NATURE MEDICINE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; HUMAN ARYLSULFATASE-A; ENZYME REPLACEMENT THERAPY; CENTRAL-NERVOUS-SYSTEM; LONG-TERM; LYSOSOMAL STORAGE; IN-VIVO; CEREBROSIDE SULFATE; BETA-GLUCURONIDASE; DEFICIENT MICE	Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning Impairments. We show that selective degeneration of hippocampal neurons Is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.	Sci Inst HS Raffaele HSR TIGET, Telethon Inst Gene Therapy, Milan, Italy; Sci Inst HS Raffaele HSR TIGET, Dept Neurol, Milan, Italy; Div Surg Res, Lausanne, Switzerland; Gene Therapy Ctr, Lausanne, Switzerland; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; CNR, Inst Psychobiol & Psychopharmacol, Rome, Italy; Univ Turin, Lab Gene Transfer & Therapy, Inst Canc Res & Treatment, Turin, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Brescia; Consiglio Nazionale delle Ricerche (CNR); University of Turin	Bordignon, C (corresponding author), Sci Inst HS Raffaele HSR TIGET, Telethon Inst Gene Therapy, Milan, Italy.	claudio.bordignon@hsr.it	Oliverio, Alberto/ABG-7454-2021; consiglio, antonella/AAA-5864-2019; Dolcetta, Diego/AAD-2079-2019; Naldini, Luigi/E-9083-2012; consiglio, antonella/G-1815-2016; Martino, Sabata/F-2309-2014; Dunnett, Stephen B/A-5869-2010; Quattrini, Angelo/J-8373-2018	consiglio, antonella/0000-0002-3988-6254; consiglio, antonella/0000-0002-3988-6254; Martino, Sabata/0000-0002-3942-237X; Dunnett, Stephen B/0000-0003-1826-1578; NALDINI, Luigi/0000-0002-7835-527X; Cestari, Vincenzo/0000-0002-9623-157X; Quattrini, Angelo/0000-0002-8226-8320; Dolcetta, Diego/0000-0002-2864-9667	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BAUM H, 1959, CLIN CHIM ACTA, V4, P453, DOI 10.1016/0009-8981(59)90119-6; Bosch A, 2000, MOL THER, V1, P63, DOI 10.1006/mthe.1999.0005; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Cestari V, 1996, BRAIN RES, V713, P286, DOI 10.1016/0006-8993(95)01556-6; D'Hooge R, 1999, BRAIN RES, V847, P352, DOI 10.1016/S0006-8993(99)02085-5; D'Hooge R, 1999, NEUROSCI LETT, V273, P93, DOI 10.1016/S0304-3940(99)00647-3; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Ferraresi S, 1997, MULT SCLER, V3, P80, DOI 10.1177/135245859700300204; Gieselmann V, 1998, J INHERIT METAB DIS, V21, P564, DOI 10.1023/A:1005471106088; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Hess B, 1996, P NATL ACAD SCI USA, V93, P14821, DOI 10.1073/pnas.93.25.14821; Kapaun P, 1999, J CHILD NEUROL, V14, P222, DOI 10.1177/088307389901400402; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; Krivit W, 1999, Curr Opin Neurol, V12, P167, DOI 10.1097/00019052-199904000-00007; Learish R, 1996, GENE THER, V3, P343; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; MARCHESINI S, 1990, CHEM PHYS LIPIDS, V53, P165, DOI 10.1016/0009-3084(90)90042-P; MCGAUGH JL, 1970, PHYSIOL BEHAV, V5, P1109, DOI 10.1016/0031-9384(70)90197-6; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MONTI E, 1992, BIOCHIM BIOPHYS ACTA, V1124, P80, DOI 10.1016/0005-2760(92)90129-J; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NEMNI R, 1992, BRAIN RES, V591, P248, DOI 10.1016/0006-8993(92)91704-I; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; OHASHI T, 1993, J INHERIT METAB DIS, V16, P881, DOI 10.1007/BF00714283; Ohashi T, 1997, P NATL ACAD SCI USA, V94, P1287, DOI 10.1073/pnas.94.4.1287; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; PENZIEN JM, 1993, AM J HUM GENET, V52, P557; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sangalli A, 1998, HUM GENE THER, V9, P2111, DOI 10.1089/hum.1998.9.14-2111; STEIN C, 1989, J BIOL CHEM, V264, P1252; Taylor RM, 1997, NAT MED, V3, P771, DOI 10.1038/nm0797-771; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; VIANI P, 1989, BIOCHIM BIOPHYS ACTA, V1002, P20, DOI 10.1016/0005-2760(89)90059-3; VOS JP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P269, DOI 10.1016/0005-2760(92)90240-V; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	45	171	180	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					310	316		10.1038/85454	http://dx.doi.org/10.1038/85454			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231629				2022-12-25	WOS:000167380400036
J	Kiosses, WB; Shattil, SJ; Pampori, N; Schwartz, MA				Kiosses, WB; Shattil, SJ; Pampori, N; Schwartz, MA			Rac recruits high-affinity integrin alpha v beta 3 to lamellipodia in endothelial cell migration	NATURE CELL BIOLOGY			English	Article							ADHESION RECEPTOR; RHO-GTPASES; ALPHA(V)BETA(3); 3-KINASE; LIGAND; IIIA; CYTOSKELETON; VITRONECTIN; INHIBITION; FIBRINOGEN	Integrin alphav beta3 has an important role in the proliferation, survival, invasion and migration of vascular endothelial cells(1,2). Like other integrins, alphav beta3 can exist in different functional states with respect to ligand binding. These changes involve both affinity modulation, by which conformational changes in the integrin heterodimer govern affinity for individual extracellular matrix proteins, and avidity modulation, by which changes in lateral mobility and integrin clustering affect the binding of cells to multivalent matrices. Here we have used an engineered monoclonal antibody Fab (antigen-binding fragment) named WOW-1, which binds to activated integrins alphav beta3 and alphav beta5 from several species(3), to investigate the role of alphav beta3 activation in endothelial cell behaviour. Because WOW-1 is monovalent, it is insensitive to changes in integrin clustering and therefore reports only changes in affinity. WOW-1 contains an RGD tract in its variable region and binds only to unoccupied, high-affinity integrins. By using WOW-1, we have identified the selective recruitment of high-affinity integrins as a mechanism by which lamel-lipodia promote formation of new adhesions at the leading edge in cell migration.	Dept Vasc Biol, La Jolla, CA 92037 USA; Dept Expt Med, La Jolla, CA 92037 USA		Kiosses, WB (corresponding author), Dept Vasc Biol, 10550 N torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243				BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	24	223	226	0	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					316	320		10.1038/35060120	http://dx.doi.org/10.1038/35060120			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231584				2022-12-25	WOS:000167365800021
J	Lefebvre, L; Dionne, N; Karaskova, J; Squire, JA; Nagy, A				Lefebvre, L; Dionne, N; Karaskova, J; Squire, JA; Nagy, A			Selection for transgene homozygosity in embryonic stem cells results in extensive loss of heterozygosity	NATURE GENETICS			English	Letter							MICE; LACKING; ALLELE	Embryonic stem cells offer unprecedented opportunities for random or targeted genome alterations in the mouse. We present here an efficient strategy to create chromosome-specific loss of heterozygosity in embryonic stem cells. The combination of this method with genome-wide mutagenesis in ES cells (using chemical mutagens or gene-trap vectors) opens up the possibility for in vitro or in vivo functional screening of recessive mutations in the mouse.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Lefebvre, L (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.		Squire, Jeremy A/A-9352-2012; Nagy, Andras/G-6465-2013	Squire, Jeremy A/0000-0002-9863-468X; Nagy, Andras/0000-0003-4311-0413				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; Dufort D, 1998, DEVELOPMENT, V125, P3015; Festing MFW, 1999, MAMM GENOME, V10, P836, DOI 10.1007/s003359901099; Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Munroe RJ, 2000, NAT GENET, V24, P318, DOI 10.1038/73563; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PALUDAN K, 1989, GENE, V85, P421, DOI 10.1016/0378-1119(89)90435-6; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Robinson WP, 2000, BIOESSAYS, V22, P452; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453	15	36	39	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					257	258		10.1038/85808	http://dx.doi.org/10.1038/85808			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242104				2022-12-25	WOS:000167304200014
J	Bussemaker, HJ; Li, H; Siggia, ED				Bussemaker, HJ; Li, H; Siggia, ED			Regulatory element detection using correlation with expression	NATURE GENETICS			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATOR; CELL-CYCLE; GENOME; PATTERNS; SEQUENCE; PROTEIN; HYBRIDIZATION; MICROARRAY	We present here a new computational method for discovering cis-regulatory elements that circumvents the need to cluster genes based on their expression profiles. Based on a model in which upstream motifs contribute additively to the log-expression level of a gene, this method requires a single genome-wide set of expression ratios and the upstream sequence for each gene, and outputs statistically significant motifs. Analysis of publicly available expression data for Saccharomyces cerevisiae reveals several new putative regulatory elements, some of which plausibly control the early, transient induction of genes during sporulation. Known motifs generally have high statistical significance.	Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University	Bussemaker, HJ (corresponding author), Univ Amsterdam, Amsterdam Ctr Computat Sci, Swammerdam Inst Life Sci, Kruislaan 403, Amsterdam, Netherlands.							Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Ptashne M, 1998, CURR BIOL, V8, pR897; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	24	509	526	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					167	171		10.1038/84792	http://dx.doi.org/10.1038/84792			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175784				2022-12-25	WOS:000166839200017
J	Johnson, KR; Zheng, QY; Bykhovskaya, Y; Spirina, O; Fischel-Ghodsian, N				Johnson, KR; Zheng, QY; Bykhovskaya, Y; Spirina, O; Fischel-Ghodsian, N			A nuclear-mitochondrial DNA interaction affecting hearing impairment in mice	NATURE GENETICS			English	Article							RIBOSOMAL-RNA MUTATION; NON-SYNDROMIC DEAFNESS; MOUSE; GENE; STRAINS; PHENOTYPE	The pathophysiologic pathways and clinical expression of mitochondrial DNA (mtDNA) mutations are not well understood. This is mainly the result of the heteroplasmic nature of most pathogenic mtDNA mutations and of the absence of clinically relevant animal models with mtDNA mutations, mtDNA mutations predisposing to hearing impairment in humans are generally homoplasmic, yet some individuals with these mutations have severe hearing loss, whereas their maternal relatives with the identical mtDNA mutation have normal hearing(1,2). Epidemiologic, biochemical and genetic data indicate that nuclear genes are often the main determinants of these differences in phenotype(3-5). To identify a mouse model for maternally inherited hearing loss, we screened reciprocal backcrosses of three inbred mouse strains, A/J. NOD/LtJ and SKH2/J, with age-related hearing loss (AHL). In the (A/JxCAST/Ei)xA/J backcross. mtDNA derived from the A/J strain exerted a significant detrimental effect on hearing when compared with mtDNA from the CAST/Ei strain. This effect was not seen in the (NOD/LtJ xCAST/Ei)xNOD/LtJ and (SKH2/JxCAST/Ei)xSKH2/J backcrosses. Genotyping revealed that this effect was seen only in mice homozygous for the A/J allele at the Ahl locus on mouse chromosome 10. Sequencing of the mitochondrial genome in the three inbred strains revealed a single nucleotide insertion in the fRNA-Arg gene (mt-Tr) as the probable mediator of the mitochondrial effect. This is the first mouse model with a naturally occurring mtDNA mutation affecting a clinical phenotype, and it provides an experimental model to dissect the pathophysiologic processes connecting mtDNA mutations to hearing loss.	Jackson Lab, Bar Harbor, ME 04609 USA; Cedars Sinai Med Ctr, Ahmanson Dept Pediat,Burns & Allen Res Inst, Steven Spielberg Pediat Res Ctr, Ctr Med Genet Birth Defects, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	Jackson Laboratory; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fischel-Ghodsian, N (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Zheng, Qing/C-1731-2012		NIDCD NIH HHS [R01 DC004301-01, R01 DC005827, R01 DC001402, R01 DC005827-01, R03 DC004376-01A1, R01 DC004092-01, R01 DC001402-07, R01 DC004301] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402, R01DC004092, R03DC004376, R01DC005827, R01DC004301] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAL U, 1997, AM J OTOL, V18, P449; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Bryda EC, 1997, MAMM GENOME, V8, P1, DOI 10.1007/s003359900336; Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914; Chaib H, 1996, HUM MOL GENET, V5, P1061, DOI 10.1093/hmg/5.7.1061; DEOL MS, 1956, PROC R SOC SER B-BIO, V145, P206, DOI 10.1098/rspb.1956.0028; FERRIS SD, 1982, NATURE, V295, P163, DOI 10.1038/295163a0; Fischel-Ghodsian N, 1998, MOL GENET METAB, V65, P97, DOI 10.1006/mgme.1998.2751; Fischel-Ghodsian N, 1999, HUM MUTAT, V13, P261, DOI 10.1002/(SICI)1098-1004(1999)13:4<261::AID-HUMU1>3.0.CO;2-W; FischelGhodsian N, 1997, HEARING RES, V110, P147, DOI 10.1016/S0378-5955(97)00077-4; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86; Johnson KR, 2000, GENOMICS, V70, P171, DOI 10.1006/geno.2000.6377; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955; LI HS, 1994, ORL J OTO-RHINO-LARY, V56, P61, DOI 10.1159/000276611; Liu W, 1999, BBA-GEN SUBJECTS, V1473, P356, DOI 10.1016/S0304-4165(99)00143-9; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SLIGH JE, 2000, AM J HUM GENET S2, V67, pA53; Spongr VP, 1997, J ACOUST SOC AM, V101, P3546, DOI 10.1121/1.418315; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; WAYNE S, 1996, HUM MOL GENET, V10, P1689; Willott JF, 1998, HEARING RES, V119, P27, DOI 10.1016/S0378-5955(98)00029-X; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	30	127	135	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					191	194		10.1038/84831	http://dx.doi.org/10.1038/84831			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175788	Green Accepted			2022-12-25	WOS:000166839200021
J	Taddei, A; Maison, C; Roche, D; Almouzni, G				Taddei, A; Maison, C; Roche, D; Almouzni, G			Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases	NATURE CELL BIOLOGY			English	Article							FISSION YEAST CENTROMERES; CHROMOSOME SEGREGATION; HISTONE DEACETYLATION; DEPENDENT MANNER; DNA; ACETYLATION; INHERITANCE; PROTEIN-1; CELLS; CYCLE	Histone modifications might act to mark and maintain functional chromatin domains during both interphase and mitosis. Here we show that pericentric heterochromatin in mammalian cells is specifically responsive to prolonged treatment with deacetylase inhibitors. These defined regions relocate at the nuclear periphery and lose their properties of retaining HP1 (heterochromatin protein 1) proteins. Subsequent defects in chromosome segregation arise in mitosis. All these changes can reverse rapidly after drug removal. Our data point to a crucial role of histone under-acetylation within pericentric heterochromatin regions for their association with HP1 proteins, their nuclear compartmentalization and their contribution to centromere function.	Inst Curie, UMR 218 CNRS, Res Sect, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Almouzni, G (corresponding author), Inst Curie, UMR 218 CNRS, Res Sect, 26 Rue Ulm, F-75248 Paris 05, France.		Almouzni, Genevieve/ABG-1029-2021	Almouzni, Genevieve/0000-0001-5570-0723				Belyaev ND, 1996, EXP CELL RES, V225, P277, DOI 10.1006/excr.1996.0177; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Cerda MC, 1999, BIOL CELL, V91, P55, DOI 10.1016/S0248-4900(99)80031-8; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Grewal SIS, 1998, GENETICS, V150, P563; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; KELLUM R, 1995, J CELL SCI, V108, P1419; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; MARRAZZINI A, 1994, MUTAGENESIS, V9, P505, DOI 10.1093/mutage/9.6.505; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Paro R, 2000, NATURE, V406, P579, DOI 10.1038/35020675; PUVIONDUTILLEUL F, 1992, EUR J CELL BIOL, V58, P149; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Remboutsika E, 1999, J CELL SCI, V112, P1671; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhao T, 2000, J BIOL CHEM, V275, P28332	41	299	310	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					114	120		10.1038/35055010	http://dx.doi.org/10.1038/35055010			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175742				2022-12-25	WOS:000166793000011
J	Zhang, XH; Zhao, J; Li, CF; Gao, S; Qiu, CC; Liu, P; Wu, GY; Qiang, BQ; Lo, WHY; Shen, Y				Zhang, XH; Zhao, J; Li, CF; Gao, S; Qiu, CC; Liu, P; Wu, GY; Qiang, BQ; Lo, WHY; Shen, Y			DSPP mutation in dentinogenesis imperfecta Shields type II	NATURE GENETICS			English	Article							GENOMIC ORGANIZATION; DENTIN PHOSPHOPROTEIN; CAUSATIVE ROLE; LOCUS; GENE; SIALOPROTEIN; PATHOGENESIS; EXCLUSION; SEQUENCE	We identified a nonsense mutation (Gln45stop) in exon 3 of the dentin sialophospho-protein (DSPP) gene in a Chinese family with dentinogenesis imperfecta Shields type II(DGI-II), in which the affected members showed discoloration and severe attrition of their teeth, with obliterated pulp chambers.	Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing, Peoples R China; Tianjin Univ, Stomatol Hosp, Tianjin 300072, Peoples R China; Natl Ctr Human Genome Res, Beijing 100176, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Tianjin University	Shen, Y (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing, Peoples R China.							Aplin HM, 1999, J DENT RES, V78, P1270, DOI 10.1177/00220345990780061201; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; CROSBY AH, 1995, AM J HUM GENET, V57, P832; Crosby AH, 1996, MAMM GENOME, V7, P149, DOI 10.1007/s003359900037; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; TAKAGI Y, 1986, J ORAL PATHOL MED, V15, P463, DOI 10.1111/j.1600-0714.1986.tb00659.x; VELS A, 1998, EUR J ORAL SCI, V106, P234; WITKOP C J, 1957, Acta Genet Stat Med, V7, P236	12	211	243	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					151	152		10.1038/84765	http://dx.doi.org/10.1038/84765			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175779				2022-12-25	WOS:000166839200012
J	Raamsdonk, LM; Teusink, B; Broadhurst, D; Zhang, NS; Hayes, A; Walsh, MC; Berden, JA; Brindle, KM; Kell, DB; Rowland, JJ; Westerhoff, HV; van Dam, K; Oliver, SG				Raamsdonk, LM; Teusink, B; Broadhurst, D; Zhang, NS; Hayes, A; Walsh, MC; Berden, JA; Brindle, KM; Kell, DB; Rowland, JJ; Westerhoff, HV; van Dam, K; Oliver, SG			A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations	NATURE BIOTECHNOLOGY			English	Article						functional genomics; metabolome; yeast; Saccharomyces cerevisiae; silent mutations; phenotype analysis; metabolic central analysis; co-response analysis	YEAST; 6-PHOSPHOFRUCTO-2-KINASE; IDENTIFICATION; CONSTRUCTION; BACTERIA; SEQUENCE; STRAINS; CLONING; ENZYME	A large proportion of the 6,000 genes present in the genome of Saccharomyces cerevisiae, and of those sequenced in other organisms, encode proteins of unknown function. Many of these genes are "silent," that is, they show no overt phenotype, in terms of growth rate or other fluxes, when they are deleted from the genome. We demonstrate how the intracellular concentrations of metabolites can reveal phenotypes for proteins active in metabolic regulation. Quantification of the change of several metabolite concentrations relative to the concentration change of one selected metabolite can reveal the site of action, in the metabolic network, of a silent gene. In the same way, comprehensive analyses of metabolite concentrations in mutants, providing "metabolic snapshots," can reveal functions when snapshots from strains deleted for unstudied genes are compared to those deleted for known genes. This approach to functional analysis, using comparative metabolomics, we call FANCY-an abbreviation for functional analysis by co-responses in yeast.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Amsterdam, Bioctr Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands; Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DD, Dyfed, Wales; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Wales, Dept Comp Sci, Aberystwyth SY23 3DB, Dyfed, Wales; Free Univ Amsterdam, Bioctr Amsterdam, Dept Mol Cell Physiol, NL-1081 HV Amsterdam, Netherlands	University of Manchester; University of Amsterdam; Aberystwyth University; University of Cambridge; Aberystwyth University; University of Amsterdam; Vrije Universiteit Amsterdam	Oliver, SG (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	steve.oliver@man.ac.uk	Kell, Douglas/E-8318-2011; Oliver, Stephen/AAQ-5992-2021; Westerhoff, Hans V/I-5762-2012	Kell, Douglas/0000-0001-5838-7963; Oliver, Stephen/0000-0003-3410-6439; Westerhoff, Hans V/0000-0002-0443-6114; Broadhurst, David/0000-0003-0775-9581; Zhang, Nianshu/0000-0002-2690-7554; Teusink, Bas/0000-0003-3929-0423				Arkin A, 1997, SCIENCE, V277, P1275, DOI 10.1126/science.277.5330.1275; Baganz F, 1997, YEAST, V13, P1563, DOI 10.1002/(SICI)1097-0061(199712)13:16<1563::AID-YEA240>3.3.CO;2-Y; Baganz F, 1998, YEAST, V14, P1417, DOI 10.1002/(SICI)1097-0061(199811)14:15<1417::AID-YEA334>3.0.CO;2-N; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; Boles E, 1996, MOL MICROBIOL, V20, P65, DOI 10.1111/j.1365-2958.1996.tb02489.x; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; BURNS JA, 1985, TRENDS BIOCHEM SCI, V10, P16, DOI 10.1016/0968-0004(85)90008-8; CAUSTON DR, 1987, BIOL ADV MATH; Cole R., 1997, ELECTROSPRAY IONIZAT; Cornish-Bowden A, 2000, NAT BIOTECHNOL, V18, P267, DOI 10.1038/73696; CORNISHBOWDEN A, 1994, BIOCHEM J, V298, P367, DOI 10.1042/bj2980367; FELL D, 1996, UNDERSTANDING CONTRO; Gaskell SJ, 1997, J MASS SPECTROM, V32, P677, DOI 10.1002/(SICI)1096-9888(199707)32:7<677::AID-JMS536>3.3.CO;2-7; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; Goodacre R, 1997, ANAL CHIM ACTA, V348, P511, DOI 10.1016/S0003-2670(97)00062-7; Goodacre R, 1998, MICROBIOL-SGM, V144, P1157, DOI 10.1099/00221287-144-5-1157; Griffiths P., 1986, FOURIER TRANSFORM IN; HEINRICH R, 1973, ACTA BIOL MED GER, V31, P479; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Hofmeyr JHS, 1996, J THEOR BIOL, V182, P371, DOI 10.1006/jtbi.1996.0176; HOFMEYR JHS, 1993, EUR J BIOCHEM, V212, P833, DOI 10.1111/j.1432-1033.1993.tb17725.x; Hutter A, 1998, APPL MICROBIOL BIOT, V49, P511, DOI 10.1007/s002530051206; Jolliffe I. T., 2002, PRINCIPAL COMPONENT, V2nd; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KELL DB, 1986, FEMS MICROBIOL LETT, V39, P305, DOI 10.1016/0378-1097(86)90020-0; Kell DB, 2000, NATO ASI 3 HIGH TECH, V74, P3; KHOLODENKO BN, 1995, FEBS LETT, V368, P1, DOI 10.1016/0014-5793(95)00562-N; KRETSCHMER M, 1991, EUR J BIOCHEM, V197, P367, DOI 10.1111/j.1432-1033.1991.tb15920.x; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; Lindon JC, 1996, PROG NUCL MAG RES SP, V29, P1, DOI 10.1016/0079-6565(95)01027-0; MACFIE HJH, 1978, J GEN MICROBIOL, V104, P67, DOI 10.1099/00221287-104-1-67; MARTENS H, 1989, MULTIVARIATE CALLBRA; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; Oliver S, 1999, NAT GENET, V21, P245, DOI 10.1038/6748; Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; Oliver SG, 1997, MICROBIOL-UK, V143, P1483, DOI 10.1099/00221287-143-5-1483; PARAVICINI G, 1992, BIOCHEMISTRY-US, V31, P7126, DOI 10.1021/bi00146a014; Rohwer JM, 1996, J THEOR BIOL, V179, P213, DOI 10.1006/jtbi.1996.0062; ROHWER JM, 1997, THESIS U AMSTERDAM A; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; SLONIMSKI PP, 1968, BIOCHEM BIOPH RES CO, V30, P232, DOI 10.1016/0006-291X(68)90440-3; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Teusink B, 1998, METHOD MICROBIOL, V26, P297; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WINDIG W, 1983, ANAL CHEM, V55, P81, DOI 10.1021/ac00252a023; Winson MK, 1997, ANAL CHIM ACTA, V348, P273, DOI 10.1016/S0003-2670(97)00237-7; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YOCUM R, 1986, P BIO EXPO, V86, P17	54	793	852	3	187	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					45	50		10.1038/83496	http://dx.doi.org/10.1038/83496			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135551				2022-12-25	WOS:000166261400018
J	Read, TA; Sorensen, DR; Mahesparan, R; Enger, PO; Timpl, R; Olsen, BR; Hjelstuen, MHB; Haraldseth, O; Bjerkvig, R				Read, TA; Sorensen, DR; Mahesparan, R; Enger, PO; Timpl, R; Olsen, BR; Hjelstuen, MHB; Haraldseth, O; Bjerkvig, R			Local endostatin treatment of gliomas administered by microencapsulated producer cells	NATURE BIOTECHNOLOGY			English	Article						alginate; encapsulation; producer cell; brain tumors	CENTRAL-NERVOUS-SYSTEM; TUMOR-GROWTH; IMMOBILIZATION MATERIAL; ANGIOGENESIS; ALGINATE; BRAIN; INHIBITOR; DELIVERY; CARCINOMA; APOPTOSIS	We describe a technique for the treatment of malignant brain tumors based on local delivery of the anti-angiogenic protein endostatin from genetically engineered cells encapsulated in ultrapure sodium alginate. Alginate consists of L-guluronic and D-mannuronic acid, which in the presence of divalent cations forms an extended gel network, in which cells reside and remain immunoisolated, when implanted into the rat brain. Here, we show that endostatin-transfected cells encapsulated in alginate maintain endostatin secretion for at least four months after intracerebral implantation in rats. During the implantation period 70% of the encapsulated cells remained viable, as opposed to 85% in in vitro-cultured capsules. Rats that received transplants of BT4C glioma cells, together with endostatin-producing capsules (0.2 mug/ml per capsule), survived 84% longer than the controls. The endostatin released from the capsules led to an induction of apoptosis, hypoxia, and large necrotic avascular areas within 77% of the treated tumors, whereas all the controls were negative. The encapsulation technique may be used for many different cell lines engineered to potentially interfere with the complex microenvironment in which tumor and normal cells reside. The present work may thus provide the basis for new therapeutic approaches toward brain tumors.	Univ Bergen, Dept Anat & Cell Biol, N-5020 Bergen, Norway; Univ Oslo, Natl Hosp, Dept Comparat Med, N-0316 Oslo, Norway; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Harvard Univ, Sch Med, Boston, MA USA; SINTEF Unimed, MR Ctr, N-7565 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Anaesthesia & Med Imaging, N-7034 Trondheim, Norway	University of Bergen; University of Oslo; National Hospital Norway; Max Planck Society; Harvard University; Harvard Medical School; SINTEF; Norwegian University of Science & Technology (NTNU)	Read, TA (corresponding author), Univ Bergen, Dept Anat & Cell Biol, N-5020 Bergen, Norway.	Tracy-Ann.Read@PKI.UIB.NO		Read, Tracy-Ann/0000-0002-5436-1296				BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boucher Y, 1997, BRIT J CANCER, V75, P829, DOI 10.1038/bjc.1997.148; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2; Chen QR, 1999, CANCER RES, V59, P3308; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DRUCKREY H, 1971, ARZNEI-FORSCHUNG, V21, P1274; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; Hottinger AF, 1999, ADV TECH STAND NEUR, V25, P3; Kleihues P., 1997, PATHOLOGY GENETICS T, P16; Krewson CE, 1996, BRAIN RES, V727, P169; LAERUM OD, 1975, J NATL CANCER I, V55, P1177, DOI 10.1093/jnci/55.5.1177; Lang MS, 1995, CLIN EXP IMMUNOL, V102, P468; Lichtenbeld HC, 1999, MICROVASC RES, V57, P357, DOI 10.1006/mvre.1998.2140; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Mahesparan R, 1999, ACTA NEUROPATHOL, V97, P231, DOI 10.1007/s004010050979; Mahoney MJ, 1999, P NATL ACAD SCI USA, V96, P4536, DOI 10.1073/pnas.96.8.4536; MARTINSEN A, 1992, BIOTECHNOL BIOENG, V39, P186, DOI 10.1002/bit.260390210; MARTINSEN A, 1989, BIOTECHNOL BIOENG, V33, P79, DOI 10.1002/bit.260330111; Olivi A, 2000, Forum (Genova), V10, P152; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; Read TA, 1999, INT J DEV NEUROSCI, V17, P653, DOI 10.1016/S0736-5748(99)00052-0; Ross CJD, 1999, HUM GENE THER, V10, P49, DOI 10.1089/10430349950019183; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; SCHERER H. J., 1938, AMER JOUR CANCER, V34, P333; STEEN RG, 1993, J NEURO-ONCOL, V16, P81, DOI 10.1007/BF01324839; TAKEOKA T, 1980, BRAIN RES, V198, P147, DOI 10.1016/0006-8993(80)90350-9; THORSEN F, 2000, CELL TRANSPLANT  DEC; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P239, DOI 10.1097/00005072-199803000-00005; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Visted T, 2000, INT J CANCER, V85, P228, DOI 10.1002/(SICI)1097-0215(20000115)85:2<228::AID-IJC13>3.0.CO;2-9; WALKER GR, 1995, J NIH RES, V7, P76; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117	39	241	263	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					29	34		10.1038/83471	http://dx.doi.org/10.1038/83471			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135548				2022-12-25	WOS:000166261400015
J	Luo, GB; Santoro, IM; McDaniel, LD; Nishijima, I; Mills, M; Youssoufian, H; Vogel, H; Schultz, RA; Bradley, A				Luo, GB; Santoro, IM; McDaniel, LD; Nishijima, I; Mills, M; Youssoufian, H; Vogel, H; Schultz, RA; Bradley, A			Cancer predisposition caused by elevated mitotic recombination in Bloom mice	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; WERNERS-SYNDROME GENES; INTESTINAL ADENOMAS; RECQ FAMILY; HELICASE; CLONING; MOUSE; HOMOLOG; LOCALIZATION; DISRUPTION	Bloom syndrome is a disorder associated with genomic instability that causes affected people to be prone to cancer. Bloom cell lines show increased sister chromatid exchange, yet are proficient in the repair of various DNA lesions. The underlying cause of this disease are mutations in a gene encoding a RECQ DNA helicase. Using embryonic stem cell technology, we have generated viable Bloom mice that are prone to a wide variety of cancers. Cell lines from these mice show elevations in the rates of mitotic recombination. We demonstrate that the increased rate of loss of heterozygosity (LOH) resulting from mitotic recombination in vivo constitutes the underlying mechanism causing tumour susceptibility in these mice.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bradley, A (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge, England.			Bradley, Allan/0000-0002-2349-8839; Vogel, Otto Hannes/0000-0002-0960-3508				Abuin A, 1996, MOL CELL BIOL, V16, P1851; Bilger A, 1996, SEMIN CANCER BIOL, V7, P249, DOI 10.1006/scbi.1996.0033; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; COLLET B, 1995, INTERNET WORLD, V6, P8; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GERMAN J, 1994, CURRENT PROTOCOLS HU; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Jacoby RF, 1996, CANCER RES, V56, P710; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; LUONGO C, 1994, CANCER RES, V54, P5947; Luria SE, 1943, GENETICS, V28, P491; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Watt PM, 1996, GENETICS, V144, P935; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	34	319	335	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					424	429		10.1038/82548	http://dx.doi.org/10.1038/82548			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101838				2022-12-25	WOS:000165671700013
J	Martinez-Botas, J; Anderson, JB; Tessier, D; Lapillonne, A; Chang, BHJ; Quast, MJ; Gorenstein, D; Chen, KH; Chan, L				Martinez-Botas, J; Anderson, JB; Tessier, D; Lapillonne, A; Chang, BHJ; Quast, MJ; Gorenstein, D; Chen, KH; Chan, L			Absence of perilipin results in leanness and reverses obesity in Lepr db db mice	NATURE GENETICS			English	Article							HORMONE-SENSITIVE LIPASE; NEUTRAL LIPID DROPLETS; ADIPOSE-TISSUE; ADIPOCYTES; RECEPTOR; PROTEINS; CELLS; GENE	Obesity is a disorder of energy balance(1). Hormone-sensitive lipase (HSL) mediates the hydrolysis of triacylglycerol(2). the major form of stored energy in the body. Perilipin (encoded by the gene Plin), an adipocyte protein, has been postulated to modulate HSL activity(3-5). We show here that targeted disruption of Plin results in healthy mice that have constitutively activated fat-cell HSL. Plin(-/-) mice consume more food than control mice, but have normal body weight. They are much leaner and more muscular than controls, have 62% smaller white adipocytes, show elevated basal lipolysis that is resistant to beta -adrenergic agonist stimulation, and are cold-sensitive except when fed. They are also resistant to diet-induced obesity. Breeding the Plin(-/-) alleles into Lepr(db/db) mice reverses the obesity by increasing the metabolic rate of the mice. Our results demonstrate a role for perilipin in mining in basal HSL activity and regulating lipolysis and energy balance; thus, agents that inactivate perilipin may prove useful as anti-obesity medications.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; ARS, USDA, Childrens Nutr Res Ctr, Houston, TX USA; Univ Texas, Med Branch, Inst Marine Biomed, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Radiol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77550 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Chan, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.		Martinez-Botas, Javier/AAD-8733-2021	Martinez-Botas, Javier/0000-0002-5190-3619	NHLBI NIH HHS [HL-51586] Funding Source: Medline; NIEHS NIH HHS [ES-06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Holm C, 1997, METHOD ENZYMOL, V286, P45; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N	15	465	485	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					474	479		10.1038/82630	http://dx.doi.org/10.1038/82630			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101849				2022-12-25	WOS:000165671700024
J	White, R; Leonardsson, G; Rosewell, I; Jacobs, MA; Milligan, S; Parker, M				White, R; Leonardsson, G; Rosewell, I; Jacobs, MA; Milligan, S; Parker, M			The nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility	NATURE MEDICINE			English	Article							UNRUPTURED FOLLICLE SYNDROME; ESTROGEN-RECEPTOR; MICE LACKING; C/EBP-BETA; GENE; EXPRESSION; MOUSE; DISRUPTION; ANTAGONISM; OVULATION	Ovulatory dysfunction is the commonest cause of female infertility. Here we shaw that the co-repressor nuclear-receptor-interacting protein 1 (Nrip1; encoded by the gene Nrip1) is essential for ovulation. Mice null for this protein are viable, but female mice are infertile because of complete failure of mature follicles to release the oocyte at ovulation. In contrast, luteinization proceeds normally, resulting in a phenotype closely resembling that of luteinized unruptured follicle syndrome, often associated with infertility in women. Therefore, whereas the pre-ovulatory surge of luteinizing hormone induces both ovulation and luteinization, the ability to suppress the action of nuclear receptors is essential for the coordinated control of ovarian function with the essential process of oocyte release dependent on the activity of the transcriptional co-repressor Nrip1 (RIP40).	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Kings Coll London, Sch Biomed Sci, London SE1 1UL, England	Cancer Research UK; University of London; Queen Mary University London; University of London; King's College London	Parker, M (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Inst Reprod & Dev Biol, London W12 0NN, England.	M.Parker@ic.ac.uk						Abel MH, 2000, ENDOCRINOLOGY, V141, P1795, DOI 10.1210/en.141.5.1795; Brosens I A, 1980, Fertil Steril, V34, P179; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Byers M, 1997, MOL ENDOCRINOL, V11, P172, DOI 10.1210/me.11.2.172; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Coetsier T, 1996, HUM REPROD, V11, P583, DOI 10.1093/HUMREP/11.3.583; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; DONNEZ J, 1982, EUR J OBSTET GYN R B, V14, P187, DOI 10.1016/0028-2243(82)90095-8; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; Glass CK, 2000, GENE DEV, V14, P121; Groet J, 1998, GENOME RES, V8, P385, DOI 10.1101/gr.8.4.385; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hogan B, 1994, MANIPULATING MOUSE E; KONINCKX PR, 1980, BRIT J OBSTET GYNAEC, V87, P929, DOI 10.1111/j.1471-0528.1980.tb04454.x; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nokelainen P, 2000, ENDOCRINOLOGY, V141, P772, DOI 10.1210/en.141.2.772; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; PENG XR, 1991, ENDOCRINOLOGY, V129, P3200, DOI 10.1210/endo-129-6-3200; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; RAJENDRAKUMAR T, 1997, NAT GENET, V15, P201; Risma KA, 1997, ENDOCRINOLOGY, V138, P3540, DOI 10.1210/en.138.8.3540; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Wiersma A, 1998, J CLIN INVEST, V102, P532, DOI 10.1172/JCI2566; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	45	151	160	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1368	1374		10.1038/82183	http://dx.doi.org/10.1038/82183			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100122				2022-12-25	WOS:000165704100041
J	De Edeleny, FS; Rubin, C; Esteve, F; Grand, S; Decorps, M; Lefournier, V; Le Bas, JF; Remy, C				De Edeleny, FS; Rubin, C; Esteve, F; Grand, S; Decorps, M; Lefournier, V; Le Bas, JF; Remy, C			A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images	NATURE MEDICINE			English	Article							H-1 MR SPECTROSCOPY; IN-VIVO; AUTOMATED CLASSIFICATION; METABOLIC HETEROGENEITY; INTRACRANIAL TUMORS; IMAGING METHOD; MULTICENTER; DIAGNOSIS; GLIOMAS; INVIVO		CHU Grenoble, LRC CEA, Unite Mixte INSERM Univ Joseph Fourier, U438, F-38043 Grenoble 9, France; CHU Grenoble, Unite IRM, F-38043 Grenoble 9, France; CHU Grenoble, Serv Neuroradiol, F-38043 Grenoble 9, France	CEA; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Esteve, F (corresponding author), CHU Grenoble, LRC CEA, Unite Mixte INSERM Univ Joseph Fourier, U438, BP 217, F-38043 Grenoble 9, France.	FEsteve@chu-grenoble.fr	Remy, Chantal/L-9459-2014; Szabo de Edelenyi, Fabien/F-2715-2017; Grand, Sylvie/L-7958-2014	Szabo de Edelenyi, Fabien/0000-0002-8487-6557; 				BLUM A, 1995, J RADIOL, V76, P441; BURGER PC, 1989, CANCER-AM CANCER SOC, V63, P2014, DOI 10.1002/1097-0142(19890515)63:10<2014::AID-CNCR2820631025>3.0.CO;2-L; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DEMAEREL P, 1991, J COMPUT ASSIST TOMO, V15, P67, DOI 10.1097/00004728-199101000-00009; ElDeredy W, 1997, NMR BIOMED, V10, P99, DOI 10.1002/(SICI)1099-1492(199705)10:3<99::AID-NBM461>3.0.CO;2-#; FULHAM MJ, 1992, RADIOLOGY, V185, P675, DOI 10.1148/radiology.185.3.1438744; Furuya S, 1997, NMR BIOMED, V10, P25, DOI 10.1002/(SICI)1099-1492(199701)10:1<25::AID-NBM445>3.0.CO;2-M; Hagberg G, 1998, NMR BIOMED, V11, P148, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<148::AID-NBM511>3.0.CO;2-4; HAGBERG G, 1995, MAGN RESON MED, V34, P242, DOI 10.1002/mrm.1910340216; Hand D. J, 1981, WILEY SERIES PROBABI; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; Negendank WG, 1996, J NEUROSURG, V84, P449, DOI 10.3171/jns.1996.84.3.0449; OTT D, 1993, RADIOLOGY, V186, P745, DOI 10.1148/radiology.186.3.8430183; PAULUS W, 1989, CANCER, V64, P442, DOI 10.1002/1097-0142(19890715)64:2<442::AID-CNCR2820640217>3.0.CO;2-S; Preul MC, 1998, NMR BIOMED, V11, P192, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<192::AID-NBM535>3.0.CO;2-3; Preul MC, 1996, NAT MED, V2, P323, DOI 10.1038/nm0396-323; REMY C, 1995, MAGNET RESON MED, V34, P508, DOI 10.1002/mrm.1910340404; Roser W, 1997, MAGN RESON MATER PHY, V5, P179, DOI 10.1007/BF02594580; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; SIJENS PE, 1995, MAGNET RESON MED, V33, P818, DOI 10.1002/mrm.1910330612; Tate AR, 1998, NMR BIOMED, V11, P177, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<177::AID-NBM534>3.0.CO;2-U; Usenius JP, 1996, NEUROREPORT, V7, P1597, DOI 10.1097/00001756-199607080-00013	23	116	118	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1287	1289		10.1038/81401	http://dx.doi.org/10.1038/81401			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062544				2022-12-25	WOS:000165114800040
J	Lorenzen, N; Cupit, PM; Einer-Jensen, K; Lorenzen, E; Ahrens, P; Secombes, CJ; Cunningham, C				Lorenzen, N; Cupit, PM; Einer-Jensen, K; Lorenzen, E; Ahrens, P; Secombes, CJ; Cunningham, C			Immunoprophylaxis in fish by injection of mouse antibody genes	NATURE BIOTECHNOLOGY			English	Article						single-chain antibody; rhabdovirus; gene therapy	SINGLE-CHAIN ANTIBODY; TROUT ONCORHYNCHUS-MYKISS; RAINBOW-TROUT; INTRACELLULAR EXPRESSION; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY; LETHAL INFECTION; DNA VACCINES; FV FRAGMENTS; VIRUS	Antibodies are a crucial part of the body's specific defense against infectious diseases and have considerable potential as therapeutic and prophylactic agents in humans and animals, The development of recombinant single-chain antibodies allows a genetic application strategy for prevention of infectious diseases. To test this in a fish model, a gene construct encoding a neutralizing single-chain antibody to the fish-pathogenic rhabdovirus VHSV (viral hemorrhagic septicemia virus) was administered to rainbow trout by intramuscular injection of plasmid DNA, Circulating recombinant antibodies could later be detected in the fish, and protective immunity to the viral disease was established.	Danish Vet Lab, DK-8200 Aarhus N, Denmark; Sars Int Ctr Marine Mol Biol, Ctr High Technol, N-5008 Bergen, Norway; Danish Vet Lab, DK-1790 Copenhagen V, Denmark; Univ Aberdeen, Dept Zool, Aberdeen AB24 2TZ, Scotland	University of Aberdeen	Lorenzen, N (corresponding author), Danish Vet Lab, Hangovej 2, DK-8200 Aarhus N, Denmark.	nl@svs.dk	Lorenzen, Ellen/B-1294-2014; Lorenzen, Niels/L-3967-2017	Ahrens, Peter/0000-0003-3776-7929; Lorenzen, Niels/0000-0002-6946-3252				AHNE W, 1986, J APPL ICHTHYOL, V2, P187, DOI 10.1111/j.1439-0426.1986.tb00427.x; BouHamdan M, 1999, GENE THER, V6, P660, DOI 10.1038/sj.gt.3300864; Cochet O, 1998, CANCER RES, V58, P1170; Cross AS, 1999, VACCINE, V17, pS13, DOI 10.1016/S0264-410X(99)00230-3; Hardie LJ, 1998, CYTOKINE, V10, P555, DOI 10.1006/cyto.1997.0334; Heppell J, 1998, FISH SHELLFISH IMMUN, V8, P271, DOI 10.1006/fsim.1997.0133; JENSEN MH, 1965, ANN NY ACAD SCI, V126, P422, DOI 10.1111/j.1749-6632.1965.tb14292.x; JIANG WR, 1995, J VIROL, V69, P1044, DOI 10.1128/JVI.69.2.1044-1049.1995; JORGENSEN P E V, 1991, Journal of Aquatic Animal Health, V3, P100, DOI 10.1577/1548-8667(1991)003&lt;0100:IHNIAV&gt;2.3.CO;2; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; LAFON M, 1994, IMMUNOBIOLOGY LYSSAV, P145; Lamarre A, 1997, EUR J IMMUNOL, V27, P3447, DOI 10.1002/eji.1830271245; LENOIR G, 1975, J VIROL, V16, P259, DOI 10.1128/JVI.16.2.259-262.1975; Lin TL, 1996, INFECT IMMUN, V64, P4085, DOI 10.1128/IAI.64.10.4085-4090.1996; LORENZEN E, 2000, IN PRESS J AQUAT ANI; Lorenzen N, 1999, FISH SHELLFISH IMMUN, V9, P345, DOI 10.1006/fsim.1999.0194; LORENZEN N, 1988, DIS AQUAT ORGAN, V4, P35, DOI 10.3354/dao004035; Lorenzen N, 1999, AQUACULTURE, V172, P41, DOI 10.1016/S0044-8486(98)00443-8; Lorenzen N, 2000, FISH SHELLFISH IMMUN, V10, P129, DOI 10.1006/fsim.1999.0232; LORENZEN N, 1990, J GEN VIROL, V71, P561, DOI 10.1099/0022-1317-71-3-561; Lorenzen N, 1998, FISH SHELLFISH IMMUN, V8, P261, DOI 10.1006/fsim.1997.0134; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MOLLOY P, 1995, J APPL BACTERIOL, V78, P359, DOI 10.1111/j.1365-2672.1995.tb03418.x; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; Muller BH, 1997, J VIROL METHODS, V67, P221, DOI 10.1016/S0166-0934(97)00099-2; NICOLET CM, 1995, CANCER GENE THER, V2, P161; Soudeyns H, 1999, IMMUNOL TODAY, V20, P446, DOI 10.1016/S0167-5699(99)01504-2; SRIKANTAN V, 1994, AIDS, V8, P1525, DOI 10.1097/00002030-199411000-00002; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Whittington HA, 1998, GENE THER, V5, P770, DOI 10.1038/sj.gt.3300685; Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664; Yamamoto M, 1999, HEPATOLOGY, V30, P300, DOI 10.1002/hep.510300105	33	26	28	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1177	1180		10.1038/81169	http://dx.doi.org/10.1038/81169			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062437	Green Published			2022-12-25	WOS:000165176600023
J	Ozaki, N; Shibasaki, T; Kashima, Y; Miki, T; Takahashi, K; Ueno, H; Sunaga, Y; Yano, H; Matsuura, Y; Iwanaga, T; Takai, Y; Seino, S				Ozaki, N; Shibasaki, T; Kashima, Y; Miki, T; Takahashi, K; Ueno, H; Sunaga, Y; Yano, H; Matsuura, Y; Iwanaga, T; Takai, Y; Seino, S			cAMP-GEFII is a direct target of cAMP in regulated exocytosis	NATURE CELL BIOLOGY			English	Article							LONG-TERM POTENTIATION; SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; PROTEIN-KINASE-A; CYCLIC-AMP; SYNAPTIC PLASTICITY; ACINAR-CELLS; TRANSMITTER RELEASE; INSULIN-SECRETION; CALCIUM	Although cAMP is well known to regulate exocytosis in many secretory cells, its direct target in the exocytotic machinery is not known. Here we show that cAMP-GEFII, a cAMP sensor, binds to Rim (Rab3-interacting molecule, Rab3 being a small G protein) and to a new isoform, RimP, both of which are putative regulators of fusion of vesicles to the plasma membrane. We also show that cAMP-GEFII, through its interaction with Rim2, mediates cAMP-induced, Ca2+-dependent secretion that is not blocked by an inhibitor of cAMP-dependent protein kinase (PKA). Accordingly, cAMP-GEFII is a direct target of cAMP in regulated exocytosis and is responsible for cAMP-dependent, PKA-independent exocytosis.	Chiba Univ, Grad Sch Med, Dept Mol Med, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Immunol, Chiba 2608670, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Chiba University; Chiba University; National Institute of Infectious Diseases (NIID); Hokkaido University; Osaka University	Ozaki, N (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Med, Chiba 2608670, Japan.		MIKI, Takashi/ABD-3995-2020	MIKI, Takashi/0000-0001-5741-1626				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIGGS CA, 1988, J PHYSIOL-LONDON, V404, P129, DOI 10.1113/jphysiol.1988.sp017282; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Calakos N, 1996, PHYSIOL REV, V76, P1; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chen CF, 1997, J NEUROSCI, V17, P8687; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIXON D, 1989, J NEUROSCI, V9, P4245; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Fujita-Yoshigaki J, 1998, CELL SIGNAL, V10, P371, DOI 10.1016/S0898-6568(97)00178-2; Goda Y, 1996, CURR BIOL, V6, P375, DOI 10.1016/S0960-9822(02)00499-2; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; KUBA K, 1986, J PHYSIOL-LONDON, V374, P515, DOI 10.1113/jphysiol.1986.sp016095; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salin PA, 1996, NEURON, V16, P797, DOI 10.1016/S0896-6273(00)80099-9; SCOTT TRD, 1993, BRIT J PHARMACOL, V110, P461, DOI 10.1111/j.1476-5381.1993.tb13833.x; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIKDAR SK, 1990, FEBS LETT, V273, P150, DOI 10.1016/0014-5793(90)81072-V; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tanaka J, 1996, ARCH HISTOL CYTOL, V59, P485, DOI 10.1679/aohc.59.485; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yoshimura K, 1998, BBA-MOL CELL RES, V1402, P171, DOI 10.1016/S0167-4889(98)00007-X	43	373	391	1	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					805	811		10.1038/35041046	http://dx.doi.org/10.1038/35041046			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056535				2022-12-25	WOS:000165207500014
J	Shanafelt, AB; Lin, Y; Shanafelt, MC; Forte, CP; Dubois-Stringfellow, N; Carter, C; Gibbons, JA; Cheng, SI; Delaria, KA; Fleischer, R; Greve, JM; Gundel, R; Harris, K; Kelly, R; Koh, B; Li, Y; Lantz, L; Mak, P; Neyer, L; Plym, MJ; Roczniak, S; Serban, D; Thrift, J; Tsuchiyama, L; Wetzel, M; Wong, M; Zolotorev, A				Shanafelt, AB; Lin, Y; Shanafelt, MC; Forte, CP; Dubois-Stringfellow, N; Carter, C; Gibbons, JA; Cheng, SI; Delaria, KA; Fleischer, R; Greve, JM; Gundel, R; Harris, K; Kelly, R; Koh, B; Li, Y; Lantz, L; Mak, P; Neyer, L; Plym, MJ; Roczniak, S; Serban, D; Thrift, J; Tsuchiyama, L; Wetzel, M; Wong, M; Zolotorev, A			A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo	NATURE BIOTECHNOLOGY			English	Article						structure-function analysis; mutagenesis; pharmacology; cancer; receptor	DOSE RECOMBINANT INTERLEUKIN-2; NATURAL-KILLER-CELLS; ESTABLISHED PULMONARY METASTASES; BETA-CHAIN P70; RECEPTORS IL-2R; PHASE-I; THERAPY; CANCER; BINDING; TOXICITY	Human interleukin 2 (IL-2; Proleukin) is an approved therapeutic for advanced-stage metastatic cancer; however, its use is restricted because of severe systemic toxicity. Its function as a central mediator of T-cell activation may contribute to its efficacy for cancer therapy. However, activation of natural killer (NK) cells by therapeutically administered IL-2 may mediate toxicity. Here we have used targeted mutagenesis of human IL-2 to generate a mutein with similar to3,000-fold in vitro selectivity for T cells over NK cells relative to wild-type IL-2, We compared the variant, termed BAY 50-4798, with human IL-2 (Proleukin) in a therapeutic dosing regimen in chimpanzees, and found that although the T-cell mobilization and activation properties of BAY 50-4788 were comparable to human IL-2, BAY 50-4798 was better tolerated in the chimpanzee. BAY 50-4798 was also shown to inhibit metastasis in a mouse tumor model. These results indicate that BAY 50-4798 may exhibit a greater therapeutic index than IL-2 in humans in the treatment of cancer and AIDS.	Bayer Corp, Div Pharmaceut, Res Sci, Biotechnol, Berkeley, CA 94701 USA; Bayer Corp, Div Pharmaceut, Proc Sci, Biotechnol, Berkeley, CA 94701 USA; Bayer Corp, Div Pharmaceut, Dept Canc & Osteoporosis Res, W Haven, CT 06556 USA	Bayer AG; Bayer AG; Bayer AG	Shanafelt, AB (corresponding author), Roche Diagnost Corp, 9115 Hague Rd, Indianapolis, IN 46250 USA.							ALLOUCHE M, 1990, LEUKEMIA RES, V14, P699, DOI 10.1016/0145-2126(90)90097-S; ANDERSON TD, 1988, LAB INVEST, V59, P598; ATKINS MB, 1986, J CLIN ONCOL, V4, P1380, DOI 10.1200/JCO.1986.4.9.1380; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; BIAC AB, 1998, LINK REACT TEST; BRONTE V, 1995, J IMMUNOL, V154, P5282; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V307, P411, DOI 10.1006/abbi.1993.1608; CALIGIURI MA, 1991, J CLIN ONCOL, V9, P2110, DOI 10.1200/JCO.1991.9.12.2110; Carson WE, 1997, EUR J IMMUNOL, V27, P354, DOI 10.1002/eji.1830270203; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; Eckenberg R, 1997, CYTOKINE, V9, P488, DOI 10.1006/cyto.1996.0192; ESPINOZADELGADO I, 1992, J IMMUNOL, V149, P2961; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; HANCOCK BW, 1990, CANCER CELL-MON REV, V2, P29; HERMANN GG, 1992, CANCER RES, V52, P726; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; KORETZ MJ, 1991, ARCH SURG-CHICAGO, V126, P898; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NASR S, 1989, CANCER, V64, P783, DOI 10.1002/1097-0142(19890815)64:4<783::AID-CNCR2820640402>3.0.CO;2-F; PEEST D, 1995, BRIT J HAEMATOL, V89, P328, DOI 10.1111/j.1365-2141.1995.tb03308.x; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1993, BLOOD, V81, P1414; STEIN RC, 1991, BRIT J CANCER, V63, P1029; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; VONDERMAASE H, 1991, EUR J CANCER, V27, P1583, DOI 10.1016/0277-5379(91)90419-E; VOSS SD, 1990, J EXP MED, V172, P1101, DOI 10.1084/jem.172.4.1101; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WEIR MP, 1988, BIOCHEMISTRY-US, V27, P6883, DOI 10.1021/bi00418a034; WITROUT RH, 1988, J IMMUNOL, V140, P3261; Xu D, 1995, EUR CYTOKINE NETW, V6, P237; ZAMBELLO R, 1994, CANCER, V74, P2562, DOI 10.1002/1097-0142(19941101)74:9<2562::AID-CNCR2820740926>3.0.CO;2-1; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	37	93	138	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1197	1202		10.1038/81199	http://dx.doi.org/10.1038/81199			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062441				2022-12-25	WOS:000165176600027
J	Movileanu, L; Howorka, S; Braha, O; Bayley, H				Movileanu, L; Howorka, S; Braha, O; Bayley, H			Detecting protein analytes that modulate transmembrane movement of a polymer chain within a single protein pore	NATURE BIOTECHNOLOGY			English	Article						biosensor; nanostructure; polymer; pore; protein engineering	STAPHYLOCOCCAL ALPHA-HEMOLYSIN; FORMING PROTEIN; CHANNEL; NANOTECHNOLOGY; STREPTAVIDIN; BINDING; BIOTIN; MUTAGENESIS; RECOGNITION; MOLECULES	Here we describe a new type of biosensor element for detecting proteins in solution at nanomolar concentrations. We tethered a 3.4 kDa polyethylene glycol chain at a defined site within the lumen of the transmembrane protein pore formed by staphylococcal alpha-hemolysin. The free end of the polymer was covalently attached to a biotin molecule. On incorporation of the modified pore into a lipid bilayer, the biotinyl group moves from one side of the membrane to the other, and is detected by reversible capture with a mutant streptavidin. The capture events are observed as changes in ionic current passing through single pores in planar bilayers. Accordingly, the modified pore allows detection of a protein analyte at the single-molecule level, facilitating both quantification and identification through a distinctive current signature. The approach has higher time resolution compared with other kinetic measurements, such as those obtained by surface plasmon resonance.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Bayley, H (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.			Howorka, Stefan/0000-0002-6527-2846; Bayley, Hagan/0000-0003-2499-6116				Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5; Bayley H, 2000, ADV MATER, V12, P139, DOI 10.1002/(SICI)1521-4095(200001)12:2<139::AID-ADMA139>3.3.CO;2-H; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; Bezrukov SM, 1996, MACROMOLECULES, V29, P8517, DOI 10.1021/ma960841j; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; CHANG CY, 1995, CHEM BIOL, V2, P391, DOI 10.1016/1074-5521(95)90220-1; Cheley S, 1999, PROTEIN SCI, V8, P1257, DOI 10.1110/ps.8.6.1257; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Chilkoti A, 1995, BIOPHYS J, V69, P2125, DOI 10.1016/S0006-3495(95)80083-4; Davis AP, 1999, NATURE, V401, P120, DOI 10.1038/43576; Gouaux E, 1998, J STRUCT BIOL, V121, P110, DOI 10.1006/jsbi.1998.3959; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Howorka S, 2000, J AM CHEM SOC, V122, P2411, DOI 10.1021/ja993221h; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; Merzlyak PG, 1999, BIOPHYS J, V77, P3023, DOI 10.1016/S0006-3495(99)77133-X; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Panchal RG, 1996, NAT BIOTECHNOL, V14, P852, DOI 10.1038/nbt0796-852; Perez-Luna VH, 1999, J AM CHEM SOC, V121, P6469, DOI 10.1021/ja983984p; Russo MJ, 1997, NAT BIOTECHNOL, V15, P278, DOI 10.1038/nbt0397-278; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Seeman NC, 1999, TRENDS BIOTECHNOL, V17, P437, DOI 10.1016/S0167-7799(99)01360-8; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1995, PROTEIN ENG, V8, P491, DOI 10.1093/protein/8.5.491; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Xie XS, 1999, J BIOL CHEM, V274, P15967, DOI 10.1074/jbc.274.23.15967; [No title captured]	37	288	336	2	102	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1091	1095		10.1038/80295	http://dx.doi.org/10.1038/80295			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017049				2022-12-25	WOS:000089744700033
J	Radkov, SA; Kellam, P; Boshoff, C				Radkov, SA; Kellam, P; Boshoff, C			The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS-DISEASE; MICROVASCULAR ENDOTHELIAL-CELLS; PRIMARY EFFUSION LYMPHOMA; LARGE-TUMOR-ANTIGEN; DNA-SEQUENCES; GENE-PRODUCT; CYCLIN-E; EXPRESSION; PROTEIN; HUMAN-HERPESVIRUS-8	Kaposi sarcoma-associated herpesvirus (KSHV) is involved in the etiopathogenesis of Kaposi sarcoma and certain lymphoproliferative disorders. Open reading frame (ORF) 73 encodes the main immunogenic latent nuclear antigen (LNA-1) of KSHV. LNA-1 maintains the KSHV episome and tethers the viral genome to chromatin during mitosis. In addition, LNA-1 interacts with p53 and represses its transcriptional activity. Here we show that LNA-1 also interacts with the retinoblastoma protein. LNA-1 transactivated an artificial promoter carrying the cell cycle transcription factor E2F DNA-binding sequences and also upregulated the cyclin E (CCNE1) promoter, but not the B-myb (MYBL2) promoter. LNA-1 overcame the flat-cell phenotype induced by retinoblastoma protein in Saos2 cells. In cooperation with the cellular oncogene Harvey rat sarcoma viral oncogene homolog (Hras), LNA-I transformed primary rat embryo fibroblasts and rendered them tumorigenic. These findings indicate that LNA-I acts as a transcription co-factor and may contribute to KSHV-induced oncogenesis by targeting the retinoblastoma protein-E2F transcriptional regulatory pathway.	UCL, Wolfson Inst Biomed Res, CRC, Viral Oncol Grp, London WC1E 6AE, England; UCL, Wohl Vir Ctr, Dept Oncol, London WC1E 6AE, England; UCL, Wohl Vir Ctr, Dept Mol Pathol, London WC1E 6AE, England	University of London; University College London; University of London; University College London; University of London; University College London	Boshoff, C (corresponding author), UCL, Wolfson Inst Biomed Res, CRC, Viral Oncol Grp, Cruciform Bldg, London WC1E 6AE, England.	c.boshoff@ucl.ac.uk		Kellam, Paul/0000-0003-3166-4734				Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bennett JD, 1996, ONCOGENE, V13, P1073; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Hamburger A W, 1980, Prog Clin Biol Res, V48, P23; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; Kellam P, 1999, J VIROL, V73, P5149, DOI 10.1128/JVI.73.6.5149-5155.1999; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Panyutich EA, 1998, AIDS, V12, P467, DOI 10.1097/00002030-199805000-00007; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	45	387	404	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1121	1127		10.1038/80459	http://dx.doi.org/10.1038/80459			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017143				2022-12-25	WOS:000089674700036
J	Tsoka, S; Ouzounis, CA				Tsoka, S; Ouzounis, CA			Prediction of protein interactions: metabolic enzymes are frequently involved in gene fusion	NATURE GENETICS			English	Article							GENOME		EMBL, European Bioinformat Inst, Res Programme, Computat Genom Grp,Cambridge Outstation, Cambridge, England	European Molecular Biology Laboratory (EMBL)	Ouzounis, CA (corresponding author), EMBL, European Bioinformat Inst, Res Programme, Computat Genom Grp,Cambridge Outstation, Cambridge, England.		Ouzounis, Christos A/G-2302-2010	Ouzounis, Christos A/0000-0002-0086-8657; Tsoka, Sophia/0000-0001-8403-1282				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bulow L, 1990, Biochem Soc Symp, V57, P123; Doolittle RF, 1999, NAT GENET, V23, P6, DOI 10.1038/12597; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Karp PD, 1999, NUCLEIC ACIDS RES, V27, P55, DOI 10.1093/nar/27.1.55; Karp PP, 1999, TRENDS BIOTECHNOL, V17, P275, DOI 10.1016/S0167-7799(99)01316-5; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Sali A, 1999, NATURE, V402, P23, DOI 10.1038/46915	10	54	56	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					141	142		10.1038/79847	http://dx.doi.org/10.1038/79847			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017064				2022-12-25	WOS:000089638800006
J	Sabatakos, G; Sims, NA; Chen, J; Aoki, K; Kelz, MB; Amling, M; Bouali, Y; Mukhopadhyay, K; Ford, K; Nestler, EJ; Baron, R				Sabatakos, G; Sims, NA; Chen, J; Aoki, K; Kelz, MB; Amling, M; Bouali, Y; Mukhopadhyay, K; Ford, K; Nestler, EJ; Baron, R			Overexpression of Delta FosB transcription factor(s) increases bone formation and inhibits adipogenesis	NATURE MEDICINE			English	Article							C-FOS; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; OSTEOCALCIN GENE; TRANSGENIC MICE; CELLS; MOUSE; OSTEOPETROSIS; OSTEOCLAST; JUN	Members of the AP-1 family of transcription factors participate in the regulation of bone cell proliferation and differentiation. We report here a potent AP-1-related regulator of osteoblast function: Delta FosB, a naturally occurring truncated form of FosB that arises from alternative splicing of the fosB transcript and is expressed in osteoblasts. Overexpression of Delta FosB in transgenic mice leads to increased bone formation throughout the skeleton and a continuous post-developmental increase in bone mass, leading to osteosclerosis. In contrast, Delta FosB inhibits adipogenesis both in vivo and in vitro, and downregulates the expression of early markers of adipocyte differentiation. Because osteoblasts and adipocytes are thought to share a common precursor, it is concluded that Delta FosB transcriptionally regulates osteoblastogenesis, possibly at the expense of adipogenesis.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA; Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Genes & Behav, New Haven, CT 06520 USA; Univ Hamburg, Sch Med, Dept Trauma Surg, D-22529 Hamburg, Germany; Hoechst Marion Roussel France, F-93235 Romainville, France	Yale University; Yale University; Yale University; Yale University; University of Hamburg	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, SHM IE-55,333 Cedar St, New Haven, CT 06520 USA.	roland.baron@yale.edu	Kelz, Max/E-4054-2010; Sims, Natalie Ann/A-7192-2012; AOKI, Kazuhiro/GRO-6475-2022	Kelz, Max/0000-0002-2803-6078; Sims, Natalie Ann/0000-0003-1421-8468; AOKI, Kazuhiro/0000-0001-6643-6315				ANDERSON RE, 1986, CALCIFIED TISSUE INT, V39, P252, DOI 10.1007/BF02555214; Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756-3282(99)00174-X; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Baron R.A., 1983, BONE HISTOMORPHOMETR, P13; BELLOWS CG, 1994, ENDOCRINOLOGY, V134, P2221, DOI 10.1210/en.134.5.2221; BELLOWS CG, 1990, DEV BIOL, V140, P132, DOI 10.1016/0012-1606(90)90060-V; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen JS, 1997, J NEUROSCI, V17, P4933; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Gruda MC, 1996, ONCOGENE, V12, P2177; Hayman AR, 1996, DEVELOPMENT, V122, P3151; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIFERT MF, 1985, AM J ANAT, V172, P141, DOI 10.1002/aja.1001720204; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	37	270	282	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					985	990		10.1038/79683	http://dx.doi.org/10.1038/79683			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973317				2022-12-25	WOS:000089190500029
J	Paris, M				Paris, M			Vapornomics	NATURE BIOTECHNOLOGY			English	Editorial Material									Murdoch Univ, W Australia State Agr Biotechnol Ctr, Perth, WA, Australia	Murdoch University	Paris, M (corresponding author), Murdoch Univ, W Australia State Agr Biotechnol Ctr, Perth, WA, Australia.								0	1	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					301	301		10.1038/86660	http://dx.doi.org/10.1038/86660			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283574	Bronze			2022-12-25	WOS:000167940700009
J	Prior, IA; Harding, A; Yan, J; Sluimer, J; Parton, RG; Hancock, JF				Prior, IA; Harding, A; Yan, J; Sluimer, J; Parton, RG; Hancock, JF			GTP-dependent segregation of H-ras from lipid rafts is required for biological activity	NATURE CELL BIOLOGY			English	Article							PLASMA-MEMBRANE; NUCLEOTIDE EXCHANGE; CAAX MOTIF; K-RAS; N-RAS; PROTEINS; ACTIVATION; RAF-1; CAVEOLIN; DOMAINS	Different sites of plasma membrane attachment may underlie functional differences between isoforms of Ras. Here we show that palmitoylation and farnesylation targets H-ras to lipid rafts and caveolae, but that the interaction of H-ras with these membrane subdomains is dynamic. GTP-loading redistributes H-ras from rafts into bulk plasma membrane by a mechanism that requires the adjacent hypervariable region of H-ras. Release of H-ras-GTP from rafts is necessary for efficient activation of Raf. By contrast, K-ras is located outside rafts irrespective of bound nucleotide. Our studies identify a novel protein determinant that is required for H-ras function, and show that the GTP/GDP state of H-ras determines its lateral segregation on the plasma membrane.	Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Brisbane, Qld 4006, Australia; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Prior, IA (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston Rd, Brisbane, Qld 4006, Australia.	j.hancock@mailbox.uq.edu.au	Harding, Angus/B-4120-2012; Parton, Robert G/C-5673-2009; Sluimer, Judith c/D-5277-2012; Yan, Jun/F-1224-2010	Parton, Robert G/0000-0002-7494-5248; Sluimer, Judith c/0000-0002-0269-4582; Yan, Jun/0000-0001-9617-0335; Hancock, John/0000-0003-0542-4710; Prior, Ian/0000-0002-4055-5161				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BERANGER F, 1994, J BIOL CHEM, V269, P13637; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; PORFIRI E, 1995, METHOD ENZYMOL, V256, P85; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	33	435	440	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					368	375		10.1038/35070050	http://dx.doi.org/10.1038/35070050			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283610				2022-12-25	WOS:000168043900015
J	Seol, JH; Shevchenko, A; Shevchenko, A; Deshaies, RJ				Seol, JH; Shevchenko, A; Shevchenko, A; Deshaies, RJ			Skp1 forms multiple protein complexes, including RAVE, a regulator of V-ATPase assembly	NATURE CELL BIOLOGY			English	Article							VACUOLAR H+-ATPASE; SCF UBIQUITIN-LIGASE; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; CELL-CYCLE; YEAST; GENOME; IDENTIFICATION; MEMBRANE; SUBUNIT	SCF ubiquitin ligases are composed of Skp1, Cdc53, Hrt1 and one member of a large family of substrate receptors known as F-box proteins (FBPs). Here we report the identification, using sequential rounds of epitope tagging, affinity purification and mass spectrometry, of 16 Skp1 and Cdc53-associated proteins in budding yeast, including all components of SCF, 9 FBPs, Yjr033 (Rav1) and Ydr202 (Rav2). Rav1, Rav2 and Skp1 form a complex that we have named 'regulator of the (H+)-ATPase of the vacuolar and endosomal membranes' (RAVE), which associates with the V, domain of the vacuolar membrane (H+)-ATPase (V-ATPase). V-ATPases are conserved throughout eukaryotes, and have been implicated in tumour metastasis and multidrug resistance, and here we show that RAVE promotes glucose-triggered assembly of the V-ATPase holoenzyme. Previous systematic genome-wide two-hybrid screens yielded 17 proteins that interact with Skp1 and Cdc53, only 3 of which overlap with those reported here. Thus, our results provide a distinct view of the interactions that link proteins into a comprehensive cellular network.	European Mol Biol Lab, Prot & Peptide Grp, D-69012 Heidelberg, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	European Molecular Biology Laboratory (EMBL); California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Shevchenko, A (corresponding author), European Mol Biol Lab, Prot & Peptide Grp, Meyerhofstr 1, D-69012 Heidelberg, Germany.	shevchenko@embl-heidelberg.de; deshaies@its.caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FOURY F, 1990, J BIOL CHEM, V265, P18554; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; GALAN JM, IN PRESS MOL CELL BI; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MORANO KA, 1994, J CELL SCI, V107, P2813; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	34	202	224	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					384	391		10.1038/35070067	http://dx.doi.org/10.1038/35070067			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283612				2022-12-25	WOS:000168043900017
J	Chen, RZ; Akbarian, S; Tudor, M; Jaenisch, R				Chen, RZ; Akbarian, S; Tudor, M; Jaenisch, R			Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice	NATURE GENETICS			English	Letter							LINKED MENTAL-RETARDATION; HISTONE DEACETYLASE; MECP2; MUTATION; EXPRESSION; BRAIN; GENE; COMPLEX; MALES; MOUSE	Mecp2 is an X-linked gene encoding a nuclear protein that binds specifically to methylated DNA (ref. 1) and functions as a general transcriptional repressor by associating with chromatin-remodeling complexes(2,3) Mecp2 is expressed at high levels in the postnatal brain(1,4), indicating that methylation-dependent regulation of gene expression may have a crucial role in the mammalian central nervous system. Consistent with this notion is the recent demonstration that MECP2 mutations cause Rett syndrome(5-8) (RTT, MIM 312750), a childhood neurological disorder that represents one of the most common causes of mental retardation in females(9-11) Here we show that Mecp2-deficient mice exhibit phenotypes that resemble some of the symptoms of RTT patients. Mecp2-null mice were normal until 5 weeks of age, when they began to develop disease, leading to death between 6 and 12 weeks. Mutant brains showed substantial reduction in both weight and neuronal cell size, but no obvious structural defects or signs of neurodegeneration. Brain-specific deletion of Mecp2 at embryonic day resulted in a phenotype identical to that of the null mutation, indicating that the phenotype is caused by Mecp2 deficiency in the CNS rather than in perpherial tissues. Deletion of Mecp2 in postnatal CNS neurons led to a similar neuronal phenotype, although at a later age. Our results indicate that role of Mecp2 is not restricted to the immature brain, but becomes critical in mature neurons. Mecp2 deficiency in these neurons is sufficient to cause neuronal dysfunction with symptomatic manifestation similar to Rett syndrome.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA.			Tudor, Matthew/0000-0001-8766-195X				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Armstrong DD, 1997, J NEUROPATH EXP NEUR, V56, P843, DOI 10.1097/00005072-199708000-00001; BAUMAN ML, 1995, NEUROLOGY, V45, P1581, DOI 10.1212/WNL.45.8.1581; BAUMAN ML, 1995, NEUROPEDIATRICS, V26, P105, DOI 10.1055/s-2007-979737; Clayton-Smith J, 2000, LANCET, V356, P830, DOI 10.1016/S0140-6736(00)02661-1; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; Dragatsis I, 2000, GENESIS, V26, P133, DOI 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V; Dragich J, 2000, HUM MOL GENET, V9, P2365, DOI 10.1093/hmg/9.16.2365; Ellaway C, 1999, J PAEDIATR CHILD H, V35, P419, DOI 10.1046/j.1440-1754.1999.355403.x; Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hagberg G, 2000, ACTA PAEDIATR, V89, P198, DOI 10.1080/080352500750028834; JELLINGER K, 1988, ACTA NEUROPATHOL, V76, P142, DOI 10.1007/BF00688098; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Meloni I, 2000, AM J HUM GENET, V67, P982, DOI 10.1086/303078; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Orrico A, 2000, FEBS LETT, V481, P285, DOI 10.1016/S0014-5793(00)01994-3; Rett A, 1966, Wien Med Wochenschr, V116, P723; Schanen C, 1998, AM J HUM GENET, V63, P267, DOI 10.1086/301932; Schanen NC, 1998, J CHILD NEUROL, V13, P229, DOI 10.1177/088307389801300507; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; Van den Veyver IB, 2000, CURR OPIN GENET DEV, V10, P275, DOI 10.1016/S0959-437X(00)00083-6; Villard L, 2000, NEUROLOGY, V55, P1188, DOI 10.1212/WNL.55.8.1188; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690	29	953	986	1	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					327	331		10.1038/85906	http://dx.doi.org/10.1038/85906			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242118				2022-12-25	WOS:000167304200028
J	Tada, S; Li, A; Maiorano, D; Mechali, M; Blow, JJ				Tada, S; Li, A; Maiorano, D; Mechali, M; Blow, JJ			Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin	NATURE CELL BIOLOGY			English	Article							REPLICATION LICENSING SYSTEM; CELL-CYCLE REGULATION; DNA-REPLICATION; S-PHASE; RECOGNITION COMPLEX; SUBCELLULAR-LOCALIZATION; PROTEIN COMPLEX; RE-REPLICATION; BUDDING YEAST; FREE-EXTRACTS	Eukaryotic replication origins are 'licensed' for replication early in the cell cycle by loading Mcm(2-7) proteins. As chromatin replicates, Mcm(2-7) are removed, thus preventing the origin from firing again. Here we report the purification of the RLF-B component of the licensing system and show that it corresponds to Cdt1. RLF-B/Cdt1 was inhibited by geminin, a protein that is degraded during late mitosis. Immunodepletion of geminin from metaphase extracts allowed them to assemble licensed replication origins. Inhibition of CDKs in metaphase stimulated origin assembly only after the depletion of geminin. These experiments suggest that geminin-mediated inhibition of RLF-B/Cdt1 is essential for repressing origin assembly late in the cell cycle of higher eukaryotes.	Dow St Univ Dundee, Wellcome Trust Bioctr, CRC, Chromosome Replicat Res Grp, Dundee DD1 5EH, Scotland; Inst Human Genet, CNRS, F-34396 Montpellier 5, France	University of Dundee; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blow, JJ (corresponding author), Dow St Univ Dundee, Wellcome Trust Bioctr, CRC, Chromosome Replicat Res Grp, Dundee DD1 5EH, Scotland.	j.j.blow@dundee.ac.uk	Blow, J. Julian/B-3977-2009; Maiorano, Domenico/N-5755-2017	Blow, J. Julian/0000-0002-9524-5849; Maiorano, Domenico/0000-0003-4229-5903	Cancer Research UK [A2335] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Chong JPJ, 1997, METHOD ENZYMOL, V283, P549; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Sun W, 2000, J CELL SCI, V113, P683; Tada S, 1999, CURR BIOL, V9, P211, DOI 10.1016/S0960-9822(99)80092-X; Tada S, 1998, BIOL CHEM, V379, P941; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Whittaker AJ, 2000, GENE DEV, V14, P1765	50	387	395	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					107	113		10.1038/35055000	http://dx.doi.org/10.1038/35055000			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175741	Green Accepted			2022-12-25	WOS:000166793000010
J	Dove, A				Dove, A			Biotech weighs up the options in obesity	NATURE BIOTECHNOLOGY			English	Article								The perfect diet pill has eluded the drug industry for decades, but now molecular genetics has put the field on the map and offered new ways to fight the "battle of the bulge".										Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	2	2	4	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					25	28		10.1038/83465	http://dx.doi.org/10.1038/83465			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135547				2022-12-25	WOS:000166261400014
J	Saha, K; Zhang, JC; Gupta, A; Dave, R; Yimen, M; Zerhouni, B				Saha, K; Zhang, JC; Gupta, A; Dave, R; Yimen, M; Zerhouni, B			Isolation of primary HIV-1 that target CD8(+) T Lymphocytes using CD8 as a receptor	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; HERPESVIRUS-SAIMIRI; CELL CLONES; V3 LOOP; SOLUBLE FACTOR(S); TYPE-1 INFECTION; BETA-CHEMOKINES; AIDS PATIENTS; IN-VIVO	HIV-1 use CD4 receptors to infect their primary targets, CD4(+) cells, whereas CD8(+) cells have a protective role against HIV-1. We recently isolated HIV-1-producing CD8(+) clones from two AIDS patients. Here we show that although HIV-1 produced by CD8(+) cells maintained the ability to infect CD4(+) cells, these viruses were able to infect CD8(+) cells independent of CD4. Evidence indicates that these viruses used CD8 as a receptor to infect CD8(+) cells. First, expression of CD8 was downmodulated after infection. Second, anti-CD8 antibodies blocked viral entry and replication in CD8(+) cells. Finally, resistant cells became susceptible after expression of CD8. Although these viruses used CXCR4 to enter CD4(+) cells, it seems that infection of CD8(+) cells was independent of CXCR4 or CCR5 co-receptors. Novel changes were observed in envelope sequences of CD8-tropic viruses. These results provide initial evidence that HIV-1 can mutate to infect CD8(+) cells using CD8 as a receptor.	Childrens Res Inst, Dept Pediat, Div Mol Med, Columbus, OH 43205 USA; Childrens Res Inst, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43205 USA; Ohio State Univ, Med Ctr, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Saha, K (corresponding author), Childrens Res Inst, Dept Pediat, Div Mol Med, Columbus, OH 43205 USA.				NIAID NIH HHS [AI-42715, AI-44974] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042715, R29AI044974] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; Douglas NW, 1996, AIDS, V10, P39, DOI 10.1097/00002030-199601000-00006; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Flamand L, 1998, P NATL ACAD SCI USA, V95, P3111, DOI 10.1073/pnas.95.6.3111; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Kaneko H, 1997, J VIROL, V71, P8918, DOI 10.1128/JVI.71.11.8918-8922.1997; Kitchen SG, 1998, J VIROL, V72, P9054, DOI 10.1128/JVI.72.11.9054-9060.1998; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaBranche CC, 1999, J VIROL, V73, P10310, DOI 10.1128/JVI.73.12.10310-10319.1999; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Reeves JD, 1999, J VIROL, V73, P7795, DOI 10.1128/JVI.73.9.7795-7804.1999; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Saha K, 1998, J VIROL, V72, P876, DOI 10.1128/JVI.72.1.876-881.1998; Saha K, 1996, J IMMUNOL, V157, P3876; Saha K, 1996, NAT MED, V2, P1272, DOI 10.1038/nm1196-1272; Saha K, 1999, J VIROL, V73, P7891, DOI 10.1128/JVI.73.9.7891-7898.1999; Saha K, 1997, J IMMUNOL METHODS, V206, P21, DOI 10.1016/S0022-1759(97)00080-X; SAHA K, UNPUB EVIDENCE PRODU; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992	30	81	89	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					65	72		10.1038/83365	http://dx.doi.org/10.1038/83365			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135618				2022-12-25	WOS:000166243100037
J	Jhaveri, S; Rajendran, M; Ellington, AD				Jhaveri, S; Rajendran, M; Ellington, AD			In vitro selection of signaling aptamers	NATURE BIOTECHNOLOGY			English	Article						aptamer; biosensor; in vitro selection; SELEX; diagnostics	PHOSPHATE-BINDING PROTEIN; RNA APTAMERS; INORGANIC-PHOSPHATE; FLOW-CYTOMETRY; NUCLEIC-ACIDS; BIOSENSORS; LIGANDS; RECOGNITION; TOOLS; PROBE	Reagentless biosensors that can directly transduce molecular recognition to optical signals should potentiate the development of sensor arrays for a wide variety of analytes. Nucleic acid aptamers that bind ligands tightly and specifically can be readily selected, but may prove difficult to adapt to biosensor applications. We have therefore attempted to develop selection methods that couple the broad molecular recognition properties of aptamers with signal transduction. Anti-adenosine aptamers were selected from a pool that was skewed to contain very few fluoresceinated uridines. The primary family of aptamers showed a doubling of relative fluorescence intensity at saturating concentrations of a cognate analyte, ATP, and could sense ATP concentrations as low as 25 muM. A single uridine was present in the best signaling aptamer. Surprisingly, other dyes could substitute for fluorescein and still specifically signal the presence of ATP, indicating that the single uridine functioned as a general "switch" for transducing molecular recognition to optical signals.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.							ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BURGSTALLER P, 1994, ANGEW CHEM INT EDIT, V33, P1084, DOI 10.1002/anie.199410841; Burke DH, 1997, NUCLEIC ACIDS RES, V25, P2020, DOI 10.1093/nar/25.10.2020; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Davis KA, 1996, NUCLEIC ACIDS RES, V24, P702, DOI 10.1093/nar/24.4.702; Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915; Ellington AD, 1999, P SOC PHOTO-OPT INS, V3858, P126, DOI 10.1117/12.372908; Famulok M, 1999, CURR TOP MICROBIOL, V243, P123; Famulok M, 1998, CURR OPIN CHEM BIOL, V2, P320, DOI 10.1016/S1367-5931(98)80004-5; Gallagher S., 2000, CURRENT PROTOCOLS MO; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; German I, 1998, ANAL CHEM, V70, P4540, DOI 10.1021/ac980638h; GILARDI G, 1994, ANAL CHEM, V66, P3840, DOI 10.1021/ac00093a047; Giuliano KA, 1998, TRENDS BIOTECHNOL, V16, P135, DOI 10.1016/S0167-7799(97)01166-9; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Hesselberth J, 2000, J Biotechnol, V74, P15, DOI 10.1016/S1389-0352(99)00005-7; Hirshberg M, 1998, BIOCHEMISTRY-US, V37, P10381, DOI 10.1021/bi980428z; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Jhaveri SD, 2000, J AM CHEM SOC, V122, P2469, DOI 10.1021/ja992393b; Lavigne JJ, 1999, PROC SPIE, V3602, P220, DOI 10.1117/12.347545; Marvin JS, 1997, P NATL ACAD SCI USA, V94, P4366, DOI 10.1073/pnas.94.9.4366; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0; Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281; POLLARD J, 2000, CURRENT PROTOCOLS NU; Potyrailo RA, 1998, ANAL CHEM, V70, P3419, DOI 10.1021/ac9802325; Rogers J, 1999, NATURE, V402, P323, DOI 10.1038/46335; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; Savoy S, 1998, P SOC PHOTO-OPT INS, V3539, P17, DOI 10.1117/12.333750; Taylor LC, 2000, ANAL BIOCHEM, V278, P132, DOI 10.1006/abio.1999.4440; WACHTERSHAUSER G, 1988, P NATL ACAD SCI USA, V85, P1134, DOI 10.1073/pnas.85.4.1134; Walt DR, 2000, SCIENCE, V287, P451, DOI 10.1126/science.287.5452.451; Westhof E, 1997, CURR OPIN STRUC BIOL, V7, P305, DOI 10.1016/S0959-440X(97)80044-9	34	216	265	1	106	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1293	1297		10.1038/82414	http://dx.doi.org/10.1038/82414			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101810				2022-12-25	WOS:000165659000028
J	Fussenegger, M; Morris, RP; Fux, C; Rimann, M; von Stockar, B; Thompson, CJ; Bailey, JE				Fussenegger, M; Morris, RP; Fux, C; Rimann, M; von Stockar, B; Thompson, CJ; Bailey, JE			Streptogramin-based gene regulation systems for mammalian cells	NATURE BIOTECHNOLOGY			English	Article						gene therapy; tissue engineering; Streptomyces; Synercid; erythropoietin	MULTIDRUG-RESISTANCE GENE; HAMSTER OVARY CELLS; STREPTOMYCES-PRISTINAESPIRALIS; ERYTHROPOIETIN DELIVERY; ENCAPSULATED MYOBLASTS; EXPRESSION; MICE; QUINUPRISTIN/DALFOPRISTIN; PRODUCTIVITY; RECEPTOR	Here we describe repressible (PipOFF) as well as inducible (PipON) systems for regulated gene expression in mammalian cells, based on the repressor Pip (pristinamycin-induced protein), which is encoded by the streptogramin resistance operon of Streptomyces coelicolor. Expression of genes placed under control of these systems was responsive to clinically approved antibiotics belonging to the streptogramin group (pristinamycin, virginiamycin, and Synercid). The versatility of these systems was demonstrated by streptogramin-regulated expression of mouse erythropoietin (EPO), human placental secreted alkaline phosphatase (SEAP), or green fluorescent protein (GFP) in diverse cell lines (BHK, CHO, HeLa, and mouse myoblasts). Analysis of isogenic constructs in CHO cells demonstrated the PipOFF system gave lower background and higher induction ratios than the widely used tetracycline-repressible (TetOFF) expression systems. The streptogramin-based expression technology was functionally compatible with the TetOFF system, thus enabling the selective use of different antibiotics to independently control two different gene activities in the same cell.	ETH Zurich, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; Univ Basel, Bioctr, Dept Microbiol, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Basel	Fussenegger, M (corresponding author), ETH Zurich, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.		Morris, Rowan/HGU-9105-2022					BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Baquero F, 1997, J ANTIMICROB CHEMOTH, V39, P1, DOI 10.1093/jac/39.suppl_1.1; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; BARRIERE JC, 1994, EXPERT OPIN INV DRUG, V3, P115; Bebear C, 1997, J ANTIMICROB CHEMOTH, V39, P59, DOI 10.1093/jac/39.suppl_1.59; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bergeron M, 1997, J ANTIMICROB CHEMOTH, V39, P129, DOI 10.1093/jac/39.suppl_1.129; Bessis N, 1999, CLIN EXP IMMUNOL, V117, P376; BLANC V, 1995, MOL MICROBIOL, V17, P989, DOI 10.1111/j.1365-2958.1995.mmi_17050989.x; Bohl D, 1997, HUM GENE THER, V8, P195, DOI 10.1089/hum.1997.8.2-195; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CORCES V, 1984, J BIOL CHEM, V259, P4812; Dalle B, 1999, GENE THER, V6, P157, DOI 10.1038/sj.gt.3300812; Fussenegger M, 1998, BIOTECHNOL BIOENG, V57, P1, DOI 10.1002/(SICI)1097-0290(19980105)57:1<1::AID-BIT1>3.0.CO;2-M; Fussenegger M, 1997, BIOTECHNOL BIOENG, V55, P927, DOI 10.1002/(SICI)1097-0290(19970920)55:6<927::AID-BIT10>3.0.CO;2-4; Fussenegger M, 1997, BIOTECHNOL PROGR, V13, P733, DOI 10.1021/bp970108r; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Regulier E, 1998, GENE THER, V5, P1014, DOI 10.1038/sj.gt.3300687; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1109, DOI 10.1111/j.1365-2958.1995.mmi_17061109.x; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1001, DOI 10.1111/j.1365-2958.1995.mmi_17051001.x; Serguera C, 1999, HUM GENE THER, V10, P375, DOI 10.1089/10430349950018823; Suhr ST, 1998, P NATL ACAD SCI USA, V95, P7999, DOI 10.1073/pnas.95.14.7999; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180	32	193	221	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1203	1208		10.1038/81208	http://dx.doi.org/10.1038/81208			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062442				2022-12-25	WOS:000165176600028
J	Jacobs, JJL; Keblusek, P; Robanus-Maandag, E; Kristel, P; Lingbeek, M; Nederlof, PM; van Welsem, T; van de Vijver, MJ; Koh, EY; Daley, GQ; van Lohuizen, M				Jacobs, JJL; Keblusek, P; Robanus-Maandag, E; Kristel, P; Lingbeek, M; Nederlof, PM; van Welsem, T; van de Vijver, MJ; Koh, EY; Daley, GQ; van Lohuizen, M			Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers	NATURE GENETICS			English	Article							ARF TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; INK4A LOCUS; C-MYC; STABILIZES P53; GENE FAMILY; MDM2; APOPTOSIS; LYMPHOMAGENESIS; AMPLIFICATION	To identify new immortalizing genes with potential roles in tumorigenesis, we performed a genetic screen aimed to bypass the rapid and tight senescence arrest of primary fibroblasts deficient for the oncogene Bmi1. We identified the T-box member TBX2 as a potent immortalizing gene that acts by downregulating Cdkn2a (p19(ARF)). TBX2 represses the Cdkn2a (p19(ARF)) promoter and attenuates E2F1, Myc or HRAS-mediated induction of Cdkn2a (p19(ARF)). We found TBX2 to be amplified in a subset of primary human breast cancers, indicating that it might contribute to breast cancer development.	Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Whitehead Inst, Cambridge, MA 02142 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.	lohuizen@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795; van de Vijver, Marc/0000-0002-0385-4787	NATIONAL CANCER INSTITUTE [R29CA076418] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Clahsen PC, 1998, J CLIN ONCOL, V16, P470, DOI 10.1200/JCO.1998.16.2.470; Couch FJ, 1999, CANCER RES, V59, P1408; Courjal F, 1997, CANCER RES, V57, P4368; Cuny M, 2000, CANCER RES, V60, P1077; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; HAUPT Y, 1993, ONCOGENE, V8, P3161; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LAW DJ, 1995, MAMM GENOME, V6, P793, DOI 10.1007/BF00539006; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; PEDEUTOUR F, 1995, CANCER RES, V55, P2400; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	306	320	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2000	26	3					291	299		10.1038/81583	http://dx.doi.org/10.1038/81583			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062467				2022-12-25	WOS:000165176500016
J	Torrance, CJ; Jackson, PE; Montgomery, E; Kinzler, KW; Vogelstein, B; Wissner, A; Nunes, M; Frost, P; Discafani, CM				Torrance, CJ; Jackson, PE; Montgomery, E; Kinzler, KW; Vogelstein, B; Wissner, A; Nunes, M; Frost, P; Discafani, CM			Combinatorial chemoprevention of intestinal neoplasia	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; HEREDITARY COLORECTAL-CANCER; HUMAN COLON-CARCINOMA; ALPHA-DIFLUOROMETHYLORNITHINE; TYROSINE KINASE; EXPRESSION; INHIBITION; CYCLOOXYGENASE-2	A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed -20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.	Wyeth Ayerst Res, Oncol & Immunoinflammatory Res, Pearl River, NY 10965 USA; Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA	Pfizer; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Frost, P (corresponding author), Wyeth Ayerst Res, Oncol & Immunoinflammatory Res, Pearl River, NY 10965 USA.	frostp@war.wyeth.com			NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57345, CA 62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADTIAN I, 1999, DRUGS, V58, P663; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Bjorkman David J., 1998, American Journal of Medicine, V105, p8S, DOI 10.1016/S0002-9343(98)00069-2; Boolbol SK, 1996, CANCER RES, V56, P2556; Brenner DE, 2000, J CELL BIOCHEM, P121; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; De Angelis E, 1999, INT J ONCOL, V14, P437; Discafani CM, 1999, BIOCHEM PHARMACOL, V57, P917, DOI 10.1016/S0006-2952(98)00356-6; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Giardiello FM, 1996, GASTROENTEROL CLIN N, V25, P349, DOI 10.1016/S0889-8553(05)70251-X; Grann VR, 2000, CANCER J SCI AM, V6, P13; HAERI R, 2000, CANCER RES, V60, P560; Hawk E, 1999, CANCER-AM CANCER SOC, V86, P2551, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2551::AID-CNCR12>3.3.CO;2-T; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Jacoby RF, 2000, CANCER RES, V60, P1864; Johnson S C, 2000, Adv Intern Med, V45, P1; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Karnes WE, 1998, GASTROENTEROLOGY, V114, P930, DOI 10.1016/S0016-5085(98)70312-9; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirschbaum MH, 2000, J CELL BIOCHEM, P52; Kokoska ER, 1999, J SURG RES, V84, P186, DOI 10.1006/jsre.1999.5640; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352, DOI 10.1038/4333; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Li H, 1999, CARCINOGENESIS, V20, P425, DOI 10.1093/carcin/20.3.425; Maurer CA, 1998, HUM PATHOL, V29, P771, DOI 10.1016/S0046-8177(98)90444-0; Normanno N, 1998, CANCER DETECT PREV, V22, P62; Osborne MP, 1999, SURG CLIN N AM, V79, P1207, DOI 10.1016/S0039-6109(05)70069-4; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Papadimitrakopoulou VA, 1999, ARCH OTOLARYNGOL, V125, P1083, DOI 10.1001/archotol.125.10.1083; RAO CV, 1991, CANCER RES, V51, P4528; Reddy BS, 1999, CARCINOGENESIS, V20, P1645, DOI 10.1093/carcin/20.8.1645; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; ROY SN, 1985, CANCER RES, V45, P3856; Rudbeck L, 1998, BIOTECHNIQUES, V25, P588, DOI 10.2144/98254bm09; SAEKI T, 1992, CANCER RES, V52, P3467; Shirai H, 1995, ANTICANCER RES, V15, P2889; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Toma S, 1999, ANN ONCOL, V10, P95; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Winde G, 1998, CANCER LETT, V134, P201, DOI 10.1016/S0304-3835(98)00254-7; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X	50	429	469	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1024	1028		10.1038/79534	http://dx.doi.org/10.1038/79534			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973323				2022-12-25	WOS:000089190500035
J	Edwards, JS; Ibarra, RU; Palsson, BO				Edwards, JS; Ibarra, RU; Palsson, BO			In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data	NATURE BIOTECHNOLOGY			English	Article						Escherichia coli; genome analysis; metabolic reconstruction; computer simulation	HAEMOPHILUS-INFLUENZAE RD; BASIC CONCEPTS; GENOME; GROWTH; MODEL; CELL; SIMULATION; COMPLEXITY; EXPRESSION; NETWORKS	A significant goal in the post-genome era is to relate the annotated genome sequence to the physiological functions of a cell. Working from the annotated genome sequence, as well as biochemical and physiological information, it is possible to reconstruct complete metabolic networks. Furthermore, computational methods have been developed to interpret and predict the optimal performance of a metabolic network under a range of growth conditions. We have tested the hypothesis that Escherichia coli uses its metabolism to grow at a maximal rate using the E. coli MG1655 metabolic reconstruction. Based an this hypothesis, we formulated experiments that describe the quantitative relationship between a primary carbon source (acetate or succinate) uptake rate, oxygen uptake rate, and maximal cellular growth rate. We found that the experimental data were consistent with the stated hypothesis, namely that the E. coli metabolic network is optimized to maximize growth under the experimental conditions considered. This study thus demonstrates how the combination of in silico and experimental biology can be used to obtain a quantitative genotype-phenotype relationship for metabolism in bacterial cells.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Delaware, Dept Chem Engn, Newark, DE 19716 USA	University of California System; University of California San Diego; University of Delaware	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785	NIGMS NIH HHS [GM57089] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057089] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JE, 1998, BIOTECHNOL PROGR, V14, P8, DOI 10.1021/bp9701269; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Chvatal V., 1983, LINEAR PROGRAMMING; COVERT MW, 2001, IN PRESS TRENDS BIOC; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOMACH MM, 1984, BIOTECHNOL BIOENG, V26, P203, DOI 10.1002/bit.260260303; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; EDWARDS JS, 1999, METAB ENG, P13; EDWARDS JS, 1999, THESIS U CALIFORNIA; FELL DA, 1986, BIOCHEM J, V238, P781, DOI 10.1042/bj2380781; Goryanin I, 1999, BIOINFORMATICS, V15, P749, DOI 10.1093/bioinformatics/15.9.749; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; JAMASHIDI N, 2001, IN PRESS BIOINFORMAT; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; Karp PD, 2000, NUCLEIC ACIDS RES, V28, P56, DOI 10.1093/nar/28.1.56; KARP PD, 1996, ISMB, V4, P116; Karp PP, 1999, TRENDS BIOTECHNOL, V17, P275, DOI 10.1016/S0167-7799(99)01316-5; Klapa MI, 1999, BIOTECHNOL BIOENG, V62, P375, DOI 10.1002/(SICI)1097-0290(19990220)62:4<375::AID-BIT1>3.3.CO;2-F; KOMPALA DS, 1986, BIOTECHNOL BIOENG, V28, P1044, DOI 10.1002/bit.260280715; LEE ID, 1992, COMPUT METH PROG BIO, V38, P195, DOI 10.1016/0169-2607(92)90102-D; Liao James C., 1993, Current Opinion in Biotechnology, V4, P211, DOI 10.1016/0958-1669(93)90127-I; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; Maniatis T., 1982, MOL CLONING LAB MANU; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Mulquiney PJ, 1999, BIOCHEM J, V342, P567, DOI 10.1042/0264-6021:3420567; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Novak B, 1999, J THEOR BIOL, V199, P223, DOI 10.1006/jtbi.1999.0956; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Overbeek R, 2000, NUCLEIC ACIDS RES, V28, P123, DOI 10.1093/nar/28.1.123; PALSSON BO, 1987, FASEB J, V46, P2485; PALSSON BO, 1993, J THEOR BIOL, V161, P299, DOI 10.1006/jtbi.1993.1057; Pramanik J, 1997, BIOTECHNOL BIOENG, V56, P398, DOI 10.1002/(SICI)1097-0290(19971120)56:4<398::AID-BIT6>3.0.CO;2-J; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 1998, BIOTECHNOL BIOENG, V59, P227, DOI 10.1002/(SICI)1097-0290(19980720)59:2<227::AID-BIT10>3.0.CO;2-B; Schilling CH, 1999, BIOTECHNOL PROGR, V15, P296, DOI 10.1021/bp990048k; Schilling CH, 1999, BIOTECHNOL PROGR, V15, P288, DOI 10.1021/bp9900357; Schilling CH, 2000, J THEOR BIOL, V203, P249, DOI 10.1006/jtbi.2000.1088; SCHILLING CH, 2001, IN PRESS BIOTECHNOL; Selkov E, 1998, NUCLEIC ACIDS RES, V26, P43, DOI 10.1093/nar/26.1.43; STRANG G, 1988, LINEAR ALGBRA ITS AP; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; VanBogelen RA, 1997, ELECTROPHORESIS, V18, P1243, DOI 10.1002/elps.1150180805; VARMA A, 1993, APPL ENVIRON MICROB, V59, P2465, DOI 10.1128/AEM.59.8.2465-2473.1993; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1993, J THEOR BIOL, V165, P503, DOI 10.1006/jtbi.1993.1203	49	683	751	3	117	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					125	130		10.1038/84379	http://dx.doi.org/10.1038/84379			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175725				2022-12-25	WOS:000166754700017
J	Xiao, SX; Yu, C; Chou, XM; Yuan, WJ; Wang, Y; Bu, L; Fu, G; Qian, MQ; Yang, J; Shi, YZ; Hu, LD; Han, B; Wang, ZM; Huang, W; Liu, J; Chen, Z; Zhao, GP; Kong, XY				Xiao, SX; Yu, C; Chou, XM; Yuan, WJ; Wang, Y; Bu, L; Fu, G; Qian, MQ; Yang, J; Shi, YZ; Hu, LD; Han, B; Wang, ZM; Huang, W; Liu, J; Chen, Z; Zhao, GP; Kong, XY			Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP	NATURE GENETICS			English	Article							OSTEOGENESIS IMPERFECTA; DENTIN SIALOPROTEIN; SEQUENCE DETERMINATION; GENOMIC ORGANIZATION; BONE SIALOPROTEIN; CAUSATIVE ROLE; I COLLAGEN; GENE; LOCUS; PATHOGENESIS	Dentinogenesis imperfecta 1 (DGI1, MIM 125490) is an autosomal dominant dental disease characterized by abnormal dentin production and mineralization. The DGI1 locus was recently refined to a 2-Mb interval on 4q21 (ref. 1). Here we study three Chinese families carrying DCI1. We find that the affected individuals of two families also presented with progressive sensorineural high-frequency hearing loss (gene DfNA39). We identified three disease-specific mutations within the dentin sialophosphoprotein gene (DSPP) in these three families. We detected a G-->A transition at the donor-splicing site of intron 3 in one family without DFNA39, a mutation predicted to result in the skipping of exon 3. In two other families affected with both DGI1 and DFNA39, however, we identified two independent nucleotide transversions in exons a and 3 of DSPP, respectively. that cause missense mutations of two adjacent amino-acid residues in the predicted transmembrane region of the protein. Moreover, transcripts of DSPP previously reported to be expressed specifically in teeth(2) are also detected in the inner ear of mice. We have thus demonstrated for the first time that distinct mutations in DSPP are responsible for the clinical manifestations of DGI1 with or without DFNA39.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Res Ctr Biotechnol, Shanghai 200233, Peoples R China; Univ Sci & Technol China, Hefei 230027, Anhui, Peoples R China; 82 Hosp Peoples Liberat Army China, Huaiyin 223001, Jiangsu, Peoples R China; Stomatol Hosp Yang Pu Community Shanghai, Shanghai 200090, Peoples R China; Fourth Mil Med Univ, Xian 710032, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Acad Sci, Natl Ctr Gene Res, Shanghai 200233, Peoples R China; Fudan Univ, Coll Med, EENT Hosp, Dept Otolaryngol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Air Force Military Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Kong, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Res Ctr Biotechnol, Shanghai 200233, Peoples R China.		Yang, Jun/B-6976-2008; Yang, Jun J./ABG-5646-2020	Yang, Jun/0000-0002-0770-9659; Yang, Jun J./0000-0002-0770-9659; Zhao, Guo-Ping/0000-0002-7621-6620				Aplin HM, 1999, J DENT RES, V78, P1270, DOI 10.1177/00220345990780061201; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Crosby AH, 1996, MAMM GENOME, V7, P149, DOI 10.1007/s003359900037; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; Nicholls AC, 1996, HUM MUTAT, V7, P219, DOI 10.1002/(SICI)1098-1004(1996)7:3<219::AID-HUMU6>3.0.CO;2-5; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1997, EUR J ORAL SCI, V105, P405, DOI 10.1111/j.1600-0722.1997.tb02137.x; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; Sobel E, 1996, AM J HUM GENET, V58, P1323; SUPERTIFURGA A, 1989, J MED GENET, V26, P358, DOI 10.1136/jmg.26.6.358; TAKAGI Y, 1988, J ORAL PATHOL MED, V17, P208, DOI 10.1111/j.1600-0714.1988.tb01526.x; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Xiao SX, 2000, GENOMICS, V68, P247, DOI 10.1006/geno.2000.6285	21	249	289	1	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					201	204		10.1038/84848	http://dx.doi.org/10.1038/84848			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175790				2022-12-25	WOS:000166839200023
J	Raveh, T; Droguett, G; Horwitz, MS; DePinho, RA; Kimchi, A				Raveh, T; Droguett, G; Horwitz, MS; DePinho, RA; Kimchi, A			DAP kinase activates a p19(ARF)/p53-mediated apoptotic checkpoint to suppress oncogenic transformation	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; DEATH DOMAIN; CELL-DEATH; P53; GROWTH; GENE; DNA; HYPERMETHYLATION; IMMORTALIZATION	DAP kinase is a pro-apoptotic calcium-regulated serine/threonine kinase, whose expression is frequently lost in human tumours, Here we show that DAP kinase counteracts oncogene-induced transformation by activating a p19(ARF)/p53-dependent apoptotic checkpoint. Ectopic expression of DAP kinase suppressed oncogenic transformation of primary embryonic fibroblasts by activating p53 in a p19(ARF)-dependent manner. Consequently, the fibroblasts underwent apoptosis, characterized by caspase activation and DNA fragmentation. In response to c-Myc or E2F-1, the endogenous DAP kinase protein was upregulated. Furthermore, functional or genetic inactivation of the endogenous DAP kinase reduced the extent of induction of p19(ARF)/p53 and weakened the subsequent apoptotic responses to c-Myc or E2F-1. These results establish a role for DAP kinase in an early apoptotic checkpoint designed to eliminate pre-malignant cells during cancer development.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Med Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Dep Adult Oncol, Boston, MA 02115 USA	Weizmann Institute of Science; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute		lvkimchi@weizmann.weizmann.ac.il		DePinho, Ronald/0000-0002-5625-577X				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 1999, CANCER RES, V59, P67; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FINLAY C, 1995, METHOD ENZYMOL, V255, P389; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	38	298	313	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					1	7		10.1038/35050500	http://dx.doi.org/10.1038/35050500			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146619				2022-12-25	WOS:000166146400013
J	Powell, SK; Kaloss, MA; Pinkstaff, A; McKee, R; Burimski, I; Pensiero, M; Otto, E; Stemmer, WPC; Soong, NW				Powell, SK; Kaloss, MA; Pinkstaff, A; McKee, R; Burimski, I; Pensiero, M; Otto, E; Stemmer, WPC; Soong, NW			Breeding of retroviruses by DNA shuffling for improved stability and processing yields	NATURE BIOTECHNOLOGY			English	Article						DNA shuffling; retroviral vectors; stress resistance; ultracentrifugation	MURINE LEUKEMIA-VIRUS; ENVELOPE PROTEIN; HIGH-TITER; GENE; VECTORS; PURIFICATION; GLYCOPROTEIN; DISSECTION; EVOLUTION	Manufacturing of retroviral vectors for gene therapy is complicated by the sensitivity of these viruses to stress forces during purification and concentration. To isolate viruses that are resistant to these manufacturing processes, we performed breeding of six ecotropic murine leukemia virus (MLV) strains by DNA shuffling. The envelope regions were shuffled to generate a recombinant library of 5 x 10(8) replication-competent retroviruses, This library was subjected to the concentration process three consecutive times, with amplification of the surviving viruses after each cycle. Several viral clones with greatly improved stabilities were isolated, with the best clone exhibiting no loss in titer under conditions that reduced the titers of the parental viruses by 30- to 100-fold. The envelopes of these resistant viruses differed in DNA and protein sequence, and all were complex chimeras derived from multiple parents. These studies demonstrate the utility of DNA shuffling in breeding viral strains with improved characteristics for gene therapy.	Novartis Co, Genet Therapy Inc, Gaithersburg, MD 20878 USA; Maxygen Inc, Redwood City, CA 94063 USA	Novartis	Otto, E (corresponding author), Novartis Co, Genet Therapy Inc, 9 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	ed.otto@pharma.novartis.com						ABOUD M, 1982, ARCH VIROL, V71, P185, DOI 10.1007/BF01314870; Bae YM, 1997, J VIROL, V71, P2092, DOI 10.1128/JVI.71.3.2092-2099.1997; Braas G, 1996, BIOSEPARATION, V6, P211; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; FRIEDMANN T, 1995, NAT MED, V1, P275, DOI 10.1038/nm0395-275; GRAY KD, 1993, J VIROL, V67, P3489, DOI 10.1128/JVI.67.6.3489-3496.1993; GREEN N, 1981, P NATL ACAD SCI-BIOL, V78, P6023, DOI 10.1073/pnas.78.10.6023; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; LYONS RM, 1995, CANCER GENE THER, V2, P273; MCGRATH M, 1978, J VIROL, V25, P923, DOI 10.1128/JVI.25.3.923-927.1978; PAUL RW, 1993, HUM GENE THER, V4, P609, DOI 10.1089/hum.1993.4.5-609; PINTER A, 1978, VIROLOGY, V91, P345, DOI 10.1016/0042-6822(78)90382-3; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zavorotinskaya T, 1999, J VIROL, V73, P10164, DOI 10.1128/JVI.73.12.10164-10172.1999	20	72	82	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1279	1282		10.1038/82391	http://dx.doi.org/10.1038/82391			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101807				2022-12-25	WOS:000165659000025
J	Aragon-Alcaide, L; Strunnikov, AV				Aragon-Alcaide, L; Strunnikov, AV			Functional dissection of in vivo interchromosome association in Saccharomyces cerevisiae	NATURE CELL BIOLOGY			English	Article							MEIOTIC PROPHASE; MITOTIC RECOMBINATION; BUDDING YEAST; NUCLEAR-ORGANIZATION; GENE-EXPRESSION; DNA; CENTROMERE; PROTEINS; CELLS; TRANSVECTION	Homologue pairing mediates both recombination and segregation of chromosomes at meiosis I. The recognition of nucleic-acid-sequence homology within the somatic nucleus has an impact on DNA repair and epigenetic control of gene expression. Here we investigate interchromosomal interactions using a non-invasive technique that allows tagging and visualization of DNA sequences in vegetative and meiotic live yeast cells. In non-meiotic cells, chromosomes are ordered in the nucleus, but preferential pairing between homologues is not observed. Association of tagged chromosomal domains occurs irrespective of their genomic location, with some preference for similar chromosomal positions. Here we describe a new phenomenon that promotes associations between sequence-identical ectopic tags with a tandem-repeat structure. These associations, termed interchromosome trans-associations, may underlie epigenetic phenomena.	NICHD, Unit Chromosome Struct & Funct, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Aragon-Alcaide, L (corresponding author), NICHD, Unit Chromosome Struct & Funct, NIH, 18T Lib Dr, Bethesda, MD 20892 USA.			Strunnikov, Alexander/0000-0002-9058-2256	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001903] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999, Z01 HD001903-11] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bass HW, 1997, J CELL BIOL, V137, P5, DOI 10.1083/jcb.137.1.5; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Burgess SM, 1999, GENE DEV, V13, P1871, DOI 10.1101/gad.13.14.1871; Burgess SM, 1999, GENE DEV, V13, P1627, DOI 10.1101/gad.13.12.1627; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dorer DR, 1997, GENETICS, V147, P1181; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; HABER JE, 1988, PROG NUCLEIC ACID RE, V35, P209, DOI 10.1016/S0079-6603(08)60615-7; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; Haber JE, 1996, P NATL ACAD SCI USA, V93, P13949, DOI 10.1073/pnas.93.24.13949; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; Inbar O, 1999, MOL CELL BIOL, V19, P4134; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; JINKSROBERTSON S, 1993, MOL CELL BIOL, V13, P3937, DOI 10.1128/MCB.13.7.3937; JINKSROBERTSON S, 1986, GENETICS, V114, P731; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KASSIS JA, 1991, GENETICS, V128, P751; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; LICHTEN M, 1989, GENETICS, V123, P261; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; MELAMED C, 1992, MOL GEN GENET, V235, P97, DOI 10.1007/BF00286186; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; ROSSIGNOL JL, 1995, CURR TOP MICROBIOL, V197, P179; SCHERTHAN H, 1994, J CELL BIOL, V127, P273, DOI 10.1083/jcb.127.2.273; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; SIKORSKI RS, 1989, GENETICS, V122, P19; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481	41	40	40	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					812	818		10.1038/35041055	http://dx.doi.org/10.1038/35041055			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056536	Green Accepted			2022-12-25	WOS:000165207500015
J	deCastro, MJ; Fondecave, RM; Clarke, LA; Schmidt, CF; Stewart, RJ				deCastro, MJ; Fondecave, RM; Clarke, LA; Schmidt, CF; Stewart, RJ			Working strokes by single molecules of the kinesin-related microtubule motor ncd	NATURE CELL BIOLOGY			English	Article							OPTICAL TWEEZERS; DIMERIC NCD; PROTEIN; DROSOPHILA; MOTILITY; DIRECTION; MOVEMENT; DOMAIN; MYOSIN; INTERFEROMETRY	The ncd protein is a dimeric, ATP-powered motor that belongs to the kinesin family of microtubule motor proteins. Here we resolve single mechanochemical cycles of recombinant, dimeric, full-length ncd, using optical-tweezers-based instrumentation and a three-bead, suspended-microtubule assay. Under conditions of limiting ATP, isolated and transient microtubule-binding events exhibit exponentially distributed and ATP-concentration-dependent lifetimes. These events do not involve consecutive steps along the microtubule, quantitatively confirming that ncd is non-processive. At low loads, a single motor molecule produces ATP-triggered working strokes of about 9 nm, which occur at the ends of binding events.	Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; Vrije Univ Amsterdam, Dept Biophys & Phys Complex Syst, Div Phys, NL-1081 HV Amsterdam, Netherlands	Utah System of Higher Education; University of Utah; Vrije Universiteit Amsterdam	Stewart, RJ (corresponding author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.		Schmidt, Christoph F/G-3787-2011	Schmidt, Christoph F/0000-0003-2864-6973	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM055679] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R55GM55679-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allersma MW, 1998, BIOPHYS J, V74, P1074, DOI 10.1016/S0006-3495(98)74031-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BUCKHEIT J, 1995, WAVELETS STAT, P55, DOI DOI 10.1007/978-1-4612-2544-75; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ENDOW SA, 1994, J CELL SCI, V107, P859; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007; Gittes F, 1998, METHOD CELL BIOL, V55, P129; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Karabay A, 1999, BIOCHEM BIOPH RES CO, V258, P39, DOI 10.1006/bbrc.1999.0572; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Stewart RJ, 1998, EUR BIOPHYS J BIOPHY, V27, P353, DOI 10.1007/s002490050142; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	35	68	69	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					724	729		10.1038/35036357	http://dx.doi.org/10.1038/35036357			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025663				2022-12-25	WOS:000089697000018
J	Sun, H; Smallwood, PM; Nathans, J				Sun, H; Smallwood, PM; Nathans, J			Biochemical defects in ABCR protein variants associated with human retinopathies	NATURE GENETICS			English	Letter							DISEASE GENE ABCR; RECESSIVE RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; STARGARDT-DISEASE; MACULAR DEGENERATION; TRANSPORTER GENE; RIM PROTEIN; MUTATIONS; DYSTROPHY; HETEROGENEITY	Mutations in the gene encoding ABCR (ABCA4), a photoreceptor-specific ATP-binding cassette (ABC) transporter(1-4), are responsible for autosomal recessive Stargardt disease (STGD), an early onset macular degeneration(1,5-11), and some forms of autosomal recessive cone-rod dystrophy(12) and autosomal recessive retinitis pigmentosa(12-14). Heterozygosity for ABCA4 mutations may also represent a risk factor for age-related macular degeneration(15) (AMD), although this idea is controversial(7,16,17). An ongoing challenge in the analysis of ABCA4-based retinopathies arises from the observation that most of the ABCA4 sequence variants identified so far are missense mutations that are rare in both patient and control populations. With the current sample size of most sequence variants, one cannot determine statistically whether a particular sequence variant is pathogenic or neutral. A related challenge is to determine the degree to which each pathogenic variant impairs ABCR function, as genotype-phenotype analyses indicate that age of onset and disease severity correlate with different ABCA4 alleles(6,8-10). To address these questions, we performed a functional analysis of human ABCR and its variants. These experiments reveal a wide spectrum of biochemical defects in these variants and provide insight into the transport mechanism of ABCR.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.			Nathans, Jeremy/0000-0001-8106-5460				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; HORIO T, 1971, METHOD ENZYMOL, V23, P650; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323; MERBS SL, 1992, PHOTOCHEM PHOTOBIOL, V56, P869, DOI 10.1111/j.1751-1097.1992.tb09708.x; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; Papaioannou M, 2000, INVEST OPHTH VIS SCI, V41, P16; Rozet JM, 1999, J MED GENET, V36, P447; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	28	154	161	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					242	246		10.1038/79994	http://dx.doi.org/10.1038/79994			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017087				2022-12-25	WOS:000089638800028
J	Bechert, T; Steinrucke, P; Guggenbichler, JP				Bechert, T; Steinrucke, P; Guggenbichler, JP			A new method for screening anti-infective biomaterials	NATURE MEDICINE			English	Article							CENTRAL VENOUS CATHETER; STAPHYLOCOCCUS-EPIDERMIDIS; ANTIMICROBIAL ACTIVITY; ADHERENCE; SILVER; BIOCOMPATIBILITY; POLYMERS		Univ Erlangen Nurnberg, Clin Children & Adolescents, D-91054 Erlangen, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany	University of Erlangen Nuremberg	Bechert, T (corresponding author), Univ Erlangen Nurnberg, Clin Children & Adolescents, Loschgestr 15, D-91054 Erlangen, Germany.	tbechert@bio-gate.de						Bechert T, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561613; Behr A, 1998, INTENSIVMED, V35, P475; Bisno AL, 1994, INFECT ASS INDWELLIN; Boswald M, 1995, ZBL BAKT-INT J MED M, V283, P187; CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996, DOI 10.1128/JCM.22.6.996-1006.1985; CHRISTENSEN GD, 1994, INDWELLING MED DEVIC; DUNNE WM, 1991, APPL ENVIRON MICROB, V57, P863, DOI 10.1128/AEM.57.3.863-866.1991; Guggenbichler JP, 1999, INFECTION, V27, pS16, DOI 10.1007/BF02561612; Heilmann C, 1996, INFECT IMMUN, V64, P277, DOI 10.1128/IAI.64.1.277-282.1996; Jansen B, 1994, J Biomater Appl, V9, P55, DOI 10.1177/088532829400900103; Joyce-Wohrmann RM, 1999, INFECTION, V27, pS46, DOI 10.1007/BF02561618; MACK D, 1992, INFECT IMMUN, V60, P2048, DOI 10.1128/IAI.60.5.2048-2057.1992; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MERMEL LA, 1993, J INFECT DIS, V167, P920, DOI 10.1093/infdis/167.4.920; Merritt K, 1998, J BIOMED MATER RES, V39, P415, DOI 10.1002/(SICI)1097-4636(19980305)39:3<415::AID-JBM10>3.0.CO;2-9; TEBBS SE, 1994, EUR J CLIN MICROBIOL, V13, P111, DOI 10.1007/BF01982182; Thomas VL, 1997, CURR MICROBIOL, V35, P249, DOI 10.1007/s002849900248; Zhao GJ, 1998, BIOMETALS, V11, P27, DOI 10.1023/A:1009253223055	18	79	89	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1053	1056		10.1038/79568	http://dx.doi.org/10.1038/79568			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973328				2022-12-25	WOS:000089190500040
J	Chen, AS; Marsh, DJ; Trumbauer, ME; Frazier, EG; Guan, XM; Yu, H; Rosenblum, CI; Vongs, A; Feng, Y; Cao, LH; Metzger, JM; Strack, AM; Camacho, RE; Mellin, TN; Nunes, CN; Min, W; Fisher, J; Gopal-Truter, S; MacIntyre, DE; Chen, HY; Van der Ploeg, LHT				Chen, AS; Marsh, DJ; Trumbauer, ME; Frazier, EG; Guan, XM; Yu, H; Rosenblum, CI; Vongs, A; Feng, Y; Cao, LH; Metzger, JM; Strack, AM; Camacho, RE; Mellin, TN; Nunes, CN; Min, W; Fisher, J; Gopal-Truter, S; MacIntyre, DE; Chen, HY; Van der Ploeg, LHT			Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass	NATURE GENETICS			English	Article							FRAMESHIFT MUTATION; OBESITY; MICE; IDENTIFICATION; MELANOTROPIN; ANTAGONIST; PEPTIDES; LINKAGE; PROTEIN; MC4R	Genetic(1-8) and pharmacological(6,9-12) studies have defined a role for the melanocortin-4 receptor (Mc4r) in the regulation of energy homeostasis. The physiological function of Mc3r, a melanocortin receptor expressed at high levels in the hypothalamus(13), has remained unknown. We evaluated the potential role of Mc3r in energy homeostasis by studying Mc3r-deficient (Mc3r(-/-)) mice and compared the functions of Mc3r and Mc4r in mice deficient for both genes. The 4-6-month Mc3r(-/-) mice have increased fat mass, reduced lean mass and higher feed efficiency than wild-type littermates. despite being hypophagic and maintaining normal metabolic rates. (Feed efficiency is the ratio of weight gain to food intake.) Consistent with increased fat mass. Mc3r(-/-) mice are hyperleptinaemic and male Mc3r(-/-) mice develop mild hyperinsulinaemia. Mc3r(-/-) mice did not have significantly altered corticosterone or total thyroxine (T4) levels. Mice lacking both Mc3r and Mc4r become significantly heavier than Mc4r(-/-) mice. We conclude that Mc3r and Mc4r serve nonredundant roles in the regulation of energy homeostasis.	Merck Res Labs, Dept Obes Res, Rahway, NJ 07065 USA; Merck Res Labs, Dept Anim Pharmacol, Rahway, NJ USA; Merck Res Labs, Dept Comparat Med, Rahway, NJ USA	Merck & Company; Merck & Company; Merck & Company	Van der Ploeg, LHT (corresponding author), Merck Res Labs, Dept Obes Res, Rahway, NJ 07065 USA.		chen, airu/HHM-4281-2022					Bagnol D, 1999, J NEUROSCI, V19; Chagnon YC, 1997, MOL MED, V3, P663, DOI 10.1007/BF03401705; CHEN A, IN PRESS TRANSGENIC; Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73; Ellis KJ, 2000, PHYSIOL REV, V80, P649, DOI 10.1152/physrev.2000.80.2.649; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fekete C, 2000, J NEUROSCI, V20, P1550; FRIGERI LG, 1988, INT J OBESITY, V12, P305; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JOHNSON PR, 1972, J LIPID RES, V13, P2; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kelly TL, 1998, APPL RADIAT ISOTOPES, V49, P511, DOI 10.1016/S0969-8043(97)00226-1; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SHIMIZU H, 1989, LIFE SCI, V45, P543, DOI 10.1016/0024-3205(89)90105-7; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN TT, 1976, BIOCHIM BIOPHYS ACTA, V441, P213, DOI 10.1016/0005-2760(76)90164-8; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	30	720	748	0	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					97	102		10.1038/79254	http://dx.doi.org/10.1038/79254			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973258				2022-12-25	WOS:000089078000027
J	Haanen, JBAG; Van Oijen, MGCT; Tirion, F; Oomen, LCJM; Kruisbeek, AM; Vyth-Dreese, FA; Schumacher, TNM				Haanen, JBAG; Van Oijen, MGCT; Tirion, F; Oomen, LCJM; Kruisbeek, AM; Vyth-Dreese, FA; Schumacher, TNM			In situ detection of virus- and tumor-specific T-cell immunity	NATURE MEDICINE			English	Article							VIRAL-INFECTION; LYMPHOCYTES; ACTIVATION; SELECTION; MELANOMA; COMPLEX; GROWTH; VIVO		Netherlands Canc Inst, Dept Immunol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Dept Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO;2-0; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; LIPPONEN PK, 1993, EUR J CANCER, V29A, P69, DOI 10.1016/0959-8049(93)90579-5; MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Naito Y, 1998, CANCER RES, V58, P3491; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680	21	64	73	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1056	1060		10.1038/79573	http://dx.doi.org/10.1038/79573			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973329				2022-12-25	WOS:000089190500041
J	Jin, LQ; Zeng, H; Chien, S; Otto, KG; Richard, RE; Emery, DW; Blau, CA				Jin, LQ; Zeng, H; Chien, S; Otto, KG; Richard, RE; Emery, DW; Blau, CA			In vivo selection using a cell-growth switch	NATURE GENETICS			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; IN-VIVO; PROLIFERATION; TRANSDUCTION; EXPRESSION	A major obstacle to stem-cell gene therapy rests in the inability to deliver a gene into a therapeutically relevant fraction of stem cells'. One way to circumvent this obstacle is to use selection. Vectors containing two linked genes serve as the basis for selection. with one gene encoding a selectable product and the other, a therapeutic protein. Applying selection in vivo has the potential to bring a minor population of genetically corrected cells into the therapeutic range. But strategies for achieving in vivo selection have traditionally relied on genes that confer resistance to cytotoxic drugs(2,3) and are encumbered by toxicity. Here we describe a new system for in vivo selection that uses a 'cell-growth switch'. allowing a minor population of genetically modified cells to be inducibly amplified, thereby averting the risks associated with cytotoxic drugs. This system provides a general platform for conditionally expanding genetically modified cell populations in vivo. and may have widespread applications in gene and cell therapy.	Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Blau, CA (corresponding author), Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA.				NHLBI NIH HHS [2P01HL53750] Funding Source: Medline; NIDDK NIH HHS [5R01DK52997, 1R01DK57525] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052997, R01DK057525] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allay JA, 1998, NAT MED, V4, P1136, DOI 10.1038/2632; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; HAWLEY RG, 1994, GENE THER, V1, P136; HODGSON GS, 1973, CELL TISSUE KINET, V6, P199, DOI 10.1111/j.1365-2184.1973.tb01608.x; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SORRENTION BP, IN PRESS MOL BASIS B; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0	17	91	101	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					64	66		10.1038/79194	http://dx.doi.org/10.1038/79194			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973250				2022-12-25	WOS:000089078000019
J	Coco, WM; Levinson, WE; Crist, MJ; Hektor, HJ; Darzins, A; Pienkos, PT; Squires, CH; Monticello, DJ				Coco, WM; Levinson, WE; Crist, MJ; Hektor, HJ; Darzins, A; Pienkos, PT; Squires, CH; Monticello, DJ			DNA shuffling method for generating highly recombined genes and evolved enzymes	NATURE BIOTECHNOLOGY			English	Article							SP STRAIN IGTS8; IN-VITRO RECOMBINATION; DIRECTED EVOLUTION; DIBENZOTHIOPHENE DESULFURIZATION; MOLECULAR EVOLUTION; CHAIN-REACTION; ADVANTAGE; FIDELITY; LIGASE; FAMILY	We introduce a method of in vitro recombination or "DNA shuffling" to generate libraries of evolved enzymes. The approach relies on the ordering, trimming, and joining of randomly cleaved parental DNA fragments annealed to a transient polynucleotide scaffold. We generated chimeric libraries averaging 14.0 crossovers per gene, a several-fold higher level of recombination than observed for other methods. We also observed an unprecedented four crossovers per gene in regions of 10 or fewer bases of sequence identity. These properties allow generation of chimeras unavailable by other methods. We detected no unshuffled parental clones or duplicated "sibling" chimeras, and relatively few inactive clones. We demonstrated the method by molecular breeding of a monooxygenase for increased rate and extent of biodesulfurization on complex substrates, as well as for 20-fold faster conversion of a nonnatural substrate. This method represents a conceptually distinct and improved alternative to sexual PCR for gene family shuffling.	Enchina Biotechnol Corp, The Woodlands, TX 77381 USA		Coco, WM (corresponding author), Enchina Biotechnol Corp, 4200 Res Forest Dr, The Woodlands, TX 77381 USA.	wcoco@enchira.com						ARENSDORF JJ, 2000, 100 GEN M AM SOC MIC, P501; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BIGEY F, 1995, GENE, V154, P77, DOI 10.1016/0378-1119(94)00886-W; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; COCO WM, 2000, SOC IND MICR ANN M S, P97; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DENOME SA, 1994, J BACTERIOL, V176, P6707, DOI 10.1128/JB.176.21.6707-6716.1994; ECKERT KA, 1991, PCR PRACTICAL APPROA, P225; FELSENSTEIN J, 1974, GENETICS, V78, P737; FELSENSTEIN J, 1976, GENETICS, V83, P845; FRIDRICK C, 1999, 99 GEN M AM SOC MICR; Kikuchi M, 2000, GENE, V243, P133, DOI 10.1016/S0378-1119(99)00547-8; KONDRASHOV AS, 1984, GENET RES, V44, P199, DOI 10.1017/S0016672300026392; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; Lei BF, 1996, J BACTERIOL, V178, P5699, DOI 10.1128/jb.178.19.5699-5705.1996; LEVICHKIN IV, 1995, MOL BIOL+, V29, P572; LEVINSON W, 2000, ANN M SOC IND MICR S, P128; Liu Wen-En, 1998, Hunan Yike Daxue Xuebao, V23, P278; LORIMER IAJ, 1995, NUCLEIC ACIDS RES, V23, P3067, DOI 10.1093/nar/23.15.3067; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Minshull J, 1999, CURR OPIN CHEM BIOL, V3, P284, DOI 10.1016/S1367-5931(99)80044-1; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; OConnor KE, 1997, APPL ENVIRON MICROB, V63, P4287, DOI 10.1128/AEM.63.11.4287-4291.1997; Oldfield C, 1997, MICROBIOL-UK, V143, P2961, DOI 10.1099/00221287-143-9-2961; Ostermeier M, 1999, BIOORGAN MED CHEM, V7, P2139, DOI 10.1016/S0968-0896(99)00143-1; PIDDINGTON CS, 1995, APPL ENVIRON MICROB, V61, P468, DOI 10.1128/AEM.61.2.468-475.1995; Sambrook J, 1989, MOL CLONING; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P3536, DOI 10.1093/nar/26.15.3536; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	37	167	279	2	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					354	359		10.1038/86744	http://dx.doi.org/10.1038/86744			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283594				2022-12-25	WOS:000167940700025
J	Gopal, S; Schroeder, M; Pieper, U; Sczyrba, A; Aytekin-Kurban, G; Bekiranov, S; Fajardo, JE; Eswar, N; Sanchez, R; Sali, A; Gaasterland, T				Gopal, S; Schroeder, M; Pieper, U; Sczyrba, A; Aytekin-Kurban, G; Bekiranov, S; Fajardo, JE; Eswar, N; Sanchez, R; Sali, A; Gaasterland, T			Homology-based annotation yields 1,042 new candidate genes in the Drosophila melanogaster genome	NATURE GENETICS			English	Letter							PSI-BLAST; DATABASE; DNA; DISCOVERY	The approach to annotating a genome critically affects the number acid accuracy of genes identified in the genome sequence. Genome annotation based on stringent gene identification is prone to underestimate the complement of genes encoded in a genome. In contrast, over-prediction of putative genes followed by exhaustive computational sequence, motif and structural homology search will find rarely expressed, possibly unique, new genes at the risk of including non-functional genes. We developed a two-stage approach that combines the merits of stringent genome annotation with the benefits of over-prediction. First we identify plausible genes regardless of matches with EST, cDNA or protein sequences from the organism (stage 1). In the second stage, proteins predicted from the plausible genes are compared at the protein level with EST. cDNA and protein sequences, and protein structures from other organisms (stage 2). Remote but biologically meaningful protein sequence or structure homologies provide supporting evidence for genuine genes. The method, applied to the Drosophila melanogaster genome, validated 1,042 novel candidate genes after filtering 19,410 plausible genes, of which 12,124 matched the original 13,601 annotated genes(1). This annotation strategy is applicable to genomes of all organisms, including human.	Rockefeller Univ, Lab Computat Genom, New York, NY 10021 USA; Rockefeller Univ, Dept Biophys, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Gaasterland, T (corresponding author), Rockefeller Univ, Lab Computat Genom, 1230 York Ave, New York, NY 10021 USA.	gaasterland@rockefeller.edu	Pieper, Ursula/E-4444-2010	Pieper, Ursula/0000-0002-3168-8122	NCI NIH HHS [R33CA84699] Funding Source: Medline; NIGMS NIH HHS [P50GM62529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA084699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Bhat TN, 2001, NUCLEIC ACIDS RES, V29, P214, DOI 10.1093/nar/29.1.214; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Gaasterland T, 2000, GENOME RES, V10, P502, DOI 10.1101/gr.10.4.502; Gaasterland T, 1998, Microb Comp Genomics, V3, P177, DOI 10.1089/omi.1.1998.3.177; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Reboul J, 2001, NAT GENET, V27, P332, DOI 10.1038/85913; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; Reese MG, 2000, GENOME RES, V10, P529, DOI 10.1101/gr.10.4.529; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1999, BIOINFORMATICS, V15, P1060, DOI 10.1093/bioinformatics/15.12.1060; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Sanchez R, 1997, PROTEINS, P50; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455	26	47	51	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					337	340		10.1038/85922	http://dx.doi.org/10.1038/85922			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242120				2022-12-25	WOS:000167304200030
J	Nemoto, T; Kimura, R; Ito, K; Tachikawa, A; Miyashita, Y; Iino, M; Kasai, H				Nemoto, T; Kimura, R; Ito, K; Tachikawa, A; Miyashita, Y; Iino, M; Kasai, H			Sequential-replenishment mechanism of exocytosis in pancreatic acini	NATURE CELL BIOLOGY			English	Article							CA2+-DEPENDENT AMYLASE SECRETION; CA2+ SPIKES; REGULATED EXOCYTOSIS; STRUCTURAL-CHANGES; CALCIUM; RAT; RELEASE; SINGLE; MULTIPLE; GRANULES	Here we report exocytosis of zymogen granules, as examined by multiphoton excitation imaging in intact pancreatic acini, Cholecystokinin induces Ca2+ oscillations that trigger exocytosis when the cytosolic Ca2+ concentration exceeds 1 muM. Zymogen granules fused with the plasma membrane maintain their Omega -shaped profile for an average of 220 s and serve as targets for sequential fusion of granules that are located within deeper layers of the cell. This secondary exocytosis occurrs as rapidly as the primary exocytosis and accounts for most exocytotic events. Granule-granule fusion does not seem to precede primary exocytosis, indicating that secondary fusion events may require a plasma-membrane factor, This sequential-replenishment mechanism of exocytosis allows the cell to take advantage of a large supply of fusion-ready granules without needing to transport them to the plasma membrane.	Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan; Univ Tokyo, Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of Tokyo; Japan Science & Technology Agency (JST)	Kasai, H (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan.	hkasai@nips.ac.jp	KIMURA, RYOICHI/N-8982-2014; Miyashita, Yasushi/B-7171-2019; Nemoto, Tomomi/B-4412-2012	KIMURA, RYOICHI/0000-0002-1975-5548; Miyashita, Yasushi/0000-0003-3496-8637; Nemoto, Tomomi/0000-0001-6102-1495; Kasai, Haruo/0000-0003-2327-9027				Albright TD, 2000, NEURON, V25, pS1, DOI 10.1016/S0896-6273(00)80912-5; ALVAREZ DT, 1990, J GEN PHYSIOL, V95, P397, DOI DOI 10.1085/JGP.95.3.397; AMSTERDAM A, 1969, J CELL BIOL, V41, P753, DOI 10.1083/jcb.41.3.753; ANDERSON P, 1973, ACTA PHYSIOL SCAND, V88, P359, DOI 10.1111/j.1748-1716.1973.tb05465.x; Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; BAKER PF, 1981, PHILOS T R SOC B, V296, P83, DOI 10.1098/rstb.1981.0174; Chestkov VV, 1998, J BIOL CHEM, V273, P2445, DOI 10.1074/jbc.273.4.2445; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; DVORAK AM, 1981, LAB INVEST, V44, P174; FORTE JG, 1981, AM J PHYSIOL, V241, pG349, DOI 10.1152/ajpgi.1981.241.5.G349; Fox GQ, 1996, CELL TISSUE RES, V284, P303, DOI 10.1007/s004410050590; FURUYA S, 1989, J ELECTRON MICROSC, V38, P143; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; ICHIKAWA A, 1965, J CELL BIOL, V24, P369, DOI 10.1083/jcb.24.3.369; Ito K, 1999, J CELL BIOL, V146, P405, DOI 10.1083/jcb.146.2.405; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; Kasai H, 1999, PHILOS T ROY SOC B, V354, P331, DOI 10.1098/rstb.1999.0384; Kasai H, 1999, P NATL ACAD SCI USA, V96, P945, DOI 10.1073/pnas.96.3.945; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; ORCI L, 1980, DIABETES, V29, P943, DOI 10.2337/diab.29.11.943; Padfield PJ, 1998, BIOCHEM J, V330, P329; Padfield PJ, 1997, AM J PHYSIOL-GASTR L, V273, pG655, DOI 10.1152/ajpgi.1997.273.3.G655; PADFIELD PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG647, DOI 10.1152/ajpgi.1995.269.5.G647; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; Segawa A, 1996, EUR J MORPHOL, V34, P215, DOI 10.1076/ejom.34.3.215.13023; Segawa A, 1999, METHOD ENZYMOL, V307, P328; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; Williams RM, 1999, BIOPHYS J, V76, P1835, DOI 10.1016/S0006-3495(99)77343-1; WOLF DE, 1989, METHOD CELL BIOL, V30, P271; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9	41	142	144	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					253	258		10.1038/35060042	http://dx.doi.org/10.1038/35060042			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231574				2022-12-25	WOS:000167365800011
J	Sorek, R; Amitai, M				Sorek, R; Amitai, M			Piecing together the significance of splicing	NATURE BIOTECHNOLOGY			English	Editorial Material									Compugen, IL-69512 Tel Aviv, Israel		Sorek, R (corresponding author), Compugen, 72 Pinchas Rosen St, IL-69512 Tel Aviv, Israel.	rotem.sorek@cgen.com; mor.amitai@cgen.com						Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2	8	24	25	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					196	196		10.1038/85613	http://dx.doi.org/10.1038/85613			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231539	Bronze			2022-12-25	WOS:000167283100011
J	Makinen, T; Jussila, L; Veikkola, T; Karpanen, T; Kettunen, MI; Pulkkanen, KJ; Kauppinen, R; Jackson, DG; Kubo, H; Nishikawa, SI; Yla-Herttuala, S; Alitalo, K				Makinen, T; Jussila, L; Veikkola, T; Karpanen, T; Kettunen, MI; Pulkkanen, KJ; Kauppinen, R; Jackson, DG; Kubo, H; Nishikawa, SI; Yla-Herttuala, S; Alitalo, K			Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR-C EXPRESSION; IN-VIVO; LYMPHATIC ENDOTHELIUM; TUMOR-GROWTH; GENE-EXPRESSION; ANGIOGENESIS; SUPPRESSION; METASTASIS; ANTIBODIES	The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. Recent reports have focused on the molecular mechanisms regulating the lymphatic vessels. Vascular endothelial growth factor (VEGF)-C and VEGF-D have been shown to stimulate lymphangiogenesis and their receptor, VEGFR-3, has been linked to human hereditary lymphedema. Here we show that a soluble form of VEGFR-3 is a potent inhibitor of VEGF-C/VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal. Transgenic mice develop a lymphedema-like phenotype characterized by swelling of feet, edema and dermal fibrosis. They survive the neonatal period in spite of a virtually complete lack of lymphatic Vessels in several tissues, and later show regeneration of the lymphatic vasculature, indicating that induction of lymphatic regeneration may also be possible in humans.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, Helsinki, Finland; Univ Kuopio, AI Virtanen Inst, Dept Mol Med, Kuopio, Finland; Univ Kuopio, Natl BioNMR Facil, Kuopio, Finland; Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland; Univ Oxford, Mol Immunol Grp, Nuffield Dept Med, Oxford, England; Kyoto Univ, Dept Mol Genet, Kyoto, Japan	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Oxford; Kyoto University	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland.	kari.alitalo@helsinki.fi	Kettunen, Mikko I/K-2299-2012; Kauppinen, Risto A/F-3274-2011; Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014; Alitalo, Kari K/J-5013-2014	Kettunen, Mikko I/0000-0002-2004-660X; Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708; Karpanen, Terhi/0000-0002-2803-083X; , david/0000-0002-4133-9364				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karkkainen MJ, 2001, TRENDS MOL MED, V7, P18, DOI 10.1016/S1471-4914(00)01864-5; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kubo H, 2000, BLOOD, V96, P546; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; MANDRIOTA SJ, 2001, IN PRESS EMBO J; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Morishita M, 1998, MITSUBISHI ELECTR AD, V83, P1; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takayama K, 2000, CANCER RES, V60, P2169; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Witte M H, 1997, EXS, V79, P65; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	45	594	652	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					199	205		10.1038/84651	http://dx.doi.org/10.1038/84651			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175851				2022-12-25	WOS:000166756300037
J	Peeper, DS; Dannenberg, JH; Douma, S; Riele, HT; Bernards, R				Peeper, DS; Dannenberg, JH; Douma, S; Riele, HT; Bernards, R			Escape from premature senescence is not sufficient for oncogenic transformation by Ras	NATURE CELL BIOLOGY			English	Article							TUMOR SUPPRESSION; ACTIVATED RAS; INK4A LOCUS; P53; EXPRESSION; CELLS; PREREQUISITE; FIBROBLASTS; P19(ARF); PROTEIN	Resistance of primary cells to transformation by oncogenic Ras has been attributed to the induction of replicative growth arrest(1-3). This irreversible 'fail-safe mechanism' resembles senescence and requires induction by Ras of p19(ARF) and p53 (refs 3-5). Mutation of either p19ARF or p53 alleviates Ras-induced senescence and facilitates oncogenic transformation by Ras(3,6,7). Here we report that, whereas Rb and p107 are each dispensable for Ras-induced replicative arrest, simultaneous ablation of both genes disrupts Ras-induced senescence and results in unrestrained proliferation. This occurs despite activation by Ras of the p19(ARF)/p53 pathway, identifying pRb and p107 as essential mediators of Ras-induced antiproliferative p19ARF/p53 signalling. Unexpectedly, in contrast to p19ARF or p53 deficiency, loss of Rb/p107 function does not result in oncogenic transformation by Ras, as Ras-expressing Rb-/-/p107(-/-) fibroblasts fail to grow anchorage-independently in vitro and are not tumorigenic in vivo. These results demonstrate that in the absence of both Rb and p107 cells are resistant to p19(ARF)/p53-dependent protection against Ras-induced proliferation, and uncouple escape from Ras-induced premature senescence from oncogenic transformation.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	bernards@nki.nl	Peeper, Daniel/AAA-2430-2020	Bernards, Rene/0000-0001-8677-3423				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8	26	84	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					198	203		10.1038/35055110	http://dx.doi.org/10.1038/35055110			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175753	Green Published			2022-12-25	WOS:000166793000022
J	Daluiski, A; Engstrand, T; Bahamonde, ME; Gamer, LW; Agius, E; Stevenson, SL; Cox, K; Rosen, V; Lyons, KM				Daluiski, A; Engstrand, T; Bahamonde, ME; Gamer, LW; Agius, E; Stevenson, SL; Cox, K; Rosen, V; Lyons, KM			Bone morphogenetic protein-3 is a negative regulator of bone density	NATURE GENETICS			English	Article							SIGNALING PATHWAYS; II RECEPTORS; ACTIVIN-A; DIFFERENTIATION; EXPRESSION; CELLS; IDENTIFICATION; CULTURES; OSTEOPOROSIS; DROSOPHILA	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-beta) superfamily. Many BMPs are produced in bone and show osteogenic activity, suggesting that they may be determinants of bone mass. BMP3 was originally purified from bone as osteogenin, which induces osteogenic differentiation(1). Recombinant BMP3 (rhBMP3) has no biological activity, however, leaving its role in skeletal growth unclear. Here we show that BMP3 is an antagonist of osteogenic BMPs: BMP3 dorsalizes Xenopus laevis embryos, inhibits BMP2-mediated induction of Msx2 and blocks BMP2-mediated differentiation of osteoprogenitor cells into osteoblasts. These effects appear to be mediated through activin receptors. Finally, Smp3(-/-) mice have twice as much trabecular bone as wild-type littermates, indicating that BMP3, the most abundant BMP in adult bone, is a negative determinant of bone density.	Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA; Inst Genet, Cambridge, MA USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Case Western Reserve University	Lyons, KM (corresponding author), Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90024 USA.		agius, Eric/AHC-9705-2022	Agius, Eric/0000-0003-2123-9283	NIAMS NIH HHS [AR44528] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044528] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Candia AF, 1997, DEVELOPMENT, V124, P4467; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Engstrand T, 2000, HUM GENE THER, V11, P205, DOI 10.1089/10430340050016274; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.3.CO;2-K; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; LUYTEN FP, 1992, J BIOL CHEM, V267, P3691; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Piek E, 1999, J CELL PHYSIOL, V180, P141, DOI 10.1002/(SICI)1097-4652(199908)180:2<141::AID-JCP1>3.0.CO;2-I; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; Takao M, 1996, BIOCHEM BIOPH RES CO, V219, P656, DOI 10.1006/bbrc.1996.0289; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Wozney J. M., 1993, PHYSL PHARM BONE, P725; Yi SE, 2000, DEVELOPMENT, V127, P621; Zhao RB, 1999, DEV BIOL, V212, P68, DOI 10.1006/dbio.1999.9326; Zmuda JM, 1999, GENET EPIDEMIOL, V16, P356, DOI 10.1002/(SICI)1098-2272(1999)16:4<356::AID-GEPI3>3.0.CO;2-I	30	313	358	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					84	88		10.1038/83810	http://dx.doi.org/10.1038/83810			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138004				2022-12-25	WOS:000166187900021
J	Lewandoski, M; Sun, X; Martin, GR				Lewandoski, M; Sun, X; Martin, GR			Fgf8 signalling from the AER is essential for normal limb development	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; VERTEBRATE LIMB; MOUSE; OUTGROWTH; INITIATION; ROLES; GENE; MORPHOGENESIS; GASTRULATION; MAINTENANCE	Vertebrate limb development depends on signals from the apical ectodermal ridge (AER), which rims the distal tip of the limb bud(1). Removal of the AER in chick results in limbs lacking distal skeletal elements(2,3). Fibroblast growth factor (FGF) proteins can substitute for the AER (refs 4-7), suggesting that FGF signalling mediates AER activity. Of the four mouse Fgf genes (Fgf4, Fgf8, Fgf9, Fgf17) known to display AER-specific expression domains within the limb bud (AER-Fgfs), only Fgf8 is expressed throughout the AER. Moreover, Fgf8 expression precedes that of other AER-Fgfs (refs 8-13), suggesting that Fgf8 may perform unique functions early in limb development(6,7). In mice, loss of function of Fgf4 (refs 13,14), Fgf9 (D. Ornitz, pers. comm.) or Fgf17 (ref. 15) has no effect on limb formation. We report here that inactivating Fgf8 in early limb ectoderm causes a substantial reduction in limb-bud size, a delay in Shh expression, misregulation of Fgf4 expression, and hypoplasia or aplasia of specific skeletal elements. Our data identify Fgf8 as the only known AER-Fgf individually necessary for normal limb development, and provide insight into the function of Fgf signalling from the AER in the normal outgrowth and patterning of the limb.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.			Lewandoski, Mark/0000-0002-1066-3735	NICHD NIH HHS [R01 HD34380] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Merino R, 1999, DEVELOPMENT, V126, P5515; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Moon AM, 2000, DEVELOPMENT, V127, P989; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Pizette S, 1999, DEVELOPMENT, V126, P883; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; Tabin CJ, 1998, NATURE, V396, P322, DOI 10.1038/24516; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; Vogel A, 1996, DEVELOPMENT, V122, P1737; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Xu JS, 2000, DEVELOPMENT, V127, P1833; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	30	345	357	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					460	463		10.1038/82609	http://dx.doi.org/10.1038/82609			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101846				2022-12-25	WOS:000165671700021
J	Gharavi, AG; Yan, Y; Scolari, F; Schena, FP; Frasca, GM; Ghiggeri, GM; Cooper, K; Amoroso, A; Viola, BF; Battini, G; Caridi, G; Canova, C; Farhi, A; Subramanian, V; Nelson-Williams, C; Woodford, S; Julian, BA; Wyatt, RJ; Lifton, RP				Gharavi, AG; Yan, Y; Scolari, F; Schena, FP; Frasca, GM; Ghiggeri, GM; Cooper, K; Amoroso, A; Viola, BF; Battini, G; Caridi, G; Canova, C; Farhi, A; Subramanian, V; Nelson-Williams, C; Woodford, S; Julian, BA; Wyatt, RJ; Lifton, RP			IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; NATURAL-HISTORY; IMMUNOGLOBULIN; DISEASE; POLYMORPHISM; POPULATIONS; GUIDELINES; WORLDWIDE; LOCI	End-stage renal disease (ESRD) is a major public: health problem, affecting 1 in 1,000 individuals and with an annual death rate of 20% despite dialysis treatment(1,2). IgA nephropathy (IgAN) is the most common form of glomerulonephritis, a principal cause of ESRD worldwide(1,2); it affects up to 1.3% of the population(3-6) and its pathogenesis Is unknown. Kidneys of people with IgAN show deposits of IgA-containing immune complexes with proliferation of the glomerular mesangium (Fig. 1). Typical clinical features include onset before age 40 with haematuria and proteinuria (blood and protein in the urine), and episodes of gross haematuria following mucosal infections are common; 30% of patients develop progressive renal failure(6-9). Although not generally considered a hereditary disease, striking ethnic variation in prevalence(1-6,10) and familial clustering(11-16), along with subclinical renal abnormalities among relatives of IgAN cases(9,14-16), have suggested a heretofore undefined genetic component. By genome-wide analysis of linkage in 30 multiplex IgAN kindreds, we demonstrate linkage of IgAN to 6q22-23 under a dominant model of transmission with incomplete penetrance, with a lod score of 5.6 and 60% of kindreds linked. These findings for the first time indicate the existence of a locus with large effect on development of IgAN and identify the chromosomal location of this disease gene.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Mt Sinai Sch Med, Dept Med, New York, NY USA; Univ Brescia, Spedali Civili, Div Nephrol, Brescia, Italy; Univ Brescia, Spedali Civili, Chair Nephrol, Brescia, Italy; Univ Bari, Inst Nephrol, Polyclin, Bari, Italy; Policlin S Orsola, Div Nephrol, Bologna, Italy; Giannina Gaslini Inst, Lab Nephrol, Genoa, Italy; Giannina Gaslini Inst, Dept Nephrol, Genoa, Italy; IRCCS Burlo Garofolo, Serv Genet, Trieste, Italy; IRCCS Burlo Garofolo, Cattedra Genet, Trieste, Italy; Denzenzano Hosp, Dialysis Serv, Desenzano, Italy; St Orsola Univ Hosp, Dept Nephrol, Bologna, Italy; Univ Tennessee, Ctr Hlth Sci, Crippled Childrens Res Fdn, Memphis, TN 38163 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Icahn School of Medicine at Mount Sinai; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Universita degli Studi di Bari Aldo Moro; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Burlo Garofolo; IRCCS Burlo Garofolo; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.		amoroso, antonio/AAL-1475-2020; AMOROSO, ANTONIO/AAN-3884-2020; Ghiggeri, Gian Marco/N-4712-2015; Schena, Francesco P/K-6982-2016; Caridi, Gianluca/F-7052-2010; scolari, francesco/AAC-5957-2022	amoroso, antonio/0000-0002-9437-9407; Ghiggeri, Gian Marco/0000-0003-3659-9062; Schena, Francesco P/0000-0001-7927-5207; Caridi, Gianluca/0000-0001-6700-3001; Scolari, Francesco/0000-0003-0233-9705; Wyatt, Robert/0000-0001-6077-0259				Allen AC, 1997, NEPHROL DIAL TRANSPL, V12, P701, DOI 10.1093/ndt/12.4.701; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; DAMICO G, 1987, Q J MED, V64, P709; FARAWAY JJ, 1993, GENET EPIDEMIOL, V10, P75, DOI 10.1002/gepi.1370100108; Fennessy M, 1996, KIDNEY INT, V49, P477, DOI 10.1038/ki.1996.67; HOY WE, 1993, AM J KIDNEY DIS, V21, P486, DOI 10.1016/S0272-6386(12)80394-5; IBELS LS, 1994, MEDICINE, V73, P79, DOI 10.1097/00005792-199403000-00002; JENNETTE JC, 1985, KIDNEY INT, V28, P944, DOI 10.1038/ki.1985.222; Julian B A, 1999, Adv Nephrol Necker Hosp, V29, P53; JULIAN BA, 1985, NEW ENGL J MED, V312, P202, DOI 10.1056/NEJM198501243120403; JULIAN BA, 1988, AM J MED, V84, P129, DOI 10.1016/0002-9343(88)90019-8; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Maisonneuve P, 2000, AM J KIDNEY DIS, V35, P157, DOI 10.1016/S0272-6386(00)70316-7; SCHENA FP, 1993, CONTRIB NEPHROL, V104, P36; SCHENA FP, 1990, AM J MED, V89, P209; SCHENA FP, 1995, KIDNEY INT, V48, P1998, DOI 10.1038/ki.1995.503; Scolari F, 1999, AM J KIDNEY DIS, V33, P857, DOI 10.1016/S0272-6386(99)70417-8; SCOLARI F, 1992, NEPHROL DIAL TRANSPL, V7, P587, DOI 10.1093/ndt/7.7.587; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; STEPHENS JC, 1994, AM J HUM GENET, V55, P809; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; *US REN DAT SYST, USRDS 1999 ANN DAT R; van Zandbergen G, 1998, NEPHROL DIAL TRANSPL, V13, P3058, DOI 10.1093/ndt/13.12.3058; VARIS J, 1993, J CLIN PATHOL, V46, P607, DOI 10.1136/jcp.46.7.607; WYATT RJ, 1987, AM J HUM GENET, V41, P36; Yano N, 1998, J IMMUNOL, V160, P4936; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zheng F, 1999, NAT MED, V5, P1018, DOI 10.1038/12458	30	225	253	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					354	357		10.1038/81677	http://dx.doi.org/10.1038/81677			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062479	Green Published			2022-12-25	WOS:000165176500028
J	Janssens, K; Gershoni-Baruch, R; Guanabens, N; Migone, N; Ralston, S; Bonduelle, M; Lissens, W; Van Maldergem, L; Vanhoenacker, F; Verbruggen, L; Van Hul, W				Janssens, K; Gershoni-Baruch, R; Guanabens, N; Migone, N; Ralston, S; Bonduelle, M; Lissens, W; Van Maldergem, L; Vanhoenacker, F; Verbruggen, L; Van Hul, W			Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; PRO REGION; TGF-BETA; BONE; FACTOR-BETA-1; CULTURES		Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Rambam Med Ctr, Inst Human Genet, Haifa, Israel; Hosp Clin Barcelona, Dept Rheumatol, Barcelona, Spain; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB9 2ZD, Scotland; Univ Hosp Brussels, Dept Med Genet, Brussels, Belgium; Univ Hosp Brussels, Dept Rheumatol, Brussels, Belgium; Inst Pathol & Genet, Ctr Human Genet, Loverval, Belgium; Univ Antwerp Hosp, Dept Radiol, Antwerp, Belgium	University of Antwerp; Rambam Health Care Campus; Technion Israel Institute of Technology; University of Barcelona; Hospital Clinic de Barcelona; University of Turin; University of Aberdeen; University Hospital Brussels; University Hospital Brussels; University of Antwerp	Van Hul, W (corresponding author), Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium.	vhuh@uia.ua.ac.be	Lissens, Willy/B-2892-2013; Van Maldergem, Lionel/G-9849-2017; Van Maldergem, Lionel/O-3242-2019	Lissens, Willy/0000-0003-3875-9955; Van Maldergem, Lionel/0000-0001-8880-5214; Van Maldergem, Lionel/0000-0001-8880-5214; Van Hul, Wim/0000-0002-5065-7858; Bonduelle, Mary-Louise/0000-0002-1805-9962				BECK LS, 1991, J BONE MINER RES, V6, P961; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; Fuller K, 2000, J CELL SCI, V113, P2445; Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632; Ghadami M, 2000, AM J HUM GENET, V66, P143, DOI 10.1086/302728; Janssens K, 2000, J MED GENET, V37, P245, DOI 10.1136/jmg.37.4.245; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; MUNDY GR, 1991, CIBA F SYMP, V157, P137; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Roberts Anita B., 2000, P221; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; Vaughn SP, 2000, GENOMICS, V66, P119, DOI 10.1006/geno.2000.6192; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569	16	163	178	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2000	26	3					273	275		10.1038/81563	http://dx.doi.org/10.1038/81563			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062463				2022-12-25	WOS:000165176500012
J	Pelletier, L; Jokitalo, E; Warren, G				Pelletier, L; Jokitalo, E; Warren, G			The effect of Golgi depletion on exocytic transport	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; LIVING CELLS; BREFELDIN-A; PROTEIN; ER; COMPLEX; APPARATUS; VESICLES; MITOSIS; REVEALS	Here we evaluate the idea that the Golgi is in dynamic equilibrium with the endoplasmic reticulum (ER). In cytoplasts that lack the Golgi apparatus, no regrowth of the Golgi is observed, nor is any transport from the ER to the cell surface detected. However, introduction of the smallest measurable amount of Golgi (equivalent to a few per cent per cell) yields significant exocytic transport. Our results indicate that the steady-state levels of Golgi in the ER are far smaller than the 30% that has been postulated, and that the Golgi may be an independent organelle and not simply an extension of the ER.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Univ Helsinki, Inst Biotechnol, Electron Microscopy Unit, Helsinki 00014, Finland	Yale University; University of Helsinki	Pelletier, L (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA.	graham.warren@yale.edu	Pelletier, Laurence/F-8858-2013; Jokitalo, Eija/C-8375-2009	Jokitalo, Eija/0000-0002-4159-6934	NIGMS NIH HHS [GM60478-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1993, J BIOL CHEM, V268, P873; Cabrera-Poch N, 1998, BBA-MOL CELL RES, V1404, P139, DOI 10.1016/S0167-4889(98)00051-2; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Farmaki T, 1999, J CELL SCI, V112, P589; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Hauri HP, 2000, J CELL SCI, V113, P587; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; JOKITALO E, UNPUB J CELL BIOL; Kano F, 2000, BIOPHYS CHEM, V84, P261, DOI 10.1016/S0301-4622(00)00133-2; KAWANO JI, 1994, J HISTOCHEM CYTOCHEM, V42, P363, DOI 10.1177/42.3.8308253; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MORRE DJ, 1974, SUBCELLULAR STUDIES, P195; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacchetti A, 1999, NAT BIOTECHNOL, V17, P1046, DOI 10.1038/14990; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SEELIG HP, 1995, MOL CELL BIOL, V15, P591; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; SEEMANN J, IN PRESS NATURE; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; SHIMA DT, 1998, DYNAMICS CELL DIVISI, P248; Shugrue CA, 1999, J CELL SCI, V112, P4547; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Terasaki M, 2000, MOL BIOL CELL, V11, P897, DOI 10.1091/mbc.11.3.897; Wacker I, 1997, J CELL SCI, V110, P1453; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	44	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					840	846		10.1038/35041089	http://dx.doi.org/10.1038/35041089			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056540				2022-12-25	WOS:000165207500019
J	Shafer, RW; Jung, DR; Betts, BJ				Shafer, RW; Jung, DR; Betts, BJ			Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries	NATURE MEDICINE			English	Article							SEQUENCE DATABASE		Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA; Stanford Univ, Sch Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Shafer, RW (corresponding author), Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.			Betts, Bradley/0000-0002-1618-8285	NIAID NIH HHS [R01 AI046148, R01 AI046148-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashburner M, 1997, CURR OPIN GENET DEV, V7, P750, DOI 10.1016/S0959-437X(97)80036-6; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Frishman D, 1998, BIOINFORMATICS, V14, P551, DOI 10.1093/bioinformatics/14.7.551; HAMMOND J, 1998, HUMAN RETROVIRUSES A; HARDT D, 1998, PERL RESOURCE KIT WI; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Imamichi T, 2000, J VIROL, V74, P1023, DOI 10.1128/JVI.74.2.1023-1028.2000; KORBER BT, 1998, HUMAN RETROVIRUSES A; LARDER B, 1999, ANTIVIR THER S, V4, P41; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; *NAT CTR BIOT INF, 1998, HIV 1 SUBT TOOL; *PN CLIN PRACT TRE, 2000, GUID US ANT AG HIV I; Shafer RW, 1999, NUCLEIC ACIDS RES, V27, P348, DOI 10.1093/nar/27.1.348; STEUBAL J, 1997, INTRO COMPUTATIONAL, P61; Stoesser G, 1999, NUCLEIC ACIDS RES, V27, P18, DOI 10.1093/nar/27.1.18; Sugawara H, 1999, NUCLEIC ACIDS RES, V27, P25, DOI 10.1093/nar/27.1.25; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948	17	63	65	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1290	1292		10.1038/81407	http://dx.doi.org/10.1038/81407			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062545	Green Accepted			2022-12-25	WOS:000165114800041
J	Blaskovich, MA; Lin, Q; Delarue, FL; Sun, J; Park, HS; Coppola, D; Hamilton, AD; Sebti, SM				Blaskovich, MA; Lin, Q; Delarue, FL; Sun, J; Park, HS; Coppola, D; Hamilton, AD; Sebti, SM			Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice	NATURE BIOTECHNOLOGY			English	Article						platelet-derived growth factor; angiogenesis; oncogenesis; cancer drug discovery	ANGIOGENESIS IN-VITRO; RECEPTOR-BINDING; PDGF-BB; ANTIBODY; DOMAIN; IDENTIFICATION; PROLIFERATION; RECOGNITION; INHIBITION; ACTIVATION	We have designed a molecule, GFB-111, that binds to platelet-derived growth factor (PDGF), prevents it from binding to its receptor tyrosine kinase, and blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases, and DNA synthesis. GFB-111 is highly potent (IC50 = 250 nM) and selective for PDGF over EGF, IGF-1, aFGF, bFGF, and HRG beta (IC50 values > 100 mu M), but inhibits VEGF-induced Flk-1 tyrosine phosphorylation and Erk1/Erk2 activation with an IC50 of 10 mu M. GFB-111 treatment of nude mice bearing human tumors resulted in significant inhibition of tumor growth and angiogenesis. The results demonstrate the feasibility of designing novel growth factor-binding molecules with potent anticancer and antiangiogenic activity.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA.			Park, Hyung Soon/0000-0003-0558-2874	NCI NIH HHS [P01 CA78038-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Brennand DM, 1997, FEBS LETT, V413, P70, DOI 10.1016/S0014-5793(97)00885-5; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; Hamuro Y, 1997, ANGEW CHEM INT EDIT, V36, P2680, DOI 10.1002/anie.199726801; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1996, MOL CELLULAR BIOL WO; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; Kumar R, 1998, INT J ONCOL, V12, P749; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Park HS, 1999, J AM CHEM SOC, V121, P8, DOI 10.1021/ja981504o; RAINES EW, 1990, HDB EXPT PHARM PEPTI; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; Shulman T, 1997, J BIOL CHEM, V272, P17400, DOI 10.1074/jbc.272.28.17400; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Sun JZ, 1999, CANCER RES, V59, P4919; Thommen R, 1997, J CELL BIOCHEM, V64, P403; Wang DG, 1999, CANCER RES, V59, P1464; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	33	117	126	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1065	1070		10.1038/80257	http://dx.doi.org/10.1038/80257			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017044				2022-12-25	WOS:000089744700028
J	Anastasiadis, PZ; Moon, SY; Thoreson, MA; Mariner, DJ; Crawford, HC; Zheng, Y; Reynolds, AB				Anastasiadis, PZ; Moon, SY; Thoreson, MA; Mariner, DJ; Crawford, HC; Zheng, Y; Reynolds, AB			Inhibition of RhoA by p120 catenin	NATURE CELL BIOLOGY			English	Article							CELL-CELL-ADHESION; E-CADHERIN; TYROSINE PHOSPHORYLATION; FAMILY GTPASES; LYSOPHOSPHATIDIC ACID; MORPHOLOGICAL-CHANGES; CARCINOMA-CELLS; STRESS FIBERS; ERM FAMILY; MDCK CELLS	RhoA organizes actin stress fibres and is necessary for cell transformation by oncogenes such as src and ras. Moreover, RhoA is implicated in cadherin clustering during the formation of adherens junctions. The catenin p120 has also been implicated in cadherin clustering through an unknown mechanism. Here we show that p120 selectively inhibits RhoA activity in vitro and in vivo. RhoA inhibition and the interaction of p120 with cadherins are mutually exclusive, suggesting a mechanism for regulating the recruitment and exchange of RhoA at nascent cell-cell contacts. By affecting RhoA activation, p120 could modulate cadherin functions, including suppression of invasion, neurite extension and junction formation.	Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center	Reynolds, AB (corresponding author), Vanderbilt Univ, Dept Cell Biol, MCN C-2310, Nashville, TN 37232 USA.	al.reynolds@mcmail.vanderbilt.edu	Zheng, Yi/J-7235-2015; Crawford, Howard/A-2874-2008	Zheng, Yi/0000-0001-7089-6074; 	NCI NIH HHS [CA55724, CA69485] Funding Source: Medline; NIGMS NIH HHS [GM53943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055724, R01CA055724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1998, J CELL BIOCHEM, P147; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mariner DJ, 2000, J CELL SCI, V113, P1481; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; REVNOLDS AB, 1994, MOL CELL BIOL, V14, P8333; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wu J, 1998, HYBRIDOMA, V17, P175, DOI 10.1089/hyb.1998.17.175; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609	39	365	372	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					637	644		10.1038/35023588	http://dx.doi.org/10.1038/35023588			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980705				2022-12-25	WOS:000089250600016
J	Henderson, BR				Henderson, BR			Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; EXPORT SIGNAL; COLON-CANCER; GENE-PRODUCT; CELL-LINES; WILD-TYPE; IN-VIVO; CRM1	Mutational inactivation of the APC gene is a key early event in the development of familial adenomatous polyposis and colon cancer. APC suppresses tumour progression by promoting degradation of the oncogenic transcriptional activator beta-catenin. APC gene mutations can lead to abnormally high levels of beta-catenin in the nucleus, and the consequent activation of transforming genes. Here, we show that APC is a nuclear-cytoplasmic shuttling protein, and that it can function as a beta-catenin chaperone. APC contains two active nuclear export sequences (NES) at the amino terminus, and mutagenesis of these conserved motifs blocks nuclear export dependent on the CRM1 export receptor. Treatment of cells with the CRM1-specific export inhibitor leptomycin B shifts APC from cytoplasm to nucleus. beta-catenin localization is also regulated by CRM1, but in an APC-dependent manner. Transient expression of wild-type APC in SW480 (APC(mut/mut)) colon cancer cells enhances nuclear export and degradation of beta-catenin, and these effects can be blocked by mutagenesis of the APC NES. These findings suggest that wild-type APC controls the nuclear accumulation of beta-catenin by a combination of nuclear export and cytoplasmic degradation.	Univ Sydney, Westmead Millenium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Millenium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.							Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BRENZ M, 1999, CURR OPIN GENE DEV, V9, P595; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRODEN J, 1995, CANCER RES, V55, P1531; GURNBINER BM, 1997, CURR BIOL, V7, pR443; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HATASHI S, 1997, P NATL ACAD SCI USA, V94, P242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HENGEL J, 1999, P NATL ACAD SCI USA, V96, P7980; IETSU O, 1999, NATURE, V398, P422; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Laken SJ, 1999, P NATL ACAD SCI USA, V96, P2322, DOI 10.1073/pnas.96.5.2322; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MIVASHIRO I, 1995, ONCOGENE, V11, P89; MIVOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452; MIVOSHI Y, 1992, HUM MOL GENET, V1, P229; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakagawa H, 1998, CANCER RES, V58, P5176; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SMITH KJ, 1994, CANCER RES, V54, P3672; SO IK, 1993, SCIENCE, V262, P1734; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SU IK, 1995, CANCER RES, V55, P2972; SU LK, 1993, CANCER RES, V53, P2728; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	50	390	403	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					653	660		10.1038/35023605	http://dx.doi.org/10.1038/35023605			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980707				2022-12-25	WOS:000089250600018
J	Kureishi, Y; Luo, ZY; Shiojima, I; Bialik, A; Fulton, D; Lefer, DJ; Sessa, WC; Walsh, K				Kureishi, Y; Luo, ZY; Shiojima, I; Bialik, A; Fulton, D; Lefer, DJ; Sessa, WC; Walsh, K			The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; ENDOTHELIAL GROWTH-FACTOR; CHOLESTEROL REDUCTION; SURVIVAL; ISCHEMIA; THERAPY; GENE; PRAVASTATIN; VESSELS; PATHWAY	Recent studies suggest that statins can function to protect the vasculature in a manner that is independent of their lipid-lowering activity. We show here that statins rapidly activate the protein kinase Akt/PKB in endothelial cells. Accordingly, simvastatin enhanced phosphorylation of the endogenous Akt substrate endothelial nitric oxide synthase (eNOS), inhibited apoptosis and accelerated vascular structure formation in vitro in an Akt-dependent manner. Similar to vascular endothelial growth factor (VEGF) treatment,both simvastatin administration and enhanced Akt signaling in the endothelium promoted angiogenesis in ischemic limbs of normocholesterolemic rabbits. Therefore, activation of Akt represents a mechanism that can account for some of the beneficial side effects of statins, including the promotion of new blood vessel growth.	Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02135 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; Louisiana State Univ, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University; Yale University; Yale University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Walsh, K (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA.	kwalsh@opal.tufts.edu	Lefer, David/A-6372-2012; Bando, Yasuko K./M-4831-2014; Sessa, William C/B-6844-2011	Bando, Yasuko K./0000-0003-4166-6784; Sessa, William C/0000-0001-5759-1938; Walsh, Kenneth/0000-0001-7580-2276; Lefer, David/0000-0003-2293-7278	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50692, R01 HL050692-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197, R01 AR040197-11, R01-AR40197] Funding Source: Medline; NIA NIH HHS [R01 AG015052, R01-AG15052, R01 AG015052-03] Funding Source: Medline; NICHD NIH HHS [P01 HD023681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Baller D, 1999, CIRCULATION, V99, P2871, DOI 10.1161/01.CIR.99.22.2871; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guo K, 1998, CIRCULATION, V97, P2066, DOI 10.1161/01.CIR.97.20.2066; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LUO Z, 2000, IN PRESS J CLIN INVE; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; PEDERSEN TR, 1994, LANCET, V344, P1383; Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894; PU LQ, 1993, J SURG RES, V54, P575, DOI 10.1006/jsre.1993.1088; Qian HS, 1999, CIRCULATION, V99, P2979, DOI 10.1161/01.CIR.99.23.2979; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; *TASCWORK GROUP, 2000, J VASC SURG S, V31, pS62; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	36	1194	1283	7	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1004	1010		10.1038/79510	http://dx.doi.org/10.1038/79510			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973320	Green Accepted			2022-12-25	WOS:000089190500032
J	Lane, KB; Machado, RD; Pauciulo, MW; Thomson, JR; Phillips, JA; Loyd, JE; Nichols, WC; Trembath, RC				Lane, KB; Machado, RD; Pauciulo, MW; Thomson, JR; Phillips, JA; Loyd, JE; Nichols, WC; Trembath, RC		Int PPH Consortium	Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; II RECEPTOR; CLONING; PROTEINS; COMPLEX; GENE	Primary pulmonary hypertension (PPH). characterized by obstruction of pre-capillary pulmonary arteries, leads to sustained elevation of pulmonary arterial pressure (mean >25 mm Hg at rest or >30 mm Hg during exercise(1)). The aetiology is unknown, but the histological features reveal proliferation of endothelial and smooth muscle cells with vascular remodelling(2) (Fig. 1). More than one affected relative has been identified in at least 6% of cases(3) (familial PPH, MIM 178600). Familial PPH (FPPH) segregates as an autosomal dominant disorder with reduced penetrance and has been mapped to a locus designated PPH1 on 2q33. with no evidence of heterogeneity(4-6). We now show that FPPH is caused by mutations in BMPR2. encoding a TGF-beta type II receptor (BMPR-II). Members of the TGF-beta superfamily transduce signals by binding to heteromeric complexes of type I and II receptors, which activates serine/threonine kinases. leading to transcriptional regulation by phosphorylated Smads(7). By comparison with in vitro studies, identified defects of BMPR-II in FPPH are predicted to disrupt ligand binding, kinase activity and heteromeric dimer formation(8-10). Our data demonstrate the molecular basis of FPPH and underscore the importance in vivo of the TGF-beta signalling pathway in the maintenance of blood vessel integrity.	Vanderbilt Univ, Med Ctr, Nashville, TN 37240 USA; Univ Leicester, Dept Genet, Div Med Genet, Leicester, Leics, England; Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Indiana Univ, Sch Med, Indianapolis, IN USA	Vanderbilt University; University of Leicester; University of Leicester; Cincinnati Children's Hospital Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis	Loyd, JE (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37240 USA.	Jim.Loyd@mcmail.vanderbilt.edu; bill.nichols@chmcc.org; rtrembat@hgmp.mrc.ac.uk	Vilarino-Guell, Carles/D-8628-2011; Machado, Rajiv D./AAD-7813-2019; Morgan, Neil V/A-5475-2009	Vilarino-Guell, Carles/0000-0002-5612-5940; Machado, Rajiv D./0000-0001-9247-0744; Morgan, Neil V/0000-0001-6433-5692; Loyd, James/0000-0002-5042-7390; Trembath, Richard/0000-0003-0550-3400	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061997, R01HL048164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61997, HL48164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beppu H, 1997, BIOCHEM BIOPH RES CO, V235, P499, DOI 10.1006/bbrc.1997.6816; BOTNEY MD, 1994, AM J PATHOL, V144, P286; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Gaine SP, 1998, LANCET, V352, P719, DOI 10.1016/S0140-6736(98)02111-4; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Hadano S, 1999, GENOMICS, V55, P106, DOI 10.1006/geno.1998.5637; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOYD JE, 1984, AM REV RESPIR DIS, V129, P194; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MACHADO RD, IN PRESS GENOMICS; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 2000, GENE DEV, V14, P627; Morse JH, 1997, CIRCULATION, V95, P2603, DOI 10.1161/01.CIR.95.12.2603; Nichols WC, 1997, NAT GENET, V15, P277, DOI 10.1038/ng0397-277; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; THOMSON JR, IN PRESS J CLIN PATH; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	23	1051	1107	1	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					81	84		10.1038/79226	http://dx.doi.org/10.1038/79226			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973254				2022-12-25	WOS:000089078000023
J	Shimohata, T; Nakajima, T; Yamada, M; Uchida, C; Onodera, O; Naruse, S; Kimura, T; Koide, R; Nozaki, K; Sano, Y; Ishiguro, H; Sakoe, K; Ooshima, T; Sato, A; Ikeuchi, T; Oyake, M; Sato, T; Aoyagi, Y; Hozumi, I; Nagatsu, T; Takiyama, Y; Nishizawa, M; Goto, J; Kanazawa, I; Davidson, I; Tanese, N; Takahashi, H; Tsuji, S				Shimohata, T; Nakajima, T; Yamada, M; Uchida, C; Onodera, O; Naruse, S; Kimura, T; Koide, R; Nozaki, K; Sano, Y; Ishiguro, H; Sakoe, K; Ooshima, T; Sato, A; Ikeuchi, T; Oyake, M; Sato, T; Aoyagi, Y; Hozumi, I; Nagatsu, T; Takiyama, Y; Nishizawa, M; Goto, J; Kanazawa, I; Davidson, I; Tanese, N; Takahashi, H; Tsuji, S			Expanded polyglutamine stretches interact with TAF(II)130, interfering with CREB-dependent transcription	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; AGGREGATE FORMATION; MAMMALIAN-CELLS; ANDROGEN RECEPTOR; TRANSGENIC MICE; BINDING PROTEIN; DRPLA PROTEIN; PC12 CELLS; HUNTINGTIN	At least eight inherited neurodegenerative diseases are caused by expanded CAG repeats encoding polyglutamine (polyQ) stretches. Although cytotoxicities of expanded polyQ stretches are implicated, the molecular mechanisms of neurodegeneration remain unclear. We found that expanded! polyQ stretches preferentially bind to TAF(II)130, a coactivator involved in cAMP-responsive element binding protein (CREB)-dependent transcriptional activation, and strongly suppress CREB-dependent transcriptional activation. The suppression of CREB-dependent transcription and the cell death induced by polyQ stretches were restored by the co-expression of TAF(II)130. Our results indicate that interference of transcription by the binding of TAF(II)130 with expanded polyQ stretches is involved in the pathogenetic mechanisms underlying neurodegeneration.	Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan; Niigata Univ, Brain Res Inst, Dept Pathol, Niigata 951, Japan; Univ Tsukuba, TARA Ctr, Inst Appl Biochem, Tsukuba, Ibaraki, Japan; St Marianna Univ, Inst Med Sci, PRESTO JST, Kawasaki, Kanagawa, Japan; Hamamatsu Univ Sch Med, Dept Biochem, Shizuoka, Japan; Fujita Hlth Univ, Inst Comprehens Med Sci, Aichi, Japan; Jichi Med Sch, Dept Neurol, Jichi, Tochigi, Japan; Univ Tokyo, Fac Med, Inst Brain Res, Dept Neurol, Tokyo 113, Japan; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France; NYU Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Niigata University; Niigata University; University of Tsukuba; Japan Science & Technology Agency (JST); Saint Marianna University; Hamamatsu University School of Medicine; Fujita Health University; Jichi Medical University; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; New York University; New York University	Tsuji, S (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan.	tsuji@cc.niigaa-u.ac.jp	Onodera, Osamu/K-7327-2013	Onodera, Osamu/0000-0003-3354-5472; Sato, Toshiya/0000-0001-7844-9930; Tanese, Naoko/0000-0002-1946-3211; Hozumi, Isao/0000-0003-0984-6291; Davidson, Irwin/0000-0001-5533-1171; OHSHIMA, Takayuki/0000-0002-1501-6430				Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DESOUZA EB, 1987, BRAIN RES, V437, P355, DOI 10.1016/0006-8993(87)91651-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Li SH, 1999, J NEUROSCI, V19, P5159; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Miyashita T, 1998, BIOCHEM BIOPH RES CO, V249, P96, DOI 10.1006/bbrc.1998.9096; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moulder KL, 1999, J NEUROSCI, V19, P705; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Parker D, 1996, MOL CELL BIOL, V16, P694; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Sato A, 1999, HUM MOL GENET, V8, P997, DOI 10.1093/hmg/8.6.997; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Timmers HJLM, 1996, BRAIN RES, V728, P141, DOI 10.1016/0006-8993(96)00080-7; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	48	326	334	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					29	36		10.1038/79139	http://dx.doi.org/10.1038/79139			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973244				2022-12-25	WOS:000089078000013
J	Uruno, T; Liu, JL; Zhang, PJ; Fan, YX; Egile, C; Li, P; Mueller, SC; Zhan, X				Uruno, T; Liu, JL; Zhang, PJ; Fan, YX; Egile, C; Li, P; Mueller, SC; Zhan, X			Activation of Arp2/3 complex-mediated actin polymerization by cortactin	NATURE CELL BIOLOGY			English	Article							ALDRICH-SYNDROME PROTEIN; TYROSINE PHOSPHORYLATION; N-WASP; LISTERIA-MONOCYTOGENES; CELLS; NUCLEATION; BINDING; CYTOSKELETON; SUBSTRATE; MOTILITY	Cortactin, a filamentous actin (F-actin)-associated protein and prominent substrate of Src, is implicated in progression of breast tumours through gene amplification at chromosome 11q13. However, the function of cortactin remains obscure. Here we show that cortactin co-localizes with the Arp2/3 complex, a de novo actin nucleator, at dynamic particulate structures enriched with actin filaments. Cortactin binds directly to the Arp2/3 complex and activates it to promote nucleation of actin filaments. The interaction of cortactin with the Arp2/3 complex occurs at an amino-terminal domain that is rich in acidic amino acids. Mutations in a conserved amino-acid sequence of DDW abolish both the interaction with the Arp2/3 complex and complex activation. The N-terminal domain is not only essential but also sufficient to target cortactin to actin-enriched patches within cells. Interestingly, the ability of cortactin to activate the Arp2/3 complex depends on an activity for F-actin binding; which is almost 20-fold higher than that of the Arp2/3 complex. Our data indicate a new mechanism for activation of actin polymerization involving an enhanced interaction between the Arp2/3 complex and actin filaments.	Amer Red Cross, Dept Expt Pathol, Holland Lab, Rockville, MD 20855 USA; Chinese Acad Sci, Inst Oceanol, Qingdao 266071, Peoples R China; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20007 USA; George Washington Univ, Dept Cell Biol & Anat, Washington, DC 20037 USA	American Red Cross; Chinese Academy of Sciences; Institute of Oceanology, CAS; Harvard University; Harvard Medical School; Georgetown University; George Washington University	Uruno, T (corresponding author), Amer Red Cross, Dept Expt Pathol, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Uruno, Takehito/AAF-7998-2019	Uruno, Takehito/0000-0002-2812-9645				BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Cantarelli VV, 2000, INFECT IMMUN, V68, P382, DOI 10.1128/IAI.68.1.382-386.2000; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fawaz FS, 1997, INFECT IMMUN, V65, P5301, DOI 10.1128/IAI.65.12.5301-5308.1997; Gallet C, 1999, J BIOL CHEM, V274, P23610, DOI 10.1074/jbc.274.33.23610; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HIURA K, 1995, CELL MOTIL CYTOSKEL, V30, P272, DOI 10.1002/cm.970300405; Huang C, 2000, METH MOL B, V144, P289; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; ZHAN X, 1993, J BIOL CHEM, V268, P24427	41	442	454	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					259	266		10.1038/35060051	http://dx.doi.org/10.1038/35060051			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231575				2022-12-25	WOS:000167365800012
J	Islam, D; Bandholtz, L; Nilsson, J; Wigzell, H; Christensson, B; Agerberth, B; Gudmundsson, GH				Islam, D; Bandholtz, L; Nilsson, J; Wigzell, H; Christensson, B; Agerberth, B; Gudmundsson, GH			Downregulation of bactericidal peptides in enteric infections: A novel immune escape mechanism with bacterial DNA as a potential regulator	NATURE MEDICINE			English	Article							EPITHELIAL-CELLS; ANTIBACTERIAL PEPTIDES; ANTIMICROBIAL PEPTIDES; BETA-DEFENSIN; HOST-DEFENSE; PANETH CELLS; SHIGELLA; GENE; EXPRESSION; PARADIGM	Antibacterial peptides are active defense components of innate Immunity. Several studies confirm their importance at epithelial surfaces as immediate barrier effecters in preventing Infection. Here we report that early in Shigella spp. infections, expression of the antibacterial peptides LL-37 and human beta -defensin-1. is reduced or turned off. The downregulation is detected in biopsies from patients with bacillary dysenteries and in Shigella- infected cell cultures of epithelial and monocyte origin. This downregulation of immediate defense effecters might promote bacterial adherence and invasion into host epithelium and could be an important virulence parameter. Analyses of bacterial molecules causing the downregulation indicate Shigella plasmid DNA as one mediator.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Dhaka 1000, Bangladesh; Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden; Huddinge Hosp, Dept Immunol Microbiol & Pathol, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; International Centre for Diarrhoeal Disease Research (ICDDR)	Gudmundsson, GH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Gudmundsson, Gudmundur H/K-9178-2015	Gudmundsson, Gudmundur H/0000-0001-5793-0565; Nilsson, Jakob/0000-0001-5091-8133				AGER, 2000, INFECT IMMUN, V68, P5412; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Albert MJ, 1999, J CLIN MICROBIOL, V37, P3458, DOI 10.1128/JCM.37.11.3458-3464.1999; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Chu RS, 1999, J IMMUNOL, V163, P1188; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Dorman CJ, 1998, MOL MICROBIOL, V29, P677, DOI 10.1046/j.1365-2958.1998.00902.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; ISLAM D, 1995, INFECT IMMUN, V63, P2054, DOI 10.1128/IAI.63.5.2054-2061.1995; Islam D, 1997, INFECT IMMUN, V65, P739, DOI 10.1128/IAI.65.2.739-749.1997; Islam D, 1997, J CLIN PATHOL, V50, P513, DOI 10.1136/jcp.50.6.513; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; MandicMulec I, 1997, INFECT IMMUN, V65, P110, DOI 10.1128/IAI.65.1.110-115.1997; Menard R, 1996, TRENDS MICROBIOL, V4, P220, DOI 10.1016/0966-842X(96)10039-1; O'Neil DA, 1999, J IMMUNOL, V163, P6718; RAQIB R, 1995, INFECT IMMUN, V63, P289, DOI 10.1128/IAI.63.1.289-296.1995; Sansonetti PJ, 1998, FOLIA MICROBIOL, V43, P239, DOI 10.1007/BF02818608; Shafer WM, 1998, P NATL ACAD SCI USA, V95, P1829, DOI 10.1073/pnas.95.4.1829; SIEBERS A, 1995, TRENDS MICROBIOL, V3, P207, DOI 10.1016/S0966-842X(00)88923-4; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; Zychlinsky A, 1997, TRENDS MICROBIOL, V5, P201, DOI 10.1016/S0966-842X(97)01044-5	36	341	349	2	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					180	185		10.1038/84627	http://dx.doi.org/10.1038/84627			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175848				2022-12-25	WOS:000166756300034
J	Abdulkadir, SA; Qu, ZC; Garabedian, E; Song, SK; Peters, TJ; Svaren, J; Carbone, JM; Naughton, CK; Catalona, WJ; Ackerman, JJH; Gordon, JI; Humphrey, PA; Milbrandt, J				Abdulkadir, SA; Qu, ZC; Garabedian, E; Song, SK; Peters, TJ; Svaren, J; Carbone, JM; Naughton, CK; Catalona, WJ; Ackerman, JJH; Gordon, JI; Humphrey, PA; Milbrandt, J			Impaired prostate tumorigenesis in Egr1-deficient mice	NATURE MEDICINE			English	Article							PROTEIN NGFI-A; TRANSGENIC MOUSE; GENE-EXPRESSION; PC12 CELLS; CANCER; GROWTH; TRANSCRIPTION; PROGRESSION; NAB2; DIFFERENTIATION	The transcription factor, early growth response protein 1 (ECR1), is overexpressed in a majority of human prostate cancers and is implicated in the regulation of several genes important for prostate tumor progression. Here we have assessed the effect of Egr1 deficiency on tumor development in two transgenic mouse models of prostate cancer (CR2-T-Ag and TRAMP). Using a combination of high-resolution magnetic resonance imaging and histopathological and survival analyses, we show that tumor progression was significantly impaired in Egr1(-/-) mice. Tumor initiation and tumor growth rate were not affected by the lack of Egr1; however, Egr1 deficiency significantly delayed the progression from prostatic intra-epithelial neoplasia to invasive carcinoma. These results indicate a unique role for Egr1 in regulating the transition from localized, carcinoma in situ to invasive carcinoma.	Washington Univ, Dept Pathol, St Louis, MO 63119 USA; Washington Univ, Dept Mol Biol, St Louis, MO 63119 USA; Washington Univ, Dept Pharmacol, St Louis, MO 63119 USA; Washington Univ, Dept Chem, St Louis, MO 63119 USA; Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Washington Univ, Div Urol Surg, St Louis, MO 63119 USA; Washington Univ, Dept Med, St Louis, MO 63119 USA; Washington Univ, Dept Radiol, St Louis, MO 63119 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63119 USA.		Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [5 T32CA09547-13, 5P01 CA49712-08, 1KO8CA8790101, R24 CA83060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA083060, K08CA087901, T32CA009547, P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrack ER, 1997, PROSTATE, V31, P61; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eid MA, 1998, CANCER RES, V58, P2461; FUDGE K, 1994, MODERN PATHOL, V7, P549; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kirsch KH, 1996, ONCOGENE, V12, P963; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Miano JM, 1999, AM J PATHOL, V155, P1009, DOI 10.1016/S0002-9440(10)65200-5; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; NAGLE RB, 1992, J CELL BIOCHEM, P26; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Riggs PK, 2000, MOL CARCINOGEN, V27, P247, DOI 10.1002/(SICI)1098-2744(200004)27:4<247::AID-MC1>3.0.CO;2-4; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santiago FS, 1999, NAT MED, V5, P1438, DOI 10.1038/71020; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SVAREN J, IN PRESS J BIOL CHEM; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261-5268.2000	36	153	159	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					101	107		10.1038/83231	http://dx.doi.org/10.1038/83231			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135623				2022-12-25	WOS:000166243100042
J	Anderson, CC; Matzinger, P				Anderson, CC; Matzinger, P			Immunity or tolerance: Opposite outcomes of microchimerism from skin grafts	NATURE MEDICINE			English	Article							T-CELLS; BONE-MARROW; TRANSPLANTATION TOLERANCE; ORGAN-TRANSPLANTATION; ALLOGRAFT TOLERANCE; INDUCE TOLERANCE; DENDRITIC CELL; CHIMERISM; LIVER; REJECTION	Solid organ transplants contain small numbers of leukocytes that can migrate into the host and establish long-lasting microchimerism. Although such microchimerism is often associated with graft acceptance and tolerance, it has been difficult to demonstrate a true causal link. Using skin from mutant mice deficient for leukocyte subsets, we found that donor T-cell chimerism Is a 'double-edged sword' that can result in very different outcomes depending on the host's immunological maturity and the antigenic disparities involved. In immunologically mature hosts, chimerism resulted in immunity and stronger graft rejection. In immature hosts, it resulted in tolerance to the chimeric T cells, but not to graft antigens not expressed by the chimeric cells. Clinical efforts aimed at augmenting chimerism to induce tolerance must take into account the maturation state of host T cells, the type of chimerism produced by each organ and the antigenic disparities involved, lest the result be increased rejection rather than tolerance.	NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Anderson, CC (corresponding author), NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol, NIH Bldg 4 Room 111,9000 Rockville Pike, Bethesda, MD 20892 USA.	canderson@niaid.nih.gov		/0000-0003-1733-4237	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000581, ZIAAI000581] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARD P, 1995, TRANSPLANTATION, V60, P1125, DOI 10.1097/00007890-199511270-00012; BONOMO A, 1993, J EXP MED, V177, P1153, DOI 10.1084/jem.177.4.1153; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; DONOHOE JA, 1983, TRANSPLANTATION, V35, P62, DOI 10.1097/00007890-198301000-00012; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; INTRONA M, 1981, TRANSPLANTATION, V31, P113, DOI 10.1097/00007890-198102000-00004; Jhaver KG, 1999, J IMMUNOL, V163, P4851; Ko S, 1999, NAT MED, V5, P1292, DOI 10.1038/15248; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCULLAGH P, 1989, IMMUNOLOGY, V67, P489; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; Morita H, 1998, P NATL ACAD SCI USA, V95, P6947, DOI 10.1073/pnas.95.12.6947; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; RAMMENSEE HG, 1989, EUR J IMMUNOL, V19, P643, DOI 10.1002/eji.1830190411; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SHIMONKEVITZ RP, 1988, J EXP MED, V168, P143, DOI 10.1084/jem.168.1.143; SNELL GD, 1957, ANNU REV MICROBIOL, V11, P439, DOI 10.1146/annurev.mi.11.100157.002255; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; SUN JH, 1995, TRANSPLANTATION, V60, P233, DOI 10.1097/00007890-199508000-00004; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022; THOMSON AW, 1995, STEM CELLS, V13, P622, DOI 10.1002/stem.5530130607; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Wise M, 1999, EUR J IMMUNOL, V29, P156, DOI 10.1002/(SICI)1521-4141(199901)29:01<156::AID-IMMU156>3.0.CO;2-K; Wise MP, 1998, J IMMUNOL, V161, P5813; WOOD KJ, 1991, IMMUNOL LETT, V29, P133, DOI 10.1016/0165-2478(91)90214-U; ZAMOYSKA R, 1989, EUR J IMMUNOL, V19, P111, DOI 10.1002/eji.1830190118; ZHANG L, 1994, J IMMUNOL, V152, P2222; ZHANG L, 1993, TRANSPLANTATION, V56, P918, DOI 10.1097/00007890-199310000-00027; Zijenah L, 1998, J INFECT DIS, V178, P109, DOI 10.1086/514264; ZWAN AD, BLOOD; 章梅荣, 1992, Acta Mathematica Sinica. New Series, V8, P148	45	91	94	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					80	87		10.1038/83393	http://dx.doi.org/10.1038/83393			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135620				2022-12-25	WOS:000166243100039
J	He, L; Gunn, TM; Bouley, DM; Lu, XY; Watson, SJ; Schlossman, SF; Duke-Cohan, JS; Barsh, GS				He, L; Gunn, TM; Bouley, DM; Lu, XY; Watson, SJ; Schlossman, SF; Duke-Cohan, JS; Barsh, GS			A biochemical function for attractin in agouti-induced pigmentation and obesity	NATURE GENETICS			English	Article							STIMULATING-HORMONE-RECEPTOR; YELLOW A(Y) MUTATION; MELANOCORTIN RECEPTORS; TRANSGENIC MICE; COAT COLOR; NERVOUS-SYSTEM; IN-VITRO; PROTEIN; MOUSE; EXPRESSION	Agouti protein, a paracrine signaling molecule normally limited to skin, is ectopically expressed in lethal yellow (A(y)) mice, and causes obesity by mimicking agouti-related protein (Agrp), found primarily in the hypothalamus. Mouse attractin (Atrn) is a widely expressed transmembrane protein whose loss of function in mahogany (Atrn(mg-3J)/Atrn(mg-3J)) mutant mice blocks the pleiotropic effects of A(y). Here we demonstrate in transgenic, biochemical and genetic-interaction experiments that attractin is a low-affinity receptor for agouti protein, but not Agrp, in vitro and in vivo. Additional histopathologic abnormalities in Atrn(mg-3J)/Atrn(mg-3J) mice and cross-species genomic comparisons indicate that Atrn has multiple functions distinct from both a physiologic and an evolutionary perspective.	Stanford Univ, Sch Med, Dept Pediat & Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; Univ Michigan, Sch Med, Mental Hlth Res Inst, Ann Arbor, MI USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Barsh, GS (corresponding author), Stanford Univ, Sch Med, Dept Pediat & Genet, Stanford, CA 94305 USA.		Lu, Xin-Yun/M-8657-2016; Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609; Gunn, Teresa/0000-0003-2688-6420	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48506] Funding Source: Medline; NIMH NIH HHS [MH42251] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cone RD, 1996, RECENT PROG HORM RES, V51, P287; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Dinulescu DM, 1998, P NATL ACAD SCI USA, V95, P12707, DOI 10.1073/pnas.95.21.12707; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; DUHL DMJ, 1994, DEVELOPMENT, V120, P1695; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; EBERLE AN, 1988, MELANOTROPINS CHEM P; Fuh G, 2000, J BIOL CHEM, V275, P26690; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; Jackson IJ, 1999, TRENDS GENET, V15, P429, DOI 10.1016/S0168-9525(99)01824-7; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; KURAMOTO T, IN PRESS P NATL ACAD; LAMOREUX ML, 1986, GENET RES, V48, P35, DOI 10.1017/S0016672300024630; LANE PRISCILLA W., 1960, JOUR HEREDITY, V51, P228; Little CC, 1916, AM NAT, V50, P335, DOI 10.1086/279546; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Lu XY, 1999, FEBS LETT, V462, P101, DOI 10.1016/S0014-5793(99)01494-5; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MILLAR SE, 1995, DEVELOPMENT, V121, P3223; Miller KA, 1997, GENETICS, V146, P1407; Nagle DL, 1999, NATURE, V398, P148, DOI 10.1038/18210; Ollmann MM, 1999, J BIOL CHEM, V274, P15837, DOI 10.1074/jbc.274.22.15837; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; Perry WL, 1996, GENETICS, V144, P255; QUISTAD GB, 1994, J BIOL CHEM, V269, P11098; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rosenfeld RD, 1998, BIOCHEMISTRY-US, V37, P16041, DOI 10.1021/bi981027m; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Suto J, 2000, MAMM GENOME, V11, P639, DOI 10.1007/s003350010136; Takeuchi S, 2000, BBA-MOL CELL RES, V1496, P261, DOI 10.1016/S0167-4889(00)00022-7; Tang W, 2000, P NATL ACAD SCI USA, V97, P6025, DOI 10.1073/pnas.110139897; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148	50	115	122	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					40	47		10.1038/83741	http://dx.doi.org/10.1038/83741			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137996				2022-12-25	WOS:000166187900013
J	Keiser, N; Venkataraman, G; Shriver, Z; Sasisekharan, R				Keiser, N; Venkataraman, G; Shriver, Z; Sasisekharan, R			Direct isolation and sequencing of specific protein-binding glycosaminoglycans	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; MAMMALIAN HEPARANASE; HEPARIN; ANTITHROMBIN; METASTASIS; DROSOPHILA; COMPLEX; CLONING		MIT, Harvard Mit Div Hlth Sci & Technol, Ctr Biomed Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, Ctr Biomed Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA.				NHLBI NIH HHS [R01HL59966] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059966] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Conrad H. E., 1998, HEPARIN BINDING PROT; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wang H, 1999, ANAL CHEM, V71, P2014, DOI 10.1021/ac981347b	23	49	59	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					123	128		10.1038/83263	http://dx.doi.org/10.1038/83263			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135627				2022-12-25	WOS:000166243100046
J	Meacham, GC; Patterson, C; Zhang, WY; Younger, JM; Cyr, DM				Meacham, GC; Patterson, C; Zhang, WY; Younger, JM; Cyr, DM			The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation	NATURE CELL BIOLOGY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; ENDOPLASMIC-RETICULUM; DELTA-F508 CFTR; PROTEIN; IDENTIFICATION; PATHWAY; EXPRESSION; HOMOLOG; HEAT-SHOCK-PROTEIN-70	The folding of both wild-type and mutant forms of the cystic-fibrosis transmembrane-conductance regulator (CFTR), a plasma-membrane chloride-ion channel, is inefficient(1-4). Most nascent CFTR is retained in the endoplasmic reticulum and degraded by the ubiquitin proteasome pathway(5-7). Aberrant folding and defective trafficking of CFTR Delta F508 is the principal cause of cystic fibrosis(3,8,9), but how the endoplasmic-reticulum quality-control system targets CFTR for degradation remains unknown. CHIP is a cytosolic U-box protein that interacts with Hsc70 through a set of tetratricorepeat motifs(10). The U-box represents a modified form of the ring-finger motif that is found in ubiquitin ligases(11) and that defines the E4 family of polyubiquitination factors(12,13). Here we show that CHIP functions with Hsc70 to sense the folded state of CFTR and targets aberrant forms for proteasomal degradation by promoting their ubiquitination. The U-box appeared essential for this process because overexpresion of CHIP DeltaU-box inhibited the action of endogenous CHIP and blocked CFTR ubiquitination and degradation. CHIP is a co-chaperone that converts Hsc70 from a protein-folding machine into a degradation factor that functions in endoplasmic-reticulum quality control.	Univ Alabama Birmingham, Med Ctr, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Ctr, Cystic Fibrosis Ctr, Birmingham, AL 35294 USA; Univ N Carolina, Program Mol Cardiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Alabama System; University of Alabama Birmingham; Cystic Fibrosis Foundation; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cyr, DM (corresponding author), Univ Alabama Birmingham, Med Ctr, Dept Cell Biol, 1918 Univ Blvd, Birmingham, AL 35294 USA.	dcyr@cellbio.bhs.uab.edu		Cyr, Douglas/0000-0002-4928-3414	NIGMS NIH HHS [R01 GM056981] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CONNELL P, NATURE CELL BIOL, V3, P93; CYR DM, 1992, J BIOL CHEM, V267, P20927; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Katsanis N, 1998, GENOMICS, V51, P128, DOI 10.1006/geno.1998.5263; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lin HJ, 1999, J BIOL CHEM, V274, P14685, DOI 10.1074/jbc.274.21.14685; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Moyer BD, 1998, J BIOL CHEM, V273, P26256; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PIND S, 1994, J BIOL CHEM, V269, P12784; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wigley WC, 1999, J CELL BIOL, V145, P481; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	40	671	687	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					100	105		10.1038/35050509	http://dx.doi.org/10.1038/35050509			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146634				2022-12-25	WOS:000166146400028
J	Donahue, JK; Heldman, AW; Fraser, H; McDonald, AD; Miller, JM; Rade, JJ; Eschenhagen, T; Marban, E				Donahue, JK; Heldman, AW; Fraser, H; McDonald, AD; Miller, JM; Rade, JJ; Eschenhagen, T; Marban, E			Focal modification of electrical conduction in the heart by viral gene transfer	NATURE MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; IN-VIVO; REPLICATION-DEFICIENT; MYOCARDIAL-INFARCTION; G-PROTEINS; ADENOVIRUS; EXPRESSION; MORTALITY; MYOCYTES; ARTERIES	Modern treatment of cardiac arrhythmias is limited to pharmacotherapy, radiofrequency ablation, or implantable devices. Antiarrhythmic medications suppress arrhythmias, but their systemic effects are often poorly tolerated and their proarrhythmic tendencies increase mortality(1-3). Radiofrequency ablation can cure only a limited number of arrhythmias. Implantable devices can be curative for bradyarrhythmias and lifesaving for tachyarrhythmias, but require a lifetime commitment to repeated procedures, are a significant expense, and may lead to severe complications. One possibility is the use of gene therapy as an antia(r)rhythmic strategy. As an initial attempt to explore this option, we focused on genetic modification of the atrioventricular node. First, we developed an intracoronary perfusion model for gene delivery, building on our previous work in isolated cardiac myocytes and hearts perfused ex vivo(4,5). Using this method, we infected porcine hearts with Ad beta gal (recombinant adenovirus expressing Escherichia coli beta -galactosidase) or with AdG(i) (adenovirus encoding the G alpha (i2) subunit). We hypothesized that excess G alpha (i2)would mimic the effects of beta -adreneric antagonists, in effect creating a localized beta -blockade. G alpha (i2), overexpression suppressed baseline atrioventricular conduction and slowed the heart rate during atrial fibrillation without producing complete heart block. In contrast, expression of the reporter gene beta -galactosidase had no electrophysiological effects. Our results demonstrate the feasibility of using myocardial gene transfer strategies to treat common arrhythmias.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	Johns Hopkins University; Johns Hopkins University; University of Erlangen Nuremberg	Donahue, JK (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Ross 844,720 N Rutland Ave, Baltimore, MD 21205 USA.	kdonahue@jhmi.edu	Heldman, Alan W./K-8784-2012; Miller, Julie/B-6492-2009; Marban, Eduardo/GWC-8514-2022	Heldman, Alan W./0000-0002-1615-3883; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052307] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL52307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Channon KM, 1998, CIRC RES, V82, P1253, DOI 10.1161/01.RES.82.12.1253; Cichon G, 1999, J GENE MED, V1, P360, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO;2-Q; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Donahue JK, 1997, P NATL ACAD SCI USA, V94, P4664, DOI 10.1073/pnas.94.9.4664; Donahue JK, 1998, GENE THER, V5, P630, DOI 10.1038/sj.gt.3300649; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ESCHENHAGEN T, 1993, CELL BIOL INT, V17, P723, DOI 10.1006/cbir.1993.1135; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498; KASSEISLER A, 1994, GENE THER, V1, P395; Lafont A, 1998, HUM GENE THER, V9, P2795, DOI 10.1089/hum.1998.9.18-2795; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Muhlhauser J, 1996, GENE THER, V3, P145; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735	19	148	194	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1395	1398						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100126				2022-12-25	WOS:000165704100045
J	Laus, R; Graddis, TJ; Hakim, I; Vidovic, D				Laus, R; Graddis, TJ; Hakim, I; Vidovic, D			Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides	NATURE BIOTECHNOLOGY			English	Article						cytotoxic T cells; antigen presentation; dendritic cells	MHC CLASS-I; DENDRITIC CELLS; LYMPHOCYTES-T; MOLECULES; GENE	Soluble extracellular protein antigens are notoriously poor stimulators of CD8(+) cytotoxic T-lymphocyte (CTL) responses, largely because these antigens have inefficient access to an endogenous cytosolic pathway of the major histocompatibility complex (MHC) class I-dependent antigen presentation. Here, we present a strategy that facilitates antigen penetration into the cytosol of antigen-presenting cells (APC) by addition to the antigen of charge-modifying peptide sequences. As a result of this intervention, the charge modification enhances antigen uptake into APC by counteracting the repulsive cell surface charge, and then endosomal membranes are disrupted with a subsequent release of antigen into the cytosol. This technology significantly improves MHC class I-dependent antigen presentation to CTL, enabling a more efficient generation of specific CTL immunity in vivo. The strategy described here has potential for use in developing efficient vaccines for antigen-specific immunotherapy of human malignancies.	Dendreon Corp, Seattle, WA 98121 USA	Dendreon	Vidovic, D (corresponding author), Dendreon Corp, Seattle, WA 98121 USA.	dvidovic@dendreon.com						AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; Brossart P, 1997, J IMMUNOL, V158, P3270; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; GERMAIN RN, 1995, ANN NY ACAD SCI, V754, P114, DOI 10.1111/j.1749-6632.1995.tb44444.x; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Kim DT, 1997, J IMMUNOL, V159, P1666; KOCH F, 1995, J IMMUNOL, V155, P93; KRUISBEEK AM, 1998, CURRENT PROTOCOLS IM, V1; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PLANK C, 1994, J BIOL CHEM, V269, P12918; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Sambrook J., 1989, MOL CLONING LAB MANU, V2; WUNDERLICH J, 1998, CURRENT PROTOCOLS IM, V1	21	29	35	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1269	1272		10.1038/82377	http://dx.doi.org/10.1038/82377			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101805				2022-12-25	WOS:000165659000023
J	Thompson, AA; Nguyen, LT				Thompson, AA; Nguyen, LT			Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation	NATURE GENETICS			English	Article							HOMEOBOX GENES; HEMATOPOIESIS; HOXD13; MOUSE		Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Thompson, AA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA.		Nguyen, T.T. Loan/D-2495-2019	Nguyen, T.T. Loan/0000-0001-6440-6462				ALTER BP, 1992, J HAND SURG-AM, V17A, P566, DOI 10.1016/0363-5023(92)90372-V; Davis AP, 1996, DEVELOPMENT, V122, P1175; Evans T, 1997, HEMATOL ONCOL CLIN N, V11, P1115, DOI 10.1016/S0889-8588(05)70485-8; Favier B, 1996, DEVELOPMENT, V122, P449; HALL JG, 1987, J MED GENET, V24, P79, DOI 10.1136/jmg.24.2.79; Johnson KR, 1998, HUM MOL GENET, V7, P1033, DOI 10.1093/hmg/7.6.1033; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; SCHROEDERKURTH TM, 1989, FANCONI ANEMIA CLIN, P264; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495	15	134	140	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					397	398		10.1038/82511	http://dx.doi.org/10.1038/82511			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101832				2022-12-25	WOS:000165671700008
J	Silva, JP; Kohler, M; Graff, C; Oldfors, A; Magnuson, MA; Berggren, PO; Larsson, NG				Silva, JP; Kohler, M; Graff, C; Oldfors, A; Magnuson, MA; Berggren, PO; Larsson, NG			Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes	NATURE GENETICS			English	Article							GENE MUTATION; DNA; MEDICINE; MOUSE	Mitochondrial dysfunction is an important contributor to human pathology(1-4) and it is estimated that mutations of mitochondrial DNA (mtDNA) cause approximately 0.5-1% of all types of diabetes mellitus(5,6). We have generated a mouse model for mitochondrial diabetes by tissue-specific disruption of the nuclear gene encoding mitochondrial transcription factor A (Tfam, previously mtTFA; ref, 7) in pancreatic beta -cells. This transcriptional activator is imported to mitochondria, where it is essential for mtDNA expression and maintenance(8,9). The Tfam-mutant mice developed diabetes from the age of approximately 5 weeks and displayed severe mtDNA depletion, deficient oxidative phosphorylation and abnormal appearing mitochondria in islets at the ages of 7-9 weeks, We performed physiological studies of beta -cell stimulus-secretion coupling in islets isolated from 7-9-week-old mutant mice and found reduced hyperpolarization of the mitochondrial membrane potential, impaired Ca2+-signalling and lowered insulin release in response to glucose stimulation. We observed reduced beta -cell mass in older mutants. Our findings identity two phases in the pathogenesis of mitochondrial diabetes; mutant beta -cells initially display reduced stimulus-secretion coupling, later followed by beta -cell loss, This animal model reproduces the beta -cell pathology of human mitochondrial diabetes and provides genetic evidence for a critical role of the respiratory chain in insulin secretion.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-10401 Stockholm, Sweden; Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Vanderbilt University	Larsson, NG (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-10401 Stockholm, Sweden.			Graff, Caroline/0000-0002-9949-2951; Berggren, Per-Olof/0000-0001-8991-413X; Magnuson, Mark/0000-0002-8824-6499; Larsson, Nils-Goran/0000-0001-5100-996X; Oldfors, Anders/0000-0002-5758-7397; Kohler, Martin/0000-0001-6487-4303				BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Graff C, 1999, J INTERN MED, V246, P11, DOI 10.1046/j.1365-2796.1999.00514.x; GUENETTE DR, 1995, CD-ROM PROF, V8, P10; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KANATSUNA T, 1981, DIABETES, V30, P231, DOI 10.2337/diabetes.30.3.231; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6; Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959; Otabe S, 1999, BIOCHEM BIOPH RES CO, V259, P149, DOI 10.1006/bbrc.1999.0650; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089	21	340	345	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					336	340		10.1038/81649	http://dx.doi.org/10.1038/81649			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062475				2022-12-25	WOS:000165176500024
J	Tyagi, S; Marras, SAE; Kramer, FR				Tyagi, S; Marras, SAE; Kramer, FR			Wavelength-shifting molecular beacons	NATURE BIOTECHNOLOGY			English	Article						hybridization probes; FRET; real-time PCR; homogeneous assays; haplotype determination	FLUORESCENCE ENERGY-TRANSFER; REAL-TIME DETECTION; MULTIPLEX DETECTION; TRANSFER PRIMERS; LIVING CELLS; DISEASE; RNA; HYBRIDIZATION; MUTATION; PROBES	We describe wavelength-shifting molecular beacons, which are nucleic acid hybridization probes that fluoresce in a variety of different colors, yet are excited by a common monochromatic light source. The twin functions of absorption of energy from the excitation light and emission of that energy in the form of fluorescent light are assigned to two separate fluorophores in the same probe. These probes contain a harvester fluorophore that absorbs strongly in the wavelength range of the monochromatic light source, an emitter fluorophore of the desired emission color, and a nonfluorescent quencher. In the absence of complementary nucleic acid targets, the probes are dark, whereas in the presence of targets, they fluoresce-not in the emission range of the harvester fluorophore that absorbs the light, but rather in the emission range of the emitter fluorophore. This shift in emission spectrum is due to the transfer of the absorbed energy from the harvester fluorophore to the emitter fluorophore by fluorescence resonance energy transfer, and it only takes place in probes that are bound to targets. Wavelength-shifting molecular beacons are substantially brighter than conventional molecular beacons that contain a fluorophore that cannot efficiently absorb energy from the available monochromatic light source. We describe the spectral characteristics of wavelength-shifting molecular beacons, and we demonstrate how their use improves and simplifies multiplex genetic analyses.	Publ Hlth Res Inst City New York Inc, Dept Mol Genet, New York, NY 10016 USA		Tyagi, S (corresponding author), Publ Hlth Res Inst City New York Inc, Dept Mol Genet, 455 1St Ave, New York, NY 10016 USA.		Tyagi, Sanjay/F-1109-2010	Tyagi, Sanjay/0000-0001-7303-5827; Marras, Salvatore/0000-0003-2040-0354	NHLBI NIH HHS [HL-43521] Funding Source: Medline; NIEHS NIH HHS [ES-10536] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010536] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Belgrader P, 1999, SCIENCE, V284, P449, DOI 10.1126/science.284.5413.449; Giesendorf BAJ, 1998, CLIN CHEM, V44, P482; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hung SC, 1996, ANAL BIOCHEM, V243, P15, DOI 10.1006/abio.1996.0477; Hung SC, 1997, ANAL BIOCHEM, V252, P78, DOI 10.1006/abio.1997.2287; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Kostrikis LG, 1998, SCIENCE, V279, P1228, DOI 10.1126/science.279.5354.1228; KRAMER FR, MOL BEACONS HYBRIDIZ; Lee LG, 1997, NUCLEIC ACIDS RES, V25, P2816, DOI 10.1093/nar/25.14.2816; Leone G, 1998, NUCLEIC ACIDS RES, V26, P2150, DOI 10.1093/nar/26.9.2150; Marras SAE, 1999, GENET ANAL-BIOMOL E, V14, P151, DOI 10.1016/S1050-3862(98)00018-7; Matsuo T, 1998, BBA-GEN SUBJECTS, V1379, P178, DOI 10.1016/S0304-4165(97)00090-1; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; PLATEK AS, 1998, NAT BIOTECHNOL, V16, P359; Sokol DL, 1998, P NATL ACAD SCI USA, V95, P11538, DOI 10.1073/pnas.95.20.11538; Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91, DOI 10.1038/72006; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vet JAM, 1999, P NATL ACAD SCI USA, V96, P6394, DOI 10.1073/pnas.96.11.6394; WITTWER CT, 1997, BIOTECHNIQUES, V22, P134	24	266	331	3	77	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1191	1196		10.1038/81192	http://dx.doi.org/10.1038/81192			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062440				2022-12-25	WOS:000165176600026
J	Harris, T				Harris, T			Clear vision for a structure-seeking business	NATURE BIOTECHNOLOGY			English	Editorial Material									Struct GenomiX, San Diego, CA 92121 USA		Harris, T (corresponding author), Struct GenomiX, 10505 Roselle St, San Diego, CA 92121 USA.							Fraser CM, 2000, NATURE, V406, P799, DOI 10.1038/35021244; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1017	1017		10.1038/80119	http://dx.doi.org/10.1038/80119			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11016992	hybrid			2022-12-25	WOS:000089744700003
J	Krings, M; Capelli, C; Tschentscher, F; Geisert, H; Meyer, S; von Haeseler, A; Grossschmidt, K; Possnert, G; Paunovic, M; Paabo, S				Krings, M; Capelli, C; Tschentscher, F; Geisert, H; Meyer, S; von Haeseler, A; Grossschmidt, K; Possnert, G; Paunovic, M; Paabo, S			A view of Neandertal genetic diversity	NATURE GENETICS			English	Article							DNA; MITOCHONDRIAL; SEQUENCE		Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; Univ Cattolica Sacro Cuore, Inst Legal Med, Rome, Italy; Univ Munich, Inst Zool, D-8000 Munich, Germany; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria; Angstrom Lab, Div Ion Phys, Uppsala, Sweden; Croatian Acad Sci & Arts, Inst Quaternay Paleontol & Geol, Zagreb, Croatia	Max Planck Society; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Munich; University of Vienna; Croatian Academy of Sciences & Arts	Paabo, S (corresponding author), Max Planck Inst Evolutionary Anthropol, Leipzig, Germany.		von Haeseler, Arndt/HCI-9958-2022	von Haeseler, Arndt/0000-0002-3366-4458; Capelli, Cristian/0000-0001-9348-9084				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Burckhardt F, 1999, NUCLEIC ACIDS RES, V27, P138, DOI 10.1093/nar/27.1.138; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Krings M, 1999, P NATL ACAD SCI USA, V96, P5581, DOI 10.1073/pnas.96.10.5581; KRINGS M, IN PRESS VINDIJA NEA; Malez M., 1982, PALAEONTOLOGIA JUGOS, V29, P1; Nordborg M, 1998, AM J HUM GENET, V63, P1237, DOI 10.1086/302052; Ovchinnikov IV, 2000, NATURE, V404, P490, DOI 10.1038/35006625; Poinar HN, 1998, SCIENCE, V281, P402, DOI 10.1126/science.281.5375.402; Poinar HN, 1996, SCIENCE, V272, P864, DOI 10.1126/science.272.5263.864; SAUNDERS IW, 1984, ADV APPL PROBAB, V16, P471, DOI 10.2307/1427285; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; WOLPOFF MH, 1981, AM J PHYS ANTHROPOL, V54, P499, DOI 10.1002/ajpa.1330540407	14	224	236	2	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					144	146		10.1038/79855	http://dx.doi.org/10.1038/79855			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017066				2022-12-25	WOS:000089638800008
J	Lunardi, C; Bason, C; Navone, R; Millo, E; Damonte, G; Corrocher, R; Puccetti, A				Lunardi, C; Bason, C; Navone, R; Millo, E; Damonte, G; Corrocher, R; Puccetti, A			Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells	NATURE MEDICINE			English	Article							AUTOIMMUNE-DISEASE; PEPTIDE LIBRARIES; MOLECULAR MIMICRY; IN-VITRO; ANTIBODIES; INFECTION; SCLERODERMA; EXPRESSION	Systemic sclerosis is an autoimmune disease characterized by immunological and vascular abnormalities. Autoantibodies against intracellular antigens are associated with particular clinical features of the disease(1), whereas autoantibodies against cell surface antigens may be pathogenic by inducing endothelial cell damage(2,3), considered the primary event in the pathogenesis of the disease. Latent human cytomegalovirus infection may contribute to progression of systemic sclerosis through its ability to infect endothelial cells(4); however, direct links between human cytomegalovirus infection and systemic sclerosis are still lacking(5). Molecular mimicry is one of the mechanisms that account for the link between infection and autoimmunity(6-8). Here we have identified an immunodominant peptide using systemic sclerosis serum screening of a random peptide library; such peptide shares homology with autoantigens and with the human cytomegalovirus late protein UL94 (ref. 9). Immunoglobulin C antibodies against the peptide affinity-purified from the sera of patients with systemic sclerosis specifically recognized the viral product and autoantigens; moreover, such antibodies induced endothelial cell apoptosis through specific interaction with the cell surface integrin-NAG-2 protein complex(10). Our results provide evidence that antibodies against human cytomegalovirus cause apoptosis of endothelial cells(11), considered the initial pathogenic event of systemic sclerosis, and indicate a previously unknown mechanism for the etiological link between human cytomegalovirus infection and autoimmunity.	Univ Verona, Dept Clin & Expt Med, Policlin GB Rossi, I-37134 Verona, Italy; Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Natl Canc Inst IST, I-16132 Genoa, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Genoa	Lunardi, C (corresponding author), Univ Verona, Dept Clin & Expt Med, Policlin GB Rossi, I-37134 Verona, Italy.		Millo, Enrico/K-3218-2018	Millo, Enrico/0000-0002-4019-0051				Bordron A, 1998, J CLIN INVEST, V101, P2029, DOI 10.1172/JCI2261; Bowditch RD, 1996, BLOOD, V88, P4579, DOI 10.1182/blood.V88.12.4579.bloodjournal88124579; Carvalho D, 1996, J CLIN INVEST, V97, P111, DOI 10.1172/JCI118377; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Di Rosa F, 1998, IMMUNOL REV, V164, P17; Harvey Georgina R., 1999, Current Opinion in Rheumatology, V11, P495, DOI 10.1097/00002281-199911000-00010; Lunardi C, 1998, EUR J IMMUNOL, V28, P936, DOI 10.1002/(SICI)1521-4141(199803)28:03<936::AID-IMMU936>3.3.CO;2-O; Madaio MP, 1996, EUR J IMMUNOL, V26, P3035, DOI 10.1002/eji.1830261232; Neidhart M, 1999, ARTHRITIS RHEUM-US, V42, P389, DOI 10.1002/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P; Pandey JP, 1998, ARTHRITIS RHEUM, V41, P10, DOI 10.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P; Rose NR, 1998, SEMIN IMMUNOL, V10, P5, DOI 10.1006/smim.1997.0100; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sgonc R, 1996, J CLIN INVEST, V98, P785, DOI 10.1172/JCI118851; Shahgasempour S, 1997, ARCH VIROL, V142, P125, DOI 10.1007/s007050050063; Sibille P, 1997, EUR J IMMUNOL, V27, P1221, DOI 10.1002/eji.1830270525; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wing BA, 1996, J VIROL, V70, P3339, DOI 10.1128/JVI.70.6.3339-3345.1996; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	20	219	226	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1183	1186		10.1038/80533	http://dx.doi.org/10.1038/80533			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017152				2022-12-25	WOS:000089674700045
J	Bitner-Glindzicz, M; Lindley, KJ; Rutland, P; Blaydon, D; Smith, VV; Milla, PJ; Hussain, K; Furth-Lavi, J; Cosgrove, KE; Shepherd, RM; Barnes, PD; O'Brien, RE; Farndon, PA; Sowden, J; Liu, XZ; Scanlan, MJ; Malcolm, S; Dunne, MJ; Aynsley-Green, A; Glaser, B				Bitner-Glindzicz, M; Lindley, KJ; Rutland, P; Blaydon, D; Smith, VV; Milla, PJ; Hussain, K; Furth-Lavi, J; Cosgrove, KE; Shepherd, RM; Barnes, PD; O'Brien, RE; Farndon, PA; Sowden, J; Liu, XZ; Scanlan, MJ; Malcolm, S; Dunne, MJ; Aynsley-Green, A; Glaser, B			A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene	NATURE GENETICS			English	Article							RECTIFYING POTASSIUM CHANNEL; SYNDROME TYPE-I; BETA-CELLS; HYPOGLYCEMIA; INFANCY; MAPS; LOCALIZATION; EXPRESSION; PROTEIN; MEMBRANE	Usher syndrome type 1 describes the association of profound, congenital sensorineural deafness, vestibular hypofunction and childhood onset retinitis pigmentosa(1). It is an autosomal recessive condition and is subdivided on the basis of linkage analysis into types 1A through 1E (refs 2-6), Usher type 1C maps to the region containing the genes ABCC8 and KCNJ11 (encoding components of ATP-sensitive K+ (KATP) channels), which may be mutated in patients with hyperinsulinism(7-10). We identified three individuals from two consanguineous families with severe hyperinsulinism, profound congenital sensorineural deafness, enteropathy and renal tubular dysfunction. The molecular basis of the disorder is a homozygous 122-kb deletion of 11p14-15. which includes part of ABCC8 and overlaps with the locus for Usher syndrome type 1C and DFNB18 (ref. 11). The centromeric boundary of this deletion includes part of a gene shown to be mutated in families with type 1C Usher syndrome, and is hence assigned the name USH1C. The pattern of expression of the USH1C protein is consistent with the clinical features exhibited by individuals with the contiguous gene deletion and with isolated Usher type 1C.	Inst Child Hlth, Dept Clin & Mol Genet, London, England; Great Ormond St Hosp Children NHS Trust, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Gastroenterol, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Histopathol, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, London Ctr Paediat Endocrinol & Metab, London WC1N 3JH, England; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Endocrinol & Metab, IL-91010 Jerusalem, Israel; Univ Sheffield, Inst Mol Physiol, Western Bank, Sheffield, S Yorkshire, England; Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield, S Yorkshire, England; Birmingham Womens Hosp, Clin Genet Unit, Birmingham, W Midlands, England; Inst Child Hlth, Dev Biol Unit, London, England; Med Coll Virginia, Dept Human Genet, Richmond, VA USA; Mem Sloan Kettering Canc Ctr, New York Branch, Ludwig Inst Canc Res, New York, NY 10021 USA	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Hebrew University of Jerusalem; University of Sheffield; University of Sheffield; Birmingham Women's Hospital; University of London; University College London; Virginia Commonwealth University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Bitner-Glindzicz, M (corresponding author), Inst Child Hlth, Dept Clin & Mol Genet, 30 Guilford St, London, England.		hussain, khalid/C-5730-2008; Glaser, Benjamin/F-8411-2017; Smith, Virpi/C-2159-2008; Bitner-Glindzicz, Maria/A-4231-2009	Glaser, Benjamin/0000-0003-4711-5000; Sowden, Jane/0000-0003-0937-2479; Blaydon, Diana/0000-0002-9998-2563; Cosgrove, Karen/0000-0002-5162-0985	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004530] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC04530] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Glaser B, 1999, TRENDS ENDOCRIN MET, V10, P55, DOI 10.1016/S1043-2760(98)00102-7; Hibino H, 1997, J NEUROSCI, V17, P4711; Higgins MJ, 1998, GENOME RES, V8, P57, DOI 10.1101/gr.8.1.57; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Ishii M, 1997, J NEUROSCI, V17, P7725; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; Kane C, 1997, J CLIN INVEST, V100, P1888, DOI 10.1172/JCI119718; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KLOEPFER HW, 1966, LARYNGOSCOPE, V76, P850; Kobayashi I, 1999, GASTROENTEROLOGY, V117, P823, DOI 10.1016/S0016-5085(99)70340-9; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; PELIAS MZ, 1998, CELL GENET, V47, P111; Scanlan MJ, 1999, BBA-GENE STRUCT EXPR, V1445, P39, DOI 10.1016/S0167-4781(99)00033-0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	25	235	237	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					56	60		10.1038/79178	http://dx.doi.org/10.1038/79178			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973248				2022-12-25	WOS:000089078000017
J	Korchev, YE; Negulyaev, YA; Edwards, CRW; Vodyanoy, I; Lab, MJ				Korchev, YE; Negulyaev, YA; Edwards, CRW; Vodyanoy, I; Lab, MJ			Functional localization of single active ion channels can the surface of a living cell	NATURE CELL BIOLOGY			English	Article							POTASSIUM CHANNELS; SKELETAL-MUSCLE; SODIUM-CHANNELS; CA2+ CHANNELS; K+ CHANNELS; CONDUCTANCE MICROSCOPE; VENTRICULAR MYOCYTES; HIPPOCAMPAL-NEURONS; CLAMP TECHNIQUE; FROG	The spatial distribution of ion channels in the cell plasma membrane has an important role in governing regional specialization, providing a precise and localized control over cell function. We report here a novel technique based on scanning ion conductance microscopy that allows, for the first time, mapping of single active ion channels in intact cell plasma membranes. We have mapped the distribution of ATP-regulated K+ channels (K-ATP channels) in cardiac myocytes. The channels are organized in small groups and anchored in the Z-grooves of the sarcolemma. The distinct pattern of distribution of these channels may have important functional implications.	Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Div Med, London W12 0NN, England; Rusian Acad Sci, Inst Cytol, St Petersburg, Russia; Off Naval Res, Int Field Off, London NW1 5TH, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London W6 8RP, England	Imperial College London; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Imperial College London	Korchev, YE (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Div Med, Du Cane Rd, London W12 0NN, England.		Negulyaev, Yuri/N-6531-2015; Korchev, Yuri/D-2498-2009	Negulyaev, Yuri/0000-0002-1773-9798; Korchev, Yuri/0000-0002-4872-8696				Abrami L, 1997, EUR J CELL BIOL, V73, P215; ALMERS W, 1983, J PHYSIOL-LONDON, V336, P261, DOI 10.1113/jphysiol.1983.sp014580; Alonso G, 1997, NEUROSCIENCE, V77, P617; ANGELIDES KJ, 1986, NATURE, V321, P63, DOI 10.1038/321063a0; Anson BD, 1998, BIOPHYS J, V74, P2963, DOI 10.1016/S0006-3495(98)78003-8; Barbosa CTF, 1996, NEUROSCI LETT, V210, P177, DOI 10.1016/0304-3940(96)12679-3; BARD AJ, 1991, SCIENCE, V254, P68, DOI 10.1126/science.254.5028.68; BEAM KG, 1985, NATURE, V313, P588, DOI 10.1038/313588a0; CHENG H, 1994, PFLUG ARCH EUR J PHY, V428, P415, DOI 10.1007/BF00724526; COHEN MW, 1991, J NEUROSCI, V11, P1032; DENK W, 1994, P NATL ACAD SCI USA, V91, P6629, DOI 10.1073/pnas.91.14.6629; FROSCH MP, 1992, NEUROSCI LETT, V138, P59, DOI 10.1016/0304-3940(92)90472-J; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSMA PK, 1989, SCIENCE, V243, P641, DOI 10.1126/science.2464851; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; Korchev YE, 1997, BIOPHYS J, V73, P653, DOI 10.1016/S0006-3495(97)78100-1; Korchev YE, 2000, BIOPHYS J, V78, P451, DOI 10.1016/S0006-3495(00)76607-0; Korchev YE, 1997, J MICROSC-OXFORD, V188, P17, DOI 10.1046/j.1365-2818.1997.2430801.x; LEDERER WJ, 1989, J PHYSIOL-LONDON, V413, P329, DOI 10.1113/jphysiol.1989.sp017657; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ruff RL, 1996, ACTA PHYSIOL SCAND, V156, P159, DOI 10.1046/j.1365-201X.1996.189000.x; SHRAGER P, 1987, J PHYSIOL-LONDON, V392, P587, DOI 10.1113/jphysiol.1987.sp016798; Smith PR, 1997, AM J PHYSIOL-CELL PH, V272, pC1295, DOI 10.1152/ajpcell.1997.272.4.C1295; STOCKBRIDGE N, 1984, NATURE, V309, P266, DOI 10.1038/309266a0; TOUSSON A, 1989, J CELL SCI, V93, P349; Yokoshiki H, 1997, PFLUG ARCH EUR J PHY, V434, P203, DOI 10.1007/s004240050384	31	136	147	0	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					616	619		10.1038/35023563	http://dx.doi.org/10.1038/35023563			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980702				2022-12-25	WOS:000089250600013
J	Smith, AN; Skaug, J; Choate, KA; Nayir, A; Bakkaloglu, A; Ozen, S; Hulton, SA; Sanjad, SA; Al-Sabban, EA; Lifton, RP; Scherer, SW; Karet, FE				Smith, AN; Skaug, J; Choate, KA; Nayir, A; Bakkaloglu, A; Ozen, S; Hulton, SA; Sanjad, SA; Al-Sabban, EA; Lifton, RP; Scherer, SW; Karet, FE			Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing	NATURE GENETICS			English	Article							H+-ATPASE; GENE; HYPERTENSION; LINKAGE; VPH1P	The multi-subunit H+-ATPase pump is present at particularly high density on the apical (luminal) surface of alpha-intercalated cells of the cortical collecting duct of the distal nephron, where vectorial proton transport is required for urinary acidification(1). The complete subunit composition of the apical ATPase, however, has not been fully agreed upon. Functional failure of alpha-intercalated cells results in a group of disorders, the distal renal tubular acidoses (dRTA), whose features include metabolic acidosis accompanied by disturbances of potassium balance, urinary calcium solubility, bone physiology and growth(2). Mutations in the gene encoding the B-subunit of the apical pump (ATP6B1) cause dRTA accompanied by deafness(3). We previously localized a gene for dRTA with preserved hearing to 7q33-34 (ref. 4). We report here the identification of this gene, ATP6N1B, which encodes an 840 amino acid novel kidney-specific isoform of ATP6N1A, the 116-kD non-catalytic accessory subunit of the proton pump. Northern-blot analysis demonstrated ATP6N1B expression in kidney but not other main organs. Immunofluorescence studies in human kidney cortex revealed that ATP6N1B localizes almost exclusively to the apical surface of alpha-intercalated cells. We screened nine dRTA kindreds with normal audiometry that linked to the ATP6N1B locus, and identified different homozygous mutations in ATP6N1B in eight. These include nonsense, deletion and splice-site changes, all of which will truncate the protein. Our findings identify a new kidney-specific proton pump 116-kD accessory subunit that is highly expressed in proton-secreting cells in the distal nephron, and illustrate its essential role in normal vectorial acid transport into the urine by the kidney.	Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Yale Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Istanbul Univ, Dept Pediat Nephrol, Istanbul, Turkey; Univ Hacettepe, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England; Amer Univ Beirut, Dept Pediat, Med Ctr, Beirut, Lebanon; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia	University of Cambridge; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Istanbul University; Hacettepe University; University of Birmingham; American University of Beirut; King Faisal Specialist Hospital & Research Center	Karet, FE (corresponding author), Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England.		OZEN, SEZA/I-9096-2013; Scherer, Stephen W./B-3785-2013; NAYIR, AHMET NEVZAT/A-9276-2019	Scherer, Stephen W./0000-0002-8326-1999; Karet, Fiona/0000-0002-2457-2869				Bastani B, 1996, MINER ELECTROL METAB, V22, P396; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BRODY LC, 1995, GENOMICS, V25, P238, DOI 10.1016/0888-7543(95)80131-5; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; Karet FE, 1999, AM J HUM GENET, V65, P1656, DOI 10.1086/302679; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Mansfield TA, 1997, NAT GENET, V16, P202, DOI 10.1038/ng0697-202; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PENG SB, 1994, J BIOL CHEM, V269, P17262; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X	21	320	340	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					71	75		10.1038/79208	http://dx.doi.org/10.1038/79208			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973252				2022-12-25	WOS:000089078000021
J	Cookson, WOCM; Ubhi, B; Lawrence, R; Abecasis, GR; Walley, AJ; Cox, HE; Coleman, R; Leaves, NI; Trembath, RC; Moffatt, MF; Harper, JI				Cookson, WOCM; Ubhi, B; Lawrence, R; Abecasis, GR; Walley, AJ; Cox, HE; Coleman, R; Leaves, NI; Trembath, RC; Moffatt, MF; Harper, JI			Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci	NATURE GENETICS			English	Article							17Q; REGION; SCAN; 3Q21; MAPS; HLA; 4Q	We have carried out a genome screen for atopic dermatitis (AD) and have identified linkage to AD on chromosomes 1q21, 17q25 and 20p. These regions correspond closely with known psoriasis loci, as does a previously identified AD locus on chromosome 3q21. The results indicate that AD is influenced by genes with general effects on dermal inflammation and immunity.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Inst Child Hlth, London, England; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Oxford; Wellcome Centre for Human Genetics; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Leicester	Cookson, WOCM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.	william.cookson@ndm.ox.ac.uk	Walley, Andrew J/D-2573-2009; Abecasis, Goncalo R/B-7840-2010; Cookson, William/HHC-1790-2022	Walley, Andrew J/0000-0001-7707-7549; Trembath, Richard/0000-0003-0550-3400; Abecasis, Goncalo/0000-0003-1509-1825				Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; BOS J, 2000, IMMUNOLOGY ATOPIC DE, P178; Capon F, 1999, J INVEST DERMATOL, V112, P32, DOI 10.1046/j.1523-1747.1999.00471.x; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Enlund F, 1999, EUR J HUM GENET, V7, P783, DOI 10.1038/sj.ejhg.5200365; Enlund F, 1999, HUM HERED, V49, P2, DOI 10.1159/000022832; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Matthews D, 1996, NAT GENET, V14, P231, DOI 10.1038/ng1096-231; Nair RP, 1997, HUM MOL GENET, V6, P1349, DOI 10.1093/hmg/6.8.1349; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813	15	284	296	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2001	27	4					372	373		10.1038/86867	http://dx.doi.org/10.1038/86867			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279517				2022-12-25	WOS:000167811200010
J	Dawkins, JL; Hulme, DJ; Brahmbhatt, SB; Auer-Grumbach, M; Nicholson, GA				Dawkins, JL; Hulme, DJ; Brahmbhatt, SB; Auer-Grumbach, M; Nicholson, GA			Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I	NATURE GENETICS			English	Letter							SPHINGOLIPID SYNTHESIS; CHROMOSOME 9Q22.1-Q22.3; BIOSYNTHESIS; INHIBITION; APOPTOSIS; LINKAGE; ENZYME; CELLS; LOCI; GENE	Hereditary sensory neuropathy type I (HSN1) is the most common hereditary disorder of peripheral sensory neurons. HSN1 is an autosomal dominant progressive degeneration of dorsal root ganglia and motor neurons with onset in the second or third decades. Initial symptoms are sensory loss in the feet followed by distal muscle wasting and weakness. Loss of pain sensation leads to chronic: skin ulcers and distal amputations(1,2). The HSN1 locus has been mapped to chromosome 9q22.1-22.3 (refs. 3,4). Here we map the gene SPTLC1, encoding serine palmitoyltransferase. long chain base subunit-l. to this locus. Mutation screening revealed 3 different missense mutations resulting in changes to 2 amino acids in all affected members of 11 HSN1 families. We found two mutations to be located in exon 5 (C133Y and C133W) and one mutation to be located in exon 6 of SPTLC1 (V144D). All families showing definite or probable linkage to chromosome 9 had mutations in these two exons. These mutations are associated with increased de novo glucosyl ceramide synthesis in lymphoblast cell lines in affected individuals. Increased de novo ceramide synthesis triggers apoptosis(5,6) and is associated with massive cell death during neural tube closure(7), raising the possibility that neural degeneration in HSN1 is due to ceramide-induced apoptotic cell death.	Univ Sydney, Concord Hosp, Anzac Res Inst, Neurobiol Lab, Concord, NSW, Australia; Karl Franzens Univ Graz, Dept Neurol, Graz, Austria	Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; University of Graz	Nicholson, GA (corresponding author), Univ Sydney, Concord Hosp, Anzac Res Inst, Neurobiol Lab, Concord, NSW, Australia.		Ekanayake, Kanchana/P-8817-2016; Research Institute, ANZAC/CAE-9030-2022	Nicholson, Garth/0000-0001-9694-066X				AndreuttiZaugg C, 1997, CANCER RES, V57, P3288; Auer-Grumbach M, 2000, NEUROLOGY, V54, P45, DOI 10.1212/WNL.54.1.45; Bejaoui K, 1999, NEUROLOGY, V52, P510, DOI 10.1212/WNL.52.3.510; Blair IP, 1998, GENOMICS, V51, P277, DOI 10.1006/geno.1998.5373; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dyck P. J., 1993, PERIPHERAL NEUROPATH, V3rd, P1065; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; MATHEWS CK, 1990, BIOCHEMISTRY, V617; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; Nicholson GA, 1996, NAT GENET, V13, P101, DOI 10.1038/ng0596-101; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; SNELL EE, 1970, CHEM PHYS LIPIDS, V5, P116, DOI 10.1016/0009-3084(70)90013-7; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; THOMAS PK, 1993, BRAIN PATHOL, V3, P157, DOI 10.1111/j.1750-3639.1993.tb00740.x; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x	20	299	312	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					309	312		10.1038/85879	http://dx.doi.org/10.1038/85879			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242114				2022-12-25	WOS:000167304200024
J	Petit-Zeman, S				Petit-Zeman, S			Regenerative medicine	NATURE BIOTECHNOLOGY			English	Article							STEM-CELLS; IN-VIVO; MARROW; BRAIN											Bonadio J, 2000, ADV DRUG DELIVER REV, V44, P185, DOI 10.1016/S0169-409X(00)00094-6; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Hadlock T, 2000, TISSUE ENG, V6, P119, DOI 10.1089/107632700320748; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lee KY, 2000, NATURE, V408, P998, DOI 10.1038/35050141; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	10	64	67	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					201	206		10.1038/85619	http://dx.doi.org/10.1038/85619			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231542				2022-12-25	WOS:000167283100014
J	Subramanian, C; Cotter, MA; Robertson, ES				Subramanian, C; Cotter, MA; Robertson, ES			Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: A molecular link to cancer metastasis	NATURE MEDICINE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LYMPHOCYTE GROWTH TRANSFORMATION; INVASIVE BREAST CANCERS; ANTIGEN 3C; LATENT MEMBRANE-PROTEIN-1; CELL-LINES; IN-VITRO; EXPRESSION; TRANSFECTION; INHIBITION	Epstein-Barr virus (EBV) is an oncogenic virus associated with a number of human malignancies including Burkitt lymphoma, nasopharyngeal carcinoma, lymphoproliferative disease and, though still debated, breast carcinoma. A subset of latent EBV antigens is required for mediating immortalization of primary B-lymphocytes. Here we demonstrate that the carboxy-terminal region of the essential latent antigen, EBNA-3C, interacts specifically with the human metastatic suppressor protein Nm23-H1. Moreover, EBNA-3C reverses the ability of Nm23-H1 to suppress the migration of Burkitt lymphoma cells and breast carcinoma cells. We propose that EBNA-3C contributes to EBV-associated human cancers by targeting and altering the role of the metastasis suppressor Nm23-H1.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Comprehens Canc & Geriatr Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA.	esrobert@umich.edu			NATIONAL CANCER INSTITUTE [R29CA072150, R01CA072150] Funding Source: NIH RePORTER; NCI NIH HHS [CA072150-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Brink AATP, 2000, J NATL CANCER I, V92, P655, DOI 10.1093/jnci/92.8.655; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Glaser SL, 1998, INT J CANCER, V75, P555; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; KANTOR JD, 1993, CANCER RES, V53, P1971; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, EPSTEINBARR VIRUS IT, P2343; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; Lim SH, 1998, CANCER LETT, V133, P143, DOI 10.1016/S0304-3835(98)00219-5; Liu F, 2000, J CANCER RES CLIN, V126, P85; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MACDONALD NJ, 1995, EUR J CANCER, V31A, P1096, DOI 10.1016/0959-8049(95)00152-9; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; Martin KK, 1998, ANTICANCER RES, V18, P919; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; RICKINSON AB, 1996, EPSTEIN BARR VIRUS F, P2397; Robertson E.S, 1997, EPSTEINBARR VIRUS RE, V4, P143; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; Speck P, 2000, J NATL CANCER I, V92, P1849, DOI 10.1093/jnci/92.22.1849; STEEG PS, 1988, CANCER RES, V48, P6550; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WANG LM, 1993, CANCER RES, V53, P3652; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; Zhao B, 2000, J VIROL, V74, P5151, DOI 10.1128/JVI.74.11.5151-5160.2000	48	116	123	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					350	355		10.1038/85499	http://dx.doi.org/10.1038/85499			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231635				2022-12-25	WOS:000167380400042
J	Degterev, A; Lugovskoy, A; Cardone, M; Mulley, B; Wagner, G; Mitchison, T; Yuan, JY				Degterev, A; Lugovskoy, A; Cardone, M; Mulley, B; Wagner, G; Mitchison, T; Yuan, JY			Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-x(L)	NATURE CELL BIOLOGY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; CELL-DEATH; APOPTOSIS; BAX; MITOCHONDRIA; CHANNEL; HETERODIMERIZATION; DIMERIZATION; BINDING	To study the role of the BH3 domain in mediating pro-apoptotic and anti-apoptotic activities of Bcl-2 family members, we identified a series of novel small molecules (BH3Is) that inhibit the binding of the Bak BH3 peptide to Bcl-x(L). NMR analyses revealed that BH3Is target the BH3-binding pocket of Bcl-x(L). Inhibitors specifically block the BH3-domain-mediated heterodimerization between Bcl-2 family members in vitro and in vivo and induce apoptosis. Our results indicate that BH3-dependent heterodimerization is the key function of anti-apoptotic Bcl-2 family members and is required for the maintenance of cellular homeostasis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Mol Pharmacol & Biochem, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	junying_yuan@hms.harvard.edu						Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Baba M, 2000, INT J CANCER, V85, P260, DOI 10.1002/(SICI)1097-0215(20000115)85:2<260::AID-IJC18>3.3.CO;2-I; Chang BS, 1999, MOL CELL BIOL, V19, P6673; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Conus S, 2000, EMBO J, V19, P1534, DOI 10.1093/emboj/19.7.1534; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1999, GENE DEV, V13, P371; Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3; Decaudin D, 1998, INT J ONCOL, V12, P141; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hajduk PJ, 1999, J MED CHEM, V42, P2315, DOI 10.1021/jm9901475; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vander Heiden MG, 1999, MOL CELL, V3, P159; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Young K, 1998, NAT BIOTECHNOL, V16, P946, DOI 10.1038/nbt1098-946; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	48	497	581	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					173	182		10.1038/35055085	http://dx.doi.org/10.1038/35055085			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175750				2022-12-25	WOS:000166793000019
J	Iwawaki, T; Hosoda, A; Okuda, T; Kamigori, Y; Nomura-Furuwatari, C; Kimata, Y; Tsuru, A; Kohno, K				Iwawaki, T; Hosoda, A; Okuda, T; Kamigori, Y; Nomura-Furuwatari, C; Kimata, Y; Tsuru, A; Kohno, K			Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress	NATURE CELL BIOLOGY			English	Article							PROTEIN-RESPONSE PATHWAY; KAR2 BIP GENE; ENDOPLASMIC-RETICULUM; RIBOSOMAL-RNA; UNFOLDED PROTEINS; MAMMALIAN-CELLS; KINASE; NUCLEUS; PHOSPHORYLATION; INTERFERON	Under conditions of endoplasmic reticulum (ER) stress, mammalian cells induce both translational repression and the unfolded protein response that transcriptionally activates genes encoding ER-resident molecular chaperones, To date, the only known pathway for translational repression in response to ER stress has been the phosphorylation of eIF-2 alpha by the double-stranded RNA-activated protein kinase (PKR) or the transmembrane PKR-like ER kinase (PERK). Here we report another pathway in which the ER transmembrane kinase/ribonuclease IRE1 beta induces translational repression through 28S ribosomal RNA cleavage in response to ER stress. The evidence suggests that both pathways are important for efficient translational repression during the ER stress response.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST)	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.		Longo, Kenneth A/A-5631-2010; Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551; Iwawaki, Takao/0000-0001-8753-1979				Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CHEN YS, 1995, IEEE SIGNAL PROC LET, V2, P105, DOI 10.1109/97.388909; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROSFELD H, 1980, P NATL ACAD SCI-BIOL, V77, P6526, DOI 10.1073/pnas.77.11.6526; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Korth MJ, 2000, CURR TOP MICROBIOL, V242, P197; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; Sood R, 2000, GENETICS, V154, P787; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571	36	227	236	0	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					158	164		10.1038/35055065	http://dx.doi.org/10.1038/35055065			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175748				2022-12-25	WOS:000166793000017
J	Puccio, H; Simon, D; Cossee, M; Criqui-Filipe, P; Tiziano, F; Melki, J; Hindelang, C; Matyas, R; Rustin, P; Koenig, M				Puccio, H; Simon, D; Cossee, M; Criqui-Filipe, P; Tiziano, F; Melki, J; Hindelang, C; Matyas, R; Rustin, P; Koenig, M			Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits	NATURE GENETICS			English	Article							RESPIRATORY-CHAIN; MITOCHONDRIAL; FRATAXIN; HOMOLOG; ACCUMULATION; ACONITASE	Friedreich ataxia (FRDA), the most common autosomal recessive ataxia, is characterized by degeneration of the large sensory neurons and spinocerebellar tracts, cardiomyopathy and increased incidence in diabetes(1,2). FRDA is caused by severely reduced levels of frataxin, a mitochondrial protein(3) of unknown function. Yeast knockout models as well as histological and biochemical data from heart biopsies or autopsies of FRDA patients have shown that frataxin defects cause a specific iron-sulfur protein deficiency and intramitochondrial iron accumulation(4-7). We have recently shown that complete absence of frataxin in the mouse leads to early embryonic lethality(8), demonstrating an important role for frataxin during mouse development. Through a conditional gene-targeting approach, we have generated in parallel a striated muscle frataxin-deficient line and a neuron/cardiac muscle frataxin-deficient line, which together reproduce important progressive pathophysiological and biochemical features of the human disease: cardiac hypertrophy without skeletal muscle involvement, large sensory neuron dysfunction without alteration of the small sensory and motor neurons, and deficient activities of complexes I-III of the respiratory chain and of the aconitases, Our models demonstrate time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes. These mutant mice represent the first mammalian models to evaluate treatment strategies for the human disease.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Illkirch, CU Strasbourg, France; GENOPOLE, INSERM E9913, Mol Neurogenet Lab, Evry, France; Hop Necker Enfants Malad, INSERM U393, Unite Rech Handicaps Gent Enfant, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Genopole; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Koenig, M (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, Illkirch, CU Strasbourg, France.		Tiziano, Francesco Danilo/A-7260-2010; Puccio, Hélène/G-1717-2013	Tiziano, Francesco Danilo/0000-0002-5545-6158; Puccio, Hélène/0000-0003-4711-2248				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BURCK U, 1981, NEUROPEDIATRICS, V12, P267, DOI 10.1055/s-2008-1059657; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; Doevendans PA, 1998, CARDIOVASC RES, V39, P34, DOI 10.1016/S0008-6363(98)00073-X; Dupe V, 1997, DEVELOPMENT, V124, P399; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Frugier T, 2000, HUM MOL GENET, V9, P849, DOI 10.1093/hmg/9.5.849; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Jiralerspong S, 1997, NEUROBIOL DIS, V4, P103, DOI 10.1006/nbdi.1997.0139; KOENIG M, 2001, METABOLIC MOL BASIS; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; Musco G, 2000, STRUCTURE, V8, P695, DOI 10.1016/S0969-2126(00)00158-1; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sambrook J., 2002, MOL CLONING LAB MANU; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; WATMOUGH NJ, 1990, J CLIN INVEST, V85, P177, DOI 10.1172/JCI114409	26	544	560	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					181	186		10.1038/84818	http://dx.doi.org/10.1038/84818			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175786				2022-12-25	WOS:000166839200019
J	Tzung, SP; Kim, KM; Basanez, G; Giedt, CD; Simon, J; Zimmerberg, J; Zhang, KYJ; Hockenbery, DM				Tzung, SP; Kim, KM; Basanez, G; Giedt, CD; Simon, J; Zimmerberg, J; Zhang, KYJ; Hockenbery, DM			Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-ALPHA; MITOCHONDRIAL-MEMBRANE; CYTOCHROME-C; PERMEABILITY TRANSITION; NUCLEAR APOPTOSIS; BCL-X(L); BAX; BINDING; CHANNEL; PROTEIN	The Bcl-2-related survival proteins confer cellular resistance to a wide range of agents. Bcl-x(L)-expressing hepatocyte cell lines are resistant to tumour necrosis factor and anti-cancer drugs, but are more sensitive than isogenic control cells to antimycin A, an inhibitor of mitochondrial electron transfer. Computational molecular docking analysis predicted that antimycin A interacts with the Bcl-2 homology domain 3 (BH3)-binding hydrophobic groove of Bclx(L). We demonstrate that antimycin A and a Bak BH3 peptide bind competitively to recombinant Bcl-2. Antimycin A and BH3 peptide both induce mitochondrial swelling and loss of Delta Psi (m), on addition to mitochondria expressing Bcl-x(L). The 2-methoxy derivative of antimycin A(3) is inactive as an inhibitor of cellular respiration but still retains toxicity for Bcl-(+)(L) cells and mitochondria. Finally, antimycin A inhibits the pore-forming activity of Bcl-x(L) in synthetic liposomes, demonstrating that a small non-peptide ligand can directly inhibit the function of Bcl-2-related proteins.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Basanez, Gorka/L-9509-2014; Zhang, Kam Y. J./B-3552-2012	Basanez, Gorka/0000-0002-7475-7861; Zhang, Kam Y. J./0000-0002-9282-8045	NCI NIH HHS [CA15704-26] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001409] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001409] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V256, P199, DOI 10.1016/0005-2728(72)90053-9; CAMPO ML, 1992, J BIOL CHEM, V267, P8123; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Decaudin D, 1997, CANCER RES, V57, P62; DUNSHEE BR, 1949, J AM CHEM SOC, V71, P2436, DOI 10.1021/ja01175a057; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FONYO A, 1981, ACTA BIOL MED GER, V40, P907; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Middleton G, 1996, DEVELOPMENT, V122, P695; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYOSHI H, 1995, BBA-BIOENERGETICS, V1229, P149, DOI 10.1016/0005-2728(94)00185-8; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SLATER EC, 1961, HAEMATIN ENZYMES, P575; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TOKUTAKE N, 1994, BBA-BIOENERGETICS, V1185, P271, DOI 10.1016/0005-2728(94)90241-0; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANTAMELEN E, 1961, J AM CHEM SOC, V83, P1639, DOI 10.1021/ja01468a023; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	408	427	1	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					183	191		10.1038/35055095	http://dx.doi.org/10.1038/35055095			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175751				2022-12-25	WOS:000166793000020
J	Vigneri, P; Wang, JYJ				Vigneri, P; Wang, JYJ			Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; C-ABL; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; POSITIVE CELLS; IN-VIVO; INHIBITOR; PROTEIN; MICE; TRANSFORMATION	The chimeric BCR-ABL oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). BCR-ABL contains nuclear import and export signals but it is localized only In the cytoplasm where it activates mitogenic and anti-apoptotic pathways. We have found that inhibition of the BCR-ABL tyrosine kinase, either by mutation or by the drug STI571, can stimulate its nuclear entry. By combining STI571 with leptomycin B (LMB) to block nuclear export, we trapped BCR-ABL in the nucleus and the nuclear BCR-ABL tyrosine kinase activates apoptosis. As a result, the combined treatment with STI571 and LMB causes the irreversible and complete killing of BCR-ABL transformed cells, whereas the effect of either drug alone is fully reversible. The combined treatment with STI571 and LMB also preferentially eliminates mouse bone marrow cells that express BCR-ABL. These results indicate that nuclear entrapment of BCR-ABL can be used as a therapeutic strategy to selectively kill chronic myelogenous leukemia cells.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Studi Catanzaro, Catanzaro, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Vigneri, Paolo G/K-8504-2016	Vigneri, Paolo G/0000-0002-5943-6066	NCI NIH HHS [R01 CA043054, CA 43054, R37 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beran M, 1998, CLIN CANCER RES, V4, P1661; Buchdunger E, 1996, CANCER RES, V56, P100; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Goldman JM, 2000, LANCET, V355, P1031, DOI 10.1016/S0140-6736(00)02029-8; Gong JG, 1999, NATURE, V399, P806; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Jost CA, 1999, NATURE, V399, P817, DOI 10.1038/21710; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KLEIN E, 1976, INT J CANCER, V18, P421, DOI 10.1002/ijc.2910180405; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Vastag B, 2000, J NATL CANCER I, V92, P6, DOI 10.1093/jnci/92.1.6; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WANG JYJ, 2000, INTEGRATIVE SIGNALIN, P303; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	45	256	268	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					228	234		10.1038/84683	http://dx.doi.org/10.1038/84683			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175855				2022-12-25	WOS:000166756300041
J	Bolz, H; von Brederlow, B; Ramirez, A; Bryda, EC; Kutsche, K; Nothwang, HG; Seeliger, M; Cabrera, MDS; Vila, MC; Molina, OP; Gal, A; Kubisch, C				Bolz, H; von Brederlow, B; Ramirez, A; Bryda, EC; Kutsche, K; Nothwang, HG; Seeliger, M; Cabrera, MDS; Vila, MC; Molina, OP; Gal, A; Kubisch, C			Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D	NATURE GENETICS			English	Article							MYOSIN VIIA GENE; CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX; RECESSIVE DEAFNESS; MAP	Usher syndrome type I (USH1) is an autosomal recessive disorder characterized by congenital sensorineural hearing loss, vestibular dysfunction and visual impairment due to early onset retinitis pigmentosa(1) (RP). So far, six loci (USH1A-USH1F) have been mapped, but only two USH1 genes have been identified: MYO7A (ref. 2) for USH1B and the gene encoding harmonin(3,4) for USH1C. We identified a Cuban pedigree linked to the locus for Usher syndrome type 1D (MIM 601067) within the q2 region of chromosome 10 (ref. 5). Affected individuals present with congenital deafness and a highly variable degree of retinal degeneration. Using a positional candidate approach, we identified a new member of the cadherin gene superfamily, CDH23. It encodes a protein of 3,354 amino acids with a single transmembrane domain and 27 cadherin repeats. In the Cuban family, we detected two different mutations: a severe course of the retinal disease was observed in individuals homozygous for what is probably a truncating splice-site mutation (c.4488G-->C), whereas mild RP is present in individuals carrying the homozygous missense mutation R1746Q. A variable expression of the retinal phenotype was seen in patients with a combination of both mutations. In addition, we identified two mutations, Delta M1281 and IVS51+5G-->A, in a German USH1 patient. Our data show that different mutations in CDH23 result in USH1D with a variable retinal phenotype. In an accompanying paper(6), it is shown that mutations in the mouse ortholog cause disorganization of inner ear stereocilia and deafness in the waltzer mouse.	Univ Hamburg, Krankenhaus Eppendorf, Inst Human Genet, D-2000 Hamburg, Germany; Univ Bonn, Inst Humangenet, D-5300 Bonn, Germany; Marshall Univ, Dept Microbiol Immunol & Mol Genet, Huntington, WV USA; MPI Mol Genet, Berlin, Germany; Univ Tubingen, Abt 2, Augenklin, Tubingen, Germany; Ctr Int REtinosis Pigmentaria, Habana, Cuba	University of Hamburg; University of Bonn; Marshall University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gal, A (corresponding author), Univ Hamburg, Krankenhaus Eppendorf, Inst Human Genet, D-2000 Hamburg, Germany.		Nothwang, Hans G/C-5847-2011; Ramirez, Alfredo/S-5126-2019; Kubisch, Christian/F-1893-2011	Ramirez, Alfredo/0000-0003-4991-763X; Kubisch, Christian/0000-0003-4220-0978; Nothwang, Hans Gerd/0000-0001-7695-6437				Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bitner-Glindzicz M, 2000, NAT GENET, V26, P56, DOI 10.1038/79178; Bryda EC, 1997, MAMM GENOME, V8, P1, DOI 10.1007/s003359900336; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Chaib H, 1996, HUM MOL GENET, V5, P1061, DOI 10.1093/hmg/5.7.1061; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eudy JD, 1998, SCIENCE, V280, P1753, DOI 10.1126/science.280.5370.1753; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; Keats BJB, 1999, AM J MED GENET, V89, P158, DOI 10.1002/(SICI)1096-8628(19990924)89:3<158::AID-AJMG6>3.3.CO;2-R; Legan PK, 1997, SEMIN CELL DEV BIOL, V8, P217, DOI 10.1006/scdb.1997.0145; Liu XZ, 1998, AM J HUM GENET, V63, P909, DOI 10.1086/302026; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; WAYNE S, 1996, HUM MOL GENET, V10, P1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WELL D, 1997, NAT GENET, V16, P191; Yagi T, 2000, GENE DEV, V14, P1169; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919	27	360	377	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					108	112		10.1038/83667	http://dx.doi.org/10.1038/83667			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138009				2022-12-25	WOS:000166187900026
J	Mazumdar, A; Wang, RA; Mishra, SK; Adam, L; Bagheri-Yarmand, R; Mandal, M; Vadlamudi, RK; Kumar, R				Mazumdar, A; Wang, RA; Mishra, SK; Adam, L; Bagheri-Yarmand, R; Mandal, M; Vadlamudi, RK; Kumar, R			Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor	NATURE CELL BIOLOGY			English	Article							BREAST-CANCER CELLS; HISTONE DEACETYLASE; ESTROGEN-RECEPTOR; PROMYELOCYTIC LEUKEMIA; GENE; EXPRESSION; COMPLEX; YEAST; OVEREXPRESSION; ACETYLATION	Activation of the heregulin/HER2 pathway in oestrogen receptor (ER)-positive breast-cancer cells leads to suppression of oestrogen-receptor element (ERE)-driven transcription and disruption of oestradiol responsiveness, and thus contributes to progression of tumours to more invasive phenotypes. Here we report the identification of metastatic-associated protein 1 (MTA1), a component of histone deacetylase (HDAC) and nucleosome-remodelling complexes, as a gene product induced by heregulin-beta1 (HRG). Stimulation of cells with HRG is accompanied by suppression of histone acetylation and enhancement of deacetylase activity. MTA1 is also a potent corepressor of ERE transcription, as it blocks the ability of oestradiol to stimulate ER-mediated transcription. The histone-deacetylase inhibitor trichostatin A blocks MTA1-mediated repression of ERE transcription, Furthermore, MTA1 directly interacts with histone deacetylase-l and -2 and with the activation domain of ER-alpha. Overexpression of MTA1 in breast-cancer cells is accompanied by enhancement of the ability of cells to invade and to grow in an anchorage-independent manner. HRG also promotes interaction of MTA1 with endogenous ER and association of MTA1 or HDAC with ERE-responsive target-gene promoters in vivo. These results identify ER-mediated transcription as a nuclear target of MTA1 and indicate that HDAC complexes associated with the MTA1 corepressor may mediate ER transcriptional repression by HRG.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022	Mandal, Mahitosh/0000-0003-3861-3323; Mishra, Sandip/0000-0002-0776-6581; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA65746, CA80066, CA84456, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084456, U01CA065746, R01CA065746, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BENZ CC, 1995, BREAST CANC RES TREA, V24, P85; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DUBIK D, 1992, ONCOGENE, V7, P1587; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harris JG, 1999, TEXTUAL PRACT, V13, P311; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Kleene R, 1999, J CELL SCI, V112, P2539; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krane IM, 1996, ONCOGENE, V12, P1781; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; LAHEY BB, 1997, DSM 4 SOURCEBOOK, V3, P189; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Tang CK, 1996, CANCER RES, V56, P3350; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P229; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 1999, BIOL REPROD, V61, P999, DOI 10.1095/biolreprod61.4.999; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	40	315	329	2	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					30	37		10.1038/35050532	http://dx.doi.org/10.1038/35050532			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146623				2022-12-25	WOS:000166146400017
J	Roegiers, F; Younger-Shepherd, S; Jan, LY; Jan, YN				Roegiers, F; Younger-Shepherd, S; Jan, LY; Jan, YN			Two types of asymmetric divisions in the Drosophila sensory organ precursor cell lineage	NATURE CELL BIOLOGY			English	Article							MITOTIC SPINDLE; LOCALIZATION; NUMB; PROSPERO; PROTEIN; ORIENTATION; MIRANDA; YEAST; FATE; SEGREGATION	Asymmetric partitioning of cell-fate determinants during development requires coordinating the positioning of these determinants with orientation of the mitotic spindle. In the Drosophila peripheral nervous system, sensory organ progenitor cells (SOPs) undergo several rounds of division to produce five cells that give rise to a complete sensory organ. Here we have observed the asymmetric divisions that give rise to these cells in the developing pupae using green fluorescent protein fusion proteins. We find that spindle orientation and determinant localization are tightly coordinated at each division. Furthermore, we find that two types of asymmetric divisions exist within the sensory organ precursor cell lineage: the anterior-posterior pI cell-type division, where the spindle remains symmetric throughout mitosis, and the strikingly neuroblast-like apical-basal division of the pIIb cell, where the spindle exhibits a strong asymmetry at anaphase. In both these divisions, the spindle reorientates to position itself perpendicular to the region of the cortex containing the determinant. On the basis of these observations, we propose that two distinct mechanisms for controlling asymmetric cell divisions occur within the same lineage in the developing peripheral nervous system in Drosophila.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.	ynjan@itsa.ucsf.edu		Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; BRAND A, 1995, TRENDS GENET, V11, P324, DOI 10.1016/S0168-9525(00)89091-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buescher M, 1998, GENE DEV, V12, P1858, DOI 10.1101/gad.12.12.1858; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; CHIBA A, 1998, COMMUNICATION; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; Fuerstenberg S, 1998, MOL CELL NEUROSCI, V12, P325, DOI 10.1006/mcne.1998.0724; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gho M, 1999, DEVELOPMENT, V126, P3573; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Hassan BA, 1998, GENETICS, V150, P1527; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; LUTZ DA, 1986, METHOD CELL BIOL, V27, P89, DOI 10.1016/S0091-679X(08)60344-1; Manning L, 1999, DEVELOPMENT, V126, P2063; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Reddy GV, 1999, DEVELOPMENT, V126, P2083; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shaw SL, 1997, J CELL BIOL, V139, P985, DOI 10.1083/jcb.139.4.985; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Wang SW, 1997, DEVELOPMENT, V124, P4435; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	48	89	90	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					58	67		10.1038/35050568	http://dx.doi.org/10.1038/35050568			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146627				2022-12-25	WOS:000166146400021
J	Bishop, CE; Whitworth, DJ; Qin, YJ; Agoulnik, AI; Agoulnik, IU; Harrison, WR; Behringer, RR; Overbeek, PA				Bishop, CE; Whitworth, DJ; Qin, YJ; Agoulnik, AI; Agoulnik, IU; Harrison, WR; Behringer, RR; Overbeek, PA			A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse	NATURE GENETICS			English	Article							Y-CHROMOSOME; CAMPOMELIC DYSPLASIA; DETERMINING REGION; SRY; GENE; EXPRESSION; TYROSINASE; MUTATIONS; SEQUENCES; SUGGESTS	In most mammals, male development is triggered by the transient expression of the Y-chromosome gene, Sry, which initiates a cascade of gene interactions ultimately leading to the formation of a testis from the indifferent fetal gonad(1-4). Several genes(5-8), in particular Sox9, have a crucial role in this pathway(9-14). Despite this, the direct downstream targets of Sry and the nature of the pathway itself remain to he clearly established(15,16). We report here a new dominant insertional mutation, Odsex (Ods), in which XX mice carrying a 150-kb deletion (approximately 1 Mb upstream of Sox9) develop as sterile XX males lacking Sry, During embryogenesis, wild-type XX fetal gonads downregulate Sox9 expression, whereas XY and XX Ods/+ fetal gonads upregulate and maintain its expression(13,14). We propose that Ods has removed a long-range, gonad-specific regulatory element that mediates the repression of Sox9 expression in XX fetal gonads. This repression would normally be antagonized by Sry protein in XY embryos. Our data ate consistent with Sox9 being a direct downstream target of Sry and provide genetic evidence to support a general repressor model of sex determination in mammals(17,18).	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Bishop, CE (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.	bishop@bcm.tmc.edu	Agoulnik, Irina/AAD-4687-2020; Agoulnik, Alexander/AAK-3213-2020; Whitworth, Deanne/AAE-1019-2020	Agoulnik, Irina/0000-0003-4889-0324; Agoulnik, Alexander/0000-0001-6587-6845; Whitworth, Deanne/0000-0002-9097-0240; Overbeek, Paul/0000-0001-9784-2084; Qin, Jane Yangjun/0000-0003-0116-6988				BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bishop CE, 1998, MAMM GENOME, V8, pS378, DOI 10.1007/s003359900666; Burgoyne PS, 1998, BIOESSAYS, V20, P363, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;363::AID-BIES2&gt;3.0.CO;2-P; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; Capel B, 1998, ANNU REV PHYSIOL, V60, P497, DOI 10.1146/annurev.physiol.60.1.497; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Grandi A, 2000, MECH DEVELOP, V90, P323, DOI 10.1016/S0925-4773(99)00282-8; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; Hustert E, 1996, MAMM GENOME, V7, P881, DOI 10.1007/s003359900261; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; Moniot B, 2000, MECH DEVELOP, V91, P323, DOI 10.1016/S0925-4773(99)00267-1; Pfeifer D, 1999, AM J HUM GENET, V65, P111, DOI 10.1086/302455; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhao SL, 1999, DEV BIOL, V216, P154, DOI 10.1006/dbio.1999.9480	29	287	299	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2000	26	4					490	494		10.1038/82652	http://dx.doi.org/10.1038/82652			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101852				2022-12-25	WOS:000165671700027
J	Crotty, S; Maag, D; Arnold, JJ; Zhong, WD; Lau, JYN; Hong, Z; Andino, R; Cameron, CE				Crotty, S; Maag, D; Arnold, JJ; Zhong, WD; Lau, JYN; Hong, Z; Andino, R; Cameron, CE			The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; POLYMERASE 3D(POL); POLIOVIRUS; MECHANISM; INHIBITION; NUCLEOSIDE; MUTATIONS; MUTANTS; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; INTERFERON-ALPHA-2B	The ribonucleoside analog ribavirin (1-beta -D-ribofuranosyl-1,2,4-triazole-3-carboxamide) shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Here we show in vitro use of ribavirin triphosphate by a model viral RNA polymerase, poliovirus 3D(pol). Ribavirin incorporation is mutagenic, as it templates incorporation of cytidine and uridine with equal efficiency. Ribavirin reduces infectious poliovirus production to as little as 0.00001% in cell culture. The antiviral activity of ribavirin correlates directly with its mutagenic activity. These data indicate that ribavirin forces the virus into 'error catastrophe'. Thus, mutagenic ribonucleosides may represent an important class of anti-RNA virus agents.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Schering Plough Corp, Res Inst, Antiviral Therapy, Kenilworth, NJ 07033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco; Merck & Company; Schering Plough Corporation	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu	Crotty, Shane/AAC-6703-2019; Yang, Chen/G-1379-2010	Crotty, Shane/0000-0002-6484-6262; 	NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI45818, AI40085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045818, R21AI040085, R01AI040085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AFHS, 2000, AFHS DRUG INF; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; BALTERA RF, 1989, J VIROL, V63, P4441, DOI 10.1128/JVI.63.10.4441-4444.1989; CASSIDY LF, 1989, ANTIMICROB AGENTS CH, V33, P2009, DOI 10.1128/AAC.33.11.2009; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEA P, 1974, BIOCHEMISTRY-US, V13, P1862, DOI 10.1021/bi00706a014; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; Domingo E, 2000, VIROLOGY, V270, P251, DOI 10.1006/viro.2000.0320; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; DOMINGO E, 1994, EVOLUTIONARY BIOL VI, V11, P353; ERIKSSON B, 1977, ANTIMICROB AGENTS CH, V11, P946, DOI 10.1128/AAC.11.6.946; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; GOSWAMI BB, 1979, BIOCHEM BIOPH RES CO, V89, P830, DOI 10.1016/0006-291X(79)91853-9; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; Lee CH, 1997, J VIROL, V71, P3636, DOI 10.1128/JVI.71.5.3636-3640.1997; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992; Pfister T, 1999, J BIOL CHEM, V274, P6992, DOI 10.1074/jbc.274.11.6992; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PRINGLE CR, 1970, J VIROL, V5, P559, DOI 10.1128/JVI.5.5.559-567.1970; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; SMITH RA, 1980, RIBAVIRIN BROAD SPEC, V13, P237; SMITH RA, 1984, CLIN APPL RIBAVIRIN, V19, P222; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Wyde PR, 1998, ANTIVIR RES, V39, P63, DOI 10.1016/S0166-3542(98)00029-1	35	621	658	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1375	1379		10.1038/82191	http://dx.doi.org/10.1038/82191			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100123				2022-12-25	WOS:000165704100042
J	Ostergaard, S; Olsson, L; Johnston, M; Nielsen, J				Ostergaard, S; Olsson, L; Johnston, M; Nielsen, J			Increasing galactose consumption by Saccharomyces cerevisiae through metabolic engineering of the GAL gene regulatory network	NATURE BIOTECHNOLOGY			English	Article						metabolic engineering; gene regulation; Saccharomyces cerevisiae; GAL system	YEAST; REPRESSOR; TRANSFORMATION; SSN6-TUP1; INDUCTION; PATHWAY; INVIVO; CELLS; MIG1	Increasing the flux through central carbon metabolism is difficult because of rigidity in regulatory structures, at both the genetic and the enzymatic levels. Here we describe metabolic engineering of a regulatory network to obtain a balanced increase in the activity of all the enzymes in the pathway, and ultimately, increasing metabolic flux through the pathway of interest, By manipulating the GAL gene regulatory network of Saccharomyces cerevisiae, which is a tightly regulated system, we produced prototroph mutant strains, which increased the flux through the galactose utilization pathway by eliminating three known negative regulators of the GAL system: Gale, Gal80, and Mig1. This led to a 41% increase in flux through the galactose utilization pathway compared with the wild-type strain. This is of significant interest within the field of biotechnology since galactose is present in many industrial media. The improved galactose consumption of the gal mutants did not favor biomass formation, but rather caused excessive respiro-fermentative metabolism, with the ethanol production rate increasing linearly with glycolytic flux.	Tech Univ Denmark, Dept Biotechnol, Ctr Proc Biotechnol, DK-2800 Lyngby, Denmark; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Technical University of Denmark; Washington University (WUSTL)	Nielsen, J (corresponding author), Tech Univ Denmark, Dept Biotechnol, Ctr Proc Biotechnol, Bldg 223, DK-2800 Lyngby, Denmark.		Johnston, Mark/R-6156-2019; Johnston, Mark/K-3543-2019; Nielsen, Jens/Q-1347-2017	Johnston, Mark/0000-0002-4932-7229; /0000-0002-0827-5442; Nielsen, Jens/0000-0002-9955-6003	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032540] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACERENZA L, 1990, BIOCHEM J, V269, P697, DOI 10.1042/bj2690697; ADAM AC, 1995, YEAST, V11, P395, DOI 10.1002/yea.320110502; Bailey JE, 1999, NAT BIOTECHNOL, V17, P616, DOI 10.1038/10794; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CAMERON DC, 1993, APPL BIOCHEM BIOTECH, V38, P105, DOI 10.1007/BF02916416; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IGARASHI M, 1987, MOL GEN GENET, V207, P273, DOI 10.1007/BF00331589; Johnson Kenneth M., 1992, RURAL DEV PERSPECTIV, V8, P8; JOHNSTON M, 1988, GENETICS, V120, P63; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MARTEGANI E, 1993, YEAST, V9, P575, DOI 10.1002/yea.320090603; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NIEDERBERGER P, 1992, BIOCHEM J, V287, P473, DOI 10.1042/bj2870473; Ostergaard S, 2000, MICROBIOL MOL BIOL R, V64, P34, DOI 10.1128/MMBR.64.1.34-50.2000; Ostergaard S, 2000, BIOTECHNOL BIOENG, V68, P252, DOI 10.1002/(SICI)1097-0290(20000505)68:3<252::AID-BIT3>3.3.CO;2-B; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SCHADE DS, 1985, DIABETES CARE, V8, P5, DOI 10.2337/diacare.8.1.5; SMALL JR, 1993, EUR J BIOCHEM, V213, P613, DOI 10.1111/j.1432-1033.1993.tb17801.x; SuzukiFujimoto T, 1996, MOL CELL BIOL, V16, P2504; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wiselogel A., 1996, HDB BIOETHANOL PRODU, P105; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	30	140	149	2	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1283	1286		10.1038/82400	http://dx.doi.org/10.1038/82400			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101808				2022-12-25	WOS:000165659000026
J	Prakken, B; Wauben, M; Genini, D; Samodal, R; Barnett, J; Mendivil, A; Leoni, L; Albani, S				Prakken, B; Wauben, M; Genini, D; Samodal, R; Barnett, J; Mendivil, A; Leoni, L; Albani, S			Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'	NATURE MEDICINE			English	Article							T-CELLS; POSITIVE SELECTION; PEPTIDE COMPLEXES; RESPONSES; COSTIMULATION	Recent progress in molecular medicine has provided important tools to identify antigen-specific T cells. In most cases, the approach is based on oligomeric combinations of recombinant major histocompatibility complex-peptide complexes fixed to various rigid supports available for binding by the T-cell receptor(1-8). These tools have greatly increased our insight into mechanisms of immune responses mediated by CD8(+) T cells(1,2). Examples of the diverse fields of application for this technology include immunization, viral infections and oral tolerance induction(1-6).	Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, NL-3508 TD Utrecht, Netherlands; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Androcius Therapeut, I-95030 Catania, Italy	University of California System; University of California San Diego; Utrecht University; University of California System; University of California San Diego	Albani, S (corresponding author), Univ Calif San Diego, Dept Pediat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	salbani@ucsd.edu		Wauben, Marca/0000-0003-0360-0311				ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anderson DE, 1997, J IMMUNOL, V159, P1669; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; Bonnin D, 1999, EUR J IMMUNOL, V29, P3826, DOI 10.1002/(SICI)1521-4141(199912)29:12<3826::AID-IMMU3826>3.0.CO;2-S; BRIAN L, 2000, P NATL ACAD SCI USA, V97, P291; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Janssen EM, 2000, J IMMUNOL, V164, P580, DOI 10.4049/jimmunol.164.2.580; KIRSTEN J, 1998, IMMUNITY, V8, P683; LaCava A, 1997, J CLIN INVEST, V100, P658, DOI 10.1172/JCI119577; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Luxembourg AT, 1998, NAT BIOTECHNOL, V16, P281, DOI 10.1038/nbt0398-281; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563; NANDA NK, 1998, IMMUNOL TODAY, V19, P495; Rees W, 1999, P NATL ACAD SCI USA, V96, P9781, DOI 10.1073/pnas.96.17.9781; SETTE A, 1992, J IMMUNOL, V148, P844; van Rensen AJML, 1999, PHARMACEUT RES, V16, P198, DOI 10.1023/A:1018864005620; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680	22	100	109	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1406	1410		10.1038/82231	http://dx.doi.org/10.1038/82231			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100129				2022-12-25	WOS:000165704100048
J	Klugherz, BD; Jones, PL; Cui, XM; Chen, WL; Meneveau, NF; DeFelice, S; Connolly, J; Wilensky, RL; Levy, RJ				Klugherz, BD; Jones, PL; Cui, XM; Chen, WL; Meneveau, NF; DeFelice, S; Connolly, J; Wilensky, RL; Levy, RJ			Gene delivery from a DNA controlled-release stent in porcine coronary arteries	NATURE BIOTECHNOLOGY			English	Article						plasmid; transfection; drug delivery; polymer; angioplasty	MUSCLE CELL-PROLIFERATION; C-MYB OLIGONUCLEOTIDES; BALLOON ANGIOPLASTY; IN-VIVO; NEOINTIMA FORMATION; TISSUE; INJURY; MODEL; EXPRESSION; THERAPY	Expandable intra-arterial stents are widely used for treating coronary disease. We hypothesized that local gene delivery could be achieved with the controlled release of DNA from a polymer coating on an expandable stent. Our paper reports the first successful transfection in vivo using a DNA controlled-release stent. Green fluorescent protein (GFP) plasmid DNA within emulsion-coated stents was efficiently expressed in cell cultures (7.9% +/- 0.7% vs. 0.6% +/- 0.2% control, p < 0.001) of rat aortic smooth muscle cells. In a series of pig stent-angioplasty studies, GFP expression was observed in all coronary arteries (normal, nondiseased) in the DNA-treated group, but not in control arteries, GFP plasmid DNA in the arterial wall was confirmed by PCR, and GFP presence in the pig coronaries was confirmed by immunohistochemistry. Thus, DNA-eluting stents are capable of arterial transfection, and could be useful as delivery systems for candidate vectors for gene therapy of cardiovascular diseases.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Div Cardiovasc Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Levy, RJ (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.			Jones, Peter Lloyd/0000-0003-1445-4081				Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; Cable DG, 1997, CARDIOVASC RES, V35, P553, DOI 10.1016/S0008-6363(97)00161-2; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Felgner PL, 1995, ANN NY ACAD SCI, V772, P126, DOI 10.1111/j.1749-6632.1995.tb44738.x; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Labhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+; Labhasetwar V, 1999, COLLOID SURFACE B, V16, P281, DOI 10.1016/S0927-7765(99)00079-X; Lincoff AM, 1997, J AM COLL CARDIOL, V29, P808, DOI 10.1016/S0735-1097(96)00584-0; Luo ZY, 1999, CIRCULATION, V99, P1776, DOI 10.1161/01.CIR.99.14.1776; Moreno PR, 1999, AM J CARDIOL, V84, P462, DOI 10.1016/S0002-9149(99)00334-3; MORISHITA R, 1994, GENE, V149, P13, DOI 10.1016/0378-1119(94)90406-5; Petersen M, 1999, BIOCONJUGATE CHEM, V10, P66, DOI 10.1021/bc980073w; ROME JJ, 1994, HUM GENE THER, V5, P1249, DOI 10.1089/hum.1994.5.10-1249; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; SELLS MA, 1995, METHOD ENZYMOL, V254, P184; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Simari RD, 1996, J CLIN INVEST, V98, P225, DOI 10.1172/JCI118770; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Sirois MG, 1997, CIRCULATION, V95, P669, DOI 10.1161/01.CIR.95.3.669; Stephan DJ, 1996, HUM GENE THER, V7, P1803, DOI 10.1089/hum.1996.7.15-1803; vanderGiessen WJ, 1996, CIRCULATION, V94, P1690, DOI 10.1161/01.CIR.94.7.1690; VILLA AE, 1995, CIRC RES, V76, P505, DOI 10.1161/01.RES.76.4.505; Yang R, 1979, Methods Enzymol, V68, P176	26	193	238	3	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1181	1184		10.1038/81176	http://dx.doi.org/10.1038/81176			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062438				2022-12-25	WOS:000165176600024
J	Liu, Z; Steward, R; Lu, LQ				Liu, Z; Steward, R; Lu, LQ			Drosophila Lis1 is required for neuroblast proliferation, dendritic elaboration and axonal transport	NATURE CELL BIOLOGY			English	Article							PLATELET-ACTIVATING-FACTOR; DIEKER LISSENCEPHALY GENE; CYTOPLASMIC DYNEIN; ASPERGILLUS-NIDULANS; OOCYTE DIFFERENTIATION; NEURONAL MIGRATION; MICROTUBULE MOTOR; MUSHROOM BODIES; KINESIN; PROTEINS	Haplo-insufficiency of human Lis1 causes lissencephaly. Reduced Lis1 activity in both humans and mice results in a neuronal migration defect. Here we show that Drosophila Lis1 is highly expressed in the nervous system. Lis1 is essential for neuroblast proliferation and axonal transport, as shown by a mosaic analysis using a Lis1 null mutation. Moreover, it is cell-autonomously required for dendritic growth, branching and maturation. Analogous mosaic analysis shows that neurons containing a mutated cytoplasmic-dynein heavy chain (Dhc64C) exhibit phenotypes similar to Lis1 mutants. These results implicate Lis1 as a regulator of the microtubule cytoskeleton and show that it is important for diverse physiological functions in the nervous system.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Rutgers State Univ, Waksman Inst, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Stanford University; Rutgers State University New Brunswick	Liu, Z (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Luo, Liqun/0000-0001-5467-9264	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036623] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS36623] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; BERRY M, 1976, BRAIN RES, V112, P1, DOI 10.1016/0006-8993(76)90331-0; Bowman AB, 1999, J CELL BIOL, V146, P165; BRAND AH, 1993, DEVELOPMENT, V118, P401; Clark IE, 1997, DEVELOPMENT, V124, P461; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Fleck MW, 2000, J NEUROSCI, V20, P2439; Gepner J, 1996, GENETICS, V142, P865; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hurd DD, 1996, GENETICS, V144, P1075; Ito K, 1998, LEARN MEMORY, V5, P52; Lee T, 1999, DEVELOPMENT, V126, P4065; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee TM, 2000, NEURON, V25, P307, DOI 10.1016/S0896-6273(00)80896-X; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; Liu Z, 1999, DEVELOPMENT, V126, P4477; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; McGrail M, 1997, DEVELOPMENT, V124, P2409; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; WILLINS DA, 1995, GENETICS, V141, P1287; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297	34	180	184	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					776	783		10.1038/35041011	http://dx.doi.org/10.1038/35041011			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056531				2022-12-25	WOS:000165207500010
J	Akama, TO; Nishida, K; Nakayama, J; Watanabe, H; Ozaki, K; Nakamura, T; Dota, A; Kawasaki, S; Inoue, Y; Maeda, N; Yamamoto, S; Fujiwara, T; Thonar, EJMA; Shimomura, Y; Kinoshita, S; Tanigami, A; Fukuda, MN				Akama, TO; Nishida, K; Nakayama, J; Watanabe, H; Ozaki, K; Nakamura, T; Dota, A; Kawasaki, S; Inoue, Y; Maeda, N; Yamamoto, S; Fujiwara, T; Thonar, EJMA; Shimomura, Y; Kinoshita, S; Tanigami, A; Fukuda, MN			Macular corneal dystrophy type I and type II are caused by distinct mutations in a new sulphotransferase gene	NATURE GENETICS			English	Letter							KERATAN SULFATE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SULFOTRANSFERASE; EXPRESSION; HETEROGENEITY; MARKER; BLOOD	Macular corneal dystrophy (MCD; MIM 217800) is an autosomal recessive hereditary disease in which progressive punctate opacities in the cornea result in bilateral loss of vision, eventually necessitating corneal transplantation. MCD is classified into two subtypes. type I and type II, defined by the respective absence and presence of sulphated keratan sulphate in the patient serum, although both types have clinically indistinguishable phenotypes(1,2). The gene responsible for MCD type I has been mapped to chromosome 16q22, and that responsible for MCD type II may involve the same locus(3-5). Here we identify a new carbohydrate sulphotransferase gene (CHST6). encoding an enzyme designated corneal N-acetylglucosamine-6-sulphotransferase (C-GlcNAc6ST), within the critical region of MCD type I. In MCD type I. we identified several mutations that may lead to inactivation of C-GlcNAc6ST within the coding region of CHST6. In MCD type II, we found large deletions and/or replacements caused by homologous recombination in the upstream region of CHST6. In situ hybridization analysis did not detect CHST6 transcripts in corneal epithelium in an MCD type II patient, suggesting that the mutations found in type II lead to loss of cornea-specific expression of CHST6.	Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA; Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Matsumoto, Nagano 390, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan; Otsuka Pharmaceut Co Ltd, Otsuka GEN Res Inst, Tokushima 77101, Japan; Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Biochem & Internal Med, Chicago, IL 60612 USA	Sanford Burnham Prebys Medical Discovery Institute; Kyoto Prefectural University of Medicine; Shinshu University; Shinshu University; Osaka University; Otsuka Pharmaceutical; Rush University	Fukuda, MN (corresponding author), Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA.			Nishida, Kohji/0000-0001-9069-3610; Ozaki, Kouichi/0000-0003-0028-1570	NCI NIH HHS [CA71932] Funding Source: Medline; NIAMS NIH HHS [AR39239] Funding Source: Medline; NIA NIH HHS [AG04736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; EDWARD DP, 1990, OPHTHALMOLOGY, V97, P1194; EDWARD DP, 1988, ARCH OPHTHALMOL-CHIC, V106, P1579, DOI 10.1001/archopht.1988.01060140747049; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; HUDSON TJ, 1997, CURRENT PROTOCOLS HU; Jonasson F, 1996, OPHTHALMOLOGY, V103, P1111, DOI 10.1016/S0161-6420(96)30559-9; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kawakami M, 1997, CANCER RES, V57, P2321; Klinkhammer GP, 1997, MAR CHEM, V56, P1, DOI 10.1016/S0304-4203(96)00079-5; KLINTWORTH GK, 1986, OPHTHALMIC PAED GEN, V7, P139, DOI 10.3109/13816818609004130; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Liu NP, 1998, AM J HUM GENET, V63, P912, DOI 10.1086/302001; Liu NP, 1998, BRIT J OPHTHALMOL, V82, P241, DOI 10.1136/bjo.82.3.241; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; SHIOZAWA T, 1991, GYNECOL OBSTET INVES, V32, P239, DOI 10.1159/000293040; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THONAR EJM, 1986, AM J OPHTHALMOL, V102, P561, DOI 10.1016/0002-9394(86)90525-8; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Vance JM, 1996, AM J HUM GENET, V58, P757; YANG CJ, 1988, AM J OPHTHALMOL, V106, P65, DOI 10.1016/S0002-9394(14)76390-1	25	197	211	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					237	241		10.1038/79987	http://dx.doi.org/10.1038/79987			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017086				2022-12-25	WOS:000089638800027
J	Frangioni, JV; LaRiccia, LM; Cantley, LC; Montminy, MR				Frangioni, JV; LaRiccia, LM; Cantley, LC; Montminy, MR			Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening	NATURE BIOTECHNOLOGY			English	Article						CREB binding protein; p300; transcriptional control; phage display; gene therapy	TRANSCRIPTIONAL ACTIVATION; SECONDARY STRUCTURE; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; FUSION PROTEINS; COACTIVATOR; COMPLEX; CREB; TRANSDUCTION; MODULATION	Human gene therapy approaches involving transcription factors often rely on artificial activation domains for transcriptional activation. These domains are often large (e.g., 80 amino acids for VP16), recruit multiple cc-activation complexes at once, and offer no fine control over the level of transcription. In an attempt to understand the sequence and structural requirements of a minimal mammalian activator, we employed a molecular diversity approach with a peptide phage display library composed of random eight-amino acid peptides. Using the KIX domain of the mammalian co-activators p300 and CBP as target, we discovered a family of synthetic binding peptides. These peptides share significant homology with natural KIX domain ligands, and are shown to bind an overlapping, yet distinct, surface of p300/CREB-binding protein (CBP). When fused to a heterologous DNA binding domain, these synthetic peptides function as titratable, modular, and potent transcriptional activators in living cells through specific recruitment of p300/CBP, with the level of transcriptional activation proportional to the affinity of the synthetic peptide for the KIX domain. Taken together, our data demonstrate that a molecular diversity approach can be used to discover minimal, cc-activator domain-specific synthetic activators, and that transcriptional activation can be modulated as desired at the level of co-activator recruitment.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA	Salk Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Montminy, MR (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056203, GM56203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Bohl D, 1998, CELL BIOL TOXICOL, V14, P83, DOI 10.1023/A:1007480419685; Briesewitz R, 1999, P NATL ACAD SCI USA, V96, P1953, DOI 10.1073/pnas.96.5.1953; Cantley LC, 2000, SOLID-PHASE SYNTHESIS, pXV; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; Kay B. K, 1996, PHAGE DISPLAY PEPTID; Kurtz TW, 1998, HYPERTENSION, V32, P380, DOI 10.1161/01.HYP.32.3.380; Leor J, 1997, CARDIOVASC RES, V35, P431, DOI 10.1016/S0008-6363(97)00159-4; Mapp AK, 2000, P NATL ACAD SCI USA, V97, P3930, DOI 10.1073/pnas.97.8.3930; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1996, MOL CELL BIOL, V16, P694; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Pfeilschifter J, 1999, EUR J PHARMACOL, V375, P237, DOI 10.1016/S0014-2999(99)00361-1; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEIPEL K, 1994, BIOL CHEM H-S, V375, P463, DOI 10.1515/bchm3.1994.375.7.463; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Wang BS, 1999, P NATL ACAD SCI USA, V96, P9568, DOI 10.1073/pnas.96.17.9568	32	42	46	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1080	1085		10.1038/80280	http://dx.doi.org/10.1038/80280			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017047				2022-12-25	WOS:000089744700031
J	Boyd, SD; Tsai, KY; Jacks, T				Boyd, SD; Tsai, KY; Jacks, T			An intact HDM2 RING-finger domain is required for nuclear exclusion of p53	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR P53; UBIQUITIN LIGASE; EXPORT SIGNAL; MDM2; PROTEIN; DEGRADATION; CRM1; INTERNALIZATION; LOCALIZATION; ACTIVATION	The p53 tumour-suppressor protein is negatively regulated by HDM2. Recent reports indicate that the leucine-rich nuclear-export sequence (NES) of HDM2 enables it to shuttle to the cytoplasm, and that this activity is required for degradation of p53. However, it is unclear whether HDM2 is involved in nuclear export of p53, partly because p53 has itself been shown to contain a functional NES within its tetramerization domain. Here we show that co-expression of HDM2 with green fluorescent protein (GFP)-tagged p53 causes redistribution of p53 from the nucleus to the cytoplasm of the cell. This activity is dependent on binding of p53 to HDM2, and requires an intact p53 NES, but is independent of the HDM2 NES. A mutant of the HDM2 RING-finger domain that is unable to ubiquitinate p53 does not cause relocalization of p53, indicating that ubiquitin ligation or other activities of this region of HDM2 may be necessary for its regulation of p53 localization.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute	Jacks, T (corresponding author), MIT, Ctr Canc Res, Dept Biol, Massachusetts Ave, Cambridge, MA 02139 USA.			Tsai, Kenneth/0000-0001-5325-212X				Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	33	278	285	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					563	568		10.1038/35023500	http://dx.doi.org/10.1038/35023500			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980695				2022-12-25	WOS:000089250600006
J	Katsanis, N; Beales, PL; Woods, MO; Lewis, RA; Green, JS; Parfrey, PS; Ansley, SJ; Davidson, WS; Lupski, JR				Katsanis, N; Beales, PL; Woods, MO; Lewis, RA; Green, JS; Parfrey, PS; Ansley, SJ; Davidson, WS; Lupski, JR			Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome	NATURE GENETICS			English	Article							GENETIC-HETEROGENEITY; SYNDROME LOCUS; 5TH LOCUS; IDENTIFICATION; POPULATION	Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder predominantly characterized by obesity, retinal dystrophy, polydactyly, learning difficulties, hypogenitalism and renal malformations, with secondary features that include diabetes mellitus, endocrinological dysfunction and behavioural abnormalities(1,2) Despite an initial expectation of genetic homogeneity due to relative clinical uniformity, five BBS loci have been reported, with evidence for additional loci in the human genome(3-7); however, no genes for BBS have yet been identified. We performed a genome screen with BBS families from Newfoundland that were excluded from BBS1-5 and identified linkage with D205189. Fine-mapping reduced the critical interval to 1.9 cM between D20S851 and D20S189, encompassing a chaperonin-like gene. Mutations in this gene were recently reported to be associated with McKusick-Kaufman syndrome (MKKS; ref. 8). Given both the mapping position and clinical similarities of these two syndromes, we screened MKKS and identified mutations in five Newfoundland and two European-American BBS pedigrees. Most are frameshift alleles that are likely to result in a non-functional protein. Our data suggest that a complete loss of function of the MKKS product, and thus an inability to fold a range of target proteins, is responsible for the clinical manifestations of BBS.	Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX USA; Baylor Coll Med, Dept Med, Houston, TX USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX USA; Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; Mem Univ Newfoundland, Fac Med, St John, NF, Canada; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; UCL, Inst Child Hlth, Mol Med Unit, London, England	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Memorial University Newfoundland; Simon Fraser University; University of London; University College London	Lupski, JR (corresponding author), Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA.	jlupski@bcm.tmc.edu	Beales, Philip L/C-7367-2009; Katsanis, Nicholas/E-1837-2012	Katsanis, Nicholas/0000-0002-2480-0171	NATIONAL EYE INSTITUTE [R01EY012666] Funding Source: NIH RePORTER; NEI NIH HHS [EY12666] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Beales PL, 1999, J MED GENET, V36, P437; BEAR JC, 1988, AM J MED GENET, V29, P649, DOI 10.1002/ajmg.1320290324; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; David A, 1999, J MED GENET, V36, P599; DAVIDSON WS, 2000, BIOTECH FOCUS, V2, P13; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; Scharf B., 1970, FDN MODERN AUDITORY, V1, P157; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Woods MO, 1999, GENOMICS, V55, P2, DOI 10.1006/geno.1998.5626; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	17	238	246	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					67	70		10.1038/79201	http://dx.doi.org/10.1038/79201			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973251				2022-12-25	WOS:000089078000020
J	Guo, W; Tamanoi, F; Novick, P				Guo, W; Tamanoi, F; Novick, P			Spatial regulation of the exocyst complex by Rho1 GTPase	NATURE CELL BIOLOGY			English	Article							CELL-CELL CONTACTS; PROTEIN-KINASE-C; CLASS-V MYOSIN; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; ACTIN CYTOSKELETON; BINDING PROTEIN; POLARIZED SECRETION; VESICULAR TRANSPORT; SEC6/8 COMPLEX	Spatial regulation of membrane traffic is fundamental to many biological processes, including epithelial cell polarization and neuronal synaptogenesis. The multiprotein exocyst complex is localized to sites of polarized exocytosis, and is required for vesicle targeting and docking at specific domains of the plasma membrane. One component of the complex, Sec3, is thought to be a spatial landmark for polarized exocytosis, We have searched for proteins that regulate the polarized localization of the exocyst in the budding yeast Saccharomyces cerevisiae. Here we report that certain rho1 mutant alleles specifically affect the localization of the exocyst proteins. Sec3 interacts directly with Rho1 in its GTP-bound form, and functional Rho1 is needed both to establish and to maintain the polarized localization of Sec3, Sec3 is not the only mediator of the effect of Rho1 on the exocyst, because some members of the complex are correctly targeted independently of the interaction between Rho1 and Sec3. These results reveal the action of parallel pathways for the polarized localization of the exocytic machinery, both of which are under the control of Rho1, a master regulator of cell polarity.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	Yale University; University of California System; University of California Los Angeles	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA.	peter.novick@yale.edu						Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; AYSCOUGH KR, 1999, J CELL BIOL, V146, P1201; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Haarer BK, 1996, GENETICS, V144, P495; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Karpova TS, 2000, MOL BIOL CELL, V11, P1727, DOI 10.1091/mbc.11.5.1727; Kim SK, 2000, NAT CELL BIOL, V2, pE143, DOI 10.1038/35019620; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Reck-Peterson SL, 1999, MOL BIOL CELL, V10, P1001, DOI 10.1091/mbc.10.4.1001; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Roth D, 1998, MOL BIOL CELL, V9, P1725, DOI 10.1091/mbc.9.7.1725; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	46	248	255	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					353	360		10.1038/35070029	http://dx.doi.org/10.1038/35070029			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283608				2022-12-25	WOS:000168043900013
J	Song, JW; Takeda, M; Morimoto, RI				Song, JW; Takeda, M; Morimoto, RI			Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth	NATURE CELL BIOLOGY			English	Article							HSP70 CHAPERONE ACTIVITY; APOPTOTIC PROTEIN BAG-1; HEAT-SHOCK; IN-VIVO; NEGATIVE REGULATOR; DROSOPHILA CELLS; RECEPTOR; KINASE; IDENTIFICATION; ACTIVATION	Survival after stress requires the precise orchestration of cell-signalling events to ensure that biosynthetic processes are alerted and cell survival pathways are initiated. Here we show that Bag1, a co-chaperone for heat-shock protein 70 (Hsp70), coordinates signals for cell growth in response to cell stress, by downregulating the activity of Raf-1 kinase. Raf-1 and Hsp70 compete for binding to Bag1, such that Bag1 binds to and activates Raf-1, subsequently activating the downstream extracellular signal-related kinases (ERKs). When levels of Hsp70 are elevated after heat shock, or in cells conditionally overexpressing Hsp70, Bag1-Raf-1 is displaced by Bag1-Hsp70, and DNA synthesis is arrested. Mutants Bag1C204A and Bag1E208A, which cannot bind Hsp70, constitutively activate Raf-1/ERK kinases but are unaffected by Hsp70; consequently neither Bag1-Raf-1 nor DNA synthesis is negatively affected during heat shock. Likewise, mutants Hsp70F245S, Hsp70R262W and Hsp70L282R, which retain chaperone activity but do not bind to Bag1, fail to repress Bag1 activation of Raf-1/ERK kinase, We propose that Bag1 functions in the heat-shock response to coordinate cell growth signals and mitogenesis, and that Hsp70 functions as a sensor in stress signalling.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.			Song, Jaewhan/0000-0001-8152-9210				ANDERSEN HA, 1970, CR TRAV LAB CARLSB, V38, P123; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MITCHELL HK, 1978, CELL, V15, P907, DOI 10.1016/0092-8674(78)90275-1; MORIMOTO IR, 1994, BIOL HEAT SHOCK PROT; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SPRADLING A, 1977, J MOL BIOL, V109, P559, DOI 10.1016/S0022-2836(77)80091-0; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063	40	219	236	1	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					276	282		10.1038/35060068	http://dx.doi.org/10.1038/35060068			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231577				2022-12-25	WOS:000167365800014
J	van Steensel, B; Delrow, J; Henikoff, S				van Steensel, B; Delrow, J; Henikoff, S			Chromatin profiling using targeted DNA adenine methyltransferase	NATURE GENETICS			English	Letter							GAGA TRANSCRIPTION FACTOR; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; IN-VIVO; SACCHAROMYCES-CEREVISIAE; PROTEINS; HETEROCHROMATIN; PROMOTER; SIR2P	Chromatin is the highly complex structure consisting of DNA and hundreds of associated proteins. Most chromatin proteins exert their regulatory and structural functions by binding to specific chromosomal loci. Knowledge of the identity of these in vivo target loci is essential for the understanding of the functions and mechanisms of action of chromatin proteins. We report here large-scale mapping of in vivo binding sites of chromatin proteins, using a novel approach based on a combination of targeted DNA methylation and microarray technology. We show that three distinct chromatin proteins in Drosophila melanogaster cells each associate with specific sets of genes. HP1 binds predominantly to pericentric genes and transposable elements. GAGA factor associates with euchromatic genes that are enriched in (GA), motifs, A Drosophila homolog of Saccharomyces cerevisiae Sir2p is associated with several active genes and is excluded from heterochromatin. High-resolution, genome-wide maps of target loci of chromatin proteins ('chromatin profiles') provide new insights into chromatin structure and gene regulation.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, DNA Array Facil, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	van Steensel, B (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Kruislaan 403, Amsterdam, Netherlands.			Henikoff, Steven/0000-0002-7621-8685				Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; CARMENA M, 1995, CHROMOSOMA, V103, P676; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; Cockell MM, 2000, GENETICS, V154, P1069; Cuperus G, 2000, EMBO J, V19, P2641, DOI 10.1093/emboj/19.11.2641; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; Guarente L, 2000, GENE DEV, V14, P1021; Henikoff S, 2000, BBA-REV CANCER, V1470, pO1, DOI 10.1016/S0304-419X(99)00034-7; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; OBRIEN T, 1995, GENE DEV, V9, P1098, DOI 10.1101/gad.9.9.1098; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; Wines DR, 1996, CHROMOSOMA, V104, P332, DOI 10.1007/s004120050123	26	241	254	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2001	27	3					304	308		10.1038/85871	http://dx.doi.org/10.1038/85871			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242113				2022-12-25	WOS:000167304200023
J	Furlong, EEM; Profitt, D; Scott, MP				Furlong, EEM; Profitt, D; Scott, MP			Automated sorting of live transgenic embryos	NATURE BIOTECHNOLOGY			English	Article						Drosophila; embryo; development; green fluorescent protein	DROSOPHILA	The vast selection of Drosophila mutants is an extraordinary resource for exploring molecular events underlying development and disease. We have designed and constructed an instrument that automatically separates Drosophila embryos of one genotype from a larger population of embryos, based on a fluorescent protein marker. This instrument can also sort embryos from other species, such as Caenorhabditis elegans. The machine sorts 15 living Drosophila embryos per second with more than 99% accuracy. Sorting living embryos will solve longstanding problems, including (1) the need for large quantities of RNA from homozygous mutant embryos to use in DNA microarray or gene-chip experiments, (2) the need for large amounts of protein extract from homozygous mutant embryos for biochemical studies, for example to determine whether a multiprotein complex forms or localizes correctly in vivo when one component is missing, and (3) the need for rapid genetic screening for gene expression changes in living embryos using a fluorescent protein reporter.	Stanford Univ, Sch Med, Beckman Ctr B300, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr B300, Howard Hughes Med Inst,Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Scott, MP (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B300, Howard Hughes Med Inst,Dept Dev Biol, 279 Campus Dr, Stanford, CA 94305 USA.			Furlong, Eileen/0000-0002-9544-8339				Ashburner M., 1989, DROSOPHILA LAB HDB; Casso D, 1999, MECH DEVELOP, V88, P229, DOI 10.1016/S0925-4773(99)00174-4; CROSLANDTAYLOR PJ, 1953, NATURE, V171, P37, DOI 10.1038/171037b0; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; GOLDSTEIN LSB, 1994, PRACTICAL USES CELL; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; Mendel G., 1865, VORGELEGT SITZUNGEN, P8; REUTER R, 1994, DEVELOPMENT, V120, P1137; Shapiro H. M., 1995, PRACTICAL FLOW CYTOM; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Wood WB, 1988, NEMATODE CAENORHABDI	11	76	81	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					153	156		10.1038/84422	http://dx.doi.org/10.1038/84422			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175730				2022-12-25	WOS:000166754700022
J	Morgan, D; Whitworth, JAG				Morgan, D; Whitworth, JAG			The natural history of HIV-1 infection in Africa	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; TRIMETHOPRIM-SULFAMETHOXAZOLE; RAPID PROGRESSION; UGANDAN ADULTS; COTE-DIVOIRE; SEX WORKERS; SURVIVAL; AIDS; COHORT; SEROCONVERSION		Uganda Virus Res Inst, MRC, Programme AIDS, Entebbe, Uganda	Uganda Virus Research Institute	Morgan, D (corresponding author), Uganda Virus Res Inst, MRC, Programme AIDS, POB 49, Entebbe, Uganda.	mrc@starcom.co.ug						*AIDS INC HIV SURV, 2000, LANCET, V355, P1131; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 1986, Weekly Epidemiological Record, V61, P69; Anzala AO, 2000, J INFECT DIS, V182, P459, DOI 10.1086/315733; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BWAYO JJ, 1995, J ACQ IMMUN DEF SYND, V10, P457, DOI 10.1097/00042560-199512000-00009; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; COLEBUNDERS R, 1991, J INFECT DIS, V164, P450, DOI 10.1093/infdis/164.3.450; French N, 1999, J ACQ IMMUN DEF SYND, V22, P509; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GHIRARDINI A, 1995, AIDS, V9, P1351, DOI 10.1097/00002030-199512000-00008; Hendriks JCM, 1998, AIDS, V12, P1537, DOI 10.1097/00002030-199812000-00017; Koblin BA, 1999, AM J EPIDEMIOL, V150, P1026, DOI 10.1093/oxfordjournals.aje.a009926; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; MANN JM, 1986, LANCET, V2, P707; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Morgan D, 2000, SEX TRANSM INFECT, V76, P193, DOI 10.1136/sti.76.3.193; MORGAN D, 2000, 13 INT AIDS C DURB 9; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; Rogers P A, 1997, Commun Dis Rep CDR Rev, V7, pR93; Touloumi G, 1998, J ACQ IMMUN DEF SYND, V19, P89, DOI 10.1097/00042560-199809010-00014; *UNAIDS, 2000, REP GLOB HIV AIDS EP; van Benthem BHB, 1998, AIDS, V12, P1039, DOI 10.1097/00002030-199809000-00011; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0	31	67	68	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					143	145		10.1038/84564	http://dx.doi.org/10.1038/84564			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175832				2022-12-25	WOS:000166756300016
J	Young, LE; Fernandes, K; McEvoy, TG; Butterwith, SC; Gutierrez, CG; Carolan, C; Broadbent, PJ; Robinson, JJ; Wilmut, I; Sinclair, KD				Young, LE; Fernandes, K; McEvoy, TG; Butterwith, SC; Gutierrez, CG; Carolan, C; Broadbent, PJ; Robinson, JJ; Wilmut, I; Sinclair, KD			Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture	NATURE GENETICS			English	Article							BINDING-PROTEINS; PERINATAL LETHALITY; IN-VITRO; GROWTH; GENE; CATTLE; SERUM	Manipulation or non-physiological embryo culture environments can lead to defective fetal programming in livestock. Our demonstration of reduced fetal methylation and expression of ovine IGF2R suggests pre-implantation embryo procedures may be vulnerable to epigenetic alterations in imprinted genes. This highlights the potential benefits of epigenetic diagnostic screening in developing embryo procedures.	Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Scottish Agr Coll, Aberdeen, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Scottish Agricultural College	Young, LE (corresponding author), Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland.		Gutierrez, Carlos G/H-3192-2013	Gutierrez, Carlos G/0000-0002-6098-3913; Young, Lorraine/0000-0001-5450-5723; Sinclair, Kevin/0000-0002-6375-215X				ARMSTRONG DG, 1989, J ENDOCRINOL, V120, P373, DOI 10.1677/joe.0.1200373; BUTLER JH, 1986, J ENDOCRINOL, V109, P333, DOI 10.1677/joe.0.1090333; Dean W, 1998, DEVELOPMENT, V125, P2273; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Gutierrez CG, 1997, J ENDOCRINOL, V153, P231, DOI 10.1677/joe.0.1530231; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Sinclair KD, 1998, THERIOGENOLOGY, V49, P218, DOI 10.1016/S0093-691X(98)90571-4; Vogt T, 1998, CLIN CANCER RES, V4, P791; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Young LE, 2000, THERIOGENOLOGY, V53, P627, DOI 10.1016/S0093-691X(99)00263-0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155	15	619	658	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					153	154		10.1038/84769	http://dx.doi.org/10.1038/84769			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175780				2022-12-25	WOS:000166839200013
J	Faria, M; Spiller, DG; Dubertret, C; Nelson, JS; White, MRH; Scherman, D; Helene, C; Giovannangeli, C				Faria, M; Spiller, DG; Dubertret, C; Nelson, JS; White, MRH; Scherman, D; Helene, C; Giovannangeli, C			Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo	NATURE BIOTECHNOLOGY			English	Article						antisense oligonucleotides; phosphoramidate; translation initiation; PPT/HIV-I	HUMAN LEUKEMIA-CELLS; MESSENGER-RNA; N3'->P5' PHOSPHORAMIDATE; GENE-EXPRESSION; SKELETAL-MUSCLE; IN-VIVO; ANALOG; TRANSCRIPTION; ELONGATION; DELIVERY	Antisense oligonucleotides are designed to specifically hybridize to a target messenger RNA (mRNA) and interfere with the synthesis of the encoded protein. Uniformly modified oligonucleotides containing N3'-P5' phosphoramidate linkages exhibit (NP) extremely high-affinity binding to single-stranded RNA, do not induce RNase H activity, and are resistant to cellular nucleases. In the present work, we demonstrate that phosphoramidate oligonucleotides are effective at inhibiting gene expression at the mRNA level, by binding to their complementary target present in the 5'-untranslated region. Their mechanism of action was demonstrated by comparative analysis of three expression systems that differ only by the composition of the oligonucleotide target sequence (HIV-1 polypurine tract or PPT sequence) present just upstream from the AUG codon of the firefly luciferase reporter gene: the experiments have been done on isolated cells using oligonucleotide delivery mediated by cationic molecules or streptolysin O (SLO), and in vivo by oligonucleotide electrotransfer to skeletal muscle. In our experimental system phosphoramidate oligonucleotides act as potent and specific antisense agents by steric blocking of translation initiation; they may prove useful to modulate RNA metabolism while maintaining RNA integrity.	Museum Natl Hist Nat, Biophys Lab, INSERM,U201, CNRS,UMR 8646, F-75005 Paris, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 72B, Merseyside, England; PE Biosyst, Foster City, CA USA; ENSCP Aventis, CRVA, CNRS, UMR 7001, F-94403 Vitry Sur Seine, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); University of Liverpool; Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France	Giovannangeli, C (corresponding author), Museum Natl Hist Nat, Biophys Lab, INSERM,U201, CNRS,UMR 8646, 43 Rue Cuvier, F-75005 Paris, France.	giovanna@mnhn.fr	Spiller, David G/I-3645-2012	White, Michael/0000-0002-3617-3232; Scherman, Daniel/0000-0003-1207-1298; Spiller, David Geoffrey/0000-0003-2502-6787				Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Dheur S, 1999, ANTISENSE NUCLEIC A, V9, P515, DOI 10.1089/oli.1.1999.9.515; Dias N, 1999, J MOL BIOL, V294, P403, DOI 10.1006/jmbi.1999.3277; Escude C, 1996, P NATL ACAD SCI USA, V93, P4365, DOI 10.1073/pnas.93.9.4365; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Fearon KL, 1998, NUCLEIC ACIDS RES, V26, P3813, DOI 10.1093/nar/26.16.3813; Flanagan WM, 1999, P NATL ACAD SCI USA, V96, P3513, DOI 10.1073/pnas.96.7.3513; Flanagan WM, 1998, CANCER METAST REV, V17, P169, DOI 10.1023/A:1006098218335; Giles RV, 1997, NUCLEOS NUCLEOT, V16, P1155, DOI 10.1080/07328319708006151; Giles RV, 1999, ANTISENSE NUCLEIC A, V9, P213, DOI 10.1089/oli.1.1999.9.213; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; Giovannangeli C, 2000, CURR OPIN MOL THER, V2, P288; Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508; GRYAZNOV S, 1994, J AM CHEM SOC, V116, P3143, DOI 10.1021/ja00086a062; Hawley P, 1999, ANTISENSE NUCLEIC A, V9, P61, DOI 10.1089/oli.1.1999.9.61; Heidenreich O, 1997, NUCLEIC ACIDS RES, V25, P776, DOI 10.1093/nar/25.4.776; Iyer RP, 1999, CURR OPIN MOL THER, V1, P344; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; McCurdy SN, 1997, TETRAHEDRON LETT, V38, P207, DOI 10.1016/S0040-4039(96)02254-X; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Mir LM, 1998, CR ACAD SCI III-VIE, V321, P893, DOI 10.1016/S0764-4469(99)80003-1; Nelson JS, 1997, J ORG CHEM, V62, P7278, DOI 10.1021/jo970801t; PETRIE CR, 1992, BIOCONJUGATE CHEM, V3, P85, DOI 10.1021/bc00013a014; Schmajuk G, 1999, J BIOL CHEM, V274, P21783, DOI 10.1074/jbc.274.31.21783; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Skorski T, 1997, P NATL ACAD SCI USA, V94, P3966, DOI 10.1073/pnas.94.8.3966; Spiller DG, 1998, ANTISENSE NUCLEIC A, V8, P281, DOI 10.1089/oli.1.1998.8.281; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Testa SM, 1999, P NATL ACAD SCI USA, V96, P2734, DOI 10.1073/pnas.96.6.2734; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	35	84	115	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					40	44		10.1038/83489	http://dx.doi.org/10.1038/83489			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135550				2022-12-25	WOS:000166261400017
J	Kerr, DE; Plaut, K; Bramley, AJ; Williamson, CM; Lax, AJ; Moore, K; Wells, KD; Wall, RJ				Kerr, DE; Plaut, K; Bramley, AJ; Williamson, CM; Lax, AJ; Moore, K; Wells, KD; Wall, RJ			Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						mastitis; animal biotechnology; antibacterial protein; Staphylococcus aureus	SOMATIC-CELL COUNT; HUMAN LYSOZYME; PLASMINOGEN-ACTIVATOR; DAIRY SCIENCE; CHEESE YIELD; MOUSE MILK; MASTITIS; AUREUS; PROTEIN; GENE	Infection of the mammary gland, in addition to causing animal distress, is a major economic burden of the dairy industry. Staphylococcus aureus is the major contagious mastitis pathogen, accounting for approximately 15-30% of infections, and has proved difficult to control using standard management practices. As a first step toward enhancing mastitis resistance of dairy animals, we report the generation of transgenic mice that secrete a potent anti-staphylococcal protein into milk. The protein, lysostaphin, is a peptidoglycan hydrolase normally produced by Staphylococcus simulans. When the native form is secreted by transfected eukaryotic cells it becomes glycosylated and inactive. However, removal of two glycosylation motifs through engineering asparagine to glutamine codon substitutions enables secretion of Gln(125,232)-lysostaphin, a bioactive variant. Three lines of transgenic mice, in which the 5'-flanking region of the ovine beta -lactoglobulin gene directed the secretion of Gln(125,232)-lysostaphin into milk, exhibit substantial resistance to an intramammary challenge of 10(4) colony-forming units (c.f.u.) of S. aureus, with the highest expressing line being completely resistant. Milk protein content and profiles of transgenic and nontransgenic mice are similar. These results clearly demonstrate the potential of genetic engineering to combat the most prevalent disease of dairy cattle.	Univ Vermont, Dept Anim Sci, Burlington, VT 05405 USA; Inst Anim Hlth, Compton Lab, Newbury RG20 7NN, Berks, England; ARS, Gene Evaluat & Mapping Lab, USDA, Beltsville, MD 20705 USA	University of Vermont; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; United States Department of Agriculture (USDA)	Kerr, DE (corresponding author), Univ Vermont, Dept Anim Sci, Burlington, VT 05405 USA.		Williamson, Christine/GSE-3696-2022	Lax, Alistair/0000-0002-1424-5071				AULDIST MJ, 1995, AUST J EXP AGR, V35, P427, DOI 10.1071/EA9950427; Auldist MJ, 1996, J DAIRY RES, V63, P377, DOI 10.1017/S0022029900031903; BARBANO DM, 1991, J DAIRY SCI, V74, P369, DOI 10.3168/jds.S0022-0302(91)78179-4; BRAMLEY AJ, 1984, J DAIRY RES, V51, P481, DOI 10.1017/S0022029900023797; BRAMLEY AJ, 1990, RES VET SCI, V49, P120, DOI 10.1016/S0034-5288(18)31061-0; CHANDLER RL, 1970, J MED MICROBIOL, V3, P273, DOI 10.1099/00222615-3-2-273; CRAVEN N, 1984, J DAIRY RES, V51, P513, DOI 10.1017/S0022029900032830; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; EBERT KM, 1991, BIO-TECHNOL, V9, P835, DOI 10.1038/nbt0991-835; GORDON K, 1987, BIO-TECHNOL, V5, P1183, DOI 10.1038/nbt1187-1183; HARMON RJ, 1975, AM J VET RES, V36, P1001; Klei L, 1998, J DAIRY SCI, V81, P1205, DOI 10.3168/jds.S0022-0302(98)75680-2; Kossaibati MA, 1998, VET REC, V143, P649, DOI 10.1136/vr.143.24.649; KRIMPENFORT P, 1991, BIO-TECHNOL, V9, P844, DOI 10.1038/nbt0991-844; Maga EA, 1998, J FOOD PROTECT, V61, P52, DOI 10.4315/0362-028X-61.1.52; MAGA EA, 1994, TRANSGENIC RES, V3, P36, DOI 10.1007/BF01976025; Maga EA, 1995, J DAIRY SCI, V78, P2645, DOI 10.3168/jds.S0022-0302(95)76894-1; Marais R, 1997, NAT BIOTECHNOL, V15, P1373, DOI 10.1038/nbt1297-1373; Myllys V, 1998, ACTA VET SCAND, V39, P119; OLDHAM ER, 1991, J DAIRY SCI, V74, P4175, DOI 10.3168/jds.S0022-0302(91)78612-8; PLATENBURG GJ, 1994, TRANSGENIC RES, V3, P99, DOI 10.1007/BF01974087; REITER B, 1978, J DAIRY RES, V45, P131, DOI 10.1017/S0022029900016290; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SUTRA L, 1994, J MED MICROBIOL, V40, P79, DOI 10.1099/00222615-40-2-79; TAKAHASHI N, 1992, J DAIRY SCI, V75, P1810, DOI 10.3168/jds.S0022-0302(92)77939-9; VERDI RJ, 1987, J DAIRY SCI, V70, P230, DOI 10.3168/jds.S0022-0302(87)80002-4; WALL RJ, 1992, THERIOGENOLOGY, V38, P337, DOI 10.1016/0093-691X(92)90239-N; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WATSON DL, 1992, RES VET SCI, V53, P346, DOI 10.1016/0034-5288(92)90138-R; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; WILLIAMSON CM, 1994, APPL ENVIRON MICROB, V60, P771, DOI 10.1128/AEM.60.3.771-776.1994; WRIGHT G, 1991, BIO-TECHNOL, V9, P830, DOI 10.1038/nbt0991-830; YANCEY RJ, 1991, EUR J CLIN MICROBIOL, V10, P107, DOI 10.1007/BF01964421; Yarus S, 1996, P NATL ACAD SCI USA, V93, P14118, DOI 10.1073/pnas.93.24.14118	34	105	126	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					66	70		10.1038/83540	http://dx.doi.org/10.1038/83540			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135555				2022-12-25	WOS:000166261400022
J	Marchand, JB; Kaiser, DA; Pollard, TD; Higgs, HN				Marchand, JB; Kaiser, DA; Pollard, TD; Higgs, HN			Interaction of WASP/Scar proteins with actin and vertebrate Arp2/3 complex	NATURE CELL BIOLOGY			English	Article							WISKOTT-ALDRICH-SYNDROME; ACANTHAMOEBA ACTOPHORIN ADF/COFILIN; CIRCULAR-DICHROISM SPECTRA; SECONDARY STRUCTURE; N-WASP; QUANTITATIVE-ANALYSIS; FILAMENT NUCLEATION; PROFILIN; MUTATIONS; MOTILITY	The Wiskott-Aldrich-syndrome protein (WASP) regulates polymerization of actin by the Arp2/3 complex. Here we show, using fluorescence anisotropy assays, that the carboxy-terminal WA domain of WASP binds to a single actin monomer with a K-d of 0.6 muM in an equilibrium with rapid exchange rates. Both WH-2 and CA sequences contribute to actin binding. A favourable DeltaH of -10 kcal mol(-1) drives binding. The WA domain binds to the Arp2/3 complex with a K-d of 0.9 muM; both the C and A sequences contribute to binding to the Arp2/3 complex. Wiskott-Aldrich-syndrome mutations in the WA domain that alter nucleation by the Arp2/3 complex over a tenfold range without affecting affinity for actin or the Arp2/3 complex indicate that there may be an activation step in the nucleation pathway. Actin filaments stimulate nucleation by producing a fivefold increase in the affinity of WASP-WA for the Arp2/3 complex.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Higgs, Henry/0000-0002-2917-9644	NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; FEDOROV AA, 1994, J MOL BIOL, V241, P480, DOI 10.1006/jmbi.1994.1522; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Ochs HD, 1998, SEMIN HEMATOL, V35, P332; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Schwarz K, 1996, IMMUNOL TODAY, V17, P496, DOI 10.1016/0167-5699(96)30061-3; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	42	245	248	1	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					76	82		10.1038/35050590	http://dx.doi.org/10.1038/35050590			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146629				2022-12-25	WOS:000166146400023
J	Napolitano, LA; Grant, RM; Deeks, SG; Schmidt, D; De Rosa, SC; Herzenberg, LA; Herndier, BG; Andersson, J; McCune, JM				Napolitano, LA; Grant, RM; Deeks, SG; Schmidt, D; De Rosa, SC; Herzenberg, LA; Herndier, BG; Andersson, J; McCune, JM			Increased production of IL-7 accompanies HIV-l-mediated T-cell depletion: implications for T-cell homeostasis	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANT; THYMIC FUNCTION; GROWTH-HORMONE; INTERLEUKIN-7; LYMPHOCYTES; VIRUS; MICE; PROLIFERATION; LYMPHOPOIESIS; REPLICATION	We hypothesized that HIV-1-mediated T-cell loss might induce the production of factors that are capable of stimulating lymphocyte development and expansion. Here we perform cross-sectional (n = 168) and longitudinal (n = 11) analyses showing that increased circulating levels of interleukin (IL)-7 are strongly associated with CD4+ T lymphopenia in HIV-1 disease. Using immunohistochemistry with quantitative image analysis, we demonstrate that IL-7 is produced by dendritic-like cells within peripheral lymphoid tissues and that IL-7 production by these cells is greatly increased in lymphocyte-depleted tissues. We propose that IL-7 production increases as part of a homeostatic response to T-cell depletion.	San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94110 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Karolinska Institutet	McCune, JM (corresponding author), San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.	nunccune@gladstone.ucsf.edu		Grant, Robert/0000-0002-0851-7085	NATIONAL CANCER INSTITUTE [U01CA066529, R01CA042059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041536] Funding Source: NIH RePORTER; NCI NIH HHS [CA42059, CA66529] Funding Source: Medline; NIAID NIH HHS [AI01597, AI41536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; BARDAYAN Y, 1994, THYMUS, V23, P95; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; BESCHORNER WE, 1991, TRANSPLANTATION, V52, P879, DOI 10.1097/00007890-199111000-00024; Bjork L, 1996, J LEUKOCYTE BIOL, V59, P287; Bolotin E, 1996, BLOOD, V88, P1887; Bolotin E, 1999, BONE MARROW TRANSPL, V23, P783, DOI 10.1038/sj.bmt.1701655; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; Chene L, 1999, J VIROL, V73, P7533; Di Santo JP, 1999, J EXP MED, V189, P563, DOI 10.1084/jem.189.3.563; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Elbeik T, 2000, J CLIN MICROBIOL, V38, P1113, DOI 10.1128/JCM.38.3.1113-1120.2000; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2986, DOI 10.1002/eji.1830271135; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; GRZEGORZEWSKI KJ, 1995, J EXP MED, V181, P369, DOI 10.1084/jem.181.1.369; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Haynes BF, 1999, J CLIN INVEST, V103, P453, DOI 10.1172/JCI5201; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HICKMAN CJ, 1990, J IMMUNOL, V145, P2415; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kato T, 1998, STEM CELLS, V16, P322, DOI 10.1002/stem.160322; KELLEY KW, 1986, P NATL ACAD SCI USA, V83, P5663, DOI 10.1073/pnas.83.15.5663; Komschlies KL, 1995, J LEUKOCYTE BIOL, V58, P623, DOI 10.1002/jlb.58.6.623; Kroncke R, 1996, EUR J IMMUNOL, V26, P2541, DOI 10.1002/eji.1830261040; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Litton MJ, 1997, AM J PATHOL, V150, P1607; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Mackall C L, 1997, Semin Immunol, V9, P339, DOI 10.1006/smim.1997.0091; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MORRISSEY PJ, 1991, J IMMUNOL, V146, P1547; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; RYAN DH, 1995, LEUKEMIA LYMPHOMA, V17, P375, DOI 10.3109/10428199509056848; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Smithgall MD, 1996, J IMMUNOL, V156, P2324; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Tang JH, 1997, J IMMUNOL, V159, P117; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	46	434	441	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					73	79		10.1038/83381	http://dx.doi.org/10.1038/83381			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135619				2022-12-25	WOS:000166243100038
J	Daubersies, P; Thomas, AW; Millet, P; Brahimi, K; Langermans, JAM; Ollomo, B; Ben Mohamed, L; Slierendregt, B; Eling, W; Van Belkum, A; Dubreuil, G; Meis, JFGM; Guerin-Marchand, C; Cayphas, S; Cohen, J; Gras-Masse, H; Druilhe, P				Daubersies, P; Thomas, AW; Millet, P; Brahimi, K; Langermans, JAM; Ollomo, B; Ben Mohamed, L; Slierendregt, B; Eling, W; Van Belkum, A; Dubreuil, G; Meis, JFGM; Guerin-Marchand, C; Cayphas, S; Cohen, J; Gras-Masse, H; Druilhe, P			Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved preerythrocytic liver-stage antigen 3	NATURE MEDICINE			English	Article							IRRADIATED SPOROZOITES; IMMUNE-RESPONSES; T-HELPER; VACCINE; INDUCTION; PROTEIN; HUMANS; INFECTION; PARASITES; POTENT	In humans, sterile immunity against malaria can be consistently induced through exposure to the bites of thousands of irradiated infected mosquitoes. The same level of protection has yet to be achieved using subunit vaccines. Recent studies have indicated an essential function for intrahepatic parasites, the stage after the mosquito bite, and thus for antigens expressed during this stage. We report here the identification of liver-stage antigen 3, which is expressed both in the mosquito and liver-stage parasites. This Plasmodium falciparum 200-kilodalton protein is highly conserved, and showed promising antigenic and immunogenic properties. In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites.	Inst Pasteur, Unite Parasitol Biomed, F-75015 Paris, France; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Nijmegen, Dept Med Microbiol, Nijmegen, Netherlands; Univ Nijmegen, Dept Med Parasitol, Nijmegen, Netherlands; SmithKline Beecham Biol SA, B-1330 Rixensart, Belgium; Inst Pasteur, Lab Chim Biomol, CNRS, URA 1309, F-59019 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Radboud University Nijmegen; Radboud University Nijmegen; GlaxoSmithKline; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Druilhe, P (corresponding author), Inst Pasteur, Unite Parasitol Biomed, 28 Rue Dr Roux, F-75015 Paris, France.	druilhe@pasteur.fr	Slierendregt, Bas/AAB-4535-2021; Meis, Jacques F/A-9241-2010	Meis, Jacques F/0000-0003-3253-6080				Aidoo M, 2000, INFECT IMMUN, V68, P227, DOI 10.1128/IAI.68.1.227-232.2000; Anders RF, 2000, PARASITOL TODAY, V16, P444, DOI 10.1016/S0169-4758(00)01784-1; [Anonymous], 1997, NEW ENGL J MED, DOI DOI 10.1056/NEJM199701093360202; BARNES DA, 1995, EXP PARASITOL, V81, P79, DOI 10.1006/expr.1995.1095; Benmohamed L, 2000, VACCINE, V18, P2843, DOI 10.1016/S0264-410X(00)00068-2; BenMohamed L, 1997, EUR J IMMUNOL, V27, P1242, DOI 10.1002/eji.1830270528; Bottius E, 1996, J IMMUNOL, V156, P2874; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; DRUILHE P, 1984, AM J TROP MED HYG, V33, P336, DOI 10.4269/ajtmh.1984.33.336; Druilhe P., 1998, MALARIA PARASITE BIO; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; Facer CA, 1997, ADV PARASIT, V39, P1, DOI 10.1016/S0065-308X(08)60044-5; FIDOCK DA, 1994, J IMMUNOL, V153, P190; Gahery-Segard H, 2000, J VIROL, V74, P1694, DOI 10.1128/JVI.74.4.1694-1703.2000; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; KEMP DJ, 1990, ADV PARASIT, V29, P75; Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X; LONDONO JA, 1990, J IMMUNOL, V145, P1557; MARCHAND C, 1990, B WORLD HEALTH ORGAN, V68, P158; MEIS JFGM, 1990, EXP PARASITOL, V70, P1, DOI 10.1016/0014-4894(90)90080-V; MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P; MIYAMOTO MM, 1988, P NATL ACAD SCI USA, V85, P7627, DOI 10.1073/pnas.85.20.7627; MOELANS IIMD, 1992, PARASITOL TODAY, V8, P118, DOI 10.1016/0169-4758(92)90278-A; MURPHY JR, 1989, J CLIN MICROBIOL, V27, P1434, DOI 10.1128/JCM.27.7.1434-1437.1989; NUSSLER AK, 1993, EUR J IMMUNOL, V23, P882, DOI 10.1002/eji.1830230417; PONNUDURAI T, 1989, T ROY SOC TROP MED H, V83, P67, DOI 10.1016/0035-9203(89)90708-6; Roggero MA, 1995, MOL IMMUNOL, V32, P1301, DOI 10.1016/0161-5890(95)00136-0; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662	32	136	151	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1258	1263		10.1038/81366	http://dx.doi.org/10.1038/81366			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062538	Bronze			2022-12-25	WOS:000165114800034
J	Iamtham, S; Day, A				Iamtham, S; Day, A			Removal of antibiotic resistance genes from transgenic tobacco plastids	NATURE BIOTECHNOLOGY			English	Article						glufosinate; GM crops; marker-free; plastid transformation; tobacco	CHLOROPLAST GENOME; SELECTABLE MARKER; HERBICIDE RESISTANCE; HIGHER-PLANTS; TRANSFORMATION; PROTEIN; EXPRESSION; CHLAMYDOMONAS	Removal of antibiotic resistance genes from genetically modified (GM) crops removes the risk of their transfer to the environment or gut microbes. Integration of foreign genes into plastid DNA enhances containment in crops that inherit their plastids maternally. Efficient plastid transformation requires the aadA marker gene, which confers resistance to the antibiotics spectinomycin and streptomycin. We have exploited plastid DNA recombination and cytoplasmic sorting to remove aadA from transplastomic tobacco plants. A 4.9 kbp insert, composed of aadA flanked by bar and uidA genes, was integrated into plastid DNA and selected to remove wild-type plastid genomes. The bar gene confers tolerance to the herbicide glufosinate despite being GC-rich. Excision of aadA and uidA mediated by two 174 bp direct repeats generated aadA-free T-0 transplastomic plants containing the bar gene. Removal of aadA and bar by three 418 bp direct repeats allowed the isolation of marker-free T-2 plants containing a plastid-located uidA reporter gene.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Day, A (corresponding author), Univ Manchester, Sch Biol Sci, 3-614 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anil.day@man.ac.uk		Day, Anil/0000-0001-7835-9572				BIRKY CW, 1983, INT REV CYTOL, P49; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; Frey JE, 1999, NATURE, V398, P115, DOI 10.1038/18139; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Guda C, 2000, PLANT CELL REP, V19, P257, DOI 10.1007/s002990050008; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Khan MS, 1999, NAT BIOTECHNOL, V17, P910, DOI 10.1038/12907; Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; MCBRIDE KE, 1995, BIO-TECHNOL, V13, P362, DOI 10.1038/nbt0495-362; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott SE, 1999, NAT BIOTECHNOL, V17, P390, DOI 10.1038/7952; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; Sidorov VA, 1999, PLANT J, V19, P209, DOI 10.1046/j.1365-313X.1999.00508.x; Sikdar SR, 1998, PLANT CELL REP, V18, P20, DOI 10.1007/s002990050525; Staub JM, 2000, NAT BIOTECHNOL, V18, P333, DOI 10.1038/73796; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; SUGIURA M, 1986, PLANT SCI, V44, P211, DOI 10.1016/0168-9452(86)90093-2; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; WHITE J, 1990, NUCLEIC ACIDS RES, V18, P1062, DOI 10.1093/nar/18.4.1062; YODER JI, 1994, BIO-TECHNOL, V12, P263, DOI 10.1038/nbt0394-263; ZOUBENKO OV, 1994, NUCLEIC ACIDS RES, V22, P3819, DOI 10.1093/nar/22.19.3819; Zubko MK, 1998, PLANT J, V15, P265, DOI 10.1046/j.1365-313X.1998.00195.x	27	166	212	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1172	1176		10.1038/81161	http://dx.doi.org/10.1038/81161			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062436				2022-12-25	WOS:000165176600022
J	Cox, GA; Mahaffey, CL; Nystuen, A; Letts, VA; Frankel, WN				Cox, GA; Mahaffey, CL; Nystuen, A; Letts, VA; Frankel, WN			The mouse fidgetin gene defines a new role for AAA family proteins in mammalian development	NATURE GENETICS			English	Letter							ENCODES; SUBUNIT; ATPASE; DOMAIN	The mouse mutation fidget arose spontaneously in a heterogeneous albino stock(1). This mutant mouse is characterized by a side-to-side head-shaking and circling behaviour, due to reduced or absent semicircular canals(2). Fidget mice also have small eyes, associated with cell-cycle delay and insufficient growth of the retinal neural epithelium(3,4) and lower penetrance skeletal abnormalities, including pelvic girdle dysgenesis, skull bone fusions and polydactyly(2,5). By positional cloning, we found the gene mutated in fidget mice, fidgetin (Fign), which encodes a new member of the 'meiotic'(6) or subfamily-7 (SF7; ref. 7) group of ATPases associated with diverse cellular activities (AAA proteins). We also discovered two closely related mammalian genes. AAA proteins are molecular chaperones that facilitate a variety of functions, including membrane fusion, proteolysis, peroxisome biogenesis. endosome sorting and meiotic spindle formation(8), but functions for the SF7 AAA proteins are largely unknown. Fidgetin is the first mutant AAA protein found in a mammalian developmental mutant, thus defining a new role for these proteins in embryonic development.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Frankel, WN (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.				NIDCD NIH HHS [DC03611] Funding Source: Medline; NINDS NIH HHS [NS32801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032801, R01NS032801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003611] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Beyer A, 1997, PROTEIN SCI, V6, P2043; Brown NL, 1998, DEVELOPMENT, V125, P4821; CARTER TC, 1950, HEREDITY, V4, P373, DOI 10.1038/hdy.1950.29; CLARKMAQUIRE S, 1994, GENETICS, V136, P53; Cox GA, 1998, NEURON, V21, P1327, DOI 10.1016/S0896-6273(00)80652-2; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gruneberg H, 1943, J GENET, V45, P22, DOI 10.1007/BF02982771; GRUNEBERG HANS, 1955, JOUR GENETICS, V53, P515, DOI 10.1007/BF02981671; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Kaufmann MH, 1992, ATLAS MOUSE DEV; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KONYUKHO.BV, 1972, GENETIKA+, V8, P79; KONYUKHOV BV, 1976, DEV BIOL, V54, P13, DOI 10.1016/0012-1606(76)90282-7; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Letts VA, 1997, GENOMICS, V43, P62, DOI 10.1006/geno.1997.4780; Muller JMM, 1999, J BIOL CHEM, V274, P10154, DOI 10.1074/jbc.274.15.10154; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Swaffield JC, 1997, J MOL EVOL, V45, P549, DOI 10.1007/PL00006259; Truslove G. M., 1956, Journal of Genetics, V54, P64, DOI 10.1007/BF02981704; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	21	86	89	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					198	202		10.1038/79923	http://dx.doi.org/10.1038/79923			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017077				2022-12-25	WOS:000089638800018
J	Nienaber, VL; Richardson, PL; Klighofer, V; Bouska, JJ; Giranda, VL; Greer, J				Nienaber, VL; Richardson, PL; Klighofer, V; Bouska, JJ; Giranda, VL; Greer, J			Discovering novel ligands for macromolecules using X-ray crystallographic screening	NATURE BIOTECHNOLOGY			English	Article							DRUG DESIGN; BINDING-SITES; NMR; INHIBITORS; PROTEINS; PROGRESS; SEARCH		Abbott Labs, Dept Biol Struct, Abbott Pk, IL 60064 USA; Abbott Labs, Dept Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories; Abbott Laboratories	Nienaber, VL (corresponding author), Abbott Labs, Dept Biol Struct, Abbott Pk, IL 60064 USA.	vicki.nienaber@abbott.com	ID, IMCACAT/D-5867-2014					Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CAFLISCH A, 1993, J MED CHEM, V36, P2142, DOI 10.1021/jm00067a013; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHENG XH, 1995, J AM CHEM SOC, V117, P8859, DOI 10.1021/ja00139a023; Fejzo J, 1999, CHEM BIOL, V6, P755, DOI 10.1016/S1074-5521(00)80022-8; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; Lin MF, 1997, J ORG CHEM, V62, P8930, DOI 10.1021/jo971183j; Menear K, 1998, CURR MED CHEM, V5, P457; MUCHMORE S, IN PRESS STRUCTURE; Nienaber V, 2000, J BIOL CHEM, V275, P7239, DOI 10.1074/jbc.275.10.7239; Nienaber VL, 2000, STRUCTURE, V8, P553, DOI 10.1016/S0969-2126(00)00136-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRICE SR, 1995, CURR OPIN BIOTECH, V6, P425, DOI 10.1016/0958-1669(95)80072-7; Reuning U, 1998, INT J ONCOL, V13, P893; Salemme FR, 1997, STRUCTURE, V5, P319, DOI 10.1016/S0969-2126(97)00189-5; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sundberg SA, 2000, CURR OPIN BIOTECH, V11, P47, DOI 10.1016/S0958-1669(99)00051-8; Verlinde C., 1997, STRUCTURE BASED DRUG, P365; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424; VERLINDE CLMJ, 1994, STRUCTURE, V2, P577, DOI 10.1016/S0969-2126(00)00060-5; DAYLIGHT CHEM INFORM, V1	25	279	307	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1105	1108		10.1038/80319	http://dx.doi.org/10.1038/80319			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017052				2022-12-25	WOS:000089744700036
J	Ivankovic-Dikic, I; Gronroos, E; Blaukat, A; Barth, BU; Dikic, I				Ivankovic-Dikic, I; Gronroos, E; Blaukat, A; Barth, BU; Dikic, I			Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; JNK SIGNALING PATHWAY; PDGF-BETA-RECEPTORS; TYROSINE PHOSPHORYLATION; PC12 CELLS; NEURONAL DIFFERENTIATION; NEUROBLASTOMA-CELLS; EGF RECEPTOR; TRANSDUCTION	Integration of signalling pathways initiated by receptor tyrosine kinases and integrins is essential for growth-factor-mediated biological responses. Here we show that co-stimulation of growth-factor receptors and integrins activates the focal-adhesion kinase (FAK) family to promote outgrowth of neurites in PC12 and SH-SY5Y cells. Pyk2 and FAK associate with adhesion-based complexes that contain epidermal growth factor (EGF) receptors, through their carboxy- and amino-terminal domains. Expression of the C-terminal domain of Pyk2 or of FAK is sufficient to block neurite outgrowth, but not activation of extracellular-signal-regulated kinase (ERK). Moreover, activation and autophosphorylation of Pyk2/FAK, as well as of effecters of their adhesion-targeting domains, such as paxillin, ave important for propagation of signals that control neurite formation. Thus, Pyk2/FAK have important functions in signal integration proximal to integrin/growth-factor receptor complexes in neurons.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.		Dikic, Ivan/O-4650-2015; Gronroos, Eva/P-6951-2015; Gronroos, Eva/E-9351-2013	Dikic, Ivan/0000-0001-8156-9511; Gronroos, Eva/0000-0001-8303-5409				Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fagerstrom S, 1998, J BIOL CHEM, V273, P2336, DOI 10.1074/jbc.273.4.2336; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FUJII DK, 1982, J NEUROSCI, V2, P1157; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	50	181	186	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					574	581		10.1038/35023515	http://dx.doi.org/10.1038/35023515			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980697				2022-12-25	WOS:000089250600008
J	Kelley, MJ; Jawien, W; Ortel, TL; Korczak, JF				Kelley, MJ; Jawien, W; Ortel, TL; Korczak, JF			Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly	NATURE GENETICS			English	Article							DIFFERENTIAL LOCALIZATION; ISOFORMS; GENE; PLATELETS; SEQUENCE; BLOOD; CELLS	May-Hegglin anomaly(1,2) (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia. giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal(3-7). suggesting a defect in megakaryocyte fragmentations(5). The disorder has been linked to chromosome 22q12-13. Here we screen a candidate gene in this region, encoding nonmuscle myosin heavy chain A (MYH9). for mutations in ten families. In each family, we identified one of three sequence variants within either the alpha-helical coiled coil or the tailpiece domain that co-segregated with disease status. The E1841K mutation was found in 5 families and occurs at a conserved site in the rod domain. This mutation was not found in 40 normal individuals. Four families had a nonsense mutation that resulted in truncation of most of the tailpiece. One family had a T1155I mutation present in an affected mother and daughter, but not in the mother's parents, thus representing a new mutation. Among the 30 affected individuals. 21 unaffected individuals and 13 spouses in the 10 families, there was correlation of a variant of MYH9 with the presence of MHA. The identification of MYH9 as the disease gene for MHA establishes the pathogenesis of the disorder, should provide further insight into the processes of normal platelet formation and may facilitate identification of the genetic basis of related disorders.	Duke Univ, Dept Med, Durham, NC 27706 USA; Portsmouth Naval Hosp, Portsmouth, VA USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Duke University; Georgetown University	Kelley, MJ (corresponding author), Duke Univ, Dept Med, Durham, NC 27706 USA.	kelleym@duke.edu	Kelley, Michael/AAC-8939-2019	Kelley, Michael/0000-0001-9523-6080	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066192] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CIULLA TA, 1988, ANAL BIOCHEM, V174, P485, DOI 10.1016/0003-2697(88)90047-4; COLLER BS, 1981, BLOOD, V58, P279; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; Cripps RM, 1999, EMBO J, V18, P1793, DOI 10.1093/emboj/18.7.1793; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; GODWIN HA, 1974, BRIT J HAEMATOL, V26, P117, DOI 10.1111/j.1365-2141.1974.tb00455.x; HAMILTON RW, 1980, AM J CLIN PATHOL, V74, P663; HEGGLIN R, 1945, Helv Med Acta, V12, P439; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kelley MJ, 2000, HUM GENET, V106, P557, DOI 10.1007/s004390050025; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kolega J, 1998, J CELL SCI, V111, P2085; Kunishima S, 1999, HUM GENET, V105, P379, DOI 10.1007/s004390051119; LUSHER JM, 1968, BLOOD, V32, P950, DOI 10.1182/blood.V32.6.950.950; Martignetti JA, 2000, AM J HUM GENET, V66, P1449, DOI 10.1086/302873; MAUPIN P, 1994, J CELL SCI, V107, P3077; May R, 1909, DTSCH ARCH KLIN MED, V96, P1; MCLAUGHLIN ML, 1982, HUM COMMUN RES, V8, P299, DOI 10.1111/j.1468-2958.1982.tb00669.x; Moores SL, 1998, MOL CELL, V1, P1043, DOI 10.1016/S1097-2765(00)80104-5; Noris P, 1998, AM J MED, V104, P355, DOI 10.1016/S0002-9343(98)00062-X; Redowicz MJ, 1999, J MUSCLE RES CELL M, V20, P241, DOI 10.1023/A:1005403725521; RICCI G, 1985, THROMB HAEMOSTASIS, V54, P862; Weiss A, 1999, J MOL BIOL, V290, P61, DOI 10.1006/jmbi.1999.2865; Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506; 2000, NATURE GENET, V26, P105	27	184	194	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					106	108		10.1038/79069	http://dx.doi.org/10.1038/79069			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973260				2022-12-25	WOS:000089078000029
J	Reilly, KM; Loisel, DA; Bronson, RT; McLaughlin, ME; Jacks, T				Reilly, KM; Loisel, DA; Bronson, RT; McLaughlin, ME; Jacks, T			Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects	NATURE GENETICS			English	Article							NF1 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-1; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MOLECULAR ANALYSIS; TRANSGENIC MICE; P53 MUTATIONS; BRAIN-TUMORS; PROGRESSION; PATHWAYS; CELLS	Astrocytomas are the leading cause of brain cancer in humans. Because these tumours are highly infiltrative, current treatments that rely on targeting the tumour mass are often ineffective. A mouse model for astrocytoma would be a powerful tool for dissecting tumour progression and testing therapeutics. Mouse models of astrocytoma have been designed to express oncogenic proteins in astrocytes, but have had limited success due to low tumour penetrance or limited tumour progression(1-3). We present here a mouse model of astrocytomas involving mutation of two tumour-suppressor genes, Nf1 and Trp53. Humans with mutations in NF1 develop neurofibromatosis type I (NF1) and have increased risk of optic gliomas, astrocytomas and glioblastomas(4,5). The TP53 tumour suppressor is often mutated in a subset of astrocytomas that develop at a young age and progress slowly to glioblastoma (termed secondary glioblastomas, in contrast to primary glioblastomas that develop rapidly de novo(6-10)). This mouse model shows a range of astrocytoma stages, from low-grade astrocytoma to glioblastoma multiforme, and may accurately model human secondary glioblastoma involving TP53 loss. This is the first reported mouse model of astrocytoma initiated by loss of tumour suppressors, rather than overexpression of transgenic oncogenes.	MIT, Dept Biol, Cambridge, England; MIT, Ctr Canc Res, Cambridge, England; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; MIT, Howard Hughes Med Inst, Cambridge, MA USA	Tufts University; Tufts University; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Dept Biol, Cambridge, England.		Reilly, Karlyne/V-4475-2019; Loisel, Dagan/A-6671-2010	Reilly, Karlyne/0000-0001-9109-4409; 				Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DANKS RA, 1995, CANCER RES, V55, P4302; EASTGATE AR, 1993, J ANAL ATOM SPECTROM, V8, P305, DOI 10.1039/ja9930800305; GOULD VE, 1986, HUM PATHOL, V17, P979, DOI 10.1016/S0046-8177(86)80080-6; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huson SHR, 1994, NEUROFIBROMATOSES PA; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kleihues P., 1997, PATHOLOGY GENETICS T; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARSDEN HB, 1983, INT J CANCER, V31, P439, DOI 10.1002/ijc.2910310408; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; RASHEED BKA, 1994, CANCER RES, V54, P1324; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Scherer HJ, 1940, BRAIN, V63, P1, DOI 10.1093/brain/63.1.1; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; TISCHLER AS, 1995, ENDOCR PATHOL, V6, P323, DOI 10.1007/BF02738732; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168	27	267	278	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					109	113		10.1038/79075	http://dx.doi.org/10.1038/79075			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973261				2022-12-25	WOS:000089078000030
J	Schaner, P; Richards, N; Wadhwa, A; Aksentijevich, I; Kastner, D; Tucker, P; Gumucio, D				Schaner, P; Richards, N; Wadhwa, A; Aksentijevich, I; Kastner, D; Tucker, P; Gumucio, D			Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states	NATURE GENETICS			English	Letter							FAMILIAL MEDITERRANEAN-FEVER; GENE; MEFV; SUBSTITUTION; INHERITANCE; FREQUENCY; SELECTION	Familiar Mediterranean fever (FMF; MIM 249100) is an autosomal recessive disease characterized by recurrent attacks of fever with synovial, pleural or peritoneal inflammation(1). The disease is caused by mutations in the gene encoding the pyrin protein(2-4), Human population studies have revealed extremely high allele frequencies for several different pyrin mutations, leading to the conclusion that the mutant alleles confer a selective advantage(5-7). Here we examine the ret finger protein (rfp) domain (which contains most of the disease-causing mutations) of pyrin during primate evolution. Amino acids that cause human disease are often present as wild type in other species. This is true at positions 653 (a novel mutation), 680, 681. 726. 744 and 761, For several of these human mutations, the mutant represents the reappearance of an ancestral amino acid state. Examination of lineage-specific d(N)/d(S) ratios revealed a pattern consistent with the signature of episodic positive selection, Our data, together with previous human population studies, indicate that selective pressures may have caused functional evolution of pyrin in humans and other primates.	Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Cellular & Mol Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; NIAMSD, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Gumucio, D (corresponding author), Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.	dgumucio@umich.edu	Aksentijevich, Ivona/AAF-1335-2019		NICHD NIH HHS [T32-HD07505] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041083] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akar E, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<71::AID-HUMU8>3.0.CO;2-3; Aksentijevich I, 1999, AM J HUM GENET, V64, P949, DOI 10.1086/302327; Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1998, HUM MOL GENET, V7, P1317, DOI 10.1093/hmg/7.8.1317; Bernot A, 1997, NAT GENET, V17, P25; Booth DR, 2000, QJM-INT J MED, V93, P217, DOI 10.1093/qjmed/93.4.217; Booth DR, 1998, QJM-INT J MED, V91, P603, DOI 10.1093/qjmed/91.9.603; Cazeneuve C, 1999, AM J HUM GENET, V65, P88, DOI 10.1086/302459; Chae JJ, 2000, MAMM GENOME, V11, P428, DOI 10.1007/s003350010082; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Kastner DL, 1998, HOSP PRACT, V33, P131, DOI 10.3810/hp.1998.04.90; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; Stewart CB, 1998, CURR BIOL, V8, pR582, DOI 10.1016/S0960-9822(07)00367-3; Stoffman N, 2000, EUR J HUM GENET, V8, P307, DOI 10.1038/sj.ejhg.5200446; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; Tunca M, 1999, LANCET, V353, P1415, DOI 10.1016/S0140-6736(99)00990-3; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2000, MOL BIOL EVOL, V17, P1446, DOI 10.1093/oxfordjournals.molbev.a026245; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957; YANG ZH, 1999, PAML PHYLOGENETIC AN; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	24	95	97	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					318	321		10.1038/85893	http://dx.doi.org/10.1038/85893			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242116				2022-12-25	WOS:000167304200026
J	Connell, P; Ballinger, CA; Jiang, JH; Wu, YX; Thompson, LJ; Hohfeld, J; Patterson, C				Connell, P; Ballinger, CA; Jiang, JH; Wu, YX; Thompson, LJ; Hohfeld, J; Patterson, C			The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins	NATURE CELL BIOLOGY			English	Article							GLUCOCORTICOID RECEPTOR; MOLECULAR CHAPERONES; HSP90; BINDING; GELDANAMYCIN; DEGRADATION; MACHINERY	To maintain quality control in cells, mechanisms distinguish among improperly folded peptides, mature and functional proteins, and proteins to be targeted for degradation. The molecular chaperones, including heat-shock protein Hsp90, have the ability to recognize misfolded proteins and assist in their conversion to a functional conformation. Disruption of Hsp90 heterocomplexes by the Hsp90 inhibitor geldanamycin leads to substrate degradation through the ubiquitin-proteasome pathway(1-3), implicating this system in protein triage decisions. We previously identified CHIP (carboxyl terminus of Hsc70-interacting protein) to be an interaction partner of Hsc70 (ref. 4). CHIP also interacts directly with a tetratricopeptide repeat acceptor site of Hsp90, incorporating into Hsp90 heterocomplexes and eliciting release of the regulatory cofactor p23. Here we show that CHIP abolishes the steroid-binding activity and transactivation potential of the glucocorticoid receptor, a well-characterized Hsp90 substrate(5), even though it has little effect on its synthesis. Instead, CHIP induces ubiquitylation of the glucocorticoid receptor and degradation through the proteasome. By remodelling Hsp90 heterocomplexes to favour substrate degradation, CHIP modulates protein triage decisions that regulate the balance between protein folding and degradation for chaperone substrates.	Univ N Carolina, Program Mol Cardiol, Chapel Hill, NC 27514 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77550 USA; Max Planck Inst Biochem, Dept Mol Cell Biol, Martinsried, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Medical Branch Galveston; Max Planck Society	Patterson, C (corresponding author), Univ N Carolina, Program Mol Cardiol, Chapel Hill, NC 27514 USA.							Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; MEACHAM G, IN PRESS NATURE CELL; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497	24	782	811	0	41	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					93	96		10.1038/35050618	http://dx.doi.org/10.1038/35050618			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146632				2022-12-25	WOS:000166146400026
J	Mavrogiannis, LA; Antonopoulou, I; Baxova, A; Kutilek, S; Kim, CA; Sugayama, SM; Salamanca, A; Wall, SA; Morriss-Kay, GM; Wilkie, AOM				Mavrogiannis, LA; Antonopoulou, I; Baxova, A; Kutilek, S; Kim, CA; Sugayama, SM; Salamanca, A; Wall, SA; Morriss-Kay, GM; Wilkie, AOM			Haploinsufficiency of the human homeobox gene ALX4 causes skull ossification defects	NATURE GENETICS			English	Article							FORAMINA PARIETALIA PERMAGNA; MULTIPLE EXOSTOSES; FAMILY; CLONING	Inherited defects of skull ossification often manifest as symmetric parietal foramina (PFM; MIM 168500). We previously identified mutations of MSX2 in non-syndromic PFM and demonstrated genetic heterogeneity(1). Deletions of 11p11-p12 (proximal 11p deletion syndrome, P11pDS; MIM 601224; ref. 2) are characterized by multiple exostoses, attributable to haploinsufficiency of EXT2 (refs. 3,4) and PFM. Here we identify ALX4, which encodes a paired-related homeodomain transcription factor, as the PFM disease gene in P11pDS.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Univ Oxford, Dept Human Anat & Genet, Oxford, England; Charles Univ, Fac Med 1, Dept Paediat, Prague, Czech Republic; Charles Univ, Fac Med 1, Dept Med Genet, Prague, Czech Republic; Univ Sao Paulo, Fac Med, Hosp Clin, Inst Crianca, Sao Paulo, Brazil; Univ Granada, Hosp Clin S Cecilio, Dept Obstet & Ginecol, Granada, Spain; Radcliffe Infirm, Craniofacial Unit, Oxford OX2 6HE, England; Dept Clin Genet, Oxford, England	University of Oxford; University of Oxford; Charles University Prague; Charles University Prague; Universidade de Sao Paulo; University of Granada; Radcliffe Infirmary	Wilkie, AOM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.		Baxova, Alice/L-7197-2017; Wilkie, Andrew/AAC-3820-2020	Baxova, Alice/0000-0002-0651-0410; Wilkie, Andrew/0000-0002-2972-5481; Mavrogiannis, Lampros/0000-0002-2869-2067; Kim, Chong/0000-0002-1754-1300				Bartsch O, 1996, AM J HUM GENET, V58, P734; Hudson R, 1998, DEV DYNAM, V213, P159, DOI 10.1002/(SICI)1097-0177(199810)213:2<159::AID-AJA1>3.0.CO;2-F; Iseki S, 1999, DEVELOPMENT, V126, P5611; Kutilek S, 1997, J PAEDIATR CHILD H, V33, P168, DOI 10.1111/j.1440-1754.1997.tb01023.x; MCGAUGHRAN JM, 1995, J MED GENET, V32, P823, DOI 10.1136/jmg.32.10.823; Qu SM, 1997, DEVELOPMENT, V124, P3999; Qu SM, 1997, GENE, V203, P217, DOI 10.1016/S0378-1119(97)00497-6; Qu SM, 1998, DEVELOPMENT, V125, P2711; SALAMANCA A, 1994, PRENATAL DIAG, V14, P766, DOI 10.1002/pd.1970140820; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Takahashi M, 1998, DEVELOPMENT, V125, P4417; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Wu YQ, 2000, AM J HUM GENET, V67, P1327; Wuyts W, 1999, EUR J HUM GENET, V7, P579, DOI 10.1038/sj.ejhg.5200339; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547	15	103	108	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					17	18		10.1038/83703	http://dx.doi.org/10.1038/83703			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137991				2022-12-25	WOS:000166187900008
J	Nicole, O; Docagne, F; Ali, C; Margaill, I; Carmeliet, P; MacKenzie, ET; Vivien, D; Buisson, A				Nicole, O; Docagne, F; Ali, C; Margaill, I; Carmeliet, P; MacKenzie, ET; Vivien, D; Buisson, A			The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling	NATURE MEDICINE			English	Article							GROWTH; INJURY	Tissue-plasminogen activator (t-PA) is now available for the treatment of thrombo-embolic stroke but adverse effects have been reported in some patients, particularly hemorrhaging. In contrast, the results of animal studies have indicated that t-PA could increase neuronal damage after focal cerebral ischemia. Here we report for the first time that t-PA potentiates signaling mediated by glutamatergic receptors by modifying the properties of the N-methyl-D-aspartate (NMDA) receptor. When depolarized, cortical neurons release bio-active t-PA that interacts with and cleaves the NR1 subunit of the NMDA receptor. Moreover, the treatment with recombinant t-PA leads to a 37% increase in NMDA-stimulated fura-2 fluorescence, which may reflect an increased NMDA-receptor function. These results were confirmed in vivo by the intrastriatal injection of recombinant-PA, which potentiated the excitotoxic lesions induced by NMDA. These data provide insight into the regulation of NMDA-receptor-mediated signaling and could initiate therapeutic strategies to improve the efficacy of t-PA treatment in man.	Univ Caen, CNRS, UMR 6551, F-14074 Caen, France; CEA Univ LRA10V, UPRES EA 2609, F-14074 Caen, France; Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol, F-75006 Paris, France; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; CEA; UDICE-French Research Universities; Universite Paris Cite	Buisson, A (corresponding author), Univ Caen, CNRS, UMR 6551, Bd H Becquerel,Cyeron BP 5229, F-14074 Caen, France.	d.vivien@neuro.unicaen.fr; a.buisson@neuro.unicaen.fr	buisson, alain/AAI-8218-2020; Nicole, Olivier/AAZ-2865-2020; Margaill, Isabelle/ABA-4362-2020; Mackenzie, Eric Thomson/L-1938-2015; Docagne, Fabian/S-8308-2018; Carmeliet, Peter/AAQ-5140-2020	buisson, alain/0000-0002-4281-7911; Nicole, Olivier/0000-0001-9981-1820; Margaill, Isabelle/0000-0002-7941-6644; Carmeliet, Peter/0000-0001-7961-1821; Ali, Carine/0000-0001-8007-7910; MacKenzie, Eric T/0000-0003-1057-7033; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185				Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; CAMRELIET P, 1997, AM J PHYSIOL, V273, pH2091; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Kim YH, 1999, SCIENCE, V284, P647, DOI 10.1126/science.284.5414.647; Kirkegaard T, 1999, EUR J BIOCHEM, V263, P577, DOI 10.1046/j.1432-1327.1999.00545.x; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; Paxinos G., 2004, J CHEM INF MODEL, V5th; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Rose K, 1993, IN VITRO BIOL METHOD, P46; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Sattler R, 1998, J NEUROCHEM, V71, P2349; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Verderio C, 1999, J NEUROSCI, V19, P6723, DOI 10.1523/JNEUROSCI.19-16-06723.1999; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228	27	577	608	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					59	64		10.1038/83358	http://dx.doi.org/10.1038/83358			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135617				2022-12-25	WOS:000166243100036
J	Petronczki, M; Knoblich, JA				Petronczki, M; Knoblich, JA			DmPAR-6 directs epithelial polarity and asymmetric cell division of neuroblasts in Drosophila	NATURE CELL BIOLOGY			English	Article							C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; PROTEIN; LOCALIZATION; BAZOOKA; PAR-3; EXPRESSION; MECHANISMS; ARMADILLO; PROSPERO	The Drosophila protein Bazooka is required for both apical-basal polarity in epithelial cells and directing asymmetric cell division in neuroblasts. Here we show that the PDZ-domain protein DmPAR-6 cooperates with Bazooka for both of these functions. DmPAR-6 colocalizes with Bazooka at the apical cell cortex of epithelial cells and neuroblasts, and binds to Bazooka in vitro. DmPAR-6 localization requires Bazooka, and mislocalization of Bazooka through overexpression redirects DmPAR-6 to ectopic sites of the cell cortex. In the absence of DmPAR-6, Bazooka fails to localize apically in neuroblasts and epithelial cells, and is distributed in the cytoplasm instead. Epithelial cells lose their apical-basal polarity in DmPAR-6 mutants, asymmetric cell divisions in neuroblasts are misorientated, and the proteins Numb and Miranda do not segregate correctly into the basal daughter cell, Bazooka and DmPAR-6 are Drosophila homologues of proteins that direct asymmetric cell division in early Caenorhabditis elegans embryos, and our results indicate that homologous protein machineries may direct this process in worms and flies.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Knoblich, JA (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	knoblich@nt.imp.univie.ac.at	Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404				Boyd L, 1996, DEVELOPMENT, V122, P3075; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHOU TB, 1992, GENETICS, V131, P643; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Hung TJ, 1999, DEVELOPMENT, V126, P127; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; Muller HAJ, 2000, DEV DYNAM, V218, P52; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	39	313	319	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					43	49		10.1038/35050550	http://dx.doi.org/10.1038/35050550			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146625				2022-12-25	WOS:000166146400019
J	Young, DB				Young, DB			A post-genomic perspective	NATURE MEDICINE			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; MICROARRAY	The complete genome sequence of Mycobacterium tuberculosis, along with novel genetic tools, provides the foundation for a new era of post-genomic research. The challenge is now to translate these opportunities into an improved understanding of the complex biology of tuberculosis infection.	Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England	Imperial College London	Young, DB (corresponding author), Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England.							Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Brosch R, 2000, RES MICROBIOL, V151, P135, DOI 10.1016/S0923-2508(00)00117-0; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dillon DC, 1999, INFECT IMMUN, V67, P2941, DOI 10.1128/IAI.67.6.2941-2950.1999; Duncan K, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P297; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Hatfull GF, 2000, MOL GENETICS MYCOBAC; Ho TBL, 2000, YEAST, V17, P272, DOI 10.1002/1097-0061(200012)17:4&lt;272::AID-YEA48&gt;3.0.CO;2-2; Jungblut PR, 1999, MOL MICROBIOL, V33, P1103, DOI 10.1046/j.1365-2958.1999.01549.x; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Musser JM, 2000, GENETICS, V155, P7; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; REES RJ, 1961, BRIT J EXP PATHOL, V42, P83; Rich A., 1951, PATHOGENESIS TUBERCU, V2nd; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; WALLACE JG, 1961, AM REV RESPIR DIS, V83, P866; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	21	15	16	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					11	13		10.1038/83250	http://dx.doi.org/10.1038/83250			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135599				2022-12-25	WOS:000166243100016
J	Pishvaee, B; Costaguta, G; Yeung, BG; Ryazantsev, S; Greener, T; Greene, LE; Eisenberg, E; McCaffery, JM; Payne, GS				Pishvaee, B; Costaguta, G; Yeung, BG; Ryazantsev, S; Greener, T; Greene, LE; Eisenberg, E; McCaffery, JM; Payne, GS			A yeast DNA J protein required for uncoating of clathrin-coated vesicles in vivo	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE DELETION; DOMAIN; AUXILIN; HSC70; ENDOCYTOSIS; RECRUITMENT; COMPARTMENT; CHAPERONE; APPENDAGE	Clathrin-coated vesicles mediate diverse processes such as nutrient uptake, downregulation of hormone receptors, formation of synaptic vesicles, virus entry, and transport of biosynthetic proteins to lysosomes. Cycles of coat assembly and disassembly are integral features of clathrin-mediated vesicular transport (Fig. la). Coat assembly involves recruitment of clathrin triskelia, adaptor complexes and other factors that influence coat assembly, cargo sequestration, membrane invagination and scission(1-3) (Fig. 1a). Coat disassembly is thought to be essential for fusion of vesicles with target membranes and for recycling components of clathrin coats to the cytoplasm for further rounds of vesicle formation. In vitro, cytosolic heat-shock protein 70 (Hsp70) and the J-domain co-chaperone auxilin catalyse coat disassembly(4). However, a specific function of these factors in uncoating in vivo has not been demonstrated, leaving the physiological mechanism and significance of uncoating unclear. Here we report the identification and characterization of a Saccharomyces cerevisiae J-domain protein, Aux1. Inactivation of Aux1 results in accumulation of clathrin-coated vesicles, impaired cargo delivery, and an increased ratio of vesicle-associated to cytoplasmic clathrin. Our results demonstrate an in vivo uncoating function of a J domain cc-chaperone and establish the physiological significance of uncoating in transport mediated by clathrin-coated vesicles.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90024 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Biol, Integrated Imaging Ctr, Baltimore, MD 21218 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University	Pishvaee, B (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90024 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000516, Z01HL000516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039040] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM39040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; HONING S, 1994, J CELL SCI, V107, P1185; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Pishvaee B, 1997, EMBO J, V16, P2227, DOI 10.1093/emboj/16.9.2227; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; RYAZANTSEV S, 1990, EUR J BIOCHEM, V190, P393, DOI 10.1111/j.1432-1033.1990.tb15588.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Vowels JJ, 1998, MOL BIOL CELL, V9, P1351, DOI 10.1091/mbc.9.6.1351; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643	32	82	86	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					958	963		10.1038/35046619	http://dx.doi.org/10.1038/35046619			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146663				2022-12-25	WOS:000165814500021
J	Shemer, R; Hershko, AY; Perk, J; Mostoslavsky, R; Tsuberi, B; Cedar, H; Buiting, K; Razin, A				Shemer, R; Hershko, AY; Perk, J; Mostoslavsky, R; Tsuberi, B; Cedar, H; Buiting, K; Razin, A			The imprinting box of the Prader-Willi/Angelman syndrome domain	NATURE GENETICS			English	Article							IGF2R GENE; SNRPN GENE; METHYLATION; ANTISENSE; MUTATION; PATTERN; WILLI	A subset of mammalian genes is monoallelically expressed in a parent-of-origin manner. These genes are subject to an imprinting process that epigenetically marks alleles according to their parental origin during gametogenesis. Imprinted genes can be organized in clusters as exemplified by the 2-Mb domain on human chromosome 15q11-q13 and its mouse orthologue on chromosome 7c (ref. 1). Loss of this 2-Mb domain on the paternal or maternal allele results in two neurogenetic disorders, Prader-Willi syndrome (PWS) or Angelman syndrome (AS), respectively. Microdeletions on the paternal allele share a 4.3-kb short region of overlap (SRO), which includes the SNRPN promoter/exon1. cause PWS and silence paternally expressed genes(2). Microdeletions on the maternal allele share a 0.88-kb SRO located 35 kb upstream to the SNRPN promoter(3), cause AS and alleviate repression of genes on the maternal allele(4). Individuals carrying both AS and PWS deletions on the paternal allele show a PWS phenotype and genotype. These observations suggest that cis elements within the AS-SRO and PWS-SRO constitute an imprinting box that regulates the entire domain on both chromosomes. Here we show that a minitransgene composed of a 200-bp Snrpn promoter/exon1 and a 1-kb sequence located approximately 35 kb upstream to the SNRPN promoter confer imprinting as judged by differential methylation, parent-of-origin-specific transcription and asynchronous replication.	Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91010 Jerusalem, Israel; Univ Clin, Inst Human Genet, Essen, Germany	Hebrew University of Jerusalem; University of Duisburg Essen	Razin, A (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91010 Jerusalem, Israel.							Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Blaydes SM, 1999, MAMM GENOME, V10, P549, DOI 10.1007/s003359901042; Buiting K, 1999, HUM GENET, V105, P665, DOI 10.1007/s004390051160; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; Ohta T, 1999, AM J HUM GENET, V64, P385, DOI 10.1086/302232; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	12	86	87	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					440	443		10.1038/82571	http://dx.doi.org/10.1038/82571			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101841				2022-12-25	WOS:000165671700016
J	Wade-Martins, R; White, RE; Kimura, H; Cook, PR; James, MR				Wade-Martins, R; White, RE; Kimura, H; Cook, PR; James, MR			Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene	NATURE BIOTECHNOLOGY			English	Article							EPSTEIN-BARR-VIRUS; MAMMALIAN-CELLS; REPLICATING VECTORS; DNA; EXPRESSION; IDENTIFICATION; MAINTENANCE; CHROMOSOME; DOSAGE; LOCUS		Univ Oxford, Wellcome Trust Human Genet, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Wade-Martins, R (corresponding author), Univ Oxford, Wellcome Trust Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.		Kimura, Hiroshi/B-9524-2015	Kimura, Hiroshi/0000-0003-0854-083X; Cook, Peter/0000-0002-6639-188X; White, Robert/0000-0002-5115-2173; Wade-Martins, Richard/0000-0001-6691-580X				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BANERJEE S, 1995, NAT MED, V1, P1303, DOI 10.1038/nm1295-1303; Calos MP, 1996, TRENDS GENET, V12, P463, DOI 10.1016/0168-9525(96)40049-X; CASKEY CT, 1979, CELL, V16, P1, DOI 10.1016/0092-8674(79)90182-X; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Manson AL, 1997, EMBO J, V16, P4238, DOI 10.1093/emboj/16.14.4238; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Simpson K, 1996, MOL CELL BIOL, V16, P5117; Wade-Martins R, 1999, NUCLEIC ACIDS RES, V27, P1674, DOI 10.1093/nar/27.7.1674; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wohlgemuth JG, 1996, GENE THER, V3, P503; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XW, 1999, NAT GENET, V22, P327, DOI 10.1038/11896; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YEE JK, 1987, GENE, V53, P97, DOI 10.1016/0378-1119(87)90096-5	24	70	70	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1311	1314		10.1038/82444	http://dx.doi.org/10.1038/82444			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101814				2022-12-25	WOS:000165659000032
J	Tsai, SC; Valkov, N; Yang, WM; Gump, J; Sullivan, D; Seto, E				Tsai, SC; Valkov, N; Yang, WM; Gump, J; Sullivan, D; Seto, E			Histone deacetylase interacts directly with DNA topoisomerase II	NATURE GENETICS			English	Article							TRANSCRIPTIONAL REPRESSION; ALPHA; BETA; GENE; PHOSPHORYLATION; PROLIFERATION; ACETYLATION; COMPLEX; INVIVO	Histone deacetylases (HDACs) modify nucleosomal histones, have a key role in the regulation of gene transcription(1,2), and may be involved in cell-cycle regulation, differentiation and human cancer(3,4). Purified recombinant human HDAC1 protein was used to screen a cDNA expression library, and one of the clones identified encoded DNA topoisomerase II (Topo II), an enzyme known to have a role in transcriptional regulation and chromatin organization(5,6). Coimmunoprecipitation experiments indicate that HDAC1 and HDAC2 are associated with Topo II in vivo under normal physiological conditions. Complexes containing Topo II possess HDAC activities, and complexes containing HDAC1 or HDAC2 possess Topo II activities. HDAC and Topo II modify each other's activity in vitro and in vivo. Our results indicate the existence of a functionally coupled complex between these two enzymes and offer insights into the potential mechanisms of action of both enzymes.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33620 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Seto, E (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33620 USA.			Yang, Wen-Ming/0000-0002-5871-5979	NIGMS NIH HHS [GM58486] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058486] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; BOEGE F, 1995, AM J PATHOL, V146, P1302; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hochhauser D, 1999, J CELL BIOCHEM, V75, P245; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Valkov NI, 2000, BRIT J HAEMATOL, V108, P331; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	28	130	132	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					349	353		10.1038/81671	http://dx.doi.org/10.1038/81671			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062478				2022-12-25	WOS:000165176500027
J	Guo, A; Salomoni, P; Luo, JY; Shih, A; Zhong, S; Gu, W; Pandolfi, PP				Guo, A; Salomoni, P; Luo, JY; Shih, A; Zhong, S; Gu, W; Pandolfi, PP			The function of PML in p53-dependent apoptosis	NATURE CELL BIOLOGY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CREB BINDING-PROTEIN; RAR-ALPHA; DNA-DAMAGE; NUCLEAR-BODIES; P53 GENE; IN-VIVO; TRANSCRIPTION; ACTIVATION; COMPLEX	The PML gene of acute promyelocytic leukaemia (APL) encodes a growth- and tumour-suppresor protein that is essential for several apoptotic signals. The mechanisms by which PML exerts its pro-apoptotic function are still unknown. Here we show that PML acts as a transcriptional cc-activator with p53. PML physically interacts with p53 both in vitro and in vivo and co-localizes with p53 in the PML nuclear body (PML-NB), The co-activatory role of PML depends on its ability to localize in the PML-NB, p53-dependent, DNA-damage-induced apoptosis, transcriptional activation by p53, the DNA-binding ability of p53, and the induction of p53 target genes such as Bar and p21 upon gamma-irradiation are all impaired in PML-/- primary cells. These results define a new PML-dependent, p53-regulatory pathway for apoptosis and shed new light on the function of PML in tumour suppression.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University; Columbia University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914	NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08748, CA 71692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MIYASHITA T, 1995, CELL, V80, P293; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	47	378	392	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					730	736		10.1038/35036365	http://dx.doi.org/10.1038/35036365			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025664				2022-12-25	WOS:000089697000019
J	Inoue, K; Nakada, K; Ogura, A; Isobe, K; Goto, Y; Nonaka, I; Hayashi, JI				Inoue, K; Nakada, K; Ogura, A; Isobe, K; Goto, Y; Nonaka, I; Hayashi, JI			Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes	NATURE GENETICS			English	Article							TRANSMITOCHONDRIAL MICE; PROTEIN-SYNTHESIS; CELL LINES; DNA; DISEASE; MUTATION; MYOPATHY; CHLORAMPHENICOL; MICROINJECTION; HETEROPLASMY	Mice carrying mitochondrial DNA (mtDNA) with pathogenic mutations would provide a system in which to study how mutant mtDNAs are transmitted and distributed in tissues, resulting in expression of mitochondrial diseases. However, no effective procedures are available for the generation of these mice. Isolation of mouse cells without mtDNA (rho(0)) enabled us to trap mutant mtDNA that had accumulated in somatic tissues into rho(0) cells repopulated with mtDNA (cybrids). We isolated respiration-deficient cybrids with mtDNA carrying a deletion and introduced this mtDNA into fertilized eggs. The mutant mtDNA was transmitted maternally, and its accumulation induced mitochondrial dysfunction in various tissues. Moreover, most of these mice died because of venal failure, suggesting the involvement of mtDNA mutations in the pathogeneses of new diseases.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Natl Inst Infect Dis, Dept Vet Sci, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo, Japan	University of Tsukuba; University of Tsukuba; National Institute of Infectious Diseases (NIID); National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan.		Ogura, Atsuo/J-3916-2014	Ogura, Atsuo/0000-0003-0447-1988				BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CLAYTON DA, 1967, NATURE, V216, P652, DOI 10.1038/216652a0; DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HOLTZWORTHMUNROE A, 1988, CLIN PSYCHOL REV, V8, P331, DOI 10.1016/0272-7358(88)90095-5; Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955; Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; NELSON I, 1993, MAMM GENOME, V4, P680, DOI 10.1007/BF00360907; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; POULTON J, 1989, LANCET, V1, P236; ROTIG A, 1992, AM J HUM GENET, V50, P364; Shitara H, 1998, GENETICS, V148, P851; SHITARA H, IN PRESS GENETICS; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; VOLZLINGENHOHL A, 1992, P NATL ACAD SCI USA, V89, P11528, DOI 10.1073/pnas.89.23.11528; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Yamaoka M, 2000, GENETICS, V155, P301; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	34	303	312	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					176	181		10.1038/82826	http://dx.doi.org/10.1038/82826			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017072				2022-12-25	WOS:000089638800013
J	Irizarry, K; Kustanovich, V; Li, C; Brown, N; Nelson, S; Wong, W; Lee, CJ				Irizarry, K; Kustanovich, V; Li, C; Brown, N; Nelson, S; Wong, W; Lee, CJ			Genome-wide analysis of single-nucleotide polymorphisms in human expressed sequences	NATURE GENETICS			English	Letter							HUMAN GENES; SNPS; IDENTIFICATION; DISCOVERY; DIVERSITY; MAP; DNA	Single-nucleotide polymorphisms (SNPs) have been explored as a high-resolution marker set for accelerating the mapping of disease genes(1-11). Here we report 48,196 candidate SNPs detected by statistical analysis of human expressed sequence tags (ESTs). associated primarily with coding regions of genes. We used Bayesian inference to weigh evidence for true polymorphism versus sequencing error, misalignment or ambiguity, misclustering or chimaeric EST sequences, assessing data such as raw chromatogram height, sharpness, overlap and spacing, sequencing error rates, context-sensitivity and cDNA library origin. Three separate validation-comparison with 54 genes screened for SNPs independently, verification of HLA-A polymorphisms and restriction fragment length polymorphism (RFLP) testing-verified 70%, 89% and 71% of our predicted SNPs, respectively. Our method detects tenfold more true HLA-A SNPs than previous analyses of the EST data. We found SNPs in a large fraction of known disease genes, including some disease-causing mutations (for example, the HbS sickle-cell mutation). Our comprehensive analysis of human coding region polymorphism provides a public resource for mapping of disease genes (available at http://www.bioinformatics.ucla.edu/snp).	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Grad Program Comp Sci, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lee, CJ (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90024 USA.		Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08375, GM07104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUR EW, 1965, HUMANGENETIK, V1, P621; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; INGRAM VM, 1959, BIOCHIM BIOPHYS ACTA, V36, P402, DOI 10.1016/0006-3002(59)90183-0; Jackson AL, 1998, GENETICS, V148, P1483; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; LI WH, 1991, GENETICS, V129, P513; MAEDA M, 1989, TISSUE ANTIGENS, V34, P290, DOI 10.1111/j.1399-0039.1989.tb01745.x; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Masood E, 1999, NATURE, V398, P545, DOI 10.1038/19126; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Pennisi E, 1998, SCIENCE, V281, P1787, DOI 10.1126/science.281.5384.1787; Picoult-Newberg L, 1999, GENOME RES, V9, P167; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Taillon-Miller P, 1998, GENOME RES, V8, P748, DOI 10.1101/gr.8.7.748; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	22	117	123	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					233	236		10.1038/79981	http://dx.doi.org/10.1038/79981			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017085				2022-12-25	WOS:000089638800026
J	Tillier, ERM; Collins, RA				Tillier, ERM; Collins, RA			Genome rearrangement by replication-directed translocation	NATURE GENETICS			English	Article							PATHOGEN HELICOBACTER-PYLORI; ESCHERICHIA-COLI CHROMOSOME; BACTERIAL GENOMES; SEQUENCE; DNA; ORGANIZATION; TRACHOMATIS; EVOLUTION	Gene order in bacteria is poorly conserved during evolution(1-3). For example, although many homologous genes are shared by the proteobacteria Escherichia coli. Haemophilus influenzae and Helicobacter pylori. their relative positions are very different in each genome, except local functional clusters such as operons(3-6). The complete sequences of the more closely related bacterial genomes, such as pairs of Chlamydia(7-9), H. pylori(10,11) and Mycobacterium species(12), now allow identification of the processes and mechanisms involved in genome evolution. Here we provide evidence that a substantial proportion of rearrangements in gene order results from recombination sites that are determined by the positions of the replication forks. Our observations suggest that replication has a major role in directing genome evolution.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Toronto	Tillier, ERM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada.	e.tillier@utoronto.ca		Tillier, Elisabeth/0000-0003-2194-9058				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; CARO LG, 1968, COLD SPRING HARB SYM, V33, P559, DOI 10.1101/SQB.1968.033.01.063; Casjens S, 1998, ANNU REV GENET, V32, P339, DOI 10.1146/annurev.genet.32.1.339; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Huynen MA, 1998, P NATL ACAD SCI USA, V95, P5849, DOI 10.1073/pnas.95.11.5849; IKEDA H, 1980, COLD SPRING HARB SYM, V45, P399; Itaya M, 1997, MICROBIOL-UK, V143, P3723, DOI 10.1099/00221287-143-12-3723; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kolsto AB, 1997, MOL MICROBIOL, V24, P241, DOI 10.1046/j.1365-2958.1997.3501715.x; Kuzminov A, 1999, GENE DEV, V13, P345, DOI 10.1101/gad.13.3.345; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; LIU SL, 1995, P NATL ACAD SCI USA, V92, P1018, DOI 10.1073/pnas.92.4.1018; Lobry JR, 1996, SCIENCE, V272, P745, DOI 10.1126/science.272.5262.745; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mushegian AR, 1996, TRENDS GENET, V12, P289, DOI 10.1016/0168-9525(96)20006-X; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; REBOLLO JE, 1988, P NATL ACAD SCI USA, V85, P9391, DOI 10.1073/pnas.85.24.9391; SCHMID MB, 1987, J BACTERIOL, V169, P2872, DOI 10.1128/jb.169.6.2872-2875.1987; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHMID MB, 1983, GENETICS, V105, P539; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tamames J, 1997, J MOL EVOL, V44, P66, DOI 10.1007/PL00006122; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Tillier ERM, 2000, J MOL EVOL, V50, P249, DOI 10.1007/s002399910029; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	30	156	158	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2000	26	2					195	197		10.1038/79918	http://dx.doi.org/10.1038/79918			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017076				2022-12-25	WOS:000089638800017
J	Weiss, EL; Bishop, AC; Shokat, KM; Drubin, DG				Weiss, EL; Bishop, AC; Shokat, KM; Drubin, DG			Chemical genetic analysis of the budding-yeast p21-activated kinase Cla4p	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; ACTIN CYTOSKELETON; CELL-CYCLE; BINDING PROTEIN; SEPTIN FUNCTION; FAMILY KINASES; CDC42 GTPASE; PAK-FAMILY; MYOSIN-I	The p21-activated kinases (PAKs) are effecters for the Rho-family GTPase Cdc42p. Here we define the in vivo function of the kinase activity of the budding yeast PAK Cla4p, using cla4 alleles that are specifically inhibited by a cell-permeable compound that does not inhibit the wild-type kinase. CLA4 kinase inhibition in cells lacking the partially redundant PAK Ste20p causes reversible SWE1-dependent cell-cycle arrest and gives rise to narrow, highly elongated buds in which both actin and septin are tightly polarized to bud tips. Inhibition of Cla4p does not prevent polarization of F-actin, and cytokinesis is blocked only in cells that have not formed a bud before inhibitor treatment; cell polarization and bud emergence are not affected by Cla4p inhibition. Although localization of septin to bud necks is restored in swe1 Delta cells, cytokinesis remains defective, inhibition of Cla4p activity in swe1 Delta cells causes a delay of bud emergence after cell polarization, indicating that this checkpoint may mediate an adaptive response that is capable of promoting budding when Cla4p function is reduced. Our data indicate that CLA4 PAK activity is required at an early stage of budding, after actin polarization and coincident with formation of the septin ring, for early bud morphogenesis and assembly of a cytokinesis site.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; Princeton University; University of California System; University of California San Francisco	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bi EF, 2000, MOL BIOL CELL, V11, P773, DOI 10.1091/mbc.11.2.773; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Guthrie C, 1991, GUIDE YEAST GENETICS; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Johnston LH, 1997, METHOD ENZYMOL, V283, P342; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623	41	115	115	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					677	685		10.1038/35036300	http://dx.doi.org/10.1038/35036300			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025657				2022-12-25	WOS:000089697000012
J	Lin, HZ; Yang, SQ; Chuckaree, C; Kuhajda, F; Ronnet, G; Diehl, AM				Lin, HZ; Yang, SQ; Chuckaree, C; Kuhajda, F; Ronnet, G; Diehl, AM			Metformin reverses fatty liver disease in obese, leptin-deficient mice	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; UNCOUPLING PROTEIN-2 EXPRESSION; DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN-RESISTANCE; CULTURED RAT HEPATOCYTES; ADIPOSE-TISSUE; CELLULAR MECHANISMS; NUCLEAR SREBP-1C; ZUCKER RATS; GLUCOSE	There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease. However, because it is associated with hyperinsulinemia and insulin-resistance, insulin-sensitizing agents might be beneficial. To evaluate this possibility, insulin-resistant ob/ob mice with fatty livers were treated with metformin, an agent that improves hepatic insulin-resistance. Metformin improved fatty liver disease, reversing hepatomegaly, steatosis and aminotransferase abnormalities. The therapeutic mechanism likely involves inhibited hepatic expression of tumor necrosis factor (TNF) alpha and TNF-inducible factors that promote hepatic lipid accumulation and ATP depletion. These findings suggest a mechanism of action for metformin and identify novel therapeutic targets in insulin-resistant states.	Dept Med, Baltimore, MD 21224 USA; Dept Pathol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Neurosci & Neurol, Baltimore, MD 21205 USA	Johns Hopkins University	Diehl, AM (corresponding author), Dept Med, Bldg AA,Room 154-A,4940 Eastern Ave, Baltimore, MD 21224 USA.							Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774, DOI 10.1259/0007-1285-65-777-774; GIEHL AM, 1994, AM J PHYSIOL, V267, pG552; HOLLENBECK CB, 1991, DIABETES METAB, V17, P483; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HUUPPONEN R, 1993, RES COMMUN CHEM PATH, V79, P219; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Marceau P, 1999, J CLIN ENDOCR METAB, V84, P1513, DOI 10.1210/jc.84.5.1513; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MEGLASSON MD, 1993, J PHARMACOL EXP THER, V266, P1454; MELIN B, 1990, METABOLISM, V39, P1089, DOI 10.1016/0026-0495(90)90171-8; NI N, 1994, HEPATOLOGY, V19, P182; Paolisso G, 1998, EUR J CLIN INVEST, V28, P441, DOI 10.1046/j.1365-2362.1998.00304.x; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; Pizer ES, 2000, CANCER RES, V60, P213; PURRELLO F, 1988, DIABETOLOGIA, V31, P385, DOI 10.1007/BF02341508; Ricquier D, 1998, BIOCHEM SOC T, V26, P120, DOI 10.1042/bst0260120; ROURU J, 1992, LIFE SCI, V50, P1813, DOI 10.1016/0024-3205(92)90066-X; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Solomon SS, 1997, HORM METAB RES, V29, P379, DOI 10.1055/s-2007-979059; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wiernsperger NF, 1999, DRUGS, V58, P31, DOI 10.2165/00003495-199958001-00009; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; ZAIBI MS, 1995, BIOCHEM PHARMACOL, V50, P775, DOI 10.1016/0006-2952(95)00199-A	43	525	556	3	40	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					998	1003		10.1038/79697	http://dx.doi.org/10.1038/79697			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973319				2022-12-25	WOS:000089190500031
J	Backskai, BJ; Kajdasz, ST; Christie, RH; Carter, C; Games, D; Seubert, P; Schenk, D; Hyman, BT				Backskai, BJ; Kajdasz, ST; Christie, RH; Carter, C; Games, D; Seubert, P; Schenk, D; Hyman, BT			Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PEPTIDE; MOUSE; ANTIBODIES; PATHOLOGY; NEURONS		Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Elan Pharmaceut, S San Francisco, CA USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA.				NIA NIH HHS [AG08487, P01AG15453] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32GM07753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG008487, P01AG015453, R01AG008487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GomezIsla T, 1996, J NEUROSCI, V16, P4491; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Yang XJ, 1998, P NATL ACAD SCI USA, V95, P7715, DOI 10.1073/pnas.95.13.7715	14	393	442	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					369	372		10.1038/85525	http://dx.doi.org/10.1038/85525			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231639				2022-12-25	WOS:000167380400046
J	Marszalek, PE; Li, HB; Fernandez, JM				Marszalek, PE; Li, HB; Fernandez, JM			Fingerprinting polysaccharides with single-molecule atomic force microscopy	NATURE BIOTECHNOLOGY			English	Article							ELASTICITY; SPECTROSCOPY; DNA; TRANSITIONS; STARCH; AGAR	We report the use of an atomic force microscopy (AFM)-based force spectroscopy technique to identify, at the single-molecule level, the components of mixtures of polysaccharides. Previously, we showed that the elasticity of certain types of polysaccharides is governed by force-induced conformational transitions of the pyranose ring. These transitions produce atomic fingerprints in the force-extension spectrum that are characteristic of the ground-energy conformation of the pyranose ring and the type of glycosidic linkages. Using this approach we find that commercially available agarose and lambda -carrageenan contain molecules that, when stretched in an atomic force microscope, produce a force spectrum characteristic of alpha-(1-->4) D-glucans. We have identified these molecules as amylopectin or floridean starch, a storage polysaccharide in algae. Our methodology can identify individual polysaccharide molecules in solution, which is not possible by any other spectroscopic technique, and therefore is an important addition to the arsenal of analytical techniques used in carbohydrate research.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA	Mayo Clinic	Marszalek, PE (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.	Marszalek.piotr@mayo.edu; Fernandez.julio@mayo.edu	Li, Hongbin/G-2949-2012	Li, Hongbin/0000-0001-7813-1332				Brant DA, 1999, CURR OPIN STRUC BIOL, V9, P556, DOI 10.1016/S0959-440X(99)00005-6; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Chandrasekaran R, 1997, ADV CARBOHYD CHEM BI, V52, P311, DOI 10.1016/S0065-2318(08)60094-3; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Fisher TE, 1999, J PHYSIOL-LONDON, V520, P5, DOI 10.1111/j.1469-7793.1999.00005.x; Fisher TE, 2000, NEURON, V27, P435, DOI 10.1016/S0896-6273(00)00055-6; Fisher TE, 2000, NAT STRUCT BIOL, V7, P719; Fisher TE, 1999, TRENDS BIOCHEM SCI, V24, P379, DOI 10.1016/S0968-0004(99)01453-X; Flory P. J, 1953, PRINCIPLES POLYM CHE; Flory P.J., 1988, STAT MECH CHAIN MOL; Fournet I, 1999, EUR J PHYCOL, V34, P125, DOI 10.1080/09670269910001736182; James, 1993, IND GUMS POLYSACCHAR; Jol CN, 1999, ANAL BIOCHEM, V268, P213, DOI 10.1006/abio.1998.3059; KENNEDY JF, 1979, COMPREHENSIVE ORGANI, V5, P755; Li HB, 1999, CHEM PHYS LETT, V305, P197, DOI 10.1016/S0009-2614(99)00389-9; Li HB, 1998, ADV MATER, V10, P316; Marszalek PE, 1999, P NATL ACAD SCI USA, V96, P7894, DOI 10.1073/pnas.96.14.7894; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; O'Donoghue P, 2000, J PHYS CHEM B, V104, P10398, DOI 10.1021/jp002478v; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; OZAKI H, 1967, J BIOCHEM-TOKYO, V61, P497, DOI 10.1093/oxfordjournals.jbchem.a128574; Rao V. S. R., 1998, CONFORMATION CARBOHY; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; RINCONES RE, 1993, HYDROBIOLOGIA, V261, P633; SEKKAL M, 1993, MIKROCHIM ACTA, V112, P1, DOI 10.1007/BF01243315; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TURQUOIS T, 1993, CARBOHYD RES, V238, P27, DOI 10.1016/0008-6215(93)87003-B; Zinoun M, 1996, J APPL PHYCOL, V8, P29, DOI 10.1007/BF02186219	31	121	129	5	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					258	262		10.1038/85712	http://dx.doi.org/10.1038/85712			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231560				2022-12-25	WOS:000167283100027
J	Pravenec, M; Landa, V; Zidek, V; Musilova, A; Kren, V; Kazdova, L; Aitman, TJ; Glazier, AM; Ibrahimi, A; Abumrad, NA; Qi, NN; Wang, JM; St Lezin, EM; Kurtz, TW				Pravenec, M; Landa, V; Zidek, V; Musilova, A; Kren, V; Kazdova, L; Aitman, TJ; Glazier, AM; Ibrahimi, A; Abumrad, NA; Qi, NN; Wang, JM; St Lezin, EM; Kurtz, TW			Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats	NATURE GENETICS			English	Article							FATTY-ACID; METABOLISM; TRANSPORT; MUTATION; GLUCOSE	Spontaneously hypertensive rats (SHR) display several features of the human insulin-resistance syndromes. Cd36 deficiency is genetically linked to insulin resistance in SHR. We show that transgenic expression of Cd36 in SHR ameliorates insulin resistance and lowers serum fatty acids. Our results provide direct evidence that Cd36 deficiency can promote defective insulin action and disordered fatty-acid metabolism in spontaneous hypertension.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic; Charles Univ, Fac Med 1, Inst Biol & Med Genet, Prague, Czech Republic; Inst Clin & Expt Med, Prague, Czech Republic; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, MRC Clin Sci Ctr,Mol Med Grp, London, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Div Natl Heart & Lung Inst, London, England; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	University of California System; University of California San Francisco; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Institute for Clinical & Experimental Medicine (IKEM); Imperial College London; Imperial College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kurtz, TW (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.		Landa, Vladimir/B-8908-2012; Zidek, Vaclav/C-6685-2012; Pravenec, Michal/B-1666-2012	Pravenec, Michal/0000-0001-9197-5871; Aitman, Timothy/0000-0002-7875-4502; Ibrahimi, Azeddine/0000-0003-3226-3836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056028, P01HL035018, R01HL063709] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL35018, R01 HL56028, R01 HL63709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aitman TJ, 1997, NAT GENET, V16, P197, DOI 10.1038/ng0697-197; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583	9	165	167	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					156	158		10.1038/84777	http://dx.doi.org/10.1038/84777			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175782				2022-12-25	WOS:000166839200015
J	Wigley, WC; Stidham, RD; Smith, NM; Hunt, JF; Thomas, PJ				Wigley, WC; Stidham, RD; Smith, NM; Hunt, JF; Thomas, PJ			Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein	NATURE BIOTECHNOLOGY			English	Article						aggregation; folding; solubility; complementation; protein-folding diseases	TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; WILD-TYPE; DISEASE; MUTANT; FRAGMENTS; MUTATION; PEPTIDE; ALPHA	Protein misfolding is the basis of a number of human diseases and presents an obstacle to the production of soluble recombinant proteins. We present a general method to assess the solubility and folding of proteins in vivo. The basis of this assay is structural complementation between the alpha- and omega -fragments of beta -galactosidase (beta -gal). Fusions of the alpha -fragment to the C terminus of target proteins with widely varying in vivo folding yield and/or solubility levels, including the Alzheimer's amyloid beta (A beta) peptide and a non-amyloidogenic mutant thereof, reveal an unambiguous correlation between beta -gal activity and the solubility/folding of the target. Thus, structural complementation provides a means of monitoring protein solubility/misfolding in vivo, and should find utility in the screening for compounds that influence the pathological consequences of these processes.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Grad Program Mol Biophys, Dallas, TX 75235 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	thomas07@utsw.swmed.edu	Thomas, Philip J/F-7115-2012					BELL ET, 1952, DIABETES, V1, P341, DOI 10.2337/diab.1.5.341; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Culvenor JG, 1998, AMYLOID, V5, P79, DOI 10.3109/13506129808995285; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fischbeck KH, 1999, PHILOS T R SOC B, V354, P1075, DOI 10.1098/rstb.1999.0461; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HIND CRK, 1983, J PATHOL, V139, P159, DOI 10.1002/path.1711390207; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Huang EX, 1998, PROTEIN EXPRES PURIF, V13, P90, DOI 10.1006/prep.1998.0870; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JAPPELLI R, 1992, J MOL BIOL, V227, P532, DOI 10.1016/0022-2836(92)90905-Y; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; King J, 1999, NAT BIOTECHNOL, V17, P637, DOI 10.1038/10848; King SA, 1998, METHOD ENZYMOL, V292, P686; KO YH, 1993, J BIOL CHEM, V268, P24330; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE SC, 1990, EUR J BIOCHEM, V187, P417, DOI 10.1111/j.1432-1033.1990.tb15320.x; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Maxwell KL, 1999, PROTEIN SCI, V8, P1908, DOI 10.1110/ps.8.9.1908; PECORARI F, 1993, PROTEIN ENG, V6, P313, DOI 10.1093/protein/6.3.313; Pelletier JN, 1999, NAT BIOTECHNOL, V17, P683, DOI 10.1038/10897; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schonberger O, 1996, P NATL ACAD SCI USA, V93, P9612, DOI 10.1073/pnas.93.18.9612; Senut MC, 2000, J NEUROSCI, V20, P219, DOI 10.1523/JNEUROSCI.20-01-00219.2000; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TANIUCHI H, 1971, J BIOL CHEM, V246, P2291; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wells R.D., 1998, GENETIC INSTABILITIE; WELPLY JK, 1981, J BIOL CHEM, V256, P6811; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZABIN I, 1975, ANNU REV BIOCHEM, V44, P295, DOI 10.1146/annurev.bi.44.070175.001455	59	132	155	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					131	136		10.1038/84389	http://dx.doi.org/10.1038/84389			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175726				2022-12-25	WOS:000166754700018
J	Cornelis, GR; Denecker, G				Cornelis, GR; Denecker, G			Yersinia lead SUMO attack	NATURE MEDICINE			English	Editorial Material							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; DOWN-REGULATION; SUPPRESSION; INHIBITION; PROTEIN; YOPJ; MACROPHAGES; ACTIVATION; INFECTION	Little is known about the mechanism by which Yops, proteins that Yersinia inject into the cytosol of macrophage, cause downregulation of the inflammatory response and diseases such as the plague. Now it appears that Yops are the first bacterial member of a new family of ubiquitin-like proteases.	Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, B-1200 Brussels, Belgium; Univ Louvain, Fac Med, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Cornelis, GR (corresponding author), Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, 74 Av Hippocrate, B-1200 Brussels, Belgium.		Denecker, Geertrui/E-8134-2010	Denecker, Geertrui/0000-0002-2515-2911				Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Meijer LK, 2000, CELL MICROBIOL, V2, P231, DOI 10.1046/j.1462-5822.2000.00049.x; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; NAKAJIMA R, 1993, INFECT IMMUN, V61, P23, DOI 10.1128/IAI.61.1.23-31.1993; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	14	13	14	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					21	23		10.1038/83298	http://dx.doi.org/10.1038/83298			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135606				2022-12-25	WOS:000166243100021
J	Ashcroft, GS; Lei, KJ; Jin, WW; Longenecker, G; Kulkarni, AB; Greenwell-Wild, T; Hale-Donze, H; McGrady, G; Song, XY; Wahl, SM				Ashcroft, GS; Lei, KJ; Jin, WW; Longenecker, G; Kulkarni, AB; Greenwell-Wild, T; Hale-Donze, H; McGrady, G; Song, XY; Wahl, SM			Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; AMINO-ACID SEQUENCE; LATENT TGF-BETA; INFLAMMATORY RESPONSE; NEUTROPHIL ELASTASE; POTENT INHIBITOR; AGED HUMANS; ANTILEUKOPROTEASE; MATRIX; DEGRADATION	Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor with anti-microbial properties found in mucosal fluids. It is expressed during cutaneous wound healing. Impaired healing states are characterized by excessive proteolysis and often bacterial infection, leading to the hypothesis that SLPI may have a role in this process. We have generated mice null for the gene encoding SLPI (Slpi), which show impaired cutaneous wound healing with increased inflammation and elastase activity. The altered inflammatory profile involves enhanced activation of local TGF-beta in Slpi-null mice. We propose that SLPI is a pivotal endogenous factor necessary for optimal wound healing.	Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wahl, SM (corresponding author), Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bldg,30 Convent Dr,MSC 4352, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000046, Z01DE000691] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; CERGNEUX M, 1982, J PERIODONTAL RES, V17, P169, DOI 10.1111/j.1600-0765.1982.tb01142.x; Chen WJ, 1998, J IMMUNOL, V161, P6297; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; Ferry G, 1997, FEBS LETT, V402, P111, DOI 10.1016/S0014-5793(96)01508-6; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; GRINNELL F, 1994, J INVEST DERMATOL, V103, P155, DOI 10.1111/1523-1747.ep12392625; GROSSO LE, 1993, ARCH BIOCHEM BIOPHYS, V305, P401, DOI 10.1006/abbi.1993.1438; HEINE U I, 1990, Archiv fuer Geschwulstforschung, V60, P289; Herrick S, 1997, LAB INVEST, V77, P281; Hiemstra PS, 1998, EUR RESPIR J, V12, P1200, DOI 10.1183/09031936.98.12051200; JAMES J, 1986, HISTOCHEMISTRY, V85, P129, DOI 10.1007/BF00491759; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Karonen T, 1997, BRIT J DERMATOL, V137, P51, DOI 10.1046/j.1365-2133.1997.17671859.x; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; NUNES I, 1995, J IMMUNOL, V155, P1450; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; Pemberton AD, 1998, BBA-GEN SUBJECTS, V1379, P29, DOI 10.1016/S0304-4165(97)00078-0; Raghunath M, 1998, J INVEST DERMATOL, V111, P559, DOI 10.1046/j.1523-1747.1998.00339.x; SANKAR G, 1998, ANNU REV IMMUNOL, V161, P6297; Schiessler H, 1976, Methods Enzymol, V45, P847; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SHAH M, 1995, J CELL SCI, V108, P985; Song XY, 1999, J EXP MED, V190, P535, DOI 10.1084/jem.190.4.535; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Tomee JFC, 1997, J INFECT DIS, V176, P740, DOI 10.1086/514098; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WEISS SJ, 1986, J IMMUNOL, V136, P636; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254	45	328	348	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1147	1153		10.1038/80489	http://dx.doi.org/10.1038/80489			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017147				2022-12-25	WOS:000089674700040
J	Boon, EM; Ceres, DM; Drummond, TG; Hill, MG; Barton, JK				Boon, EM; Ceres, DM; Drummond, TG; Hill, MG; Barton, JK			Mutation detection by electrocatalysis at DNA-modified electrodes	NATURE BIOTECHNOLOGY			English	Article						DNA chip; DNA monolayer; SNPs; mutation detection; damage detection; electrochemistry; electrocatalysis; p53 gene; methylene blue; DNA-mediated electron transfer	NEAREST-NEIGHBOR THERMODYNAMICS; OLIGONUCLEOTIDE; MISMATCHES; DUPLEXES; TUMORS; CHIPS; NMR	Detection of mutations and damaged DNA bases is important for the early diagnosis of genetic disease. Here we describe an electrocatalytic method for the detection of single-base mismatches as well as DNA base lesions in fully hybridized duplexes, based on charge transport through DNA films. Gold electrodes modified with preassembled DNA duplexes are used to monitor the electrocatalytic signal of methylene blue, a redox-active DNA intercalator, coupled to pFe(CN)6](3-). The presence of mismatched or damaged DNA bases substantially diminishes the electrocatalytic signal. Because this assay is not a measure of differential hybridization, all single-base mismatches, including thermodynamically stable GT and GA mismatches, can be detected without stringent hybridization conditions. Furthermore, many common DNA lesions and "hot spot" mutations in the human p53 genome can be distinguished from perfect duplexes. Finally, we have demonstrated the application of this technology in a chip-based format. This system provides a sensitive method for probing the integrity of DNA sequences and a completely new approach to single-base mismatch detection.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Occidental Coll, Dept Chem, Los Angeles, CA 90041 USA	California Institute of Technology; Occidental College	Hill, MG (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.		Boon, Elizabeth/AAR-8229-2020		NIGMS NIH HHS [GM61077] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061077] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Forman JE, 1998, ACS SYM SER, V682, P206; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasper SM, 1998, J AM CHEM SOC, V120, P12402, DOI 10.1021/ja981761t; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Harrison JG, 1997, BIOORG MED CHEM LETT, V7, P1041, DOI 10.1016/S0960-894X(97)00152-2; HOLMLIN RE, 1997, ANGEW CHEM INT EDIT, V36, P2714; Hunter WN, 1998, ACS SYM SER, V682, P77; Izzotti A, 1998, TOXICOL METHOD, V8, P175, DOI 10.1080/105172398242880; Kelley SO, 1999, SCIENCE, V283, P375, DOI 10.1126/science.283.5400.375; Kelley SO, 1998, LANGMUIR, V14, P6781, DOI 10.1021/la980874n; Kelley SO, 1999, NUCLEIC ACIDS RES, V27, P4830, DOI 10.1093/nar/27.24.4830; Kelley SO, 1997, BIOCONJUGATE CHEM, V8, P31, DOI 10.1021/bc960070o; Kelley SO, 1997, J AM CHEM SOC, V119, P9861, DOI 10.1021/ja9714651; Kelley SO, 1999, ANGEW CHEM INT EDIT, V38, P941, DOI 10.1002/(SICI)1521-3773(19990401)38:7<941::AID-ANIE941>3.0.CO;2-7; Kirby GM, 1996, INT J CANCER, V68, P21, DOI 10.1002/(SICI)1097-0215(19960927)68:1<21::AID-IJC4>3.0.CO;2-Z; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; Luxon BA, 1995, METHOD ENZYMOL, V261, P45; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; Ropp PA, 1999, CHEM BIOL, V6, P599, DOI 10.1016/S1074-5521(99)80111-2; RYBERG D, 1994, CANCER RES, V54, P1551; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33	26	649	669	2	162	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1096	1100		10.1038/80301	http://dx.doi.org/10.1038/80301			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017050				2022-12-25	WOS:000089744700034
J	Roper, K; Corbeil, D; Huttner, WB				Roper, K; Corbeil, D; Huttner, WB			Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane	NATURE CELL BIOLOGY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; GPI-ANCHORED PROTEINS; EPITHELIAL-CELLS; MDCK CELLS; SURFACE; MICRODOMAINS; CYCLODEXTRIN; EXPRESSION; TRANSPORT; CYTOSKELETON	Membrane cholesterol-sphingolipid 'rafts', which are characterized by their insolubility in the non-ionic detergent Triton X-100 in the cold, have been implicated in the sorting of certain membrane proteins, such as placental alkaline phosphatase (PLAP), to the apical plasma membrane domain of epithelial cells. Here we show that prominin, an apically sorted pentaspan membrane protein, becomes associated in the trans-Golgi network with a lipid raft that is soluble in Triton X-100 but insoluble in another non-ionic detergent, Lubrol WX. At the cell surface, prominin remains insoluble in Lubrol WX and is selectively associated with microvilli, being largely segregated from the membrane subdomains containing FLAP. Cholesterol depletion results in the loss of prominin's microvillus-specific localization but does not lead to its complete intermixing with FLAP. We propose the coexistence within a membrane domain, such as the apical plasma membrane, of different cholesterol-based lipid rafts, which underlie the generation and maintenance of membrane subdomains.	Heidelberg Univ, Interdisciplinary Ctr Neurosci, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Ruprecht Karls University Heidelberg; Max Planck Society	Huttner, WB (corresponding author), Heidelberg Univ, Interdisciplinary Ctr Neurosci, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	whuttner@sun0.urz.uni-heidelberg.de	Corbeil, Denis/AFL-1008-2022; Corbeil, Denis/A-6519-2010; Huttner, Wieland B./P-4080-2018; Corbeil, Denis/L-2340-2019	Corbeil, Denis/0000-0003-1181-3659; Roper, Katja/0000-0002-3361-766X				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; BRECKENRIDGE WC, 1972, BIOCHIM BIOPHYS ACTA, V266, P695, DOI 10.1016/0005-2736(72)90365-3; Bretscher A, 1997, J CELL SCI, V110, P3011; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Corbeil D, 1999, J CELL SCI, V112, P1023; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FEV EG, 1984, J CELL BIOL, V98, P1973; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRANT DAW, 1977, BIOCHEM J, V164, P465, DOI 10.1042/bj1640465; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huttner WB, 1995, COLD SPRING HARB SYM, V60, P315, DOI 10.1101/SQB.1995.060.01.036; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KERJASCHKI D, 1984, J CELL BIOL, V98, P1505, DOI 10.1083/jcb.98.4.1505; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KUMMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Miseta A, 1995, BIOPHYS J, V69, P2563, DOI 10.1016/S0006-3495(95)80127-X; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; *ROHM HAAS CO, 1986, SURF MICR DISP HDB P; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; UMBREIT JN, 1973, P NATL ACAD SCI USA, V70, P2997, DOI 10.1073/pnas.70.10.2997; VANEDE J, 1989, J CHROMATOGR, V476, P319, DOI 10.1016/S0021-9673(01)93879-8; Verkade P, 2000, J CELL BIOL, V148, P727, DOI 10.1083/jcb.148.4.727; WERGMANN A, 1997, P NATL ACAD SCI USA, V94, P12425; 1999, ALDRICH CATALOGUE	51	470	476	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					582	592		10.1038/35023524	http://dx.doi.org/10.1038/35023524			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980698				2022-12-25	WOS:000089250600009
J	Buseyne, F; Le Gall, S; Boccaccio, C; Abastado, JP; Lifson, JD; Arthur, LO; Riviere, Y; Heard, JM; Schwartz, O				Buseyne, F; Le Gall, S; Boccaccio, C; Abastado, JP; Lifson, JD; Arthur, LO; Riviere, Y; Heard, JM; Schwartz, O			MHC-I-restricted presentation of HIV-1 virion antigens without viral replication	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; EXOGENOUS ANTIGENS; CHEMOKINE-CORECEPTORS; NEF PROTEIN; MOLECULES; INFECTION; RESPONSES; TYPE-1	Dendritic cells and macrophages can process extracellular antigens for presentation by MHC-I molecules. This exogenous pathway may have a crucial role in the activation of CD8(+) cytotoxic T lymphocytes during human viral infections. We show here that HIV-1 epitopes derived from incoming virions are presented through the exogenous MHC-I pathway in primary human dendritic cells, and to a lower extent in macrophages, leading to cytotoxic T-lymphocyte activation in the absence of viral protein synthesis. Exogenous antigen presentation required adequate virus-receptor interactions and fusion of viral and cellular membranes. These results provide new insights into how anti-HIV cytotoxic T lymphocytes can be activated and have implications for anti-HIV vaccine design.	Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France; Inst Pasteur, Lab Immunopathol Virale, Paris, France; Inst Cordeliers, ImmunoDesigned Mol Res Labs, Paris, France; NCI, Retroviral Pathogenesis Lab, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Schwartz, O (corresponding author), Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France.		Schwartz, Olivier/AAZ-3765-2021	Schwartz, Olivier/0000-0002-0729-1475; Le Gall, Sylvie/0000-0003-0385-926X	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311; Ayehunie S, 1997, BLOOD, V90, P1379, DOI 10.1182/blood.V90.4.1379.1379_1379_1386; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BERGERON L, 1992, J VIROL, V66, P2389, DOI 10.1128/JVI.66.4.2389-2397.1992; Brander C, 1999, CURR OPIN IMMUNOL, V11, P451, DOI 10.1016/S0952-7915(99)80076-4; Buseyne F, 1996, VIROLOGY, V225, P248, DOI 10.1006/viro.1996.0597; Buseyne F, 1998, VIROLOGY, V250, P316, DOI 10.1006/viro.1998.9373; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Goxe B, 1998, RES IMMUNOL, V149, P643, DOI 10.1016/S0923-2494(99)80031-5; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; Klagge IM, 1999, J GEN VIROL, V80, P823, DOI 10.1099/0022-1317-80-4-823; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reimann J, 1999, IMMUNOL REV, V172, P131, DOI 10.1111/j.1600-065X.1999.tb01362.x; ROCK KL, 1996, IMMUNOL TODAY, V17, P129; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Rossiter J C, 1992, Contemp Nurse, V1, P75; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585	45	132	134	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					344	349		10.1038/85493	http://dx.doi.org/10.1038/85493			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231634				2022-12-25	WOS:000167380400041
J	De Backer, MD; Nelissen, B; Logghe, M; Viaene, J; Loonen, I; Vandoninck, S; de Hoogt, R; Dewaele, S; Simons, FA; Verhasselt, P; Vanhoof, G; Contreras, R; Luyten, WHML				De Backer, MD; Nelissen, B; Logghe, M; Viaene, J; Loonen, I; Vandoninck, S; de Hoogt, R; Dewaele, S; Simons, FA; Verhasselt, P; Vanhoof, G; Contreras, R; Luyten, WHML			An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; HOMOLOGY REGIONS; QUANTITATIVE PCR; YEAST; EXPRESSION; DISRUPTION; TRANSCRIPTION; EUKARYOTES; RIBOZYME; SEQUENCE	Converting the complete genome sequence of Candida albicans into meaningful biological information will require comprehensive screens for identifying functional classes of genes. Most systems described so far are not applicable to C. albicans because of its difficulty with mating, its diploid nature, and the lack of functional random insertional mutagenesis methods. We examined artificial gene suppression as a means to identify gene products critical for growth of this pathogen; these represent new antifungal drug targets. To achieve gene suppression we combined antisense RNA inhibition and promoter interference. After cloning antisense complementary DNA (cDNA) fragments under control of an inducible GAL1 promoter, we transferred the resulting libraries to C. albicans. Over 2,000 transformant colonies were screened for a promoter-induced diminished-growth phenotype. After recovery of the plasmids, sequence determination of their inserts revealed the messenger RNA (mRNA) they inhibited or the gene they disrupted. Eighty-six genes critical for growth were identified, 45 with unknown function. When used in high-throughput screening for antifungals, the crippled C. albicans strains generated in this study showed enhanced sensitivity to specific drugs.	Janssen Pharmaceut, Dept Adv Biotechnol, B-2340 Beerse, Belgium; Janssen Pharmaceut, Dept Biotechnol & High Throughput Screening, B-2340 Beerse, Belgium; State Univ Ghent, Dept Mol Biol, Subunit Fundamental & Appl Mol Biol, B-9000 Ghent, Belgium; Vlaams Inst Bevordering Wetenschappelijk Technol, B-9000 Ghent, Belgium	Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Ghent University	De Backer, MD (corresponding author), Janssen Pharmaceut, Dept Adv Biotechnol, Turnhoutseweg 30, B-2340 Beerse, Belgium.							ATKINS D, 1994, BIOL CHEM H-S, V375, P721; ATKINS D, 1994, ANTISENSE RES DEV, V4, P109, DOI 10.1089/ard.1994.4.109; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; De Backer MD, 1999, YEAST, V15, P1609, DOI 10.1002/(SICI)1097-0061(199911)15:15&lt;1609::AID-YEA485&gt;3.0.CO;2-Y; De Backer MD, 2000, MICROBIOL-SGM, V146, P353, DOI 10.1099/00221287-146-2-353; De Backer MD, 2000, ANNU REV MICROBIOL, V54, P463, DOI 10.1146/annurev.micro.54.1.463; de Hoogt R, 2000, BIOTECHNIQUES, V28, P1112, DOI 10.2144/00286st01; DEBACKER MD, 1993, BIOCHEM BIOPH RES CO, V197, P1601, DOI 10.1006/bbrc.1993.2662; DelRosario M, 1996, NAT BIOTECHNOL, V14, P1592; Fairhead C, 1998, GENE, V223, P33, DOI 10.1016/S0378-1119(98)00171-1; Ferbeyre G, 1996, J BIOL CHEM, V271, P19318, DOI 10.1074/jbc.271.32.19318; FISHERHOCH SP, 1995, CLIN INFECT DIS, V21, P897, DOI 10.1093/clinids/21.4.897; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FONZI WA, 1993, GENETICS, V134, P717; FOX JL, 1993, ASM NEWS, V10, P515; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GIESE K, 1997, Patent No. 9710360; Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5; Hull CM, 2000, SCIENCE, V289, P307, DOI 10.1126/science.289.5477.307; Jack D B, 1998, Drug News Perspect, V11, P306; Jensen-Pergakes KL, 1998, ANTIMICROB AGENTS CH, V42, P1160, DOI 10.1128/AAC.42.5.1160; Leuker CE, 1997, GENE, V192, P235, DOI 10.1016/S0378-1119(97)00069-3; Lie YS, 1998, CURR OPIN BIOTECH, V9, P43, DOI 10.1016/S0958-1669(98)80082-7; Magee BB, 2000, SCIENCE, V289, P310, DOI 10.1126/science.289.5477.310; Matthews GD, 1997, J BACTERIOL, V179, P7118, DOI 10.1128/jb.179.22.7118-7128.1997; MOEHLE CM, 1995, Patent No. 9511969; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; NUMATA K, 1986, J ANTIBIOT, V39, P994, DOI 10.7164/antibiotics.39.994; Oliver S, 1999, NAT GENET, V21, P245, DOI 10.1038/6748; Orlando C, 1998, CLIN CHEM LAB MED, V36, P255, DOI 10.1515/CCLM.1998.045; Pla J, 1996, YEAST, V12, P1677; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; Sambrook J., 2002, MOL CLONING LAB MANU; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; ZHU JD, 1985, BIO-TECHNOL, V3, P1014, DOI 10.1038/nbt1185-1014	37	87	103	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					235	241		10.1038/85677	http://dx.doi.org/10.1038/85677			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231556				2022-12-25	WOS:000167283100023
J	Devriendt, K; Kim, AS; Mathijs, G; Frints, SGM; Schwartz, M; Van den Oord, JJ; Verhoef, GEG; Boogaerts, MA; Fryns, JP; You, DQ; Rosen, MK; Vandenberghe, P				Devriendt, K; Kim, AS; Mathijs, G; Frints, SGM; Schwartz, M; Van den Oord, JJ; Verhoef, GEG; Boogaerts, MA; Fryns, JP; You, DQ; Rosen, MK; Vandenberghe, P			Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia	NATURE GENETICS			English	Letter							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN WASP; ACTIN NUCLEATION; ARP2/3 COMPLEX; N-WASP; CDC42; EXPRESSION; GENE; BINDING; CELLS	The Wiskott-Aldrich syndrome protein (WASP; encoded by the gene WAS) and its homologs are important regulators of the actin cytoskeleton, mediating communication between Rho-family GTPases and the actin nucleation/crosslinking factor. the Arp2/3 complex(1). Many WAS mutations impair cytoskeletal control in hematopoietic tissues, resulting in functional and developmental defects that define the X-linked Wiskott-Aldrich syndrome (NAS) and the related X-linked thrombocytopenia(2) (XLT), These diseases seem to result from reduced WASP signaling, often through decreased transcription or translation of the gene(3-8). Here we describe a new disease, X-linked severe congenital neutropenia (XLN), caused by a novel L270P mutation in the region of WAS encoding the conserved GTPase binding domain (GBD), In vitro. the mutant protein is constitutively activated through disruption of an autoinhibitory domain in the wild-type protein, indicating that loss of WASP autoinhibition is a key event in XLN. Our findings highlight the importance of precise regulation of WASP in hematopoietic development and function, as impairment versus enhancement of its activity give rise to distinct spectra of cellular defects and clinical phenotypes.	Katholieke Univ Leuven, Lab Expt Hematol, Louvain, Belgium; Katholieke Univ Leuven Hosp, Ctr Human Genet, Louvain, Belgium; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, DK-4062 Copenhagen, Denmark; Katholieke Univ Leuven Hosp, Dept Pathol, Lab Histo & Cytochem, Louvain, Belgium	KU Leuven; Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Memorial Sloan Kettering Cancer Center; Rigshospitalet; University of Copenhagen; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	Vandenberghe, P (corresponding author), Katholieke Univ Leuven, Lab Expt Hematol, Louvain, Belgium.	rosen@mrnmr1.mskcc.org; peter.vandenberghe@med.kuleuven.ac.be		Vandenberghe, Peter/0000-0003-4719-1935; Frints, Suzanna G.M./0000-0002-5027-8364; Matthijs, Gert/0000-0001-6710-1912				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Coakley G, 2000, ARTHRITIS RHEUM, V43, P834, DOI 10.1002/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Devriendt K, 1997, AM J HUM GENET, V60, P581; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; ELSNER J, 1993, EXP HEMATOL, V21, P38; Facchetti F, 1998, J PATHOL, V185, P99, DOI 10.1002/(SICI)1096-9896(199805)185:1<99::AID-PATH48>3.0.CO;2-L; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Lemahieu V, 1999, HUM MUTAT, V14, P54, DOI 10.1002/(SICI)1098-1004(1999)14:1<54::AID-HUMU7>3.3.CO;2-5; MacCarthy-Morrogh L, 1998, CLIN IMMUNOL IMMUNOP, V88, P22, DOI 10.1006/clin.1998.4557; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Parolini O, 1997, BLOOD, V90, P70; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Scherbina A, 1999, J IMMUNOL, V163, P6314; Schwartz M, 1996, THROMB HAEMOSTASIS, V75, P546; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Zhu QL, 1997, BLOOD, V90, P2680, DOI 10.1182/blood.V90.7.2680.2680_2680_2689	30	311	323	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					313	317		10.1038/85886	http://dx.doi.org/10.1038/85886			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242115				2022-12-25	WOS:000167304200025
J	Hoch, W; McConville, J; Helms, S; Newsom-Davis, J; Melms, A; Vincent, A				Hoch, W; McConville, J; Helms, S; Newsom-Davis, J; Melms, A; Vincent, A			Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies	NATURE MEDICINE			English	Article							MUSCLE-SPECIFIC KINASE; NEUROMUSCULAR-JUNCTION; PHOSPHORYLATION; AGGREGATION; COMPLEX; CELLS	Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor (AChR) are present(1). These antibodies cause loss of AChR numbers and function, and lead to failure of neuromuscular transmission with muscle weakness(2). The pathogenic mechanisms acting in the 20% of patients with generalized MC who are seronegative for AChR-antibodies (AChR-Ab)(3) have not been elucidated, but there is evidence that they also have an antibody-mediated disorder(4,5), with the antibodies directed towards another, previously unidentified muscle-surface-membrane target(6-8). Here we show that 70% of AChR-Ab-seronegative MC patients, but not AChR-Ab-seropositive MG patients, have serum auto-antibodies against the muscle-specific receptor tyrosine kinase, MUSK. MuSK mediates the agrin-induced clustering of AChRs during synapse formation, and is also expressed at the mature neuromuscular junction(9-12). The MUSK antibodies were specific for the extracellular domains of MUSK expressed in transfected COS7 cells and strongly inhibited MUSK function in cultured myotubes. Our results indicate the involvement of MUSK antibodies in the pathogenesis of AChR-Ab-seronegative MC, thus defining two immunologically distinct forms of the disease. Measurement of MUSK antibodies will substantially aid diagnosis and clinical management.	Max Planck Inst Dev Biol, Tubingen, Germany; John Radcliffe Hosp, Inst Mol Med, Neurosci Grp, Oxford OX3 9DU, England; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany	Max Planck Society; University of Oxford; Eberhard Karls University of Tubingen	Vincent, A (corresponding author), Max Planck Inst Dev Biol, Tubingen, Germany.	angela.vincent@imm.ox.ac.uk	Barrett-Jolley, Richard/G-7704-2011; Vincent, Angela/AAE-7310-2019	Barrett-Jolley, Richard/0000-0003-0449-9972; 				Aarli JA, 1998, ANN NY ACAD SCI, V841, P505, DOI 10.1111/j.1749-6632.1998.tb10971.x; Blaes F, 2000, ANN NEUROL, V47, P504, DOI 10.1002/1531-8249(200004)47:4<504::AID-ANA14>3.3.CO;2-H; BROOKS EB, 1990, J NEUROIMMUNOL, V28, P83, DOI 10.1016/0165-5728(90)90043-M; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; DRACHMAN DB, 1987, ANN NY ACAD SCI, V505, P90; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hopf C, 1998, EUR J BIOCHEM, V253, P382, DOI 10.1046/j.1432-1327.1998.2530382.x; Hopf C, 1998, J BIOL CHEM, V273, P6467, DOI 10.1074/jbc.273.11.6467; Hopf C, 1997, EUR J NEUROSCI, V9, P1170, DOI 10.1111/j.1460-9568.1997.tb01471.x; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; MIER AK, 1985, POSTGRAD MED J, V61, P725, DOI 10.1136/pgmj.61.718.725; MOSSMAN S, 1986, LANCET, V1, P116; NAKANO S, 1993, NEUROLOGY, V43, P1167, DOI 10.1212/WNL.43.6.1167; NewsomDavis J, 1997, NEUROSCIENTIST, V3, P337, DOI 10.1177/107385849700300515; Robertson NP, 1998, J NEUROL NEUROSUR PS, V65, P492, DOI 10.1136/jnnp.65.4.492; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Sanders Donald B., 1997, Neurology, V48, pS40; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; TAYLOR SI, 1989, ENDOCRIN METAB CLIN, V18, P123, DOI 10.1016/S0889-8529(18)30392-X; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; VINCENT A, 1993, ANN NY ACAD SCI, V681, P529, DOI 10.1111/j.1749-6632.1993.tb22936.x; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; WILLCOX N, 1991, J NEUROL, V238, P256; YAMAMOTO T, 1991, ANN NEUROL, V30, P550, DOI 10.1002/ana.410300407; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	25	791	832	3	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					365	368		10.1038/85520	http://dx.doi.org/10.1038/85520			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231638				2022-12-25	WOS:000167380400045
J	Miele, G; Manson, J; Clinton, M				Miele, G; Manson, J; Clinton, M			A novel erythroid-specific marker of transmissible spongiform encephalopathies	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; DIFFERENTIAL DISPLAY; BONE-MARROW; GENE-EXPRESSION; PRION PROTEIN; MESSENGER-RNA; SCRAPIE; PRP; MOUSE; INFECTIVITY	Transmissible spongiform encephalopathies (TSE) are a group of invariably fatal neurodegenerative diseases and include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease in deer and elk, and Kuru disease, Creutzfeldt-Jakob disease (CJD) and variant CID in humans(1,2). The pathological effects of disease occur predominantly in the CNS (central nervous system), where common hallmarks include vacuolation, gliosis, accumulation of a protease-resistant, abnormally folded isoform of the prion protein (PrPSc) and neuronal cell death(1,2). Lack of understanding of the molecular mechanisms underlying disease pathogenesis, particularly in non-CNS tissues, means that there are currently no effective strategies for early diagnosis or therapeutic intervention of TSEs. Here we report the first identification of a molecular marker that is easily detectable in readily accessible tissues. We demonstrate that a dramatic: decrease in expression of a transcript specific to erythroid lineage cells is a common feature of TSEs. Our findings indicate a previously unrecognized role for involvement of the erythroid lineage in the etiology of TSE pathogenesis and should provide a new focus for research into diagnostic and therapeutic strategies.	Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland; BBSRC, Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Roslin Institute; University of Edinburgh	Clinton, M (corresponding author), Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland.							BERNARD J, 1991, BLOOD CELLS, V17, P5; Bessis M, 1983, HEMATOLOGY, P257; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARP RI, 1981, INTERVIROLOGY, V16, P8, DOI 10.1159/000149241; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Miele G, 1998, BIOTECHNIQUES, V25, P138, DOI 10.2144/98251rr02; Miele G, 1999, PREP BIOCHEM BIOTECH, V29, P245, DOI 10.1080/10826069908544927; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schmerr MJ, 1999, J CHROMATOGR A, V853, P207, DOI 10.1016/S0021-9673(99)00514-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Voura EB, 1997, EXP HEMATOL, V25, P1172; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Wells GAH, 1999, VET REC, V144, P292, DOI 10.1136/vr.144.11.292	29	117	129	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					361	364		10.1038/85515	http://dx.doi.org/10.1038/85515			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231637				2022-12-25	WOS:000167380400044
J	Ohdo, S; Koyanagi, S; Suyama, H; Higuchi, S; Aramaki, H				Ohdo, S; Koyanagi, S; Suyama, H; Higuchi, S; Aramaki, H			Changing the dosing schedule minimizes the disruptive effects of interferon on clock function	NATURE MEDICINE			English	Article							CIRCADIAN-RHYTHM; SUPRACHIASMATIC NUCLEUS; PERIPHERAL-TISSUES; EXPRESSION; ALPHA; LIGHT; INDUCTION; PACEMAKER; LOCOMOTOR; RECEPTOR	The effectiveness and toxicity of many drugs vary depending on the relationship between the dosing schedule and the 24-hour rhythms of biochemical, physiological and behavioral processes. In addition, several drugs can cause alterations to the 24-hour rhythms leading to illness and altered homeostatic regulation. However, the mechanisms of this drug-based disruption of circadian 'clock' genes remain unclear. Here, we show the disruptive effect of interferon-alpha on the rhythm of locomotor activity, body temperature and clock-gene mRNA expression in the periphery and suprachiasmatic nuclei, a primary circadian pacemaker. The rhythmicity of clock genes and the photic induction of the Per gene in suprachiasmatic nuclei were disturbed by the repetitive administration of interferon-alpha. Moreover, alteration of clock function, a new concept of adverse effects, can be overcome by optimizing the dosing schedule to minimize adverse drug effects.	Kyushu Univ, Grad Sch, Dept Clin Pharmacokinet, Div Pharmaceut Sci,Higashi Ku, Fukuoka 812, Japan; Fukuoka Univ, Fac Pharmaceut Sci, Dept Biochem, Jonan Ku, Fukuoka 81401, Japan; Daiichi Coll Pharmaceut Sci, Dept Mol Biol, Minami Ku, Fukuoka 815, Japan	Kyushu University; Fukuoka University	Ohdo, S (corresponding author), Kyushu Univ, Grad Sch, Dept Clin Pharmacokinet, Div Pharmaceut Sci,Higashi Ku, Fukuoka 812, Japan.	ohdo@phar.kyushu-u.ac.jp	Koyanagi, Satoru/AAE-6843-2020	Koyanagi, Satoru/0000-0003-4849-2377				Akiyama M, 1999, J NEUROSCI, V19, P1115; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; BOCCI V, 1985, CANC DRUG DEL, V2, P313, DOI 10.1089/cdd.1985.2.313; BOULOS Z, 1980, NEUROSCI BIOBEHAV R, V4, P119, DOI 10.1016/0149-7634(80)90010-X; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Duncan WC, 1996, PHARMACOL THERAPEUT, V71, P253, DOI 10.1016/S0163-7258(96)00092-7; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; Horikawa K, 2000, J NEUROSCI, V20, P5867, DOI 10.1523/JNEUROSCI.20-15-05867.2000; Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6; IACOBELLI S, 1995, AM J CLIN ONCOL-CANC, V18, P27; JANSSENS W, 1994, AIDS, V8, P21, DOI 10.1097/00002030-199401000-00004; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; KOREN S, 1993, J NATL CANCER I, V85, P1927, DOI 10.1093/jnci/85.23.1927; Koyanagi S, 1997, J PHARMACOL EXP THER, V283, P259; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LABRECQUE G, 1991, PHARMACOL THERAPEUT, V52, P95, DOI 10.1016/0163-7258(91)90088-4; LEMMER B, 1991, ANN NY ACAD SCI, V618, P166, DOI 10.1111/j.1749-6632.1991.tb27245.x; Lohmann CP, 1999, LANCET, V353, P1326, DOI 10.1016/S0140-6736(99)00403-1; Lu JQ, 1997, CELL MOL LIFE SCI, V53, P224, DOI 10.1007/PL00000594; Lundkvist GB, 1998, NEUROREPORT, V9, P1059, DOI 10.1097/00001756-199804200-00018; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NAGAYAMA H, 1987, EXPERIENTIA, V43, P625, DOI 10.1007/BF02126357; Ohdo S, 1996, J PHARMACOL EXP THER, V278, P74; Ohdo S, 2000, J PHARMACOL EXP THER, V294, P488; PURVIN VA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1041, DOI 10.1001/archopht.1995.01100080093034; REINBERG A, 1971, ANNU REV PHARMACOLOG, V11, P455, DOI 10.1146/annurev.pa.11.040171.002323; Ripperger JA, 2000, GENE DEV, V14, P679; ROOSTH J, 1986, J NEUROIMMUNOL, V12, P311, DOI 10.1016/0165-5728(86)90037-8; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Takane H, 2000, J PHARMACOL EXP THER, V294, P746; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueyama T, 1999, NAT NEUROSCI, V2, P1051, DOI 10.1038/15973; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	40	161	172	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					356	360		10.1038/85507	http://dx.doi.org/10.1038/85507			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231636				2022-12-25	WOS:000167380400043
J	Di Cristofano, A; De Acetis, M; Koff, A; Cordon-Cardo, C; Pandolfi, PP				Di Cristofano, A; De Acetis, M; Koff, A; Cordon-Cardo, C; Pandolfi, PP			Pten and p27(KIP1) cooperate in prostate cancer tumor suppression in the mouse	NATURE GENETICS			English	Article							MICE LACKING; HYPERPLASIA; PTEN/MMAC1	The genetic bases underlying prostate tumorigenesis are poorly understood. Inactivation of the tumor-suppressor gene PTEN and lack of p27(KIP1) expression have been detected in most advanced prostate cancers(1,2). But mice deficient for Cdkn1b (encoding p27(KIp1)) do not develop prostate cancer(3-5). PTEN activity leads to the induction of p27(KIP1) expression, which in turn can negatively regulate the transition through the cell cycle(6). Thus, the inactivation of p27(KIP1)may epistatic to PTEN in the control of the cell cycle. Here we show that the concomitant inactivation of one Pten allele and one or both Cdkn1b alleles accelerates spontaneous neoplastic transformation and incidence of tumors of various histological origins. Cell proliferation, but not cell survival, is increased in Pten(+/-)/Cdkn1b(-/-)mice. Moreover, Pten(+/-)/Cdkn1b(-/-) mice develop prostate carcinoma at complete penetrance within three months from birth. These cancers recapitulate the natural history and pathological features of human prostate cancer. Our findings reveal the crucial relevance of the combined tumor-suppressive activity of Pten and p27(Kip1) through the control of cell-cycle progression.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		di cristofano, antonio/AAJ-3796-2020; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; Koff, Andrew/0000-0003-3271-3067				Cairns P, 1997, CANCER RES, V57, P4997; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Osman I, 1997, CLIN CANCER RES, V3, P531; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; PRICE D, 1963, BIOL PROSTATE RELATE, P1; Verma RS, 1999, CANCER INVEST, V17, P441, DOI 10.3109/07357909909021436	18	386	400	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					222	224		10.1038/84879	http://dx.doi.org/10.1038/84879			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175795				2022-12-25	WOS:000166839200028
J	Horiike, T; Hamada, K; Kanaya, S; Shinozawa, T				Horiike, T; Hamada, K; Kanaya, S; Shinozawa, T			Origin of eukaryotic cell nuclei by symbiosis of Archaea in Bacteria is revealed by homology-hit analysis	NATURE CELL BIOLOGY			English	Article							COMPLETE GENOME SEQUENCE; GENE-TRANSFER; HYPOTHESIS; LIFE	The origin of eukaryotic cell nuclei by symbiosis of Archaea in Bacteria was proposed on the basis of the phylogenetic topologies of genes(1-3). However, it was not possible to conclude whether or not the genes involved were authentic representative genes'. Furthermore, using the BLAST(5) and FASTA(6) programs, the similarity of open reading frame (ORF) groups between three domains (Eukarya, Archaea and Bacteria) was estimated at one threshold(7,8). Therefore, their similarities at other thresholds could not be clarified. Here we use our newly developed 'homology-hit analysis' method, which uses multiple thresholds, to determine the origin of the nucleus. We removed mitochondria related ORFs from yeast ORFs, and determined the number of yeast orthologous ORFs in each functional category to the ORFs in six Archaea and nine Bacteria at several thresholds (E-values) using the BLAST. Our results indicate that yeast ORFs related to the nucleus may share their origins with archaeal ORFs, whereas ORFs that are related to the cytoplasm may share their origins with bacterial ORFs. Our results thus strongly support the idea of nucleus symbiosis.	Gunma Univ, Fac Engn, Dept Biol & Chem Engn, Kiryu, Gumma 3768515, Japan; Yamagata Univ, Fac Engn, Dept Biosyst Engn, Yonezawa, Yamagata 9920038, Japan	Gunma University; Yamagata University	Shinozawa, T (corresponding author), Gunma Univ, Fac Engn, Dept Biol & Chem Engn, Kiryu, Gumma 3768515, Japan.	shinozawa@bce.gunma-u.ac.jp						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade MA, 1999, J MOL EVOL, V49, P551, DOI 10.1007/PL00006576; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Kaneko T, 1996, DNA Res, V3, P109; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P2880, DOI 10.1073/pnas.91.8.2880; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Philippe H, 1999, J MOL EVOL, V49, P509, DOI 10.1007/PL00006573; Ribeiro S, 1998, MOL BIOL EVOL, V15, P779, DOI 10.1093/oxfordjournals.molbev.a025983; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	30	86	90	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					210	214		10.1038/35055129	http://dx.doi.org/10.1038/35055129			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175755				2022-12-25	WOS:000166793000024
J	Rondot, S; Koch, J; Breitling, F; Dubel, S				Rondot, S; Koch, J; Breitling, F; Dubel, S			A helper phage to improve single-chain antibody presentation in phage display	NATURE BIOTECHNOLOGY			English	Article							FILAMENTOUS PHAGE; GENE-III; CLONING VECTORS; LIBRARIES; EXPRESSION; SURFACE; PROTEIN; DELETION; DOMAIN; MUTANT	We show here that the number of single-chain antibody fragments (scFv) presented on filamentous phage particles generated with antibody display phagemids can be increased by more than two orders of magnitude by using a newly developed helper phage (hyperphage). Hyperphage have a wild-type pIII phenotype and are therefore able to infect F+ Escherichia coli cells with high efficiency; however, their lack of a functional pIII gene means that the phagemid-encoded pIII-antibody fusion is the sore source of pIII in phage assembly. This results in an considerable increase in the fraction of phage particles carrying an antibody fragment on their surface. Antigen-binding activity was increased about 400-fold by enforced oligovalent antibody display on every phage particle. When used for packaging a universal human scFv library, hyperphage improved the specific enrichment factor obtained when panning on tetanus toxin. After two panning rounds, more than 50% of the phage were found to bind to the antigen, compared to 3% when conventional M13KO7 helper phage was used. Thus, hyperphage is particularly useful in stoichiometric situations, when there is little chance that a single phage will locate the desired antigen.	Univ Heidelberg, D-69120 Heidelberg, Germany; Mol Genet Lab Prof Raue, D-69117 Heidelberg, Germany; Heidelberger Akad Wissensch, Forschungsstelle Hantaviren, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Genomanal, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Dubel, S (corresponding author), Univ Heidelberg, Neuenheimer Feld 230, D-69120 Heidelberg, Germany.		/I-1543-2013	Dubel, Stefan/0000-0001-8811-7390				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BREITLING F, 1991, GENE, V104, P147, DOI 10.1016/0378-1119(91)90244-6; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; Davis W C, 1985, Prog Vet Microbiol Immunol, V1, P1; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; DOTTO GP, 1984, NATURE, V311, P279, DOI 10.1038/311279a0; DUBEL S, 1993, GENE, V128, P97, DOI 10.1016/0378-1119(93)90159-Z; DUENAS M, 1995, FEMS MICROBIOL LETT, V125, P317, DOI 10.1016/0378-1097(94)00517-U; Fisch I, 1996, P NATL ACAD SCI USA, V93, P7761, DOI 10.1073/pnas.93.15.7761; Gavilondo JV, 2000, BIOTECHNIQUES, V29, P128, DOI 10.2144/00291ov01; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KOCH J, IN PRESS ANTIBODY EN; Kramer A, 1998, METH MOL B, V87, P25; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MICHEEL B, 1994, J IMMUNOL METHODS, V171, P103, DOI 10.1016/0022-1759(94)90233-X; NELSON FK, 1981, VIROLOGY, V108, P338, DOI 10.1016/0042-6822(81)90442-6; Rakonjac J, 1997, GENE, V198, P99, DOI 10.1016/S0378-1119(97)00298-9; RONDOT S, 1997, THESIS U HELDELBERG; Sambrook J., 2002, MOL CLONING LAB MANU; Sblattero D, 2000, NAT BIOTECHNOL, V18, P75, DOI 10.1038/71958; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Smith G P, 1988, Biotechnology, V10, P61; Welschof M, 1997, P NATL ACAD SCI USA, V94, P1902, DOI 10.1073/pnas.94.5.1902; Yuan QP, 1997, APPL ENVIRON MICROB, V63, P263, DOI 10.1128/AEM.63.1.263-269.1997	26	198	233	3	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					75	78		10.1038/83567	http://dx.doi.org/10.1038/83567			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135557				2022-12-25	WOS:000166261400024
J	Liu, Y; Jones, M; Hingtgen, CM; Bu, GJ; Laribee, N; Tanzi, RE; Moir, RD; Nath, A; He, JJ				Liu, Y; Jones, M; Hingtgen, CM; Bu, GJ; Laribee, N; Tanzi, RE; Moir, RD; Nath, A; He, JJ			Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-AMYLOID PRECURSOR; LONG TERMINAL REPEAT; ALZHEIMER-DISEASE; INFECTION; EXPRESSION; APOPTOSIS; CELLS; ASTROCYTES; ACTIVATION	Neurological disorders develop in most people infected with human immunodeficiency virus type 1 (HIV-1). However, the underlying mechanisms remain largely unknown. Here we report that binding of HIV-1 transactivator (Tat) protein to low-density lipoprotein receptor-related protein (LRP) promoted efficient uptake of Tat into neurons. LRP-mediated uptake of Tat was followed by translocation to the neuronal nucleus. Furthermore, the binding of Tat to LRP resulted in substantial inhibition of neuronal binding, uptake and degradation of physiological ligands for LRP, including alpha (2)-macroglobulin, apolipoprotein E4, amyloid precursor protein and amyloid beta -protein. In a model of macaques infected with a chimeric strain of simian-human immunodeficiency virus, increased staining of amyloid precursor protein was associated with Tat expression in the brains of simian-human immunodeficiency virus-infected macaques with encephalitis. These results indicate that HIV-1 Tat may mediate HIV-1-induced neuropathology through a pathway involving disruption of the metabolic balance of LRP ligands and direct activation of neuronal genes.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Immunol, Lexington, KY 40536 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA; Walther Canc Inst, Indianapolis, IN 46206 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Kentucky; University of Kentucky; University of Kentucky; Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Walther Cancer Institute	He, JJ (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.		Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019	Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Laribee, R. Nicholas/0000-0003-4519-4470	NINDS NIH HHS [NS39253] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CHANAKYA HN, 1997, BIOENERGY NEWS, V1, P11; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FITZGERALD DJ, 1995, J CELL BIOL, V130, P1015; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HIGUCHI M, 1994, GENE, V141, P155, DOI 10.1016/0378-1119(94)90565-7; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOLSON DL, 1993, AIDS RES HUM RETROV, V9, P677, DOI 10.1089/aid.1993.9.677; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kruman II, 1999, AM J PATHOL, V155, P39, DOI 10.1016/S0002-9440(10)65096-1; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; LEE SHC, 1993, AM J PATHOL, V143, P1032; Liu S, 1999, J POROUS MEDIA, V2, P295, DOI 10.1615/JPorMedia.v2.i3.60; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Mouchel Y, 1995, NEUROREPORT, V7, P205; Narita M, 1997, J NEUROCHEM, V69, P1904; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Raghavan R, 1997, BRAIN PATHOL, V7, P851, DOI 10.1111/j.1750-3639.1997.tb00888.x; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0	46	309	316	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1380	1387		10.1038/82199	http://dx.doi.org/10.1038/82199			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100124				2022-12-25	WOS:000165704100043
J	Maleck, K; Levine, A; Eulgem, T; Morgan, A; Schmid, J; Lawton, KA; Dangl, JL; Dietrich, RA				Maleck, K; Levine, A; Eulgem, T; Morgan, A; Schmid, J; Lawton, KA; Dangl, JL; Dietrich, RA			The transcriptome of Arabidopsis thaliana during systemic acquired resistance	NATURE GENETICS			English	Article							ELICITOR-RESPONSIVE ELEMENT; PLANT-DISEASE RESISTANCE; SALICYLIC-ACID; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; LEAF SENESCENCE; HYDROGEN-PEROXIDE; NUCLEAR EVENTS; CELL-DEATH; PR-1 GENE	Infected plants undergo transcriptional reprogramming during initiation of both local defence and systemic acquired resistance (SAR). We monitored gene-expression changes in Arabidopsis thaliana under 14 different SAR-inducing or SAR-repressing conditions using a DNA microarray representing approximately 25-30% of all A. thaliana genes. We derived groups of genes with common regulation patterns, or regulons. The regulon containing PR-1, a reliable marker gene for SAR in A. thaliana, contains known PR genes and novel genes likely to function during SAR and disease resistance. We identified a common promoter element in genes of this regulon that binds members of a plant-specific transcription factor family. Our results extend expression profiling to definition of regulatory networks and gene discovery in plants.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet, Chapel Hill, NC 27599 USA; Syngenta, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Syngenta	Dangl, JL (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.		Levine, Aaron/E-6495-2010; Bruening, Stefan/B-8505-2011; Levine, Alex/A-6867-2008					Batz O, 1998, BIOL CHEM, V379, P1127, DOI 10.1515/bchm.1998.379.8-9.1127; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Delseny M, 1997, FEBS LETT, V403, P221, DOI 10.1016/S0014-5793(97)00075-6; DEPRES D, 2000, PLANT CELL, V12, P279; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eulgem T, 1999, EMBO J, V18, P4689, DOI 10.1093/emboj/18.17.4689; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fukuda Y, 1997, PLANT MOL BIOL, V34, P81, DOI 10.1023/A:1005737128339; Glazebrook J, 1997, ANNU REV GENET, V31, P547, DOI 10.1146/annurev.genet.31.1.547; Hao DY, 1998, J BIOL CHEM, V273, P26857, DOI 10.1074/jbc.273.41.26857; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lawton KA, 1996, PLANT J, V10, P71, DOI 10.1046/j.1365-313X.1996.10010071.x; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; Li X, 1999, CELL, V98, P329, DOI 10.1016/S0092-8674(00)81962-5; Maleck K, 1999, TRENDS PLANT SCI, V4, P215, DOI 10.1016/S1360-1385(99)01415-6; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Menke FLH, 1999, EMBO J, V18, P4455, DOI 10.1093/emboj/18.16.4455; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Oh SA, 1996, PLANT MOL BIOL, V30, P739, DOI 10.1007/BF00019008; Park JH, 1998, PLANT MOL BIOL, V37, P445, DOI 10.1023/A:1005958300951; Quirino BF, 1999, PLANT MOL BIOL, V40, P267, DOI 10.1023/A:1006199932265; Ruan Y, 1998, PLANT J, V15, P821, DOI 10.1046/j.1365-313X.1998.00254.x; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Somssich IE, 1998, TRENDS PLANT SCI, V3, P86, DOI 10.1016/S1360-1385(98)01199-6; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; Yang YO, 1996, P NATL ACAD SCI USA, V93, P14972, DOI 10.1073/pnas.93.25.14972; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	49	752	825	5	107	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					403	410		10.1038/82521	http://dx.doi.org/10.1038/82521			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101835				2022-12-25	WOS:000165671700010
J	Nishimune, H; Vasseur, S; Wiese, S; Birling, MC; Holtmann, B; Sendtner, M; Iovanna, JL; Henderson, CE				Nishimune, H; Vasseur, S; Wiese, S; Birling, MC; Holtmann, B; Sendtner, M; Iovanna, JL; Henderson, CE			Reg-2 is a motoneuron neurotrophic factor and a signalling intermediate in the CNTF survival pathway	NATURE CELL BIOLOGY			English	Article							PANCREATITIS-ASSOCIATED PROTEIN; MOTOR-NEURON DISEASE; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MESSENGER-RNA; EMBRYONIC MOTONEURONS; SPINAL MOTONEURONS; TROPHIC SUPPORT; FACTOR PREVENTS; GENE-THERAPY	Cytokines that are related to ciliary neurotrophic factor (CNTF) are physiologically important survival factors for motoneurons, but the mechanisms by which they prevent neuronal cell death remain unknown. Reg-2/PAP I (pancreatitis-associated protein I), referred to here as Reg-2, is a secreted protein whose expression in motoneurons during development is dependent on cytokines. Here we show that CNTF-related cytokines induce Reg-2 expression in cultured motoneurons. Purified Reg-E can itself act as an autocrine/paracrine neurotrophic factor for a subpopulation of motoneurons, by stimulating a survival pathway involving phosphatidylinositol-3-kinase, Akt kinase and NF-kappaB. Blocking Reg-2 expression in motoneurons using Reg-2 antisense adenovirus specifically abrogates the survival effect of CNTF on cultured motoneurons, indicating that Reg-2 expression is a necessary step In the CNTF survival pathway. Reg-2 shows a unique pattern of expression in late embryonic spinal cord: it is progressively upregulated in individual motoneurons on a cell-by-cell basis, indicating that only a fraction of motoneurons in a given motor pool may be exposed to cytokines. Thus, Reg-P is a neurotrophic factor for motoneurons, and is itself an obligatory intermediate in the survival signalling pathway of CNTF-related cytokines.	Univ Mediterranee, INSERM, U382, IBDM,CNRS, F-13288 Marseille 9, France; INSERM, U315, F-13009 Marseille, France; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Wurzburg	Henderson, CE (corresponding author), Univ Mediterranee, INSERM, U382, IBDM,CNRS, Campus Luminy,Case 907, F-13288 Marseille 9, France.		vasseur, sophie/O-9803-2017; Sendtner, Michael/J-1542-2012; Iovanna, Juan/M-9805-2017; Nishimune, Hiroshi/B-7226-2013; Sendtner, Michael/M-8137-2014	vasseur, sophie/0000-0002-2339-8854; Sendtner, Michael/0000-0002-4737-2974; Iovanna, Juan/0000-0003-1822-2237; Sendtner, Michael/0000-0002-4737-2974; Birling, Marie-Christine/0000-0002-3372-8108; Henderson, Christopher/0000-0002-9936-3279				ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Arce V, 1999, J NEUROSCI RES, V55, P119, DOI 10.1002/(SICI)1097-4547(19990101)55:1<119::AID-JNR13>3.3.CO;2-Y; Bodeker H, 1999, Mol Cell Biol Res Commun, V2, P150, DOI 10.1006/mcbr.1999.0166; DAVIES AM, 1995, CURR BIOL, V5, P723, DOI 10.1016/S0960-9822(95)00144-8; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; deLapeyriere O, 1997, CURR OPIN GENET DEV, V7, P642, DOI 10.1016/S0959-437X(97)80012-3; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; Garces A, 2000, J NEUROSCI RES, V60, P1, DOI 10.1002/(SICI)1097-4547(20000401)60:1<1::AID-JNR1>3.0.CO;2-P; Gould TW, 1999, DEV BIOL, V216, P611, DOI 10.1006/dbio.1999.9490; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; HARRIS AJ, 1984, J NEUROSCI, V4, P13; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Kahane N, 1996, J NEUROBIOL, V29, P277, DOI 10.1002/(SICI)1097-4695(199603)29:3<277::AID-NEU1>3.0.CO;2-6; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; MacLennan AJ, 1996, J NEUROSCI, V16, P621; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; McKay SE, 1996, DEVELOPMENT, V122, P715; METTLING C, 1995, J NEUROSCI, V15, P3128; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; Nakashima K, 1999, J NEUROSCI, V19, P5429; Okamoto H, 1999, J Hepatobiliary Pancreat Surg, V6, P254, DOI 10.1007/s005340050115; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Sagot Y, 1996, J NEUROSCI, V16, P2335; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Sendtner M, 1997, NAT MED, V3, P380, DOI 10.1038/nm0497-380; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Yamamoto Y, 1999, DEV BIOL, V214, P60, DOI 10.1006/dbio.1999.9413	50	182	193	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					906	914		10.1038/35046558	http://dx.doi.org/10.1038/35046558			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146655				2022-12-25	WOS:000165814500013
J	Yang, DQ; Kastan, MB				Yang, DQ; Kastan, MB			Participation of ATM in insulin signalling through phosphorylation of eIf-4E-binding protein 1	NATURE CELL BIOLOGY			English	Article							ATAXIA-TELANGIECTASIA GENE; P70 S6 KINASE; PHAS-I; TRANSLATIONAL REGULATOR; CELL-GROWTH; DNA-DAMAGE; DEFICIENT MICE; FAT-CELLS; INITIATION; RAPAMYCIN	One of the critical responses to insulin treatment is the stimulation of protein synthesis through induced phosphorylation of the eIF-4E-binding protein 1 (4E-BP1), and the subsequent release of the translation initiation factor, eIF-4E. Here we report that ATM, the protein product of the ATM gene that is mutated in the disease ataxia telangiectasia, phosphorylates 4E-BP1 at Ser 111 in vitro and that insulin treatment induces phosphorylation of 4E-BP1 at Ser 111 in vivo in an ATM-dependent manner In addition, insulin treatment of cells enhances the specific kinase activity of ATM. Cells lacking ATM kinase activity exhibit a significant decrease in the insulin-induced dissociation of 4E-BP1 from eIF-4E. These results suggest an unexpected role for ATM in an insulin-signalling pathway that controls translation initiation. Through this mechanism, a lack of ATM activity probably contributes to some of the metabolic abnormalities, such as poor growth and insulin resistance, reported in ataxia telangiectasia cells and patients with ataxia telangiectasia.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAR RS, 1978, NEW ENGL J MED, V298, P1164, DOI 10.1056/NEJM197805252982103; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Blevins LS, 1996, SOUTHERN MED J, V89, P619, DOI 10.1097/00007611-199606000-00013; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; ELMORE E, 1976, J CELL PHYSIOL, V89, P429, DOI 10.1002/jcp.1040890308; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fadden P, 1998, FEBS LETT, V435, P105, DOI 10.1016/S0014-5793(98)01047-3; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Proud CG, 1997, BIOCHEM J, V328, P329; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHALCH DS, 1970, NEW ENGL J MED, V282, P1396, DOI 10.1056/NEJM197006182822503; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Tuhackova Z, 1999, INT J CANCER, V81, P963, DOI 10.1002/(SICI)1097-0215(19990611)81:6<963::AID-IJC20>3.0.CO;2-C; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Westphal CH, 1997, CANCER RES, V57, P1664; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	50	189	199	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					893	898		10.1038/35046542	http://dx.doi.org/10.1038/35046542			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146653				2022-12-25	WOS:000165814500011
J	Ojala, PM; Yamamoto, K; Castanos-Velez, E; Biberfeld, P; Korsmeyer, SJ; Makela, TP				Ojala, PM; Yamamoto, K; Castanos-Velez, E; Biberfeld, P; Korsmeyer, SJ; Makela, TP			The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2	NATURE CELL BIOLOGY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; PROTEIN-KINASE; CELL-DEATH; RETINOBLASTOMA PROTEIN; ECTOPIC EXPRESSION; CANCER-CELLS; C-JUN; CYCLIN; VIRUS; SUPPRESSION	v-cyclin encoded by Kaposi's sarcoma herpesvirus/human herpesvirus 8 (KSHV or HHV8) associates with cellular cyclin-dependent kinase 6 (CDK6) to form a kinase complex that promotes cell-cycle progression, but can also induce apoptosis in cells with high levels of CDK6. Here we show that whereas HHV8-encoded v-Bcl-5 protects against this apoptosis, cellular Bcl-2 has lost its anti-apoptotic potential as a result of an inactivating phosphorylation in its unstructured loop region. Moreover, we identify Bcl-2 as a new substrate for v-cyclin-CDK6 in vitro, and show that it is present in a complex with CDK6 in cell lysates, A Bcl-2 mutant with a S70A S87A double substitution in the loop region is not phosphorylated and provides resistance to apoptosis, indicating that inactivation of Bcl-2 by v-cyclin-CDK6 may be required for the observed apoptosis. Furthermore, the identification of phosphorylated Bcl-2 in HHV8-positive Kaposi's sarcoma indicates that HHV8-mediated interference with host apoptotic signalling pathways may encourage the development of Kaposi's sarcoma.	Univ Helsinki, Haartman Inst, Helsinki 00014, Finland; Univ Helsinki, Biocentrum, Helsinki 00014, Finland; Univ Helsinki, Cent Hosp, HUCH Lab Diagnost, Hyks 00029, Finland; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Karolinska Inst Hosp, Dept Pathol & Oncol, Immunopathol Lab, S-17176 Stockholm, Sweden	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Karolinska Institutet; Karolinska University Hospital	Ojala, PM (corresponding author), Univ Helsinki, Haartman Inst, POB 21,Haartmaninkatu 3, Helsinki 00014, Finland.		Ojala, Paivi M/J-3266-2014; makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Ojala, Paivi/0000-0001-9065-1832				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Cannell E, 1999, SEMIN CANCER BIOL, V9, P221, DOI 10.1006/scbi.1999.0090; Chan SR, 1998, VIROLOGY, V240, P118, DOI 10.1006/viro.1997.8911; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Dobashi U, 1999, BIOCHEM BIOPH RES CO, V260, P806, DOI 10.1006/bbrc.1999.0983; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Fang GF, 1998, CANCER RES, V58, P3202; Friborg J, 1998, J VIROL, V72, P10073, DOI 10.1128/JVI.72.12.10073-10082.1998; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Hardwick JM, 1998, SEMIN CELL DEV BIOL, V9, P339, DOI 10.1006/scdb.1998.0243; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KAAYA E, IN PRESS MED ONCOL; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Ojala PM, 1999, CANCER RES, V59, P4984; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Sastry KJ, 1996, ONCOGENE, V13, P487; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; SWANTON C, 1997, NATURE, V390, P1864; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	50	133	137	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					819	825		10.1038/35041064	http://dx.doi.org/10.1038/35041064			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056537				2022-12-25	WOS:000165207500016
J	Reiser, V; Salah, SM; Ammerer, G				Reiser, V; Salah, SM; Ammerer, G			Polarized localization of yeast Pbs2 depends on osmostress, the membrane protein Sho1 and Cdc42	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; SIGNAL-TRANSDUCTION; RESPONSE PATHWAY; KINASE CASCADE; CELL POLARITY; ACTIVATION; BINDING; REQUIRES; MAPKK	In Saccharomyces cerevisiae cells, high external osmolarity leads to the activation of a p38-related mitogen-activated protein (MAP) kinase though Pbs2, Pbs2 tagged with green fluorescent protein (Pbs2-GFP) is evenly distributed in the cytoplasm but excluded from the nucleus before and after exposure to stress. Mere we show that a catalytically inactive form of Pbs2 attains a highly polarised localization during osmostress. This phenomenon depends of the osmosensor Sho1 and on a functional Cdc42 GTPase. Cdc42, but not the actin cytoskeleton, influences Sho1-dependent activation of the MAP kinase. Sho1 itself accumulates at sites of polar growth, but independently of stress conditions and Cdc42. These observations allow us to define the sequence of events that occurs during propogation of osmostress signals.	Ludwig Boltzmann Forschungsstelle, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	Ludwig Boltzmann Institute	Ammerer, G (corresponding author), Ludwig Boltzmann Forschungsstelle, Dept Biochem & Mol Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.	ga@abc.univie.ac.at						Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Carroll MC, 1999, CURR OPIN IMMUNOL, V11, P11, DOI 10.1016/S0952-7915(99)80002-8; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Miller PJ, 1997, YEAST, V13, P561; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Oehlen LJWM, 1998, J BIOL CHEM, V273, P8556, DOI 10.1074/jbc.273.15.8556; Palmieri SJ, 1998, CURR OPIN MICROBIOL, V1, P678, DOI 10.1016/S1369-5274(98)80115-X; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	34	113	118	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					620	627		10.1038/35023568	http://dx.doi.org/10.1038/35023568			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980703				2022-12-25	WOS:000089250600014
J	Seri, M; Cusano, R; Gangarossa, S; Caridi, G; Bordo, D; Lo Nigro, C; Ghiggeri, GM; Ravazzolo, R; Savino, M; Del Vecchio, M; d'Apolito, M; Iolascon, A; Zelante, LL; Savoia, A; Balduini, CL; Noris, P; Magrini, U; Belletti, S				Seri, M; Cusano, R; Gangarossa, S; Caridi, G; Bordo, D; Lo Nigro, C; Ghiggeri, GM; Ravazzolo, R; Savino, M; Del Vecchio, M; d'Apolito, M; Iolascon, A; Zelante, LL; Savoia, A; Balduini, CL; Noris, P; Magrini, U; Belletti, S		May-Hegglin Fechtner Syndrome Cors	Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes	NATURE GENETICS			English	Article							MYOSIN HEAVY-CHAINS; LEUKOCYTE INCLUSIONS; NONMUSCLE; MACROTHROMBOCYTOPENIA; VARIANT; PROTEIN; GENE	The autosomal dominant, giant-platelet disorders(1), May-Hegglin anomaly(2,3) (MHA; MIM 155100). Fechtner syndrome(4) (FTNS; MIM 153640) and Sebastian syndrome(5) (SBS), share the triad of thrombocytopenia. large platelets and characteristic leukocyte inclusions ('Dohle-like' bodies). MHA and SBS can be differentiated by subtle ultrastructural leukocyte inclusion features, whereas FTNS is distinguished by the additional Alport-like clinical features of sensorineural deafness, cataracts and nephritis(4). The similarities between these platelet disorders and our recent refinement of the MHA (ref. 6) and FTNS (ref. 7) disease loci to an overlapping region of 480 kb on chromosome 22 suggested that all three disorders are allelic. Among the identified candidate genes is the gene encoding nonmuscle myosin heavy chain 9 (MYH9; refs 8-10). which is expressed in platelets(9) and upregulated during granulocyte differentiation(10). We identified six MYH9 mutations (one nonsense and five missense) in seven unrelated probands from MHA. SBS and FTNS families. On the basis of molecular modelling, the two mutations affecting the myosin head were predicted to impose electrostatic and conformational changes, whereas the truncating mutation deleted the unique carboxyterminal tailpiece. The remaining missense mutations, all affecting highly conserved coiled-coil domain positions, imparted destabilizing electrostatic and polar changes. Thus, our results suggest that mutations in MYH9 result in three megakaryocyte/platelet/leukocyte syndromes and are important in the pathogenesis of sensorineural deafness, cataracts and nephritis.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Struct Neurobiol & Proteom Lab, New York, NY USA; Osped Civile, Clin Pathol Lab, Venice, Italy; Univ Pavia, IRCCS San Matteo, Dept Internal Med, I-27100 Pavia, Italy; Univ Pavia, IRCCS San Matteo, Dept Pathol, I-27100 Pavia, Italy; Univ Bari, Dept Biomed Evolut Age, Bari, Italy; IRCCS Hosp CSS, Med Genet Serv, Foggia, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; IST, Adv Biotechnol Ctr, Genoa, Italy; Inst G Gaslini, Lab Nephrol, Genoa, Italy; Inst G Gaslini, Genet Mol Lab, Genoa, Italy	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; Universita degli Studi di Bari Aldo Moro; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Seri, M (corresponding author), Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.		Ghiggeri, Gian Marco/N-4712-2015; Savoia, Anna/AIC-4560-2022; Caridi, Gianluca/F-7052-2010; Balduini, Carlo L/D-9299-2015; d'Apolito, Maria/G-5793-2012; Iolascon, Achille/A-4461-2014; Savoia, Anna/B-6463-2014; Heath, K. E./ABG-4658-2020; d'Apolito, Maria/AAQ-9290-2021; Heath, Karen Elise/K-7760-2014; Seri, Marco/A-4339-2014	Ghiggeri, Gian Marco/0000-0003-3659-9062; Savoia, Anna/0000-0002-2407-2696; Caridi, Gianluca/0000-0001-6700-3001; Balduini, Carlo L/0000-0001-6121-9311; Savoia, Anna/0000-0002-2407-2696; Heath, K. E./0000-0002-5816-7044; Heath, Karen Elise/0000-0002-5816-7044; Noris, Patrizia/0000-0002-5035-3707; Cusano, Roberto/0000-0001-5543-7881; Seri, Marco/0000-0003-2425-2176	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034045] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01 RR00071] Funding Source: Medline; NICHD NIH HHS [5 P30 HD28822] Funding Source: Medline; NIDDK NIH HHS [5 R37 DK34045] Funding Source: Medline; Telethon [E.1313] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		BIZZARO N, 1997, MED LAB, V5, P165; CITI S, 1988, J MUSCLE RES CELL M, V9, P306, DOI 10.1007/BF01773874; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CUSANO R, IN PRESS EUR J HUM G; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; EPSTEIN CJ, 1972, AM J MED, V52, P299, DOI 10.1016/0002-9343(72)90017-4; GREINACHER A, 1990, BLUT, V61, P282, DOI 10.1007/BF01732878; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HEGGLIN R, 1945, Helv Med Acta, V12, P439; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; Kunishima S, 1999, HUM GENET, V105, P379, DOI 10.1007/s004390051119; Lalwani AK, 1999, AM J HUM GENET, V64, P318, DOI 10.1086/302216; LUCAS RC, 1975, PROTIDES BIOL FLUIDS, P465; Martignetti JA, 2000, AM J HUM GENET, V66, P1449, DOI 10.1086/302873; May R, 1909, DTSCH ARCH KLIN MED, V96, P1; Mhawech P, 2000, AM J CLIN PATHOL, V113, P176, DOI 10.1309/FC4H-LM5V-VCW8-DNJU; Moxey-Mims MM, 1999, PEDIATR NEPHROL, V13, P782, DOI 10.1007/s004670050700; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; Noris P, 1998, AM J MED, V104, P355, DOI 10.1016/S0002-9343(98)00062-X; PETERSON LC, 1985, BLOOD, V65, P397; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TOOTHAKER LE, 1991, BLOOD, V78, P1826; Toren A, 1999, AM J HUM GENET, V65, P1711, DOI 10.1086/302654; Urato AC, 1998, AM J OBSTET GYNECOL, V179, P260, DOI 10.1016/S0002-9378(98)70283-2; Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506	30	320	331	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					103	105						3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973259				2022-12-25	WOS:000089078000028
J	Dubertret, B; Calame, M; Libchaber, AJ				Dubertret, B; Calame, M; Libchaber, AJ			Single-mismatch detection using gold-quenched fluorescent oligonucleotides	NATURE BIOTECHNOLOGY			English	Article							OPTICAL-PROPERTIES; MULTIPLEX DETECTION; DNA; POLYNUCLEOTIDES; SPECIFICITY	Here we describe a hybrid material composed of a single-stranded DNA (ssDNA) molecule, a 1.4 nm diameter gold nanoparticle, and a fluorophore that is highly quenched by the nanoparticle through a distance-dependent process. The fluorescence of this hybrid molecule increases by a factor of as much as several thousand as it binds to a complementary ssDNA. We show that this composite molecule is a different type of molecular beacon with a sensitivity enhanced up to 100-fold. In competitive hybridization assays, the ability to detect singlemismatch is eightfold greater with this probe than with other molecular beacons.	Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University	Dubertret, B (corresponding author), Rockefeller Univ, Ctr Studies Phys & Biol, 1230 York Ave, New York, NY 10021 USA.	benoit@pollux.rockefeller.edu	Calame, Michel/O-8818-2019; Calame, Michel/A-5037-2008	Calame, Michel/0000-0001-7467-9915; Calame, Michel/0000-0001-7467-9915				Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Bonnet G, 1998, P NATL ACAD SCI USA, V95, P8602, DOI 10.1073/pnas.95.15.8602; Bonnet G, 1999, P NATL ACAD SCI USA, V96, P6171, DOI 10.1073/pnas.96.11.6171; Bonnet G, 1999, PHYSICA A, V263, P68, DOI 10.1016/S0378-4371(98)00516-0; CHANCE RR, 1978, ADV CHEM PHYS, V37, P1, DOI DOI 10.1002/9780470142561.CH1; Chang SS, 1999, LANGMUIR, V15, P701, DOI 10.1021/la980929l; DOREMUS RH, 1964, J CHEM PHYS, V40, P2389, DOI 10.1063/1.1725519; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; GERSTEN J, 1981, J CHEM PHYS, V75, P1139, DOI 10.1063/1.442161; HAINFELD JF, 1989, COLLOIDAL GOLD PRINC, V2, P413, DOI DOI 10.1016/B978-0-12-333928-7.50026-5; Kreibig U., 1995, OPTICAL PROPERTIES M, P1, DOI [10.1007/978-3-662-09109-8_1, DOI 10.1007/978-3-662-09109-8_1]; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Loweth CJ, 1999, ANGEW CHEM INT EDIT, V38, P1808, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1808::AID-ANIE1808>3.0.CO;2-C; Lyon LA, 1998, ANAL CHEM, V70, p341R; Marras SAE, 1999, GENET ANAL-BIOMOL E, V14, P151, DOI 10.1016/S1050-3862(98)00018-7; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Mitchell GP, 1999, J AM CHEM SOC, V121, P8122, DOI 10.1021/ja991662v; MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783; Niemeyer CM, 1998, ANGEW CHEM INT EDIT, V37, P2265, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2265::AID-ANIE2265>3.0.CO;2-F; Schultz S, 2000, P NATL ACAD SCI USA, V97, P996, DOI 10.1073/pnas.97.3.996; Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91, DOI 10.1038/72006; Storhoff JJ, 2000, J AM CHEM SOC, V122, P4640, DOI 10.1021/ja993825l; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vet JAM, 1999, P NATL ACAD SCI USA, V96, P6394, DOI 10.1073/pnas.96.11.6394; WEITZ DA, 1983, J CHEM PHYS, V78, P5324, DOI 10.1063/1.445486; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043	29	1036	1110	6	469	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					365	370		10.1038/86762	http://dx.doi.org/10.1038/86762			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283596				2022-12-25	WOS:000167940700027
J	Sebbagh, M; Renvoize, C; Hamelin, J; Riche, N; Bertoglio, J; Breard, J				Sebbagh, M; Renvoize, C; Hamelin, J; Riche, N; Bertoglio, J; Breard, J			Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing	NATURE CELL BIOLOGY			English	Article							RHO-ASSOCIATED KINASE; LIGHT-CHAIN PHOSPHORYLATION; BINDING PROTEIN; MYOSIN PHOSPHATASE; MORPHOLOGICAL-CHANGES; ENDOTHELIAL-CELLS; DNA FRAGMENTATION; FOCAL ADHESIONS; NUCLEAR EVENTS; SMOOTH-MUSCLE	Increased phosphorylation of myosin light chain (MLC) is necessary for the dynamic membrane blebbing that is observed at the onset of apoptosis. Here we identify ROCK I, an effector of the small GTPase Rho, as a new substrate for caspases. ROCK I is cleaved by caspase-3 at a conserved DETD1113/G sequence and its carboxy-terminal inhibitory domain is removed, resulting in deregulated and constitutive kinase activity. ROCK proteins are known to regulate MLC-phosphorylation and apoptotic cells exhibit a gradual increase in levels of phosphorylated MLC concomitant with ROCK I cleavage. This phosphorylation, as well as membrane blebbing, is abrogated by inhibition of caspases or ROCK proteins, but both processes are independent of Rho activity. We also show that expression of active truncated ROCK I induces cell blebbing. Thus, activation of ROCK I by caspase-3 seems to be responsible for bleb formation in apoptotic cells.	Fac Pharm Chatenay Malabry, INSERM U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Breard, J (corresponding author), Fac Pharm Chatenay Malabry, INSERM U461, F-92296 Chatenay Malabry, France.		Sebbagh, Michael/E-8502-2017; HAMELIN, Jocelyne JH/R-4590-2018	Sebbagh, Michael/0000-0003-2468-7006; HAMELIN, Jocelyne JH/0000-0003-4222-0792				ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KERR JF, 1994, CANCER, V73, P3108; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kohama K, 1996, TRENDS PHARMACOL SCI, V17, P284, DOI 10.1016/0165-6147(96)10033-X; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; Laster SM, 1996, MICROSC RES TECHNIQ, V34, P272, DOI 10.1002/(SICI)1097-0029(19960615)34:3<272::AID-JEMT10>3.0.CO;2-J; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MAJNO G, 1995, AM J PATHOL, V146, P3; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Rao JY, 1999, J CELL BIOCHEM, V75, P686, DOI 10.1002/(SICI)1097-4644(19991215)75:4<686::AID-JCB14>3.0.CO;2-F; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudolf E, 2000, FRONT BIOSCI, V5, pF1, DOI 10.2741/Rudolf; Scaffidi C, 1999, METHODS, V17, P287, DOI 10.1006/meth.1999.0742; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	45	680	719	2	48	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					346	352		10.1038/35070019	http://dx.doi.org/10.1038/35070019			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283607				2022-12-25	WOS:000168043900012
J	Yaffe, MB; Leparc, GG; Lai, J; Obata, T; Volinia, S; Cantley, LC				Yaffe, MB; Leparc, GG; Lai, J; Obata, T; Volinia, S; Cantley, LC			A motif-based profile scanning approach for genome-wide prediction of signaling pathways	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHOSPHORYLATION; DATABASE; SITES; PATTERNS; SURVIVAL; PEPTIDE; DOMAINS; SHC	The rapid increase in genomic information requires new techniques to infer protein function and predict protein-protein interactions. Bioinformatics identifies modular signaling domains within protein sequences with a high degree of accuracy. In contrast, little success has been achieved in predicting short linear sequence motifs within proteins targeted by these domains to form complex signaling networks. Here we describe a peptide library-based searching algorithm, accessible over the World Wide Web, that identifies sequence motifs likely to bind to specific protein domains such as 14-3-3, SH2, and SH3 domains, or likely to be phosphorylated by specific protein kinases such as Src and AKT Predictions from database searches for proteins containing motifs matching two different domains in a common signaling pathway provides a much higher success rate. This technology facilitates prediction of cell signaling networks within proteomes, and could aid in the identification of drug targets for the treatment of human diseases.	Harvard Univ, Inst Med, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; Dip Morfol & Embriol, Sez Istol, I-44100 Ferrara, Italy; Ctr Mol Genet Fdn CARISBO, Bologna, Italy; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Yaffe, MB (corresponding author), Harvard Univ, Inst Med, Dept Med, Div Signal Transduct, 10th Floor,330 Brookline Ave, Boston, MA 02215 USA.	myaffe@mit.edu	Volinia, Stefano/AAA-9264-2019; Cantley, Lewis C/D-1800-2014; Volinia, Stefano/A-3029-2010	Volinia, Stefano/0000-0003-0910-3893; Cantley, Lewis C/0000-0002-1298-7653; Volinia, Stefano/0000-0003-0910-3893	NHLBI NIH HHS [HL03601] Funding Source: Medline; NIGMS NIH HHS [GM56203, R01 GM056203, GM59281] Funding Source: Medline; Telethon [E.0887] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, R01GM059281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LUTHY R, 1994, PROTEIN SCI, V3, P139; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Rebhan M., 1997, GENECARDS ENCY GENES; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2000, METHOD ENZYMOL, V328, P157, DOI 10.1016/S0076-6879(00)28397-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou SY, 1998, METH MOL B, V87, P87	31	455	474	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					348	353		10.1038/86737	http://dx.doi.org/10.1038/86737			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283593				2022-12-25	WOS:000167940700024
J	Freichel, M; Suh, SH; Pfeifer, A; Schweig, U; Trost, C; Weissgerber, P; Biel, M; Philipp, S; Freise, D; Droogmans, G; Hofmann, F; Flockerzi, V; Nilius, B				Freichel, M; Suh, SH; Pfeifer, A; Schweig, U; Trost, C; Weissgerber, P; Biel, M; Philipp, S; Freise, D; Droogmans, G; Hofmann, F; Flockerzi, V; Nilius, B			Lack of an endothelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in TRP4(-)/(-) mice	NATURE CELL BIOLOGY			English	Article							CAPACITATIVE CALCIUM-ENTRY; HUMAN UMBILICAL VEIN; CATION CHANNELS; NITRIC-OXIDE; HTRP3 CHANNELS; TRP PROTEINS; CELLS; DEPLETION; INFLUX; ACTIVATION	Agonist-induced Ca2+ entry into cells by both store-operated channels and channels activated independently of Ca2+-store depletion has been described in various cell types. The molecular structures of these channels are unknown as is, in most cases, their impact on various cellular functions. Here we describe a store-operated Ca2+ current in vascular endothelium and show that endothelial cells of mice deficient in TRP4 (also known as CCE1) lack this current. As a consequence, agonist-induced Ca2+ entry and vasorelaxation is reduced markedly, showing that TRP4 is an indispensable component of store-operated channels in native endothelial cells and that these channels directly provide an Ca2+-entry pathway essentially contributing to the regulation of blood vessel tone.	Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80808 Munich, Germany	Saarland University; KU Leuven; Technical University of Munich	Flockerzi, V (corresponding author), Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.		Biel, Martin/G-1175-2014; Philipp, Stephan/AAR-7519-2020	Biel, Martin/0000-0002-9974-3052; Philipp, Stephan/0000-0003-1959-9167				BERRY P, 1995, DRUG-EDUC PREV POLIC, V2, P59, DOI 10.3109/09687639509006672; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; CARTER TD, 1992, NEWS PHYSIOL SCI, V7, P64; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; Freichel M, 1998, FEBS LETT, V422, P354, DOI 10.1016/S0014-5793(98)00041-6; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Iouzalen L, 1996, CELL CALCIUM, V20, P501, DOI 10.1016/S0143-4160(96)90092-5; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kamouchi M, 1999, J MEMBRANE BIOL, V169, P29, DOI 10.1007/PL00005898; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Lantoine F, 1998, BIOCHEM J, V330, P695, DOI 10.1042/bj3300695; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; MENDELOWITZ D, 1992, AM J PHYSIOL, V262, pH942, DOI 10.1152/ajpheart.1992.262.4.H942; MONCADA S, 1991, PHARMACOL REV, V43, P109; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; NILIUS B, 1997, ANN REV PHYSL, V59; OIKE M, 1994, CELL CALCIUM, V16, P367, DOI 10.1016/0143-4160(94)90030-2; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Somasundaram B, 1997, J PHYSIOL-LONDON, V501, P485, DOI 10.1111/j.1469-7793.1997.485bm.x; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Suh SH, 2000, ENDOTHELIUM-J ENDOTH, V7, P155, DOI 10.3109/10623320009165314; Suh Suk Hyo, 1999, Korean Journal of Physiology and Pharmacology, V3, P415; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; VACA L, 1993, AM J PHYSIOL, V264, pH1319, DOI 10.1152/ajpheart.1993.264.4.H1319; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	41	458	485	1	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					121	127		10.1038/35055019	http://dx.doi.org/10.1038/35055019			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175743				2022-12-25	WOS:000166793000012
J	Jaffrey, SR; Erdjument-Bromage, H; Ferris, CD; Tempst, P; Snyder, SH				Jaffrey, SR; Erdjument-Bromage, H; Ferris, CD; Tempst, P; Snyder, SH			Protein S-nitrosylation: a physiological signal for neuronal nitric oxide	NATURE CELL BIOLOGY			English	Article							NMDA RECEPTOR ACTIVATION; POLYMERASE-II HOLOENZYME; DROSOPHILA DEVELOPMENT; CREATINE-KINASE; SERUM-ALBUMIN; NO; NITROSOGLUTATHIONE; NITROSOTHIOLS; SYNTHASE; GLUTATHIONE	Nitric oxide (NO) has been linked to numerous physiological and pathophysiological events that ave not readily explained by the well established effects of NO on soluble guanylyl cyclase. Exogenous NO S-nitrosylates cysteine residues in proteins, but whether this is an important function of endogenous NO is unclear. Here, using a new proteomic approach, we identify a population of proteins that are endogenously S-nitrosylated, and demonstrate the loss of this modification in mice harbouring a genomic deletion of neuronal NO synthase (nNOS). Targets of NO include metabolic, structural and signalling proteins that may be effecters for neuronally generated PIG. These findings establish protein S-nitrosylation as a physiological signalling mechanism for nNOS.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Memorial Sloan Kettering Cancer Center	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu		Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Jaffrey, Samie/0000-0003-3615-6958				Andrade FH, 1998, J PHYSIOL-LONDON, V509, P577, DOI 10.1111/j.1469-7793.1998.577bn.x; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; Borgs M, 1996, HEPATOLOGY, V23, P1564, DOI 10.1053/jhep.1996.v23.pm0008675178; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dicks AP, 1996, CHEM BIOL, V3, P655, DOI 10.1016/S1074-5521(96)90133-7; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; Inglis FM, 1998, J NEUROSCI, V18, P10493; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KashibaIwatsuki M, 1997, J BIOCHEM-TOKYO, V122, P1208; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kluge I, 1997, J NEUROCHEM, V69, P2599; Kuzin B, 2000, CURR BIOL, V10, P459, DOI 10.1016/S0960-9822(00)00443-7; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Sato T, 1995, BRAIN RES, V704, P117, DOI 10.1016/0006-8993(95)01165-X; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADTMAN TC, 1980, ANNU REV BIOCHEM, V49, P93, DOI 10.1146/annurev.bi.49.070180.000521; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STUCHBURY T, 1975, BIOCHEM J, V151, P417, DOI 10.1042/bj1510417; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	47	1163	1205	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					193	197		10.1038/35055104	http://dx.doi.org/10.1038/35055104			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175752				2022-12-25	WOS:000166793000021
J	Paul, R; Zhang, ZG; Eliceiri, BP; Jiang, Q; Boccia, AD; Zhang, RL; Chopp, M; Cheresh, DA				Paul, R; Zhang, ZG; Eliceiri, BP; Jiang, Q; Boccia, AD; Zhang, RL; Chopp, M; Cheresh, DA			Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke	NATURE MEDICINE			English	Article							TYROSINE KINASE; FAMILY KINASES; MUTANT MICE; BRAIN; CELLS; ISCHEMIA; INJURY; WATER; EDEMA; RAT	Vascular endothelial growth factor (VEGF), an angiogenic factor produced in response to ischemic injury, promotes vascular permeability (VP). Evidence is provided that Src kinase regulates VEGF-mediated VP in the brain following stroke and that suppression of Src activity decreases VP thereby minimizing brain injury. Mice lacking pp60(c-sr)c are resistant to VEGF-induced VP and show decreased infarct volumes after stroke whereas mice deficient in pp59(c-fyn), another Src family member, have normal VEGF-mediated VP and infarct size. Systemic application of a Src-inhibitor given up to six hours following stroke suppressed VP protecting wild-type mice from ischemia-induced brain damage without influencing VEGF expression. This was associated with reduced edema, improved cerebral perfusion and decreased infarct volume 24 hours after injury as measured by magnetic resonance imaging and histological analysis. Thus, Src represents a key intermediate and novel therapeutic target in the pathophysiology of cerebral ischemia where it appears to regulate neuronal damage by influencing VEGF-mediated VP.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA	Scripps Research Institute; Scripps Research Institute; Henry Ford Health System; Henry Ford Hospital	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	cheresh@scripps.edu		Eliceiri, Brian/0000-0003-1811-1916	NATIONAL CANCER INSTITUTE [R03CA050287, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009435] Funding Source: NIH RePORTER; NCI NIH HHS [CA50287, CA45726] Funding Source: Medline; NHLBI NIH HHS [1F32HL09435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES A, 1968, AM J PATHOL, V52, P437; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Go K G, 1997, Adv Tech Stand Neurosurg, V23, P47; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JIANG Q, 1993, J NEUROL SCI, V120, P123, DOI 10.1016/0022-510X(93)90262-W; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Patel SC, 1999, PROG CARDIOVASC DIS, V42, P217, DOI 10.1016/S0033-0620(99)70004-6; Pfister HW, 1997, CURR OPIN NEUROL, V10, P254, DOI 10.1097/00019052-199706000-00015; Risau W, 1998, PATHOL BIOL, V46, P171; Rosenberg GA, 1999, PROG CARDIOVASC DIS, V42, P209, DOI 10.1016/S0033-0620(99)70003-4; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Takagi N, 1999, J CEREBR BLOOD F MET, V19, P880, DOI 10.1097/00004647-199908000-00007; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 1997, J CEREBR BLOOD F MET, V17, P1081, DOI 10.1097/00004647-199710000-00010	31	294	329	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					222	227		10.1038/84675	http://dx.doi.org/10.1038/84675			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175854				2022-12-25	WOS:000166756300040
J	Alagramam, KN; Murcia, CL; Kwon, HY; Pawlowski, KS; Wright, CG; Woychik, RP				Alagramam, KN; Murcia, CL; Kwon, HY; Pawlowski, KS; Wright, CG; Woychik, RP			The mouse Ames waltzer hearing-loss mutant is caused by mutation of Pcdh15, a novel protocadherin gene	NATURE GENETICS			English	Article							DEAFNESS	The neuroepithelia of the inner ear contain hair cells that function as mechanoreceptors to transduce sound and motion signals. Mutations affecting these neuroepithelia cause deafness and vestibular dysfunction in humans(1-3). Ames waltzer (av) is a recessive mutation found in mice that causes deafness and a balance disorder associated with the degeneration of inner ear neuroepithelial. Here we report that the gene that harbours the av mutation encodes a novel protocadherin. Cochlear hair cells in the av mutants show abnormal stereocilia by 10 days after birth (P10). This is the first evidence for the requirement of a protocadherin for normal function of the mammalian inner ear.	Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Oak Ridge Natl Lab, Div Biol, Oak Ridge, TN 37831 USA; Div Genet Engn, Korean Ind Property Off, Seo Ku, Taejon, South Korea; Univ Texas, SW Med Ctr, Dept Otorhinolaryngol, Dallas, TX USA; Pfizer Global Res & Dev, Alameda, CA USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pfizer	Woychik, RP (corresponding author), Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003420] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07104] Funding Source: Medline; NIDCD NIH HHS [1RO1-DC03420] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Alagramam KN, 1999, GENETICS, V152, P1691; Alagramam KN, 2000, HEARING RES, V148, P181, DOI 10.1016/S0378-5955(00)00152-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; BORK JM, IN PRESS AM J HUM GE; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; COOK S, 1993, MOUSE GENOME, V91, P554; Corwin JT, 1998, P NATL ACAD SCI USA, V95, P12080, DOI 10.1073/pnas.95.21.12080; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; OSAKO S, 1971, ACTA OTO-LARYNGOL, V71, P365, DOI 10.3109/00016487109125376; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; SCHAIBLE RH, 1956, MOUSE NEWS LETT, V15, P29; SCHAIBLE RH, 1961, MOUSE NEWS LETT, V24, P38; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VandenHeuvel GB, 1996, BIOL REPROD, V55, P731, DOI 10.1095/biolreprod55.4.731; Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506; Xu Y, 1994, Genet Eng (N Y), V16, P241	19	242	252	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					99	102		10.1038/83837	http://dx.doi.org/10.1038/83837			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138007				2022-12-25	WOS:000166187900024
J	Schwikowski, B; Uetz, P; Fields, S				Schwikowski, B; Uetz, P; Fields, S			A network of protein-protein interactions in yeast	NATURE BIOTECHNOLOGY			English	Article						protein interactions; Saccharomyces cerevisiae; functional genomics; proteomics; bioinformatics	INTERACTION MAP; GENOME; DATABASE; SYSTEM	A global analysis of 2,709 published interactions between proteins of the yeast Saccharomyces cerevisiae has been performed, enabling the establishment of a single large network of 2,358 interactions among 1,548 proteins. Proteins of known function and cellular location tend to cluster together, with 63% of the interactions occurring between proteins with a common functional assignment and 76% occurring between proteins found in the same subcellular compartment. Possible functions can be assigned to a protein based on the known functions of its interacting partners. This approach correctly predicts a functional category for 72% of the 1,393 characterized proteins with at least one partner of known function, and has been applied to predict functions for 364 previously uncharacterized proteins.	Inst Syst Biol, Seattle, WA 98105 USA; Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	Institute for Systems Biology (ISB); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Schwikowski, B (corresponding author), Inst Syst Biol, 4225 Roosevelt Way NE,Suite 200, Seattle, WA 98105 USA.	benno@systemsbiology.org; uetz@u.washington.edu; fields@u.washington.edu	Uetz, Peter/A-7119-2012	Uetz, Peter/0000-0001-6194-4927; Schwikowski, Benno/0000-0001-5127-5619	NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; Harrington CA, 2000, CURR OPIN MICROBIOL, V3, P285, DOI 10.1016/S1369-5274(00)00091-6; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kumar A, 2000, NUCLEIC ACIDS RES, V28, P81, DOI 10.1093/nar/28.1.81; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SUGIYAMA K, 1981, IEEE T SYST MAN CYB, V11, P109, DOI 10.1109/TSMC.1981.4308636; UETZ P, 2000, NATURE, V3, P304; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289; Zhang MQ, 1999, COMPUT CHEM, V23, P233, DOI 10.1016/S0097-8485(99)00020-0	24	937	1000	1	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1257	1261		10.1038/82360	http://dx.doi.org/10.1038/82360			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101803				2022-12-25	WOS:000165659000021
J	Lagasse, E; Connors, H; Al-Dhalimy, M; Reitsma, M; Dohse, M; Osborne, L; Wang, X; Finegold, M; Weissman, IL; Grompe, M				Lagasse, E; Connors, H; Al-Dhalimy, M; Reitsma, M; Dohse, M; Osborne, L; Wang, X; Finegold, M; Weissman, IL; Grompe, M			Purified hematopoietic stem cells can differentiate into hepatocytes in vivo	NATURE MEDICINE			English	Article							TYROSINEMIA TYPE-I; BONE-MARROW; MONOCLONAL-ANTIBODIES; HEPATIC-DYSFUNCTION; BETA-GALACTOSIDASE; MURINE MODEL; TRANSPLANTATION; PROGENITORS; EXPRESSION; GENE	The characterization of hepatic progenitor cells is of great scientific and clinical interest. Here we report that intravenous injection of adult bone marrow cells in the FAH(-/-) mouse, an animal model of tyrosinemia type I, rescued the mouse and restored the biochemical function of its liver. Moreover, within bone marrow, only rigorously purified hematopoietic stem cells gave rise to donor-derived hematopoietic and hepatic regeneration. This result seems to contradict the conventional assumptions of the germ layer origins of tissues such as the liver, and raises the question of whether the cells of the hematopoietic stem cell phenotype are pluripotent hematopoietic cells that retain the ability to transdifferentiate, or whether they are more primitive multipotent cells.	StemCells, Sunnyvale, CA 94085 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Texas Childrens Hosp, Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Stanford Univ, Sch Med, Dept Pathol & Dev Biol, Stanford, CA 94305 USA	Oregon Health & Science University; Baylor College of Medicine; Stanford University	Lagasse, E (corresponding author), StemCells, 525 Del Rey Ave,Suite C, Sunnyvale, CA 94085 USA.			Grompe, Markus/0000-0002-6616-4345				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Braun KM, 2000, NAT MED, V6, P320; Carella AM, 2000, BONE MARROW TRANSPL, V25, P345, DOI 10.1038/sj.bmt.1702204; Ferrari G, 1998, SCIENCE, V281, P923; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hale DA, 2000, TRANSPLANTATION, V69, P1242, DOI 10.1097/00007890-200004150-00008; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Murata M, 1997, INT J HEMATOL, V66, P239; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Overturf K, 1996, NAT GENET, V12, P458, DOI 10.1038/ng0496-458a; Overturf K, 1999, AM J PATHOL, V155, P2135, DOI 10.1016/S0002-9440(10)65531-9; Overturf K, 1997, AM J PATHOL, V151, P1273; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; RITT AW, 1988, JAMA-J AM MED ASSOC, V259, P3099; SELL S, 1997, LIVER STEM CELLS, P29; Shizuru J A, 1996, Biol Blood Marrow Transplant, V2, P3; SHIZURU JA, 1996, BIOL BLOOD MARROW TR, V3, P50; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Strom SC, 1999, SEMIN LIVER DIS, V19, P39, DOI 10.1055/s-2007-1007096; TALBOT NC, 1994, IN VITRO CELL DEV-AN, V30A, P851; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; TILL J, 1961, RAD RES, V14; Uchida N, 1997, BLOOD, V90, P4354; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; UCHIDA N, 1992, THESIS STANFORD U ST, P152; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; WU AM, 1968, J EXP MED, V127, P455, DOI 10.1084/jem.127.3.455; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	48	1880	2152	4	130	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1229	1234		10.1038/81326	http://dx.doi.org/10.1038/81326			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062533				2022-12-25	WOS:000165114800029
J	Liechty, KW; MacKenzie, TC; Shaaban, AF; Radu, A; Moseley, AB; Deans, R; Marshak, DR; Flake, AW				Liechty, KW; MacKenzie, TC; Shaaban, AF; Radu, A; Moseley, AB; Deans, R; Marshak, DR; Flake, AW			Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep	NATURE MEDICINE			English	Article							MARROW STROMAL CELLS; BONE-MARROW; NONHEMATOPOIETIC TISSUES; OSTEOGENESIS IMPERFECTA; EXPRESSION; DYSTROPHIN; MICE	Mesenchymal stem cells are multipotent cells that can be isolated from adult bone marrow and can be induced in vitro and in vivo to differentiate into a variety of mesenchymal tissues, including bone, cartilage, tendon, fat, bone marrow stroma, and muscle(1,2). Despite their potential clinical utility for cellular and gene therapy, the fate of mesenchymal stem cells after systemic administration is mostly unknown. To address this, we transplanted a well-characterized human mesenchymal stem cell population(3) into fetal sheep early in gestation, before and after the expected development of immunologic competence. In this xenogeneic system, human mesenchymal stem cells engrafted and:persisted in multiple tissues for as long as 13 months after transplantation. Transplanted human cells underwent site-specific differentiation into chondrocytes, adipocytes, myocytes and cardiomyocytes, bone marrow stromal cells and thymic stroma. Unexpectedly, there was long-term engraftment even when cells were transplanted after the expected development of immunocompetence. Thus, mesenchymal stem cells maintain their multipotential capacity after transplantation, and seem to have unique immunologic characteristics that allow persistence in-a xenogeneic environment. Our data support the possibility of the transplantability of mesenchymal stem cells and their potential utility in tissue engineering, and cellular and gene therapy applications.	Childrens Hosp Philadelphia, Childrens Inst Surg Sci, Philadelphia, PA 19104 USA; Osiris Therapeut, Baltimore, MD 21231 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Osiris Therapeutics	Flake, AW (corresponding author), Childrens Hosp Philadelphia, Childrens Inst Surg Sci, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Shaaban, Aimen/0000-0002-9459-107X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009856] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL009856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKLESARIA P, 1987, P NATL ACAD SCI USA, V84, P7681, DOI 10.1073/pnas.84.21.7681; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; Culling CFA, 1974, HDB HISTOPATHOLOGICA, V3rd; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; Fourcade C, 1992, Eur Cytokine Netw, V3, P539; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hou Z, 1999, P NATL ACAD SCI USA, V96, P7294, DOI 10.1073/pnas.96.13.7294; KEATING A, 1982, NATURE, V298, P280, DOI 10.1038/298280a0; NICHOLSON LVB, 1992, ACTA NEUROL SCAND, V86, P8, DOI 10.1111/j.1600-0404.1992.tb08046.x; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; SHARP AH, 1993, J NEUROSCI, V13, P3051; SILVERSTEIN AM, 1964, J EXP MED, V119, P955, DOI 10.1084/jem.119.6.955; VANDERLOOS CM, 1993, HISTOCHEM J, V25, P1; Zanjani ED, 1996, INT J HEMATOL, V63, P179; Zanjani ED, 1998, EXP HEMATOL, V26, P353; ZANJANI ED, 1993, BLOOD, V81, P399; Zanjani ED, 1997, STEM CELLS, V15, P79, DOI 10.1002/stem.5530150812; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; [No title captured]	25	963	1137	2	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1282	1286		10.1038/81395	http://dx.doi.org/10.1038/81395			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062543				2022-12-25	WOS:000165114800039
J	Naqvi, NI; Wong, KCY; Tang, X; Balasubramanian, MK				Naqvi, NI; Wong, KCY; Tang, X; Balasubramanian, MK			Type II myosin regulatory light chain relieves auto-inhibition of myosin-heavy-chain function	NATURE CELL BIOLOGY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DICTYOSTELIUM-DISCOIDEUM; CYTOKINESIS; GENE; IDENTIFICATION; DISRUPTION; CELLS; RING	The F-actin based motor protein myosin II has a key role in cytokinesis. Here we show that the Schizosaccharomyces pombe regulatory light chain (RLC) protein Rlc1p binds to Myo2p in manner that is dependent on the IQ sequence motif (the RLC-binding site), and that Rlc1p is a component of the actomyosin ring. Rlc1p is important for cytokinesis at all growth temperatures and is essential for this process at lower temperatures. Interestingly, all deleterious phenotypes associated with the loss of Rlc1p function are suppressed by deletion of the RLC binding site on Myo2p. We conclude that the sole essential function of RLCs in fission yeast is to relieve the auto-inhibition of myosin ii function, which is mediated by the RLC-binding site, on the myosin heavy chain (MHC).	Natl Univ Singapore, Inst Mol Agrobiol, Cell Div Lab, Singapore 117604, Singapore	National University of Singapore	Naqvi, NI (corresponding author), Natl Univ Singapore, Inst Mol Agrobiol, Cell Div Lab, 1 Res Link, Singapore 117604, Singapore.		Naqvi, Naweed/CAG-5662-2022	Balasubramanian, Mohan/0000-0002-1292-8602; Naqvi, Naweed/0000-0002-3619-4906				Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Balasubramanian MK, 1998, GENETICS, V149, P1265; Bezanilla M, 2000, CURR BIOL, V10, P397, DOI 10.1016/S0960-9822(00)00420-6; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KEENEY JB, 1994, GENETICS, V136, P849; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; May KM, 1997, CELL MOTIL CYTOSKEL, V38, P385, DOI 10.1002/(SICI)1097-0169(1997)38:4<385::AID-CM8>3.0.CO;2-2; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; Motegi F, 2000, J CELL SCI, V113, P1813; Motegi F, 1997, FEBS LETT, V420, P161, DOI 10.1016/S0014-5793(97)01510-X; Mulvihill DP, 2000, MICROSC RES TECHNIQ, V49, P152; Naqvi NI, 1999, EMBO J, V18, P854, DOI 10.1093/emboj/18.4.854; Neujahr R, 1997, J CELL SCI, V110, P123; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074	22	72	72	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					855	858		10.1038/35041107	http://dx.doi.org/10.1038/35041107			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056543				2022-12-25	WOS:000165207500022
J	Niemann, S; Muller, U				Niemann, S; Muller, U			Mutations in SDHC cause autosomal dominant paraganglioma, type 3	NATURE GENETICS			English	Article							CHROMOSOME; TUMORS; 11Q23; GENE		Univ Giessen, Inst Human Genet, Giessen, Germany	Justus Liebig University Giessen	Muller, U (corresponding author), Univ Giessen, Inst Human Genet, Giessen, Germany.							Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; GRUFFERMAN S, 1980, CANCER, V46, P2116, DOI 10.1002/1097-0142(19801101)46:9<2116::AID-CNCR2820460934>3.0.CO;2-S; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075; Niemann S, 1999, NEUROGENETICS, V2, P167, DOI 10.1007/s100480050078; VANDERMEY AGL, 1989, LANCET, V2, P1291	8	701	719	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					268	270		10.1038/81551	http://dx.doi.org/10.1038/81551			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062460				2022-12-25	WOS:000165176500009
J	Tian, XC; Xu, J; Yang, XZ				Tian, XC; Xu, J; Yang, XZ			Normal telomere lengths found in cloned cattle	NATURE GENETICS			English	Article							CELLS; ADULT; MICE		Univ Connecticut, Dept Anim Sci, Storrs, CT 06268 USA; Univ Connecticut, Ctr Biotechnol, Storrs, CT USA	University of Connecticut; University of Connecticut	Yang, XZ (corresponding author), Univ Connecticut, Dept Anim Sci, Storrs, CT 06268 USA.		Pillay, Nischalan/F-9536-2012					Betts DH, 1999, DEV GENET, V25, P397, DOI 10.1002/(SICI)1520-6408(1999)25:4&lt;397::AID-DVG13&gt;3.0.CO;2-J; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kozik A, 1998, MOL REPROD DEV, V51, P98, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;98::AID-MRD12&gt;3.0.CO;2-Q; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Xu J, 2000, BIOL REPROD, V63, P1124, DOI 10.1095/biolreprod63.4.1124; Zhu LX, 1998, P NATL ACAD SCI USA, V95, P8648, DOI 10.1073/pnas.95.15.8648	16	123	140	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					272	273		10.1038/81559	http://dx.doi.org/10.1038/81559			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062462				2022-12-25	WOS:000165176500011
J	Alexander, C; Votruba, M; Pesch, UEA; Thiselton, DL; Mayer, S; Moore, A; Rodriguez, M; Kellner, U; Leo-Kottler, B; Auburger, G; Bhattacharya, SS; Wissinger, B				Alexander, C; Votruba, M; Pesch, UEA; Thiselton, DL; Mayer, S; Moore, A; Rodriguez, M; Kellner, U; Leo-Kottler, B; Auburger, G; Bhattacharya, SS; Wissinger, B			OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28	NATURE GENETICS			English	Letter							MITOCHONDRIAL-DNA MUTATION; CLINICAL-FEATURES; LINKAGE ANALYSIS; YEAST; PROTEIN; REGION; LOCUS; IDENTIFICATION; MAINTENANCE; REFINEMENT	Autosomal dominant optic atrophy (ADOA) is the most prevalent hereditary optic neuropathy resulting in progressive loss of visual acuity. centrocoecal scotoma and bilateral temporal atrophy of the optic nerve with an onset within the first two decades of life(1,2). The predominant locus for this disorder (OPA1; MIM 165500) has been mapped to a 1.4-cM interval on chromosome 3q28-q29 flanked by markers D3S3669 and D3S3562 (ref. 3). We established a PAC contig covering the entire OPA1 candidate region of approximately 1 Mb and a sequence skimming approach allowed us to identify a gene encoding a polypeptide of 960 amino acids with homology to dynamin-related GTPases. The gene comprises 28 coding exons and spans more than 40 kb of genomic sequence. Upon sequence analysis. we identified mutations in seven independent families with ADOA. The mutations include missense and nonsense alterations, deletions and insertions, which all segregate with the disease in these families. Because most mutations probably represent null alleles, dominant inheritance of the disease may result from haploinsufficiency of OPA1. OPA1 is widely expressed and is most abundant in the retina. The presence of consensus signal peptide sequences suggests that the product of the gene OPA1 is targeted to mitochondria and may exert its function in mitochondrial biogenesis and stabilization of mitochondrial membrane integrity.	UCL, Inst Ophthalmol, Dept Mol Genet, London, England; Univ Tubingen Hosp, Mol Genet Lab, Tubingen, Germany; Addenbrookes Hosp, Dept Ophthalmol, Cambridge, England; Ctr Med Genet, Sancti Spiritus, Cuba; Free Univ Berlin, Klinikum Benjamin Franklin, Eye Dept, D-12200 Berlin, Germany; Univ Eye Hosp, Dept Pathophysiol Vis & Neuroophthalmol, Tubingen, Germany; Univ Hosp Dusseldorf, Dept Neurol, Dusseldorf, Germany	University of London; University College London; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Bhattacharya, SS (corresponding author), UCL, Inst Ophthalmol, Dept Mol Genet, London, England.	smbcssb@ucl.ac.uk; bernd.wissinger@uni-tuebingen.de	Votruba, Marcela/A-6182-2011; Votruba, Marcela/B-7306-2015; Bhattacharya, Shom/N-2926-2016	Votruba, Marcela/0000-0002-7680-9135; Votruba, Marcela/0000-0002-7680-9135; Bhattacharya, Shom/0000-0002-1601-6344				Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brown J, 1997, ARCH OPHTHALMOL-CHIC, V115, P95, DOI 10.1001/archopht.1997.01100150097016; EIBERG H, 1994, HUM MOL GENET, V3, P977, DOI 10.1093/hmg/3.6.977; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; HOYT CS, 1980, OPHTHALMOLOGY, V87, P245; JOHNSTON PB, 1979, AM J OPHTHALMOL, V88, P868, DOI 10.1016/0002-9394(79)90565-8; Johnston RL, 1999, OPHTHALMOLOGY, V106, P123, DOI 10.1016/S0161-6420(99)90013-1; Jonasdottir A, 1997, HUM GENET, V99, P115; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805; KIVLIN JD, 1983, AM J HUM GENET, V35, P1190; Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; Kubokawa K, 1998, FEBS LETT, V431, P231, DOI 10.1016/S0014-5793(98)00762-5; LUNKES A, 1995, AM J HUM GENET, V57, P968; Lyle WM., 1990, GENETIC RISKS; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Pelloquin L, 1998, BIOCHEM BIOPH RES CO, V251, P720, DOI 10.1006/bbrc.1998.9539; RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Staden R, 2000, Methods Mol Biol, V132, P115; Votruba M, 1998, ARCH OPHTHALMOL-CHIC, V116, P351, DOI 10.1001/archopht.116.3.351; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231	28	972	1006	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2000	26	2					211	215		10.1038/79944	http://dx.doi.org/10.1038/79944			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017080				2022-12-25	WOS:000089638800021
J	Kikuchi, T; Worgall, S; Singh, R; Moore, MAS; Crystal, RG				Kikuchi, T; Worgall, S; Singh, R; Moore, MAS; Crystal, RG			Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4(+) T cells	NATURE MEDICINE			English	Article							IN-VIVO; ADENOVIRUS VECTOR; PSEUDOMONAS-AERUGINOSA; ANTITUMOR IMMUNITY; CYSTIC-FIBROSIS; B-LYMPHOCYTES; GENE-TRANSFER; RESPONSES; INFECTION; MICE	We have investigated whether dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can trigger B cells to produce antigen-specific antibodies without CD4(+) T-cell help. Dendritic cells modified with a recombinant adenovirus vector to express CD40 ligand and pulsed with heat-killed Pseudomonas induced naive B cells to produce antibodies against Pseudomonas in the absence of CD4(+) T cells in vitro, initiated Pseudomonas-specific humoral immune responses in vivo in wild-type and CD4(-/-) mice, and protected immunized wild-type and CD4(-/-), but not B-cell(-/-) mice, from lethal intrapulmonary challenge with Pseudomonas. Thus, genetic modification of dendritic cells with CD40 ligand enables them to present a complex mixture of microbial antigens and establish CD4(+) T cell-independent, B cell-mediated protective immunity against a specific microbe.	Cornell Univ, Weill Med Coll, Dept Med, Div Pulm & Crit Care Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY USA; Cornell Univ, Weill Med Coll, Belfer Gene Therapy Core Facil, New York, NY USA; Cornell Univ, Weill Med Coll, Inst Med Genet, New York, NY USA; Mem Sloan Kettering Canc Ctr, James Ewing Lab Dev Hematopoiesis, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	Crystal, RG (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Pulm & Crit Care Med, New York, NY 10021 USA.		Singh, Ravi/B-1221-2010; Singh, Ravi N/A-5740-2011	Singh, Ravi N/0000-0003-0750-1804	NHLBI NIH HHS [P01 HL51746-06A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051746] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson WF, 1998, NATURE, V392, P25; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barr TA, 1999, INFECT IMMUN, V67, P3637, DOI 10.1128/IAI.67.7.3637-3640.1999; Beland JL, 1998, BLOOD, V92, P4472, DOI 10.1182/blood.V92.11.4472.423k47_4472_4478; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Dubois B, 1998, J IMMUNOL, V161, P2223; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gurunathan S, 1998, J IMMUNOL, V161, P4563; HERSH J, 1995, GENE THER, V2, P124; Kikuchi T, 1999, HUM GENE THER, V10, P1375, DOI 10.1089/10430349950018049; Kikuchi T, 2000, BLOOD, V96, P91, DOI 10.1182/blood.V96.1.91.013k19_91_99; Kovacs JA, 2000, NEW ENGL J MED, V342, P1416, DOI 10.1056/NEJM200005113421907; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; REIS, 1999, CURR OPIN IMMUNOL, V11, P392; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; STARKE JR, 1987, PEDIATR RES, V22, P698, DOI 10.1203/00006450-198712000-00017; STEVENSON MM, 1995, CLIN EXP IMMUNOL, V99, P98, DOI 10.1111/j.1365-2249.1995.tb03478.x; Svensson M, 1997, J IMMUNOL, V158, P4229; Timmerman JM, 1999, ANNU REV MED, V50, P507; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Wiley JA, 1997, J IMMUNOL, V158, P2932; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; WORGALL S, 1999, PEDIAT PULMONOL, V19, P311	34	68	94	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1154	1159		10.1038/80498	http://dx.doi.org/10.1038/80498			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017148				2022-12-25	WOS:000089674700041
J	Wong, KK; Chang, S; Weiler, SR; Ganesan, S; Chaudhuri, J; Zhu, CM; Artandi, SE; Rudolph, KL; Gottlieb, GJ; Chin, L; Alt, FW; DePinho, RA				Wong, KK; Chang, S; Weiler, SR; Ganesan, S; Chaudhuri, J; Zhu, CM; Artandi, SE; Rudolph, KL; Gottlieb, GJ; Chin, L; Alt, FW; DePinho, RA			Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MAMMALIAN-CELLS; LIGASE-IV; CHROMOSOME BREAKAGE; STEM-CELLS; MICE; KU; IDENTIFICATION; PROTEINS	Telomeres are specialized nucleoprotein complexes that serve as protective caps of linear eukaryotic chromosomes. Loss of telomere function is associated with rampant genetic instability and loss of cellular viability and renewal potential. The telomere also participates in processes of chromosomal repair, as evidenced by the 'capture' or de novo synthesis of telomere repeats at double-stranded breaks(1-4) and by the capacity of yeast telomeres to serve as repositories of essential components of the DNA repair machinery, particularly those involved in non-homologous end-joining(5-7) (NHEJ). Here we used the telomerase-deficient mouse. null for the essential telomerase RNA gene (Terc). to assess the role of telomerase and telomere function on the cellular and organismal response to ionizing radiation. Although the loss of telomerase activity per se had no discernable impact on the response to ionizing radiation, the emergence of telomere dysfunction in late-generation Terc(-/-) mice imparted a radiosensitivity syndrome associated with accelerated mortality. On the cellular level, the gastrointestinal crypt stem cells and primary thymocytes showed increased rates of apoptosis, and mouse embryonic fibroblasts (MEFs) showed diminished dose-dependent clonogenic survival. The radiosensitivity of telomere dysfunctional cells correlated with delayed DNA break repair kinetics, persistent chromosomal breaks and cytogenetic profiles characterized by complex chromosomal aberrations and massive fragmentation. Our findings establish a intimate relationship between functionally intact telomeres and the genomic. cellular and organismal response to ionizing radiation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA 02115 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.			Rudolph, Karl Lenhard/0000-0002-4839-2862; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317, R01HD034880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG001019] Funding Source: NIH RePORTER; NIAMS NIH HHS [K08AR02104-01] Funding Source: Medline; NIA NIH HHS [K08 AG001019] Funding Source: Medline; NICHD NIH HHS [R01HD28317, R01HD 34880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; Hall E.J., 2019, RADIOBIOLOGY RADIOLO, Veighth; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kiltie AE, 1997, NUCLEIC ACIDS RES, V25, P2945, DOI 10.1093/nar/25.14.2945; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SAVAGE JRK, 1975, J MED GENET, V12, P103; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Slijepcevic P, 1998, MUTAGENESIS, V13, P45; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20	30	263	282	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					85	88		10.1038/79232	http://dx.doi.org/10.1038/79232			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973255				2022-12-25	WOS:000089078000024
J	Ashton, G				Ashton, G			Growing pains for biopharmaceuticals	NATURE BIOTECHNOLOGY			English	Article									Ctr Med Res Int, Surrey, England	University of Surrey	Ashton, G (corresponding author), Ctr Med Res Int, Surrey, England.	gashton@cmr.org						AITKEN M, 1999, WINNING PHARM LICENS, P49; BIENZTADMOR B, 1992, BIO-TECHNOL, V10, P521, DOI 10.1038/nbt0592-521; GRONER C, 1999, BIOPEOPLE        AUT, P26; GROSSE ME, 1996, DRUG INF J, V30, P991; Haseltine WA, 1998, NAT BIOTECHNOL, V16, P1295, DOI 10.1038/4244; HENKEL J, 1999, FDA CONSUMER MAGAZIN, V33; HODGE MJ, 1997, EC ASPECTS BIOTECH 1, P219; Kettler H, 2000, JCB, V7, P62; LOBO LI, 2000, CMR00146R; MACINNES R, 1994, CLIN PHARMACOL THER, V56, P339; *TUFTS CTR STUD DR, 2001, OUTL 2001; VANBRUNT J, 2000, SIGNALS MAGAZIN 0624; Walsh G, 2000, NAT BIOTECHNOL, V18, P831, DOI 10.1038/78720; Werner RG, 1998, ARZNEIMITTEL-FORSCH, V48, P523; 2000, MED AD NEWS      MAY, P56	15	12	19	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					307	311		10.1038/86670	http://dx.doi.org/10.1038/86670			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283578				2022-12-25	WOS:000167940700014
J	Bosco, G; Du, W; Orr-Weaver, TL				Bosco, G; Du, W; Orr-Weaver, TL			DNA replication control through interaction of E2F-RB and the origin recognition complex	NATURE CELL BIOLOGY			English	Article							S-PHASE COMPLETION; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DROSOPHILA-MELANOGASTER; REPRESS TRANSCRIPTION; GENE AMPLIFICATION; DISTINCT ROLES; EMBRYOGENESIS; MUTATIONS	The E2F transcription factor and retinoblastoma protein control cell-cycle progression and DNA replication during S phase. Mutations in the Drosophila dE2F1 and dDP genes affect the origin recognition complex (DmORC) and initiation of replication at the chorion gene replication origin. Here we show that mutants of Rbf (an retinoblastoma protein homologue) fail to limit DNA replication. We also show that the dDP, dE2F1 and Rbf proteins are located in a complex with DmORC, and that dE2F1 and DmORC are bound to the chorion origin of replication in vivo. Our results indicate that dE2F1 and Rbf function together at replication origins to limit DNA replication through interactions with DmORC.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Chicago; University of Chicago	Orr-Weaver, TL (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057960] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; CALVI BR, 1999, GENETIC APPROACHES E, P407; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Du W, 1999, EMBO J, V18, P916, DOI 10.1093/emboj/18.4.916; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elfring LK, 1997, MOL BIOL CELL, V8, P583, DOI 10.1091/mbc.8.4.583; Fenger DD, 2000, DEVELOPMENT, V127, P4763; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Royzman I, 1998, GENES CELLS, V3, P767, DOI 10.1046/j.1365-2443.1998.00232.x; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Spradling AC, 1999, GENE DEV, V13, P2619, DOI 10.1101/gad.13.20.2619; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Yamaguchi M, 1997, NUCLEIC ACIDS RES, V25, P3847, DOI 10.1093/nar/25.19.3847; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	37	189	191	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					289	295		10.1038/35060086	http://dx.doi.org/10.1038/35060086			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231579				2022-12-25	WOS:000167365800016
J	Farre, EM; Bachmann, A; Willmitzer, L; Trethewey, RN				Farre, EM; Bachmann, A; Willmitzer, L; Trethewey, RN			Acceleration of potato tuber sprouting by the expression of a bacterial pyrophosphatase	NATURE BIOTECHNOLOGY			English	Article							INORGANIC PYROPHOSPHATASE; GLUCOSE PYROPHOSPHORYLASE; STARCH SYNTHESIS; DORMANCY; INHIBITION; METABOLISM; SYNTHASE; STORAGE; LEADS; DNA	Potato is a globally important crop. Unfortunately, potato farming is plagued with problems associated with the sprouting behavior of seed tubers. The data presented here demonstrate that using transgenic technology can influence this behavior. Transgenic tubers cytosolically expressing an inorganic pyrophosphatase gene derived from Escherichia coli under the control of the tuber-specific patatin promoter display significantly accelerated sprouting. The period of presprouting dormancy for transgenic tubers planted immediately after harvest is reduced by six to seven weeks when compared to wild-type tubers. This study demonstrates a method with which to regulate dormancy, an important aspect of potato crop management.	Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany	Max Planck Society	Farre, EM (corresponding author), Max Planck Inst Mol Pflanzenphysiol, Muhlenberg 1, D-14476 Golm, Germany.	farre@mpimp-golm.mpg.de	Willmitzer, Lothar/F-7377-2011	Farre, Eva M./0000-0003-1566-7572				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRELL MM, 1994, PLANTA, V194, P95, DOI 10.1007/BF00201039; Dietze J., 1995, P24; Espen L, 1999, POTATO RES, V42, P189, DOI 10.1007/BF02358409; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; GALLOWAY CM, 1994, PHYSIOL PLANTARUM, V92, P479, DOI 10.1111/j.1399-3054.1994.tb08839.x; Geigenberger P, 1998, PLANTA, V205, P428, DOI 10.1007/s004250050340; GEIGENBERGER P, 1993, PLANTA, V189, P329, DOI 10.1007/BF00194429; GIELEN J, 1984, EMBO J, V3, P835, DOI 10.1002/j.1460-2075.1984.tb01894.x; GROSS P, 1986, PLANTA, V167, P140, DOI 10.1007/BF00446381; Hemberg T., 1985, Potato physiology, P353; JELITTO T, 1992, PLANTA, V188, P238, DOI 10.1007/BF00216819; KORNBERG A, 1984, TRENDS BIOCHEM SCI, V9, P122, DOI 10.1016/0968-0004(84)90114-2; MOORE S, 1948, J BIOL CHEM, V176, P367; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; REES TA, 1990, AM POTATO J, V67, P835, DOI 10.1007/BF03044296; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; SONNEWALD U, 1992, PLANT J, V2, P571; Sorce C, 1996, J PLANT PHYSIOL, V149, P548, DOI 10.1016/S0176-1617(96)80332-4; Sorce C, 2000, AUST J PLANT PHYSIOL, V27, P371, DOI 10.1071/PP99150; STITT M, 1989, METHOD ENZYMOL, V174, P518; Suttle JC, 2000, PHYSIOL PLANTARUM, V109, P68, DOI 10.1034/j.1399-3054.2000.100110.x; SUTTLE JC, 1995, PHYSIOL PLANTARUM, V95, P233, DOI 10.1111/j.1399-3054.1995.tb00832.x; Suttle Jeffrey C., 1996, P133; TURNBULL CGN, 1985, PLANTA, V165, P359, DOI 10.1007/BF00392233; Wiltshire JJJ, 1996, ANN APPL BIOL, V129, P553, DOI 10.1111/j.1744-7348.1996.tb05776.x; ZRENNER R, 1993, PLANTA, V190, P247, DOI 10.1007/BF00196618; ZRENNER R, 1995, PLANT J, V7, P97, DOI 10.1046/j.1365-313X.1995.07010097.x	30	34	45	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2001	19	3					268	272		10.1038/85726	http://dx.doi.org/10.1038/85726			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	407QW	11231562				2022-12-25	WOS:000167283100029
J	Liston, P; Fong, WG; Kelly, NL; Toji, S; Miyazaki, T; Conte, D; Tamai, K; Craig, CG; McBurney, MW; Korneluk, RG				Liston, P; Fong, WG; Kelly, NL; Toji, S; Miyazaki, T; Conte, D; Tamai, K; Craig, CG; McBurney, MW; Korneluk, RG			Identification of XAF1 as an antagonist of XIAP anti-caspase activity	NATURE CELL BIOLOGY			English	Article							APOPTOSIS INHIBITORY PROTEIN; SIGNALING COMPLEX; EXPRESSION; IAP; FAMILY; GENE; SURVIVIN; CELLS; NAIP; HID	The inhibitors of apoptosis (IAPs) suppress apoptosis through the inhibition of the caspase cascade and thus are key proteins in the control of cell death. Here we have isolated the protein XIAP-associated factor 1 (XAF1) on the basis of its ability to bind XIAP, a member of the IAP family. XIAP suppresses caspase activation and cell death in vitro, and XAF1 antagonizes these XIAP activities. Expression of XAF1 triggers a redistribution of XIAP from the cytosol to the nucleus. XAF1 is ubiquitously expressed in normal tissues, but is present at low or undetectable levels in many different cancer cell lines. Loss of control over apoptotic signalling is now recognized as a critical event in the development of cancer. Our results indicate that XAF1 may be important in mediating the apoptosis resistance of cancer cells.	Ottawa Reg Canc Ctr, Canc Res Grp, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada; Aegera Oncol Inc, Ottawa, ON K1H 8MS, Canada; Med & Biol Labs Co, Naka Ku, Nagoya, Aichi 460, Japan	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Korneluk, RG (corresponding author), Ottawa Reg Canc Ctr, Canc Res Grp, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huang HK, 2000, J BIOL CHEM, V275, P26661; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Li J, 1998, ENDOCRINOLOGY, V139, P1321, DOI 10.1210/en.139.3.1321; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	29	349	385	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2001	3	2					128	133		10.1038/35055027	http://dx.doi.org/10.1038/35055027			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	399CG	11175744				2022-12-25	WOS:000166793000013
J	Chinetti, G; Lestavel, S; Bocher, V; Remaley, AT; Neve, B; Torra, IP; Teissier, E; Minnich, A; Jaye, M; Duverger, N; Brewer, HB; Fruchart, JC; Clavey, V; Staels, B				Chinetti, G; Lestavel, S; Bocher, V; Remaley, AT; Neve, B; Torra, IP; Teissier, E; Minnich, A; Jaye, M; Duverger, N; Brewer, HB; Fruchart, JC; Clavey, V; Staels, B			PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway	NATURE MEDICINE			English	Article							BINDING CASSETTE TRANSPORTER-1; RECEPTOR LXR-ALPHA; TANGIER-DISEASE; DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS; METABOLISM; EXPRESSION; CORONARY; DIFFERENTIATION; PROGRESSION	Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-gamma may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR- activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which inducer ABCA1- promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.	Inst Pasteur, F-59019 Lille, France; INSERM, U325, Lille, France; Univ Lille 2, Lille, France; NHLBI, NIH, Bethesda, MD 20892 USA; Aventis Pharma, Collegeville, PA 19426 USA; Aventis Pharma, Core Genom Dept, Vitry Sur Seine, France; Aventis Pharma, Cardiovasc Dept, Vitry Sur Seine, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sanofi-Aventis; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Staels, B (corresponding author), Inst Pasteur, F-59019 Lille, France.		chinetti, giulia/Q-6901-2016; Staels, Bart/N-9497-2016; Neve, Bernadette/J-6008-2014; Lestavel, Sophie/B-4658-2017	chinetti, giulia/0000-0001-8048-8138; Staels, Bart/0000-0002-3784-1503; Neve, Bernadette/0000-0003-1516-1379; Lestavel, Sophie/0000-0001-7839-4757				Balfour JAB, 1999, DRUGS, V57, P921; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Costet P, 2000, J BIOL CHEM, V275, P28240; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; Frick MH, 1997, CIRCULATION, V96, P2137; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Hobbs HH, 1999, J CLIN INVEST, V104, P1015, DOI 10.1172/JCI8509; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torra IP, 1999, CURR OPIN LIPIDOL, V10, P151, DOI 10.1097/00041433-199904000-00009; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wolffenbuttel BHR, 2000, DIABETIC MED, V17, P40, DOI 10.1046/j.1464-5491.2000.00224.x	38	924	983	4	79	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					53	58		10.1038/83348	http://dx.doi.org/10.1038/83348			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135616				2022-12-25	WOS:000166243100035
J	Albert, ML; Kim, JI; Birge, RB				Albert, ML; Kim, JI; Birge, RB			alpha(v)beta(5) integrin recruits the Crkll-Dock180-Rac1 complex for phagocytosis of apoptotic cells	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; DENDRITIC CELLS; MYOBLAST FUSION; T-CELLS; PROTEIN; DOCK180; INDUCTION; MIGRATION; ANTIGEN; INVITRO	Integrin receptors are important for the phagocytosis of apoptotic cells. However, little is known about their function in mediating internalization, as previous studies used blocking antibodies for the inhibition of binding. Here we show that the alpha (v)beta (5) receptor mediates both binding and internalization of apoptotic cells. Internalization is dependent upon signalling through the beta (5) cytoplasmic tail, and engagement of the alpha (v)beta (5) heterodimer results in recruitment of the p130(cas)-CrkII-Dock180 molecular complex, which its turn triggers Rad activation and phagosome formation. In addition to defining integrin-receptor signalling as critical for the internalization of apoptotic material, our results also constitute the first evidence in human cells that the CED-2-CED-5-CED-10 complex defined in Caenorhabditis elegans is functionally analagous to the CrkII-Dock180-Rac1 molecular complex in mammalian cells. By linking the alpha (v)beta (5) receptor to this molecular switch, we reveal an evolutionarily conserved signalling pathway that is responsible for the recognition and internalization of apoptotic cells by both professional and non-professional phagocytes.	Rockefeller Univ, Lab NeuroOncol, New York, NY 10021 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07214 USA	Rockefeller University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Albert, ML (corresponding author), Rockefeller Univ, Lab NeuroOncol, 1230 York Ave,Box 226, New York, NY 10021 USA.	albertm@rockvax.rockefeller.edu; birgera@umdnj.edu	Albert, Matthew L/C-9782-2009; KIM, JONG-IL/D-1019-2011	KIM, JONG-IL/0000-0002-7240-3744				Albert ML, 1998, IMMUNOLOGIST, V6, P194; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; Hughes J, 1997, J IMMUNOL, V158, P4389; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; PATCH LA, 1995, J CELL SCI, V108, P1371; Paululat A, 1999, MECH DEVELOP, V83, P17, DOI 10.1016/S0925-4773(99)00029-5; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; STEINKAMP JA, 1982, SCIENCE, V215, P64, DOI 10.1126/science.7053559	28	307	316	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					899	905		10.1038/35046549	http://dx.doi.org/10.1038/35046549			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146654				2022-12-25	WOS:000165814500012
J	Borisjuk, N; Borisjuk, L; Komarnytsky, S; Timeva, S; Hemleben, V; Gleba, Y; Raskin, I				Borisjuk, N; Borisjuk, L; Komarnytsky, S; Timeva, S; Hemleben, V; Gleba, Y; Raskin, I			Tobacco ribosomal DNA spacer element stimulates amplification and expression of heterologous genes	NATURE BIOTECHNOLOGY			English	Article						gene amplification; enhanced transcription; protein expression; transgenic plants; recombinant proteins	PROMOTING SEQUENCES; MAMMALIAN-CELLS; PLANT-CELLS; RNA GENES; RDNA; REPLICATION; NICOTIANA; PROTEIN; VECTOR; TRANSFORMATION	Here we show that the cis-acting genetic element aps (amplification-promoting sequence), isolated from the nontranscribed spacer region of tobacco ribosomal DNA (rDNA), increases the level of expression of recombinant proteins. Transgenic tobacco plants, transformed with expression cassettes containing the herbicide-resistant acetolactate synthase (hr-ALS) gene or the green fluorescent protein (GFP) gene fused to the aps sequence, had greater levels of corresponding messenger RNAs (mRNAs) and proteins compared to transformants lacking aps. Analysis of transgenic plants showed that aps increased the copy number and transcription of the adjacent heterologous genes and, in the case of hr-ALS, enhanced the herbicide resistance phenotype. Both the increased transgene copy number and enhanced expression were stably inherited. These data provide the first evidence that the aps sequence can be used for gene amplification in transgenic plants and possibly other multicellular organisms.	Rutgers State Univ, Cook Coll, Biotech Ctr, New Brunswick, NJ 08901 USA; Phytomed Inc, Dayton, NJ 08810 USA; Univ Tubingen, Ctr Plant Mol Biol, D-72076 Tubingen, Germany; Inst Cell Biol & Genet Engn, UA-252650 Kiev, Ukraine	Rutgers State University New Brunswick; Eberhard Karls University of Tubingen; National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine	Raskin, I (corresponding author), Rutgers State Univ, Cook Coll, Biotech Ctr, Foran Hall,59 Dudley Rd, New Brunswick, NJ 08901 USA.	raskin@AESOP.RUTGERS.EDU	Borisjuk, Nikolai/AAI-3809-2020; Komarnytsky, Slavko/A-9575-2009	Borisjuk, Nikolai/0000-0001-5250-9771; Komarnytsky, Slavko/0000-0003-4665-4993; Borisjuk, Ljudmilla/0000-0001-6910-0841; Gleba, Yuri/0000-0003-4675-7474				ALT FW, 1978, J BIOL CHEM, V253, P1357; BEDBROOK JR, 1980, NATURE, V288, P133, DOI 10.1038/288133a0; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bogorad L, 2000, TRENDS BIOTECHNOL, V18, P257, DOI 10.1016/S0167-7799(00)01444-X; Borisjuk N, 1998, PLANTA, V206, P504, DOI 10.1007/s004250050427; BORISJUK N, 1993, PLANT MOL BIOL, V21, P381, DOI 10.1007/BF00019953; Borisjuk NV, 1999, NAT BIOTECHNOL, V17, P466, DOI 10.1038/8643; Borisjuk NV, 1997, PLANT MOL BIOL, V35, P655, DOI 10.1023/A:1005856618898; BORISJUK NV, 1988, THEOR APPL GENET, V76, P108, DOI 10.1007/BF00288839; BORISJUK NV, 1988, PLANT CELL ENG RESUL, V9, P73; BRUN C, 1993, EXP CELL RES, V208, P104, DOI 10.1006/excr.1993.1227; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; DECARVALHO F, 1992, EMBO J, V11, P2595, DOI 10.1002/j.1460-2075.1992.tb05324.x; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; DONN G, 1984, Journal of Molecular and Applied Genetics, V2, P621; HAUGHN GW, 1988, MOL GEN GENET, V211, P266, DOI 10.1007/BF00330603; HEMANN C, 1994, DNA CELL BIOL, V13, P437, DOI 10.1089/dna.1994.13.437; Hemleben V, 1994, Results Probl Cell Differ, V20, P3; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; KELLEMS RE, 1994, METH MOL G, V5, P143; KNEIDL C, 1995, PLANT MOL BIOL, V27, P705, DOI 10.1007/BF00020224; KUMAGAI MH, 1993, P NATL ACAD SCI USA, V90, P427, DOI 10.1073/pnas.90.2.427; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MCARTHUR JG, 1991, NUCLEIC ACIDS RES, V19, P2477, DOI 10.1093/nar/19.9.2477; MCARTHUR JG, 1991, J BIOL CHEM, V266, P6000; MEYER J, 1993, GENE, V129, P263, DOI 10.1016/0378-1119(93)90277-A; PASION SG, 1987, DNA-J MOLEC CELL BIO, V6, P419, DOI 10.1089/dna.1987.6.419; PHILLIPS RL, 1994, P NATL ACAD SCI USA, V91, P5222, DOI 10.1073/pnas.91.12.5222; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STOLZENBURG F, 1994, CHROMOSOMA, V103, P209, DOI 10.1007/BF00368014; Volkov RA, 1999, MOL BIOL EVOL, V16, P311, DOI 10.1093/oxfordjournals.molbev.a026112; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909	34	33	41	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2000	18	12					1303	1306		10.1038/82430	http://dx.doi.org/10.1038/82430			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	379TR	11101812				2022-12-25	WOS:000165659000030
J	Moon, AM; Capecchi, MR				Moon, AM; Capecchi, MR			Fgf8 is required for outgrowth and patterning of the limbs	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; VERTEBRATE LIMB; SONIC-HEDGEHOG; TRANSGENIC MICE; FEEDBACK LOOP; STEM-CELLS; GROWTH; GENE; BUD; INITIATION	The expression pattern and activity of fibroblast growth factor-8 (FGF8) in experimental assays indicate that it has important roles in limb development(1-3), but early embryonic lethality resulting from mutation of Fgf8 in the germ line of mice has prevented direct assessment of these roles(4). Here we report that conditional disruption of Fgf8 in the forelimb of developing mice bypasses embryonic lethality and reveals a requirement for Fgf8 in the formation of the stylopod, anterior zeugopod and autopod. Lack of Fgf8 in the apical ectodermal ridge (AER) alters expression of other Fgf genes, Shh and Bmp2.	Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Human Mol Biol & Genet, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA.			moon, anne/0000-0002-9090-1093	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001373] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Colvin JS, 1999, DEV DYNAM, V216, P72; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Moon AM, 2000, DEVELOPMENT, V127, P989; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; REYNOLDS K, 1991, MECH DEVELOP, V36, P15, DOI 10.1016/0925-4773(91)90068-H; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROGALA EJ, 1974, J MED GENET, V11, P221, DOI 10.1136/jmg.11.3.221; Ros MA, 1996, DEVELOPMENT, V122, P2319; ROWE DA, 1981, J EMBRYOL EXP MORPH, V65, P309; RUBIN L, 1972, DEV BIOL, V28, P94, DOI 10.1016/0012-1606(72)90129-7; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Tabin CJ, 1998, NATURE, V396, P322, DOI 10.1038/24516; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Vogel A, 1996, DEVELOPMENT, V122, P1737; Wolpert L, 1975, Ciba Found Symp, V0, P95; Xu XL, 1998, DEVELOPMENT, V125, P753	30	255	262	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2000	26	4					455	459		10.1038/82601	http://dx.doi.org/10.1038/82601			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101845	Green Accepted			2022-12-25	WOS:000165671700020
J	Fruman, DA; Mauvais-Jarvis, F; Pollard, DA; Yballe, CM; Brazil, D; Bronson, RT; Kahn, CR; Cantley, LC				Fruman, DA; Mauvais-Jarvis, F; Pollard, DA; Yballe, CM; Brazil, D; Bronson, RT; Kahn, CR; Cantley, LC			Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha	NATURE GENETICS			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; DIFFERENTIAL REGULATION; SKELETAL-MUSCLE; RAT-LIVER; IRS-1; STIMULATION; RESISTANCE; TRANSPORT	Phosphoinositide 3-kinases produce 3'-phosphorylated phosphoinositides that act as second messengers to recruit other signalling proteins to the membrane(1). Pi3ks are activated by many extracellular stimuli and have been implicated in a variety of cellular responses(1). The Pi3k gene family is complex and the physiological roles of different classes and isoforms are not clear. The gene Pik3r1 encodes three proteins (p85 alpha, p55 alpha and p50 alpha) that serve as regulatory subunits of class I-A Pi3ks (ref. 2). Mice lacking only the p85a isoform are viable but display hypoglycaemia and increased insulin sensitivity correlating with upregulation of the p55 alpha and p50 alpha variants(3). Here we report that loss of all protein products of Pik3r1 results in perinatal lethality. We observed, among other abnormalities, extensive hepatocyte necrosis and chylous ascites, We also noted enlarged skeletal muscle fibres, brown fat necrosis and calcification of cardiac tissue. In liver and muscle, loss of the major regulatory isoform caused a great decrease in expression and activity of class I-A Pi3k catalytic subunits: nevertheless, homozygous mice still displayed hypoglycaemia, lower insulin levels and increased glucose tolerance. Our findings reveal that p55 alpha and/or p50 alpha are required for survival, but not for development of hypoglycaemia, in mice lacking p85 alpha.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Tufts Sch Vet Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Cantley, LC (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Signal Transduct, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021; Cantley, Lewis C/D-1800-2014	Kahn, Ronald/0000-0002-7583-9228; Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55545] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; FRANK J, 1997, RETINOIDS, V13, P88; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; PONS S, 1995, MOL CELL BIOL, V15, P4453; PRESS OW, 1982, ANN INTERN MED, V96, P358, DOI 10.7326/0003-4819-96-3-358; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	28	228	237	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2000	26	3					379	382		10.1038/81715	http://dx.doi.org/10.1038/81715			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	371JU	11062485				2022-12-25	WOS:000165176500034
J	Steiner, H; Kostka, M; Romig, H; Basset, G; Pesold, B; Hardy, J; Capell, A; Meyn, L; Grim, ML; Baumeister, R; Fechteler, K; Haass, C				Steiner, H; Kostka, M; Romig, H; Basset, G; Pesold, B; Hardy, J; Capell, A; Meyn, L; Grim, ML; Baumeister, R; Fechteler, K; Haass, C			Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases	NATURE CELL BIOLOGY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; MUTATION; ENDOPROTEOLYSIS; NOTCH-1	Endoproteolysis of beta -amyloid precursor protein (beta APP) and Notch requires conserved aspartate residues in presenilins 1 and 2 (PS1 and PS2). Although PS1 and PS2 have therefore been proposed to be aspartyl proteases, no homology to other aspartyl proteases has been found. Here we identify homology between the presenilin active site and polytopic aspartyl proteases of bacterial origin, thus supporting the hypothesis that presenilins are novel aspartyl proteases.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; Boehringer Ingelheim Pharma KG, CNS Res, D-55216 Ingelheim, Germany; Mayo Clin, Jacksonville, FL 32224 USA; Univ Munich, Gene Ctr, D-81377 Munich, Germany	University of Munich; Boehringer Ingelheim; Mayo Clinic; University of Munich	Steiner, H (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany.		Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423	NATIONAL INSTITUTE ON AGING [Z01AG000950, ZIAAG000950] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; De Jonghe C, 1999, NEUROBIOL DIS, V6, P280, DOI 10.1006/nbdi.1999.0247; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	30	239	243	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					848	851		10.1038/35041097	http://dx.doi.org/10.1038/35041097			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056541				2022-12-25	WOS:000165207500020
J	Gilad, Y; Segre, D; Skorecki, K; Nachman, MW; Lancet, D; Sharon, D				Gilad, Y; Segre, D; Skorecki, K; Nachman, MW; Lancet, D; Sharon, D			Dichotomy of single-nucleotide polymorphism haplotypes in olfactory receptor genes and pseudogenes	NATURE GENETICS			English	Letter							HUMAN LIPOPROTEIN-LIPASE; STATISTICAL TESTS; DNA POLYMORPHISM; DIVERSITY; EVOLUTION; CLUSTER; HUMAN-CHROMOSOME-17; RECOMBINATION; NEUTRALITY; ANCESTRY	Substantial efforts are focused on identifying single-nucleotide polymorphisms (SNPs) throughout the human genome, particularly in coding regions (cSNPs), for both linkage disequilibrium and association studies(1,2). Less attention, however, has been directed to the clarification of evolutionary processes that are responsible for the variability in nucleotide diversity among different regions of the genome(3). We report here the population sequence diversity of genomic segments within a 450-kb cluster(4,5) of olfactory receptor (OR) genes(6,7) on human chromosome 17. We found a dichotomy in the pattern of nucleotide diversity between OR pseudogenes and introns on the one hand and the closely interspersed intact genes on the other. We suggest that weak positive selection is responsible for the observed patterns of genetic variation. This is inferred from a lower ratio of polymorphism to divergence in genes compared with pseudogenes or introns, high non-synonymous substitution rates in OR genes. and a small but significant overall reduction in variability in the entire OR gene cluster compared with other genomic regions. The dichotomy among functionally different segments within a short genomic distance requires high recombination rates within this OR cluster. Our work demonstrates the impact of weak positive selection on human nucleotide diversity, and has implications for the evolution of the olfactory repertoire.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Crown Human Genome Ctr, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Fac Med, Mol Med Lab, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Nephrol, Haifa, Israel; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ USA	Weizmann Institute of Science; Weizmann Institute of Science; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Arizona	Lancet, D (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Sharon, Dror/P-4539-2015; Segrè, Daniel/A-1993-2009	Sharon, Dror/0000-0002-1789-5811; Segrè, Daniel/0000-0003-4859-1914	NIDCD NIH HHS [DC00305] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; FU YX, 1993, GENETICS, V133, P693; Glusman G, 2000, GENOMICS, V63, P227, DOI 10.1006/geno.1999.6030; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; Harding RM, 1997, AM J HUM GENET, V60, P772; Harris EE, 1999, P NATL ACAD SCI USA, V96, P3320, DOI 10.1073/pnas.96.6.3320; HUDSON RR, 1987, GENETICS, V116, P153; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LI WH, 1991, GENETICS, V129, P513; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MIYAMOTO MM, 1987, SCIENCE, V238, P369, DOI 10.1126/science.3116671; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Nachman MW, 1998, GENETICS, V150, P1133; NACHMAN MW, IN PRESS GENETICS; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; OHTA T, 1995, J MOL EVOL, V40, P56, DOI 10.1007/BF00166595; PAYSEUR BA, IN PRESS GENETICS; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; Sharon D, 1999, GENOMICS, V61, P24, DOI 10.1006/geno.1999.5900; Sherry ST, 1999, GENOME RES, V9, P677; SIMONSEN KL, 1995, GENETICS, V141, P413; TAJIMA F, 1989, GENETICS, V123, P585; Trask BJ, 1998, HUM MOL GENET, V7, P2007, DOI 10.1093/hmg/7.13.2007; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9	30	72	76	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					221	224		10.1038/79957	http://dx.doi.org/10.1038/79957			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017082				2022-12-25	WOS:000089638800023
J	Gonzalez-Suarez, E; Samper, E; Flores, JM; Blasco, MA				Gonzalez-Suarez, E; Samper, E; Flores, JM; Blasco, MA			Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis	NATURE GENETICS			English	Article							IMMORTAL HUMAN-CELLS; HUMAN TUMOR-CELLS; MOUSE TELOMERASE; CANCER; RAS; CARCINOGENESIS; PAPILLOMAS; INHIBITION; EXPRESSION; SUBUNIT	Inhibition of telomerase is proposed to limit the growth of cancer cells by triggering telomere shortening and cell death(1-9). Telomere maintenance by telomerase is sufficient, in some cell types, to allow immortal growth(1-5). Telomerase has been shown to cooperate with oncogenes in transforming cultured primary human cells into neoplastic cells, suggesting that telomerase activation contributes to malignant transformation(6). Moreover. telomerase inhibition in human tumour cell lines using dominant-negative versions of TERT leads to telomere shortening and cell death(7,8). These findings have led to the proposition that telomerase inhibition may result in cessation of tumour growth(9). The absence of telomerase from most normal cells supports the potential efficacy of anti-telomerase drugs for tumour therapy, as its inhibition is unlikely to have toxic effects. Mice deficient for Terc RNA (encoding telomerase) lack telomerase activity, and constitute a model for evaluating the role of telomerase and telomeres in tumourigenesis(10). Late-generation Terc(-/-) mice show defects in proliferative tissues(10-15) and a moderate increase in the incidence of spontaneous tumours in highly proliferative cell types (lymphomas, teratocarcinomas(12)). The appearance of these tumours is thought to be a consequence of chromosomal instability in these mice(10,12,16,17). These observations have challenged the expected effectiveness of anti-telomerase-based cancer therapies(18). Different cell types may nonetheless vary in their sensitivity to the chromosomal instability produced by telomere lost; or to the activation of telomere-rescue mechanisms. Here we show that late-generation Terc(-/-) mice, which have short telomeres and are telomerase-deficient(10), are resistant to tumour development in multi-stage skin carcinogenesis. Our results predict that an anti-telomerase-based tumour therapy may be effective in epithelial tumours.	Natl Biotechnol Ctr, Dept Immunol & Oncol, Madrid, Spain; Univ Complutense Madrid, Fac Vet, Dept Anim Pathol 2, Madrid, Spain	Complutense University of Madrid	Blasco, MA (corresponding author), Natl Biotechnol Ctr, Dept Immunol & Oncol, Madrid, Spain.	mblasco@cnb.uam.es	Gonzalez-Suarez, Eva/L-6298-2014; Blasco, Maria A./M-1694-2014	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Blasco, Maria A./0000-0002-4211-233X				BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1992, PRINCESS TAKAMATSU S, V22, P97; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HECKNER E, 1982, CARCINOGENESIS COMPR; HENNINGS H, 1994, KERATINOCYTE METHODS, P21; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zumstein LA, 1999, NAT MED, V5, P1129, DOI 10.1038/13451	30	269	286	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					114	117		10.1038/79089	http://dx.doi.org/10.1038/79089			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973262				2022-12-25	WOS:000089078000031
J	Hong, SE; Shugart, YY; Huang, DT; Shahwan, SA; Grant, PE; Hourihane, JOB; Martin, NDT; Walsh, CA				Hong, SE; Shugart, YY; Huang, DT; Shahwan, SA; Grant, PE; Hourihane, JOB; Martin, NDT; Walsh, CA			Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations	NATURE GENETICS			English	Article							NEURONAL MIGRATION; CORTICAL DEVELOPMENT; VLDL RECEPTOR; REELIN GENE; PROTEIN; EXPRESSION; SEQUENCE; ENCODES; CORTEX; MICE	Normal development of the cerebral cortex requires long-range migration of cortical neurons from proliferative regions deep in the brain. Lissencephaly ("smooth brain." from "lissos," meaning smooth, and "encephalos," meaning brain) is a severe developmental disorder in which neuronal migration is impaired, leading to a thickened cerebral cortex whose normally folded contour is simplified and smooth. Two identified lissencephaly genes(1-3) do not account for all known cases(4), and additional lissencephaly syndromes have been described(5). An autosomal recessive form of lissencephaly (LCH) associated with severe abnormalities of the cerebellum, hippocampus and brainstem maps to chromosome 7q22, and is associated with two independent mutations in the human gene encoding reelin (RELN). The mutations disrupt splicing of RELN cDNA, resulting in low or undetectable amounts of reelin protein. LCH parallels the reeler mouse mutant (Reln(rl)). in which Rein mutations cause cerebellar hypoplasia, abnormal cerebral cortical neuronal migration and abnormal axonal connectivity(6,7). RELN encodes a large (388 kD) secreted proteins that acts on migrating cortical neurons by binding to the very low density lipoprotein receptor (VLDLR), the apolipoprotein E receptor 2 (ApoER2; refs 9-11), alpha 3 beta 1 integrin(12) and protocadherins(13). Although reelin was previously thought to function exclusively in brain, some humans with RELN mutations show abnormal neuromuscular connectivity and congenital lymphoedema, suggesting previously unsuspected functions for reelin in and outside of the brain.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA; Johns Hopkins Univ, Ctr Inherited Dis Res, Baltimore, MD USA; Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; Riyadh Armed Forces Hosp, Dept Neurosci, Riyadh, Saudi Arabia; Massachusetts Gen Hosp, Dept Radiol, Serv Neuroradiol, Boston, MA 02114 USA; Kent & Canterbury Hosp, Dept Pediat, Canterbury, Kent, England	Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Prince Sultan Military Medical City; Prince Sultan Military Medical City; Harvard University; Massachusetts General Hospital; University of Kent	Walsh, CA (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA.			Grant, Patricia/0000-0003-1005-4013; Walsh, Christopher/0000-0002-0156-2238	NINDS NIH HHS [P01 NS39404, R01 NS38097, R01 NS35129] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039404, R01NS035129, R01NS038097] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; de Rouvroit CL, 1999, EXP NEUROL, V156, P229, DOI 10.1006/exnr.1999.7019; de Rouvroit CL, 1998, GENOMICS, V53, P246, DOI 10.1006/geno.1998.5523; deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6; des Portes V, 1998, CELL, V92, P51; DeSilva U, 1997, GENOME RES, V7, P157, DOI 10.1101/gr.7.2.157; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; GUYER M, 1992, SCIENCE, V258, P67; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOURIHANE JO, 1993, NEUROPEDIATRICS, V24, P43, DOI 10.1055/s-2008-1071511; Impagnatiello F, 1998, P NATL ACAD SCI USA, V95, P15718, DOI 10.1073/pnas.95.26.15718; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Royaux I, 1997, GENOMICS, V42, P479, DOI 10.1006/geno.1997.4772; Royaux I, 1997, GENOMICS, V46, P240, DOI 10.1006/geno.1997.4983; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Smalheiser NR, 2000, P NATL ACAD SCI USA, V97, P1281, DOI 10.1073/pnas.97.3.1281; Takahara T, 1996, HUM MOL GENET, V5, P989, DOI 10.1093/hmg/5.7.989; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Walsh CA, 1999, NEURON, V23, P19, DOI 10.1016/S0896-6273(00)80749-7	28	609	635	1	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					93	96		10.1038/79246	http://dx.doi.org/10.1038/79246			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973257				2022-12-25	WOS:000089078000026
J	Meyer, CJ; Alenghat, FJ; Rim, P; Fong, JHJ; Fabry, B; Ingber, DE				Meyer, CJ; Alenghat, FJ; Rim, P; Fong, JHJ; Fabry, B; Ingber, DE			Mechanical control of cyclic AMP signalling and gene transcription through integrins	NATURE CELL BIOLOGY			English	Article							ENDOTHELIAL-CELLS; G-PROTEINS; ADHESION; CYTOSKELETAL; MODULATION; TENSION; STRESS; GROWTH; SHAPE; CREB	This study was carried out to discriminate between two alternative hypotheses as to how cells sense mechanical forces and transduce them into changes in gene transcription. Do cells sense mechanical signals through generalized membrane distortion(1,2) or through specific transmembrane receptors, such as integrins(3)? Here we show that mechanical stresses applied to the cell surface alter the cyclic AMP signalling cascade and downstream gene transcription by modulating local release of signals generated by activated integrin receptors in a G-protein-dependent manner, whereas distortion of integrins in the absence of receptor occupancy has no effect.	Harvard Univ, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Ingber, DE (corresponding author), Harvard Univ, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.	ingber@al.tch.harvard.edu	Fabry, Ben/AAT-5717-2020; Fabry, Ben/C-5496-2013; Alenghat, Francis/T-3059-2019; Ingber, Donald E/AAC-5894-2019	Fabry, Ben/0000-0003-1737-0465; Fabry, Ben/0000-0003-1737-0465; Alenghat, Francis/0000-0003-4151-9258; 	NATIONAL CANCER INSTITUTE [R01CA055833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009] Funding Source: NIH RePORTER; NCI NIH HHS [CA55833] Funding Source: Medline; NHLBI NIH HHS [HL33009] Funding Source: Medline; NIDCR NIH HHS [DE00275] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKE MSF, 1992, J CELL SCI, V102, P533; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; Fong JHJ, 1996, BIOCHEM BIOPH RES CO, V221, P19, DOI 10.1006/bbrc.1996.0537; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; GINRY D, 1993, SCIENCE, V260, P238; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON EA, 1986, ANN NY ACAD SCI, V485, P249, DOI 10.1111/j.1749-6632.1986.tb34587.x; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Gudi SRP, 1998, AM J PHYSIOL-CELL PH, V274, pC1424, DOI 10.1152/ajpcell.1998.274.5.C1424; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161	22	216	228	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					666	668		10.1038/35023621	http://dx.doi.org/10.1038/35023621			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980709				2022-12-25	WOS:000089250600020
J	Yu, KR; Saint, RB; Sullivan, W				Yu, KR; Saint, RB; Sullivan, W			The Grapes checkpoint coordinates nuclear envelope breakdown and chromosome condensation	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE; DROSOPHILA EMBRYOS; FISSION YEAST; PROTEIN-KINASE; PHOSPHORYLATION; CDC25; CHK1; GENE; LOCALIZATION	Mutations in the embryonic Drosophila Grapes/Chk1 checkpoint result in an abbreviated interphase, chromosome condensation defects and metaphase delays. To clarify the relationship between these phenotypes, we simultaneously timed multiple nuclear and cytoplasmic events in mutant grp-derived embryos. These studies support a model in which grp disrupts an S-phase checkpoint, which results in progression into metaphase with incompletely replicated chromosomes, We also show that chromosome condensation is independent of the state of DNA replication in the early embryo. Therefore, grp condensation defects are not a direct consequence of entering metaphase with incompletely replicated chromosomes. Rather, initiation of chromosome condensation (ICC) occurs at the normal time in grp-derived embryos, but the shortened interval between ICC and metaphase does not provide sufficient time to complete condensation. Our results suggest that these condensation defects, rather than incomplete DNA replication, are responsible for the extensive metaphase delays observed in grp-derived embryos. This analysis provides an example of how the loss of a checkpoint can disrupt the timing of multiple events not directly monitored by that checkpoint. These results are likely to apply to vertebrate cells and suggest new strategies for destroying checkpoint-compromised cancer cells.	Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	University of California System; University of California Santa Cruz; University of Adelaide	Sullivan, W (corresponding author), Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA.		Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043	NIGMS NIH HHS [1T32GM0864601A1, 5R01 GM 46409-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046409, T32GM008646] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BUCHENAU P, 1993, J CELL SCI, V104, P1175; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; Debec A, 1996, J CELL BIOL, V134, P103, DOI 10.1083/jcb.134.1.103; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FOGARTY P, 1994, DEVELOPMENT, V120, P2131; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; FRANCISLANG H, 1999, CONFOCAL MICROSCOPY; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Megraw TL, 1999, DEVELOPMENT, V126, P2829; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NOVITSKI E, 1981, GENETICS, V98, P257; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Phalle BD, 1998, J CELL BIOL, V141, P1383, DOI 10.1083/jcb.141.6.1383; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Su TT, 1999, CURR BIOL, V9, P919, DOI 10.1016/S0960-9822(99)80399-6; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; SULLIVAN W, 1993, MOL BIOL CELL, V4, P885, DOI 10.1091/mbc.4.9.885; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	39	50	52	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					609	615		10.1038/35023555	http://dx.doi.org/10.1038/35023555			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980701				2022-12-25	WOS:000089250600012
J	Brouns, MR; Matheson, SF; Settleman, J				Brouns, MR; Matheson, SF; Settleman, J			p190 RhoGAP is the principal Src substrate in brain and regulates axon outgrowth, guidance and fasciculation	NATURE CELL BIOLOGY			English	Article							LONG-TERM POTENTIATION; C-SRC; NEURITE OUTGROWTH; TYROSINE KINASES; COMMISSURAL AXONS; GENE-PRODUCT; PHOSPHORYLATION; INTEGRIN; PROTEIN; FAMILY	The Src tyrosine kinases have been implicated in several aspects of neural development and nervous system function; however, their relevant substrates in brain and their mechanism of action in neurons remain to be established clearly. Here we identify the potent Rho regulatory protein, p190 RhoGAP (GTPase-activating protein), as the principal Src substrate detected in the developing and mature nervous system. We also find that mice lacking functional p190 RhoGAP exhibit defects in axon guidance and fasciculation, p190 RhoGAP is cc-enriched with F-actin in the distal tips of axons, and overexpressing p190 RhoGAP in neuroblastoma cells promotes extensive neurite outgrowth, indicating that p190 RhoGAP may be an important regulator of Rho-mediated actin reorganization in neuronal growth cones. p190 RhoGAP transduces signals downstream of cell-surface adhesion molecules, and we find that p190-RhoGAP-mediated neurite outgrowth is promoted by the extracellular matrix protein laminin. Together with the fact that mice lacking neural adhesion molecules or Src kinases also exhibit defects in axon outgrowth, guidance and fasciculation, our results suggest that p190 RhoGAP mediates a Src-dependent adhesion signal for neuritogenesis to the actin cytoskeleton through the Rho GTPase.	Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Settleman, J (corresponding author), Massachusetts Gen Hosp, MGH Canc Ctr, 149 13th St, Boston, MA 02129 USA.	settleman@helix.mgh.harvard.edu		Brouns, M.R./0000-0002-9058-4438; Matheson, Stephen/0000-0003-0561-8152				Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Del Rio JA, 2000, CEREB CORTEX, V10, P784, DOI 10.1093/cercor/10.8.784; Dumenil G, 2000, J CELL SCI, V113, P71; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FIFKOVA E, 1992, INT REV CYTOL, V139, P267, DOI 10.1016/S0074-7696(08)61414-X; Fincham VJ, 1999, J CELL SCI, V112, P947; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Fukuda T, 1997, J COMP NEUROL, V382, P141; Goslin K., 1998, CULTURING NERVE CELL, P339; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARK M, 1993, DEVELOPMENT, V119, P319; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Morse WR, 1998, J NEUROBIOL, V36, P53, DOI 10.1002/(SICI)1097-4695(199807)36:1<53::AID-NEU5>3.0.CO;2-9; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sharma SV, 1998, ONCOGENE, V17, P271, DOI 10.1038/sj.onc.1201921; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	50	198	201	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					361	367		10.1038/35070042	http://dx.doi.org/10.1038/35070042			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283609				2022-12-25	WOS:000168043900014
J	Wang, EM; Wang, R; DeParasis, J; Loughrin, JH; Gan, SS; Wagner, GJ				Wang, EM; Wang, R; DeParasis, J; Loughrin, JH; Gan, SS; Wagner, GJ			Suppression of a P450 hydroxylase gene in plant trichome glands enhances natural-product-based aphid resistance	NATURE BIOTECHNOLOGY			English	Article							SUCROSE ESTERS; BIOSYNTHESIS	Trichome glands on the surface of many higher plants produce and secrete exudates affecting insects, microbes, and herbivores. Metabolic engineering of gland exudation has potential for improving pest/disease resistance, and for facilitating molecular farming. We identified a cytochrome P450 hydroxylase gene specific to the trichome gland and used both antisense and sense co-suppression strategies to investigate its function. P P450-suppressed transgenic tobacco plants showed a greater than or equal to 41% decrease in the predominant exudate component, cembratriene-diol (CBT-diol), and a greater than or equal to 19-fold increase in its precursor, cembratriene-ol (CBT-ol). Thus, the level of CBT-ol was raised from 0.2 to greater than or equal to4.3% of leaf dry weight. Exudate from antisense-expressing plants had higher aphidicidal activity, and transgenic plants with exudate containing high concentrations of CBT-ol showed greatly diminished aphid colonization responses. Our results demonstrate the feasibility of significantly modifying the natural-product chemical composition and aphid-interactive properties of gland exudates using metabolic engineering. The results also have implications for molecular farming.	Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA	University of Kentucky	Wagner, GJ (corresponding author), Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, N212 ASCN, Lexington, KY 40546 USA.	gwagner@ca.uky.edu	Loughrin, John/Q-6226-2018	Loughrin, John/0000-0002-5079-3331				Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; Dell B, 1978, ADV BOT RES, P277; Duke SO, 1999, NATURAL PRODUCTS AGR, P127; GUO ZH, 1994, ARCH BIOCHEM BIOPHYS, V308, P103, DOI 10.1006/abbi.1994.1015; GUO ZH, 1995, PLANT SCI, V110, P1, DOI 10.1016/0168-9452(95)04174-S; HORSLEVPETERSEN K, 1988, RHEUMATOL INT, V8, P1, DOI 10.1007/BF00541343; Hutvagner G, 1997, GENE, V188, P247, DOI 10.1016/S0378-1119(96)00819-0; Jackson D.M., 1996, PLANT CUTICLES INTEG, P231; KROUMOVA AB, 1994, P NATL ACAD SCI USA, V91, P11437, DOI 10.1073/pnas.91.24.11437; KROUMOVA AB, 1998, ADV PLANT LIPID RES, V13, P91; LIN Y, 1994, J CHEM ECOL, V20, P1907, DOI 10.1007/BF02066232; Mehta, 1984, BIOL CHEM PLANT TRIC, P187; OLSSON E, 1993, PLANTA MED, V59, P293, DOI 10.1055/s-2006-959684; Phillips MA, 1999, TRENDS PLANT SCI, V4, P184, DOI 10.1016/S1360-1385(99)01401-6; ROBERTSON JL, 1996, PESTICIDE BIOASSAYS; Sambrook J, 1989, MOL CLONING; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SEVERSON RF, 1994, ACS SYM SER, V551, P172; SEVERSON RF, 1985, J AGR FOOD CHEM, V33, P870, DOI 10.1021/jf00065a026; Silverstein R.M., 2015, SPECTROMETRIC IDENTI, VEighth; TIUS MA, 1988, CHEM REV, V88, P719, DOI 10.1021/cr00087a001; Wagner G.J., 1999, TOBACCO PRODUCTION C, P292; WAGNER GJ, 1991, PLANT PHYSIOL, V96, P675, DOI 10.1104/pp.96.3.675; Wahlberg I., 1992, FORT CHEM ORG NAT, V59, P141	24	141	217	6	64	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2001	19	4					371	374		10.1038/86770	http://dx.doi.org/10.1038/86770			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	419GJ	11283597				2022-12-25	WOS:000167940700028
J	Guris, DL; Fantes, J; Tara, D; Druker, BJ; Imamoto, A				Guris, DL; Fantes, J; Tara, D; Druker, BJ; Imamoto, A			Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome	NATURE GENETICS			English	Letter							CARDIAC NEURAL CREST; CRITICAL REGIONS; STEM-CELL; DELETION; MUTANT; MOUSE; INDUCTION; SIGNAL; TWIST; PAX3	Heterozygous deletions within human chromosome 22q11 are the genetic basis of DiGeorge/velocardiofacial syndrome (DGS/VCFS), the most common deletion syndrome (1 in 4,000 live births) in humans(1). CRKL maps within the common deletion region for DCS/VCFS (ref. 2) and encodes an SH2-SH3-SH3 adapter protein closely related to the Crk gene products(3). Here we report that mice homozygous for a targeted null mutation at the CrkL locus (gene symbol Crkol for mice) exhibit defects in multiple cranial and cardiac neural crest derivatives including the cranial ganglia, aortic arch arteries, cardiac outflow tract, thymus, parathyroid glands and craniofacial structures, We show that the migration and early expansion of neural crest cells is unaffected in Crkol(-/-) embryos, These results therefore indicate an essential stage- and tissue-specific role for Crkol in the function, differentiation, and/or survival of neural crest cells during development. The similarity between the Crkol(-/-) phenotype and the clinical manifestations of DCS/VCFS implicate defects in CRKL-mediated signaling pathways as part of the molecular mechanism underlying this syndrome.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA	University of Chicago; University of Chicago; University of Chicago; Oregon Health & Science University	Imamoto, A (corresponding author), Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA.	aimamoto@midway.uchicago.edu		Druker, Brian/0000-0001-8331-8206				Amati F, 1999, EUR J HUM GENET, V7, P903, DOI 10.1038/sj.ejhg.5200399; Begbie J, 1999, DEVELOPMENT, V126, P895; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Conway SJ, 1997, DEVELOPMENT, V124, P505; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Eicher PS, 2000, J PEDIATR-US, V137, P158, DOI 10.1067/mpd.2000.105356; EMANUEL BS, 1999, HEART DEV, P463; Farrell M, 1999, TRENDS CARDIOVAS MED, V9, P214, DOI 10.1016/S1050-1738(00)00023-2; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Kimber WL, 1999, HUM MOL GENET, V8, P2229, DOI 10.1093/hmg/8.12.2229; Kirby M. L., 1999, HEART DEV, P179; Kurahashi H, 1997, AM J MED GENET, V72, P180, DOI 10.1002/(SICI)1096-8628(19971017)72:2<180::AID-AJMG10>3.0.CO;2-J; LaBonne C, 1998, J NEUROBIOL, V36, P175, DOI 10.1002/(SICI)1097-4695(199808)36:2<175::AID-NEU6>3.0.CO;2-Z; LEDOUARIN NM, 1988, ANNU REV CELL BIOL, V4, P375, DOI 10.1146/annurev.cellbio.4.1.375; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; MARK M, 1993, DEVELOPMENT, V119, P319; McDonaldMcGinn DM, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e9; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shaikh TH, 2000, HUM MOL GENET, V9, P489, DOI 10.1093/hmg/9.4.489; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Waldo KL, 1996, DEV DYNAM, V205, P281, DOI 10.1002/(SICI)1097-0177(199603)205:3<281::AID-AJA8>3.0.CO;2-E	30	222	231	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2001	27	3					293	298		10.1038/85855	http://dx.doi.org/10.1038/85855			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	408AK	11242111				2022-12-25	WOS:000167304200021
J	Musaro, A; McCullagh, K; Paul, A; Houghton, L; Dobrowolny, G; Molinaro, M; Barton, ER; Sweeney, HL; Rosenthal, N				Musaro, A; McCullagh, K; Paul, A; Houghton, L; Dobrowolny, G; Molinaro, M; Barton, ER; Sweeney, HL; Rosenthal, N			Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle	NATURE GENETICS			English	Article							GROWTH-FACTOR-I; DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; MICE; DIFFERENTIATION; CALCINEURIN; PROLIFERATION; MYOGENESIS; GENES	Aging skeletal muscles suffer a steady decline in mass and functional performance, and compromised muscle integrity as fibrotic invasions replace contractile tissue, accompanied by a characteristic loss in the fastest, most powerful muscle fibers(1,2). The same programmed deficits in muscle structure and function are found in numerous neurodegenerative syndromes and disease-related cachexia(3). We have generated a model of persistent, functional myocyte hypertrophy using a tissue-restricted transgene encoding a locally acting isoform of insulin-like growth factor-1 that is expressed in skeletal muscle (mlgf-1), Transgenic embryos developed normally, and postnatal increases in muscle mass and strength were not accompanied by the additional pathological changes seen in other Igf-l transgenic models. Expression of CATA-2, a transcription factor normally undetected in skeletal muscle, marked hypertrophic myocytes that escaped age-related muscle atrophy and retained the proliferative response to muscle injury characteristic: of younger animals. The preservation of muscle architecture and age-independent regenerative capacity through localized mlgf-1 transgene expression suggests clinical strategies for the treatment of age or disease-related muscle frailty.	Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA USA; Univ Rome La Sapienza, Dept Histol & Med Embryol, Rome, Italy; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Sapienza University Rome; University of Pennsylvania	Rosenthal, N (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA USA.		Sweeney, H Lee/F-1862-2010; Musarò, Antonio/K-9598-2016; Musaro, Antonio/P-2953-2019	Musarò, Antonio/0000-0002-2944-9739; Musaro, Antonio/0000-0002-2944-9739; Dobrowolny, Gabriella/0000-0001-8693-0724; Rosenthal, Nadia/0000-0002-7599-7365				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ADAMO ML, 1993, ADV EXP MED BIOL, V343, P1; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Delaughter MC, 1999, FASEB J, V13, P1923, DOI 10.1096/fasebj.13.14.1923; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GRIESHAMMER U, 1992, CELL, V69, P79, DOI 10.1016/0092-8674(92)90120-2; LEROITH D, 1991, MOL CELL ENDOCRINOL, V77, pC57, DOI 10.1016/0303-7207(91)90054-V; Lescaudron L, 1997, J MUSCLE RES CELL M, V18, P631, DOI 10.1023/A:1018679722112; Lim HW, 2000, J MOL CELL CARDIOL, V32, P697, DOI 10.1006/jmcc.2000.1113; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MUSARO A, 1995, EXP CELL RES, V221, P241, DOI 10.1006/excr.1995.1372; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Nelson KA, 2000, SEMIN ONCOL, V27, P64; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005	29	808	847	1	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					195	200		10.1038/84839	http://dx.doi.org/10.1038/84839			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175789				2022-12-25	WOS:000166839200022
J	Zuo, JR; Niu, QW; Moller, SG; Chua, NH				Zuo, JR; Niu, QW; Moller, SG; Chua, NH			Chemical-regulated, site-specific DNA excision in transgenic plants	NATURE BIOTECHNOLOGY			English	Article						DNA excision; Cre/loxP; marker-free transformants; transgenic plants; XVE	SHOOT APICAL MERISTEM; AGROBACTERIUM-TUMEFACIENS; ISOPENTENYL TRANSFERASE; RECOMBINATION SYSTEM; CELL FATE; T-DNA; GENE; GENOME; MARKER; EXPRESSION	We have developed a chemical-inducible, site-specific DNA excision system in transgenic Arabidopsis plants mediated by the Cre/loxP DNA recombination system. Expression of the Cre recombinase was tightly controlled by an estrogen receptor-based fusion transactivator XVE. Upon induction by beta -estradiol, sequences encoding the selectable marker, Cre, and XVE sandwiched by two loxP sites were excised from the Arabidopsis genome, leading to activation of the downstream GFP (green fluorescent protein) reporter gene. Genetic and molecular analyses indicated that the system is tightly controlled, showing high-efficiency inducible DNA excision in all 19 transgenic events tested with either single or multiple T-DNA insertions. The system provides a highly reliable method to generate marker-free transgenic plants after transformation through either organogenesis or somatic embryogenesis.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.			Moller, Simon/0000-0002-0460-3592				AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; BARRY GF, 1984, P NATL ACAD SCI-BIOL, V81, P4776, DOI 10.1073/pnas.81.15.4776; BAYLEY CC, 1992, PLANT MOL BIOL, V18, P353, DOI 10.1007/BF00034962; DALE EC, 1991, P NATL ACAD SCI USA, V88, P10558, DOI 10.1073/pnas.88.23.10558; Ebinuma H, 1997, P NATL ACAD SCI USA, V94, P2117, DOI 10.1073/pnas.94.6.2117; FURNER IJ, 1992, DEVELOPMENT, V115, P755; Gleave AP, 1999, PLANT MOL BIOL, V40, P223, DOI 10.1023/A:1006184221051; IRISH VF, 1992, DEVELOPMENT, V115, P745; Ishige F, 1999, PLANT J, V18, P443, DOI 10.1046/j.1365-313X.1999.00456.x; Komari T, 1996, PLANT J, V10, P165, DOI 10.1046/j.1365-313X.1996.10010165.x; KONCZ C, 1989, P NATL ACAD SCI USA, V86, P8467, DOI 10.1073/pnas.86.21.8467; Kunkel T, 1999, NAT BIOTECHNOL, V17, P916, DOI 10.1038/12914; LLOYD AM, 1994, MOL GEN GENET, V242, P653, DOI 10.1007/BF00283419; MARCOTRIGIANO M, 1995, PLANT J, V7, P193, DOI 10.1046/j.1365-313X.1995.7020193.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ODELL J, 1990, MOL GEN GENET, V223, P369, DOI 10.1007/BF00264442; OW DW, 1995, CRIT REV PLANT SCI, V14, P239, DOI 10.1080/713608117; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; RUSSELL SH, 1992, MOL GEN GENET, V234, P49, DOI 10.1007/BF00272344; Sambrook J., 2002, MOL CLONING LAB MANU; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; Sugita K, 2000, PLANT J, V22, P461, DOI 10.1046/j.1365-313X.2000.00745.x; YODER JI, 1994, BIO-TECHNOL, V12, P263, DOI 10.1038/nbt0394-263; Zubko E, 2000, NAT BIOTECHNOL, V18, P442, DOI 10.1038/74515; Zuo JR, 2000, PLANT CELL, V12, P1137, DOI 10.1105/tpc.12.7.1137; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	28	258	349	1	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					157	161		10.1038/84428	http://dx.doi.org/10.1038/84428			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175731				2022-12-25	WOS:000166754700023
J	Cho, RJ; Huang, MX; Campbell, MJ; Dong, HL; Steinmetz, L; Sapinoso, L; Hampton, G; Elledge, SJ; Davis, RW; Lockhart, DJ				Cho, RJ; Huang, MX; Campbell, MJ; Dong, HL; Steinmetz, L; Sapinoso, L; Hampton, G; Elledge, SJ; Davis, RW; Lockhart, DJ			Transcriptional regulation and function during the human cell cycle	NATURE GENETICS			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; THYMOCYTE APOPTOSIS; BINDING; EXPRESSION; PROTEIN; GENE; FAMILY; KINASE; DEATH; RHO	We report here the transcriptional profiling of the cell cycle on a genome-wide scale in human fibroblasts. We identified approximately 700 genes that display transcriptional fluctuation with a periodicity consistent with that of the cell cycle. Systematic analysis of these genes revealed functional organization within groups of coregulated transcripts. A diverse set of cytoskeletal reorganization genes exhibit cell-cycle-dependent regulation, indicating that biological pathways are redirected for the execution of cell division. Many genes involved in cell motility and remodeling of the extracellular matrix are expressed predominantly in M phase, indicating a mechanism for balancing proliferative and invasive cellular behavior. Transcripts upregulated during S phase displayed extensive overlap with genes induced by DNA damage; cell-cycle-regulated transcripts may therefore constitute coherent programs used in response to external stimuli. Our data also provide clues to biological function for hundreds of previously uncharacterized human genes.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Dept Mol & Human Genet, Houston, TX 77030 USA; Affymetrix Inc, Santa Clara, CA USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA USA; Mol Applicat Grp, Palo Alto, CA USA; Novartis Res Fdn, Genomics Inst, San Diego, CA USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Stanford University; Baylor College of Medicine; Howard Hughes Medical Institute; Affymetrix; Stanford University; Novartis; Salk Institute	Campbell, MJ (corresponding author), Celera Genomics, Foster City, CA USA.	michael.campbell@fc.celera.com	Cho, Raymond/AAO-8125-2020	Cho, Raymond/0000-0001-6090-6603; Steinmetz, Lars/0000-0002-3962-2865				Arai M, 1999, DEV DYNAM, V215, P297, DOI 10.1002/(SICI)1097-0177(199908)215:4<297::AID-AJA2>3.3.CO;2-9; Assmann V, 1999, J CELL SCI, V112, P3943; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P1421; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Kosaki R, 1999, CANCER RES, V59, P1141; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lind EF, 1999, J IMMUNOL, V162, P5374; Liu KY, 1999, MOL CELL BIOL, V19, P3696; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; McNally FJ, 1998, MOL BIOL CELL, V9, P1847, DOI 10.1091/mbc.9.7.1847; Moorman JP, 1996, J IMMUNOL, V156, P4146; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; North AJ, 1999, J CELL SCI, V112, P4325; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Radhakrishna H, 1999, J CELL SCI, V112, P855; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SATO N, 1992, J CELL SCI, V103, P131; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wei MC, 2000, GENE DEV, V14, P2060; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	51	353	365	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					48	54		10.1038/83751	http://dx.doi.org/10.1038/83751			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137997				2022-12-25	WOS:000166187900014
J	Clouse, KN; Luo, MJ; Zhou, ZL; Reed, R				Clouse, KN; Luo, MJ; Zhou, ZL; Reed, R			A Ran-independent pathway for export of spliced mRNA	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA EXPORT; NUCLEAR-PROTEIN IMPORT; BINDING-PROTEIN; TRANSPORT; YEAST; INHIBITION; RANGAP1; HOMOLOG; MEX67P; SIGNAL	All major nuclear export pathways so far examined follow a general paradigm(1-3). Specifically, a complex is formed in the nucleus, containing the export cargo, a member of the importin-beta family of transporters and RanGTP, This complex is translocated across the nuclear pore to the cytoplasm, where hydrolysis of the GTP on Ran is stimulated by the GTPase-activating protein RanGAP(4,5). The activity of RanGAP is increased by RanBP1, which also promotes disassembly of RanGTP-cargo-transporter complexes(6,7). Here we investigate the role of RanGTP in the export of mRNAs generated by splicing. We show that nuclear injection of a Ran mutant (RanT24N)(8) or the normally cytoplasmic RanGAP potently inhibits the export of both tRNA and U1 snRNA(9), but not of spliced mRNAs. Moreover, nuclear injection of RanGAP together with RanBP1 blocks tRNA export but does not affect mRNA export, These and other data indicate that export of spliced mRNA is the first major cellular transport pathway that is independent of the export co-factor Ran.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reed, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Cole CN, 2000, NAT CELL BIOL, V2, pE55, DOI 10.1038/35008681; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Pasquinelli AE, 1997, P NATL ACAD SCI USA, V94, P14394, DOI 10.1073/pnas.94.26.14394; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Wichmann I, 1999, HUM IMMUNOL, V60, P57, DOI 10.1016/S0198-8859(98)00085-8; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	30	58	58	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					97	99		10.1038/35050625	http://dx.doi.org/10.1038/35050625			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146633				2022-12-25	WOS:000166146400027
J	De Cosa, B; Moar, W; Lee, SB; Miller, M; Daniell, H				De Cosa, B; Moar, W; Lee, SB; Miller, M; Daniell, H			Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals	NATURE BIOTECHNOLOGY			English	Article						polycistrons; plastid transformation; GM crops; Bt resistance	FOREIGN GENE-EXPRESSION; BACILLUS-THURINGIENSIS; PLANTS; RESISTANCE; PROTEIN; BOMBARDMENT; KURSTAKI	In nuclear transgenic plants, expression of multiple genes requires introduction of individual genes and time-consuming subsequent backcrosses to reconstitute multi-subunit proteins or pathways, a problem that is compounded by variable expression levels. In order to accomplish expression of multiple genes in a single transformation event, we have introduced several genes into the chromoplast genome. We confirmed stable integration of the cry2Aa2 operon by PCR and Southern blot analyses in T-0 and T-1 transgenic plants. Foreign protein accumulated at 45.3% of the total soluble protein in mature leaves and remained stable even in old bleached leaves (46.1%), thereby increasing the efficacy and safety of transgenic plants throughout the growing season. This represents the highest level of foreign gene expression reported in transgenic plants to date. Insects that are normally difficult to control (10-day old cotton bollworm, beet armyworm) were killed 100% after consuming transgenic leaves. Electron micrographs showed the presence of the insecticidal protein folded into cuboidal crystals. Formation of crystals of foreign proteins (due to hyperexpression and folding by the putative chaperonin, ORF 2) provides a simple method of purification by centrifugation and enhances stability by protection from cellular proteases. Demonstration of expression of an operon in transgenic plants paves the way to engineering new pathways in plants in a single transformation event.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Univ Cent Florida, Ctr Discovery Drugs & Diagnost, Orlando, FL 32826 USA; Auburn Univ, Dept Entomol, Auburn, AL 36849 USA; Auburn Univ, Dept Plant Pathol, Auburn, AL 36849 USA; Auburn Univ, Biol Electron Microscopy Imaging Facil, Auburn, AL 36849 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Auburn University System; Auburn University; Auburn University System; Auburn University; Auburn University System; Auburn University	Daniell, H (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.		Daniell, Henry/L-3655-2019	Daniell, Henry/0000-0003-4485-1176	NIGMS NIH HHS [R01 GM063879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogorad L, 2000, TRENDS BIOTECHNOL, V18, P257, DOI 10.1016/S0167-7799(00)01444-X; BRADLEY D, 1995, J INVERTEBR PATHOL, V65, P162, DOI 10.1006/jipa.1995.1024; CRICKMORE N, 1994, MOL GEN GENET, V242, P365, DOI 10.1007/BF00280428; CRICKMORE N, 1992, MOL MICROBIOL, V6, P1533, DOI 10.1111/j.1365-2958.1992.tb00874.x; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; DANIELL H, 1993, METHOD ENZYMOL, V217, P536; DANIELL H, 1994, NATO ADV SCI INST SE, V86, P589; Daniell H, 1997, Methods Mol Biol, V62, P463; Daniell H, 1999, TRENDS PLANT SCI, V4, P467, DOI 10.1016/S1360-1385(99)01503-4; Daniell H, 1999, NAT BIOTECHNOL, V17, P855, DOI 10.1038/12841; Ge BX, 1998, FEMS MICROBIOL LETT, V165, P35, DOI 10.1111/j.1574-6968.1998.tb13124.x; Greenplate JT, 1999, J ECON ENTOMOL, V92, P1377, DOI 10.1093/jee/92.6.1377; Guda C, 2000, PLANT CELL REP, V19, P257, DOI 10.1007/s002990050008; Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MOAR WJ, 1995, APPL ENVIRON MICROB, V61, P2086, DOI 10.1128/AEM.61.6.2086-2092.1995; MOAR WJ, 1994, APPL ENVIRON MICROB, V60, P896, DOI 10.1128/AEM.60.3.896-902.1994; NAVRATH C, 1994, P NATL ACAD SCI USA, V91, P12760; ROY H, 1994, PHOTOSYNTHETIC APPAR, P347; Vrekleij AJ, 1989, IMMUNOGOLD LABELING; YAMAMOTO T, 1983, ARCH BIOCHEM BIOPHYS, V227, P233, DOI 10.1016/0003-9861(83)90366-1; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	22	388	446	2	79	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2001	19	1					71	74		10.1038/83559	http://dx.doi.org/10.1038/83559			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	389WJ	11135556	Green Accepted			2022-12-25	WOS:000166261400023
J	Jackson-Grusby, L; Beard, C; Possemato, R; Tudor, M; Fambrough, D; Csankovszki, G; Dausman, T; Lee, P; Wilson, C; Lander, E; Jaenisch, R				Jackson-Grusby, L; Beard, C; Possemato, R; Tudor, M; Fambrough, D; Csankovszki, G; Dausman, T; Lee, P; Wilson, C; Lander, E; Jaenisch, R			Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation	NATURE GENETICS			English	Article							DNA METHYLTRANSFERASE GENE; EMBRYONIC STEM-CELLS; CYTOSINE METHYLATION; IMMUNODEFICIENCY SYNDROME; MAMMALIAN DEVELOPMENT; CRE RECOMBINASE; P53; EXPRESSION; MUTATION; MICE	Cytosine methylation of mammalian DNA is essential for the proper epigenetic regulation of gene expression and maintenance of genomic integrity. To define the mechanism through which demethylated cells die, and to establish a paradigm for identifying genes regulated by DNA methylation, we have generated mice with a conditional allele for the maintenance DNA methyltransferase gene Dnmt1. Cre-mediated deletion of Dnmt1 causes demethylation of cultured fibroblasts and a uniform p53-dependent cell death. Mutational inactivation of Trp53 partially rescues the demethylated fibroblasts for up to five population doublings in culture. Oligonucleotide microarray analysis showed that up to 10% of genes are aberrantly expressed in demethylated fibroblasts. Our results demonstrate that loss of Dnmt1 causes cell-type-specific changes in gene expression that impinge on several pathways, including expression of imprinted genes, cell-cycle control, growth factor/receptor signal transduction and mobilization of retroelements.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA.	jaenisch@wi.mit.edu		Csankovszki, Gyorgyi/0000-0001-5918-034X; Tudor, Matthew/0000-0001-8766-195X	NCI NIH HHS [R-35-CA44339] Funding Source: Medline; NICHD NIH HHS [HD18184] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD018184, R01HD018184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BIRD A, 1995, PHILOS T ROY SOC B, V349, P249, DOI 10.1098/rstb.1995.0109; Bird A, 1997, TRENDS GENET, V13, P469, DOI 10.1016/S0168-9525(97)01310-3; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; Cormier RT, 2000, CANCER RES, V60, P3965; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FAN GP, IN PRESS J NEUROSCI; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Onishi M, 1996, EXP HEMATOL, V24, P324; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Ruggiu M, 1997, NATURE, V389, P73, DOI 10.1038/37987; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Stancheva I, 2000, GENE DEV, V14, P313; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	52	537	557	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					31	39		10.1038/83730	http://dx.doi.org/10.1038/83730			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137995				2022-12-25	WOS:000166187900012
J	Peterfy, M; Phan, J; Xu, P; Reue, K				Peterfy, M; Phan, J; Xu, P; Reue, K			Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCUS; SERUM LEPTIN LEVELS; MUTANT MOUSE; INSULIN-RESISTANCE; DIABETES-MELLITUS; ADIPOSE-TISSUE; MICE; REVEALS; GENOME; MAP	Mice carrying mutations in the fatty liver dystrophy (fld) gene have features of human lipodystrophy(1), a genetically heterogeneous group of disorders characterized by loss of body fat, fatty liver hypertriglyceridemia and insulin resistance(2-4). Through positional cloning, we have isolated the gene responsible and characterized two independent mutant alleles, fld and fld(2J). The gene (Lpin1) encodes a novel nuclear protein which we have named lipin. Consistent with the observed reduction of adipose tissue mass in fld and fld(2J) mice, wild-type Lpin1 mRNA is expressed at high levels in adipose tissue and is induced during differentiation of 3T3-L1 pre-adipocytes. Our results indicate that lipin is required for normal adipose tissue development, and provide a candidate gene for human lipodystrophy. Lipin defines a novel family of nuclear proteins containing at least three members in mammalian species, and homologs in distantly related organisms from human to yeast.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Reue, K (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.	Reuek@ucla.edu		Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL24841] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DORFLER H, 1993, CLIN INVESTIGATOR, V71, P264; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Hegele RA, 2000, J CLIN ENDOCR METAB, V85, P3089, DOI 10.1210/jc.85.9.3089; Klingenspor M, 1999, J BIOL CHEM, V274, P23078, DOI 10.1074/jbc.274.33.23078; LANGNER CA, 1991, J BIOL CHEM, V266, P11955; LANGNER CA, 1989, J BIOL CHEM, V264, P7994; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; OKANO H, 1991, J NEUROCHEM, V56, P560, DOI 10.1111/j.1471-4159.1991.tb08186.x; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Peterfy M, 1999, GENOMICS, V62, P436, DOI 10.1006/geno.1999.6023; Rehnmark S, 1998, J LIPID RES, V39, P2209; Reue K, 2000, J LIPID RES, V41, P1067; Rotimi CN, 1999, DIABETES, V48, P643, DOI 10.2337/diabetes.48.3.643; Rowe LB, 1996, MAMM GENOME, V7, P555, DOI 10.1007/s003359900166; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; SENIOR B, 1964, PEDIATRICS, V33, P593; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	26	446	469	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					121	124		10.1038/83685	http://dx.doi.org/10.1038/83685			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138012				2022-12-25	WOS:000166187900029
J	Scott, HS; Kudoh, J; Wattenhofer, M; Shibuya, K; Berry, A; Chrast, R; Guipponi, M; Wang, J; Kawasaki, K; Asakawa, S; Minoshima, S; Younus, F; Mehdi, SQ; Radhakrishna, U; Papasavvas, MP; Gehrig, C; Rossier, C; Korostishevsky, M; Gal, A; Shimizu, N; Bonne-Tamir, B; Antonarakis, SE				Scott, HS; Kudoh, J; Wattenhofer, M; Shibuya, K; Berry, A; Chrast, R; Guipponi, M; Wang, J; Kawasaki, K; Asakawa, S; Minoshima, S; Younus, F; Mehdi, SQ; Radhakrishna, U; Papasavvas, MP; Gehrig, C; Rossier, C; Korostishevsky, M; Gal, A; Shimizu, N; Bonne-Tamir, B; Antonarakis, SE			Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness	NATURE GENETICS			English	Article							LOCUS DFNB8; GENE; CLONING; TRANSLOCATIONS; LOCALIZATION; SEQUENCE; 21Q22.3; DOMAIN; HEPSIN; MAPS	Approximately 50% of childhood deafness is caused by mutations in specific genes. Autosomal recessive loci account for approximately 80% of nonsyndromic genetic deafness(1). Here Ne report the identification of a new transmembrane serine protease (TMPRSS3; also known as ECHOS1) expressed in many tissues, including fetal cochlea, which is mutated in the families used to describe both the DFNB10 and DFNB8 loci. An 8-bp deletion and insertion of 18 monomeric (similar to 68-bp) beta -satellite repeat units, normally present in tandem arrays of up to several hundred kilobases on the short arms of acrocentric chromosomes, causes congenital deafness (DFNB10), A mutation in a splice-acceptor site, resulting in a 4-bp insertion in the mRNA and a frameshift, was detected in childhood onset deafness (DFNB8). This is the first description of beta -satellite insertion into an active gene resulting in a pathogenic state, and the first description of a protease involved in hearing loss.	Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo, Japan; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Ramat Aviv, Israel; Khan Res Labs, Biomed & Genet Engn Div, Islamabad, Pakistan; Univ Hamburg, Krankenhaus Eppendorf, Inst Humangenet, D-2000 Hamburg, Germany	University of Geneva; Keio University; Tel Aviv University; Sackler Faculty of Medicine; University of Hamburg	Antonarakis, SE (corresponding author), Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland.	Stylianos.Antonarakis@medecine.unige.ch	Antonarakis, Stylianos E/N-8866-2014; Mehdi, Syed Qasim/L-2385-2015; Scott, Hamish/B-2122-2009	Antonarakis, Stylianos E/0000-0001-8907-5823; Scott, Hamish/0000-0002-5813-631X; Chrast, Roman/0000-0003-4189-3514				ASSUM G, 1993, HUM GENET, V91, P489; Bartoloni L, 2000, GENOMICS, V70, P190, DOI 10.1006/geno.2000.6395; Berry A, 2000, GENOMICS, V68, P22, DOI 10.1006/geno.2000.6253; BonneTamir B, 1996, AM J HUM GENET, V58, P1254; Chen H, 1996, GENOME RES, V6, P747, DOI 10.1101/gr.6.8.747; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Eichler EE, 1998, GENOME RES, V8, P791, DOI 10.1101/gr.8.8.791; FARRELL SA, 1993, AM J MED GENET, V46, P715, DOI 10.1002/ajmg.1320460624; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; GREIG GM, 1992, GENOMICS, V12, P573, DOI 10.1016/0888-7543(92)90450-7; Handt O, 2000, MOL GENET METAB, V70, P99, DOI 10.1006/mgme.2000.2996; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kawamura S, 1999, EUR J BIOCHEM, V262, P755, DOI 10.1046/j.1432-1327.1999.00431.x; Michaud J, 2000, GENOMICS, V68, P71, DOI 10.1006/geno.2000.6258; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Samonte RV, 1996, HUM GENET, V98, P576, DOI 10.1007/s004390050262; Scott HS, 2000, ADV OTO-RHINO-LARYNG, V56, P158; SCOTT HS, 1993, AM J HUM GENET, V53, P973; Shiels C, 1997, GENOMICS, V44, P35, DOI 10.1006/geno.1997.4817; Thalmann R, 1999, ACTA OTO-LARYNGOL, V119, P293, DOI 10.1080/00016489950181260; TSUJI A, 1991, J BIOL CHEM, V266, P16948; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; Veske A, 1996, HUM MOL GENET, V5, P165, DOI 10.1093/hmg/5.1.165; WATTENHOFER M, IN PRESS HUM GENET; WOLFF DJ, 1992, AM J HUM GENET, V50, P174	28	170	186	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2001	27	1					59	63		10.1038/83768	http://dx.doi.org/10.1038/83768			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11137999	Green Published, Bronze			2022-12-25	WOS:000166187900016
J	Takeda, K; Hayakawa, Y; Smyth, M; Kayagaki, N; Yamaguchi, N; Kakuta, S; Iwakura, Y; Yagita, H; Okumura, K				Takeda, K; Hayakawa, Y; Smyth, M; Kayagaki, N; Yamaguchi, N; Kakuta, S; Iwakura, Y; Yagita, H; Okumura, K			Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells	NATURE MEDICINE			English	Article							IFN-GAMMA PRODUCTION; HUMAN NK CELLS; FAS LIGAND; T-CELLS; MEDIATED CYTOTOXICITY; TUMORICIDAL ACTIVITY; INTERLEUKIN (IL)-12; INTERFERON-GAMMA; DENDRITIC CELLS; DEATH RECEPTOR	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells in vitro, but its physiological role in tumor surveillance remains unknown. Here, we report that TRAIL is constitutively expressed on murine natural killer (NK) cells in the liver and plays a substantial role in suppressing tumor metastasis. Freshly isolated NK cells, but not natural killer T cells or ordinary T cells, from the liver expressed cell surface TRAIL, which was responsible for spontaneous cytotoxicity against TRAIL-sensitive tumor cells in vitro along with perforin and Fas ligand (FasL). Administration of neutralizing monoclonal antibody against TRAIL significantly increased experimental liver metastases of several TRAIL-sensitive tumor cell lines. Such an anti-metastatic effect of TRAIL was not observed in NK cell-depleted mice or interferon-gamma -deficient mice, the latter of which lacked TRAIL on liver NK cells. These findings provide the first evidence for the physiological function of TRAIL as a tumor suppressor.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Toyama Med & Pharmaceut Univ, Res Inst Nat Med, Dept Pathogen Biochem, Toyama, Japan; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div Cell Biol,Minato Ku, Tokyo 1088639, Japan	Juntendo University; Japan Science & Technology Agency (JST); University of Toyama; Peter Maccallum Cancer Center; University of Tokyo	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014; Iwakura, Yoichiro/E-5457-2011; Kakuta, Shigeru/L-2241-2018	Smyth, Mark J/0000-0001-7098-7240; Iwakura, Yoichiro/0000-0002-9934-5775; Kakuta, Shigeru/0000-0002-5900-1425				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnsen AC, 1999, CYTOKINE, V11, P664, DOI 10.1006/cyto.1999.0489; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kashii Y, 1999, J IMMUNOL, V163, P5358; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Kitamura H, 1999, J EXP MED, V189, P1121, DOI 10.1084/jem.189.7.1121; Kodama T, 1999, EUR J IMMUNOL, V29, P1390, DOI 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.3.CO;2-3; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Ogasawara K, 1998, J IMMUNOL, V160, P3522; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Puddu P, 1997, J IMMUNOL, V159, P3490; SAIKI I, 1991, JPN J CANCER RES, V82, P1120, DOI 10.1111/j.1349-7006.1991.tb01766.x; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 1999, J IMMUNOL, V162, P6658; Tagawa Y, 1997, J IMMUNOL, V159, P1418; Takeda K, 2000, INT IMMUNOL, V12, P909, DOI 10.1093/intimm/12.6.909; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; TALMADGE JE, 1980, NATURE, V284, P622, DOI 10.1038/284622a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Tsutsui H, 1997, J IMMUNOL, V159, P3961; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	44	567	589	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					94	100		10.1038/83416	http://dx.doi.org/10.1038/83416			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135622				2022-12-25	WOS:000166243100041
J	Bucci, M; Gratton, JP; Rudic, RD; Acevedo, L; Roviezzo, F; Cirino, G; Sessa, WC				Bucci, M; Gratton, JP; Rudic, RD; Acevedo, L; Roviezzo, F; Cirino, G; Sessa, WC			In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation	NATURE MEDICINE			English	Article							ANTENNAPEDIA HOMEODOMAIN; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; 3RD HELIX; SYNTHASE; PROTEIN; ANGIOGENESIS; CHOLESTEROL; ACTIVATION; CELLS	Caveolin-1, the primary coat protein of caveolae, has been implicated as a regulator of signal transduction through binding of its "scaffolding domain" to key signaling molecules. However, the physiological importance of caveorin-1 in regulating signaling has been difficult to distinguish from its traditional functions in caveolae assembly, transcytosis, and cholesterol transport. To directly address the importance of the caveolin scaffolding domain in vivo, we generated a chimeric peptide with a cellular internalization sequence fused to the caveolin-1 scaffolding domain (amino acids 82-101). The chimeric peptide was efficiently taken up into blood vessels and endothelial cells, resulting in selective inhibition of acetyl-choline (Ach)-induced vasodilation and nitric oxide (NO) production, respectively, More importantly, systemic administration of the peptide to mice suppressed acute inflammation and vascular leak to the same extent as a glucocorticoid or an endothelial nitric oxide synthase (eNOS) inhibitor. These data imply that the caveolin-1 scaffolding domain can selectively regulate signal transduction to eNOS in endothelial cells and that small-molecule mimicry of this domain may provide a new therapeutic approach.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Dipartimento Farmacol Sperimental, I-80131 Naples, Italy	Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Sessa, William C/B-6844-2011; Rudic, Dan/B-3432-2016	Sessa, William C/0000-0001-5759-1938; Cirino, Giuseppe/0000-0003-3954-4083; Roviezzo, Fiorentina/0000-0003-1582-7396; Rudic, Dan/0000-0001-9122-3127; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [HL64793, HL61371, HL57665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R37HL061371, R01HL061371, R01HL064793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; He P, 1997, AM J PHYSIOL-HEART C, V273, pH747, DOI 10.1152/ajpheart.1997.273.2.H747; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH W, 1997, ADV EXP MED BIOL, P989; Sternberg PW, 1999, NAT CELL BIOL, V1, pE35, DOI 10.1038/10028	29	440	470	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1362	1367		10.1038/82176	http://dx.doi.org/10.1038/82176			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100121				2022-12-25	WOS:000165704100040
J	Kwak, B; Mulhaupt, F; Myit, S; Mach, F				Kwak, B; Mulhaupt, F; Myit, S; Mach, F			Statins as a newly recognized type of immunomodulator	NATURE MEDICINE			English	Article							CLASS-II TRANSACTIVATOR; EXPRESSION; DEFICIENCY	Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or statins, are effective lipid-lowering agents, extensively used in medical practice(1-3). Statins have never been shown to be involved in the immune response, although a report has indicated a better outcome of cardiac transplantation in patients under Pravastatin therapy(4). Major histocompatibility complex class II (MHC-II) molecules are directly involved in the activation of T lymphocytes and in the control of the immune response. Whereas only a limited number of specialized cell types express MHC-II constitutively, numerous other cells become MHC-II positive upon induction by interferon gamma (IFN-gamma)(5). This complex regulation is under the control of the transactivator CIITA (refs 6,7). Here we show that statins act as direct inhibitors of induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated T-cell activation. This effect of statins is due to inhibition of the inducible promoter IV of the transactivator CIITA and is observed in several cell types, including primary human endothelial cells (ECs) and monocyte-macrophages (M phi). It is of note that this inhibition is specific for inducible MHC-II expression and does not concern constitutive expression of CIITA and MHC-II. In repressing induction of MHC-II, and subsequent T-lymphocyte activation, statins therefore provide a new type of immunomodulation. This unexpected effect provides a scientific rationale for using statins as immunosuppressors, not only in organ transplantation but in numerous other pathologies as well.	Fdn Med Res, Geneva Med Sch, Univ Hosp, Dept Med,Cardiol Div, Geneva, Switzerland	University of Geneva	Mach, F (corresponding author), Fdn Med Res, Geneva Med Sch, Univ Hosp, Dept Med,Cardiol Div, Geneva, Switzerland.	machf@cmu.unige.ch		Kwak, Brenda/0000-0003-0015-0044				Arrighi JF, 1999, BLOOD, V93, P2244, DOI 10.1182/blood.V93.7.2244.407a29_2244_2252; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Kovalik JP, 2000, J IMMUNOL, V165, P1285, DOI 10.4049/jimmunol.165.3.1285; Lee YJ, 1996, J IMMUNOL, V157, P1559; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Pedersen TR, 1999, AM HEART J, V138, pS177, DOI 10.1016/S0002-8703(99)70340-6; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	17	1088	1153	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1399	1402		10.1038/82219	http://dx.doi.org/10.1038/82219			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100127				2022-12-25	WOS:000165704100046
J	Boyko, V; Ferralli, J; Ashby, J; Schellenbaum, P; Heinlein, M				Boyko, V; Ferralli, J; Ashby, J; Schellenbaum, P; Heinlein, M			Function of microtubules in intercellular transport of plant virus RNA	NATURE CELL BIOLOGY			English	Article							TOBACCO MOSAIC-VIRUS; CELL-TO-CELL; NON-PHLOEM TISSUE; MOVEMENT PROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; TRAFFICKING; GENE; TMV; PLASMODESMATA	Cell-to-cell progression of tobacco mosaic virus (TMV) infection in plants depends on virus-encoded movement protein (MP). Here we show that a conserved sequence motif in tobamovirus MPs shares similarity with a region in tubulins that is proposed to mediate lateral contacts between microtubule protofilaments. Point mutations in this motif confer temperature sensitivity to microtubule association and viral-RNA intercellular-transport functions of the protein, indicating that MP-interacting microtubules are functionally involved in the transport of vRNA to plasmodesmata. Moreover, we show that MP interacts with microtubule-nucleation sites. Together, our results indicate that MP may mimic tubulin assembly surfaces to propel vRNA transport by a dynamic process that is driven by microtubule polymerization.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Inst Univ Technol Colmar, Dept Genie Biol, F-68008 Colmar, France	Friedrich Miescher Institute for Biomedical Research; Universites de Strasbourg Etablissements Associes; Universite de Haute-Alsace (UHA)	Boyko, V (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	heinlein@fmi.ch						Atabekov J G, 1990, Adv Virus Res, V38, P201, DOI 10.1016/S0065-3527(08)60863-5; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; BARKER H, 1987, J GEN VIROL, V68, P1223, DOI 10.1099/0022-1317-68-4-1223; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Boyko V, 2000, PLANT J, V22, P315, DOI 10.1046/j.1365-313x.2000.00740.x; BURNS RG, 1995, J CELL SCI, V108, P2123; CARR RJ, 1983, J GEN VIROL, V64, P2489, DOI 10.1099/0022-1317-64-11-2489; Chan J, 1996, PLANT J, V10, P251, DOI 10.1046/j.1365-313X.1996.10020251.x; COOPER B, 1995, VIROLOGY, V206, P307, DOI 10.1016/S0042-6822(95)80046-8; CYR RJ, 1995, CURR OPIN CELL BIOL, V7, P65, DOI 10.1016/0955-0674(95)80046-8; DEJONG W, 1992, P NATL ACAD SCI USA, V89, P6808, DOI 10.1073/pnas.89.15.6808; DEOM CM, 1994, VIROLOGY, V205, P198, DOI 10.1006/viro.1994.1635; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; Ding B, 1998, PLANT MOL BIOL, V38, P279, DOI 10.1023/A:1006051703837; EPEL BL, 1994, PLANT MOL BIOL, V26, P1343, DOI 10.1007/BF00016479; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; Heinlein M, 1998, PLANT CELL, V10, P1107, DOI 10.1105/tpc.10.7.1107; HEINLEIN M, 1995, SCIENCE, V270, P1983, DOI 10.1126/science.270.5244.1983; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kahn TW, 1998, PLANT J, V15, P15, DOI 10.1046/j.1365-313X.1998.00172.x; KASSANIS B, 1952, ANN APPL BIOL, V39, P358, DOI 10.1111/j.1744-7348.1952.tb01018.x; KOONIN EV, 1991, J GEN VIROL, V72, P2895, DOI 10.1099/0022-1317-72-12-2895; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; MALYSHENKO SI, 1988, J GEN VIROL, V69, P407, DOI 10.1099/0022-1317-69-2-407; Margolis Robert L., 1994, V13, P221; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; MCKINNEY HH, 1945, J HERED, V36, P323, DOI 10.1093/oxfordjournals.jhered.a105433; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; NEJIDAT A, 1991, VIROLOGY, V180, P318, DOI 10.1016/0042-6822(91)90036-B; NISHIGUCHI M, 1978, J GEN VIROL, V39, P53, DOI 10.1099/0022-1317-39-1-53; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; OHNO T, 1983, VIROLOGY, V131, P255, DOI 10.1016/0042-6822(83)90551-2; PADGETT HS, 1993, PLANT CELL, V5, P577, DOI 10.1105/tpc.5.5.577; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Paluh JL, 2000, MOL BIOL CELL, V11, P1225, DOI 10.1091/mbc.11.4.1225; Perbal MC, 1996, DEVELOPMENT, V122, P3433; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; SAITO T, 1988, VIROLOGY, V167, P653, DOI 10.1016/0042-6822(88)90132-8; SCHELLENBAUM P, 1993, PLANT J, V3, P253, DOI 10.1046/j.1365-313X.1993.t01-17-00999.x; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; TAKAMATSU N, 1987, EMBO J, V6, P307, DOI 10.1002/j.1460-2075.1987.tb04755.x; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433	50	140	147	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					826	832		10.1038/35041072	http://dx.doi.org/10.1038/35041072			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056538				2022-12-25	WOS:000165207500017
J	DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE				DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE			A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo	NATURE MEDICINE			English	Article							COMPLEX-FORMATION; PROTEIN; INHIBITORS	We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202, was hydrolyzed, resulting in the release of leucine-doxorubicin and doxorubicin, which are both very cytotoxic to cancer cells. However, L-377,202 was much less cytotoxic than conventional doxorubicin to cells in culture that do not secrete prostate-specific antigen. L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses. Nude mice inoculated with human prostate tumor cells secreting prostate-specific antigen showed considerable reductions in tumor burden with minimal total body weight loss when treated with L-377,202. This improvement in therapeutic index correlated with the selective localization of leucine-doxorubicin and free doxorubicin in tissues secreting prostate-specific antigen after exposure to L-377,202.	Merck Res Labs, Canc Res, W Point, PA 19486 USA; Merck Res Labs, Med Chem, W Point, PA 19486 USA; Merck Res Labs, Lab Anim Resources, W Point, PA 19486 USA; Merck Res Labs, Drug Metab, W Point, PA 19486 USA; Merck Res Labs, Safety Assessment, W Point, PA 19486 USA; Merck Res Labs, Vaccine Biometr Res, W Point, PA 19486 USA; Dupont Pharmaceut, Expt Stn, Wilmington, DE 19880 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; DuPont	Jones, RE (corresponding author), Merck Res Labs, Canc Res, W Point, PA 19486 USA.							AKIYAMA K, 1987, FEBS LETT, V225, P168, DOI 10.1016/0014-5793(87)81151-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432-1033.1994.tb18597.x; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; Denmeade SR, 1998, CANCER RES, V58, P2537; DIAMANDIS EP, 1995, SCAND J CLIN LAB INV, V55, P105, DOI 10.3109/00365519509090573; DIAMANDIS EP, 1994, BREAST CANCER RES TR, V32, P301, DOI 10.1007/BF00666007; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; HUSAIN MH, 1996, SEMIN ONCOL, V23, P24; JOHANSEN PB, 1981, CANCER CHEMOTH PHARM, V5, P267, DOI 10.1007/BF00434396; Leinonen J, 1996, J UROLOGY, V155, P1099, DOI 10.1016/S0022-5347(01)66399-7; LEVESQUE M, 1995, J CLIN LAB ANAL, V9, P123, DOI 10.1002/jcla.1860090209; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MACREZ C, 1967, PATHOL BIOL, V15, P949; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; *SAS I, 1990, SAS STAT US GUID VER, P897; SAS Institute, 1996, SAS STAT SOFTW CHANG; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WESTFALL PH, 1993, RESAMPLING BASED MUL, P112; YU H, 1994, J CLIN LAB ANAL, V8, P251, DOI 10.1002/jcla.1860080412; YU H, 1994, CLIN BIOCHEM, V27, P75, DOI 10.1016/0009-9120(94)90015-9	22	133	153	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1248	1252		10.1038/81351	http://dx.doi.org/10.1038/81351			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062536				2022-12-25	WOS:000165114800032
J	Faulkner, NE; Dujardin, DL; Tai, CY; Vaughan, KT; O'Connell, CB; Wangs, YL; Vallee, RB				Faulkner, NE; Dujardin, DL; Tai, CY; Vaughan, KT; O'Connell, CB; Wangs, YL; Vallee, RB			A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function	NATURE CELL BIOLOGY			English	Article							MILLER-DIEKER SYNDROME; PLATELET-ACTIVATING-FACTOR; DYNACTIN COMPLEX; CELL-CYCLE; ASPERGILLUS-NIDULANS; NEURONAL MIGRATION; NUCLEAR MIGRATION; MITOTIC SPINDLE; IN-VIVO; MICROTUBULE	Mutations in the LIS1 gene cause gross histological disorganization of the developing human brain, resulting in a brain surface that is almost smooth. Here we show that LIS1 protein co-immunoprecipitates with cytoplasmic dynein and dynactin, and localizes to the cell cortex and to mitotic kinetochores, which are known sites for binding of cytoplasmic dynein. Overexpression of LIS1 in cultured mammalian cells interferes with mitotic progression and leads to spindle misorientation. Injection of anti-LIS1 antibody interferes with attachment of chromosomes to the metaphase plate, and leads to chromosome loss. We conclude that LIS1 participates in a subset of dynein functions, and may regulate the division of neuronal progenitor cells in the developing brain.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Faulkner, NE (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.		Dujardin, Denis/GYA-0463-2022	Dujardin, Denis/0000-0001-6372-5293; Wang, Yu-Li/0000-0001-7917-0165	NICHD NIH HHS [HD61982] Funding Source: Medline; NIGMS NIH HHS [GM47434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047434, R01GM047434] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fogli A, 1999, ANN NEUROL, V45, P154, DOI 10.1002/1531-8249(199902)45:2<154::AID-ANA4>3.0.CO;2-P; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; GILBERT SF, 1994, DEV BIOL; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Liu Z, 1999, DEVELOPMENT, V126, P4477; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MIZUGUCHI M, 1995, AM J PATHOL, V147, P1142; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; Vallee RB, 2000, BBA-MOL CELL RES, V1496, P89, DOI 10.1016/S0167-4889(00)00011-2; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan KT, 1999, J CELL SCI, V112, P1437; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	49	362	366	0	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2000	2	11					784	791		10.1038/35041020	http://dx.doi.org/10.1038/35041020			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	371YU	11056532				2022-12-25	WOS:000165207500011
J	Dai, SM; Chen, HH; Chang, C; Riggs, AD; Flanagan, SD				Dai, SM; Chen, HH; Chang, C; Riggs, AD; Flanagan, SD			Ligation-mediated PCR for quantitative in vivo footprinting	NATURE BIOTECHNOLOGY			English	Article							TRANSCRIPTION FACTORS; DNA-BINDING; METHYLATION ANALYSIS; GENE; INVIVO; PROTEINS; PROMOTER; DAMAGE; PGK-1; BETA		City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Flanagan, SD (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA.		Dai, Shu-Mei/AAT-5249-2021	Riggs, Arthur/0000-0002-8184-5288; Chang, Cheng/0000-0003-3109-2588; Dai, Shu-Mei/0000-0002-6546-2631	NCI NIH HHS [CA69449] Funding Source: Medline; NIA NIH HHS [AG15695] Funding Source: Medline; NIGMS NIH HHS [GM50575] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG015695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Becker MM, 1993, FOOTPRINTING NUCL AC, P129; Cairns MJ, 1996, BIOCHEMISTRY-US, V35, P8753, DOI 10.1021/bi9600207; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; HEBERT B, 1993, MOL CELL PROBE, V7, P249, DOI 10.1006/mcpr.1993.1036; HILL CS, 1991, PAIN DIGEST, V1, P7; HORTON RM, 1994, BIOTECHNIQUES, V16, P42; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Machida M, 1997, BIOTECHNIQUES, V23, P300, DOI 10.2144/97232st08; Maxam A M, 1980, Methods Enzymol, V65, P499; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1992, CURRENT PROTOCOLS MO; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Rodriguez H, 1997, ARCH BIOCHEM BIOPHYS, V338, P207, DOI 10.1006/abbi.1996.9820; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439	25	41	46	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2000	18	10					1108	1111		10.1038/80323	http://dx.doi.org/10.1038/80323			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	361VJ	11017053				2022-12-25	WOS:000089744700037
J	Morita, Y; Perez, GI; Paris, F; Miranda, SR; Ehleiter, D; Haimovitz-Friedman, A; Fuks, Z; Xie, ZH; Reed, JC; Schuchman, EH; Kolesnick, RN; Tilly, JL				Morita, Y; Perez, GI; Paris, F; Miranda, SR; Ehleiter, D; Haimovitz-Friedman, A; Fuks, Z; Xie, ZH; Reed, JC; Schuchman, EH; Kolesnick, RN; Tilly, JL			Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; SPHINGOSINE 1-PHOSPHATE; CHEMOTHERAPY; SURVIVAL; BAX; EXPRESSION; GROWTH; MOUSE; INVOLVEMENT; REQUIREMENT	The time at which ovarian failure (menopause) occurs in females is determined by the size of the oocyte reserve provided at birth, as well as by the rate at which this endowment is depleted throughout post-natal life. Here we show that disruption of the gene for acid sphingomyelinase in female mice suppressed the normal apoptotic deletion of fetal oocytes, leading to neonatal ovarian hyperplasia. Ex vivo, oocytes lacking the gene for acid sphingomyelinase or wild-type oocytes treated with sphingosine-1-phosphate resisted developmental apoptosis and apoptosis induced by anti-cancer therapy, confirming cell autonomy of the death defect. Moreover, radiation-induced oocyte loss in adult wild-type female mice, the event that drives premature ovarian failure and infertility in female cancer patients, was completely prevented by in vivo therapy with sphingosine-1-phosphate. Thus, the sphingomyelin pathway regulates developmental death of oocytes, and sphingosine-1-phosphate provides a new approach to preserve ovarian function in vivo.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute	Tilly, JL (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022; Paris, francois E/L-4915-2015	Paris, francois E/0000-0002-0176-7348	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline; NIEHS NIH HHS [R01-ES08430] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blumenfeld Z, 1999, J SOC GYNECOL INVEST, V6, P229, DOI 10.1016/S1071-5576(99)00028-3; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Edsall LC, 1997, J NEUROSCI, V17, P6952; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Gosden R, 1996, NATURE, V383, P485, DOI 10.1038/383485a0; Gosden RG, 1998, REPROD FERT DEVELOP, V10, P73, DOI 10.1071/R98043; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hammond CB, 1996, OBSTET GYNECOL, V87, pS2, DOI 10.1016/0029-7844(95)00429-7; Hardy K, 1999, REV REPROD, V4, P125; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jurisicova A, 1995, HUM REPROD UPDATE, V1, P558, DOI 10.1093/humupd/1.6.558; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LANTZ ME, 1999, CANC OBSTET GYNECOLO, P87; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Morita Y, 1999, ENDOCRINOLOGY, V140, P2696, DOI 10.1210/en.140.6.2696; Morita Y, 1999, ENDOCRINOLOGY, V140, P941, DOI 10.1210/en.140.2.941; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 2000, NATURE, V403, P500, DOI 10.1038/35000651; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Reynolds T, 1999, J NATL CANCER I, V91, P664, DOI 10.1093/jnci/91.8.664; RIED HL, 1994, SEMIN ROENTGENOL, V29, P6, DOI 10.1016/S0037-198X(05)80068-9; Rudin CM, 1997, ANNU REV MED, V48, P267; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WANG E, 1991, J BIOL CHEM, V266, P14486; WAXMAN J, 1983, J ROY SOC MED, V76, P144, DOI 10.1177/014107688307600212; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	46	464	490	2	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1109	1114		10.1038/80442	http://dx.doi.org/10.1038/80442			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017141				2022-12-25	WOS:000089674700034
J	Jimenez, GS; Nister, M; Stommel, JM; Beeche, M; Barcarse, EA; Zhang, XQ; O'Gorman, S; Wahl, GM				Jimenez, GS; Nister, M; Stommel, JM; Beeche, M; Barcarse, EA; Zhang, XQ; O'Gorman, S; Wahl, GM			A transactivation-deficient mouse model provides insights into Trp53 regulation and function	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; NUCLEAR EXPORT; P53 PROTEIN; APOPTOSIS; MDM2; PATHWAY; MICE	The gene Trp53 is among the most frequently mutated and studied genes in human cancer, but the mechanisms by which it suppresses tumour formation remain unclear. We generated mice with an allele encoding changes at Leu25 and Trp26, known to be essential for transcriptional transactivation and Mdm2 binding, to enable analyses of Trp53 structure and function in vivo. The mutant Trp53 was abundant, its level was not affected by DNA damage and it bound DNA constitutively; however, it showed defects in cell-cycle regulation and apoptosis. Both mutant and Trp53-null mouse embryonic fibroblasts (MEFs) were readily transformed by oncogenes, and the corresponding mice were prone to tumours. We conclude that the determining pathway for Trp53 tumour-suppressor function in mice requires the transactivation domain.	Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Uppsala, Rudbeck Lab, Dept Genet & Pathol, Tumor Biol Lab, Uppsala, Sweden; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Salk Institute; Uppsala University; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA.		Stommel, Jayne M/M-3439-2017					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wahl GM, 1997, CANCER SURV, V29, P183; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	181	187	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					37	43		10.1038/79152	http://dx.doi.org/10.1038/79152			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973245				2022-12-25	WOS:000089078000014
J	Charlier, C; Segers, K; Karim, L; Shay, T; Gyapay, G; Cockett, N; Georges, M				Charlier, C; Segers, K; Karim, L; Shay, T; Gyapay, G; Cockett, N; Georges, M			The callipyge mutation enhances the expression of coregulated imprinted genes in cis without affecting their imprinting status	NATURE GENETICS			English	Article							GTL2	The callipyge (CLPG) phenotype (from kappa alpha lambda iota, "beautiful," and pi iota gamma epsilon, "buttocks") described in sheep is an inherited muscular hypertrophy that is subject to unusual parent-of-origin effect referred to as polar overdominance:only heterozygous individuals having inherited the CLPG mutation from their sire exhibit muscular hypertrophy(1). The callipyge (clpg) locus was mapped to a segment of approximately 400 kb (refs, 2-4), which was shown to contain genes (DLK1, GTL2, PEG11 and MEG8) that are preferentially expressed in skeletal muscle and subject to parental imprinting in this tissue(5-9). Here we describe effect of the CLPG mutation on the expression of these four genes, and demonstrate that callipyge individuals have a unique expression profile that may for the observed polar overdominance. for the observed polar overdominance.	Univ Liege B43, Fac Med Vet, Dept Genet, Liege, Belgium; Ctr Natl Sequencage, Genoscope, Evry, France; Utah State Univ, Coll Agr, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA	University of Liege; Utah System of Higher Education; Utah State University	Georges, M (corresponding author), Univ Liege B43, Fac Med Vet, Dept Genet, Liege, Belgium.	michel.georges@ulg.ac.be		Charlier, Carole/0000-0002-9694-094X; Georges, Michel/0000-0003-4124-2375				Berghmans S, 2001, MAMM GENOME, V12, P183, DOI 10.1007/s003350010246; CHARLIER C, IN PRESS GENOME RES; Cockett NE, 1996, SCIENCE, V273, P236, DOI 10.1126/science.273.5272.236; Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x; Schmidt JV, 2000, GENE DEV, V14, P1997; Segers K, 2000, ANIM GENET, V31, P352, DOI 10.1046/j.1365-2052.2000.00676.x; Shay TL, 2001, MAMM GENOME, V12, P141, DOI 10.1007/s003350010248; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600	9	136	146	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2001	27	4					367	369		10.1038/86856	http://dx.doi.org/10.1038/86856			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279514				2022-12-25	WOS:000167811200007
J	Kovtun, IV; McMurray, CT				Kovtun, IV; McMurray, CT			Trinucleotide expansion in haploid germ cells by gap repair	NATURE GENETICS			English	Article							DNA SECONDARY STRUCTURE; CAG REPEAT; CTG REPEATS; HUNTINGTON-DISEASE; INSTABILITY; YEAST; LENGTH; REPLICATION; ORIENTATION; DELETION	Huntington disease (HD) is one of eight progressive neurodegenerative disorders in which the underlying mutation is a CAG expansion encoding a polyglutamine tract(1). The mechanism of trinucleotide expansion is poorly understood. Expansion is mediated by misaligned pairing of repeats and the inappropriate formation of DNA secondary structure as the duplex unpairs(2-7). It has never been clear, however, whether duplex unpairing occurs during mitotic replication or during strand-break repair. In simple organisms, trinucleotide expansion arises by replication slippage on either the leadings or the lagging strand(9-12), homologous recombination(13,14), gene conversion(15,16), double-strand break repair(13-17) and base excision repair(18); it is not clear which of these mechanisms is used in mammalian cells in vivo. We have followed heritable changes in CAG length in male transgenic mice. In germ cells, expansion is limited to the post-meiotic, haploid cell and therefore cannot involve mitotic replication or recombination between a homologous chromosome or a sister chromatid. Our data support a model in which expansion in the germ cells arises by gap repair and depends on a complex containing Msh2. Expansion occurs during gap-filling synthesis when DNA loops comprising the CAG trinucleotide repeats are sealed into the DNA strand.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu	Kovtun, Irina/ABA-8484-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43694] Funding Source: Medline; NIMH NIH HHS [MH56207] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cemal CK, 1999, GENE, V236, P53, DOI 10.1016/S0378-1119(99)00273-5; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GACY AM, 1995, CELL, V81, P533; Goellner GM, 1997, AM J HUM GENET, V60, P879; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kovtun IV, 2000, HUM MOL GENET, V9, P2767, DOI 10.1093/hmg/9.18.2767; Leeflang EP, 1999, HUM MOL GENET, V8, P173, DOI 10.1093/hmg/8.2.173; Lyons-Darden T, 1999, J BIOL CHEM, V274, P25975, DOI 10.1074/jbc.274.37.25975; MACDONALD ME, 1993, J MED GENET, V30, P982, DOI 10.1136/jmg.30.12.982; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; MAYSHOOPES LL, 1995, BIOL REPROD, V53, P1003, DOI 10.1095/biolreprod53.5.1003; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; MCPHERSON SMG, 1993, DEV BIOL, V158, P122, DOI 10.1006/dbio.1993.1173; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NORREMOLLE A, 1995, CLIN GENET, V47, P113; Petersen A, 1999, EXP NEUROL, V157, P1; RANEN NG, 1995, AM J HUM GENET, V57, P593; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Sarkar PS, 1998, CELL, V95, P531, DOI 10.1016/S0092-8674(00)81620-7; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Smith A, 1998, BIOTECHNIQUES, V25, P496, DOI 10.2144/98253rr05; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1	30	213	216	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2001	27	4					407	411		10.1038/86906	http://dx.doi.org/10.1038/86906			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279522				2022-12-25	WOS:000167811200015
J	Wang, PJ; McCarrey, JR; Yang, F; Page, DC				Wang, PJ; McCarrey, JR; Yang, F; Page, DC			An abundance of X-linked genes expressed in spermatogonia	NATURE GENETICS			English	Article							RADIATION HYBRID MAP; MOUSE Y-CHROMOSOME; GERM-CELLS; SEX-CHROMOSOMES; MEIOTIC DRIVE; DAZ GENE; STERILITY; EVOLUTION; HOMOLOG; EXPLANATION	Spermatogonia are the self-renewing, mitotic germ cells of the testis from which sperm arise by means of the differentiation pathway known as spermatogenesis'. By contrast with hematopoietic and other mammalian stem-cell populations. which have been subjects of intense molecular genetic investigation, spermatogonia have remained largely unexplored at the molecular level. Here we describe a systematic search for genes expressed in mouse spermatogonia, but not in somatic tissues. We identified 25 genes (19 of which are novel) that are expressed in only mate germ cells. Of the 25 genes, 3 are Y-linked and 10 are X-linked. If these genes had been distributed randomly in the genome, one would have expected zero to two of the genes to be X-linked. Our findings indicate that the X chromosome has a predominant role in pre-meiotic stages of mammalian spermatogenesis. We hypothesize that the X chromosome acquired this prominent role in male germ-cell development as it evolved from an ordinary, unspecialized autosome.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Whitehead Inst, Cambridge, MA USA; MIT, Dept Biol, Cambridge, MA USA; SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Texas Biomedical Research Institute	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.		Yang, Fan/GYU-4249-2022	Yang, Fengtang/0000-0002-3573-2354				BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Bergstrom DE, 1998, GENOMICS, V48, P304, DOI 10.1006/geno.1997.5176; Brooks R, 2000, NATURE, V406, P67, DOI 10.1038/35017552; CHARLESWORTH B, 1993, GENETICS, V133, P421; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Elliott DJ, 1996, HUM MOL GENET, V5, P869, DOI 10.1093/hmg/5.7.869; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; FRANK SA, 1991, EVOLUTION, V45, P262, DOI 10.1111/j.1558-5646.1991.tb04401.x; Graves JAM, 1998, CYTOGENET CELL GENET, V80, P94, DOI 10.1159/000014963; Herrmann BG, 1999, NATURE, V402, P141, DOI 10.1038/45970; Hurst LD, 1999, TRENDS GENET, V15, P383, DOI 10.1016/S0168-9525(99)01809-0; HURST LD, 1991, GENETICS, V128, P841; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Lahn BT, 1999, SCIENCE, V286, P964, DOI 10.1126/science.286.5441.964; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MORRISONGRAHAM K, 1993, BIOESSAYS, V15, P77, DOI 10.1002/bies.950150202; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; Seydoux G, 1999, DEVELOPMENT, V126, P3275; Sun C, 1999, NAT GENET, V23, P429, DOI 10.1038/70539; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962	30	613	673	1	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					422	426		10.1038/86927	http://dx.doi.org/10.1038/86927			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279525				2022-12-25	WOS:000167811200018
J	Whitelaw, E; Martin, DIK				Whitelaw, E; Martin, DIK			Retrotransposons as epigenetic mediators of phenotypic variation in mammals	NATURE GENETICS			English	Editorial Material							DNA METHYLATION; TRANSPOSABLE ELEMENTS; TRANSCRIPTIONAL INTERFERENCE; DROSOPHILA-MELANOGASTER; RNA INTERFERENCE; MOUSE EMBRYO; C-ELEGANS; GENE; INHERITANCE; EXPRESSION	Phenotypic variation in mammals is frequently attributed to the action of quantitative trait loci (QTL) or the environment, but may also be epigenetic in origin. Here we consider a mechanism for phenotypic variation based on interference of transcription by somatically active retrotransposons. Transcriptionally competent retrotransposons may number in the tens of thousands in mammalian genomes. We propose that silencing of retrotransposons occurs by cosuppression during early embryogenesis, but that this process is imperfect and produces a mosaic pattern of retrotransposon expression in somatic cells. Transcriptional interference by active retrotransposons perturbs expression of neighboring genes in somatic cells, in a mosaic pattern corresponding to activity of each retrotransposon. The epigenotype of retrotransposon activity is reset in each generation, but incomplete resetting can lead to heritable epigenetic effects. The stochastic nature of retrotransposon activity, and the very large number of genes that may be affected, produce subtle phenotypic variations even between genetically identical individuals, which may affect disease risk and be heritable in a non-mendelian fashion.	Victor Chang Cardiac Res Inst, Sydney, NSW, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	Victor Chang Cardiac Research Institute; University of Sydney	Martin, DIK (corresponding author), Victor Chang Cardiac Res Inst, Sydney, NSW, Australia.	d.martin@victorchang.unsw.edu.au						Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; ESSIEN FB, 1990, TERATOLOGY, V42, P183, DOI 10.1002/tera.1420420209; Falconer, 1989, INTRO QUANTITATIVE G, P438; FERRANTE F, 1994, CLIN EXP HYPERTENS, V16, P1, DOI 10.3109/10641969409068580; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FINCHAM JRS, 1974, ANNU REV GENET, V8, P15, DOI 10.1146/annurev.ge.08.120174.000311; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; GARTNER K, 1990, LAB ANIM, V24, P71, DOI 10.1258/002367790780890347; GARTNER K, 1981, NATURE, V292, P646, DOI 10.1038/292646a0; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; GRUNEBERG H, 1970, NATURE, V225, P39, DOI 10.1038/225039a0; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HUMMEL KP, 1958, J EXP ZOOL, V137, P389, DOI 10.1002/jez.1401370303; JABLONKA E, 1995, EPIGENETIC INHERITAN, P46; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jones L, 1999, PLANT CELL, V11, P2291, DOI 10.1105/tpc.11.12.2291; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; KRIEG AM, 1992, FASEB J, V6, P2537, DOI 10.1096/fasebj.6.8.1592206; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; Machin GA, 1996, AM J MED GENET, V61, P216, DOI 10.1002/(SICI)1096-8628(19960122)61:3<216::AID-AJMG5>3.0.CO;2-S; MARTIENSSEN R, 1994, GENETICS, V136, P1157; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; Martin N, 1997, NAT GENET, V17, P387, DOI 10.1038/ng1297-387; McClintock B, 1968, CARNEGIE I WASHINGTO, V66, P20; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MONK M, 1987, DEVELOPMENT, V99, P371; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Vasicek TJ, 1997, GENETICS, V147, P777; WLKINSON DA, 1994, RETROVIRIDAE, P465; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	52	273	284	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2001	27	4					361	365		10.1038/86850	http://dx.doi.org/10.1038/86850			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279513				2022-12-25	WOS:000167811200006
J	Zenklusen, JC; Conti, CJ; Green, ED				Zenklusen, JC; Conti, CJ; Green, ED			Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31	NATURE GENETICS			English	Article							PRIMARY BREAST-CANCER; COMMONLY DELETED REGION; LONG ARM; PHYSICAL MAP; OVARIAN-CANCER; SQUAMOUS-CELL; FREQUENT LOSS; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; CARCINOMAS	Loss of heterozygosity (LOH) of markers on human chromosome 7q31 is frequently encountered in a variety of human neoplasias, indicating the presence of a tumor-suppressor gene (TSC). By a combination of microcell-fusion and deletion-mapping studies, we previously established that this TSG resides within a critical region flanked by the genetic markers D7S522 and D7S677. Using a positional cloning strategy and aided by the availability of near-complete sequence of this genomic interval, we have identified a TSG within 7q31, named ST7 (for suppression of tumorigenicity 7; this same gene was recently reported in another context and called RAY1). ST7 is ubiquitously expressed in human tissues. Analysis of a series of cell lines derived from breast tumors and primary colon carcinomas revealed the presence of mutations in ST7. Introduction of the ST7 cDNA into the prostate-cancer-derived cell line PC3 had no effect on the in vitro proliferation of the cells, but abrogated their in vivo tumorigenicity. Our data indicate that ST7 is a TSG within chromosome 7q31 and may have an important role in the development of some types of human cancer.	NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center	Zenklusen, JC (corresponding author), NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.							ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bieche I, 1997, CLIN CANCER RES, V3, P1009; Black DM, 1999, BRIT J CANCER, V80, P42; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Cunningham JM, 1996, CANCER RES, V56, P4475; Dale TC, 1996, CANCER RES, V56, P4320; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8449; Gupta PK, 1997, CANCER RES, V57, P1188; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.0.CO;2-V; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; KIBBELAAR RE, 1993, BLOOD, V82, P904; Koike M, 1999, LEUKEMIA RES, V23, P307, DOI 10.1016/S0145-2126(98)00159-3; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Lin JC, 1996, ONCOGENE, V13, P2001; Matsuda T, 1997, ONCOGENE, V15, P2773, DOI 10.1038/sj.onc.1201461; Michaels JEA, 1996, P NATL ACAD SCI USA, V93, P14452, DOI 10.1073/pnas.93.25.14452; MOORE D, 1992, CURRENT PROTOCOLS MO; Myohanen SK, 1998, CANCER RES, V58, P591; NEUMAN WL, 1992, BLOOD, V79, P1501; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Sprenger CC, 1999, CANCER RES, V59, P2370; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Trovato M, 1999, J CLIN ENDOCR METAB, V84, P3235, DOI 10.1210/jcem.84.9.5986; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; XU Y, 1994, ISMB, V2, P376; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649	50	79	86	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2001	27	4					392	398		10.1038/86891	http://dx.doi.org/10.1038/86891			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	416ZU	11279520				2022-12-25	WOS:000167811200013
J	Carazo-Salas, RE; Gruss, OJ; Mattaj, IW; Karsenti, E				Carazo-Salas, RE; Gruss, OJ; Mattaj, IW; Karsenti, E			Ran-GTP coordinates regulation of microtubule nucleation and dynamics during mitotic-spindle assembly	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; GAMMA-TUBULIN COMPLEXES; CELL-CYCLE; ASTER FORMATION; PROTEIN IMPORT; BOUND RAN; IN-VITRO; CENTROSOME; MITOSIS; PHOSPHORYLATION	It was recently reported that GTP-bound Ran induces microtubule and pseudo-spindle assembly in mitotic egg extracts in the absence of chromosomes and centrosomes, and that chromosomes induce the assembly of spindle microtubules in these extracts through generation of Ran-GTP. Here we examine the effects of Ran-GTP on microtubule nucleation and dynamics and show that Ran-GTP has independent effects on both the nucleation activity of centrosomes and the stability of centrosomal microtubules. We also show that inhibition of Ran-GTP production, even in the presence of duplicated centrosomes and kinetochores, prevents assembly of a bipolar spindle in M-phase extracts.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Carazo-Salas, RE (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	carazosa@embl-heidelberg.de; karsenti@embl-heidelberg.de		Mattaj, Iain/0000-0002-5537-8284; Carazo-Salas, Rafael E/0000-0002-5943-3981				Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KUBIAK JZ, 1992, J CELL SCI, V102, P457; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; OHTA K, 1993, J CELL SCI, V104, P125; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pereira G, 1997, J CELL SCI, V110, P295; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Schnackenberg BJ, 2000, J CELL SCI, V113, P943; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1991, J CELL SCI, V98, P577; Vandre DD, 2000, MICROSC RES TECHNIQ, V49, P458; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Zhang CM, 1999, J CELL SCI, V112, P2453	46	180	183	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					228	234		10.1038/35060009	http://dx.doi.org/10.1038/35060009			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231571				2022-12-25	WOS:000167365800008
J	Gavioli, R; Frisan, T; Vertuani, S; Bornkamm, GW; Masucci, MG				Gavioli, R; Frisan, T; Vertuani, S; Bornkamm, GW; Masucci, MG			c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells	NATURE CELL BIOLOGY			English	Article							EPSTEIN-BARR-VIRUS; PROTEASOME SUBUNIT COMPOSITION; DEUBIQUITINATING ENZYME; BURKITTS-LYMPHOMA; PROTEINS; GROWTH; DEGRADATION; SPECIFICITY; HYDROLYSIS; EXPRESSION	Burkitt's lymphoma (BL) is a highly malignant B-cell tumour characterized by chromosomal translocations that constitutively activate the c-myc oncogene. Here we show that BL cells are resistant to apoptosis and do not accumulate ubiquitin conjugates in response to otherwise toxic doses of inhibitors of the proteasome. Deubiquitinating enzymes and the cytosolic subtilisin-like protease tripeptidylpeptidase II are upregulated in BLs, and could be rapidly induced by the overexpression of c-myc in normal B cells carrying oestrogen driven recombinant Epstein-Barr virus. Apoptosis was induced by inhibiting tripeptidylpeptidase II, suggesting that the activity of this protease may be required for the survival of BL cells. We thus show that there is a regulatory link between c-myc activation and changes in proteolysis that may affect malignant transformation.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy; GSF Munich, Res Ctr Environm & Hlth, Inst Mol Biol & Tumor Genet, D-81377 Munich, Germany	Karolinska Institutet; University of Ferrara; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Gavioli, R (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.	maria.masucci@mtc.ki.se	Masucci, Maria/AAC-6666-2019; Gavioli, Riccardo/K-7594-2016; Masucci, Maria G/B-8588-2009; Frisan, Teresa/H-8444-2019	Masucci, Maria/0000-0002-5541-2809; Gavioli, Riccardo/0000-0002-7805-4290; Frisan, Teresa/0000-0002-1209-0942				BALOW RM, 1986, J BIOL CHEM, V261, P2409; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; CIECHANOVER A, 1998, NATURE, V392, P618; DAIBATA M, 1990, J IMMUNOL, V144, P4788; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; FARVOT MC, 1984, J NATL CANCER I, V73, P841; Frisan T, 1998, J IMMUNOL, V160, P3281; Frisan T, 2000, INT J CANCER, V88, P881, DOI 10.1002/1097-0215(20001215)88:6<881::AID-IJC7>3.0.CO;2-D; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HADARI T, 1992, J BIOL CHEM, V267, P719; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; MARKU CG, 1992, ANNU REV BIOCHEM, V61, P806; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; Rorth P, 2000, MOL CELL, V6, P23; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	38	97	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2001	3	3					283	288		10.1038/35060076	http://dx.doi.org/10.1038/35060076			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	409BZ	11231578				2022-12-25	WOS:000167365800015
J	Stacker, SA; Caesar, C; Baldwin, ME; Thornton, GE; Williams, RA; Prevo, R; Jackson, DG; Nishikawa, S; Kubo, H; Achen, MG				Stacker, SA; Caesar, C; Baldwin, ME; Thornton, GE; Williams, RA; Prevo, R; Jackson, DG; Nishikawa, S; Kubo, H; Achen, MG			VEGF-D promotes the metastatic spread of tumor cells via the lymphatics	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; TYROSINE KINASES; BREAST-CANCER; FACTOR FAMILY; ANGIOGENESIS; RECEPTOR; EXPRESSION; INHIBITION; LIGAND	Metastasis to local lymph nodes via the lymphatic vessels is a common step in the spread of solid tumors. To investigate the molecular mechanisms underlying the spread of cancer by the lymphatics, we examined the ability of vascular endothelial growth factor (VEGF)-D, a ligand for the lymphatic growth factor receptor VEGFR-3/Flt-4, to induce formation of lymphatics in a mouse tumor model. Staining with markers specific for lymphatic endothelium demonstrated that VEGF-D induced the formation of lymphatics within tumors. Moreover, expression of VEGF-D in tumor cells led to spread of the tumor to lymph nodes, whereas expression of VEGF, an angiogenic growth factor which activates VEGFR-2 but not VEGFR-3, did not. VEGF-D also promoted tumor angiogenesis and growth. Lymphatic spread induced by VEGF-D could be blocked with an antibody specific for VEGF-D. This study demonstrates that lymphatics can be established in solid tumors and implicates VEGF family members in determining the route of metastatic spread.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Pathol, Parkville, Vic, Australia; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med,MRC, Human Immunol Unit,Inst Mol Med, Oxford OX3 9DU, England; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Kyoto, Japan; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne; University of Oxford; Kyoto University; University of Helsinki	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia.			Achen, Marc/0000-0002-3791-803X; , david/0000-0002-4133-9364; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ACHEN MG, IN PRESS J PATHOL; Ansink AC, 1999, CANCER, V86, P652, DOI 10.1002/(SICI)1097-0142(19990815)86:4<652::AID-CNCR14>3.0.CO;2-R; Babu S, 1998, J IMMUNOL, V161, P1428; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; deWaal RMW, 1997, AM J PATHOL, V150, P1951; Drevs J, 2000, CANCER RES, V60, P4819; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kubo H, 2000, BLOOD, V96, P546; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; Leu AJ, 2000, CANCER RES, V60, P4324; LIOTTA LA, 1992, SCI AM, V266, P34; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Lymboussaki A, 2000, CURR TOP MICROBIOL, V251, P75; MANDRIOTA SJ, 2001, IN PRESS EMBOJ; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Niki T, 2000, CLIN CANCER RES, V6, P2431; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PLATE KH, 1993, CANCER RES, V53, P5822; Prewett M, 1999, CANCER RES, V59, P5209; Saleh M, 1996, CANCER RES, V56, P393; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vujanovic Nikola L., 1996, Methods (Orlando), V9, P394, DOI 10.1006/meth.1996.0044; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; Wood JM, 2000, CANCER RES, V60, P2178	41	987	1098	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					186	191		10.1038/84635	http://dx.doi.org/10.1038/84635			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175849				2022-12-25	WOS:000166756300035
J	Myung, K; Datta, A; Chen, C; Kolodner, RD				Myung, K; Datta, A; Chen, C; Kolodner, RD			SGS1, the Saccharomyces cerevisiae homologue of BLM and WRN, suppresses genome instability and homeologous recombination	NATURE GENETICS			English	Article							WERNERS-SYNDROME GENES; DNA HELICASE; BLOOMS-SYNDROME; REPLICATION; INTERACTS; PROTEINS; PRODUCT	The Escherichia coli gene recQ was identified as a RecF recombination pathway gene(1). The gene SGS1, encoding the only RecQ-like DNA helicase in Saccharomyces cerevisiae, was identified by mutations that suppress the top3 slow-growth phenotype(2,3). Relatively little is known about the function of Sgs1p because single mutations in SCSI do not generally cause strong phenotypes. Mutations in genes encoding RecQ-like DNA helicases such as the Bloom and Werner syndrome genes, BLM and WRN, have been suggested to cause increased genome instability(4,5). But the exact DNA metabolic defect that might underlie such genome instability has remained unclear. To better understand the cellular role of the RecQ-like DNA helicases, sgs1 mutations were analyzed for their effect on genome rearrangements(6,7). Mutations in SGS1 increased the rate of accumulating gross chromosomal rearrangements (GCRs), including translocations and deletions containing extended regions of imperfect homology at their breakpoints. sgs1 mutations also increased the rate of recombination between DNA sequences that had 91% sequence homology. Epistasis analysis showed that Sgs1p is redundant with DNA mismatch repair (MMR) for suppressing GCRs and for suppressing recombination between divergent DNA sequences. This suggests that defects in the suppression of rearrangements involving divergent, repeated sequences may underlie the genome instability seen in BLM and WRN patients and in cancer cases associated with defects in these genes.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA.		Chen, Clark C/C-8714-2013	Chen, Clark C/0000-0001-6258-9277	NIGMS NIH HHS [GM50006, GM26017] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026017, R01GM026017, R01GM050006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Calin G, 1998, CANCER RES, V58, P3777; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen YL, 1998, T NONFERR METAL SOC, V8, P5; Datta A, 1996, MOL CELL BIOL, V16, P1085; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; FUKUCHI K, 1990, HUM GENET, V84, P249; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; German J, 1998, GENETIC BASIS HUMAN, P301; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; MONNAT RJ, 1992, GENOMICS, V13, P777, DOI 10.1016/0888-7543(92)90153-J; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; NAKAYAMA H, 1984, MOL GEN GENET, V195, P475; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Nicholson A, 2000, GENETICS, V154, P133; SALK D, 1985, ADV EXP MED BIOL, V190, P541; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHIRAISHI Y, 1983, CANCER GENET CYTOGEN, V9, P129, DOI 10.1016/0165-4608(83)90033-X; Watt PM, 1996, GENETICS, V144, P935; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	30	262	266	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2001	27	1					113	116		10.1038/83673	http://dx.doi.org/10.1038/83673			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	388NP	11138010				2022-12-25	WOS:000166187900027
J	Marty, T; Muller, B; Basler, K; Affolter, M				Marty, T; Muller, B; Basler, K; Affolter, M			Schnurri mediates Dpp-dependent repression of brinker transcription	NATURE CELL BIOLOGY			English	Article							MORPHOGEN GRADIENT; DROSOPHILA EMBRYOS; PROTEIN; SEQUENCE; ENCODES; REVEALS; FAMILY; TARGET; GENES	Signalling by Decapentaplegic (Dpp), a member of the TGF beta superfamily of signalling molecules, controls many aspects of Drosophila development by activating and repressing target genes. Several essential components of the Dpp signalling pathway have been identified, including the Dpp receptors Punt and Thick veins (Tkv) as well as the cytoplasmic mediators Mad and Medea, For target genes to be activated, Dpp signalling must suppress transcription of a repressor encoded by the brinker (brk) gene. Here we show that Schnurri (Shn), a large zinc-finger protein, is essential for Dpp-mediated repression of brk transcription; in contrast, Shn is not required for target-gene activation. Thus, the Dpp signalling pathway bifurcates, downstream of the signal-mediating SMAD proteins, into a Shn-dependent pathway leading to brk repression and a Shn-independent pathway leading to gene activation. The existence of several Shn-like proteins in vertebrates and the observation that Brk functions in BMP signalling in Xenopus indicates that a similar regulatory cascade may be conserved in higher organisms.	Univ Basel, Biozentrum, Abt Zellbiol, CH-4056 Basel, Switzerland; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Basel; University of Zurich	Affolter, M (corresponding author), Univ Basel, Biozentrum, Abt Zellbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Mueller, Bruno/E-9888-2017	Mueller, Bruno/0000-0003-2664-7219; Affolter, Markus/0000-0002-5171-0016; Basler, Konrad/0000-0003-3534-1529				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; Bienz M, 1996, SEMIN CELL DEV BIOL, V7, P113, DOI 10.1006/scdb.1996.0016; BRAND AH, 1993, DEVELOPMENT, V118, P401; Burke R, 1996, DEVELOPMENT, V122, P2261; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Certel K, 2000, DEVELOPMENT, V127, P3173; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GRIEDER NC, 1997, THESIS U BASEL SWITZ; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; MartinBermudo MD, 1997, EMBO J, V16, P4184, DOI 10.1093/emboj/16.14.4184; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; RUBERTE E, 1995, CELL, V80, P890; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Udagawa Y, 2000, GENES CELLS, V5, P359, DOI 10.1046/j.1365-2443.2000.00328.x	27	100	102	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					745	749		10.1038/35036383	http://dx.doi.org/10.1038/35036383			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025666				2022-12-25	WOS:000089697000021
J	Schmitt, CA; Rosenthal, CT; Lowe, SW				Schmitt, CA; Rosenthal, CT; Lowe, SW			Genetic analysis of chemoresistance in primary murine lymphomas	NATURE MEDICINE			English	Article							NON-HODGKINS-LYMPHOMAS; B-CELL; C-MYC; CLONOGENIC SURVIVAL; HEMATOLOGIC MALIGNANCIES; ANTICANCER AGENTS; INDUCED APOPTOSIS; TREATMENT FAILURE; TRANSGENIC MICE; DRUG-RESISTANCE	Understanding the basis of chemoresistance is a principal goal of molecular oncology. We have exploited a murine lymphoma model and retroviral gene transfer to rapidly generate a series of spontaneous tumors differing only in a gene of interest, and subsequently studied the impact of the test gene on the treatment sensitivity of tumors at their natural site. We demonstrate that the Bcl-2 oncoprotein produces multi-drug resistance when assessed in primary lymphomas in vivo. In contrast, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and completely missed in the standard clonogenic survival assay. This model highlights the importance of physiological test systems to address the complexity of clinical drug resistance and provides a novel strategy to evaluate compounds targeting specific genetic lesions.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Schmitt, Clemens A/S-9479-2017	Schmitt, Clemens A/0000-0002-4731-2226				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 1999, CANCER RES, V59, P3761; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELROUBY S, 1993, BLOOD, V82, P3452; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gascoyne RD, 1997, BLOOD, V90, P244; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HSU B, 1995, ONCOGENE, V11, P175; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Lock RB, 1996, CANCER RES, V56, P4006; Moller MB, 1999, CLIN CANCER RES, V5, P1085; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Navaratnam S, 1998, LEUKEMIA LYMPHOMA, V29, P139, DOI 10.3109/10428199809058389; Omer CA, 2000, CANCER RES, V60, P2680; Pomp J, 1996, RADIOTHER ONCOL, V40, P121, DOI 10.1016/0167-8140(96)01767-7; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 1999, J PATHOL, V187, P127; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; Uckun FM, 1997, BLOOD, V89, P3769, DOI 10.1182/blood.V89.10.3769.3769_3769_3777; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker A, 1997, CANCER RES, V57, P1939; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601; YIN DX, 1995, CANCER RES, V55, P4922	35	233	249	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1029	1035		10.1038/79542	http://dx.doi.org/10.1038/79542			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973324				2022-12-25	WOS:000089190500036
J	Angelillo-Scherrer, A; de Frutos, PG; Aparicio, C; Melis, E; Savi, P; Lupu, F; Arnout, J; Dewerchin, M; Hoylaerts, MF; Herbert, M; Collen, D; Dahlback, B; Carmeliet, P				Angelillo-Scherrer, A; de Frutos, PG; Aparicio, C; Melis, E; Savi, P; Lupu, F; Arnout, J; Dewerchin, M; Hoylaerts, MF; Herbert, M; Collen, D; Dahlback, B; Carmeliet, P			Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis	NATURE MEDICINE			English	Article							RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; PLASMINOGEN-ACTIVATOR INHIBITOR-1; VASCULAR SMOOTH-MUSCLE; K-DEPENDENT PROTEINS; GROWTH-ARREST; CELL-ADHESION; BLEEDING-TIME; AXL; LIGAND	The growth arrest-specific gene 6 product (Gas6) is a secreted protein related to the anticoagulant protein S but its role in hemostasis is unknown. Here we show that inactivation of the Gas6 gene prevented venous and arterial thrombosis in mice, and protected against fatal collagen/epinephrine-induced thrombo embolism. Gas6(-/-) mice did not, however, suffer spontaneous bleeding and had normal bleeding after tail clipping. In addition, we found that Gas6 antibodies inhibited platelet aggregation in vitro and protected mice against fatal thrombo embolism without causing bleeding in vivo. Gas6 amplified platelet aggregation and secretion in response to known agonists. Platelet dysfunction in Gas6(-/-) mice resembled that of patients with platelet signaling transduction defects. Thus, Gas6 is a platelet-response amplifier that plays a significant role in thrombosis. These findings warrant further evaluation of the possible therapeutic use of Gas6 inhibition for prevention of thrombosis.	Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol, Louvain, Belgium; Lund Univ, Univ Malta, Dept Clin Chem, Wallenberg Lab, Malmo, Sweden; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Thrombosis Res Inst, Vasc Biol Lab, London SW3 6LR, England	Lund University; University of Malta; Sanofi-Aventis; Sanofi France; Thrombosis Research Institute	Carmeliet, P (corresponding author), Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; de Frutos, Pablo García/B-8594-2011; Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Carmeliet, Peter/0000-0001-7961-1821; de Frutos, Pablo García/0000-0003-1547-1190; Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278; Hoylaerts, Marc/0000-0002-6474-3933; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Dahlback, Bjorn/0000-0003-1546-0328				Avanzi GC, 1997, EXP HEMATOL, V25, P1219; BENNETT JS, 1991, ANN NY ACAD SCI, V614, P214, DOI 10.1111/j.1749-6632.1991.tb43704.x; Borgel D, 1997, THROMB HAEMOSTASIS, V78, P351; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Evenas P, 2000, THROMB HAEMOSTASIS, V84, P271, DOI 10.1055/s-0037-1614007; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Gabbeta J, 1996, BLOOD, V87, P1368, DOI 10.1182/blood.V87.4.1368.bloodjournal8741368; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRINNELL BW, 1990, BLOOD, V76, P2546; HERBERT JM, 1992, BLOOD, V80, P2281; Ishimoto Y, 2000, FEBS LETT, V466, P197, DOI 10.1016/S0014-5793(99)01795-0; Kawasaki T, 1999, THROMB HAEMOSTASIS, V81, P306, DOI 10.1055/s-0037-1614471; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Li RH, 1996, J NEUROSCI, V16, P2012; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARCUS AJ, 1996, DISORDERS HEMOSTASIS, P79; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MATSUNO H, 1992, BRIT J PHARMACOL, V106, P533, DOI 10.1111/j.1476-5381.1992.tb14370.x; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; NEUBAUER A, 1994, BLOOD, V84, P1931; O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Rao AK, 2000, ARTERIOSCL THROM VAS, V20, P285, DOI 10.1161/01.ATV.20.2.285; ROTH J, 1989, METHOD CELL BIOL, V31, P513; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; STASSEN JM, 1990, FIBRINOLYSIS, V4, P15, DOI 10.1016/0268-9499(90)90349-O; Umemura K, 1996, THROMB HAEMOSTASIS, V76, P799; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; VOGEL GMT, 1989, THROMB RES, V54, P399, DOI 10.1016/0049-3848(89)90210-7; Yan SB, 1996, J MOL RECOGNIT, V9, P211	45	338	364	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					215	221		10.1038/84667	http://dx.doi.org/10.1038/84667			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175853	Green Published			2022-12-25	WOS:000166756300039
J	LaVaute, T; Smith, S; Cooperman, S; Iwai, K; Land, W; Meyron-Holtz, E; Drake, SK; Miller, G; Abu-Asab, M; Tsokos, M; Switzer, R; Grinberg, A; Love, P; Tresser, N; Rouault, TA				LaVaute, T; Smith, S; Cooperman, S; Iwai, K; Land, W; Meyron-Holtz, E; Drake, SK; Miller, G; Abu-Asab, M; Tsokos, M; Switzer, R; Grinberg, A; Love, P; Tresser, N; Rouault, TA			Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice	NATURE GENETICS			English	Article							RESPONSIVE ELEMENT; CEREBRAL-CORTEX; RNA-BINDING; SYSTEM; DEGRADATION; EXPRESSION; MEMBRANES; ACONITASE; FEATURES; FERRITIN	In mammalian cells, regulation of the expression of proteins involved in iron metabolism is achieved through interactions of iron-sensing proteins known as iron regulatory proteins (IRPs), with transcripts that contain RNA stem-loop structures referred to as iron responsive elements (IREs). Two distinct but highly homologous proteins, IRP1 and IRP2, bind IREs with high affinity when cells are depleted of iron, inhibiting translation of some transcripts, such as ferritin, or turnover of others, such as the transferrin receptor (TFRC). IRPs sense cytosolic iron levels and modify expression of proteins involved in iron uptake, export and sequestration according to the needs of individual cells(1,2). Here we generate mice with a targeted disruption of the gene encoding Irp2 (Ireb2). These mutant mice misregulate iron metabolism in the intestinal mucosa and the central nervous system. In adulthood, Ireb2(-/-) mice develop a movement disorder characterized by ataxia, bradykinesia and tremor. Significant accumulations of iron in white matter tracts and nuclei throughout the brain precede the onset of neurodegeneration and movement disorder symptoms by many months. Ferric iron accumulates in the cytosol of neurons and oligodendrocytes in distinctive regions of the brain. Abnormal accumulations of ferritin colocalize with iron accumulations in populations of neurons that degenerate, and iron-laden oligodendrocytes accumulate ubiquitin-positive inclusions. Thus, misregulation of iron metabolism leads to neurodegenerative disease in Ire62(-/-) mice and may contribute to the pathogenesis of comparable human neurodegenerative diseases.	NICHHD, Cell Biol & Metab Branch, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Off Director, Bethesda, MD USA; NCI, Div Clin Sci, Bethesda, MD 20892 USA; NeuroSci Associates, Knoxville, TN USA; NICHHD, Lab Mammalian Genet & Dev, Bethesda, MD 20892 USA; NINDS, Neuroimmunol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Rouault, TA (corresponding author), NICHHD, Cell Biol & Metab Branch, Bethesda, MD 20892 USA.		Meyron-Holtz, Esther/B-5991-2013; IWAI, KAZUHIRO/GSN-7385-2022	Abu-Asab, Mones/0000-0002-4047-1232; Iwai, Kazuhiro/0000-0001-5620-5951; Lipko, Nancy/0000-0001-9267-4587	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602, ZIAHD001803] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602, Z01HD001803] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Allerson CR, 1999, J BIOL CHEM, V274, P26439, DOI 10.1074/jbc.274.37.26439; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; ARAI N, 1994, NEUROSCI LETT, V182, P197, DOI 10.1016/0304-3940(94)90796-X; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fix AS, 2000, TOXICOL PATHOL, V28, P122, DOI 10.1177/019262330002800115; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; FRANCOIS C, 1981, BRAIN RES, V215, P317, DOI 10.1016/0006-8993(81)90510-2; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Ishino K, 2000, J CELL BIOCHEM, V76, P411, DOI 10.1002/(SICI)1097-4644(20000301)76:3<411::AID-JCB9>3.0.CO;2-J; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Katz RL, 1997, HUM PATHOL, V28, P502, DOI 10.1016/S0046-8177(97)90042-3; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KONIJN AM, 1982, J IMMUNOL METHODS, V54, P297, DOI 10.1016/0022-1759(82)90314-3; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4	30	395	406	2	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2001	27	2					209	214		10.1038/84859	http://dx.doi.org/10.1038/84859			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	399XH	11175792				2022-12-25	WOS:000166839200025
J	Lundberg, C; Jungles, SJ; Mulligan, RC				Lundberg, C; Jungles, SJ; Mulligan, RC			Direct delivery of leptin to the hypothalamus using recombinant adeno-associated virus vectors results in increased therapeutic efficacy	NATURE BIOTECHNOLOGY			English	Article							ADENOASSOCIATED VIRUS; PARKINSONS-DISEASE; MAMMALIAN BRAIN; GENE-TRANSFER; OBESE MICE; EXPRESSION; WEIGHT; RESISTANCE; INJECTION; MUSCLE		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Div Mol Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Mulligan, RC (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Lundberg, Cecilia/0000-0002-6959-2564				Bartlett JS, 1998, HUM GENE THER, V9, P1181, DOI 10.1089/hum.1998.9.8-1181; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; Mandel RJ, 1998, J NEUROSCI, V18, P4271; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Simerly Richard B., 1995, P353; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891	19	16	17	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					169	172		10.1038/84448	http://dx.doi.org/10.1038/84448			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175734				2022-12-25	WOS:000166754700026
J	Nakai, J; Ohkura, M; Imoto, K				Nakai, J; Ohkura, M; Imoto, K			A high signal-to-noise Ca2+ probe composed of a single green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article						calcium; green fluorescent protein; calmodulin; myosin light chain kinase; protein-protein interaction; photoisomerization	CALMODULIN; RECEPTOR; SEQUENCE; CELLS; INDICATORS; CAMELEONS	Recently, several groups have developed green fluorescent protein (GFP)-based Ca2+ probes. When applied in cells, however, these probes are difficult to use because of a low signal-to-noise ratio. Here we report the development of a high-affinity Ca2+ probe composed of a single GFP (named G-CaMP). G-CaMP showed an apparent K-d for Ca2+ of 235 nM. Association kinetics of Ca2+ binding were faster at higher Ca2+ concentrations, with time constants decreasing from 230 ms at 0.2 muM Ca2+ to 2.5 ms at 1 muM Ca2+. Dissociation kinetics (tau similar to 200 ms) are independent of Ca2+ concentrations. In HEK-293 cells and mouse myotubes expressing G-CaMP, large fluorescent changes were observed in response to application of drugs or electrical stimulations. G-CaMP will be a useful tool for visualizing intracellular Ca2+ in living cells. Mutational analysis, together with previous structural information, suggests the residues that may alter the fluorescence of GFP.	Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Nakai, J (corresponding author), Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan.		Ohkura, Masamichi/J-6976-2012; Nakai, Junichi/GQZ-6415-2022	Ohkura, Masamichi/0000-0002-3659-7780; Imoto, Keiji/0000-0002-2861-5985				Allen GJ, 1999, PLANT J, V19, P735, DOI 10.1046/j.1365-313x.1999.00574.x; Allen GJ, 2000, SCIENCE, V289, P2338, DOI 10.1126/science.289.5488.2338; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Fan GY, 1999, BIOPHYS J, V76, P2412, DOI 10.1016/S0006-3495(99)77396-0; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; JAMESKRACKE MR, 1992, J CELL PHYSIOL, V151, P596, DOI 10.1002/jcp.1041510320; Kerr R, 2000, NEURON, V26, P583, DOI 10.1016/S0896-6273(00)81196-4; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	27	996	1033	9	216	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					137	141		10.1038/84397	http://dx.doi.org/10.1038/84397			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175727				2022-12-25	WOS:000166754700019
J	Ishizaki, T; Morishima, Y; Okamoto, M; Furuyashiki, T; Kato, T; Narumiya, S				Ishizaki, T; Morishima, Y; Okamoto, M; Furuyashiki, T; Kato, T; Narumiya, S			Coordination of microtubules and the actin cytoskeleton by the Rho effector mDia1	NATURE CELL BIOLOGY			English	Article							BINDING PROTEIN RHO; STRESS FIBER FORMATION; SWISS 3T3 FIBROBLASTS; FOCAL ADHESIONS; CELL-MIGRATION; SACCHAROMYCES-CEREVISIAE; ARP2/3 COMPLEX; FISSION YEAST; KINASE; POLARIZATION	Coordination of microtubules and the actin cytoskeleton is important in several types of cell movement. mDia1 is a member of the formin-homology family of proteins and an effector of the small GTPase Rho. It contains the Rho-binding domain in its amino terminus and two distinct regions of formin homology, FH1 in the middle and FH2 in the carboxy terminus. Here we show that expression of mDia1(Delta N3), an active mDia1 mutant containing the FH1 and FH2 regions without the Rho-binding domain, induces bipolar elongation of HeLa cells and aligns microtubules in parallel to F-actin bundles along the long axis of the cell. The cell elongation and microtubule alignment caused by this mutant is abolished by co-expression of an FH2-region fragment, and expression of mDia1(Delta N3) containing point mutations in the FH2 region causes an increase in the amount of disorganized F-actin without cell elongation and microtubule alignment. These results indicate that mDia1 may coordinate microtubules and F-actin through its FH2 and FH1 regions, respectively.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan	Kyoto University	Ishizaki, T (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Furuyashiki, Tomoyuki/AAG-5283-2019; Morishima, Yosuke/K-8258-2013; Furuyashiki, Tomoyuki/B-8760-2014	Furuyashiki, Tomoyuki/0000-0001-8089-8399; Morishima, Yosuke/0000-0001-9363-697X; Furuyashiki, Tomoyuki/0000-0001-8089-8399				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Elbaum M, 1999, BIOCHEM SOC SYMP, V65, P147; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Niggli V, 1999, FEBS LETT, V445, P69, DOI 10.1016/S0014-5793(99)00098-8; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VASILIEV JM, 1991, J CELL SCI, V98, P1; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	39	267	273	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2001	3	1					8	14						7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	387XD	11146620				2022-12-25	WOS:000166146400014
J	Jacobsen, M; Schweer, D; Ziegler, A; Gaber, R; Schock, S; Schwinzer, R; Wonigeit, K; Lindert, RB; Kantarci, O; Schaefer-Klein, J; Schipper, HI; Oertel, WH; Heidenreich, F; Weinshenker, BG; Sommer, N; Hemmer, B				Jacobsen, M; Schweer, D; Ziegler, A; Gaber, R; Schock, S; Schwinzer, R; Wonigeit, K; Lindert, RB; Kantarci, O; Schaefer-Klein, J; Schipper, HI; Oertel, WH; Heidenreich, F; Weinshenker, BG; Sommer, N; Hemmer, B			A point mutation in PTPRC is associated with the development of multiple sclerosis	NATURE GENETICS			English	Article							TYROSINE-PHOSPHATASE CD45; RECEPTOR COMPLEX; EXON-A; ACTIVATION; SCREEN; MYELIN; FAMILY	Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. It is widely accepted that a dysregulated immune response against brain resident antigens is central to its yet unknown pathogenesis(1-4). Although there is evidence that the development of MS has a genetic component, specific genetic factors are largely unknown(5-7). Here we investigated the role of a point mutation in the gene (PTPRC) encoding protein-tyrosine phosphatase, receptor-type C (also known as CD45) in the heterozygous state in the development of MS. The nucleotide transition in exon 4 of the gene locus interferes with mRNA splicing and results in altered expression of CD45 isoforms on immune cells. In three of four independent case-control studies, we demonstrated an association of the mutation with MS. We found the PTPRC mutation to be linked to and associated with the disease in three MS nuclear families. In one additional family, we found the same variant CD45 phenotype, with an as-yet-unknown origin, among the members affected with MS. Our findings suggest an association of the mutation in PTPRC with the development of MS in some families.	Univ Marburg, Dept Neurol, Marburg, Germany; Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany; Hannover Med Sch, Viszeral & Transplantat Chirurg Klin, Transplantat Lab, D-3000 Hannover, Germany; Hannover Med Sch, Dept Neurol, D-3000 Hannover, Germany; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Schlossbergklin Wittgenstein, Bad Laasphe, Germany	Philipps University Marburg; Philipps University Marburg; Hannover Medical School; Hannover Medical School; Mayo Clinic	Hemmer, B (corresponding author), Univ Marburg, Dept Neurol, Marburg, Germany.	hemmer@mailer.uni-marburg.de	Weinshenker, Brian G/ABH-6146-2020; Hemmer, Bernhard/GPX-8451-2022; Hemmer, Bernhard/AAT-8388-2021; Ziegler, Andreas/G-4246-2012	Weinshenker, Brian G/0000-0001-5806-6203; Hemmer, Bernhard/0000-0001-5985-6784; Jacobsen, Marc/0000-0002-4703-5652; Ziegler, Andreas/0000-0002-8386-5397				Ebers GC, 1998, SEMIN NEUROL, V18, P295, DOI 10.1055/s-2008-1040880; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; HAFLER DA, 1995, IMMUNOL REV, V144, P75, DOI 10.1111/j.1600-065X.1995.tb00066.x; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Kantarci OH, 2000, J NEUROIMMUNOL, V106, P220, DOI 10.1016/S0165-5728(00)00202-2; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Kung C, 2000, NAT MED, V6, P343; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; Noseworthy JH, 1999, NATURE, V399, pA40, DOI 10.1038/399a040; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; Oksenberg JR, 1997, CURR OPIN NEUROL, V10, P181, DOI 10.1097/00019052-199706000-00003; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Sawcer S, 1997, TRENDS GENET, V13, P234, DOI 10.1016/S0168-9525(97)01140-2; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCHWINZER R, 1990, J EXP MED, V171, P1803, DOI 10.1084/jem.171.5.1803; Shenoi H, 1999, J IMMUNOL, V162, P7120; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; THUDE H, 1995, EUR J IMMUNOL, V25, P2101, DOI 10.1002/eji.1830250745; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Vergelli M, 1996, EUR J IMMUNOL, V26, P2624, DOI 10.1002/eji.1830261113; Zilch CF, 1998, EUR J IMMUNOL, V28, P22, DOI 10.1002/(SICI)1521-4141(199801)28:01<22::AID-IMMU22>3.0.CO;2-7	26	161	166	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2000	26	4					495	499		10.1038/82659	http://dx.doi.org/10.1038/82659			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	379YX	11101853				2022-12-25	WOS:000165671700028
J	Savoian, MS; Goldberg, ML; Rieder, CL				Savoian, MS; Goldberg, ML; Rieder, CL			The rate of poleward chromosome motion is attenuated in Drosophila zw10 and rod mutants	NATURE CELL BIOLOGY			English	Article							CYTOPLASMIC DYNEIN; ANAPHASE ONSET; KINETOCHORE; SPINDLE; SEGREGATION; DYNACTIN; PROTEIN; COMPLEX; MITOSIS; CELLS	Here we show that the rate of poleward chromosome motion in zw10-null mutants is greatly attenuated throughout the division process, and that chromosome disjunction at anaphase is highly asynchronous. Our results show that ZW10 protein, together with Rod, is involved in production and/or regulation of the force reponsible for poleward chromosome motion.	New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Cornell University	Rieder, CL (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA.				NIGMS NIH HHS [R37 GM040198-17, R37 GM040198] Funding Source: Medline; PHS HHS [48430, 40198] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040198] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJER AS, 1972, INT REV CYTOL      S, V3, P1; CHURCH K, 1985, CHROMOSOMA, V92, P273, DOI 10.1007/BF00329810; Church K, 1988, ANEUPLOIDY B, P227; COLE RW, 1995, MICROSC MICROANAL S, V3, P203; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Khodjakov A, 1997, J CELL BIOL, V136, P229, DOI 10.1083/jcb.136.2.229; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Scaerou F, 1999, J CELL SCI, V112, P3757; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127	21	111	115	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2000	2	12					948	952		10.1038/35046605	http://dx.doi.org/10.1038/35046605			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	382GK	11146661				2022-12-25	WOS:000165814500019
J	Fiehn, O; Kopka, J; Dormann, P; Altmann, T; Trethewey, RN; Willmitzer, L				Fiehn, O; Kopka, J; Dormann, P; Altmann, T; Trethewey, RN; Willmitzer, L			Metabolite profiling for plant functional genomics	NATURE BIOTECHNOLOGY			English	Article						functional genomics; Arabidopsis thaliana; metabolite profiling; duster analysis; metabolomics; bioinformatics	GAS-CHROMATOGRAPHY; SUGAR ALCOHOLS; ORGANIC-ACIDS; EXPRESSION; DEFICIENT; MUTANT; DGD1	Multiparallel analyses of mRNA and proteins are central to today's functional genomics initiatives. We describe here the use of metabolite profiling as a new tool for a comparative display of gene function. It has the potential not only to provide deeper insight into complex regulatory processes but also to determine phenotype directly. Using gas chromatography/mass spectrometry (GC/MS), we automatically quantified 326 distinct compounds from Arabidopsis thaliana leaf extracts. It was possible to assign a chemical structure to approximately half of these compounds. Comparison of four Arabidopsis genotypes (two homozygous ecotypes and a mutant of each ecotype) showed that each genotype possesses a distinct metabolic profile. Data mining tools such as principal component analysis enabled the assignment of "metabolic phenotypes" using these large data sets. The metabolic phenotypes of the two ecotypes were more divergent than were the metabolic phenotypes of the single-loci mutant and their parental ecotypes. These results demonstrate the use of metabolite profiling as a tool to significantly extend and enhance the power of existing functional genomics approaches.	Max Planck Inst Mol Plant Physiol, D-14424 Potsdam, Germany; Metan GmbH & Co KGaA, D-10589 Berlin, Germany	Max Planck Society	Fiehn, O (corresponding author), Max Planck Inst Mol Plant Physiol, D-14424 Potsdam, Germany.		陈, 忱/G-8409-2012; Willmitzer, Lothar/F-7377-2011	Altmann, Thomas/0000-0002-3759-360X; Kopka, Joachim/0000-0001-9675-4883				Adams MA, 1999, ANAL BIOCHEM, V266, P77, DOI 10.1006/abio.1998.2906; *ARG COMP BIOL GRO, INT MET; Baldwin D, 1999, CURR OPIN PLANT BIOL, V2, P96, DOI 10.1016/S1369-5266(99)80020-X; Berger D, 2000, GENE DEV, V14, P1119; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; Duez P, 1996, CLIN CHEM, V42, P1609; Fiehn O, 2000, ANAL CHEM, V72, P3573, DOI 10.1021/ac991142i; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hartel H, 1998, PLANT PHYSIOL BIOCH, V36, P407, DOI 10.1016/S0981-9428(98)80204-0; JURS PC, 1986, SCIENCE, V232, P1219, DOI 10.1126/science.3704647; Katona ZF, 1999, J CHROMATOGR A, V847, P91, DOI 10.1016/S0021-9673(99)00333-7; *KYOT U I CHEM RES, GEN DAT; *M PLANK I MOL PLA, MET PROF; McLafferty FW, 1999, J AM SOC MASS SPECTR, V10, P1229, DOI 10.1016/S1044-0305(99)00104-X; Mead R., 1993, STAT METHODS AGR EXP, Vsecond; Murakami Y, 2000, SCIENCE, V287, P476, DOI 10.1126/science.287.5452.476; Santoni V, 1998, PLANT J, V16, P633, DOI 10.1046/j.1365-313x.1998.00335.x; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Trethewey RN, 1999, CURR OPIN PLANT BIOL, V2, P83, DOI 10.1016/S1369-5266(99)80017-X; Vingron M, 1999, J MOL MED-JMM, V77, P3, DOI 10.1007/s001090050290; Zweiger G, 1999, TRENDS BIOTECHNOL, V17, P429, DOI 10.1016/S0167-7799(99)01359-1	22	1532	1744	23	734	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1157	1161		10.1038/81137	http://dx.doi.org/10.1038/81137			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062433				2022-12-25	WOS:000165176600019
J	Varnum-Finney, B; Xu, LW; Brashem-Stein, C; Nourigat, C; Flowers, D; Bakkour, S; Pear, WS; Bernstein, ID				Varnum-Finney, B; Xu, LW; Brashem-Stein, C; Nourigat, C; Flowers, D; Bakkour, S; Pear, WS; Bernstein, ID			Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling	NATURE MEDICINE			English	Article							DROSOPHILA-NOTCH; HUMAN HOMOLOG; GENE; PROGENITORS; EXPRESSION; MARROW; DIFFERENTIATION; JAGGED-1; LIGAND; CHOICE	Hematopoietic stem cells give rise to progeny that either self-renew in an undifferentiated state or lose self-renewal capabilities and commit to lymphoid or myeloid lineages. Here we evaluated whether hematopoietic stem cell self-renewal is affected by the Notch pathway. Notch signaling controls cell fate choices in both invertebrates and vertebrates(1-7) by inhibiting certain differentiation pathways, thereby permitting cells to either differentiate along an alternative pathway or to self-renew(1). Notch receptors are present in hematopoietic precursors and Notch signaling enhances the in vitro generation of human and mouse hematopoietic precursors(8-15), determines T- or B-cell lineage specification from a common lymphoid precursor(16,17) and promotes expansion of CD8(+) cells(18-20). Here, we demonstrate that constitutive Notch1 signaling in hematopoietic cells established immortalized, cytokine-dependent cell lines that generated progeny with either lymphoid or myeloid characteristics both in vitro and in vivo. These data support a role for Notch signaling in regulating hematopoietic stem cell self-renewal. Furthermore, the establishment of clonal, pluripotent cell lines provides the opportunity to assess mechanisms regulating stem cell commitment and demonstrates a general method for immortalizing stem cell populations for further analysis.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Washington, Dept Pediat, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle	Varnum-Finney, B (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-373, Seattle, WA 98109 USA.				NCI NIH HHS [R01-CA82308-01] Funding Source: Medline; NHLBI NIH HHS [P50 HL54881] Funding Source: Medline; NIAID NIH HHS [R01-AI47833-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082308] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047833] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; MILNER LA, 1994, BLOOD, V83, P2057; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Simpson P, 1998, SEMIN CELL DEV BIOL, V9, P581, DOI 10.1006/scdb.1998.0265; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664	27	466	524	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1278	1281		10.1038/81390	http://dx.doi.org/10.1038/81390			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062542				2022-12-25	WOS:000165114800038
J	Cohen, BA; Mitra, RD; Hughes, JD; Church, GM				Cohen, BA; Mitra, RD; Hughes, JD; Church, GM			A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROMOTER REGION; YEAST; TRANSCRIPTION; SEQUENCES; LOCATION; START	Chromosome correlation maps display correlations between the expression patterns of genes on the same chromosome. Using these maps, we show here that adjacent pairs of genes, as well as nearby non-adjacent pairs of genes, show correlated expression independent of their orientation. We present specific examples of adjacent pairs with highly correlated expression patterns, in which the promoter of only one of the two genes contains an upstream activating sequence (UAS) known to be associated with that expression pattern. Finally, we show that genes with similar functions tend to occur in adjacent positions along the chromosomes. Our results suggest that, in certain chromosomal expression domains, an UAS can affect the transcription of genes that are not immediately downstream from it.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Mitra, Robi/0000-0002-2680-4264; church, george/0000-0001-6232-9969				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; KRAAKMAN LS, 1989, NUCLEIC ACIDS RES, V17, P9693, DOI 10.1093/nar/17.23.9693; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Moore D., 1998, INTRO PRACTICE STAT; NAKAO J, 1986, MOL CELL BIOL, V6, P2613, DOI 10.1128/MCB.6.7.2613; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	17	410	426	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2000	26	2					183	186		10.1038/79896	http://dx.doi.org/10.1038/79896			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	359YC	11017073				2022-12-25	WOS:000089638800014
J	Dimitrova, DS; Gilbert, DM				Dimitrova, DS; Gilbert, DM			Temporally coordinated assembly and disassembly of replication factories in the absence of DNA synthesis	NATURE CELL BIOLOGY			English	Article							MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; S-PHASE; ORIGINS; ATM; CAFFEINE; GENES; REPLICON	Here we show that exposure of aphidicolin-arrested Chinese hamster ovary (CHO) cells to the protein-kinase inhibitors 5-aminopurine or caffeine results in initiation of replication at successively later-replicating chromosomal domains, loss of the capacity to synthesize DNA at earlier-replicating sites, release of Mcm2 proteins from chromatin, and redistribution of PCNA and RPA from early- to late-replicating domains in the absence of detectable elongation of replication forks. These results provide evidence that, under conditions of replicational stress, checkpoint controls not only prevent further initiation but may also be required to actively maintain the integrity of stalled replication complexes.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Gilbert, DM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	gilbertd@mail.upstate.edu			NIGMS NIH HHS [R01 GM057233, GM57233-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057233] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; ATEN JA, 1992, HISTOCHEM J, V24, P251, DOI 10.1007/BF01046839; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; CADDLE MS, 1990, BIOCHEM BIOPH RES CO, V170, P134, DOI 10.1016/0006-291X(90)91250-V; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; GILBERT DM, 1986, P NATL ACAD SCI USA, V83, P2924, DOI 10.1073/pnas.83.9.2924; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HEMLIN JL, 1978, EXP CELL RES, V112, P225; HOLMQUIST GP, 1986, BIOCHIM BIOPHYS ACTA, V868, P164, DOI 10.1016/0167-4781(86)90019-9; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LAWLIS SJ, 1996, J CELL BIOL, V135, P1; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1990, CELL GROWTH DIFFER, V1, P171; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VASSILEV LT, 1992, CRIT REV BIOCHEM MOL, V27, P445, DOI 10.3109/10409239209082569; Visser AE, 1999, J CELL SCI, V112, P3353; Weinberger M, 1999, J BIOL CHEM, V274, P35975, DOI 10.1074/jbc.274.50.35975; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	41	129	140	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					686	694		10.1038/35036309	http://dx.doi.org/10.1038/35036309			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025658	Green Accepted			2022-12-25	WOS:000089697000013
J	Ries, SJ; Brandts, CH; Chung, AS; Biederer, CH; Hann, BC; Lipner, EM; McCormick, F; Korn, WM				Ries, SJ; Brandts, CH; Chung, AS; Biederer, CH; Hann, BC; Lipner, EM; McCormick, F; Korn, WM			Loss of p14(ARF) in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)	NATURE MEDICINE			English	Article							P53 STATUS; G(1) ARREST; DNA-DAMAGE; MDM2; SUPPRESSOR; INFECTION; PROTEINS; P19(ARF); ACCUMULATION; EXPRESSION	The adenovirus mutant dl1520 (ONYX-015) does not express the E1B-55K protein that binds and inactivates p53. This virus replicates in tumor cells with mutant p53, but not in normal cells with functional p53. Although intra-tumoral injection of dl1520 shows promising responses in patients with solid tumors, previous in vitro studies have not established a close correlation between p53 status and dl1520 replication. Here we identify loss of p14(ARF) as a mechanism that allows dl1520 replication in tumor cells retaining wild-type p53. We demonstrate that the re-introduction of p14(ARF) into tumor cells with wild-type p53 suppresses replication of dl1520 in a p53-dependent manner. Our study supports the therapeutic use of dl1520 in tumors with lesions within the p53 pathway other than mutation of p53.	Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Korn, WM (corresponding author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA.			Brandts, Christian H./0000-0003-1732-2535				BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Billon N, 1996, ONCOGENE, V13, P2047; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Ganly I, 2000, CLIN CANCER RES, V6, P798; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth E, 1998, CLIN NUTR, V17, P1, DOI 10.1016/S0261-5614(98)80034-4; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Steegenga WT, 1999, ONCOGENE, V18, P5032, DOI 10.1038/sj.onc.1202886; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	34	165	179	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1128	1133		10.1038/80466	http://dx.doi.org/10.1038/80466			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017144				2022-12-25	WOS:000089674700037
J	Smertenko, A; Saleh, N; Igarashi, H; Mori, H; Hauser-Hahn, I; Jiang, CJ; Sonobe, S; Lloyd, CW; Hussey, PJ				Smertenko, A; Saleh, N; Igarashi, H; Mori, H; Hauser-Hahn, I; Jiang, CJ; Sonobe, S; Lloyd, CW; Hussey, PJ			A new class of microtubule-associated proteins in plants	NATURE CELL BIOLOGY			English	Article							CYTOKINETIC APPARATUS; PEPTIDE ANTIBODIES; CELLS	In plants there are three microtubule arrays involved in cellular morphogenesis that have no equivalent in animal cells. In animals, microtubules are decorated by another class of proteins - the structural MAPS - which serve to stabilize microtubules and assist in their organization. The best-studied members of this class in plants are the MAP-65 proteins that can be purified together with plant microtubules after several cycles of polymerization and depolymerization. Here we identify three similar MAP-65 complementary DNAs representing a small gene family named NtMAP65-1, which encode a new set of proteins, collectively called NtMAP65-1. We show that NtMAP65-1 protein localizes to areas of overlapping microtubules, indicating that it may function in the behaviour of antiparallel microtubules in the mitotic spindle and the cytokinetic phragmoplast.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan; Nagoya Univ, Sch Agr, Chikusa Ku, Nagoya, Aichi 464, Japan; Bayer AG, ZF Forsch Biotechnol, Bayerwerk Geb Q18, D-51368 Leverkusen, Germany; John Innes Ctr Plant Sci Res, Dept Cell Biol, Norwich NR4 7UH, Norfolk, England	University of London; Royal Holloway University London; University of Hyogo; Nagoya University; Bayer AG; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Hussey, PJ (corresponding author), Univ Durham, Dept Biol Sci, Durham DH1 3LE, England.			Smertenko, Andrei/0000-0002-5078-4881; Hussey, Patrick/0000-0002-7349-8722; Jiang, Chang-Jie/0000-0003-1845-541X				ASADA T, 1991, NATURE, V350, P238, DOI 10.1038/350238a0; Asada T, 1997, J CELL SCI, V110, P179; Chan J, 1996, PLANT J, V10, P251, DOI 10.1046/j.1365-313X.1996.10020251.x; Chan J, 1999, P NATL ACAD SCI USA, V96, P14931, DOI 10.1073/pnas.96.26.14931; COLE DG, 1992, J CELL SCI, V101, P291; EUTENEUER U, 1980, J CELL BIOL, V87, P509, DOI 10.1083/jcb.87.2.509; JIANG CJ, 1993, J CELL SCI, V105, P891; LANCELLE SA, 1986, PROTOPLASMA, V131, P153, DOI 10.1007/BF01285037; LLOYD CW, 1992, CYTOSKELETAL BASIS P; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Rutten T, 1997, P NATL ACAD SCI USA, V94, P4469, DOI 10.1073/pnas.94.9.4469; SAWIN KE, 1992, J CELL SCI, V101, P303; SHEIANSKI ML, 1973, P NATL ACAD SCI USA, V70, P765; Smertenko AP, 1998, PROTOPLASMA, V203, P138, DOI 10.1007/BF01279470; WILLIAMS BC, 1995, J CELL BIOL, V129, P709, DOI 10.1083/jcb.129.3.709	15	120	139	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2000	2	10					750	753		10.1038/35036390	http://dx.doi.org/10.1038/35036390			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	360ZJ	11025667				2022-12-25	WOS:000089697000022
J	Smits, VAJ; Klompmaker, R; Arnaud, L; Rijksen, G; Nigg, EA; Medema, RH				Smits, VAJ; Klompmaker, R; Arnaud, L; Rijksen, G; Nigg, EA; Medema, RH			Polo-like kinase-1 is a target of the DNA damage checkpoint	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; M-PHASE; PLX1; MITOSIS; MPF; PHOSPHORYLATION	Polo-like kinases (PLKs) have an important role in several stages of mitosis. They contribute to the activation of cyclin B/Cdc2 and are involved in centrosome maturation and bipolar spindle formation at the onset of mitosis(1,2). PLKs also control mitotic exit by regulating the anaphase-promoting complex (APC) and have been implicated in the temporal and spatial coordination of cytokinesis(1,2) Experiments in budding yeast have shown that the PLK Cdc5 may be controlled by the DNA damage check-point(3,4). Here we report the effects of DNA damage on Polo-like kinase-l (Plk1) in a variety of human cell lines. We show that Plk1 is inhibited by DNA damage in G(2) and in mitosis. In line with this, we show that DNA damage blocks mitotic exit. DNA damage does not inhibit the kinase activity of Plk1 mutants in which the conserved threonine residue in the T-loop has been changed to aspartic acid, suggesting that DNA damage interferes with the activation of Plk1. Significantly, expression of these mutants can override the G(2) arrest induced by DNA damage. On the basis of these data we propose that Plk1 is an important target of the DNA damage checkpoint, enabling cell-cycle arrests at multiple points in G(2) and mitosis.	Univ Utrecht, Med Ctr, Dept Hematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands; Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	Utrecht University; University of Geneva	Medema, RH (corresponding author), Univ Utrecht, Med Ctr, Dept Hematol, Jordan Lab, POB 85500, NL-3508 GA Utrecht, Netherlands.		Smits, Veronique A.J./R-2302-2019; Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Smits, Veronique A.J./0000-0002-9160-4525; nigg, erich/0000-0003-4835-5719; Medema, Rene/0000-0002-6754-0381				Abrieu A, 1998, J CELL SCI, V111, P1751; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Karaiskou A, 1999, J CELL SCI, V112, P3747; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936	29	385	404	2	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2000	2	9					672	676		10.1038/35023629	http://dx.doi.org/10.1038/35023629			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	353AB	10980711				2022-12-25	WOS:000089250600022
J	Zimhony, O; Cox, JS; Welch, JT; Vilcheze, C; Jacobs, WR				Zimhony, O; Cox, JS; Welch, JT; Vilcheze, C; Jacobs, WR			Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis	NATURE MEDICINE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; VITRO ANTIMYCOBACTERIAL ACTIVITY; SHORT-COURSE CHEMOTHERAPY; VAR BOVIS BCG; PYRAZINOIC ACID; MYCOLIC ACIDS; GENE; SYNTHASE; RESISTANCE; MUTATIONS	Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin(1,2). PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobacterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity(4). We have found that the eukaryotic-like fas1 gene(5) (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M, smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M, tuberculosis FASI, the biosynthesis of C-16 to C-24/C26 fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.	Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Montefiore Med Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Bronx, NY 10461 USA; SUNY Albany, Dept Chem, Albany, NY 12222 USA	Howard Hughes Medical Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Montefiore Med Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA.	jacobs@aecom.yu.edu		Jacobs, William/0000-0003-3321-3080				Anderson RJ, 1929, J BIOL CHEM, V85, P327; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0; BRINDLEY DN, 1969, NATURE, V224, P666, DOI 10.1038/224666a0; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cynamon MH, 1998, ANTIMICROB AGENTS CH, V42, P462; CYNAMON MH, 1995, J MED CHEM, V38, P3902, DOI 10.1021/jm00020a003; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Good R. C., 1985, Clinical Microbiology Newsletter, V7, P133, DOI 10.1016/S0196-4399(85)80012-X; GROSSET J, 1978, TUBERCLE, V59, P287, DOI 10.1016/0041-3879(78)90007-7; HAGEN SR, 1995, J CHROMATOGR A, V692, P167, DOI 10.1016/0021-9673(94)00743-S; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KONNO K, 1967, AM REV RESPIR DIS, V95, P461; KUSHNER S, 1952, J AM CHEM SOC, V74, P3617, DOI 10.1021/ja01134a045; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Mehta A, 1998, J CHROMATOGR B, V719, P9, DOI 10.1016/S0378-4347(98)00403-4; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; Omura S, 1981, Methods Enzymol, V72, P520; SALFINGER M, 1990, J INFECT DIS, V162, P201, DOI 10.1093/infdis/162.1.201; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; Scorpio A, 1997, ANTIMICROB AGENTS CH, V41, P540, DOI 10.1128/AAC.41.3.540; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; STEELE MA, 1988, CHEST, V94, P845, DOI 10.1378/chest.94.4.845; TAKAYAMA K, 1975, J LIPID RES, V16, P308; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Zhang Y, 1999, J BACTERIOL, V181, P2044, DOI 10.1128/JB.181.7.2044-2049.1999	32	193	200	0	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1043	1047		10.1038/79558	http://dx.doi.org/10.1038/79558			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973326				2022-12-25	WOS:000089190500038
